CA2223395A1 - Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics - Google Patents

Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics Download PDF

Info

Publication number
CA2223395A1
CA2223395A1 CA002223395A CA2223395A CA2223395A1 CA 2223395 A1 CA2223395 A1 CA 2223395A1 CA 002223395 A CA002223395 A CA 002223395A CA 2223395 A CA2223395 A CA 2223395A CA 2223395 A1 CA2223395 A1 CA 2223395A1
Authority
CA
Canada
Prior art keywords
seq
pylori
polypeptide
fragment
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002223395A
Other languages
French (fr)
Inventor
Bjorn L. Mellgard
O. Thomas Berglindh
Douglas Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Bjorn L. Mellgard
Astra Aktiebolag
O. Thomas Berglindh
Douglas Smith
Genome Therapeutics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bjorn L. Mellgard, Astra Aktiebolag, O. Thomas Berglindh, Douglas Smith, Genome Therapeutics Corporation filed Critical Bjorn L. Mellgard
Publication of CA2223395A1 publication Critical patent/CA2223395A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Recombinant or substantially pure preparations of H. pylori polypeptides are described. The nucleic acids encoding the polypeptides also are described. The H. pylori polypeptides are useful for diagnostics and vaccine compositions.

Description

-~ ~CA oi223395 1997-12-03 -~ '. ., ., ,"","~, " ,~ , .,. ~
: ..... . -- . ,' t DEMANDES OU BR~VETS VOLUNIINEUX
.

LA PRÉSE~YTE PARTIE DE CEl~E DEMANDE OU C~ BREVEl COMPREND Pl US D'UN TOME.

CECI EST LE TOME I --DE_~ -NOTE: Pour les tornes additionels, veuillez contac~er le 8ureau canadien ~es b~evets JUMBO APPLICAT~ONS/PATENTS

THIS SECTION ~F THE APPLICATION~PATENT ~CONTAINS MORE
~HAN ONE VOLUME

Tt~IS IS VOLUME 1 OF~

NO~E: For addit;onal ~ra~umes please cs)ntact~she Canadlan Palent OMc~ -CA 0222339~ 1997-12-03 WO 96/40893 PCT~US96/09122 NUCLEIC ACID AND AMINO ACID SEQWENCES RELATING TO
HELICOBACTER PYLORI FOR DIAGNOSTl[CS AND THERAPEUTICS

Back~round of the Invention Helicobacter pylori is a gram-negative, S-shaped, microaerophilic bacterium that" was discovered and cultured from a human gastric biopsy specimen. (Warren, J.R. and B.
Marshall, (1983) Lancet 1: 1273-1275; and Marshall et al., (1984) Microbios Lett. 25: 83-88). H. pylori has been strongly linked to chronic gastritis and duodenal ulcer disease.
(Rathbone et. al., (1986) Gut 27: 635-641). Moreover, evidence is accumulating for an etiologic role of H. pylori in nonulcer dyspepsia, gastric ulcer disease, and gastric adenocarcinoma. (Blaser M. J., (1993) Trends Microbiol. 1: 255-260). Tr~ncmicsion of the bacteria occurs via the oral route. and the risk of infection increases with age. (Taylor, D.N. and M. J. Blaser, (1991) Epidemiol. Rev 13: 42-50). H. pylori colonizes the human gastric mucosa, establishing an infection that usually persists for clee~-les Infection by H.
pylori is prevalent worldwide. Developed countries have infection rates over 50% of the adult population, while developing countries have infection rates reaching 90% of the adults over the age of 20. (Hopkins R. J. and J. G. Morris (1994) Am. J. Med. 97: 265-277).
The bacterial factors necessary for colonization of the gastric environment, and for virulence of this pathogen, are poorly understood. Examples of the putative virulence factors include the following: urease, an enzyme that may play a role in neutralizing gastric acid pH (Eaton et al., (1991) InSect. Immunol. 59: 2470-2475; Ferrero, R.L. and A. Lee (1991) Microb. Ecol. Hlth. Dis. 4: 121-134; Labigne et al., (1991) J. Bacteriol. 173: 1920-1931); the bacterial flagellar proteins responsible for motility across the mucous layer.
(Hazell et al., (1986) J. Inf~ Dis. 153: 658-663; Leying et al., (1992) Mol. Microbiol. 6:
2863-2874; and Haas et al., (1993) Mol. Microbiol. 8: 753-760); Vac A~ a bacterial toxin that induces the formation of intracellular vacuoles in epithelial cells (Schmitt~ W. and R.
Haas, (1994) Molecular Microbiol. 12(2): 307-319); and several gastric tissue-specific a-lhPcinc (Boren et al., (1993) Science 262: 1892-1895; Evans et al., (1993) J. Bacteriol.
175: 674-683; and Falk et al., (1993) Proc. Natl. Acad. Sci. USA 90: 2035-203).
Nurnerous therapeutic agents are currently available that eradicate H. pylori infections in ~itro. (Huesca et. al., (1993) Zbl. Bakt. 280: 244-252; Hopkins, R. J. and J. G.
Morris, supra). However, many of these treatment~ are suboptimally effective in vivo because of bacterial resi.ct~nce, altered drug distribution, patient non-compliance or poor drug availabilty. (Hopkins. R. J. and J. G. Morris, supra). Treatment with antibiotics combined with bismuth are part of the standard regime used to treat H. pylori infection.
(Malfertheiner, P. and J. E. Dominguez-Munoz (1993) Clinical Therapeutics 15 Supp. B:
37-48). Recently, combinations of a proton pump inhibitors and a single antibiotic have been shown to arneliorate duodenal ulcer disease. (Malfertheiner, P. and J. E. Dominguez-Munoz supra). However. methods employing antibiotic agents can have the problem of the SVBSTITUTE 5HEET (RULE 267 CA 0222339~ 1997-12-03 W O 96/40893 . PCT~US96/09122
-2--emergence of bacterial strains which are resistant to these agents. (Hopkins, R. J. and J. G.
Morris, supra). These limitations demonstrate that new more effective methods are needed to combat H. pylori infections in vivo. In particular. the design of new vaccines that may prevent infection by this bacterium is highly desirable.

Summarv of the Invention This invention relates to novel genes, e.g., genes encoding polypeptides such asbacterial surface proteins, from the organism Helicobacter pylori (H. pylori), and other related genes, their products, and uses thereof. The nucleic acids and peptides of the 10 present invention have utility for diagnostic and therapeutics for H. pylori and other Helicobacter species. They can also be used to detect the presence of H. pylori and other Helicobacter species in a sample; and for use in screening compounds for the ability to interfere with the H. pylori life cycle or to inhibit H. pylori infection. More specifically, this invention features compositions of nucleic acids co.le~ollding to entire coding 15 sequences of H. pylori proteins, including surface or secreted proteins or parts thereof.
nucleic acids capable of binding mRNA from H. pylori proteins to block protein translation, and methods for producing H. pylori proteins or parts thereof using peptide synthesis and recombinant DNA techniques. This invention also features antibodies and nucleic acids useful as probes to detect H. pylori infection. In addition, vaccine 20 compositions and methods for the protection or tre~tn~nt of infection by H. pylori are within the scope of this invention.

Detailed Des~ lion of the Drawin~s Figure 1 is a bar graph that depicts the antibody titer in serum of mice following 25 immunization with specific H. pylori antigens.

Figure 2 is a bar graph that depicts the antibody titer in mucous of mice following irnmunization with specific H. pylori antigens.

Figure 3 is a bar graph that depicts therapeutic immunization of H. pylori infected mice with specific antigens dissolved in HEPES buffer.

Figure 4 is a bar graph that depicts therapeutic immunization of H. pylori infected mice with specific antigens dissolved in buffer cont~ininp DOC.
Detailed Description ofthe Invention In one aspect~ the invention features a recombinant or substantially pure pre~ald~ion of H. pylori polypeptide of SEQ ID NO: 384. The invention also includes substantially pure nucleic acid encoding an H. pylori polypeptide of SEQ ID NO: 384, such nucleic acid SUBSTITUTE SH EFT (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 is contained in SEQID NO:l. The H. pylori polypeptide sequences of the inventiondescribed herein are contained in the Sequence T i.eting, and the nucleic acids encoding H.
pylori polypeptides of the invention are contained in the Sequence Listing.
~ In another aspect, the invention features a recombinant or substantially pure yLcpa~dLion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQID NO:384 through SEQID NO:389,SEQ ID NO:391 through SEQ
ID NO: 400,SEQ ID NO: 402 through SEQID NO:406, SEQID NO:408, SEQID NO:
411 through SEQID NO:412,SEQID NO:414 through SEQID NO:430,SEQID NO:
432 through SEQ ID NO:434,SEQID NO:436 through SEQID NO:441, and SEQID
NO:443. The invention also includes substantially pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. py~ori polypeptides SEQID NO:384 through SEQID NO:389,SEQID NO:391 through SEQ ID NO: 400,SEQ ID NO: 402 through SEQ ID NO: 406,SEQ ID NO: 408,SEQID NO: 411 through SEQ ID NO: 412, SEQID NO:414 through SEQID NO:430,SEQID NO:432 through SEQ ID NO:434, SEQ ID NO: 436 through SEQ ID NO: 441, and SEQ ID NO: 443, such nucleic acids are contdined in SEQ ID NO:l through SEQID NO:50.
In another aspect, the invention features a recombinant or subst~nti~lly pure y~ ~dlion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 444,SEQ ID NO: 446 through SEQ ID NO:448,SEQ ID
NO:450 through SEQ ID NO:462,SEQID NO:465 through SEQID NO:466,SEQID
NO:468 through SEQ ID NO:469,SEQ ID NO:471 through SEQ ID NO:473,SEQ ID
NO:475,SEQ ID NO:478 through SEQ ID NO:479,SEQ ID NO:481 through SEQ ID
NO:484,SEQ ID NO:486,SEQID NO:488 through SEQ ID NO:501, and SEQ ID NO:
503 through SEQ ID NO:506. The invention also includes substantially pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQID NO:444,SEQ ID NO:446 through SEQID NO:448,SEQ ID
NO:450 through SEQ ID NO:462,SEQ ID NO: 465 through SEQ ID NO: 466,SEQ ID
NO:468 through SEQ ID NO:469,SEQID NO:471 through SEQ ID NO: 473,SEQ ID
NO:475,SEQ ID NO:478 through SEQID NO: 479,SEQ ID NO: 481 through SEQ ID
NO:484,SEQ ID NO:486.SEQID NO: 488 through SEQ ID NO: 501, and SEQ ID NO:
503 through SEQID NO:506, such nucleic acids are contained in SEQID NO:51 through SEQ ID NO:100.
In another aspect, the invention features a recombinant or substantially pure yle~dLion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQID NO:509 through SEQ ID NO: 510,SEQ ID NO:512 through SEQ
ID NO: 514,SEQID NO:516,SEQ ID NO: 518 through SEQ ID NO: 520,SEQ ID NO:
522 through SEQ ID NO: 525,SEQ ID NO: 527 through SEQ ID NO: 533,SEQID NO:
535 through SEQ ID NO:537,SEQID NO:539 through SEQID NO:540,SEQ ID NO:
542 through SEQ ID NO:544,SEQ ID NO:546 through SEQID NO: 548,SEQID NO:

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 SSO,SEQ ID NO: 553 through SEQIDNO: 556, SEQ ID NO: 558, SEQIDNO: 560, SEQ
ID NO: 562 through SEQIDNO: 568, SEQ ID NO: 570,and SEQ ID NO: 572 through SEQ ID NO: 575. The invention also includes substantially pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ
S ID NO:509 through SEQ ID NO:510,SEQIDNO: 512 through SEQ ID NO: 514, SEQ
ID NO: 516, SEQ ID NO: 518 through SEQ ID NO: 520, SEQ ID NO:522 through SEQ
ID NO: 525, SEQ ID NO: 527 through SEQ ID NO: 533, SEQ ID NO: 535 through SEQ
ID NO:537, SEQIDNO: 539 through SEQID NO: 540, SEQ ID NO: 542 through SEQ
ID NO: 544, SEQIDNO: 546 through SEQ ID NO: 548, SEQ ID NO:550,SEQ ID NO:
0 553 through SEQIDNO: 556, SEQ ID NO: 558, SEQ ID NO: 560, SEQ ID NO: 562 through SEQ ID NO: 568, SEQ ID NO: 570, and SEQIDNO: 572 through SEQ ID NO:
575, such nucleic acids are contained in SEQ ID NO:101 through SEQ ID NO:150.
In another aspect, the invention features a recombinant or ~-lbst:~nti~lly pure ~dlion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 576 through SEQ ID NO:579, SEQIDNO: 581 through SEQ
IDNO: 583, SEQIDNO: 585 through SEQ ID NO: 593, SEQ ID NO: 596 through SEQ
ID NO: 614, SEQ ID NO: 617 through SEQ ID NO: 623, SEQ ID NO: 625, SEQ ID NO:
627, SEQ ID NO: 629 through SEQ ID NO: 631, SEQ ID NO: 633,and SEQ ID NO: 635 through SEQ ID NO: 636. The invention also includes ~ul~s~llially pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 576 through SEQ ID NO: 579, SEQ ID NO: 581 through SEQ
ID NO: 583, SEQ ID NO: 585 through SEQ ID NO: 593, SEQ ID NO: 596 through SEQ
ID NO: 614, SEQ ID NO: 617 through SEQ ID NO: 623, SEQ ID NO: 625, SEQ ID NO:
627, SEQID NO: 629 through SEQIDNO: 631, SEQ ID NO: 633, and SEQ ID NO: 635 through SEQIDNO: 636, such nucleic acids are contained in SEQID NO:151 through SEQID NO:200.
In another aspect, the invention features a recombinant or substantially pure )~a~ion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQID NO: 638 through SEQ ID NO: 640, SEQ ID NO: 642 through SEQIDNO: 643, SEQ ID NO: 647, SEQ ID NO: 649 through SEQID NO: 651, SEQ ID NO:
653 through SEQID NO: 661, SEQIDNO: 663 through SEQID NO: 670, SEQ ID NO:
673 through SEQ ID NO: 674, SEQ ID NO: 676, SEQ ID NO: 678 through SEQ ID NO:
683, SEQ ID NO: 687 through SEQ ID NO: 692, and SEQlD NO: 694 through SEQID
NO: 702. The invention also includes sllhst~nti~lly pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO:
638 through SEQIDNO: 640, SEQIDNO: 642 through SEQIDNO: 643, SEQID NO:
647, SEQIDNO: 649 through SEQID NO: 651, SEQID NO: 653 through SEQID NO:
661, SEQ ID NO: 663 through SEQ ID NO: 670, SEQ ID NO: 673 through SEQ ID NO:
674, SEQ ID NO: 676, SEQ ID NO: 678 through SEQIDNO: 683, SEQ ID NO: 687 SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 through SEQ ID NO:692, and SEQ ID NO:~94 through SEQ ID NO: 702, such nucleic acids are contained in SEQ ID NO: 201 through SEQIDNO: 250.
In another aspect. the invention features a recombinant or substantially pure ~lc~ lion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 705 through SEQ ID NO:708,SEQIDNO: 712 through SEQ
e ID NO:714, SEQID NO:716 through SEQ ID NO:722, SEQIDNO: 725 through SEQID NO: 730, SEQ ID NO:732 through SEQ ID NO:733, SEQ ID NO:735 through SEQ
ID NO: 744, SEQ ID NO:746 through SEQ ID NO: 752, SEQ ID NO:755 through SEQ
ID NO:757, SEQID NO:759, SEQ ID NO:761 through SEQ ID NO:763, and SEQ ID
NO:767 through SEQ ID NO: 770. The invention also includes s~lbst~nt~ y pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 705 through SEQ ID NO:'708,SEQIDNO:712 through SEQ
ID NO:714, SEQ ID NO:716 through SEQ ID NO: 722, SEQ ID NO:725 through SEQ
ID NO: 730, SEQIDNO: 732 through SEQIDNO: 733, SEQIDNO: 735 through SEQ
IDNO: 744, SEQ ID NO:746 through SEQID NO:752, SEQID NO:755 through SEQ
ID NO:757, SEQ ID NO:759, SEQ ID NO:761 through SEQID NO:763, and SEQ ID
NO:767 through SEQIDNO: 770, such nucleic acids are contained in SEQID NO:251 through SEQ ID NO: 300.
In another aspect, the invention features a recombinant or substantially pure pre~v~dLion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 771 through SEQ ID NO: 773, SEQ ID NO: 775, SEQ ID
NO: 777, SEQ ID NO: 779 through SEQ ID NO: 784, SEQ ID NO:786 through SEQ ID
NO:787, SEQ ID NO:789 through SEQIDNO: 792, SEQIDNO: 794, SEQIDNO: 796, SEQ ID NO: 798 through SEQ ID NO: 805, SEQ ID NO: 807 through SEQID NO:811, SEQ ID NO:813 through SEQ ID NO:819, SEQ ID NO:821 through SEQ ID NO: 822, SEQ ID NO: 824 through SEQIDNO: 826, SEQIDNO: 828 through SEQIDNO: 832, and SEQ ID NO: 835. The invention also includes substantially pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQID NO:771 through SEQIDNO: 773, SEQIDNO: 775, SEQ ID NO: 777, SEQ ID
NO: 779 through SEQ ID NO: 784, SEQIDNO: 786through SEQ ID NO:787, SEQ ID
NO: 789 through SEQ ID NO: 792, SEQ ID NO: 794, SEQ ID NO: 796, SEQ ID NO: 798 through SEQ ID NO: 805, SEQ ID NO:807 through SEQ ID NO: 811, SEQIDNO: 813 through SEQIDNO: 819, SEQ ID NO: 821 through SEQ ID NO: 822, SEQ ID NO: 824 through SEQ ID NO: 826, SEQ ID NO: 828 through SEQ ID NO: 832, and SEQ ID NO:
835, such nucleic acids are contained in SEQ ID NO: 301 through SEQ ID NO:350.
In another aspect~ the invention features a recombinant or substantially pure e~Lion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO:836 through SEQID NO:841, SEQ ID NO:843 through SEQ
ID NO: 851, SEQ ID NO: 853, SEQ ID NO: 855 through SEQ ID NO: 857, SEQ ID NO:

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03
3 PCTAUS96/09122 859 through SEQ ID NO: 862, SEQ ID NO: 866, SEQ ID NO: 868 through SEQ ID NO:
871, SEQ ID NO: 873 through SEQ ID NO: 876, and SEQ ID NO: 879. The invention also includes subst~nti~ y pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 836 through SEQ ID NO: 841, SEQ ID NO: 843 through SEQ ID NO: 851, SEQ ID NO: 853, SEQ ID NO: 855 through SEQ ID NO: 857, SEQ ID NO: 859 through SEQ ID NO: 862, SEQ ID NO: 866, SEQ ID
NO: 868 through SEQ ID NO: 871, SEQ ID NO: 873 through SEQ ID NO: 876, and SEQ
ID NO: 879, such nucleic acids are contained in SEQ ID NO: 351 through SEQ ID NO:
383.
In another aspect, the invention features a recombinant or substantially pure ~lep~dlion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 385, SEQ ID NO: 390, SEQ ID NO: 401, SEQ ID NO: 407, SEQ ID NO: 409 through SEQ ID NO: 410, SEQ ID NO: 413, SEQ ID NO: 431, SEQ ID
NO: 435, SEQ ID NO: 442, SEQ ID NO: 445, SEQ ID NO: 449, SEQ ID NO: 463 through SEQ ID NO: 464, SEQ ID NO: 467, SEQ ID NO: 470, SEQ ID NO: 474, SEQ ID NO: 476 through SEQ ID NO: 477, SEQ ID NO: 480, SEQ ID NO: 485, SEQ ID NO: 487, SEQ ID
NO: 502, SEQ ID NO: 507 through SEQ ID NO: 508, SEQ ID NO:Sll, SEQ ID NO: 515, SEQ ID NO: 517, SEQ ID NO: 521, SEQ ID NO: 526, SEQ ID NO: 534, SEQ ID NO:
538, SEQ ID NO: 541, SEQ ID NO: 545, SEQ ID NO: 549, SEQ ID NO:SSl through SEQ
ID NO: 552, SEQ ID NO: 557, SEQ ID NO: 559, SEQ ID NO: 561, SEQ ID NO: 569, SEQ ID NO: 571, SEQ ID NO: 580, SEQ ID NO: 584, SEQ ID NO: 594 through SEQ ID
NO:S95, SEQ ID NO: 615 through SEQ ID NO: 616, SEQ ID NO: 624, and SEQ ID NO:
626. The invention also includes subst~nti~lly pure nucleic acid encoding an H. pylori polypeptide selected from the group con.~i~ting of H. pylori polypeptides of SEQ ID NO:
385, SEQ ID NO: 390, SEQ ID NO: 401, SEQ ID NO: 407, SEQ ID NO: 409 through SEQ
ID NO: 410, SEQ ID NO: 413, SEQ ID NO: 431, SEQ ID NO: 435, SEQ ID NO: 442, SEQ ID NO: 445, SEQ ID NO: 449, SEQ ID NO: 463 through SEQ ID NO: 464, SEQ ID
NO: 467, SEQ ID NO: 470, SEQ ID NO: 474, SEQ ID NO: 476 through SEQ ID NO: 477, SEQ ID NO: 480, SEQ ID NO: 485, SEQ ID NO: 487, SEQ ID NO: 502, SEQ ID NO: 507 through SEQ ID NO: 508, SEQ ID NO:Sll, SEQ ID NO:S15, SEQ ID NO: 517, SEQ ID
NO: 521, SEQ ID NO: 526, SEQ ID NO: 534, SEQ ID NO: 538, SEQ ID NO: 541, SEQ
ID NO: 545, SEQ ID NO: 549, SEQ ID NO:SSl through SEQ ID NO: 552, SEQ ID NO:
557, SEQ ID NO:SS9, SEQ ID NO: 561, SEQ ID NO: 569, SEQ ID NO: 571, SEQ ID
NO: 580, SEQ ID NO: 584, SEQ ID NO: 594 through SEQ ID NO:S95, SEQ ID NO: 615 through SEQ ID NO: 616, SEQ ID NO: 624, and SEQ ID NO: 626, such nucleic acids are contained in SEQ ID NO: 881 through SEQ ID NO: 930.
In another aspect, the invention features a recombinant or substantially pure ~dlion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 628, SEQ ID NO: 632, SEQ ID NO: 634, SEQ ID NO: 637, SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 SEQ IDNO: 641, SEQ ID NO: 644 through SEQ ID NO:646, SEQ ID N 0:648, SEQ ID
NO: 652, SEQ ID NO: 662, SEQ IDNO: 671 through SEQ ID NO: 672, SEQ ID NO: 675, SEQ ID NO: 677, SEQ ID NO: 684 through SEQ ID NO: 686, SEQ ID NO: 693, SEQ ID
NO: 703 through SEQ ID NO: 704, SEQ ID NO:709 through SEQ ID NO: 711, SEQ ID
NO: 715, SEQ ID NO: 723 through SEQ ID NO: 724, SEQ ID NO: 731, SEQ ID NO: 734, SEQ ID NO: 745, SEQ ID NO: 753 through SEQ ID NO: 754, SEQ ID NO: 758, SEQ ID
NO: 760, SEQ ID N 0:764 through SEQ ID N 0:766, SEQ ID NO: 774, SEQ ID NO: 776, SEQ ID NO: 778, SEQ ID NO: 785, SEQ ID NO: 788, SEQ ID NO: 793, SEQ ID NO:
795, SEQ ID NO: 797, SEQ ID NO: 806, SEQ ID NO: 812, SEQ ID NO: 820, SEQ ID
NO: 823, and SEQ ID NO: 827. The invention also includes subst~nti~ y pure nucleic acid encoding an H. pylori polypeptide selected from the group con~i.ctin~ ofH. pylori polypeptides of SEQ ID NO: 628, SEQ ID NO: 632, SEQ ID NO: 634, SEQ ID NO: 637, SEQ ID NO: 641, SEQ ID NO: 644 through SEQ ID NO: 646, SEQ ID NO: 648, SEQ ID
NO: 652, SEQ ID NO: 662. SEQ ID NO: 671 through SEQ ID NO: 672, SEQ ID NO: 675, SEQ ID NO: 677, SEQ ID NO: 684 through SEQ ID NO: 686, SEQ ID NO: 693, SEQ ID
NO: 703 through SEQ ID NO: 704, SEQ ID NO: 709 through SEQ ID NO: 711, SEQ ID
NO: 715, SEQ ID NO: 723 through SEQ ID NO: 724, SEQ ID NO: 731, SEQ ID NO: 734, SEQ ID NO: 745, SEQ ID NO: 753 through SEQ ID NO: 754, SEQ ID NO: 758, SEQ ID
NO: 760, SEQ ID NO: 764 through SEQ ID NO: 766, SEQ ID NO: 774, SEQ ID NO: 776, SEQ ID NO: 778, SEQ ID NO: 785, SEQ ID NO: 788, SEQ ID NO: 793, SEQ ID NO:
795, SEQ ID NO: 797, SEQ ID NO: 806, SEQ ID NO: 812, SEQ ID NO: 820, SEQ ID
NO: 823, and SEQ ID NO: 827, such nucleic acids are contained in SEQ ID NO: 931 through SEQ ID NO: 980.
In another aspect, the invention features a recombinant or subst~nt~ y pure ~l~paldlion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 833 through SEQ ID NO: 834, SEQ ID NO: 842, SEQ ID
NO: 852, SEQ ID NO: 854, SEQ ID NO: 858, SEQ ID NO: 863, SEQ ID NO: 864 through SEQ ID NO: 865, SEQ ID NO: 867, SEQ ID NO: 872, SEQ ID NO: 877 through SEQ ID
NO: 878,and SEQ ID NO: 880. The invention also includes substantially pure nucleic acid encoding an H. pylori polypeptide selected from the group con~icting of H. pylori polypeptides of SEQ ID NO: 833 through SEQ ID NO: 834, SEQ ID NO: 842, SEQ ID
NO:852, SEQ ID NO: 854, SEQ ID NO: 858, SEQ ID NO: 863, SEQ ID NO: 864 through SEQ ID NO: 865, SEQ ID NO: 867, SEQ ID NO: 872, SEQ ID N 0:877 through SEQ ID
NO:878, and SEQ ID NO: 880, such nucleic acids are contained in SEQ ID N 0:981 through SEQ ID NO:994.
In another aspect, the invention features a recombinant or subst~nti~lly pure ~l~pa~dlion of an H. pylori polypeptide selected from the group con~i~tin~ of H. pylori polypeptides of SEQ ID N 0:1446 through SEQ ID NO: 1461, SEQ ID NO: 1463, and SEQ ID NO: 1465 through SEQ ID NO: 1495. The invention also includes substantially SUBSTITUTE SHEET (RULE 2~) -CA 0222339F, 1997-12-03 wO 9~ C- j3 PCI~/USg6109122 pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides SEQ ID NO:1446 through SEQ ID NO:1461, SEQ ID NO:1463, and SEQ ID NO:1465 through SEQ ID NO:1495, such nucleic acids are contained in SEQ
ID NO:995 through SEQ ID NO: SEQ ID NO:1010, SEQ ID NO:1012, and SEQ ID NO:
1014 through SEQ ID NO:1044.
In another aspect, the invention features a recombinant or subst~nti~lly pure pl~ dLion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO:1497 through SEQ ID NO:1515, and SEQ ID NO:1517 through SEQ ID NO:1545. The invention also includes substantially pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides SEQ ID NO:1497 through SEQ ID NO:1515, and SEQ ID NO:1517 through SEQ ID NO:1545, such nucleic acids are contained in SEQ ID NO:1046 through SEQ ID
NO:1064, and SEQ ID NO:1066 through SEQ ID NO:1094.
In another aspect~ the invention features a recombindnt or subst~nti~lly pure prel,~dLion of an H. pylori polypeptide selected from the group coneicting of H. pylori polypeptides of SEQ ID NO:1546 through SEQ ID NO: 1595. The invention also includes subst~nti~lly pure nucleic acid encoding an H. pylori polypeptide selected from the group coneietin~ of H. pylori polypeptides SEQ ID NO: 1546 through SEQ ID NO: 1595, such nucleic acids are contained in SEQ ID NO:1095 through SEQ ID NO:1144.
In another aspect, the invention features a recombinant or subst~ntizllly pure ~dtion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 1596 through SEQ ID NO: 1617,SEQ ID NO:1620 through SEQ ID NO:1645. The invention also includes substantially pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides SEQ ID
NO: 1596 through SEQ ID NO: 1617, SEQ ID NO: 1620 through SEQ ID NO:1645, such nucleic acids are contained in SEQ ID NO:1145 through SEQ ID NO:1166, and SEQ IDNO:1169 through SEQ ID NO: 1194.
In another aspect, the invention features a recombinant or substantially pure ~dLion of an H. pylori polypeptide selected from the group con.eieting of H. pylori polypeptides of SEQ ID NO: 1646 through SEQ ID NO: 1681, and SEQ ID NO: 1683 through SEQ ID NO: 1695. The invention also includes substantially pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides SEQ ID NO: 1646 through SEQ ID NO:1681, and SEQ ID NO:1683 through SEQ ID NO:1695, such nucleic acids are contained in SEQ ID NO:1195 through SEQ ID
NO:1230, and SEQ ID NO:1232 through SEQ ID NO:1244.
In another aspect, the invention features a recombinant or substantially pure ~lc;pald~ion of an H. pylori polypeptide selected from the group consisting of H. pylori ~, polypeptides of SEQ ID NO:1696 through SEQ ID NO: 1745. The invention also includes snhst~nti~11y pure nucleic acid encoding an H. pylori polypeptide selected from the group SUBSTITUTE SH EET (RULE 26) CA 0222339~ 1997-12-03 W096/40893 PCTrUS96/09122 conei~ting of H. pylori polypeptides SEQ ID I~O: 1696 through SEQ ID NO: 1745, such nucleic acids are contained in SEQ ID NO: 1245 through SEQ ID NO: 1294.
In another aspect, the invention features a recombinant or substantially pure - p~p~dlion of an H. pylori polypeptide selected from the group con.~istin~ of H. pylori polypeptides of SEQ ID NO: 1746 through SEQ ID NO: 1783, and SEQ ID NO: 1786 through SEQ ID NO: 1795. The invention also includes subst~ntially pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides SEQ ID NO: 1746 through SEQ ID NO: 1783, and SEQ ID NO: 1786 through SEQ ID NO: 1795, such nucleic acids are contained in SEQ ID NO: 1295 through SEQ ID
NO: 1332, and SEQ ID NO: 1335 through SEQ ID NO: 1344.
In another aspect, the invention features a recombinant or substantially pure dLion of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 1796 through SEQ ID NO: 1817, SEQ ID NO: 1819, SEQ IDNO: 1821, SEQ ID NO: 1823 through SEQ ID NO: 1836, and SEQ ID NO: 1838 through SEQ ID NO: 1845. The invention also includes substzlnti~lly pure nucleic acid encoding an . pylori polypeptide selected from the group consisting of H. pylori polypeptides SEQ ID
NO: 1796 through SEQ ID NO: 1817, SEQ ID NO: 1819, SEQ ID NO: 1821, SEQ ID NO:
1823 through SEQ ID NO: 1836, and SEQ ID NO: 1838 through SEQ ID NO: 1845, such nucleic acids are contained in SEQ ID NO: 1345 through SEQ ID NO: 1366, SEQ ID NO:
1368, SEQ ID NO: 1370, SEQ ID NO: 1372 through SEQ ID NO: 1385, and SEQ ID NO:
1387 through SEQ ID NO: 1394.
In another aspect, the invention fealLllcs a recombinant or subst~nti~lly pure preparation of an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides of SEQ ID NO: 1846 through SEQ ID NO: 1896. The invention also includes subst~nti~lly pure nucleic acid encoding an H. pylori polypeptide selected from the group consisting of H. pylori polypeptides SEQ ID NO: 1846 through SEQ ID NO: 1896, such nucleic acids are contained in SEQ ID NO: 1395 through SEQ ID NO: 1445.
In another aspect, the invention fe~Lules a recombinant or subst~nti~lly pure ~dlion of an H. pylori polypeptide selected from the group con~i~ting of H. pylori polypeptides of the invention as set forth in the Sequence Listing. The invention also includes subst~nti~lly pure nucleic acid encoding an H. pylori polypeptide selected from the group con~i~tin~ of H. pylori polypeptides of the invention as set forth in the Sequence Listing. It should be understood that this invention enco-np~çs each of the H. pylori polypeptides and nucleic acids encoding such polypeptides as identified in the Sequence Listing by a given sequence identification nurnber. For example, a Le~resell~a~ e H. pylori polypeptide is contained in SEQ ID NO: 1450. Therefore, this invention encompasses a recombinant or substz~nti~lly pure ~lep~dlion of an H. pylori polypeptide of SEQ ID NO:
1450. The invention also includes substantially pure nucleic acid encoding an ~I. pylori polypeptide of SEQ ID NO: 1450.

SUBSTITUTE S~EET (RULE 26) CA 0222339~ 1997-12-03 In another aspect, the invention pertains to any individual H. pylori polypeptide member or nucleic acid encoding such member from the above-identified groups of H.
pylori polypeptides (e.g., SEQ ID NO: 1546 through SEQ ID NO:1595) or nucleic acids (e.g., SEQ ID NO: 1095-SEQ ID NO: 1144), as well as any subgroups from within the above-identified groups. Furthermore, the subgroups can preferably consists of 1, 3, 5, 10, 15, 20, 30 or 40 members of any of the groups identified above, as well as any combinations thereof. For exarnple, the group consisting of H. pylori polypeptides SEQ ID
NO: 1846 through SEQ ID NO: 1896 can be divided into one or more subgroups as follows: SEQ ID NO:1 846-SEQ ID NO: 1860; SEQ ID NO: 1861 -SEQ ID NO: 1875;
SEQ ID NO: 1876-SEQ ID NO: 1885; SEQ ID NO: 1886-SEQ ID NO: 1896, or any combinations thereof.
Particularly perferred is an isolated nucleic acid comprising a nucleotide sequence encoding an H. pylori cell envelope polypeptide or a fragment thereof. Such nucleic acid is selected from the group consisting of SEQ ID NO: 1020, SEQ ID NO: 1021, SEQ ID NO:
1036, SEQ ID NO: 1050, SEQ ID NO: 1071, SEQ ID NO:llOl, SEQ ID NO: 1135, SEQ
ID NO: 1276, SEQ ID NO: 1150, SEQ IDNO: 1187, SEQ ID NO: 1192, SEQ ID NO:
1361, SEQ ID NO: 1379, SEQ ID NO: 1399, SEQ ID NO: 1403, SEQ ID NO: 1400, SEQ
ID NO: 1189, SEQ ID NO: 1002, SEQ ID NO: 1213, SEQ ID NO: 1214, SEQ ID NO:
1215, SEQ ID NO: 1234, SEQ ID NO: 1236, SEQ ID NO: 1237, SEQ ID NO: 1224, SEQ
ID NO: 1251, SEQ ID NO: 1262, SEQ ID NO: 1149, SEQ IDNO: 1220, SEQ ID NO:
1240, SEQ ID NO: 1164, SEQ ID NO: 1165, SEQ ID NO: 1404, SEQ ID NO: 1144, SEQ
ID NO: 1182, SEQ ID NO: 1157, SEQ ID NO: 1160, SEQ ID NO: 1300, SEQ ID NO:
1321, SEQ ID NO: 1323, SEQ ID NO: 1329, SEQ ID NO: 1332, SEQ ID NO: 1345, SEQ
ID NO: 1358, SEQ ID NO: 1375, SEQ ID NO: 1417, SEQ ID NO: 1283, SEQ ID NO:
1335, SEQ ID NO: 1368, SEQ ID NO: 1179, SEQ ID NO: 1255, SEQ ID NO: 1258, SEQ
ID NO: 1044, SEQ ID NO: 1273, SEQ ID NO: 1219, SEQ ID NO: 1274, SEQ ID NO:
1210, SEQ ID NO: 1422, SEQ ID NO: 1302, SEQ ID NO: 1308, SEQ ID NO: 1310, SEQ
ID NO: 1331, SEQ ID NO: 1432. SEQ ID NO: 1052, SEQ ID NO:1091, SEQ ID NO:
1421, SEQ ID NO: 1069~ SEQ ID NO: 1005, SEQ ID NO: 1007, SEQ ID NO: 1166, SEQ
ID NO:l 177, SEQ ID NO:l 193~ SEQ ID NO: 1206, SEQ ID NO: 1207, SEQ ID NO:
1304, SEQ ID NO: 1305, SEQ ID NO: 1346, SEQ ID NO: 1348, SEQ ID NO: 1350, SEQ
ID NO: 1032, SEQ ID NO: 1053, SEQ ID NO: 1081, SEQ ID NO: 1124, SEQ ID NO:
1382, SEQ ID NO: 1437, SEQ ID NO: 1263, SEQ ID NO: 1173, SEQ ID NO: 1405, SEQ
ID NO: 1406, SEQ ID NO: 1410. SEQ ID NO: 1086, SEQ ID NO: 1322, SEQ ID NO:
1266, SEQ lD NO: 128'7, SEQ ID NO: 1271, SEQ ID NO: 1208, SEQ ID NO: 1126, SEQ
ID NO: 1270, SEQ ID NO: 1278, SEQ ID NO: 1419, SEQ ID NO: 1125, SEQ ID NO:
1181, SEQ ID NO: 1416, SEQ ID NO: 1096, SEQ ID NO: 1082, SEQ ID NO: 1146, SEQ
ID NO: 1145, SEQ ID NO: 1108, SEQ ID NO: 1148, SEQ ID NO: 1337, SEQ ID NO:
1338. SEQ ID NO: 1424, SEQ ID NO:1000, SEQ ID NO: 1027, SEQ ID NO: 1175, SEQ

SUBSTITUTE SH EET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 ID NO:1330,SEQIDNO:217,SEQIDNC~.217,SEQ ID NO: 367,SEQ ID NO:
911,SEQ ID NO:944,SEQ ID NO:18,SEQIDNO:107,SEQIDNO:894,SEQIDNO:
943,SEQ ID NO:203,SEQIDNO:85,SEQ ID NO:2~90,SEQIDNO: S? SEQ ID NO:
- l99,SEQ ID NO:992,SEQ ID NO:934,SEQ ID NO: 899,SEQ ID NO: 302,SEQ ID
NO: 215,SEQ ID NO: 893,SEQIDNO:984,SEQ ID NO:97,SEQ ID NO:22,SEQID
NO:49,SEQ ID NO:309,SEQ ID NO: 150,SEQ ID NO:240,SEQ ID NO: 957,SEQ ID
NO: 57,SEQ ID NO:2,SEQ ID NO:92,SEQ ID NO: 255, SEQ ID NO: 164,SEQ ID NO:
201,SEQ ID NO:278,SEQ ID NO:245,SEQIDNO:921,SEQ ID NO:896,SEQ ID
NO:248,SEQ ID NO:159,SEQIDNO:979,SEQIDNO:194,SEQ ID NO:194,SEQ
ID NO:946,SEQ ID NO: 916,SEQ ID NO:76,SEQIDNO:905,SEQIDNO:914,SEQ
ID NO:931,SEQ ID NO:50,SEQIDNO:250,SEQIDNO:969,SEQIDNO:66,SEQ
ID NO:275,SEQIDNO:330,SEQIDNO:204,SEQIDNO:383,SEQ ID NO:303, SEQ ID NO: 70,SEQ ID NO: 983,SEQ ID NO: 972,SEQ ID NO: 929,SEQ ID NO:972, SEQIDNO:936,SEQ ID NO:267,SEQIDNO:197,SEQ ID NO:55,SEQ ID NO:54, SEQ ID NO:210,SEQIDNO:90,SEQIDNO:15,SEQ ID NO:913,SEQ ID NO:227, SEQ ID NO:79,SEQ ID NO:l91, SEQ ID NO: 238,S:EQ ID NO: 274,SEQIDNO:27, SEQ ID NO:258,SEQ ID NO:295,SEQ ID NO:lO,SEQIDNO:160,SEQIDNO:225, SEQIDNO:964,SEQIDNO:166,SEQIDNO:56,SEQ ID NO:980,SEQ ID NO:903, SEQIDNO:261,SEQ ID NO: 71,SEQ ID NO:955,SEQID NO: 361,SEQ ID NO:58, SEQIDNO:114,SEQ ID NO: 940,SEQ ID NO:960,SEQIDNO:144,SEQ ID NO:
362,SEQ ID NO:40,SEQ ID NO:285,SEQ ID NO:ll,SEQ ID NO:161,SEQ ID NO:
974,SEQ ID NO:lll,SEQ ID NO: 316,SEQ ID NO: 257,SEQ ID NO: 78,SEQ ID NO:
966,SEQ ID NO:352,SEQ ID NO:981,SEQ ID NO:158,SEQ ID NO:989,SEQ ID
NO:963,SEQ ID NO:48,SEQ ID NO:68,SEQ ID NO:135,SEQIDNO:910,SEQ ID
NO:236,SEQ ID NO:241,SEQ ID NO:949,SEQ ID NO: 945,SEQ ID NO: 207,SEQ
ID NO: 977,SEQ ID NO:978~SEQ ID NO:994,SEQ ID NO:163,SEQ ID NO:256, SEQ ID NO:287,SEQIDNO:184,SEQ ID NO:45,SEQ ID NO:136,SEQ ID NO:214, SEQ ID NO:16,SEQIDNO:192,SEQ ID NO:373,SEQ ID NO:892,SEQ ID NO:239, SEQ ID NO:34,SEQ ID NO:340,SEQ ID NO:41,SEQ ID NO:332,SEQIDNO:134, and SEQIDNO:330.
In one embodiment, the H. pylori cell envelope polypeptide or a fragment thereof is an H. pylori flagella-associated polypeptide or a fragment thereof encoded by the nucleic acid selected from the group consisting of SEQ ID NO:1020,SEQ ID NO:1021,SEQID
NO:1036,SEQ ID NO:1050,SEQ ID NO:1071,SEQ ID NO:llOl,SEQ ID NO:1135, SEQIDNO:1276~SEQ ID NO:1150,SEQIDNO:11~7,SEQIDNO:ll9'~,SEQID
NO:1361,SEQIDNO:1379,SEQ ID NO: 1399,SEQ ID NO: 1403,SEQ ID NO: 1400, SEQ ID NO: 1189,SEQID NO: 217,SEQ ID NO: 367,SEQ ID NO:91 l,SEQ ID NO:
944,SEQ ID NO:18,SEQ ID NO: 107,SEQ ID NO:894,SEQIDNO:943,SEQ ID NO:

SUBSTITUTE !iiHEET (RULE 26) CA 0222339~ 1997-12-03 W096/40893 PCTrUSg6/09l22 203,SEQ ID NO: 85,SEQ ID NO: 290,SEQ ID NO:5, SEQID NO:l99. SEQ ID NO:
992,SEQ ID NO: 934,SEQ ID NO:899,SEQ ID NO:302, and SEQ ID NO:215.
In another embodiment, the H. pylori cell envelope polypeptide or a fragment thereof is an H. pylori inner membrane polypeptide or a fragment thereof encoded by the nucleic acid selected from the group consisting of SEQ ID NO:1002,SEQIDNO:1213, SEQIDNO:1214,SEQ ID NO:1215,SEQ ID NO:1234,SEQ ID NO:1236,SEQ ID
NO:1237,SEQ ID NO:1224,SEQ ID NO:1251,SEQ ID NO:1262,SEQ ID NO:1149, SEQ ID NO:1220,SEQ ID NO:1240,SEQ ID NO:1164,SEQ ID NO:1165,SEQ ID
NO:1404,SEQ ID NO:1144,SEQ ID NO:1182,SEQ ID NO:1157,SEQ ID NO:1160, SEQ ID NO:1300,SEQ ID NO:1321,SEQ ID NO:1323,SEQ ID NO:1329,SEQ ID
NO:1332,SEQ ID NO:1345,SEQ ID NO:1358,SEQ ID NO:1375,SEQ ID NO:1417, SEQ ID NO: 1283,SEQ ID NO: 1335,SEQ ID NO:1368,SEQ ID NO:1179,SEQ ID
NO: 1255,SEQ ID NO:1258,SEQ ID NO:1044,SEQ ID NO:1273,SEQ ID NO:893, SEQ ID NO:984,SEQ ID NO:97,SEQ ID NO:22,SEQ ID NO:49,SEQ ID NO:309, SEQ ID NO:150,SEQ ID NO:240,SEQ ID NO:957,SEQ ID NO:57,SEQ ID NO:2, SEQ ID NO:92,SEQ ID NO:255,SEQ ID NO:164,SEQIDNO:201,SEQ ID NO:278, SEQ ID NO: 245,SEQ ID NO: 921,SEQ ID NO: 896,SEQ ID NO:248,SEQ ID NO:
159,SEQ ID NO:979,SEQ ID NO:194,SEQ ID NO:194,SEQ ID NO:946,SEQ ID
NO:916,SEQ ID NO:76,SEQ ID NO:905,SEQ ID NO:914,SEQ ID NO:931,SEQ ID
NO:50,SEQ ID NO:250,SEQ ID NO:969,SEQ ID NO:66,SEQ ID NO:275,SEQ ID
NO:330,SEQ ID NO:204,SEQ ID NO:383,SEQ ID NO: 303,SEQ ID NO:70,SEQ ID
NO:983,SEQ ID NO:972,SEQ ID NO:929,SEQ ID NO:972,SEQ ID NO:936,SEQ
ID NO:267,SEQ ID NO:197,SEQ ID NO:55,SEQ ID NO:54, and SEQIDNO:210.
In yet another embodiment, the H. pylori cell envelope polypeptide or a fragmentthereof is an H. pylori transporter polypeptide or a fragment thereof encoded by the nucleic acid selected from the group consisting of SEQ ID NO:1219,SEQ ID NO:1274,SEQ ID
NO:1210,SEQ ID NO:1422,SEQ ID NO:1302,SEQ ID NO:1308,SEQ ID NO:1310, SEQ ID NO:1331,SEQ ID NO:1432,SEQ ID NO:1052,SEQIDNO:lO91,SEQID
NO:1421,SEQ ID NO: 1069,SEQ ID NO:1005,SEQ ID NO: 1007,SEQ ID NO:1166, SEQ ID NO:1177,SEQ ID NO:1193,SEQ ID NO:1206,SEQ ID NO:1207,SEQ ID
NO:1304,SEQ ID NO:1305,SEQ ID NO:1346,SEQ ID NO:1348,SEQ ID NO:1350, SEQ ID NO: 1032,SEQ ID NO:1053,SEQ ID NO:1081,SEQ ID NO:1124,SEQ ID
NO: 1382,SEQ ID NO: 1437,SEQ ID NO:1263,SEQ ID NO:90,SEQ ID NO: 15,SEQ
ID NO:913,SEQ ID NO:227,SEQ ID NO:79,SEQ ID NO:l91, SEQ ID NO:238,SEQ
ID NO:274,SEQ ID NO:27~SEQ ID NO:258,SEQ ID NO:295,SEQ ID NO:lO,SEQ
ID NO:160,SEQ ID NO:225,SEQ ID NO:964,SEQ ID NO: 166,SEQ ID NO:56,SEQ
ID NO:980,SEQ ID NO:903.SEQ ID NO: 261,SEQ ID NO: 71,SEQ ID NO: 955,SEQ
ID NO:361,SEQIDNO:58,SEQIDNO:114,SEQ ID NO: 940,SEQ ID NO: 960,SEQ
ID NO: 144,SEQ ID NO: 362~SEQ ID NO:40.SEQ ID NO:285,SEQIDNO:ll,SEQ

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 ID NO:161,SEQID NO:974,SEQID NO:lll,SEQID NO:316,SEQID NO:257, SEQID NO:78,and SEQID NO:966.
In yet a fi~rther embodiment, the H. pylori cell envelope polypeptide or a fr~ment - thereof is an H. pylori outer membrane polypeptide or a fragment thereof encoded by the S nucleic acid selected from the group consisting of SEQID NO:1173,SEQID NO:1405, SEQID NO:1406,SEQID NO:1410,SEQID NO:1086,SEQID NO:1322~SEQID
NO:1266,SEQID NO:1282,SEQID NO:1271,SEQID NO:1208,SEQID NO:1126, SEQID NO:1270,SEQ ID NO:1278,SEQID NO:1419,SEQID NO:1125,SEQID
NO:1181,SEQID NO:1416,SEQID NO:1096,SEQID NO:1082,SEQID NO:1146, SEQID NO:1145,SEQID NO:1108,SEQID NO:1148,SEQ ID NO:1337,SEQID
NO:1338,SEQID NO:1424,SEQID NO:1000,SEQID NO:1027,SEQ~D NO:1175, SEQID NO:1330,SEQID NO:352,SEQID NO:981,SEQID NO:158,SEQID NO:
989,SEQID NO:963,SEQ ID NO:48,SEQID NO:68,SEQID NO:135,SEQ ID NO:
910,SEQ ID NO:236,SEQID NO:241,SEQID NO:949,SEQID NO:945,SEQID
NO:207,and SEQID NO:977.
Particularly ~ Ç~cd is an isolated nucleic acid comprising a nucleotide sequenceencoding an H. pylori cytoplasmic polypeptide or a fragment thereof. Such nucleic acid is selected from the group con~i~tin~ ofSEQID NO:1147,SEQID NO:1288,SEQID NO:
1324,SEQ ID NO:1363,SEQ ID NO: 997,SEQ ID NO:1015,SEQ ID NO: 1084,SEQ
ID NO: 1094,SEQ ID NO:lO99,SEQ ID NO:1229,SEQID NO:1250,SEQID NO:
1268,SEQID NO:1293,SEQID NO:1339,SEQID NO:1408,SEQID NO:1429,SEQ
ID NO:1434,SEQ ID NO:1228,SEQ ID NO:1031,SEQ ID NO:1034,SEQ ID NO:
1008,SEQ ID NO:1061,SEQID NO:1064,SEQID NO:ll91,SEQ ID NO:1217,SEQ
ID NO:1365,SEQ ID NO:1394,SEQ ID NO:1414,SEQID NO:1415,SEQID NO:
1435~SEQID NO:1058,SEQID NO: 1059,SEQ ID NO: 1080,SEQ ID NO: 1128,SEQ
ID NO:1133,SEQ ID NO:1211,SEQ ID NO:1252,SEQ ID NO:1253,SEQ ID NO:
1286,SEQ ID NO:1289,SEQID NO:1291,SEQID NO:1303,SEQID NO:1396,SEQ
ID NO:996,SEQID NO:1095,SEQ ID NO:1156,SEQID NO:1158,SEQ ID NO:1159, SEQ ID NO:1277,SEQ ID NO: 1038,SEQID NO: 1257,SEQ ID NO: 1357,SEQ ID
NO:1436,SEQID NO:1047,SEQID NO:1055,SEQID NO:SEQID NO:1141,SEQ
ID NO:1227,SEQID NO:1327,SEQID NO:1412,SEQ ID NO:1003,SEQID NO:
1087,SEQID NO:1116,SEQID NO:1130,SEQID NO:1132,SEQID NO:1185,SEQ
IDNO:1188~SEQIDNO:1198,SEQIDNO:1218,SEQIDNO:1244,SEQIDNO:
1306,SEQID NO:1325,SEQID NO:1397,SEQID NO:1398,SEQID NO:1407,SEQ
ID NO:1433,SEQID NO:1216,SEQID NO: 1239,SEQID NO:1362,SEQID NO:
1017,SEQID NO:lOl9,SEQID NO:1360,SEQID NO:1423,SEQID NO:1425,SEQ
ID NO:1374,SEQ ID NO:1028,SEQ ID NO:1037,SEQ ID NO:1077,SEQ ID NO:
1115,SEQ ID NO:1232,SEQ ID NO:1241,SEQID NO:1267,SEQID NO:1163,SEQ
ID NO:1068,SEQID NO:1025,SEQID NO:1042,SEQID NO:1046,SEQID NO:

SUB5TITUTE SH EET (RULE 26i) CA 0222339~ 1997-12-03 1056, SEQ ID NO: 1039, SEQ ID NO: 1072, SEQ ID NO: 1073, SEQ ID NO: 1092, SEQ
ID NO:llO0, SEQ ID NO: 1102, SEQ ID NO: 1103, SEQ ID NO: 1104, SEQ ID NO:
1111, SEQ ID NO:lll9, SEQ ID NO: 1136, SEQ ID NO: 1137, SEQ ID NO:1140, SEQ
ID NO: 1142. SEQ ID NO: 1233, SEQ ID NO: 1238, SEQ ID NO: 1243, SEQ ID NO:
1245, SEQ ID NO: 1247, SEQ ID NO: 1249, SEQ ID NO: 1261, SEQ ID NO: 1269, SEQ
ID NO: 1279, SEQ ID NO: 1284, SEQ ID NO: 1290, SEQ ID NO: 1297, SEQ ID NO:
1328, SEQ ID NO: 1370, SEQ ID NO: 1372, SEQ ID NO: 1377, SEQ ID NO: 1383, SEQ
ID NO: 1384, SEQ ID NO: 1385, SEQ ID NO: 1388, SEQ ID NO: 1401, SEQ ID NO:
1402, SEQ ID NO: 1418, SEQ ID NO: 1420, SEQ ID NO: 1427, SEQ ID NO: 1070, SEQ
ID NO:1151, SEQ ID NO: 1176, SEQ ID NO:999, SEQ ID NO: 1006, SEQ ID NO: 1012, SEQ ID NO: 1018, SEQ ID NO: 1030, SEQ ID NO: 1033, SEQ ID NO: 1041, SEQ ID
NO: 1049, SEQ ID NO: 1054, SEQ ID NO: 1057, SEQ ID NO:1090, SEQ ID NO: 1097, SEQ ID NO: 1129, SEQ ID NO: 1139, SEQ ID NO: 1143, SEQ ID NO: 1152, SEQ ID
NO: 1153, SEQ ID NO: 1155, SEQ ID NO: 1161, SEQ ID NO: 1162, SEQ ID NO: 1169, SEQ ID NO:11 70, SEQ ID NO:11 71, SEQ ID NO:11 80, SEQ ID NO:11 94, SEQ ID
NO:ll95, SEQ ID NO: 1199, SEQ ID NO: 1200, SEQ ID NO: 1201, SEQ ID NO: 1202, SEQ ID NO: 1205, SEQ ID NO: 1312, SEQ ID NO: 1336, SEQ ID NO: 1349, SEQ ID
NO: 1355, SEQ ID NO: 1359, SEQ ID NO: 1413, SEQ ID NO: 1426, SEQ ID NO: 1430, SEQ ID NO: 882, SEQ ID NO: 382, SEQ ID NO: 130, SEQ ID NO: 230, SEQ ID NO:
269, SEQ ID NO: 312, SEQ ID NO: 211, SEQ ID NO: 959, SEQ ID NO: 938, SEQ ID
NO:llO, SEQ ID NO: 244, SEQ ID NO: 328, SEQ ID NO: 235, SEQ ID NO: 315, SEQ
IDNO: 296, SEQ IDNO: 976, SEQ IDNO: 321, SEQ ID NO: 43, SEQ ID NO: 281, SEQ
IDNO: 326, SEQ ID NO: 272, SEQ ID NO: 344, SEQ ID NO: 139, SEQ ID NO: 30, SEQ
ID NO: 220, SEQ ID NO: 364, SEQ ID NO: 369, SEQ ID NO: 372, SEQ ID NO:991, SEQ ID NO: 128, SEQ ID NO: 347, SEQ ID NO: 52, SEQ ID NO: 12, SEQ ID NO: 247, SEQ ID NO: 64, SEQ ID NO:101, SEQ ID NO: 338, SEQ ID NO: 83, SEQ IDNO: 46, SEQ ID NO: 348, SEQ IDNO: 223, SEQ IDNO: 39, SEQ IDNO: 232, SEQ ID NO: 168, SEQ ID NO: 65, SEQ IDNO: 952, SEQ ID NO: 341, SEQ ID NO: 69, SEQ ID NO: 924, SEQ ID NO: 4, SEQ ID NO: 197, SEQ ID NO: 313, SEQ ID NO: 119, SEQ ID NO: 188, SEQ ID NO: 956, SEQ ID NO: 935, SEQ ID NO: 246, SEQ ID NO: 196, SEQ ID NO:
376, SEQ ID NO: 172, SEQ ID NO: 25, SEQ ID NO: 126, SEQ ID NO:951, SEQ ID NO:
147, SEQ ID NO: 895, SEQ ID NO: 14, SEQ ID NO: 154, SEQ ID NO: 277, SEQ ID NO:
363, SEQ ID NO: 342, SEQ ID NO: 378, SEQ ID NO: 130, SEQ ID NO: 198, SEQ ID
NO: 243, SEQ ID NO:l9, SEQ ID NO:9, SEQ ID NO: 149, SEQ ID NO: 167, SEQ ID
NO: 349, SEQ ID NO: 209, SEQ ID NO: 990, SEQ ID NO: 185, SEQ ID NO: 883, SEQ
ID NO: 8, SEQ ID NO: 887, SEQ ID NO: 350, SEQ ID NO: 987, SEQ ID NO: 63, SEQ ID
NO: 249, SEQ ID NO: 118, SEQ ID NO: 132, SEQ ID NO: 47, SEQ ID NO: 106, SEQ ID
NO: 324, SEQ ID NO: 155, SEQ ID NO: 121, SEQ ID NO: 153, SEQ ID NO: 87, SEQ ID
NO: 986. SEQ ID NO: 262, SEQ ID NO: 333, SEQ ID NO: 36, SEQ ID NO: 982, SEQ ID

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTfUS96/09122 NO:180,SEQ ID NO: 84,SEQ ID NO:900,SEQIDNO:20,SEQIDNO:7,SEQ ID NO:
61,SEQID NO:253,SEQ ID NO:120, SEQ ID NO:268, SEQ ID NO: 299,SEQ ID NO:
942,SEQ ID NO: 173,SEQ ID NO: 187,SEQ ID NO: 187,SEQ ID NO:234,SEQ ID
NO:112,SEQ ID NO:324,SEQ ID NO:971,SEQ ID NO:62,SEQ ID NO:308,SEQ ID
S NO: 74,SEQ ID NO:l, SEQID NO: 266,SEQ ID NO: 337,SEQ ID NO: 93,SEQ ID NO:
44,SEQ ID NO: 335,SEQIDNO:368,SEQID NO: 208,SEQIDNO:358,SEQ ID NO:
923,SEQ ID NO:310,SEQ ID NO:26,SEQ ID NO:2'79,SEQ ID NO: 890,SEQID NO:
325,SEQ ID NO:109, SEQ ID NO: 143,SEQ ID NO: 918,SEQ ID NO: 252,SEQ ID
NO:953,SEQ ID NO:902,SEQIDNO:174,SEQ ID NO:73,SEQIDNO:898,SEQID
NO:300,SEQIDNO:356,SEQIDNO:298,SEQIDNO:354,SEQ ID NO:138,SEQ
ID NO: 319,SEQ ID NO: 80, SEQ ID NO: 933,SEQ ID NO:891, SEQ ID NO: 366,SEQ
ID NO: 113,SEQIDNO:320,SEQ ID NO: 915,SEQ ID NO:351,SEQIDNO:162, SEQ ID NO:965,SEQ ID NO:67,SEQ ID NO:314,SEQ ID NO:904,SEQ ID NO: 345, SEQ ID NO: 374,SEQ ID NO: 962,SEQ ID NO: 270,SEQ ID NO: 186,SEQIDNO:60, SEQ ID NO:379,SEQID NO: 889,SEQ ID NO: 967,SEQ ID NO:973,SEQ ID NO:
280,SEQIDNO:170,SEQ ID NO:985j and SEQ ID NO:932.
In one embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in energy conversion encoded by the nucleic acid selected from the group con~ ting of SEQ ID NO:1147,SEQ ID NO:
1288,SEQ ID NO:1324,SEQ ID NO:1363,SEQ ID NO: 882,SEQ ID NO:382,SEQ ID
NO:130, and SEQ ID NO:230.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in amino acid metabolism encoded by the nucleic acid selected from the group con~i~ting of SEQ ID NO:997,SEQ
ID NO:lOlS,SEQ ID NO:1084,SEQ ID NO:1094,SEQ ID NO:lO99,SEQ ID NO:
1229,SEQ ID NO:1250,SEQ ID NO:1268,SEQ ID NO:1293,SEQ ID NO: 1339,SEQ
ID NO:1408,SEQ ID NO:1429,SEQ ID NO:1434,SEQ ID NO:1228,SEQ ID NO:
1031,SEQIDNO:1034,SEQIDNO:1008,SEQIDNO:269,SEQIDNO:312,SEQ ID
NO:211,SEQ ID NO:959,SEQIDNO:938,SEQ ID NO:llO,SEQ ID NO:244,SEQ
ID NO: 328,SEQ ID NO:235~SEQ ID NO:315,SEQ ID NO:296,SEQIDNO:976, SEQ ID NO:321,SEQ ID NO:43,SEQ ID NO:281,SEQ ID NO:326, and SEQ ID NO:
272.
In yet another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in nucleotide metabolism encoded by the nucleic acid selected from the group consisting of SEQ ID NO:1061,SEQ
ID NO:1064,SEQIDNO:ll91,SEQIDNO:1217,SEQ ID NO:1365,SEQIDNO:
1394,SEQIDNO:1414,SEQ ID NO:1415,SEQIDNO:1435,SEQIDNO:1058,SEQ
IDNO:1059,SEQIDNO:344,SEQ ID NO:139,SEQ ID NO:30,SEQ ID NO:220, SU BSTITUTE 5HEET(RULE 26) CA 0222339~ 1997-12-03 SEQIDNO: 364, SEQIDNO: 369, SEQIDNO: 372, SEQ ID NO:991, SEQ ID NO:
I28, SEQIDNO: 347, and SEQID NO: 52.
In yet a further embodiment, the H. pylori cytoplasmic polypeptide or a fragmentthereof is an H. pylori polypeptide or a fragment thereof involved in carbohydrate metabolism encoded by the nucleic acid selected from the group consisting of SEQIDNO:
1080, SEQ ID NO: 1128, SEQID NO: 1133, SEQ ID NO: 1211, SEQ ID NO: 1252, SEQ
IDNO: 1253, SEQIDNO: 1286, SEQIDNO: 1289, SEQrDNO: 1291, SEQ ID NO:
1303, SEQ ID NO: 1396, SEQ ID NO: 996, SEQID NO: 12, SEQ ID NO: 247, SEQ ID
NO: 64, SEQ ID NO:101, SEQ ID NO: 338, SEQ ID NO: 83, SEQ ID NO: 46, SEQ ID
NO: 348, SEQ ID NO: 223, SEQ ID NO: 39, SEQ ID NO: 232, and SEQ ID NO: 168.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in cofactor metabolism encoded by the nucleic acid selected from the group consisting of SEQID NO:lO9S, SEQID NO:
1156, SEQID NO: 1158, SEQID NO: 1159, SEQIDNO: 1277, SEQIDNO: 1038, SEQ
ID NO: 65, SEQID NO: 952, SEQ ID NO: 341, SEQIDNO: 69, SEQIDNO: 924, and SEQIDNO: 4.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in lipid metabolism encoded by the nucleic acid selected from the group consisting of SEQIDNO: 1257, SEQ ID NO:1357, SEQ ID NO: 1436, SEQ ID NO: 197, SEQ ID NO: 313, and SEQIDNO:ll9.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fr~ment thereof involved in mRNA translation and ribosome biogenesis encoded by the nucleic acid selected from the group consisting of SEQ
ID NO: 1047, SEQ ID NO: 1055, SEQ ID NO:SEQ ID NO:1141,SEQ ID NO: 1227, SEQ ID NO: 1327, SEQ ID NO: 1412, SEQID NO: 188, SEQIDNO: 956, SEQID NO:
935, SEQ ID NO: 246, SEQ ID NO: 196, and SEQ ID NO: 376.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in genome replication, transcription, recombination and repair encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1003, SEQ ID NO: 1087, SEQ ID NO: 1116, SEQIDNO: 1130, SEQ ID NO: 1132, SEQ ID NO: 1185, SEQIDNO:1188,SEQ ID NO: 1198, SEQ ID
NO: 1218, SEQ ID NO: 1244, SEQ ID NO: 1306, SEQ ID NO: 1325, SEQ ID NO: 1397, SEQIDNO: 1398, SEQ ID NO: 1407, SEQ ID NO: 1433, SEQ ID NO: I72, SEQ ID NO:
25, SEQ ID NO: 126, SEQ ID NO: 951, SEQ ID NO: 147, SEQ ID NO: 895, SEQIDNO:
14, SEQID NO: 154, SEQID NO: 277, SEQID NO: 363, SEQ ID NO: 342, SEQ ID NO:
378, SEQ ID NO: 130, SEQ ID NO: 198, SEQID NO: 243, SEQ ID NO: 19, and SEQ ID
NO: 9.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in outer membrane or cell wall SUBSTITUTE SHEET (RULE ~6) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 biosynthesis encoded by the nucleic acid sel~ted from the group consisting of SEQ ID NO:
1216,SEQID NO: 1239, SEQIDNO: 1362, SEQIDNO: 1017, SEQ ID NO:1019, SEQ
ID NO: 1360, SEQID NO: 149,SEQ ID NO: 167, SEQID NO: 349, SEQ ID NO: 209, - SEQ ID NO:990, SEQ ID NO: 185,SEQ ID NO:883,and SEQIDNO:8.
In yet another embodiment, the H. pylori cytoplasmic polypeptide is an H. pylorichaperone polypeptide or a fragment thereof encoded by the nucleic acid selected from the group consisting of SEQ ID NO:1423,SEQ ID NO: 1425, SEQIDNO: 1374, SEQID
NO: 887, SEQ ID NO: 350,and SEQ ID NO: 987.
Particularly prefelTed is an isolated nucleic acid comprising a nucleotide sequence encoding an H. pylori secreted or periplasmic polypeptide or a fra~ment thereof. Such nucleic acid is selected from the group consisting of SEQ ID NO: 1004, SEQ ID NO: 1138, SEQ ID NO: 1067, SEQ ID NO: 1078, SEQ ID NO: 1314, SEQIDNO: 1319, SEQ ID
NO: 1378, SEQ ID NO: 1105, SEQ ID NO: 1114, SEQ ID NO: 1118? SEQ ID NO: 1120, SEQ ID NO: 1123, SEQ ID NO: 1127, SEQ ID NO: 1212, SEQID NO: 1223, SEQ ID
NO: 1225, SEQ ID NO: 1246, SEQ ID NO: 1248, SEQIDNO: 1259, SEQIDNO: 1264, SEQ ID NO: 1265, SEQ ID NO: 1281, SEQ ID NO: 1285, SEQ ID NO: 1294, SEQ ID
NO: 1298, SEQ ID NO: 1299, SEQ ID NO: 1315, SEQ ID NO: 1316, SEQ ID NO: 1317, SEQIDNO: 1318, SEQ ID NO: 1344, SEQ ID NO: 1351, SEQID NO: 1353, SEQID
NO: 1373, SEQIDNO: 1380, SEQ ID NO: 1387, SEQ ID NO: 1389, SEQ ID NO: 1393, SEQID NO: 1411, SEQ ID NO: 1428, SEQ ID NO: 1431, SEQIDNO: 1439, SEQ ID
NO: 1043, SEQ ID NO: 1183, SEQIDNO:l 184, SEQIDNO: 1196, SEQIDNO: 1197, SEQ ID NO: 1203, SEQID NO: 995, SEQ ID NO: 998, SEQIDNO:lOOl,SEQIDNO:
1022, SEQ ID NO: 1023, SEQ ID NO: 1029, SEQ ID NO: 1040, SEQ ID NO: 1051, SEQ
ID NO: 1062, SEQ ID NO: 1154, SEQ ID NO: 1320, SEQID NO: 1075, SEQ ID NO:
11~)6, SEQ ID NO:llO9, SEQ ID NO: 1134, SEQ ID NO: 1221, SEQ ID NO: 1226, SEQ
IDNO: 1235, SEQ ID NO: 1301, SEQ ID NO: 1311, SEQ ID NO: 1326, SEQ ID NO:
1341, SEQIDNO: 1354, SEQ ID NO: 1364, SEQ ID NO: 1366, SEQ ID NO: 1376, SEQ
IDNO: 1391, SEQIDNO: 1395, SEQ ID NO: 1445, SEQ ID NO: 1079, SEQ ID NO:
1186, SEQIDNO:lOlO,SEQ ID NO: 1016, SEQ ID NO: 1172, SEQ ID NO: 1174, SEQ
IDNO: 117, SEQIDNO: 254, SEQIDNO: 24, SEQIDNO: 242, SEQ ID NO:950,SEQ
ID NO: 263, SEQ ID NO: 286, SEQ ID NO: 947, SEQ ID NO:51,SEQ ID NO: 177, SEQ
IDNO: 156, SEQ ID NO:l90,SEQ ID NO: 375, SEQ ID NO: 222, SEQ ID NO: 21, SEQ
IDNO: 912, SEQ ID NO: 148, SEQ ID NO: 202, SEQ ID NO: 224, SEQ ID NO: 112, SEQ ID NO: 32, SEQ ID NO: 339, SEQIDNO: 182, SEQ ID NO: 228, SEQ ID NO: 152, SEQ ID NO: 219, SEQ ID NO: 137, SEQ ID NO: 318, SEQ ID NO: 141, SEQ ID NO:
165, SEQ ID NO: 334, SEQ ID NO: 13, SEQ ID NO: 297, SEQ ID NO: 35, SEQ ID NO:
216, SEQ ID NO: 908, SEQIDNO: 124, SEQIDNO: 75, SEQID NO: 927, SEQIDNO:
221,SEQIDNO: 178, SEQ ID NO: 169, SEQ ID NO: 293, SEQ ID NO: 289, SEQ ID
NO: 926, SEQIDNO: 948, SEQID NO: 115, SEQID NO: 251, SEQ ID NO: 345, SEQ

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 ID NO:17, SEQ ID NO: 920, SEQ ID NO:95, SEQ ID NO: 86, SEQ ID NO: 360, SEQ ID
NO: 271, SEQ ID NO: 970, SEQ ID NO: 288, SEQ ID NO: 282, SEQ ID NO: 98, SEQ ID
NO: 29, SEQ ID NO: 317, SEQ ID NO: 343, SEQ ID NO: 291? SEQ ID NO: 108, SEQ ID
NO: 377, SEQ ID NO: 305, SEQ ID NO: 305, SEQ ID N O-100, SEQ ID NO: 988, SEQ
S ID NO: 212, SEQ ID NO: 884, SEQ ID NO: 37, SEQ ID NO: 968, SEQ ID NO: 975, SEQ
ID NO: 237, SEQ ID NO: 335, SEQ ID NO: 260, SEQ ID NO: 370, SEQ ID NO: 91, SEQ
ID NO: 276, SEQ ID NO: 311, SEQ ID NO: 173, SEQ ID NO:102, SEQ ID NO: 304, SEQ ID NO: 380, SEQ ID NO: 127, SEQ ID NO: 993, SEQ ID NO: 925, SEQ ID NO:
181, and SEQ ID NO: 171.
Particularly preferred is an isolated nucleic acid comprising a nucleotide sequence encoding an H. pylori surface or membrane polypeptide or a fragment thereof. Such nucleic acid is selected from the group consisting of SEQ ID NO: 1060, SEQ ID NO: 1110, SEQ ID NO: 1112, SEQ ID NO: 1230, SEQ ID NO: 1260, SEQ ID NO: 1280, SEQ ID
NO: 1292, SEQ ID NO: 1296, SEQ ID NO: 1307, SEQ ID NO: 1442, SEQ ID NO: 1444, SEQ ID NO: 1122, SEQ ID NO: 1254, SEQ ID NO: 1256, SEQ ID NO: 1272, SEQ ID
NO: 1275, SEQ ID NO: 1309, SEQ ID NO: 1313, SEQ ID NO: 1347, SEQ ID NO: 1352, SEQ ID NO: 1356, SEQ ID NO: 1438, SEQ ID NO: 1441, SEQ ID NO: 1009, SEQ ID
NO: 1026, SEQ ID NO: 1048, SEQ ID NO: 1063, SEQ ID NO: 1190, SEQ ID NO: 1083, SEQ ID NO: 1113, SEQ ID NO: 1222, SEQ ID NO: 1295, SEQ ID NO: 1343, SEQ ID
NO: 1392,SEQIDNO: 1443,SEQIDNO: 1085,SEQIDNO: 1093,SEQIDNO: 1117, SEQ ID NO: 1121, SEQ ID NO: 1131, SEQ ID NO: 1287, SEQ ID NO: 1440, SEQ ID
NO: 1209, SEQ ID NO: 1342, SEQ ID NO: 1381, SEQ ID NO: 1390, SEQ ID NO: 1409, SEQ ID NO: 1035, SEQ ID NO: 1014, SEQ ID NO: 1088, SEQ ID NO: 1242, SEQ ID
NO: 1178, SEQ ID NO: 1089, SEQ ID NO: 1340, SEQ ID NO: 1074, SEQ ID NO: 1107, SEQ ID NO: 1204, SEQ ID NO: 1066, SEQ ID NO: 381, SEQ ID NO: 229, SEQ ID NO:
323, SEQ ID NO: 371, SEQ ID NO: 284, SEQ ID NO: 116, SEQ ID NO: 3, SEQ ID NO:
6, SEQ ID NO: 907, SEQ ID NO: 193, SEQ ID NO: 145, SEQ ID NO: 59, SEQ ID NO:
322, SEQ ID NO: 94, SEQ ID NO: 306, SEQ ID NO: 939, SEQ ID NO: 205, SEQ ID NO:
123, SEQ ID NO: 906, SEQ ID NO: 928, SEQ ID NO: 346, SEQ ID NO: 129, SEQ ID
NO: 307, SEQ ID NO: 133, SEQ ID NO: 131, SEQ ID NO: 886, SEQ ID NO: 179, SEQ
ID NO: 104, SEQ ID NO: 213, SEQ ID NO: 359, SEQ ID NO: 140, SEQ ID NO: 146, SEQ ID NO: 327, SEQ ID NO: 365, SEQ ID NO: 33, SEQ ID NO: 331, SEQ ID NO: 175, SEQ ID NO: 200, SEQ ID NO: 292, SEQ ID NO: 23, SEQ ID NO: 336, SEQ ID NO: 301, SEQ ID NO: 28, SEQ ID NO: 941, SEQ ID NO: 103, SEQ ID NO: 231, SEQ ID NO: 176, SEQ ID NO: 31, SEQ ID NO: 917, SEQ ID NO: 151, SEQ ID NO: 922, SEQ ID NO: 265, SEQ ID NO: 142, SEQ ID NO: 259, SEQ ID NO: 122, SEQ ID NO: 206, SEQ ID NO: 96, SEQ ID NO: 353, SEQ ID NO: 38, SEQ ID NO: 89, SEQ ID NO: 77, SEQ ID NO: 954, SEQ ID NO: 264, SEQ ID NO: 937, SEQ ID NO: 226, SEQ ID NO: 283, SEQ ID NO: 88, SUBSTITUTE SHEET (RULE 26) -CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 SEQ ID NO:125,SEQ ID NO:183,SEQIDNO:195,SEQIDNO:81,SEQIDNO:901, SEQIDNO:82,SEQIDNO:42,SEQ ID NO: 881, and SEQIDNO:885.
In one embodiment, the H. pylori surface or mernbrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least one membrane sp~nnin~ region encoded by the nucleic acid selected from the group consisting of SEQID
. NO:1060,SEQIDNO:lllO,SEQIDNO:1112,SEQ ID NO:1230,SEQ ID NO:1260, SEQ ID NO:1280,SEQIDNO:1292,SEQIDNO:1296,SEQIDNO:1307,SEQID
NO:1442,SEQIDNO:1444,SEQ ID NO:381,SEQIDNO:229,SEQ ID NO:323,SEQ
IDNO:371,SEQ ID NO:284,SEQ ID NO:116,SEQ ID NO:3,SEQ ID NO:6,SEQ ID
NO:907,SEQ ID NO:193,SEQIDNO:145,SEQIDNO:59,SEQ ID NO:322,SEQID
NO:94,SEQ ID NO:306, and SEQ ID NO:881.
In another embodiment, the H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least two membrane spanning regions encoded by the nucleic acid selected from the group conci~tin~
ofSEQ ID NO:1122,SEQ ID NO:1254,SEQ ID NO:1256,SEQ ID NO:1272,SEQ ID
NO:1275,SEQ ID NO:1309,SEQ ID NO:1313,SEQIDNO:1347,SEQ ID NO:1352, SEQ ID NO:1356,SEQ ID NO: 1438,SEQ ID NO: 1441,SEQ ID NO:1009, SEQID
NO: 1026,SEQIDNO:1048,SEQIDNO:1063,SEQIDNO:ll90,SEQ ID NO:939, SEQ ID NO: 205,SEQ ID NO:123,SEQ ID NO:906,SEQ ID NO:928,SEQIDNO:
346,SEQIDNO:129,SEQ ID NO:307,SEQ ID NO: 133,SEQID NO: 131,SEQID
NO: 886,SEQ ID NO: 179,SEQ ID NO:104,SEQ ID NO:213,SEQ ID NO: 359,SEQ
ID NO: 140,SEQ ID NO: 146,SEQ ID NO: 327, and SEQ ID NO: 365.
In yet another embodiment, the H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least three membrane sp~nning regions encoded by the nucleic acid selected from the group consisting ofSEQ ID NO: 1083,SEQ ID NO:1113,SEQ ID NO: 1222,SEQ ID NO: 1295,SEQ ID
NO: 1343,SEQ ID NO: 1392,SEQ ID NO: 1443,SEQ ID NO: 33,SEQ ID NO: 331,SEQ
ID NO: 175,SEQ ID NO: 200,SEQ ID NO:292,SEQ ID NO:23, and SEQ ID NO:336.
In yet a further embodiment, the H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least four membrane sp~nning regions encoded by the nucleic acid selected from the group consisting ofSEQ ID NO:1085,SEQIDNO:1093,SEQ ID NO: 1117,SEQ ID NO: 1121,SEQ ID
NO:1131,SEQ ID NO:1287,SEQ ID NO:1440, SEQ ID NO: 1209,SEQ ID NO:301, SEQ ID NO:28,SEQIDNO:941,SEQIDNO:103,SEQIDNO:231,SEQIDNO:176, SEQIDNO:31,SEQID NO: 917,SEQ ID NO:lSl,and SEQID NO: .922.
In another embodiment, the H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least five membrane.spanning regions encoded by the nucleic acid selected from the group consisting ofSEQ ID NO: 1342,SEQID NO: 1381,SEQIDNO:1390,SEQID NO: 1409,SEQID

SUBSTITUTESHEET(RULE26~

CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 NO: 1035, SEQIDNO: 265, SEQ ID NO: 142, SEQ ID NO: 259, SEQ ID NO: 122, SEQ
IDNO: 206,and SEQ ID NO: 885.
In another embotlim~nt, the H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fiagment thereof having at least six membrane spanning regions encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1014, SEQ ID NO: 1088, SEQ ID NO: 1242, SEQ ID NO: 1178, SEQ ID
NO: 96, SEQ ID NO: 353, SEQ ID NO: 38, SEQ ID NO: 89, SEQ ID NO: 77, SEQ ID NO:
954, SEQ ID NO: 264.
In another emborliment, the H. pylori surface or membrane polypeptide or a 10 fragment thereof is an H. pylori polypeptide or a fragment thereof having at least seven membrane spanning regions encoded by the nucleic acid selected from the group con~i~tin~
of SEQ ID NO: 1089, SEQ ID NO: 1340, SEQ ID NO: 1074, SEQ ID NO: 1107, SEQ ID
NO: 1204, SEQ ID NO: 1066, SEQIDNO: 937, SEQ ID NO: 226, SEQ ID NO: 283, SEQ
ID NO: 88, SEQ ID NO: 125, SEQ ID NO: 183, SEQ ID NO: 195, SEQ ID NO: 81, SEQ
15 ID NO: 901, SEQ ID NO: 82,and SEQ ID NO: 42.
Particularly ~ r~ d is a punfied or isolated H. pylori cell envelope polypeptide or a fiagment thereof, wherein the polypeptide is selected from the group consisting of SEQ
ID NO: 147.1, SEQ ID NO: 1472, SEQ ID NO: 1487, SEQ ID NO:lSOl,SEQIDNO:
1522, SEQ ID NO: 1552, SEQ ID NO: 1586, SEQ ID NO: 1727, SEQ ID NO: 1601, SEQ
20 ID NO: 1638, SEQ ID NO: 1643, SEQ ID NO: 1812, SEQ ID NO: 1830, SEQ ID NO:
1850,SEQIDNO:1854,SEQIDNO:1851,SEQ ID NO: 1640, SEQ ID NO. 1453, SEQ
ID NO: 1664, SEQ ID NO: 1665, SEQ ID NO: 1666, SEQ ID NO: 1685, SEQ ID NO:
1687, SEQ ID NO: 1688, SEQ ID NO: 1675, SEQ ID NO: 1702, SEQ ID NO: 1713, SEQ
ID NO: 1600, SEQ ID NO: 1671, SEQIDNO: 1691, SEQ ID NO: 1615, SEQ ID NO:
25 1616. SEQ ID NO: 1855, SEQ ID NO: 1595, SEQ ID NO: 1633, SEQ ID NO: 1608, SEQID NO: 1611, SEQ ID NO: 1751, SEQ ID NO: 1772, SEQ ID NO: 1774, SEQ ID NO:
1780. SEQ ID NO: 1783, SEQ ID NO: 1796~ SEQ ID NO: 1809, SEQ ID NO: 1826, SEQ
ID NO: 1868, SEQ ID NO: 1734, SEQ ID NO: 1786, SEQ ID NO: 1819, SEQ ID NO:
1630, SEQ ID NO: 1706, SEQ ID NO: 1709, SEQ ID NO: 1495, SEQ ID NO: 1724, SEQ
30 ID NO: 16707 SEQ ID NO: 1725, SEQ ID NO: 1661, SEQIDNO: 1873, SEQ ID NO:
1753, SEQ ID NO: 1759, SEQ ID NO: 1761, SEQ ID NO: 1782, SEQ ID NO: 1883, SEQ
IDNO: 1503, SEQ ID NO: 1542, SEQ ID NO: 1872, SEQ ID NO: 1520, SEQ ID NO:
1456, SEQ ID NO: 1458, SEQ ID NO: 1617. SEQ ID NO: 1628, SEQ ID NO: 1644, SEQ
IDNO: 1657, SEQ ID NO: 1658, SEQ ID NO: 1755, SEQ ID NO: 1756, SEQ ID NO:
35 1797, SEQ ID NO: 1799, SEQ ID NO: 1801, SEQ ID NO: 1483, SEQ ID NO: 1504, SEQID NO: 1532, SEQ ID NO: 1575, SEQ ID NO: 1833, SEQ ID NO: 1888, SEQIDNO:
1714, SEQIDNO: 1624, SEQ ID NO: 1856, SEQ ID NO: 1857, SEQ ID NO: 1861, SEQ
IDNO: 1537, SEQ ID NO: 1773, SEQ ID NO: 1717, SEQ ID NO: 1733, SEQIDNO:
1722, SEQIDNO: 1659, SEQID NO: 1577, SEQ ID NO: 1721, SEQ ID NO: 1729, SEQ

SUBSTITUTE SH E T (RULE 26) , CA 0222339~ 1997-12-03 W O 96/1~E93 PCT~US96/09122 ID NO:1870,SEQ ID NO:1576,SEQ ID NO: 1632,SEQ ID NO: 1867,SEQ ID NO:
1547,SEQ ID NO:1533,SEQID NO:1597,SEQ ID NO:1596,SEQ ID NO:1559,SEQ
ID NO:1599,SEQ ID NO: 1788,SEQ ID NO:1789,SEQ ID NO:1875,SEQ ID NO:
- 1451,SEQID NO:1478,SEQ ID NO:1626,SEQ ID NO: 1781,SEQ ID NO:660,SEQ
ID NO: 660,SEQID NO:855,SEQID NO:534,SEQID NO:675,SEQ ID NO:404, - SEQ ID NO: 518,SEQ ID NO: 464,SEQ ID NO: 672,SEQ ID NO: 640,SEQ ID NO:490,SEQ ID NO:755,SEQID NO:389,SEQ ID NO:635,SEQ ID NO:877,SEQ ID
NO:637,SEQ ID NO:477,SEQID NO: 772,SEQ ID NO: 658,SEQ ID NO:463,SEQ
ID NO: 852,SEQ ID NO:503, SEQ ID NO:411, SEQ ID NO: 441,SEQ ID NO: 782, SEQ ID NO:575,SEQ ID NO: 691,SEQ ID NO: 724,SEQ ID NO:452,SEQ ID NO:
386,SEQ ID NO: 497,SEQ ID NO: 712,SEQ ID NO:591,SEQ ID NO:638,SEQ ID
NO: 740,SEQ ID NO: 697,SEQID NO:569,SEQ ID NO: 470,SEQ ID NO: 700,SEQ
ID NO: 586,SEQ ID NO:823,SEQID NO:627,SEQ]:D NO:627,SEQ ID NO:684, SEQ ID NO: 551,SEQID NO: 478,SEQ ID NO:508,SEQ ID NO:545,SEQ ID NO:
628,SEQ ID NO: 443,SEQ ID NO: 702,SEQ ID NO: 776,SEQ ID NO: 461,SEQ ID
NO: 737,SEQ ID NO:809,SEQID NO:642,SEQ ID NO: 879,SEQ ID NO:773,SEQ
ID NO: 468,SEQID NO:842,SEQ ID NO:788,SEQ ID NO:624,SEQ ID NO: 788, SEQ ID NO:644,SEQID NO:727,SEQID NO:631,SEQID NO:450,SEQ ID NO:
448,SEQ ID NO:653,SEQ ID NO:495,SEQ ID NO:400,SEQ ID NO:541,SEQ ID
NO:673,SEQ ID NO: 482,SEQID NO:622,SEQ ID NO:689,SEQ ID NO:736,SEQ
ID NO:417,SEQID NO:716,SEQ ID NO:762,SEQ ID NO:395,SEQ ID NO: 587, SEQ ID NO:669,SEQ ID NO:758,SEQ ID NO:593,SEQ ID NO:451,SEQ ID NO:
827,SEQ ID NO:502,SEQ ID NO:719,SEQ ID NO:469,SEQ ID NO:715,SEQ ID
NO:847,SEQ ID NO:453,SEQ ID NO:527,SEQ ID NO:652,SEQ ID NO:745,SEQ
ID NO:567,SEQ ID NO:848,SEQID NO:430,SEQID NO:748,SEQID NO: 396, SEQID NO:588,SEQ ID NO:795,SEQ ID NO:523,SEQ ID NO:791,SEQ ID NO:
714,SEQ ID NO:481,SEQ ID NO:765,SEQ ID NO:837,SEQ ID NO:833,SEQ ID
NO:585,SEQ ID NO:865,SEQ ID NO:764,SEQ ID NO: 440,SEQ ID NO:465,SEQ
ID NO:555,SEQ ID NO:526,SEQ ID NO:687,SEQ ID NO:692,SEQ ID NO:693, SEQ ID NO:677,SEQ ID NO:649,SEQID NO:812,SEQ ID NO: 820,SEQ ID NO:
880,SEQ ID NO:S90, SEQID NO:713,SEQ ID NO'750,SEQ ID NO:613,SEQ ID NO:
437,SEQ ID NO: 556,SEQ ID NO:657,SEQ ID NO:402,SEQ ID NO:623,SEQ ID
NO:862,SEQ ID NO:449,SEQ ID NO:690,SEQ ID NO: 424,SEQ ID NO:821,SEQ
ID NO: 432,SEQ ID NO:811,SEQID NO:554, and SEQID NO:809.
In one embodiment, the H. pylori cell envelope polypeptide or a fragment thereof is an H. pylori flagella-associated polypeptide or a fragment thereof selected from the group con~i~ting of SEQ ID NO:1471,SEQ ID NO: 1472,SEQ ID NO:1487,SEQ ID NO:1501, SEQ ID NO:1522,SEQID NO:1552,SEQ ID NO: 1586,SEQ ID NO: 1727,SEQID
NO:1601,SEQID NO:1638,SEQID NO:1643,SEQ]:D NO:1812,SEQ ID NO:1830, SUBSTITUTE SHEET (RULE 26~

CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 SEQ IDNO: 1850, SEQ ID NO: 1854, SEQ ID NO: 1851, SEQ ID NO: 1640. SEQ ID
NO: 660, SEQ ID NO: 660, SEQ ID NO: 855, SEQ ID NO: 534, SEQ ID NO: 675, SEQ
ID NO: 404, SEQ ID NO: 518, SEQ ID NO: 464, SEQ ID NO: 672, SEQ ID NO: 640, SEQ ID NO: 490, SEQ ID NO: 755, SEQ ID NO: 389, SEQ ID NO: 635, SEQ ID NO:
877, SEQ ID NO: 637, SEQ ID NO: 477, SEQ ID NO: 772,and SEQ ID NO: 658 In another embodiment, the H. pylori cell envelope polypeptide or a ~agment thereof is an H. pylori inner membrane polypeptide or a fragment thereof selected from the group con~i~ting of SEQ ID NO: 1453, SEQ ID NO: 1664, SEQ ID NO: 1665, SEQ ID
NO: 1666, SEQ ID NO: 1685, SEQ ID NO: 1687, SEQ ID NO: 1688, SEQ ID NO: 1675, SEQ ID NO: 1702, SEQ ID NO: 1713, SEQ ID NO: 1600, SEQ ID NO: 1671, SEQ ID
NO: 1691, SEQ ID NO: 1615, SEQ ID NO: 1616, SEQ ID NO: 1855, SEQ ID NO: 1595, SEQ ID NO: 1633, SEQ ID NO: 1608, SEQ ID NO: 1611, SEQ ID NO: 1751, SEQ ID
NO: 1772, SEQ ID NO: 1774, SEQ ID NO: 1780. SEQ ID NO: 1783, SEQ ID NO: 1796, SEQ ID NO: 1809, SEQ ID NO: 1826, SEQ ID NO: 1868, SEQ ID NO: 1734, SEQ ID
NO: 1786, SEQ ID NO: 1819, SEQ ID NO: 1630, SEQ ID NO: 1706, SEQ ID NO: 1709, SEQ ID NO: 1495, SEQ ID NO: 1724, SEQ ID NO: 463, SEQ ID NO: 852, SEQ ID NO:
503, SEQ ID NO: 411, SEQ ID NO: 441, SEQ ID NO: 782, SEQ ID NO: 575, SEQ ID
NO: 691, SEQ ID NO: 724, SEQ ID NO: 452, SEQ ID NO: 386, SEQ ID NO: 497, SEQ
ID NO: 712, SEQ ID NO: 591, SEQ ID NO: 638, SEQ ID NO: 740, SEQ ID NO: 697, SEQ ID NO: 569, SEQ ID NO: 470, SEQ ID NO: 700, SEQ ID NO: 586, SEQ ID NO:
823, SEQ ID NO: 627, SEQ ID NO: 627, SEQ ID NO: 684, SEQ IDNO: 551, SEQ ID
NO: 478, SEQ ID NO: 508, SEQ ID NO: 545, SEQ ID NO: 628, SEQ ID NO: 443, SEQ
ID NO: 702, SEQ ID NO: 776, SEQ ID NO: 461, SEQ ID NO: 737, SEQ ID NO: 809, SEQ IDNO: 642, SEQ IDNO: 879, SEQ IDNO: 773, SEQ ID NO: 468, SEQ ID NO:
842, SEQ ID NO: 788, SEQ ID NO: 624, SEQ ID NO: 788, SEQ ID NO: 644, SEQ ID
NO: 727, SEQ ID NO: 631, SEQ ID NO: 450, SEQ ID NO: 448. and SEQ ID NO: 653.
In yet another embodiment, the H. pylori cell envelope polypeptide or a fragmentthereof is an H. pylori transporter polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 1670, SEQ ID NO: 1725, SEQ ID NO: 1661, SEQ ID NO: 1873, SEQ ID NO: 1753, SEQ ID NO: 1759, SEQ ID NO: 1761, SEQ ID NO: 1782, SEQ ID
NO: 1883, SEQ ID NO: 1503, SEQ ID NO: 1542, SEQ ID NO: 1872, SEQ ID NO: 1520, SEQ ID NO: 1456, SEQ ID NO: 1458, SEQ ID NO: 1617, SEQ ID NO: 1628, SEQ ID
NO: 1644, SEQ ID NO: 1657, SEQ ID NO: 1658, SEQ ID NO: 1755, SEQ ID NO: 1756, SEQ ID NO: 1797, SEQ ID NO: 1799, SEQ ID NO: 1801, SEQ ID NO: 1483, SEQ ID
NO: 1504, SEQ ID NO: 1532, SEQ ID NO: 1575, SEQ ID NO: 1833, SEQ ID NO: 1888, SEQ ID NO: 1714, SEQ ID NO: 495, SEQ ID NO: 400, SEQ ID NO: 541, SEQ ID NO:
673, SEQ ID NO: 482, SEQ ID NO: 622, SEQ ID NO: 689, SEQ ID NO: 736, SEQ ID
NO: 417, SEQ IDNO: 716, SEQ ID NO: 762, SEQ IDNO: 395, SEQ ID NO: 587, SEQ
IDNO: 669, SEQ ID NO: 758, SEQ ID NO: 593, SEQ ID NO: 451, SEQ ID NO: 827, SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96109122 SEQIDNO:502,SEQ ID NO: 719,SEQID NO:46g, SEQ ID NO: 715,SEQ ID NO:
847,SEQ ID NO: 453,SEQ ID NO: 527,SEQ ID NO:652,SEQ ID NO:745,SEQID
NO:567,SEQIDNO:848,SEQ ID NO:430,SEQ ID NO:748,SEQ ID NO: 396,SEQ
ID NO: 588,SEQID NO: 795,SEQ ID NO: 523,SEQ ID NO: 791,SEQ ID NO: 714, S SEQ ID NO:481,and SEQIDNO:765.
- . In another embodiment, the H. pylori cell envelope polypeptide or a fragment thereof is an H. pylori outer membrane polypeptide or a fragment thereof selected ~om the group con~i~tin~ ofSEQIDNO:1624,SEQ ID NO:1856,SEQ ID NO:1857,SEQID
NO:1861,SEQ ID NO:1537,SEQ ID NO:1773,SEQ ID NO:1717,SEQ ID NO:1733, SEQIDNO:1722,SEQIDNO:1659,SEQ ID NO:1577,SEQ ID NO: 1721,SEQID
NO: 1729,SEQ ID NO:1870,SEQ ID NO:1576,SEQ ID NO:1632,SEQ ID NO:1867, SEQ ID NO:1547,SEQ ID NO:1533,SEQ ID NO:1597,SEQ ID NO:1596,SEQID
NO:1559,SEQ ID NO:1599,SEQ ID NO:1788,SEQ ID NO:1789,SEQ ID NO:1875, SEQIDNO:1451,SEQ ID NO:1478,SEQ ID NO: 1626,SEQ ID NO:1781,SEQ ID
NO:837,SEQ ID NO:833,SEQ ID NO:585,SEQ ID NO:865,SEQ ID NO:764,SEQ
ID NO:440,SEQ ID NO:465,SEQ ID NO:SSS, SEQ ID NO:526,SEQ ID NO:687, SEQ ID NO:692,SEQ ID NO:693,SEQ ID NO:677,SEQ ID NO:649,and SEQ ID NO:
812.
Particularly ~lcrt;-lc:d is a purified or isolated H. pylori cytoplasmic polypeptide or a fragment thereof, wherein the polypeptide is selected from the group consisting of SEQ ID
NO:1598,SEQ ID NO:1739,SEQ ID NO:1775,SEQ ID NO:1814,SEQ ID NO:1448, SEQ ID NO:1466,SEQ ID NO:1535,SEQ ID NO:1545,SEQ ID NO:1550,SEQID
NO:1680,SEQIDNO:1701,SEQ ID NO:1719,SEQ ID NO:1744,SEQ ID NO:1790, SEQ ID NO:1859,SEQ ID NO:1880,SEQ ID NO:1885,SEQ ID NO:1679,SEQ ID
NO:1482,SEQIDNO:1485,SEQIDNO:1459,SEQIDNO:1512,SEQ ID NO:1515, SEQIDNO:1642,SEQ ID NO:1668,SEQ ID NO:1816,SEQ ID NO:1845,SEQ ID
NO:1865,SEQ ID NO: 1866,SEQ ID NO:1886,SEQ ID NO:1509,SEQ ID NO:1510, SEQIDNO:1531,SEQ ID NO:1579,SEQ ID NO:1584,SEQIDNO:1662,SEQID
NO:1703,SEQ ID NO:1704,SEQ ID NO:1737,SEQ ID NO:1740,SEQ ID NO:1742, SEQ ID NO:1754,SEQ ID NO:1847,SEQIDNO:1447,SEQIDNO:1546,SEQID
NO:1607,SEQ ID NO:1609,SEQ ID NO:1610,SEQ ID NO:1728,SEQ ID NO:1489, SEQ ID NO:1708,SEQIDNO:1808,SEQ ID NO:1887,SEQ ID NO:1498,SEQID
NO: 1506,SEQ ID NO: 1592,SEQ ID NO:1678,SEQIDNO:1778,SEQ ID NO:1863, SEQIDNO:1454,SEQIDNO:1538,SEQIDNO:1567,SEQIDNO:1581,SEQID
NO:1583,SEQ ID NO:1636,SEQ ID NO:1639,SEQ ID NO:1649,SEQ ID NO:1669, SEQ ID NO:1695,SEQ ID NO:1757,SEQ ID NO:1776,SEQIDNO:1848,SEQID
NO:1849,SEQIDNO:1858,SEQIDNO:1884,SEQIDNO:1667,SEQ ID NO:1690, SEQ ID NO:1813,SEQ ID NO:1468,SEQIDNO:1470,SEQ ID NO:1811,SEQ ID
~ NO:1874,SEQIDNO:1876,SEQ ID NO:1825,SEQ ID NO:1479,SEQIDNO:1488, SUBSTITUTE SHEET (RULE 2~) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 SEQ ID NO: 1528, SEQ ID NO: 1566, SEQ ID NO: 1683, SEQ ID NO: 1692, SEQ ID
NO: 1718, SEQ ID NO: 1614, SEQ ID NO: 1519, SEQ ID NO: 1476, SEQ ID NO: 1493, SEQ ID NO: 1497, SEQ ID NO: 1507, SEQ ID NO: 1490, SEQ ID NO: 1523, SEQ ID
NO: 1524, SEQ ID NO: 1543, SEQ ID NO: 1551, SEQ ID NO: 1553, SEQ ID NO: 1554, SEQ ID NO: 1555, SEQ ID NO: 1562, SEQ ID NO: 1570, SEQ ID NO: 1587, SEQ ID
NO: 1588, SEQ ID NO:1591, SEQ ID NO: 1593, SEQ ID NO: 1684, SEQ ID NO: 1689, SEQ ID NO: 1694, SEQ ID NO: 1696, SEQ ID NO: 1698, SEQ ID NO: 1700, SEQ ID
NO: 1712, SEQ ID NO: 1720, SEQ ID NO: 1730, SEQ ID NO: 1735, SEQ ID NO: 1741, SEQ ID NO: 1748, SEQ ID NO: 1779, SEQ ID NO: 1821, SEQ ID NO: 1823, SEQ ID
NO: 1828, SEQ ID NO: 1834, SEQ ID NO: 1835, SEQ ID NO: 1836, SEQ ID NO: 1839, SEQ ID NO: 1852, SEQ ID NO: 1853, SEQ ID NO: 1869, SEQ ID NO: 1871, SEQ ID
NO: 1878, SEQ ID NO: 1521, SEQ ID NO: 1602, SEQ ID NO: 1627, SEQ ID NO: 1450, SEQ ID NO: 1457, SEQ ID NO: 1463, SEQ ID NO: 1469, SEQ ID NO: 1481, SEQ ID
NO: 1484, SEQ ID NO: 1492, SEQ ID NO:1500, SEQ ID NO:1505, SEQ ID NO: 1508, SEQ ID NO: 1541, SEQ ID NO: 1548, SEQ ID NO: 1580, SEQ ID NO: 1590, SEQ ID
NO: 1594, SEQ ID NO: 1603, SEQ ID NO: 1604, SEQ ID NO: 1606, SEQ ID NO: 1612, SEQ ID NO: 1613, SEQ ID NO: 1620, SEQ ID NO: 1621, SEQ ID NO: 1622, SEQ ID
NO: 1631, SEQ ID NO: 1645, SEQ ID NO: 1646, SEQ ID NO: 1650, SEQ ID NO: 1651, SEQ ID NO: 1652, SEQ ID NO: 1653, SEQ ID NO: 1656, SEQ ID NO: 1763, SEQ ID
NO: 1787,SEQIDNO: 1800,SEQIDNO: 1806,SEQIDNO: 1810,SEQIDNO: 1864, SEQ ID NO: 1877, SEQ ID NO: 1881, SEQ ID NO: 390, SEQ ID NO: 876, SEQ ID NO:
547, SEQ ID NO: 678, SEQ ID NO: 729, SEQ ID NO: 786, SEQ ID NO: 654, SEQ ID
NO: 734, SEQ ID NO: 646, SEQ ID NO: 522, SEQ ID NO: 696, SEQ ID NO: 807, SEQ
ID NO: 683, SEQ ID NO: 790, SEQ ID NO: 763, SEQ ID NO: 806, SEQ ID NO: 799, SEQ ID NO: 434, SEQ ID NO: 743, SEQ ID NO: 804, SEQ ID NO: 733, SEQ ID NO:
826, SEQ ID NO: 562, SEQ ID NO: 420, SEQ ID NO: 664, SEQ ID NO: 850, SEQ ID
NO: 857, SEQ ID NO: 861, SEQ ID NO: 872, SEQ ID NO: 544, SEQ ID NO: 830, SEQ
ID NO: 446, SEQ ID NO: 397, SEQ ID NO: 699, SEQ ID NO:459, SEQ ID NO: 509, SEQ ID NO: 818, SEQ ID NO: 488, SEQ ID NO: 438, SEQ ID NO: 831, SEQ ID NO:
667, SEQ ID NO: 429, SEQ ID NO: 680, SEQ ID NO: 597, SEQ ID NO: 460, SEQ ID
NO: 709, SEQ ID NO: 822, SEQ ID NO: 466, SEQ ID NO: 584, SEQ ID NO: 388, SEQ
ID NO: 631~ SEQ ID NO: 787, SEQ ID NO: 532, SEQ ID NO: 619, SEQ ID NO: 723, SEQ ID NO: 641, SEQ ID NO: 698, SEQ ID NO: 630, SEQ ID NO: 869, SEQ ID NO:
601, SEQ ID NO: 415, SEQ ID NO: 542, SEQ ID NO: 704, SEQ ID NO: 572, SEQ ID
NO: 467, SEQ ID NO: 399, SEQ ID NO: 579, SEQ ID NO: 739, SEQ ID NO: 849, SEQ
ID NO: 824, SEQ ID NO: 871, SEQ ID NO: 547, SEQ ID NO: 633, SEQ ID NO: 695, SEQ ID NO: 405, SEQ ID NO: 394, SEQ ID NO: 761, SEQ ID NO: 574, SEQ ID NO:
596, SEQ ID NO: 832, SEQ ID NO: 651, SEQ ID NO: 867, SEQ ID NO: 614, SEQ ID
NO: 401, SEQ ID NO: 393, SEQ ID NO: 413, SEQ ID NO: 835, SEQ ID NO: 863, SEQ

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 ID NO:458,SEQID NO:701,SEQ ID NO: 531,SEQID NO:550,SEQ ID NO:439, SEQ ID NO:516,SEQID NO:802,SEQ ID NO:581,SEQ ID NO:535,SEQ ID NO:
578,SEQ ID NO:492,SEQID NO:858,SEQID NO:720,SEQID NO:813,SEQID
NO:426,SEQ ID NO:834,SEQID NO:609,SEQ ID NO:489,SEQID NO:480,SEQ
S ID NO:406,SEQ ID NO:392,SEQ ID NO:456,SEQID NO:707,SEQID NO:533, SEQID NO:728,SEQ ID NO:769,SEQID NO:671,SEQID NO:602,SEQID NO:
618,SEQ ID NO: 618,SEQ ID NO:682,SEQID NO:524,SEQ ID NO:802.SEQ ID
NO:785,SEQ ID NO:457,SEQ ID NO:781,SEQID NO:473,SEQ ID NO:384,SEQ
ID NO:726,SEQID NO:817,SEQID NO:498,SEQID NO:436,SEQID NO:815, SEQID NO:856,SEQ ID NO:650,SEQ ID NO:844,SEQ ID NO:580,SEQ ID NO:
783,SEQ ID NO:416,SEQ ID NO:741,SEQ ID NO:442,SEQ ID NO:803,SEQ ID
NO:520,SEQ ID NO:566,SEQ ID NO:557,SEQ ID NO: 706,SEQ ID NO:710,SEQ
ID NO:487,SEQ ID NO:603,SEQ ID NO:472,SEQID NO:476,SEQ ID NO:770, SEQID NO:841,SEQID NO:768,SEQ ID NO:839,SEQ ID NO:560,SEQID NO:
796,SEQ ID NO:483,SEQ ID NO:634,SEQ ID NO: 445,SEQ ID NO: 853,SEQ ID
NO:525,SEQ ID NO:798,SEQ ID NO:549,SEQ ID NO:836,SEQ ID NO:589,SEQ
ID NO:760,SEQ ID NO:462,SEQ ID NO:789,SEQID NO:507,SEQ ID NO:828, SEQ ID NO:866,SEQ ID NO: 754,SEQ ID NO:730,SEQID NO: 617,SEQ ID NO:
455,SEQ ID NO: 873,SEQ ID NO:435,SEQ ID NO:766,SEQ ID NO:793,SEQ ID
NO:742,SEQ ID NO:599,SEQ ID NO:854, and SEQl[D NO:632.
In one embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in energy conversion selected from the group con~i~ting of SEQ ID NO:1598,SEQ ID NO:1739,SEQ ID NO:1775,SEQ ID
NO:1814,SEQ ID NO:390,SEQID NO:876,SEQID NO:547, and SEQID NO:678.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in amino acid metabolism selected from the group con~icting of SEQ ID NO: 1448,SEQ ID NO:1466,SEQ ID NO:
1535,SEQID NO:1545,SEQ ID NO:1550,SEQID NO:1680,SEQ ID NO:1701,SEQ
ID NO:1719,SEQID NO:1744,SEQ ID NO:1790,SEQ ID NO:1859,SEQ ID NO:
1880,SEQ ID NO:1885,SEQ ID NO:1679,SEQ ID NO: 1482,SEQ ID NO:1485,SEQ
ID NO:1459,SEQ ID NO:729,SEQ ID NO:786,SEQID NO:654,SEQID NO:734, SEQ ID NO:646,SEQ ID NO:522,SEQ ID NO:696,SEQ ID NO:807,SEQ ID NO:
683,SEQID NO:790,SEQ ID NO:763,SEQ ID NO: 806,SEQ ID NO:799,SEQ ID
NO:434,SEQ ID NO:743,SEQID NO:804, and SEQ ID NO:733.
In yet another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in nucleotide metabolism selected from the group consisting of SEQ ID NO:1512,SEQ ID NO:1515,~EQ ID NO:
1642,SEQID NO:1668,SEQID NO:1816,SEQID NO:1845,SEQID NO:1865,SEQ
ID NO:1866,SEQ ID NO:1886,SEQ ID NO:1509,SEQID NO:1510,SE(~ ID NO:826, SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 SEQ ID NO: 562, SEQ ID NO: 420, SEQ ID NO: 664, SEQ ID NO: 850, SEQIDNO:
857, SEQ ID NO: 861, SEQ ID NO: 872, SEQ ID NO: 544, SEQ ID NO: 830, and SEQ ID
NO: 446.
In yet a further embodiment, the H. pylori cytoplasmic polypeptide or a fragmentthereof is an H. pylori polypeptide or a fragment thereof involved in carbohydrate metabolism selected from the group consisting of SEQ ID NO: 1531, SEQ ID NO: 1579, SEQ ID NO: 1584, SEQIDNO: 1662, SEQIDNO: 1703, SEQ ID NO: 1704, SEQID
NO: 1737, SEQ ID N 0:1740, SEQ ID NO: 1742, SEQ ID NO: 1754, SEQIDNO: 1847, SEQ ID NO: 1447, SEQ ID NO: 397, SEQ ID NO: 699, SEQ ID NO: 459, SEQ ID NO:
509,SEQ ID NO: 818, SEQ ID NO: 488, SEQ ID NO: 438, SEQ ID NO: 831, SEQ ID
NO: 667, SEQ ID N 0:429, SEQ ID N 0:680, and SEQ ID NO: 597.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in cofactor metabolism selected from the group con~i~ting of SEQ ID NO: 1546, SEQIDNO: 1607, SEQIDNO: 1609, SEQ ID NO: 1610, SEQ ID NO: 1728, SEQ ID NO: 1489, SEQ ID NO: 460, SEQ ID NO:
709, SEQ ID NO: 822, SEQ ID NO: 466, SEQ ID NO: 584, and SEQ ID NO: 388.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in lipid metabolism selected from the group con.~i.ctin~ of SEQ ID NO: 1708, SEQ ID NO: 1808, SEQ ID NO: 1887, SEQ ID NO: 631, SEQIDNO: 787, and SEQ ID NO: 532.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in mRNA translation and ribosome biogenesis selected from the group consisting of SEQ ID NO: 1498, SEQ ID NO:
1506,SEQ ID NO: 1592, SEQID NO: 1678, SEQ ID NO: 1778, SEQ ID NO: 1863, SEQ
ID NO: 619, SEQ ID NO: 723, SEQ ID NO: 641, SEQ ID NO: 698, SEQIDNO: 630, and SEQ ID NO: 869.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in genome replication, transcription, recombination and repair selected from the group con.~i~tin~ of SEQ ID NO:
1454, SEQ ID NO: 1538, SEQ ID NO: 1567, SEQ ID NO: 1581, SEQ ID NO: 1583, SEQ
ID NO: 1636, SEQ ID NO: 1639, SEQ ID NO: 1649, SEQ ID NO: 1669, SEQ ID NO:
1695, SEQ ID NO: 1757, SEQID NO: 1776, SEQ ID NO: 1848, SEQ ID NO: 1849, SEQ
ID NO: 1858, SEQ ID NO: 1884, SEQ ID NO: 601, SEQ ID NO: 415, SEQ ID NO: 542, SEQIDNO: 704, SEQID NO: 572, SEQ ID NO: 467, SEQ ID NO: 399, SEQ ID NO:
579, SEQ ID NO: 739, SEQ ID NO: 849, SEQ ID NO: 824, SEQ ID NO: 871, SEQ ID
NO: 547, SEQ ID NO: 633, SEQ ID NO: 695, SEQ ID NO: 405, SEQ ID NO 394, and SEQ ID NO: 761.
In another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in outer membrane or cell wall SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O ~f'1D~93 PCTAUS96/09122 biosyn~esis selected from ~e group consisting of SEQIDNO:1667,SEQIDNO:1690, SEQIDNO:1813,SEQIDNO:1468,SEQIDNO:1470,SEQIDNO:1811,SEQID
NO:574,SEQIDNO:596,SEQIDNO:832,SEQIDNO:651,SEQIDNO:867,SEQ
IDNO:614,SEQIDNO:401, ~d SEQIDNO:393.
In yet another embodiment, the H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori chaperone polypeptide or a fragment thereof selected from the group consisting of SEQIDNO:1874,SEQIDNO:1876,SEQIDNO:1825,SEQIDNO:413, SEQIDNO:835, ~d SEQIDNO:863.
Particularly ~l~fc~ d is a purified or isolated H. pyl'ori secreted or periplasmic polypeptide or a fragment thereof, wherein the polypepl:ide is selected from the group consisting of SEQIDNO:1455,SEQIDNO:1589,SEQ ID NO:1518,SEQIDNO:1529, SEQIDNO:1765,SEQIDNO:1770,SEQIDNO:1829,SEQ ID NO:1556,SEQ ID
NO:1565,SEQIDNO:1569,SEQIDNO:1571,SEQIDNO:1574,SEQIDNO:1578, SEQIDNO:1663,SEQIDNO:1674,SEQIDNO:1676,SEQIDNO:1697,SEQID
NO:1699,SEQIDNO:1710,SEQIDNO:1715,SEQIDNO:1716,SEQIDNO:1732, SEQIDNO:1736,SEQIDNO:1745,SEQIDNO:1749,SEQIDNO:1750,SEQID
NO:1766,SEQIDNO:1767,SEQ ID NO:1768,SEQIDNO:1769,SEQ ID NO:1795, SEQ ID NO:1802,SEQIDNO:1804,SEQIDNO:1824,SEQIDNO:1831,SEQID
NO:1838,SEQIDNO:1840,SEQIDNO:1844,SEQIDNO:1862,SEQIDNO:1879, SEQIDNO:1882,SEQIDNO:1890,SEQ ID NO:1494,SEQIDNO:1634,SEQID
NO:1635,SEQIDNO:1647,SEQIDNO:1648,SEQ ID NO:1654,SEQ ID NO:1446, SEQIDNO:1449,SEQIDNO:1452,SEQIDNO:1473,SEQIDNO:1474,SEQID
NO:1480,SEQIDNO:1491,SEQIDNO:1502,SEQ ID NO:1513,SEQ ID NO:1605, SEQ ID NO:1771,SEQIDNO:1526,SEQ ID NO:1557,SEQ ID NO:1560,SEQ ID
NO:1585,SEQIDNO:1672,SEQIDNO:1677,SEQIDNO:1686,SEQ ID NO:1752, SEQ ID NO:1762,SEQIDNO:1777,SEQIDNO:1792,SEQ ID NO:1805,SEQ ID
NO:1815,SEQ ID NO:1817,SEQ ID NO:1827,SEQIDNO:1842,SEQIDNO:1846, SEQIDNO:1896,SEQIDNO:1530,SEQIDNO:1637,SEQIDNO:1461,SEQID
NO:1467,SEQIDNO:1623,SEQIDNO:1625,SEQIDNO:530,SEQ ID NO:708, SEQ ID NO:414,SEQ ID NO:694,SEQ ID NO:703,SEQ ID NO:721,SEQ ID NO:
749,SEQIDNO:685,SEQIDNO:444,SEQIDNO:606,SEQ ID NO:582,SEQID
NO:621,SEQIDNO:868,SEQ ID NO:666,SEQ ID NO: 408,SEQ ID NO:538,SEQ
ID NO:573,SEQ ID NO:639,SEQ ID NO:668,SEQl[D NO:524,SEQ ID NO:422, SEQIDNO:819,SEQIDNO:611,SEQIDNO:674,SEQIDNO:577,SEQ ID NO:
663,SEQ ID NO:558,SEQ ID NO:794,SEQ ID NO:564,SEQ ID NO:592,SEQID
NO:814,SEQ ID NO:398,SEQIDNO:767,SEQ ID NO: 425,SEQIDNO:659,SEQ
IDNO:517,SEQIDNO:539,SEQIDNO:475,SEQ ID NO:615,SEQ ID NO:665, SEQ ID NO:607,SEQIDNO:598,SEQ ID NO:759.SEQ ID NO:752,SEQIDNO:
595,SEQ ID NO:686,SEQ ID NO:528,SEQIDNO:705,SEQ ID NO:828,SEQID

SUBSTITUTE 5HEET (RULE 26) CA 0222339~ 1997-12-03 W O 9~/~D~93 PCTAUS96/09122 NO: 403, SEQ ID NO: 561, SEQ ID NO: 500, SEQ ID NO: 491, SEQ ID NO: 846, SEQ
ID NO: 732, SEQ ID NO: 778, SEQ ID NO: 751, SEQ ID NO: 744, SEQ ID NO: 504, SEQ ID NO: 419, SEQ ID NO: 792, SEQ ID NO: 825, SEQ ID NO: 756, SEQ ID NO:
519, SEQ ID NO: 870, SEQ ID NO: 777, SEQ ID NO: 808, SEQ ID NO: 506, SEQ ID
NO: 864, SEQ ID NO: 655, SEQ ID NO: 407, SEQ ID NO: 427, SEQ ID NO: 774, SEQ
ID NO: 797, SEQ ID NO: 688, SEQ ID NO: 815, SEQ ID NO: 718, SEQ ID NO: 859, SEQ ID NO: 775, SEQ ID NO: 874, SEQ ID NO: 543, SEQ ID NO: 878, SEQ ID NO:
594, SEQ ID NO: 610, and SEQ ID NO: 600.
Particularly ~-~Çt~ d is a purified or isolated H pylori surface or membrane polypeptide or a fragment thereof, wherein the polypeptide is selected from the group consistingofSEQIDNO: 1511,SEQIDNO: 1561,SEQIDNO: 1563,SEQIDNO: 1681, SEQ ID NO: 1711, SEQ ID NO: 1731, SEQ ID NO: 1743, SEQ ID NO: 1747, SEQ ID
NO: 1758, SEQ ID NO: 1893, SEQ ID NO: 1895, SEQ ID NO: 1573, SEQ ID NO: 1705, SEQ ID NO: 1707, SEQ ID NO: 1723, SEQ ID NO: 1726, SEQ ID NO: 1760, SEQ ID
NO: 1764, SEQ ID NO: 1798, SEQ ID NO: 1803, SEQ ID NO: 1807, SEQ ID NO: 1889, SEQ ID NO: 1892, SEQ ID NO: 1460, SEQ ID NO: 1477, SEQ ID NO: 1499, SEQ ID
NO: 1514, SEQ ID NO: 1641, SEQ ID NO: 1534, SEQ ID NO: 1564, SEQ ID NO: 1673, SEQ ID NO: 1746, SEQ ID NO: 1794, SEQ ID NO: 1843, SEQ ID NO: 1894, SEQ ID
NO: 1536, SEQ ID NO: 1544, SEQ ID NO: 1568, SEQ ID NO: 1572, SEQ ID NO: 1582, SEQ ID NO: 1738, SEQ ID NO: 1891, SEQ ID NO: 1660, SEQ ID NO: 1793, SEQ ID
NO: 1832, SEQ ID NO: 1841, SEQ ID NO: 1860, SEQ ID NO: 1486, SEQ ID NO: 1465, SEQ ID NO: 1539, SEQ ID NO: 1693, SEQ ID NO: 1629, SEQ ID NO: 1540, SEQ ID
NO: 1791, SEQ ID NO: 1525, SEQ ID NO: 1558, SEQ ID NO: 1655, SEQ ID NO: 1517, SEQ ID NO: 875, SEQ ID NO: 676, SEQ ID NO: 801, SEQ ID NO: 860, SEQ ID NO:
747, SEQ ID NO: 529, SEQ ID NO: 387, SEQ ID NO: 391, SEQ ID NO: 515, SEQ ID
NO: 625, SEQ ID NO: 568, SEQ ID NO: 454, SEQ ID NO: 800, SEQ ID NO: 499, SEQ
ID NO: 779, SEQ ID NO: 648, SEQ ID NO: 643, SEQ ID NO: 537, SEQ ID NO: 511, SEQ ID NO: 616, SEQ ID NO: 829, SEQ ID NO: 546, SEQ ID NO: 780, SEQ ID NO:
553, SEQ ID NO: 549, SEQ ID NO: 410, SEQ ID NO: 608, SEQ ID NO: 513, SEQ ID
NO: 656, SEQ ID NO: 845. SEQ ID NO: 563, SEQ ID NO: 570, SEQ ID NO: 805, SEQ
ID NO: 851, SEQ ID NO: 423. SEQ ID NO: 810, SEQ ID NO: 604, SEQ ID NO: 636, SEQ ID NO: 757, SEQ ID NO: 412. SEQ ID NO: 816, SEQ ID NO: 771, SEQ ID NO:
418, SEQ ID NO: 662. SEQ ID NO: 512, SEQ ID NO: 679, SEQ ID NO: 605, SEQ ID
NO: 421, SEQ ID NO: 55 '. SEQ ID NO: 576, SEQ ID NO: 571, SEQ ID NO: 725, SEQ
ID NO: 565, SEQ ID NO: 717. SEQ ID NO: 536, SEQ ID NO: 647, SEQ ID NO: 501, SEQ ID NO: 838, SEQ ID NO: 428, SEQ ID NO: 494, SEQ ID NO 479, SEQ ID NO:
711, SEQ ID NO: 722 ,SEQ ID NO: 645, SEQ ID NO: 670, SEQ ID NO: 746, SEQ ID
NO: 493, SEQ ID NO: 540, SEQ ID NO: 612, SEQ ID NO: 629, SEQ ID NO: 484, SEQ
ID NO: 485, SEQ ID NO: 486. SEQ ID NO: 433, SEQ ID NO: 385, and SEQ ID NO: 409.

SUBSTITUTE SHEET (RULE 26) W O 96/40893 PCT~US96/09122 In one embodiment, the H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least one membrane spz~nning region selected from the group consisting of SEQ ID NO: 1511, SEQ ID NO:
1561, SEQ ID NO: 1563, SEQ ID NO: 1681, SEQ ID NO: 1711, SEQ ID NO: 1731. SEQ
ID NO: 1743, SEQ ID NO: 1747, SEQ ID NO: 1758, SEQ ID NO: 1893, SEQ ID NO:
1895, SEQ ID NO: 875, SEQ ID NO: 676, SEQ ID NO: 801, SEQ ID NO: 860, SEQ ID
NO: 747, SEQ ID NO: 529, SEQ ID NO: 387, SEQ lD NO: 391, SEQ ID NO: 515, SEQ
ID NO: 62~, SBQ ID NO: 568, SEQ ID NO: 454, SEQ ID NO: 800, SEQ ID NO: 499, SEQ ID NO: 779, and SEQ ID NO: 385.
In another embodiment, the H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least two membrane spanning regions selected from the group consisting of SEQ ID NO: 1573, SEQ
ID NO: 1705, SEQ ID NO: 1707, SEQ ID NO: 1723, SEQ ID NO: 1726, SEQ ID NO:
1760, SEQ ID NO: 1764, SEQ ID NO: 1798, SEQ ID NO: 1803, SEQ ID NO: 1807, SEQ
ID NO: 1889, SEQ ID NO: 1892, SEQ ID NO: 1460, SEQ ID NO: 1477, SEQ ID NO:
1499, SEQ ID NO: 1514, SEQ ID NO: 1641, SEQ ID NO: 648, SEQ ID NO: 643, SEQ ID
NO: 537, SEQ ID NO: 511, SEQID NO: 616, SEQ ID NO: 829, SEQ ID NO: 546, SEQ
ID NO: 780, SEQ IDNO: 553, SEQ ID NO: 549, SEQ ID NO: 410, SEQ ID NO: 608, SEQ ID NO: 513, SEQ ID NO: 656, SEQ ID NO: 845, SEQ ID NO: 563, SEQ ID NO:
570, SEQ ID NO: 805, and SEQ ID NO: 851.
In yet another embodiment, the H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least three membrane sp~nnin~ regions selected from the group consisting of SEQ IDNO: 1534, SEQ
ID NO: 1564, SEQ IDNO: 1673, SEQ ID NO: 1746, SEQ ID NO: 1794, SEQ IDNO:
1843, SEQ IDNO: 1894, SEQ IDNO: 423, SEQ ID NO:810, SEQ ID NO: 604, SEQ ID
NO: 636, SEQ IDNO: 757, SEQ IDNO: 412, and SEQ ID NO: 816.
In yet a filrther embodiment, the H. pylori surface or membrane polypeptide or afragment thereof is an H. pylori polypeptide or a fragment thereof having at least four membrane sp~nnin~ regions selected from the group consisting of SEQ ID NO: 1536, SEQ
IDNO: 1544, SEQ ID NO: 1568, SEQ IDNO: 1572, SEQ ID NO: 1582, SEQ ID NO:
1738, SEQ ID NO: 1891, SEQ ID NO: 1660, SEQ ID NO: 771, SEQ IDNO: 418, SEQ ID
NO: 662, SEQ ID NO: 512, SEQ IDNO: 679, SEQ ID NO: 605, SEQ ID NO: 421, SEQ
ID NO: 552, SEQ IDNO: 576, SEQ ID NO: 571.
In another embodiment, the H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fr~gment thereof having at least five membrane spanning regions selected from the group consisting of SEQ ID NO: 1793, SEQ
IDNO: 1832, SEQ ID NO: 1841, SEQ ID NO: 1860, SEQ IDNO: 1486, SEQ ID NO: 725, SEQ ID NO: 565, SEQ IDNO: 717, SEQ ID NO: 536, SEQ ID NO: 647, and SEQ ID NO:
409.

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 In another embodiment, the H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least six membrane sp~nning regions selected from the group con~i~tinP~ of SEQ ID NO: 1~65, SEQ
ID NO: 1539, SEQ ID NO: 1693, SEQ ID NO: 1629, SEQ ID NO: 501. SEQ ID NO: 838, SEQ ID NO: 428, SEQ ID NO: 494, SEQ ID NO: 479, SEQ ID NO: 711, and SEQ ID NO:
722.
In yet another embodiment, the H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least seven membrane sp~nning regions selected from the group consisting of SEQ ID NO: 1540, SEQ
ID NO: 1791, SEQ ID NO: 1525, SEQ ID NO: 1558, SEQ ID NO: 1655, SEQ ID NO:
1517, SEQ ID NO: 645, SEQ ID NO: 670, SEQ ID NO: 746, SEQ ID NO: 493, SEQ ID
NO: 540, SEQ ID NO: 612, SEQ ID NO: 629, SEQ ID NO: 484, SEQ ID NO: 485, SEQ
ID NO: 486, and SEQ ID NO: 433.
In another aspect, the invention pertains to any individual H. pylori polypeptide member or nucleic acid encoding such a member from the above-identified groups of H.
pylori polypeptides.
In another aspect, the invention features nucleic acids capable of binding mRNA of H. pylori. Such nucleic acid is capable of acting as ~nti~erlce nucleic acid to control the translation of mRNA of H. pylori. A further aspect features a nucleic acid which is capable of binding specifically to an H. pylori nucleic acid. These nucleic acids are also referred to herein as complements and have utility as probes and as capture reagents.
In another aspect, the invention features an ex~lcs~.ion system comprising an open reading frame C~llc ~~onding to H. pylori nucleic acid. The nucleic acid further comprises a control sequence compatible with an intended host. The expression system is useful for making polypeptides corresponding to H. pylori nucleic acid.
In another aspect, the invention features a cell transformed with the expressionsystem to produce H. pylori polypeptides.
In another aspect, the invention features a method of generating antibodies against H. pylori polypeptides which are capable of binding specifically to H. pylori polypeptides.
Such antibodies have utility as reagents for immunoassays to evaluate the abundance and distribution of H. pylori-specific antigens.
In another aspect, the invention features a method of generating vaccines for immunizing an individual against H. pylori. The method includes: immunizing a subject with an H. pylori polypeptide, e.g., a surface or secreted polypeptide~ or active portion thereof, and a ph~rm~reutically acceptable carrier. Such vaccines have therapeutic and prophylactic utilities.
In another aspect, the invention provides a method for generating a vaccine comprising a modified immllnogenic H. pylori polypeptide, e.g., a surface or secreted polypeptide, or active portion thereof, and a ph~rm~rologically acceptable carrier.

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 In another aspect, the invention featu~es a method of evaluating a compound, e.g. a polypeptide, e.g., a fragment of a host cell polypeptide, for the ability to bind an H. pylori polypeptide. The method includes: contacting the candidate compound with an H. pylori polypeptide and determininP if the compound binds or otherwise interacts with an H. pylori S polypeptide. Compounds which bind H. pylori are candidates as activators or inhibitors of the ~cterizll life cycle. These assays can be performed in vitro or in vivo.
In another aspect, the invention features a method of evaluating a compound, e.g. a polypeptide, e.g., a fragment of a host cell polypeptide, for the ability to bind an H. pylori nucleic acid, e.g., DNA or RNA. The method includes: cont~ctin~ the candidate compound with an H. pylori nucleic acid and determini~g if the compound binds orotherwise interacts with an H. pylori polypeptide. Compounds which bind H. pylori are candidates as activators or inhibitors of the bacterial life cycle. These assays can be performed in vitro or in vivo.
The invention features H. pylori polypeptides, preferably a substantially pure preparation of an H. pylori polypeptide, or a recombinallt H. pylori polypeptide. In preferred embodiments: the polypeptide has biological activity; the polypeptide has an amino acid sequence at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% identical to an amino acid sequence of the invention contained in the Sequence Listing, preferably it has about 65% sequence identity with an amino acid sequence of the invention contained in the Sequence T i~fin~, and most preferably it has about 92% to about 99% sequence identity with an amino acid sequence of the invention cont~ine~l in the Sequence T ictin~; the polypeptide has an amino acid sequence l?ssPnti~lly the same as an arnino acid sequence of the invention contained in the Sequence T i~ting; the polypeptide is at least 5, 10, 20, 50, 100, or 150 amino acid residues in length; the polypeptide includes at least 5, preferably at least 10, more preferably at least 20, more preferably at least 50, 100. or 150 contiguous amino acid residues of the invention contained in the Sequence Listing. In yet another preferred embodiment, the amino acid sequence which differs in sequence identity by about 7% to about 8% from the H. pylori amino acid sequences of the invention contained in the Sequence Listing is also encompassed by the invention.
In preferred embodiments: the H. pylori polypeptide is encoded by a nucleic acid of the invention contained in the Sequence Listing, or by a nucleic acid having at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% homology with a nucleic acid of the invention contained in the Sequence Listing.
In a preferred embodiment, the subject H pylori polypeptide differs in amino acid sequence at 1, 2, 3, 5, 10 or more residues from a sequence of the invention contained in the Sequence Listing. The differences, however, are such that the H. pylori polypeptide exhibits an H. pylori biological activity, e.g., the H. pylori polypeptide retains a biological activity of a naturally occurring H. pylori enzyme.

SUBSTITI.)TE SHEET (RULE ~6 CA 0222339~ 1997-12-03 w o gc~sce~3 PCT~US96/09122 In plef~l.ed embo~1imentc, the polypeptide includes all or a fragment of an amino acid sequence of the invention contained in the Sequence T icting; fused, in reading frame, to additional amino acid residues, preferably to residues encoded by genomic DNA 5' or 3' to the genomic DNA which encodes a sequence of the invention contained in the Sequence 5 Listing.
In yet other preferred embodiments, the H. pylori polypeptide is a recombinant fusion protein having a first H. pylori polypeptide portion and a second polypeptide portion, e.g., a second polypeptide portion having an amino acid sequence unrelated to H.
pylori. The second polypeptide portion can be, e.g., any of glutathione-S-l~ r~.dse, a 10 DNA binding domain, or a polymerase activating domain. In preferred embodiment the fusion protein can be used in a two-hybrid assay.
Polypeptides of the invention include those which arise as a result of alternative transcription events, alternative RNA splicing events, and alternative translational and postranslational events.
l S The invention also encomp~ccçs an immunogenic component which includes an H.
pylori polypeptide in an immllnngenic ~ alion; the immlmogenic component being capable of eliciting an immune response specific for the H. pylori polypeptide, e.g., a humoral response, an antibody response, or a cellular response. In preferred embo-limentc, the immunogenic component comprises at least one antigenic c~le.llli.-z.lll from a polypeptide of the invention contained in the Sequence Listing.
In another aspect, the invention provides a substantially pure nucleic acid having a nucleotide sequence which encodes an H. pylori polypeptide. In plef~ d embo-limentc:
the encoded polypeptide has biological activity; the encoded polypeptide has an amino acid sequence at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% homologous to an amino acid sequence of the invention contained in the Sequence Listing; the encoded polypeptide has an amino acid sequence ecs~nti~lly the same as an amino acid sequence of the invention contained in the Sequence T.ictinp; the encoded polypeptide is at least S, 10, 20, 50, 100, or 150 amino acids in length; the encoded polypeptide comprises at least 5, preferably at least 10, more preferably at least 20, more preferably at least 50, 100, or 150 contiguous amino acids of the invention contained in the Sequence Listing.
In preferred embo~1imentc: the nucleic acid of the invention is that contained in the Sequence T.i.cting; the nucleic acid is at least 60%, 70%, 80%, 90%, 95%, 98%, or 99%
homologous with a nucleic acid sequence of the invention contained in the Sequence Listing.
In a ,.l~rt;ll~d embodiment, the encoded H. pylori polypeptide differs (e.g., byamino acid substitution, addition or deletion of at least one amino acid residue) in amino acid sequence at 1, 2, 3, 5, 10 or more residues, from a sequence of the invention contained in the Sequence T i.ctin~. The differences, however, are such that: the H. pylori encoded SUBSTITUTE SH EET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 polypeptide exhibits a H. pylori biological activity, e.g., the encoded H. pylori enzyme retains a biological activitv of a naturally occurring H pylori.
In pl~re~l. d embodiments, the encoded polypeptide includes all or a fragment of an amino acid sequence of the invention contained in the Sequence T i~tinp; fused. in reading 5 frame, to additional amino acid rç~ çs, preferably to residues encoded by genomic DNA
- 5' or 3' to the genomic DNA which encodes a sequence of the invention contained in the Sequence Listing.
In ~,er~ d embodiments, the subject H pylori nucleic acid will include a transcriptional regulatory sequence, e.g. at least one of a transcriptional promoter or transcriptional enhancer sequence, operably linked to the H. pylori gene sequence, e.g., to render the H. pylori gene sequence suitable for expression in a recombinant host cell.
In yet a further preferred embodiment, the nucleic acid which encodes an H. pylori polypeptide of the invention, hybridizes under stringent conditions to a nucleic acid probe co.l~sl~onding to at least 8 consecutive nucleotides of the invention contained in the Sequence Listing; more preferably to at least 12 consecutive nucleotides of the invention contained in the Sequence Listing; more preferably to at least 20 consecutive nucleotides of the invention contained in the Sequence Listing; more preferably to at least 40 consecutive nucleotides of the invention contained in the Sequence Listing.
In a ~l~r~lled embodiment, the nucleic acid encodes a peptide which differs by at least one amino acid residue from the sequences of the ixlvention contained in the Sequence Listing.
In a preferred embodiment, the nucleic acid diffcrs by at least one nucleotide from a nucleotide sequence of the invention contained in the Sequence Listing which encodes amino acids of the invention contained in the Sequence Listing.
In another aspect, the invention encomp~ccçs a vector including a nucleic acid which encodes an H. pylori polypeptide or an H. pylori polypeptide variant as described herein; a host cell transfected with the vector; and a method of producing a recombinant H.
pylori polypeptide or H. pylori polypeptide variant, including culturing the cell, e.g., in a cell culture medium, and isolating the H. pylori or H. pylori polypeptide variant, e.g., from the cell or from the cell culture medium.
In another aspect, the invention features, a purified recombinant nucleic acid having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% homology with a sequence of the invention contained in the Sequence Listing.
The invention also provides a probe or primer which includes a substantially purified oligonucleotide. The oligonucleotide includes a region of nucleotide sequence which hybridizes under stringent conditions to at least 10 consecutive nucleotides of sense or ~nticen~e sequence of the invention contained in the Sequence T ,i~ting, or naturally occurring ml-t~nt~ thereof. In plt:re;ll~d embodiments, the probe or primer further includes a label group attached thereto. The label group can be, e.g., a radioisotope~ a fluorescent SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 . PCTrUS96/09122 compound? an enzyme, and/or an enzyme co-factor. Preferably the oligonucleotide is at least 10 and less than 20, 30,50,100, or 150 nucleotides in length.
The invention further provides nucleic acids, e.g., RNA or DNA, encoding a polypeptide of the invention. This includes double stranded nucleic acids as well as coding and antisense single strands.
The H. pylori strain, from which genomic sequences have been sequenced~ has beendeposited in the American Type Culture Collection(ATCC # 55679) as strain HP-J99.
Included in the invention are: allelic variations; natural mllt~nt~, induced m~ltiqnt~;
proteins encoded by DNA that hybridizes under high or low stringency conditions to a 10 nucleic acid which encodes a polypeptide of the invention contained in the Sequence Listing (for definitions of high and low stringency see Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989, 6.3.1-6.3.6, hereby incol~uldL~d by reference); and, polypeptides specifically bound by antisera to H. pylori polypeptides~
especially by antisera to an active site or binding domain of H. pylori polypeptide. The invention also includes fragments, preferably biologically active fragments. These and other polypeptides are also referred to herein as H. pylori polypeptide analogs or variants.
Putative functions have been deterrnined for several of the H. pylori polypeptides of the invention, as shown in Table 1.
Accordingly, uses of the claimed H. pylori polypeptides in these identified functions are also within the scope of the invention.
In addition, the present invention encomp~es H. pylori polypeptides characterized as shown in Table 1 below, including: H. pylori cell envelope proteins, H. pylori periplasmic/secreted proteins, H. pylori cytoplasmic proteins, and other H. pylori surface and membrane proteins. Members of these groups were identified by BLAST homologysearches and by searches for secretion signal or transmembrane protein motifs.
(Polypeptides in the same row of Table 1, i.e., rows I and 3, or rows 2 and 4. are related to one another as described in Table 3 below.) SUBSTITUTE SH EET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 TABLE OF FUNCTIONAL GROUPS
nt aa nt aa ORF Name SeqID SeqID ORF N~ne SeqIDSeqID
# # # #
Row 1 2 3 4 A. CELL ENVELOPE
A. l . Flagella-associated OlgplO4010rfl 10201471 26588588.aa 217 660 OlgplO4010rf5 10211472 26588588.aa 217 660 02ael 16120rf21 10361487 6288949.aa 367 855 02celO2130rf7 10501501 22692187.aa 911 534 02ge201160rf34 10711522 29454837.aa 944 675 04ge 117130rf5 11011552 1171928.aa 18 404 04gell7130rf5 11011552 21699087.aa 107 518 05ep203220rfl l 11351586 16219090.aa 894 464 12ge203050rfl l 12761727 29298130.aa 943 672 06cp203020rfl2 11501601 25525277.aa 203 640 07ge204150rf27 11871638 19557055.aa 85 490 07ge204150rf27 11871638 36111066.aa 290 755 07ge311070rf2 11921643 104792.aa 5 389 29zplO2410rf6 13611812 24882763.aa 199 635 hp2elO91 lorf5 13791830 917152.aa 992 877 hp3el 11220rfl 13991850 25478375.aa 934 637 hp3el 11680rf2 14031854 16984442.aa 899 477 hpel 11220rf5 14001851 3942217.aa 302 772 07ge204150rf34 11891640 26380318.aa 215 658 A.2. Inner membrane proteins Olcel 10160rfl 10021453 O9apl 14060rfl4 12131664 16131887.aa 893 463 O9apl 14060rfl5 12141665 6093906.aa 984 852 O9apl 14060rf5 12151666 2082012.aa 97 503 llcell6030rfl6 12341685 1204418.aa 22 411 1 lcel 16030rfl6 12341685 14455461.aa 49 441 1 lcel 16030rf25 12361687 4035783.aa 309 782 1 lcel 16030rf6 12371688 23915877.aa 150 575 O9cplO5020rf22 12241675 30730068.aa 240 691 O9cplO5020rf22 12241675 3385833.aa 957 724 11gplO9040rf29 12511702 14713512.aa 57 452 12aplO3240rf2 12621713 10353192.aa 2 386 06cp203020rflO 11491600 203192.aa 92 497 O9ap208020rf5 12201671 32704686.aa 255 712 11gelO3090rfl4 12401691 24222885.aa 164 591 11gelO3090rfl4 12401691 2548562.aa 201 638 06gp 104090rf7 11641615 34666680.aa 278 740 06gplO4090rf8 11651616 3203142.aa 245 697 SUBSmUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 hp3elll680rf29 1404 1855 23853165.aa 921 569 06cpllll80rf6 1144 1595 16412593.aa 896 470 06cpllll80rf6 1144 1595 32236462.aa 248 700 07ee205130rf28 1182 1633 24132293.aa 159 586 07ee205130rf28 1182 1633 486075.aa 979 823 06eplO3060rfl2 1157 1608 24651083.aa 194 627 06eplO3060rf3 1160 1611 24651083.aa 194 627 06eplO3060rf3 1160 1611 30089217.aa 946 684 13epl20030rf20 1300 1751 23493756.aa 916 551 14gelO7050rfll 1321 1772 17086587.aa 76 478 14gelO7050rfll 1321 1772 21486677.aa 905 508 14gelO7050r~ 1 1321 1772 23468781.aa 914 545 14gelO7050rfll 1321 1772 24708129.aa 931 628 14gpll8200rfl3 1323 1774 14494077.aa 50 443 14gpll8200r~ 3 1323 1774 3242337.aa 250 702 14gpll8200rfl3 1323 1774 3962777.aa 969 776 14gpl20150rfl2 1329 1780 15824052.aa 66 461 14gpl20150r~ 2 1329 1780 34489543.aa 275 737 14gpl20150rfl6 1332 1783 4698838.aa 330 809 27zelO351orfl7 1345 1796 25605166.aa 204 642 29zplO2410rfl4 1358 1809 9776562.aa 383 879 hplpl39470rf2 1375 1826 3953143.aa 303 773 hp4pll3520rf4 1417 1868 16406265.aa 70 468 13apll5170rf20 1283 1734 5267037.aa 983 842 16aelOl130rfl 1335 1786 423131.aa 972 788 hplpl39220rf22 1368 1819 24611590.aa 929 624 07eell6200rf2 1179 1630 423131.aa 972 788 12aelO6220rf9 1255 1706 259665.aa 936 644 12aelO6220rf9 1255 1706 34097707.aa 267 727 12aell4040rfl5 1258 1709 24806290.aa 197 631 02celO2130r~ 4 1044 1495 14645905.aa 55 450 12gelO3050rfl5 1273 1724 14642202.aa 54 448 Olxe217170r~ 8 1024 1475 26261040.aa 210 653 A.3.Transporters O9ap208020rf27 1219 1670 20032561.aa 90 495 12gelO3050rfl6 1274 1725 11132778.aa 15 400 O9aell6010r~ 4 1210 1661 23439633.aa 913 541 O9aell6010rfl4 1210 1661 29302003.aa 227 673 hp5ell7260rf7 1422 1873 179677.aa 79 482 14cellll30rfl 1302 1753 24609593.aa 191 622 14cplO119orfl2 1308 1759 30662792.aa 238 689 14cplO119orfl5 1310 1761 34427317.aa 274 736 14gpl20150r~ 4 1331 1782 12617677.aa 27 417 hp5el54400rfl6 1432 1883 33203192.aa 258 716 hp5el54400rfl6 1432 1883 36573502.aa 295 762 02cellO220rf7 1052 1503 1071890.aa 10 395 04eplO81lorf4 1091 1542 24215.aa 160 587 SUBSTITUTE SH EET (RULE 26) -CA 0222339~ 1997-12-03 W O 96/40893 PCTAUS96/09lZ2 04ep 10811 orf4 1091 1542 289711.aa 225 669 hp5ell7260rf4 1421 1872 36203402.aa 964 758 02ge201160rf28 1069 1520 24238762.aa 166 593 Olcel 15130rf21 1005 1456 1464715.aa 56 451 Olcel 15130rf21 1005 1456 4882763.aa 980 827 Olcel 16180rflO 1007 1458 207817.aa 903 502 06gpl 12020rf7 1166 1617 33399142.aa 261 719 07cp217140rfl3 1177 1628 16406581.aa 71 469 07gpll8070rf25 1193 1644 3319687.aa 955 715 07gpl 18070rfg 1206 1657 5875152.aa 361 847 07gpl 18070rf9 1207 1658 14714687.aa 58 453 14ce202190rfl 1304 1755 22441050.aa 114 527 14ce202190rf2 1305 1756 26258562.aa 940 652 27zelO3510rfl8 1346 1797 35345228.aa 960 745 27zelO3510rf24 1348 1799 23728388.aa 144 567 27zelO3510rf29 1350 1801 5878208.aa 362 848 02ael 161 lorfl 1 1032 1483 13726562.aa 40 430 02ael 161 lorfl 1 1032 1483 35428912.aa 285 748 02cel 10220rf8 1053 1504 10723412.a~ 11 396 02cel 10220rf8 1053 1504 24218968.aa 161 588 02cel 10220rf8 1053 1504 4455467.aa 974 795 03eel 12150rf29 1081 1532 22265691.aa 111 523 05cpll9110rf41 1124 1575 4338438.aa 316 791 hp2plO6250rf28 1382 1833 32952.aa 257 714 hp5pl56410rfl2 1437 1888 17787558.aa 78 481 12aplO3240rf3 1263 1714 3906712.aa 966 765 A.4. Outer membrane proteins 07ap806010rf8 1173 1624 5083193.aa 352 837 hp3el 11680rf30 1405 1856 4960952.aa 981 833 hp3plOl560rfl2 1406 1857 24104558.aa 158 585 hp4el33940rf2 1410 1861 7116626.aa 989 865 04cel 16170rf2 1086 1537 36126938.aa 963 764 14ge 107050rf5 1322 1773 1431462.aa 48 440 14ge 107050rf5 1322 1773 16225006.aa 68 465 12aplO3240rf7 1266 1717 23531562.aa 135 555 13aelO7120rf9 1282 1733 22379952.aa 910 526 12gelO3050rfl 1271 1722 30478562.aa 236 687 12gelO3050rfl 1271 1722 31250333.aa 241 692 07gp315160rf4 1208 1659 31262.aa 949 693 05cp205180rf33 1126 1577 29479681.aa 945 677 12ap 116140rf8 1270 1721 26054702.aa 207 649 - 12ge203050rf2 1278 1729 4721061.aa 977 812 A.5. Other cell envelope proteins hp4pl 13520rf9 1419 1870 4821082.aa 978 820 05cp205180rf3 1125 1576 978477.aa 994 880 07ee205130rfl4 1181 1632 24220627.aa 163 590 hp4pl 13520rf2 1416 1867 32705252.aa 256 713 SUBSTITUTE 5HEET (RULE 2~) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 hp4pl 13520rf2 1416 1867 35445843.aa 287 750 04gel 17130rfl 1 1096 1547 24427340.aa 184 613 03eel 12150rf30 1082 1533 1416312.aa 45 437 06cpl 17220rfl5 1146 1597 23535937.aa 136 556 06cpl 17220rfl5 1146 1597 26366312.aa 214 657 06cpl 17220rfl2 1145 1596 114505.aa 16 402 05ae202200rf32 1108 1559 2461062.aa 192 623 06cpl 17220rf21 1148 1599 6828218.aa 373 862 16aelO5080rfl3 1337 1788 14642217.aa 892 449 16aelO5080rfl4 1338 1789 30703183.aa 239 690 hp5el29820rfl4 1424 1875 1365943.aa 34 424 01 ae22001 orf2 1000 1451 4826401.aa 340 821 Olxe217170rf5 1027 1478 1385937.aa 41 432 Olxe217170rf5 1027 1478 4714375.aa 332 811 07celO2030rf22 1175 1626 23526667.aa 134 554 14gpl20150rfl3 1330 1781 4698838.aa 330 809 B. CYTOPLASAMIC PROTEINS
B. l . Proteins involved in energy conversion 06cp 117220rfl 6 1147 1598 10553192.aa 882 390 13eelO2160rf55 1288 1739 914087.aa 382 876 14gpl 18200rf20 1324 1775 23475342.aa 130 547 hplpl 12440rf7 1363 1814 29500075.aa 230 678 B.2. Proteins involved in amino acid metabolism 01 ae 12021 orfl 997 1448 34109763.aa 269 729 Oleel 16210rf6 1015 1466 4177212.aa 312 786 03ge311060rfl 1084 1535 26301059.aa 211 654 04ep714030rfl5 1094 1545 34194093.aa 959 734 04gel 17130rf37 1099 1550 25992137.aa 938 646 O9gplO9030rf3 1229 1680 21976637.aa 110 522 11gplO9040rf27 1250 1701 31681556.aa 244 696 12apl 16140rf4 1268 1719 45914063.aa 328 807 13eel20160rflO 1293 1744 30082267.aa 235 683 16ae 105080rf21 1339 1790 429192.aa 315 790 hp3plO3490rfl6 1408 1859 36594167.aa 296 763 hp5el52110rf22 1429 1880 4578469.aa 976 806 hp5el 54400rfl9 1434 1885 4492217.aa 321 799 O9cplO7130rf29 1228 1679 1408.aa 43 434 02ael 161 lorfl 1031 1482 35269000.aa 281 743 02ael 16120rfl3 1034 1485 4570262.aa 326 804 Olcel 16180rfl8 1008 1459 34189716.aa 272 733 B.3. Proteins involved in nucleotide metabolism 02cp20821 orfl 0 1061 1512 4882652.aa 344 826 02ep306070rfl 0 1064 1515 23598962.aa 139 562 07ge204150rf6 1191 1642 12897656.aa 30 420 O9ap208020rfl 1217 1668 2738378.aa 220 664 hplpl38520rK 1365 1816 598933.aa 364 850 hp3el 10240rf24 1394 1845 6517040.aa 369 857 SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O g6/~95~ PCT~US96/09122 hp4el45350rf3 1414 1865 677088.aa ~ 372 861 hp4el45350rf4 1415 1866 867183.aa 991 872 hp5el54400rf21 1435 1886 23442642.aa 128 544 02cpll8220rf22 1058 lSO9 4895327.aa 347 830 02cpl 18220rf26 lOS9 lS10 14574201.aa 52 446 B.4. Proteins involved in carbohydrate metabolism 03eell2150rf26 1080 1531 10737627.aa 12 397 05cp205180rfS 1128 1579 32144532.aa 247 699 05cp205180rf64 1133 1584 15807794.aa 64 459 O9ae 11601 orf3 1211 1662 2149041.aa 101 SO9 1 lgpl 14220rfl 1252 1703 4787562.aa 338 818 1 lgpl 14220rf2 1253 1704 19541302.aa 83 488 13eelO2160rf43 1286 1737 14257751.aa 46 438 13eelO2160rf56 1289 1740 4897177.aa 348 831 13ee 102160rf9 1291 1742 2855006.aa 223 667 14cel lSl9orf2 1303 1754 13723593.aa 39 429 hp3el 10600rfl 1 1396 1847 29557266.aa 232 680 Olael 14210rfl 996 1447 24300682.aa 168 597 B.S. Proteins involved in cofactor metabolism 04ge 108160rf2 l O9S 1546 1581937.aa 65 460 06eelO7090rfS 1156 1607 3261306.aa 952 709 06eplO3060rfl3 1158 1609 485375.aa 341 822 06eplO3060rfl4 1159 1610 16251627.aa 69 466 12ge203050rfl4 1277 1728 24089437.aa 924 584 02ael 16120rf26 1038 1489 10407625.aa 4 388 B.6. Proteins involved in lipid metabolism 12ael 14040rfl4 1257 1708 24806290.aa 197 631 29zplO2410rfll 1357 1808 422937.aa 313 787 hpSelS4400rf22 1436 1887 22667967.aa 119 532 B.7. Proteins involved in mRNA kanslation and ribosome biogenesis 02ce 102130rf2 1047 1498 24500088.aa 188 619 02cpl 14040rfl 1 lOSS 1506 33601578.aa 956 723 06celOSlSorf4 1141 1592 25595387.aa 935 641 O9cplO7130rf28 1227 1678 32036462.aa 246 698 14gpl 18200rfS 1327 1778 24803280.aa 196 630 hp4el45220rfl 1 1412 1863 785437.aa 376 869 B.8. Proteins involved in genome replication.
kanscription~ recombination& repair Olcel 10160rfl4 1003 1454 24396937.aa 172 601 04cel 16170rf27 1087 1538 12520952.aa 25 415 - OSapl lSOSorfl 1116 1567 23440814.aa 126 542 OScp205180rfS6 1130 1581 32431687.aa 9S 1 704 OScp205180rf63 1132 1583 23880087.aa 147 572 07gel 15040rf4 1185 1636 16305252.aa 895 467 07ge204150rf30 1188 1639 10745275.aa 14 399 07gpll8070rf35 1198 1649 24036302.aa 154 579 SUBSTITVTE SHEFT (RULE 2611 CA 0222339~ 1997-12-03 W O 96/40893 . PCTAUS96/09122 O9ap208020rf22 1218 1669 34574062.aa 277 739 O9ap208020rf22 1218 1669 5879160.aa 363 849 11gelO3090rfSl 1244 1695 487750.aa 342 824 14ce215160rfl 1306 1757 85786.aa 378 871 14gpl 18200rf27 1325 1776 23475342.aa 130 547 hp3ellO600rf2 1397 1848 24818802.aa 198 633 hp3el 10600rf9 1398 1849 3166040.aa 243 695 hp3plOl560rf8 1407 1858 11719687.aa 19 405 hp5elS4400rfl8 1433 1884 10677187.aa 9 394 hpSelS4400rfl8 1433 1884 36523442.aa 761 B.9. Proteins involved in outer membrane or cell wall biosynthesis O9apl 14060rf8 1216 1667 23912807.aa 149 574 O9apl 14060rf8 1216 1667 24298127.aa 167 596 1 lepl201 lorf9 1239 1690 495312.aa 349 832 29zp 10241 orf7 1362 1813 26197187.aa 209 651 Olep305200rfl6 1017 1468 7225666.aa 990 867 01 ep305200rf27 1019 1470 24441412.aa 185 614 Olep305200rf27 1019 1470 11253.aa 883 401 29zplO2410rf4 1360 1811 10675632.aa 8 393 B.10. Ch~lones hpSel29820rfl3 1423 1874 12343763.aa 887 413 hp5el521 lorflO 1425 1876 50253.aa 350 835 hplpl39470rfl 1374 1825 6845425.aa 987 863 B. l l Other cytoplasmic proteins 01 xe217170rf9 1028 1479 156587.aa 63 458 02ael 16120rf25 1037 1488 32422343.aa 249 701 03ee 112150rfl 0 1077 1528 22542803.aa 118 531 OSae202200rf99 1115 1566 23492181.aa 132 550 11celO9170rfl4 1232 1683 14313885.aa 47 439 11gelO3090rfl5 1241 1692 21647676.aa 106 516 12apl 16140rf2 1267 1718 4562712.aa 324 802 06gelOl lSorfl5 1163 1614 24070250.aa 155 581 02ge201160rf22 1068 lSl9 22704567.aa 121 535 02ge201160rf22 1068 lSl9 24003758.aa 153 578 02ge201160rf22 1068 1519 19626250.aa 87 492 02cpl 14040rf9 1056 1507 6517192.aa 986 858 03aelO5160rfl l 1072 1523 33476715.aa 262 720 03aelOS160rfl 1 1072 1523 4726503.aa 333 813 03ap218200rflO 1073 1524 13673328.aa 36 426 04ep714030rflO 1092 1543 50062.aa 982 834 04gpl 12130rB6 1102 1553 24414687.aa 180 609 04gp 112130rf60 1103 1554 19556290.aa 84 489 05aelO3070rfl 1104 1555 17497107.aa 900 480 05ae202200rf54 1111 1562 1179838.aa 20 406 05cpl 191 lorfl 1 1119 1570 10664078.aa 7 392 05gpl l901orf20 1136 1587 15039062.aa 61 456 SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 WO 96/40893 PCT~US96/09122 05gpll901orf24 1137 1588 32600912.aa 253 707 06aell4050rflO 1140 lS91 22687687.aa 120 533 06cellOO20rf2 1142 1593 34099062.aa 268 728 llcelO9170rf9 1233 1684 391313.aa 299 769 llcpl20060rfl7 1238 1689 291700.aa 942 671 llgelO3090rf25 1243 1694 24406401.aa 173 602 llgelO3090rfS6 1245 1696 24495312.aa 187 618 llgelO3090rf66 1247 1698 24495312.aa 187 618 llgplO9040rfl2 1249 1700 29844512.aa 234 682 12aell4040rf9 1261 1712 22303918.aa 112 524 12apll6140rf6 1269 1720 4562712.aa 324 802 12ge203050rf30 1279 1730 4095342.aa 971 785 13apll5170rB 1 1284 1735 15126875.aa 62 457 13eelO2160rf82 1290 1741 4035262.aa 308 781 13eel20160rf24 1297 1748 16459375.aa 74 473 14gpl20150rfl 1328 1779 10009666.aa 1 384 hplpl39220rf30 1370 1821 34089087.aa 266 726 hplpl39390rfl3 1372 1823 4766691.aa 337 817 hp2elO9llorf25 1377 1828 2035936.aa 93 498 hp2plO6250rf30 1383 1834 1411681.aa 44 436 hp2plO6250rf7 1384 1835 4740887.aa 335 815 hp2plO6250rf8 1385 1836 6495137.aa 368 856 hp3elO3490rfl8 1388 1839 260941.aa 208 650 hp3elll680rfl4 1401 1852 5325005.aa 358 844 hp3elll680rfl5 1402 1853 24039587.aa 923 580 hp4pll3520rf8 1418 1869 4040928.aa 310 783 hp4pl34020rfl 1420 1871 1256885.aa 26 416 hp5el52110rfl5 1427 1878 35156938.aa 279 741 02ge201160rf33 1070 1521 14480927.aa 890 442 06cp203020rf8 llSl 1602 4569693.aa 325 803 07cell4090rf4 1176 1627 21742157.aa 109 520 Olael2021orf8 999 1450 23646885.aa 143 566 Olcell5130rf24 1006 1457 23539006.aa 918 557 Olcpll7100rf27 1012 1463 32595137.aa 252 706 Olep305200rf20 1018 1469 32627125.aa 953 710 02ael121lorfl9 1030 1481 19537968.aa 902 487 02ael161lorfS 1033 1484 24407533.aa 174 603 02celOl140rfl 1041 1492 16440842.aa 73 472 02celO2130rB2 1049 lSOO 16839562.aa 898 476 02cell2200rf2 1054 1505 3930468.aa 300 770 02cpll7210rfl3 1057 1508 5265957.aa 356 841 04eplO81lorfl 1090 1541 3907042.aa 298 768 04gell7130rf27 1097 1548 5111308.aa 354 839 OScp205180rfSO 1129 1580 23573294.aa 138 560 06aellO200rf2 1139 1590 4486092.aa 319 796 06cellOO20rf8 1143 1594 194415.aa 80 483 06cp306030r~ 1 1152 1603 24824087.aa ~ 933 634 SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 06eelO2070rf2 1153 1604 14572133.aa 891 445 06eelO7090rfl7 1155 1606 6136430.aa 366 853 06eplllO80rf20 1161 1612 22370182.aa 113 525 06gelOllSorfl2 1162 1613 4491093.aa 320 798 07aplllllorf3 1169 1620 23490686.aa 91S 549 07ap80601orflO 1170 1621 5078593.aa 351 836 07ap806010rfl2 1171 1622 24219012.aa 162 589 07ee205130rfl 1180 1631 36520792.aa 965 760 07gpll8070rf28 1194 1645 16100038.aa 67 462 07gpll8070rf29 ll9S 1646 42683.aa 314 789 07gpll8070rf38 1199 1650 214812.aa 904 507 07gpll8070rf41 1200 1651 4882842.aa 345 828 07gpll8070rf42 1201 1652 719606.aa 374 866 07gpll8070rf44 1202 1653 35949212.aa 962 754 07gpll8070rfS4 1205 1656 34161500.aa 270 730 14cplO9230rfl 1312 1763 24492192.aa 186 617 16aelOS080rflO 1336 1787 14864452.aa 60 455 27zelO3510rf25 1349 1800 875042.aa 379 873 29gplO119orf6 1355 1806 14094816.aa 889 435 29zplO2410rfl8 1359 1810 3906937.aa 967 766 hp4el45350rf2 1413 1864 43490713.aa 973 793 hpSelS21lorfl3 1426 1877 35163962.aa 280 742 hpSelS21lorf29 1430 1881 24329712.aa 170 S99 625277.aa 985 854 24816915.aa 932 632 C. SECRETED OR PERIPLASMIC PROTEINS
C.l. Secreted orperiplasmic proteins OlcellOl60rfl9 1004 1455 22460468.aa 117 530 OSgpll901orf25 1138 1589 32609403.aa 254 708 02ge201160rf20 1067 1518 12505125.aa 24 414 03eell2150rflS 1078 1529 3157067.aa 242 694 14cplO9230rf3 1314 1765 3242952.aa 950 703 14eell2170rfl 1319 1770 33595708.aa 263 721 14eell2170rfl 1319 1770 35442513.aa 286 749 hp2elO9llorf30 1378 1829 30100332.aa 947 685 OSae202200rfl24 llOS 1556 14570443.aa 51 444 05ae202200rf92 1114 1565 24410643.aa 177 606 OSap212160rf7 1118 1569 24078837.aa 156 582 05cpll91lorfl2 1120 1571 24609431.aa 190 621 05cpll91lorf27 1123 1574 783432.aa 375 868 05cp205180rf41 1127 1578 2843912.aa 222 666 O9aell601orf4 1212 1663 11876471.aa 21 408 O9cplO5020rfl7 1223 1674 23438887.aa 912 538 O9cplO7130rf25 1225 1676 23912707.aa 148 573 llgelO3090rf63 1246 1697 25501501.aa 202 639 llgelO3090rf9 1248 1699 289077.aa 224 668 12aell4040rf3 1259 1710 22303918.aa ~ 112 524 SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 9''~D~9~ PCTrUS96/09lZ2 12aplO3240rf4 1264 1715 13178562.aa 32 422 12ap 103240rf5 1265 1716 4805318.aa 339 819 13aelO7120rf4 1281 1732 24416083.aa 182 611 13apl 15170rf7 1285 1736 29386577.aa 228 674 13eel20160rflS 1294 1745 23958179.aa 152 577 13eel20160rf5 1298 1749 272058.aa 219 663 - 13eel20160rf8 1299 1750 23564012.aa 137 558 14cplO9230rf8 1315 1766 4414000.aa 318 794 14cpl 11210rf6 1316 1767 23631292.aa 141 564 14ee 103080rf8 1317 1768 24230058.aa 165 592 14eelO3080rf9 1318 1769 4728193.aa 334 814 16eplOl 170rf8 1344 1795 10742963.aa 13 398 27zelO3510rf5 1351 1802 3906963.aa 297 767 29gelOl l lorfl 1353 1804 1367157.aa 35 425 hplpl39390rf9 1373 1824 26423583.aa 216 659 hp2ell8580rf5 1380 1831 21687842.aa 908 517 hp3elO3490rfl7 1387 1838 23439055.aa 124 539 hp3elO3490rf~4 1389 1840 16603418.aa 75 475 hp3el 10240rf22 1393 1844 2445812.aa 927 615 hp3el 10240rf22 1393 1844 2774062.aa 221 665 hp4el33940rf5 1411 1862 24411011.aa 178 607 hp5el521 lorf21 1428 1879 24328910.aa 169 598 hp5el52760rfl4 1431 1882 36335436.aa 293 759 hp5plS6410rf8 1439 1890 35837767.aa 289 752 02celO2130rfl 1 1043 1494 24276587.aa 926 595 07gel 15040rf2 1183 1634 30283516.aa 948 686 07gel 15040rf3 1184 1635 22447252.aa l lS 528 07gpl 18070rf32 1196 1647 32462543.aa 251 705 07gpl 18070rf33 1197 1648 4882842.aa 345 828 07gpl 18070rf48 1203 1654 116018.aa 17 403 Olael 14030rfl 99S 1446 23594838.aa 920 561 Olael20210rf7 998 1449 20415937.aa 9S SOO
OlcelOS160rf2 1001 1452 1962590.aa 86 491 Olgpl 10160rfl4 1022 1473 5869090.aa 360 846 01 xe217170rfl 2 1023 1474 34179577.aa 271 732 02ael 121 lorflO 1029 1480 3987580.aa 970 778 02ael 16120rf4 1040 1491 35704718.aa 288 751 02celO2160rfl lOSl 1502 35336707.aa 282 744 02cp208210rfl2 1062 1513 20836042.aa 98 504 02cp20821 orfl 2 1062 1513 12698442.aa 29 419 06eelO7090rfl6 1154 1605 4339708.aa 317 792 14epl l l lSorfl 1320 1771 4882318.aa 343 825 C.2. Proteins likely to be secreted or periplasmic 03ap218200rfS 1075 1526 36131282.aa 291 756 OSae202200rf24 1106 1557 21720017.aa 108 519 OSae202200rf50 1109 1560 80257.aa 377 870 OScp205180rf9 1134 1585 3964593.aa .305 777 SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 . PCT~US96/09122 05cp205180rf9 1134 1585 4687507.aa 305 808 O9cplO5020rfl4 1221 1672 2111040.aa 100 506 O9cplO7130rf26 1226 1677 7031343.aa 988 864 1 lcel 16030rf22 1235 1686 26306340.aa 212 655 14celO7200rf2 1301 1752 1181418.aa 884 407 14cplO119orf7 1311 1762 1370202.aa 37 427 14gpl 18200rf4 1326 1777 3953952.aa 968 774 16cp30109orf6 1341 1792 4490717.aa 975 797 29gplO119orf5 1354 1805 30603402.aa 237 688 hplpl 12560rf7 1364 1815 4740887.aa 335 815 hplpl38680rf24 1366 1817 33397538.aa 260 718 hplpl40130rf4 1376 1827 663530.aa 370 859 hp3el 10240rfl6 1391 1842 20173437.aa 91 496 hp3ellO240rfl6 1391 1842 34573431.aa 276 738 hp3el 10240rf6 1395 1846 4062813.aa 311 784 hp6p 107230rf7 1445 1896 24406401.aa 173 602 03eel 12150rf20 1079 1530 2150290.aa 102 510 07ge204150rf22 1186 1637 3958537.aa 304 775 Olcel 16180rf20 1010 1461 882827.aa 380 874 01 ep 102160rf6 1016 1467 23441078.aa 127 543 07ap80601 orf5 1172 1623 917200.aa 993 878 04gel 17130rf35 1098 1549 24256572.aa 925 594 03ap218200rf9 1076 1527 24415917.aa 181 610 07celO2030rfl4 1174 1625 24395801.aa 171 600 D. OTHER SURFACE AND MEMBRANE PROTEINS
D. l . Proteins likely to contain a single membrane spanning region 02cp 118220rf8 1060 1511 907827.aa 381 875 05ae202200rf51 1110 1561 29458178.aa 229 676 OSae202200rf6 1112 1563 4548792.aa 323 801 11aelO3050rf4 1230 1681 6696887.aa 371 860 12ael 14040rf8 1260 1711 35417942.aa 284 747 12ge203050rf35 1280 1731 22453166.aa 116 529 13eel 17180rf2 1292 1743 1038312.aa 3 387 13eel20160rfl9 1296 1747 10580417.aa 6 391 13ee 120160rfl 9 1296 1747 21618785.aa 907 515 14ce215160rf3 1307 1758 24634750.aa 193 625 hp6plO7230rf20 1442 1893 23831562.aa 145 568 hp6plO7230rf5 1444 1895 14726542.aa 59 454 02ce 102130rfl 1042 1493 4531568.aa 322 800 02ael 16120rf36 1039 1490 2040717.aa 94 499 04gel 17130rf41 1100 1551 3991067.aa 306 779 10037799.aa 881 385 D.2. Proteins likely to contain two membrane spans O5cpll9110rflS 1122 1573 26052137.aa 939 648 12ae 106220rfl 6 1254 1705 25925.aa 205 643 12ael 14040rfl2 1256 1707 23438840.aa ,~ 123 537 SUBSTITUTE SHEET (RULE ~6) CA 0222339~ 1997-12-03 W O 96/40893 ~ PCTAUS96/09122 12gelO3050rflO 1272 1723 21503772.aa 906 Sl l 12gelO3050rflO 1272 1723 24488537.aa 928 616 12gelO3050rf21 1275 1726 489057.aa 346 829 14cplO119orfl4 1309 1760 23473437.aa 129 546 14cplO119orfl4 1309 1760 40339452.aa 307 780 14cplO9230rfl4 1313 1764 23515833.aa 133 553 27ze 10351 orf22 1347 1798 23486342.aa 131 548 27zelO3510rf7 1352 1803 11924177.aa 886 410 29gplO119orf7 1356 1807 24413512.aa 179 608 hpSplS6410rfS 1438 1889 21563752.aa 104 513 hp6plO7230rfl3 1441 1892 26351567.aa 213 656 Olcel 16180rfl9 1009 1460 55843.aa 359 845 Olxe217170rf40 1026 1477 23610905.aa 140 563 02ce 102130rf23 1048 1499 23867207.aa 146 570 02cp20821 orf8 1063 1514 4572168.aa 327 805 07ge204150rf39 1190 1641 5993958.aa 365 851 D.3. Proteins likely to contain 3 membrane sp~nnin~ regions 03gelOSOSorfl4 1083 1534 1364378.aa 33 423 OSae202200rf88 1113 1564 4708337.aa 331 810 O9cp 105020rfl 6 1222 1673 24409577.aa 175 604 13eel20160rfl8 1295 1746 25398250.aa 200 636 16eplOl 170rf7 1343 1794 36134661.aa 292 757 hp3el 10240rfl7 1392 1843 1206675.aa 23 412 hp6plO7230rf43 1443 1894 4744128.aa 336 816 D.4. Proteins likely to contain 4 membrane .~p~nnin~ re~ions 03xel 12150rf5 1085 1536 3933437.aa 301 771 04ep714030rfl 2 1093 1544 12694087.aa 28 418 OSapl lSOSorflO 1117 1568 26758437.aa 941 662 OScpl 191 lorfl3 1121 1572 21511555.aa 103 512 OScpll9110rfl3 1121 1572 29531590.aa 231 679 OScp205180rf61 1131 1582 24409641.aa 176 605 13eelO2160rf5 1287 1738 12969218.aa 31 421 13eelO2160rfS 1287 1738 23494043.aa 917 552 hp5p 15641 orf9 1440 1891 23945317.aa 151 576 O9ael 16010rfl 1 1209 1660 23867687.aa 922 571 D.S. Proteins likely to contain S membrane sp~nnin~ regions 16ep 101170rf6 1342 1793 hp2plO6250rfl4 1381 1832 33986087.aa 265 725 hp3elO3490rf25 1390 1841 23631317.aa 142 565 hp3plO3490rf32 1409 1860 33218912.aa 259 717 02ael 16120rfl4 1035 1486 23437502.aa 122 536 25995917.aa 206 647 11878127.aa 885 409 D.6. Proteins likely to contain 6 membrane sp~nnin~ regions Olcpl 17100rf34 1014 1465 2042312.aa 96 SOl Olcpl 17100rf34 1014 1465 5083577.aa 353 838 04eplO2060rf~2 1088 1539 13704718.aa 38 428 SUBSTITUTE SHEFT (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 04eplO2060rf22 1088 1539 20023400.aa 89 494 11gelO3090rfl8 1242 1693 17089217.aa 77 479 07cp217140rfl4 1178 1629 32663212.aa 954 711 07cpZ17140rfl4 1178 1629 3360130.aa 264 722 D.7. Proteins likely to contain 7 or more membrane spanning regions 04eplO2060rf23 1089 1540 25976418.aa 937 645 04eplO2060rf23 1089 1540 2915903.aa 226 670 16aelO5080rf3 1340 1791 35360843.aa 283 746 03ap218200rfl 3 1074 1525 197166.aa 88 493 03ap218200rfl 3 1074 1525 234391.aa 125 540 03ap218200rfl3 1074 1525 24417212.aa 183 612 O5ae202200rf31 1107 1558 24798427.aa 195 629 07gpll8070rf49 1204 1655 19531291.aa 81 484 07gpl 18070rf49 1204 1655 19536375.aa 901 485 02ep306070rf31 1066 1517 19536458.aa 82 486 02ep306070rf31 1066 1517 13865928.aa 42 433 [In Table 1, "nt" represents nucleotide Seq. ID number and "aa" r~lese~ amino Seq. ID number]
Definitions A purified or isolated polypeptide or a substantially pure ~,ep~dlion of a polypeptide are used interchangeably herein and, as used herein, mean a polypeptide that has been separated from other proteins, lipids, and nucleic acids with which it naturally occurs. Preferably, the polypeptide is also separated from substances, e.g., antibodies or gel matrix, e.g., polyacrylamide, which are used to purify it. Preferably, the polypeptide constitutes at least 10, 20, 50 70, 80 or 95% dry weight of tbe purified preparation.
Preferably, the ~ p~dlion contains: sufficient polypeptide to allow protein sequencing; at least 1, 10, or 100 ,ug of the polypeptide; at least 1, 10, or 100 mg of the polypeptide.
A purified ~l~a dLion of cells refers to, in the case of plant or animal cells, an in vitro pl~i~dlion of cells and not an entire intact plant or animal. In the case of cultured cells or microbial cells, it consists of a pr~alalion of at least 10% and more preferably 50%
of the subject cells.
A purified or isolated or a subst~nt~ y pure nucleic acid, e.g., a substantially pure DNA, (are terms used interchangeably herein) is a nucleic acid which is one or both of the following: not imm~rli~tt~ly contiguous with both of the coding sequences with which it is imme~ tely contiguous (i.e., one at the 5' end and one at the 3' end) in the naturally-occurring genome of the organism from which the nucleic acid is derived; or which is subst~nti~lly free of a nucleic acid with which it occurs in the organism from which the nucleic acid is derived. The term includes, for example, a recombinant DNA which is incorporated into a vector, e.g., into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease tre~tment) independent of other DNA sequences. Substanti,a~y pure DNA also includes a SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 9f'1L~9~ . PCTrUS96/09122 recombinant DNA which is part of a hybrid gene encoding additional H. pylori DNAsequence.
A "contig" as used herein is a nucleic acid ~~ S~ a continuous stretch of genomic sequence of an organism.
S An "open reading frame", also l~f._~lcd to herein as ORF, is a region of nucleic acid which encodes a polypeptide. This region may represent a portion of a coding sequence or a total sequence and can be cleterminPcl from a stop to stop codon or from a start to stop codon.
As used herein, a "coding sequence" is a nucleic acid which is transcribed into m~c~Pn~er RNA and/or tr~ncl~fP~ into a polypeptide when placed under the control of ap~lu~liate regulatory sequences. The boundaries of the coding sequence are ~letPrminPd by a translation start codon at the five prime tPrrninllC and a translation stop code at the three prime t'~ uc A coding sequence can include but is not limited to mPssen~er RNA, synthetic DNA, and recombinant nucleic acid sequences.
A "complement" of a nucleic acid as used herein referes to an anti-parallel or zlnti~Pnce sequence that participates in Watson-Crick base-pairing with the original sequence.
A "gene product" is a protein or structural RNA which is specifically encoded by a gene.
As used herein, the term "probe" refers to a nucleic acid, peptide or other chemical entity which specifically binds to a molecule of interest. Probes are often associated with or capable of associating with a label. A label is a chemical moiety capable of detection.
Typical labels comprise dyes, radioisotopes, lllminPscPnt and chemil~minPsc~nt moieties, fluorophores, enzymes, ~l~ci~ila~ g agents, amplification sequences, and the like.
Similarly, a nucleic acid, peptide or other chemical entity which specifically binds to a molecule of interest and immobilizes such molecule is referred herein as a "capture ligand".
Capture ligands are typically associated with or capable of associating with a support such as nitro-cellulose, glass, nylon membranes, beads, particles and the like. The specificity of hybridization is dependent on conditions such as the base pair composition of the nucleotides, and the telllp~ lule and salt concentration of the reaction. These conditions are readily ~ cPrn~hle to one of ordinary skill in the art using routine experiment~tion.
Homologous refers to the sequence similarity or sequence identity between two polypeptides or between two nucleic acid molecules. When a position in both of the two con~al~ed sequences is occupied by the same base or amino acid monomer subunit, e.g., if a position in each of two DNA molecules is occupied by ~clPninP7 then the molecules are homologous at that position. The percent of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared x 100. For example, if 6 of 10 of the positions in two sequences are m~tchPd or homologous then the two sequences are 60%

SUBSTITUTE 5HEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 homologous. By way of example, the DNA sequences ATTGCC and TATGGC share 50%
homology. Generally, a comparison is made when two sequences are aligned to give x;ll~ ll homology.
Nucleic acids are hybridizable to each other when at least one strand of a nucleic acid can anneal to the other nucleic acid under defined stringency conditions. Stringency of hybridization is dett?rminl~d by: (a) the te~ cldLul~e at which hybridization and/or washing is pc;.roll.led; and (b) the ionic strength and polarity of the hybridization and washing solutions. Hybridization requires that the two nucleic acids contain complement~ry sequences; depending on the stringency of hybridization, however, mi~m~t~h~s may be tolerated. Typically, hybridization of two sequences at high stingency (such as, for example, in a solution of 0.5X SSC, at 65~ C) requires that the sequences be esst?nti~lly completely homologous. Conditions of int~rmerli~tP stringency (such as, for example, 2X
SSC at 65 ~ C) and low stringency (such as, for example 2X SSC at 55~ C), require correspondingly less overall complem~nt~rity between the hybridizing sequences. (lX
SSC is 0.15 M NaCl, 0.015 M Na citrate).
The terms peptides, proteins, and polypeptides are used interchangeably herein.
As used herein, the term "surface protein" refers to all surface accessible proteins, e.g. inner and outer membrane proteins, proteins adhering to the cell wall, and secreted proteins.
A polypeptide has H. pylori biological activity if it has one, two and preferably more of the following ~lol,~lLies: (1) if when ~ 'essed in the course of an H. pylori infection, it can promote, or m~ fe the ~tt~rhment of H. pylori to a cell; (2) it has an enzymatic activity, structural or regulatory function characteristic of an H. pylori protein;
(3) or the gene which encodes it can rescue a lethal mutation in an H. pylori gene. A
polypeptide has biological activity if it is an antagonist, agonist, or super-agonist of a polypeptide having one of the above-listed propt;l Lies.
A biologically active fragment or analog is one having an in vivo or in vitro activity which is characteristic of the H. pylori polypeptides of the invention contained in the Sequence r i~ting, or of other naturally occurring H. pylori polypeptides, e.g., one or more of the biological activities described herein. Especially preferred are fr~gmentc which exist in vivo, e.g., fr~gment~ which arise from post transcriptional procecein~ or which arise from translation of alternatively spliced RNA's. Fragments include those expressed in native or endogenous cells as well as those made in expression systems, e.g., in CHO cells. Because peptides such as H. pylori polypeptides often exhibit a range of physiological properties and because such properties may be attributable to different portions of the molecule, a useful H. pylori fragment or H. pylori analog is one which exhibits a biological activity in any biological assay for H. pylori activity. Most preferably the fragment or analog possesses 10%, preferably 40%, more preferably 60%, 70%, 80% or 90% or greater of the activity of H. pylori, in any in vivo or in vitro assay.

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 Analogs can differ from naturally occurring H. pylori polypeptides in amino acidsequence or in ways that do not involve sequence, or both. Non-sequence modifications include changes in acetylation, metllylation, phosphorylation, carboxylation, or~ glycosylation. Preferred analogs include H. pylori polypeptides (or biologically active S fr~Pm~nt~ thereof) whose sequences differ from the wild-type sequence by one or more cons~ e amino acid substitutions or by one or more non-conservative amino acid substitutions, deletions, or insertions which do not subst~nti~liy ~limini~h the biological activity of the H. pylori polypeptide. Conservative substitutions typically include the substitution of one amino acid for another with similar ch~r~teristics~ e.g., substitutions 10 within the following groups: valine, glycine; glycine, alanine; valine, isoleucine, leucine;
aspartic acid, glutamic acid; asparagine, glllt~minl-; serine, threonine; lysine, arginine, and phenyl~l~nin~7 tyrosine. Other COllSt~l v~live substitutions can be made in view of the table below.

CONSERVATIVE AMINO ACID REPLACEMENTS

For Arnino Acid Code Replace with any of Alanine A D~Ala, Gly, beta-Ala, L-Cys, D-Cys Arginine R D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg, Met, Ile, D Met, D-Ile, Orn, D-Orn Asparagine N D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln Aspartic Acid D D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln Cysteine C D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr Gh-t~mine Q D Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp Glutarnic Acid E D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln Glycine G Ala, D-Ala, Pro, D-Pro"B-Ala, Acp Isoleucine I D-Ile, Val, D-Val, Leu, D-Leu, Met, D-Met Leucine L D-Leu, Val, D-Val, Leu, D-Leu, Met, D-Met Lysine K D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-- Met, Ile, D-Ile, Orn, D-Orn Methionine M D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val Phenylalanine F D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4, or S-phenylproline, cis-3,4, or 5-phenylproline SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 Proline P D-Pro, L-I-thioazolidine-4-carboxylic acid, D-or L-1-oxazolidine-4-carboxylic acid Serine S D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O), L-Cys, D-Cys Threonine T D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(O), D-Met(O), Vah D-Val Tyrosine Y D-Tyr, Phe, D-Phe, L-Dopa, His, D-His Valine V D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met Other analogs within the invention are those with modifications which increase peptide stability; such analogs may contain, for example, one or more non-peptide bonds (which replace the peptide bonds) in the peptide sequence. Also included are: analogs that 5 include residues other than naturally occurring L-amino acids, e.g., D-amino acids or non-naturally occurring or synthetic amino acids, e.g., ~ or y amino acids; and cyclic analogs.
As used herein, the term "fragmentl', as applied to an H. pylori analog, will ordinarily be at least about 20 residues, more typically at least about 40 residues, preferably at least about 60 residues in length. Fr~gment~ of H. pylori polypeptides can be generated 10 by methods known to those skilled in the art. The ability of a c~n-li(l~te fragment to exhibit a biological activity of H. pylori polypeptide can be ~sPsse~l by methods known to those skilled in the art as described herein. Also included are H. pylori polypeptides co~ ;..g residues that are not required for biological activity of the peptide or that result from ~l~ern~tive mRNA splicing or ~ltern~tive protein processing events.
An "immunogenic component" as used herein is a moiety, such as an H. pylori polypeptide, analog or fragment thereof, that is capable of eliciting a humoral and/or cellular immune response in a host animal.
An "antigenic co~l~pollent" as used herein is a moiety, such as an H. pylori polypeptide, analog or fragment thereof, that is capable of binding to a specific antibody 20 with sufficiently high affinity to form a detectable antigen-antibody complex.
As used herein, the term "transgene" means a nucleic acid (encoding, e.g., one or more polypeptides), which is partly or entirely heterologous, i.e., foreign, to the transgenic animal or cell into which it is introduced, or, is homologous to an endogenous gene of the transgenic animal or cell into which it is introduced, but which is designed to be inserted, or 25 is inserted, into the cell's genome in such a way as to alter the genome of the cell into which it is inserted (e.g., it is inserted at a location which differs from that of the natural gene or its insertion results in a knockout). A transgene can include one or more transcriptional regulatory sequences and any other nucleic acid, such as introns, that may be necessary for optimal expression of the selected nucleic acid. all operably linked to the selected nucleic 30 acid, and may include an enhancer sequence.

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 w o gc,~1ce~3 PCT~US96/09122 As used herein, the terrn "transgenic cell" refers to a cell cont~ining a transgene.
As used herein, a "transgenic animal" is any animal in which one or more, and preferably ee~l-nti~lly all, of the cells of the animal includes a transgene. The transgene can ~ be introduced into the cell, directly or indirectly by introduction into a precursor of the cell, 5 by way of deliberate genetic manipulation, such as by a process of transformation of - co,l,petent cells or by microinjection or by infection with a recombinant virus. This molecule may be integrated within a chromosome, or it may be extrachromosomally replicating DNA.
The term "antibody" as used herein is inten~ d to include fr~gment~ thereof which 10 are specifically reactive with H. pylori polypeptides.
As used herein, the term "cell-specific promoter" means a DNA sequence that serves as a promoter, i.e., regulates expression of a selected DNA sequence operably linked to the promoter, and which ef~ects expression of the selçct~o(l DNA sequence in specific cells of a tissue. The term also covers so-called "leaky" promoters, which 1~ regulate expression of a selected DNA priInarily in one tissue, but cause expression in other tissues as well.
Mise~ ion, as used herein, refers to a non-wild type pattern of gene expression.It includes~ ,ssion at non-wild type levels, i.e., over or under expression; a pattern of ,s~ion that differs from wild type in terms of the time or stage at which the gene is 20 expressed, e.g., increased or decreased ~ e~ion (as comlpared with wild type) at a pre~l~t~rmin~-l developmental period or stage, a pattern of e~pres~ion that differs from wild type in terms of decreased expression (as compared with wild type) in a predetermin~d cell type or tissue type; a pattern of ~ s~ion that differs from wild type in terms of the splicing size, amino acid sequence, post-transitional modification, or biological activity of 25 the expressed polypeptide; a pattern of expression that differs from wild type in terms of the effect of an environmPnt~l stimulus or extracellular stimulus on expression of the gene, e.g., a pattern of increased or decreased ex~res~ion (as compared with wild type) in the presence of an increase or decrease in the strength of the stimulus.
As used herein, "host cells" and other such terms denoting microorg~ni~m~ or 30 higher eukaryotic cell lines cultured as unicellular entities refers to cells which can become or have been used as recipients for a recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transfected. It is understood by individuals skilled in the art that the progeny of a single parental cell may not neces~rily be completely identical in genomic or total DNA compliment to the original parent, due to 35 accident or deliberate mutation.
As used herein, the term "control sequence" refers to a nucleic acid having a base sequence which is recognized by the host organism to effect the expression of encoded sequences to which they are ligated. The nature of such control sequences differs depending upon the host org~ni~m; in prokaryotes, such control sequences generally include a SUB5TITUTE 5HEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 . PCT/U'3GI~122 promoter, ribosomal binding site, ~ ;"A~ors, and in some cases operators; in euk~yotes, generally such control sequences include promoters, tçrrninAtors and in some inst~nces, enhAn~ers. The term control sequence is int~?n~le~l to include at a minimllm' all components whose presence is necessary for expression, and may also include additional components 5 whose presence is advantageous, for example, leader sequences.
As used herein, the term "operably linked" refers to sequences joined or ligated to function in their intçnrll~cl manner. For example, a control sequence is operably linked to coding sequence by ligation in such a way that t;:xp~ession of the coding sequence is achieved under conditions compatible with the control sequence and host cell.
The metabolism of a substance, as used herein, means any aspect of the, ~ ession, function, action, or regulation of the substance. The metabolism of a substance includes modifications, e.g., covalent or non-covalent modifications of the substance. The metabolism of a substance includes modifications, e.g., covalent or non-covalentmodification, the s--hst~nce induces in other substances. The metabolism of a substance also includes changes in the distribution of the substance. The metabolism of a s~-bstAn~e includes changes the substance induces in the distribution of other substances.
A "sample" as used herein refers to a biological sample, such as, for example, tissue or fluid isloated from an individual (including without limitAti~n plasma, serum, cerebrospinal fluid, lymph, tears, saliva and tissue sections) or from in vitro cell culture con~liLuents, as well as samples from the environment.
The practice of the invention will employ, unless otherwise indicated, conventional techniques of chemi~try, molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See e.g, Sambrook, Fritsch, and l\/l~niAti~, Molecular Cloning; Laboratory Manual 2nd ed. (1989); DNA Cloning, Volumes I and II (D.N Glover ed. 1985);
Oligonucleotide Synthesis (M.J. Gait ed, 1984); Nucleic Acid Hybridization (B.D. Hames &
S.J. Higgins eds. 1984); the series, Methods in Enymoloqy (Academic Press, Inc.), particularly Vol. 154 and Vol. 155 (Wu and Grossman, eds.) and PCR-A Practical Approach (McPherson, Quirke, and Taylor, eds., 1991).
I. Isolation of Nucleic Acids of H. Pvlori and Uses Therefor H. pvlori Genomic Sequence This invention provides nucleotide sequences of the genome of H. pylori which thus comprises a DNA sequence library of H. pylori genomic DNA. The detailed description that follows provides nucleotide sequences of H. pylori, and also describes how the sequences were obtained and how ORFs and protein-coding sequences were identified.
Also described are methods of using the disclosed H. pylori sequences in methodsincluding diagnostic and th~a~eulic applications. Furthermore, the library can be used as a SUBSTITUTE SH EET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 t1~t~base for identification and colllp~ on of merlie~lly h~ sequences in this and other strains of H. pylori.
To ~let~rmin~ the genomic sequence of H. pylori, DNA was isolated from a strain of ~ H. pylori (ATCC # 55679) and mechanically sheared by nebulization to a median size of 2 5 kb. Following size fractionation by gel electrophoresis, the fr~gmtontc were blunt-ended, ligated to adapter oligonucleotides, and cloned into each of 20 di~t;l~ pMPX vectors (Rice et al., abstracts of Meeting of Genome Mapping and Seqllenrin~ Cold SpringHarbor, NY, 5/11-5/15, 1994, p. 225) to construct a series of "shotgun" subclone libraries.
DNA sequencing was achieved using multiplex sequencing procedures escenti~lly as disclosed in Church et al., 1988, Science 240:185; U.S. Patents No. 4,942,124 and 5,149,625). DNA was extracted from pooled cultures and subjected to chemical or enzymatic sequencing. Sequencing reactions were resolved by electrophoresis, and the products were transferred and covalently bound to nylon rnembranes. Finally, themembranes were sequentially hybridized with a series of labelled oligonucleotides 15 complim~nt~ry to "tag" sequences present in the different shotgun cloning vectors. In this manner, a large number of sequences could be obtained fiom a single set of sequencing reactions. The cloning and sequencing procedures are described in more detail in the Exemplification.
Individual sequence reads obtained in this manner were assembled using the 20 FALCONTM program (Church et al., 1994, Automated DNA Sequencing and Analysis, J.C.
Venter, ed., AAc~d~?rnic Press) and PHRAP (P. Green, Abstracts of DOE Human Genome Program Contractor-Grantee Workshop V, Jan. 1996, p.l57). The average contig length was about 3-4 kb.
A variety of approaches are used to order the contigs so as to obtain a continuous 25 sequence representing the entire H. pylori genome. Synthetic oligonucleotides are ~ie~jpne~l that are complement~ry to sequences at the end of each contig. These oligonucleotides may be hybridized to libaries of H. pylori genomic DNA in, for example, lambda phage vectors or plasmid vectors to identify clones that contain sequences corresponding to the junctional regions between individual contigs. Such clones are then used to isolate template DNA and 30 the same oligonucleotides are used as primers in polymerase chain reaction (PCR) to amplify junctional fr~gment~, the nucleotide sequence of which is then ~letennin~rl The H. pylori sequences were analyzed for the presence of open reading frames (ORFs) comprising at least 180 nucleotides. As a result of the analysis of ORFs based on stop-to-stop codon reads, it should be understood that these ORFs may not correspond to 35 the ORF of a naturally-occurring H. pylori polypeptide. These ORFs may contain start codons which indicate the initiation of protein synthesis of a naturally-occl~rring H.
pyloripolypeptide. Such start codons within the ORFs provided herein can be identified by those of ordinary skill in the relevant art, and the resllltin~ ORF and the encoded H. pylori polypeptide is within the scope of this invention. For example, within the ORFs a codon SU85TITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 such as AUG or GUG (encoding methionine or valine) which is part of the initiation signal for protein synthesis can be identified and the ORF modified to correspond to a naturally-occurring H. pylori polypeptide. The predicted coding regions were defined by evaluating the coding potential of such sequences with the program GENEMARKTM (Borodovsky and 5 McIninch, 1993, Comp. Chem. 17:123).

Other H. pvlori Nucleic Acids The nucleic acids of this invention may be obtained directly from the DNA of theabove referenced H. pylori strain by using the polymerase chain reaction (PCR). See "PCR, 0 A Pracfical Approach" (McPherson, Quirke. and Taylor, eds., IRL Press, Oxford, UK, 1991) for details about the PCR. High fidelity PCR can be used to ensure a faithful DNA
copy prior to expression. In addition, the ~llthpnticity of amplified products can be checked by conventional sequencing methods. Clones carrying the desired sequences described in this invention may also be obtained by screening the libraries by means of the PCR or by 15 hybridi_ation of synthetic oligonucleotide probes to filter lifts of the library colonies or plaques as known in the art (see, e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual 2nd edition. 1989, Cold Spring Harbor Press, NY).
It is also possible to obtain nucleic acids encoding H. pylori polypeptides from a cDNA library in accordance with protocols herein described. A cDNA encoding an H.
20 pylori polypeptide can be obtained by isolating total mRNA from an appropriate strain.
Double stranded cDNAs can then be prepared from the total mRNA. Subsequently, the cDNAs can be inserted into a suitable plasmid or viral (e.g., bacteriophage) vector using any one of a number of known techniques. Genes encoding H. pylori polypeptides can also be cloned using established polymerase chain reaction techniques in accordance with the 25 nucleotide sequence information provided by the invention. The nucleic acids of the invention can be DNA or RNA. Preferred nucleic acids of the invention are contained in the Sequence Listing.
The nucleic acids of the invention can also be chemically synthP~i7~l using standard techniques. Various methods of chemically synthPci7ing polydeoxynucleotides 30 are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthP~i7Prs (See e.g., Itakura et al. U.S. Patent No. 4,598,049; Caruthers et ak U.S. Patent No. 4,458,066; and Itakura U.S. Patent Nos.
4,401,796 and 4~373,071, incorporated by reference herein).
Nucleic acids isolated or synth~si7Pcl in accordance with features of the present 35 invention are useful, by way of example, without limitation, as probes, primers. capture n-l~ antisense genes and for developing expression systems for the synthesis of proteins and peptides corresponding to such sequences. As probes, primers, capture ligands and ~nti~Pn~e agents. the nucleic acid normally consists of all or part (approximately twenty or more nucleotides for specificity as well as the ability to form stable hybridi_ation products) SUBSTITUTE SHEET (RULE 26) -CA 0222339~ 1997-12-03 W O 96/40893 . PCTAUS96/09122 of the nucleic acids of the invention contained in the Sequence Listing. These uses are described in f~rther detail below.

Probes A nucleic acid isolated or synthçci7Pd in accordance with the sequence of the invention contained in the Sequence Listing can be used as a probe to specifically detect H.
pylori. With the sequence information set forth in the present application, sequences of twenty or more nucleotides are identified which provide the desired inclusivity and exclusivity with respect to H. pylori, and extraneous nucleic acids likely to be encountered 10 during hybridization conditions. More preferably, the sequence will comprise at least twenty to thirty nucleotides to convey stability to the hybridi_ation product formed between the probe and the intended target molecules.
Sequences larger than 1000 nucleotides in length are difficult to synthP~i7P but can be generated by recombinant DNA techniques. Individuals skilled in the art will readily 15 recognize that the nucleic acids, for use as probes, can be provided with a label to facilitate detection of a hybridization product.
Nucleic acid isolated and synthP~i7Pd in accordance with the sequence of the invention contained in the Sequence Listing can also be useful as probes to detect homologous regions (especially homologous genes) of other Helicobacter species using a~ Bate stringency hybridization conditions as described herein.
Capture Li~and For use as a capture ligand, the nucleic acid selected in the manner described above with respect to probes, can be readily associated with a support. The manner in which nucleic acid is associated with supports is well known. Nucleic acid having twenty or more nucleotides in a sequence of the invention contained in the Sequence Listing have utility to separate H. pylori nucleic acid from the nucleic acid of each other and other org~nicm~
Nucleic acid having twenty or more nucleotides in a sequence of the invention contained in the Sequence Listing can also have utility to separate other Helicobacter species from each other and from other org~ni~m~ Preferably, the sequence will comprise at least twenty nucleotides to convey stability to the hybridization product formed between the probe and the inten-lecl target molecules. Sequences larger than 1000 nucleotides in length are difficult to synthP~i7P but can be generated by recombinant DNA techniques.
Primers Nucleic acid isolated or synth~si7Pd in accordance with the sequences described herein have utility as primers for the amplification of H. pylori nucleic acid. These nucleic acids may also have utility as primers for the amplification of nucleic acids in other Helicobacter species. With respect to polymerase chain reaction (PCR) techniques, nucleic acid sequences of > 10-15 nucleotides of the invention contained in the Sequence Listing have utility in conjunction with suitable enzymes and reagents to create copies of H. pylori SUBSTITUTE SH EET (RULE Z6~

CA 0222339~ 1997-12-03 W O 96/40893 . PCTAUS96/09122 nucleic acid. More preferably, the sequence will comprise twenty or more nucleotides to convey stability to the hybridization product formed between the primer and the inten~ed target molecules. Binding conditions of primers greater than 100 nucleotides are more difficult to control to obtain specificity. High fidelity PCR can be used to ensure a faithful S DNA copy prior to expression. In addition, amplified products can be checked by conventional sequencing methods.
The copies can be used in diagnostic assays to detect specific sequences, including genes from H. pylori and/or other Helicobacter species. The copies can also be incorporated into cloning and e~ es~ion vectors to generate polypeptides corresponding to the nucleic acid synthesized by PCR, as is described in greater detail herein.
Antisense Nucleic acid or nucleic acid-hybridizing derivatives isolated or synth~i7~d in accordance with the sequences described herein have utility as ~nti~Pn~e agents to prevent the e~le~ion of H. pylori genes. These sequences also have utility as ~nti~ence agents to prevent e~ ssion of genes of other Helicobacter species.
In one embodiment, nucleic acid or derivatives cul,~spollding to H. pylori nucleic acids is loaded into a suitable carrier such as a liposome or bacteriophage for introduction into bacterial cells. For example, a nucleic acid having twenty or more nucleotides is capable of binding to bacteria nucleic acid or bacteria mPsc~nger RNA. Preferably, the antisense nucleic acid is comprised of 20 or more nucleotides to provide n~cP~s~ry stability of a hybridization product of non-naturally occurring nucleic acid and bacterial nucleic acid and/or bacterial messenger RNA. Nucleic acid having a sequence greater than 1000nucleotides in length is difficult to synth~ci~ but can be generated by recombinant DNA
techniques. Methods for loading ~nti~n~e nucleic acid in liposomes is known in the art as exemplified by U.S. Patent 4.241,046 issued December 23, 1980 to Papahadjopoulos et al.

II. Expression of H p~lori Nucleic Acids Nucleic acid isolated or synthesi7Pd in accordance with the sequences described herein have utility to generate polypeptides. The nucleic acid of the invention exemplified 30 in the Sequence Listing or fragments of said nucleic acid encoding active portions of H.
pylori polypeptides can be cloned into suitable vectors or used to isolate nucleic acid. The isolated nucleic acid is combined with suitable DNA linkers and cloned into a suitable vector.
The function of a specific gene or operon can be ascertained by expression in a 35 bacterial strain under conditions where the activity of the gene product(s) specified by the gene or operon in question can be specifically measured. Alternatively, a gene product may be produced in large quantities in an expressing strain for use as an antigen, an industrial reagent, for structural studies, etc. This ~ sion can be accomplished in a mutant strain which lacks the activity of the gene to be tested. or in a strain that does not produce the SUBSTITUTE SHEET (RULE 26) -CA 0222339~ 1997-12-03 w o ~ ce~3 . PCTAUS96/09122 same gene product(s). This includes, but is not limited to other Helicobacter strains, or other bacteri~l strains such as E. coli, Norcardia? Coryne~acterium, Campylobacter, and Streptomyces species. In some cases the c~x~ saion host will utilize the naturalHelicobacter promoter whereas in others, it will be n.oce~ry to drive the gene with a
5 promoter sequence derived from the expressing organism (e.g., an E. coli beta-- galactosidase promoter for ex~le~ion in E. coli).
To express a gene product using the natural H. py,lori promoter, a procedure such as the following can be used. A restriction fragment cont~ining the gene of interest, together with its associated natural promoter element and regulatory sequences (identified using the DNA sequence data) is cloned into an al.~.o~liate recombinant plasmid cont~ininE an origin of replication that functions in the host organism and an ~plo~l;ate selectable marker. This can be accomplished by a number of procedures known to those skilled in the art. It is most preferably done by cutting the plasmid and the fragment to be cloned with the same restriction enzyme to produce compatible ends that can be ligated to join the two pieces together. The recombinant plasmid is introduced into the host organism by, for example, electroporation and cells cont~ining the recombinant plasmid are identified by selection for the marker on the plasmid. Expression of the desired gene product is ~letectecl using an assay specific for that gene product.
In the case of a gene that requires a dirr~ promoter, the body of the gene (coding sequence) is specifically excised and cloned into an ~lopBate ex~l~ssion plasmid. This subcloning can be done by several methods, but is most easily accomplished by PCR
amplification of a specific fragment and ligation into an ex~.ession plasmid after treating the PCR product with a restriction enzyme or exonuclease to create suitable ends for cloning.
A suitable host cell for t;xples~ion of a gene can be any procaryotic or eucaryotic cell. For example, an H. pylori polypeptide can be expressed in bacterial cells such as E.
coli, insect cells (baculovirus), yeast, or m~mm~ n cells such as Chinese hamster ovary cell (CHO). Other suitable host cells are known to those skilled in the art.
Expression in eucaryotic cells such as m~mm~ n, yeast, or insect cells can lead to partial or complete glycosylation and/or formation of relevant inter- or intra-chain disulfide bonds of a recombinant peptide product. Exarnples of vectors for expression in yeast S. cerivisae include pYepSecl (Baldari. et al., (1987) Em~o J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al., (1987) Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA). Baculovirus vectors available for expression of proteins in cultured insect cells (SF 9 cells) include the pAc series (Smith et al., (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow, V.A., and Surnrners, M.D., (1989) Virology 170:31-39). Generally, COS cells (Gluzrnan, Y., (1981) Cell 23:175-182) are used in conjunction with such vectors as pCDM 8 (Aruffo, A. and Seed, B., (1987) Proc. Natl. Acad. Sci. USA 84:8573-8577) for transient SUBSTITUTE SHE~T (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 amplification/expression in m~nnm~ n cells, while CHO (dhfr~ Chinese Hamster Ovary) cells are used with vectors such as pMT2PC (Kzlllfm~n et al. (1987), EMBO J. 6:187-195) for stable amplification/expression in m~mm~ n cells. Vector DNA can be introduced into m~mm~ n cells via conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, or ele~ opolalion.
Suitable methods for transforming host cells can be found in Sambrook et al. (Molecular Clonin~: A Laboratorv Manual. 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.
Expression in procaryotes is most often carried out in E. coli with either fusion or non-fusion inducible t~ es ,ion vectors. Fusion vectors usually add a number of NH2 termin~l amino acids to the expressed target gene. These NH2 termin~l amino acids often are referred to as a reporter group. Such reporter groups usually serve two purposes: 1 ) to increase the solubility of the target recombinant protein; and 2) to aid in the purification of the target recombinant protein by acting as a ligand in affinity purification. Often, in fusion t:~,e~ion vectors, a proteolytic cleavage site is introduced at the junction of the repo group and the target recombinant protein to enable separation of the target recombinant protein from the reporter group subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New Fnpl~nl1 Biolabs, Beverly, MA) and pRIT5 (Ph~rm~
Piscataway, NJ) which fuse glutathione S-transferase, maltose E binding protein, or protein A, respectively, to the target recombinant protein. A ~.cfe,,c:d reporter group is poly(His), which may be fused to the amino or carboxy termin~-c of the protein and which renders the recombinant fusion protein easily purifiable by metal chelate chromatography.
Inducible non-fusion expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET1 1 d (Studier et al., Gene Expression Technolo~Y: Methods inEnzvmolo~Y 185, Academic Press, San Diego, California (1990) 60-89). While target gene expression relies on host RNA polymerase transcription from the hybrid trp-lac fusion promoter in pTrc~ expression of target genes inserted into pET1 ld relies on transcription from the T7 gnlO-lac 0 fusion promoter me~i~ted by coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident ~ prophage harboring a T7 gn 1 under the transcriptional control of the lacUV 5 promoter.
For example~ a host cell transfected with a nucleic acid vector directing expression of a nucleotide sequence encoding an H. pylori polypeptide can be cultured underul~;ate conditions to allow expression of the polypeptide to occur. The polypeptide may be secreted and isolated from a mixture of cells and medium cont~ining the peptide.
Alternatively, the polypeptide may be retained cytoplasmically and the cells harvested, lysed and the protein isolated. A cell culture includes host cells. media and other SUBSTITUTE SHEFT (RULE ~6) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 _59 byproducts. Suitable media for cell culture are well known in the art. Polypeptides of the invention can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifyin~ proteins including ion-exchange chromatography, gel filkation chromatography, ultrafiltration, electrophoresis, and imml-no~ffinity purification 5 with antibodies specific for such polypeptides. Additionally, in many situations, polypeptides can be produced by chemical cleavage of a native protein (e.g., tryptic digestion) and the cleavage products can then be purifled by standard techniques.
In the case of membrane bound proteins, these can be isolated from a host cell by contacting a membrane-associated protein fraction with a detergent forming a solubilized 10 complex, where the membrane-associated protein is no longer entirely embedded in the membrane fraction and is solubilized at least to an extent which allows it to bechromatographically isolated from the membrane fraction. Several different criteria are used for choosing a detergent suitable for solubilizing these complexes. For example, one property considered is the ability of the detergent to solubilize the H. pylori protein within 15 the membrane fraction at minim~l denaturation of the membrane-associated protein allowing for the activity or functionality of the membrane-associated protein to return upon recon~liluLion of the protein. Another ~rup~l Ly considered when selecting the dt:Le,g~.lL is the critical micelle concentration (CMC) of the d~Le.~,e.lL in that the detergent of choice preferably has a high CMC value allowing for ease of rennoval after reconstitution. A third 20 property considered when selecting a detergent is the hydrophobicity of the d~Lelg~llt.
Typically, membrane-associated proteins are very hydrophobic and therefore d~ gell~s which are also hydrophobic, e.g., the triton series, would be useful for solubilizing the hydrophobic proteins. Another property important to a d~-lerg~;l.l can be the capability of the detergent to remove the H. pylori protein with minim:~l protein-protein interaction 25 facilitating further purification. A fifth property of the deL~.g~ilt which should be considered is the charge of the delt:.gellt. For example, if it is desired to use ion exchange resins in the purification process then preferably deL~ ..t should be an uncharged detergent. Chromatographic techniques which can be used in the final purification step are known in the art and include hydrophobic interaction, lectin affinity, ion exchange, dye 30 affinity and immunoaffinity.
One strategy to maximize recombinant H. pylori peptide ~x~ ssion in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottecm~n~ S., Gene Expression Technolo~y: Methods in Enzymolo~y 1 85, Academic Press, San Diego, California (1990) 1 19-128). Another35 strategy would be to alter the nucleic acid encoding an H. pylori peptide to be inserted into an expression vector so that the individual codons for each amino acid would be those preferentially utilized in highly expressed E. coli proteins (Wada et al., ( 1992) Nuc. Acids Res. 20:21 1 1-21 18). Such alteration of nucleic acids of the invention can be carried out by standard DNA synthesis techniques.

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTAUS96/09~22 The nucleic acids of the invention can also be chemically synthesi7~d using standard techniques. Various methods of chemically synth~o~i7in~ polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthe~i7Prs (See, e.g., Itakura et al. U.S. Patent No. 4,598,049; Caruthers et al. U.S. Patent No. 4,458,066; and Itakura U.S. Patent Nos.
4,401,796 and 4,373,071, incorporated by reference herein).

III. H. nvlori PolYpeptides This invention encomp~es isolated H. pylori polypeptides encoded by the 10 disclosed H. pylori genomic sequences, including the polypeptides of the invention contained in the Sequence Listing. Polypeptides of the invention are preferably at least S
amino acid residues in length. Using the DNA sequence information provided herein~ the amino acid sequences of the polypeptides encomp~esec~ by the invention can be cle~llced using methods well-known in the art. It will be understood that the sequence of an entire nucleic acid encoding an H. pylori polypeptide can be isolated and identified based on an ORF that encodes only a fragment of the cognate protein-coding region. This can be acheived, for example, by using the isolated nucleic acid encoding the ORF, or fragments thereof, to prime a polymerase chain reaction with genomic H. pylori DNA as template;
this is followed by sequencing the amplified product.
The polypeptides of the invention can be isolated from wild-type or mutant H.
pylori cells or from heterologous org;~ni~mc or cells (including, but not limited to, bacteria, yeast, insect, plant and m~mm~ n cells) into which an H. pylori nucleic acid has been introduced and expressed. In addition, the polypeptides can be part of recombinant fusion proteins.
H. pylori polypeptides of the invention can be chemically synthesi7~-d using commercially automated procedures such as those referenced herein.
Many of the polypeptides of the invention are related to one another. Some of these relationships are described in Table 3 below. Most polypeptides described in Table 3 are over 90% identical to one another as noted in the last two columns; some are between 70%
and 90% identical to one another; and very few share between 60% and 70% identity with each other. The polypeptides represented by the sequence identification numbers in the third column of Table 3 result from translations carried out from stop codon to stop codon in the genomic nucleotide sequence of the invention, while those in the first column result from translations carried out from the first methionine or valine codon following the prior stop codon and procee~ling to the final stop codon in the nucleotide sequence. In some cases, the nucleotide sequence encoding the related polypeptides is slightly different, resulting in some differences in amino acid residues of the related polypeptides. In many cases, the related polypeptides differ significantly in length, with one polypeptide cont~inin~ amino acid residues in addition to those in common between the tWO

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 WO 96/40893 PCTnJS96/09122 polypeptides. In all cases, the relationships described in Table 3 are highly significant, and the nucleotide sequences encoding these related polypeptides are also very similar to one another. For example, the nucleotide probes derived from the coding sequence of the polypeptides in column one can be used in PCR or hybridization ~e~illlents to identify 5 clones carrying the nucleotide sequence encoding the polypeptides of column three.
The relationships between the polypeptides shown in Table 3 can be clzlc~ified in five broad categories as follows. First, for many polypeptides (de~ign~t~ "A" in the last column ofthe Table 3), the polypeptide denoted in column one is identical to thepolypeptide denoted in column three except for an occasional addition of a few putative 10 arnino acid residues at the N-tl?rrninns which result from the fact that the polypeptides of column three were derived by trancl:~tin~ from stop codon to stop codon instead of from a predicted start codon (i.e., Met or Val) to a stop codon as was done for the polypeptides in column one.
Second, for most polypeptides (~l~cign~t~l "B" in the last column of the Table 3), 15 the polypeptide of column one is at least 95% identical to the polypeptide of column three except that the polypeptide in column three is longer (at either or both ends) by one or more amino acid residues which do not result from the difference between reading from stop to stop instead of from start to stop.
Third, for some polypeptides (clesign~tec~ "C" in the last column of Table 3), the 20 converse is true, the polypeptide of column one is at least 95% identical to the polypeptide of column three except that the polypeptide in column three is shorter (at either or both ends).
Fourth, for some polypeptides (designated "D" in the last column of Table 3), the polypeptide of column one shares a high level of amino acid identity (i.e., at least 95%) 25 with the polypeptide of column three in the region in which they overlap, but shares little or no identity (i.e., less than 95%) at one or both ends. The level of identity of the polypeptides in columns one and three in categories "B", "C" and "D" is highly significant.
For example, a typical H. pylori gene product will exhibit arnino acid sequence identities of between 92% to 100% arnong strains of H. pylori isolated from human patients (see Table 30 10 below).
Finally, a fifth class of polypeptides in column one (desi~n~te~l "E" in the last column of Table 3) are closely related but differ significantly (i.e., less than 95% identical) from the polypeptide of column three. These polypeptides are likely "paralogs," members of related gene families in H. pylori.

SUBST1TUTE SHEET (RULE 26h Length Length% Identity:
SeqID # (aa) SeqID #(aa)Overlap Length Category 77~ 9,lCO.0:574 aa B
fi . 7 cr9~.- :1'7 aa B
~ 5 7~ ~9 , :1 5 aa B
'lC~.O: ~S aa B
f'' ''~'.': fi~ aa D
,) 6. ~v ~ , aa E
6 ~ ~~',' 15-.3:6~8 aa B
~0 39~ 1 aa E
~3 r) 597.1: 6 aa B
r~ ~ ~49~.5:433 aa B
71)0.~:84 aa B
~fi ~ 8.'.:34 aa E
.S :'67 aa C
.C : 2 aa C
'~ 6 ~~fi.~: 7 aa B
~Il) .'2 7 ~ 1 aa B
'~ _ 7 ' ' ~ ~7 aa D
6 ' ~n ' 1~ . .: ll aa B
7 n /~ : aa B
' '' -7 ~ '0~ ~~ aa B
2~ : n aa B
2r~i n ~ ' n aa B
~' 6' ~~ ~7",'.t~: aa E
S~ 74~7. :~,~aa B
17 l:lS aa E
. ~l n ~ 7~.0:1'~ aa B
.O l J aa A
:lr~ aa D
_ ~ r~11 O. ~ r ~~ 5 aa B
7.~: aa B
9.1:~ aa B
~ 7 ''' ~~.' : J~ aa E
6 .J~ 41 ~ : 5 aa B
54 , - 7~-.n: J l aa E
~' ) 12~ f'' J~91~ -- aa B
' 24 ,'' ~r~9 .~:2~ aa B
~' 8~ ~ ~ 'S7. :7'~aa B
12 ~' ~.lOC.r~:l 8 aa B
93 , ,11.1:$3 aa B
88 ~ 1,~ .,:88 aa B
r.~' ~:117 aa E
~_ ', . ~r~ 18 aa A
fi1~ . 8 aa B
5~ .r. ~ aa E
) '. 4 ~ -~. r - ~ aa B
7 ~ ._: ' aa D
, ~~r,.~: aa D
2 4, ~ : _ aa B
r, 51,' ~_n ~ a D

SUBSTITUTE SH EET (RULE 26) W O 96/40893 PCT,rUS96/O91Z2 7~ 403 100.0--153 aa B
rj 173 98.1: lr~l aa B
n 5~ 7.~ aa E
~ 2 2 ' ~ 1 ~. :.. 'l aa B
53 J ~ _n ' :~ aa E
109 6 ' ' 1 ) ~):, 1 aa B
~) 73 7 '~ : :C .0:- aa B
~37 ,n ' ~ ~ n, ~ 13 aa D
~2 n~6 ~ aa D
~7 ~ ''~.~7 Il. :, n aa B
~- -80 ~ lC~.C :280 aa A
~ 87 ~ 9 5:15 aa D
''fi ~ 9t,.~:'5 aa B
C~ aa B
C ~ aa A
7 :~ .o l~n aa D
.0:1,2 aa B
~J ' ....... ~ 126 aa E
~' ~ ' 7 C: lSri aa D
24 aa A
~J~ aa B
' ~ 7~ :54 aa D
n 9, , 7 . ~ : 7 aa B
~ ~ 2C'5 ~ ' 1 ~ 5 aa B
'~ 4] ~ ~ .-.G:~ aa B
, 1 ). :2 9 aa B
~r~0 ~ 6 ~5 ;.3: 1 7 aa E
~r- '' ~ C ~'8 .3:2_: aa B
~' n3 f~ 7 1 1 10 0: I- aa B
.. 3 nh~ _~r ~. . . aa B
~r~- 7 ' ~ : aa B
3 - .. '~ aa B
~r.n 4- ~ C 0:- aa B
~n'' ~,4~ n~ 1 2 , aa B
0 f ~ 6 6: 2 6 aa B
~n ~_ n, ' 98.~:65 aa D
~,) 22~ 6.5:2,8 aa B
'7 ~~ , .. 0 ~ I.1:7 aa E
~7 ~ 4, . 5~ .4: 8, aa B
~7 1 -8 7~ 1183 1rO.0:1178 aa A
~7~ ' 113 2.7:109 aa E
~7~ , fJ ~ 88 ~3. :~ aa E
~7~ ~n~ ~ '67 1 ~0. :~n6 aa A
~7r~ 6~ .7. : , aa D
~7~ 2~ aa B
~7 4~ .--2 J .CC O ~-~ aa B
~7~ ~~ 1 , n ~ ~, . : 4' aa A
) u7 ' ' ~ aa B
0 0: aa B
~~7 ~ ~r~ 7 : ,, r- aa B
9. : ~ aa C
' ' f~ ' on ~ : 7 aa E
I ,n~ ~r~ 7 aa B
n ' 9 ,5, _ 1 ~):2 9 aa A
, 17 ~ 1 ~. :1 aa E
' 8 77 , 4 ' ~ 10~.~:77 aa B

SUBSTITUTE SHEET (RULE ~6~

' 80 10~ O aa A
r~ 577 9~. : 2C ~ aa E
j7 1( ~ 8 aa B
94 ,Il 2 l aa B
~J ~ ,r779~ : 1 8 aa D
73 ~7n9 .8:,I aa B
- r.~ n9~.0: 31 aa B
~f ' . ~ 9~1: ll~aa B
_r~ .n: 2no aa B
,f~ J~ . : 2~4 aa B
'f~.5i., :33~aa B
n .~ 9~r 4: 14 , aa E
~f' ~l9 ,3 5 aa B
~ ' 3 1 ~J ''~ .6: 3~fiaa B
J~, 2 3 fif~ .3: 2~ aa E
5~ 32 J ~~'C 0: ' aa B
171 ~fi ~_ :1, aa B
~~n '3 f''.... . 1~ ): 2~- aa D
ni ~ : 91 ~ aa E
~- '~' ~ .: 7 aa E
7~ hf., 8 r~.~: 5 aa D
1' ~ I. O aa A
5- - r~ aa E
" 7 , ~ aa D
r IC 2 ~ aa B
J ~ 15 r,r~~)7~C.O: ' aa B
J 378 ,~~','4 1'~.~:'~,aa B
fi 1027 r~;'2~40lr~'l. I: I27 aa B
~ 155 ~.t!: 4aa E
62 5' r~.': 47 aa E
, 237 ~ ,lCO.C: 237 aa A
fi 7 ~ 1.1: 83 aa B
5,~, ri~ : 63 aa B
22 ' ~~ .f: 22 aa B
~7 ~ ~ aa C
~ ~ 7 - ~ J aa C
5 ~ 15 f' _ r!5 ~ aa B
_f~ 115 ,' ' ' 4.~':1 aa C
67 7~ 'n C '~aa D
3' 3 6 ' ~ f.1l 1.1 322 aa B
,. ' I 7J .~l 10aa B
O ' ~ 1.1: 12 aa B
5~.5~: 79 aa B
' 9 ~ ' ~ 11~.0: 95 aa B
~, 154 ~ f lC~.C: 152aa B
68 ~) ~ Inl 1 67 aa B
9~. : 31' aa B
fi ~ ~ n ' lC ).0: 31 ~ aa A
9~ 4: 11~ aa E
- 8G ,fi~~r~2: 7~, aa E
9,' , ' ~.0: ~2 aa A
5'0 ' 3 ,_ ' ~,'fi.~: - 7 aa B
', aa D
4 Jr~ aa B
~ ~~ 5 ~ f7 ~ aa B
5 ~ 3 7 6 fi~0.0: ,,,aa B

SUBSTITUTE SHEET (RULE 26) CA 0222339' 1997-12-03 W O 96/40893 PCT~US96/09122 -65.-"~ 94 772 ' i. ~ a E
5~ 2 7~ r~ ' aa B
.~7 7 n ~: ~riaa C
'~7 _~7 7 ~ I aa C
5' ~22 7~ .-.2 aa A
fi_ 78f~.~: c, aa B
~ r r~ aa E
'5 2~ ~ ~8.C :2~7aa B
51 7 ,~.5: 8 aa D
.11 7n~ : . I l aa B
37 6_fi 1-C~.O :,4aa D
.. 24 7, :. ~.2 :1 1 aa E
f 5~6 ~ .7 ~ .7: 1 ' aa E
~ 7 .~ 7 ~~I O.O:, -~ aa B
~~ ' : aa B
rr ~ r~ 7.... ~- aa B
Sn) '' I ~:'' . aa B
~n . n ~n ~~ Q~._: _ 'I aa E
~n ~ n .~ aa B
~n~ ~r~7 ~13.1~ ' aa B
~r'~ ~.1. ~ -'~ .C . :~' aa A
Sn~ l ~ f.~: f~. aa D
5n ~~ ~ ~9~.J 1 ~9 aa D
IC ~ O: 28 aa B
.rl 4~ ~ n ~~ :125 aa E
5l ) 7~ . : 53 aa D
7 : ,/ nri I '1~ .~: 193 aa B
~7 1 ~ n5f.5: 1 0 aa D
~7 I .r~~n ~lC ~.0: 3~8 aa B
7 - ~ nl~' ~n 9.. 1: 3 5 aa B
~75 ., n ~9 .1: 2 7 aa A
'7f. _'1 _rJ~.0: 2J 1 aa B
~7 6~ n.7: 6. aa D
7 ~~ .- aa B
~7 . ~ .7: _ aa B
.~ . SJ _~. . ~ .' _, ~ I aa D
.. ' _rl ~ ~ . 1 .3 aa B
J '. _7~ Sr;; ' ~19 1 1 : 74aa B
S J ''_ _ J ' - . ~7 ~.~: '2 aa E
3 ~ 7_ 6C 0: ~7 aa B
71~ . ~ ~ 7;l.i: 7 1~. aa B
fi 2 ~ r~ 64'~,. : 2 aa B
~ ~2 .J~_ ~' 9 _ (,.0 J_ aa B
r 1 ' _JI ~ ~ .9 10'). ) 1 . ~ aa B
~ . 2~...... h ' _~2 9 .~,: 2'1 aa B
J ) 4 f; _ 61 57. :4~aa B
5~ -~ n~ 7 7 9~.1: 113aa D
~ . ~r~ 1 0.'~: 113 aa B
_ ~J ~ O. : 437 aa A
6 . ~ ' / '' ;~ .'.: 1~6 aa E
. ~ '.8 .~.;4 . ~.. 1'7aa B
5~h ~5 fin7 ~ 1,.1: 3 aa B
~7 :l2 ~7 ~ 1 .1l: 3 aa D
5~8 .'7 ~9 . lC-.O: 127aa B
~49 ~l 2 1 ~9 ~.2: 500 aa B

SUBSTITUTE SHEET (RULE 26~

W O 96/40893 pcTrus96/o9l22 f I') 4' .f'' ~1 . 1O.O: ~' aa B
f ~~ ~r~ _.7: 3~ . aa B
rl ~f~ ,,fi f' ~ ' ' aa D
~ _~U~ . 9fl ~ ~ ~ .1 r aa D
~ - --f .~ : . J aa D
n ~ ~ f~ 7.~: 2~ aa D
flll- r ~ ~ r. : 56 aa E
f~ ~~ n h _1~ :37n aa B
n ~_ 5' , n J 5~ 1: 35.. aa B
h~l8 ~ 5 .7:7, aa D
3 ' 7 .C :82 aa E
~ )'n ~_7" :C).~:76 aa A
f ~ _ r' 18~ .5 :95 aa B
rl,,,162 ~::7751.3:161 aa E
f 8 ,~, '98.3:58 aa B
t- f f6 -,C ~85.2:61 aa E
rl,~117 ~' .95 5:11: aa D
r._f~83 -~'' r.~tl.3 :8' aa B
n ~ 77 7~1'7 .6:7, aa E
n :7fi ~ .6:125 aa E
n_ ,7n r-~ 2.3:65 aa E
f '~ ~ _f-756.(1: 124 aa D
r~ ,7~ .~:9~ aa B
r,,,~r, ~ :2r-8 aa B
r-,-, ' ~ 'lf ~ aa B
n ) ' __-- 00: ~ aa D
n ~ aa E
r._ f_ 7 ~ 9.n 2 3 aa B
n n,,, ~ - fi~ 00.~ aa C
f.~ 2~ n ~~9~.~ :~,,l aa B
n_7~ 2' nl ~~7 C7. - aa C
n 6 ,~ ~- J~ : aa E
r~ fi S~ l .C~: f~ 6 aa B
r- ) - , 7~_,_5~.1:1 6 aa D
r~ , , 7,. ,7-'.9:1 8 aa E
n~, 7 ~n60 9: ~6 aa E
n ~ 93 , ~'~6'~(.0:~' aa B
t- ~177 n ~ aa B
~ ~ 8 , . ~3 , 00:8 aa A
fic h~ ~rl'~'1~1.~:1:5 aa B
. Il~ ~nl aa B
r., n ~.~ ~ aa B
r~ , f~ .J: ~_ aa B
n~ 5lC~.~:342 aa D
n~ -n ._ I9~.n l~r~ aa B
h~ nnlC ).~ 1 aa B
f~ - . 7~1J.~~9, ~:4~ aa D
r.~f~'f~ ~f 7~1rl ~ aa A
n~S' I ~1,f3. : .~ ~ aa D
rl~r.. ~ll . : aa B
r~ 7~ 5: 155 aa D
f~ :''2 aa A
n') 6 _ ~f~ : :.aa D
_f5~5.5:1;6 aa B
' ',' f ;~ 96.3:81 aa D
~r 4,~'7100.0:~9 aa B

SUBSTITUTE SH EET (RULE 26) r~ ~ 1 1 ' ' ~ ',1~ 9 2:1 1 aa B
r.~ ~ O_ ,r~ fi 7r' 9 .3 '~ aa D
f~f 2f _7lC .C : f~8 aa A
f'~ 1 ~,~3~lr~.~: '4 aa D
n~ ~ ~ , rj~O ' 71 ~ aa D
rl~ ~ 2~ ~ S aa B
nf~ '67~ .~ n~ aa D
nn~ I I ,~ ~7'186~Q.7: ~ aa D
~ 3 f 95 ~ 9: aa B
r~' O ~' 7C~ .7: 7 aa B
~r~ r 14 ~~ 0 2 4 aa B
r~n~ 78 ~f ,~'7 3 : 75 aa D
rl~ 177 , ~ 6: 17i aa E
fnf 258 17 ~1:25~ aa E
nn' ' 75 ~4 _fC0.0:75 aa B
ri~ 421 f.~ ~ ~5 4~ aa A
ffi 81 ~ ~-lO~O . aa B
n7) ','' ,~ 'Q~7r~. 1 aa E
r-7, ' ~ ,fi ~9 : 2 aa E
n7, _ ~ 7.~,1(:'.~:',1 aa A
n7 7 6n,~41 ~ ~: 78 aa B
f7~ 4C~ 7 ~~ ~1C~ 00 aa B
r-7~ 9 ~,'~, '.: aa D
n7n 1'6 'Q l)~.J: ~5 aa A
~7 ' 1 5 ~ , 0,~. :1,~ aa E
r-7 -2 4;~~ .6: ~ aa B
f~ 11 ~-2= 91) .O: l aa B
ri ) 14' ~7' 7G~.6 135 aa E
f 6 '' f~ ~-6.4:56 aa D
~i '.31 l , ~ 65~. :301 aa B
n ~ 16~ 7 ~ : 69 aa B
n ~ 85 n''~''.: ~ aa E
n ~ 77 ~_ '7. : 7 aa D
r~ n 197 n ~~ ~~9~.0: 194 aa D
n ~ 142 ~ ,lC~.0:136 aa D
~ 86 r 871~l0.0: 8f aa A
r~ 121 , 35697.5: 11 aa B
f 0 5~ 7 ~7784.6:5' aa E
n~ 1~' r~ 'O971: 14~aa B
n~', 8~ ' '', ' 7 '.3: 6~Jaa E
n~ 18~ ,f 71 C :1;~ aa B
f~ 75 ~ :7 aa B
r~ 9 ~ aa B
n~f ' 09 ' '~l :2~ aa B
f~ 75 f.,,ri ',4n 'lO O: 7 aa B
n~ ','' n7 ~flC~.~: 121 aa B
.~ aa B
~ .' : aa B
7 ' ~ . : / _n aa D
7 7 7 ~ 7~ . :' Q aa D
7 ~ _ 7 7~5_7~ : ' 7 aa E
7 ' 4O ~ 19 .~ : ~1 aa D
~ 71~5 11~ f~~ 710 C: llS aa A
7 r. 8~ ~n' ',C l. l: n aa B
7 7 4~ - r~,0 . :~aa B
7 8 56~ 51~ 38~8 5fC aa B

SVBSTITUTE SHEET (RULE 26) 7~i 125 ,n l7 ~3 ~5 8:118 aa D
7 0 96 ~r~ 0:73 aa D
7 81 f ~ aa D
7 : 141 f ,~ln .): 5 aa 'D
7 ~ 51 , r.~ 9 n.,: aa B
7 ~ . _ : 4)44.: 218 aa D
7 5 ~ 710~.~:2f5 aa B
7 f~ ~ ~~n9~.~: 15~ aa E
7 ~ n~ l C ~ aa B
7 :~-J _ ~ -Jr~j j.n: ~ aa B
7 ~ _ f. n 7 nf.~ 6 aa B
7 ) 7~ ,. : aa B
7 2f ~~ ~ , : aa E
7_ 7~ f- ~.O:,~ aa D
7 6~ .. JI~ '' 0:44 aa D
7 ~ _rl.: : 13- aa E
7 ~ :2 laa A
7~r. J _ ~ aa D
7- n _~h . . n~5~.1 :IC6 aa D
7~ ~ In ~57. :91 aa D
7 3 ~1~00: ~3 aa B
7......... ' ~ n C~ aa B
7 ~ ~ ~Jn _~ . :_ aa B
7 f, ~nl l .l ~: ~ aa B
7 ~ '~' :~C .C: aa A
7 _ ~ . : aa D
7 ~ =5 :22- aa B
7 ~ 2 aa D
7 r- -f . ~ 8 aa B
7 ~ ; . :Gt8 aa E
7 ~ n~ 3 aa D
7 " r.f. , ~- ~f:,~ aa E
~7- :7J aa D
7~ 49 , ~1. :4rlaa E
7~ 412 7, " ,~7.8 :4' aa B
7~ 9 ~0 0: aa B
7~ aa B
7~ ) ,, / "~ ~r.. : ~aa B
7~n , n 7~ : n aa B
7~'' .. ~J_ _- . lC'.C~: 1r-3 aa B
7~ 0.0:~ aa B
7~ 4 ~~~ _4 1~ .~: 4_ aa D
7~0 1 ~~ 9,92 :lln aa E
7~ 2~ 1lCO.~: 2C~aa B
7~ lC~.~:7 aa A
9 ~ 2~~ .,: 74 aa D
7J~ 4n n ~.0:141 aa B
75~ Or. f.~ ~7,9~ 7:2-~6 aa B
7~r~ 91~ ~ 0:~6 aa D
7~ 197 ~ ~ ~8 1~ 7 aa A
7~ 149 ~~ ~4,.5:8 ~aa D
7 68 _ ~l O.~ n aa B
7n) 135 ,,n, 6'.3: 1 ~ aa B
7f~ 9' ~ )0.0: niaa D
7n_ 7 _2~CO.O:, aa B
7r- 26 ~ ~3~.4:26, aa B

SUBSTITUTE SHEET (RULE 26) -CA 02223395 l997-l2-03 7n~274 ' 5,7 277 ~ lCO.O: 273 aa B
7n_ 134 7 ~ 136 9~2: 133 aa A
7nn 72 1~ 74 ,i .: 7 aa A
7fi ' 147 ~ ' ~ 5 1 I". : 1 7 aa B
7.~ 144 ~ . : 1'4 aa B
7r. 47 , r. ~ 7 C ~ ~7 aa B
7,' ) ' 2~ ' ' ''.2: ' ',~ aa E
77 '4., ~'f; ' ~ '7 .1 :' _aa C
77~ ~, ,, G~ t~ aa B
77~ 143 ~ u.,: 1'3 aa B
77~ 21 ~'"' ~jt~,5 2 7 aa B
77~ 8' 637 ~ )0.0: 4 aa B
77~ 7f. 77~ S.9:,3 aa D
~; ,, ;.~7,7 '' aa E
77 _ ~ _ ~.. 3: aa E
77 ~, ~ :, aa B
7 ) ~ 7fi r~. 7;~.': 2 aa D
7 7r 7" ~7 ~(,.o: 7 1 ad B
7 ;. 1 3 r- ~ _- .0: 1-~ aa B
7, 1 3 ~ .C: l 3 aa A
7 ~ 1~7 , ~r~ 7 aa B
7 ~ r. ~ ~.': ~', aa B
7 h -- nr. ,- .1 nn aa D
7 ' ~ :'' aa D
7 , r. ;;.~: ' .'~ aa E
7 , j~,r. l. ,~ , r, aa E
7 ~ n, ~ ;.': '' aa D
7 ~ jt~ _n~ ~ 7 ~0.0:, aa C
7 ) '. '-~ ~73 1~~.0: 132aa B
77 ' S~S . 16 ~.',: 2 3 aa A
77'. 47 l~ 6 C.O: ~7 aa B
77 1~3r~. 34~ ' aa E
77 6'7~rln '7: C.O: 6 aa B
77~ 1'4~ ~ ' '7 7: 1: aa D
7;~ 0-' f' ~ .n: 1 ;0 aa A
7i'~ 84~;~' _ ' .~: 7~ aa E
71t ' 3 ~ _ ,' ] .~: S aa A
,r- ' ' aa B
aa E
: 12n aa C
3 ' "~ : 25' aa A
~C- n_I _l) 7 ~ ~. ~: 88 aa C
,, r.~ 7 ~1 ; .7: 82 aa E
7f~ ' 2,7 ~.S l '; i~ aa E
fi~ ~, rj~ 0 0: r.,, aa B
J 7~ aa B
f~ C ~.':l~Caa E
~_ r l aa B
) 5 3 .. f~- 9 . : 8~~aa B
~7 7 ~ 9~.~: 3' 1 aa D
7 9 .:: 1 7aa C
_ .,n~ _ lC ~.~ ' 18 aa B
~7 -~ 9 : 1 -)2 aa B
aa B
_~ S~ '~' .: aa D
. 7n Oc~ ~_.3: 13r,aa E

SU~3STITUTE SHEEl- (RULE 26)1 W O 96/40893 PCT~US96/09122 r ~ 48 7 .~ ~ aa E
S ~ . J 77~. :12. aa E
fi 05 ~ .0 ~:30~aa A
f~4 - ~n ~ ~J. 7 1 J aa D
~4 ~ ~ rO 0 ' aa B
r~ - n~. 7 r.' ~ aa B
~) n ~~ aa D
f .~ 1O~.1 . 6 aa B
_- ~~ fin C~ 6r~:5 aa D
.~ 1 Z r. ~r.~~4; ' 1 aa D
r~4~ 701 '~.~1 aa B
J- ~ aa B
_ . ~' .'' ~. : ~aa D
.6 ~1 aa B
I ~J~ ;5~ .7:127 aa E
' n~ ~ C~.. 0:155aa C
_ ~ n~ ~ .): I ~ aa D
nn ,'......~ 7 ~ . :n aa B
) '7 .5:~~7 ~ ' aa B
_~ 7~ aa B
. I f~ . ) aa B
J ~ r) _ ~f~r 1C ~. ) 3 S aa C
. ~- . 90. ~1 4 aa D
. 7 ~ C ~.0 5~4 aa B
't; 6 r'~ . ~ ~ ~ aa B
~ r7 n~ r ~ aa B
~ r~ 6. 1~ aa B
5CI ~ 2.~: 85 aa E
~) 277 .. ~ 5~.~:277 aa B
_~G8.1 54 aa D
~' 13~ 3 4 129aa E
27~ ~ 6~7r~ 9 aa C
31 l . ~ 83 ~.~ n aa B
fi-9c~'.1 ' ~ aa B
~n 27 ~' 7 . . 5 aa D
~~ '7~ 6~- ~._I'~. :'- ,f aa B
~fi . ~1 79 .~: le 5a~ B
r.n~ S9 0:2 ~aa D
~) ~ . n~ . 7CC.I:l 1 aa B
~ r~. 4~ ~ 1 4 aa B
r' ~ ~ . n6 7~ ': J l 4 aa C
7 nl ~fi ~ ~ ~7. 7~aa B
6~ ~ . 9~rl. r~l aa B
~n ~ fi~2C 0: Jaa B
S /n ~''7. . .~ aa B
J~n~ 5 2C' aa B
7 . C~ 4~ aa D
f) ~J n ~C .~1 7~ aa D
r. 1~ nU,,~ aa B
~' ~r~ 5 aa B
3 . ~. . ~ _ aa B
rl~ ~ r. ~~7.': ..aa B
n~ 2 4 n_~ .5~.1: 3 aa B
.r) 2 ~ ~J'.~1~59 ;~.2 ~3 aa B
~7 8u ' fi.' .~7.4: 3'aa E
n8 28~ 57 ''94.4: ~ 84 .aa E

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/~0893 PCTfUS96/09122 6~~Jf~ . r~ 2 10. '~4J6aa B
7) ~ r l O ): 1 4aa B
7 ~ ~~ 1 3 aa B
7' fi rl6 ~ J ~ .. 1~5 aa D
7 , _ _ 7 "~ r~ . ~: aa E
7 _7 7~ .,: aa E
7 .~7 l ) 6, 7.~: aa D
7~ 7 7 '2.~ aa E
7~ O aa B
' ~ ~; 3' ~ ; .'J aa D
7~ aa B
7 ~ aa D
7 I r~ ~ c7 ) ~~ aa D
7 . r~ ~nfi 89. ~. 5 aa B
8 ~ r~ r~ ~~ 98.r~ 6 aa D

IV. Identification of Nucleic Acids Encodin~ Vaccine Components and Tar~ets for A~ents Effective A~ainst H. pvlori The disclosed H. pylori genome sequence includes segments that direct the 5 synthesis of ribonucleic acids and polypeptides, as well as origins of replication, promoters, other types of regulatory sequences, and inl~,ellic nucleic acids. The inventionencomp~cses nucleic acids en-~o~iin~ immlmt~genic components of vaccines and targets for agents effective a~ainst H. pylori. I~lentific~tion of said immllnogenic components involved in the ~iet~rmin~tion of the function of the disclosed sequences, which can be 10 achieved using a variety of approaches. Non-limitin~ examples of these approaches are described briefly below.
Homology to known sequences: Computer-~c~i~tecl comparison of the disclosed H.
pylori sequences with previously reported sequences present in publicly available ~l~t~bz~es is useful for identifying functional H. pylori nucleic acid and polypeptide sequences. It will 15 be understood that protein-coding sequences, for example, may be compared as a whole, and that a high degree of sequence homology between two proteins (such as, for example, >80-90%) at the amino acid level indicates that the two proteins also possess some degree of functional homology, such as, for example, among enzymes involved in metabolism, DNA synthesis, or cell wall synthesis, and proteins involved in transport, cell division, etc.
20 In addition, many structural features of particular protein classes have been identified and correlate with specific con~n~lc sequences, such as, for example, binding domains for nucleotides, DNA, metal ions, and other small molecules; sites for covalent modifications such as phosphorylation, acylation, and the like; sites of protein:protein interactions, etc.
These consensus sequences may be quite short and thus may represent only a fraction of the 25 entire protein-coding sequence. Identification of such a feature in an H. pylori sequence is therefore useful in deterrnining the function of the encoded protein and identifying useful targets of antibacterial drugs.
Of particular relevance to the present invention are structural features that are common to secretory, transmembrane, and surface proteins, including secretion signal SUBSTITUTE SHEET (RULE 26~

CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 peptides and hydrophobic tr~n~membrane domains. H. pylori proteins identified asc~ g putative signal sequences and/or transmembrane domains are useful as immunogenic components of vaccines.
Identification of essential ~enes: Nucleic acids that encode proteins esscnti~l for growth or viability of H. pylori are preferred drug targets. H. pylori genes can be tested for their biological relevance to the organism by ex~"~illil)g the effect of deleting and/or disrupting the genes, i.e., by so-called gene "knockout", using techniques known to those skilled in the relevant art. In this manner, e~senti~l genes may be identified.
Strain-specific sequences: Because of the evolutionary relationship between l 0 different H. pylori strains, it is believed that the presently disclosed H. pylori sequences are useful for identifying, and/or discrimin~ting between, previously known and new H. pylori strains. It is believed that other H. pylori strains will exhibit at least 70% sequence homology with the presently disclosed sequence. Systematic and routine analyses of DNA
sequences derived from samples cont~ininp H. pylori strains, and col.lpalison with the present sequence allows for the identification of sequences that can be used to discriminate between strains, as well as those that are cornmon to all H. pylori strains. In one embodiment, the invention provides nucleic acids, including probes, and peptide and polypeptide sequences that discriminate between different strains of H. pylori. Strain-specific components can also be identified functionally by their ability to elicit or react with antibodies that selectively recognize one or more H. pylori strains.
In another embodiment, the invention provides nucleic acids, including probes, and peptide and polypeptide sequences that are common to all H. pylori strains but are not found in other bacterial species.

Specific ExamPle: Determination Of Candidate Protein Anti~ens For Antibodv And Vaccine Development The selection of candidate protein antigens for vaccine development can be derived from the nucleic acids encoding H. pylori polypeptides. First, the ORF's can be analyzed for homology to other known exported or membrane proteins and analyzed using thediscrimin~nt analysis described by Klein, et al. (Klein, P., ~nçh~i~ M., and DeLisi, C.
(1985) Biochimica et Biophysica Acta 815, 468-476) for predicting exported and membrane proteins.
Homology searches can be performed using the BLAST algorithm contained in the Wisconsin Sequence Analysis Package (Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711) to compare each predicted ORF amino acid sequence with all sequences found in the current GenBank, SWISS-PROT and PIR
A~t~h~es BLAST searches for local ~lignment~ between the ORF and the databank sequences and reports a probability score which indicates the probability of finding this sequence by chance in the A~t~h~e. ORF's with significant homology (e.g. probabilities SUBSTITUTE SHEET (RULE 26) CA 0222339c. 1997-12-03 lower than 1 x 1 o-6 that the homology is only due to random chance) to membrane or exported proteins represent protein antigens for vaccine development. Possible functions can be provided to H. pylori genes based on sequence homology to genes cloned in other org~ni~m~
Discrimin~nt analysis (Klein, et al. supra) can be used to ~mine the ORF amino acid sequences. This algorithm uses the intrinsic information contained in the ORF amino acid sequence and col~lpa~s it to information derived from the ~ .Lies of known membrane and exported proteins. This comparison predicts which proteins will be exported, membrane associated or cytoplasmic. ORF a~nino acid sequences identified as exported or membrane associated by this algorithîn are likely protein antigens for vaccine development.
Infrequently it is not possible to distinguish between multiple possible nucleotides at a given position in the nucleic acid sequence. In those cases the ambiguities are denoted by an extended alphabet as follows:
These are the official IUPAC-IUB single-letter base codes Code Base Description G Guanine A Adenine T Thymine C Cytosine R Purine (A or G) Y Pyrimidine (C or T or U) M Amino (A orC) K Ketone (G or T) S Strong interaction (C orG) W Weak interaction (A or T) H Not-G (A or C or T) B Not-A (C or G or T) V Not-T (not-U) (A or C or G) D Not-C (A or G or T) N Any (A or C or G or T) The amino acid translations of this invention account for the ambiguity in the ~ nucleic acid sequence by tr~n~l~ting the ambiguous codon as the letter "X". In all cases, the 20 permissible amino acid residues at a position are clear from an e~min~tion of the nucleic acid sequence based on the standard genetic code.

SUBSTITUTE SHEET ~RULE 26 CA 0222339~ 1997-12-03 W O 9~ 8~3 PCTAUS96/09122 V. Production of Fra~ments and Analo~s of H. pvlori Nucleic Acids and PolYpeptides Based on the discovery of the H. pylori gene products of the invention provided in the Sequence Lsiting, one skilled in the art can alter the disclosed structure (of H. pylori genes), e.g., by producing fragments or analogs, and test the newly produced structures for activity. Examples of techniques known to those skilled in the relevant art which allow the production and testing of fr~Pm~ont~ and analogs are discussed below. These, or analogous methods can be used to make and screen libraries of polypeptides, e.g., libraries of random peptides or libraries of fr~gment~ or analogs of cellular proteins for the ability to bind H.
pylori polypeptides. Such screens are useful for the identification of inhibitors of H. pylori.
Generation of Fra~ments Fr~gment~ of a protein can be produced in several ways, e.g., recombinantly, by proteolytic digestion, or by chemical synthesis. Tntern~l or termin~l fr~gment~ of a polypeptide can be generated by removing one or more nucleotides from one end (for a termin~l fragment) or both ends (for an internal fragment) of a nucleic acid which encodes the polypeptide. Expression of the mutagenized DNA produces polypeptide fr~gment~
Digestion with "end-nibbling" endonucleases can thus generate DNA's which encode an array of fra~mPntc DNA's which encode fragments of a protein can also be generated by random shearing, restriction digestion or a combination of the above-discussed methods.
Fr~gment~ can also be chemically synthesi7~1 using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chPmi~try. For example, peptides of the present invention may be a~ dlily divided into fragments of desired length with no overlap of the fragments, or divided into overlapping fragments of a desired length.

Alteration of Nucleic Acids and Polvpeptides: Random Methods Amino acid sequence variants of a protein can be prepared by random mutagenesis of DNA which encodes a protein or a particular domain or region of a protein. Useful methods include PCR mutagenesis and saturation mutagenesis. A library of random amino acid sequence variants can also be generated by the synthesis of a set of degenerate oligonucleotide sequences. (Methods for screening proteins in a library of variants are elsewhere herein).
(A) PCR Muta~enesis In PCR mutagenesis, reduced Taq polymerase fidelity is used to introduce random mutations into a cloned fragment of DNA (Leung et al., 1989, Technique 1:1 1-15). The DNA region to be mutagenized is amplified using the polymerase chain reaction (PCR) under conditions that reduce the fidelity of DNA synthesis by Taq DNA polymerase, e.g., by using a dGTP/dATP ratio of five and adding Mn2+ to the PCR reaction. The pool of amplified DNA fr~gment~ are inserted into ~lopl.ate cloning vectors to provide random mutant libraries.

SUBSTITUTE SH EET (RULE 26) CA 0222339~ 1997-12-03 (B) Saturation Muta~enesis Saturation mutagenesis allows for the rapid introduction of a large number of single base substitutions into cloned DNA fr~gment~ (Mayers et al., 1985, Science 229:242). This technique includes generation of mutations, e.g., by chemical treatment or irradiation of 5 single-stranded DNA in vitro, and synthesis of a complimentary DNA strand. Themutation frequency can be modulated by mod~ ting the severity of the tre~tmen~, and çcsçnti~lly all possible base substitutions can be obtained. Because this procedure does not involve a genetic selection for mutant fr~gmentc both neutral substitutions, as well as those that alter fimction, are obtained. The distribution of point mutations is not biased toward 10 conserved sequence elements.
(C) De~enerate Oli~onucleotides A library of homologs can also be generated from a set of degenerate oligonucleotide sequences. Chemical synthesis of a degenerate sequences can be carried out in an automatic DNA synth~si7t-r, and the synthetic genes then ligated into an 15 a~,ol.liate expression vector. The synthesis of degenerate oligonucleotides is known in the art (see for example, Narang, SA (1983) Tetrahedron 39:3; Itakura et al. (1981) Recombinant DNA, Proc 3rd Cleveland Sympos. Macromolecules, ed. AG Walton, Amsterdarn: Elsevier pp273-289; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198: 1056; Ike et al. (1983) Nucleic Acid Res. 11 :477. Such techniques 20 have been employed in the directed evolution of other proteins (see, for example, Scott et al. (1990) Science 249:386-390; Roberts et al. (1992) PNAS 89:2429-2433; Devlin et al.
(1990) Science 249: 404-406; Cwirla et al. (1990) PN~S 87: 6378-6382; as well as U.S.
Patents Nos. 5,223,409, 5,198,346, and 5,096,815).

25 Alteration of Nucleic Acids and PolYpeptides: Methods for Directed Muta~enesis Non-random or directed, mutagenesis techniques can be used to provide specific sequences or mutations in specific regions. These techniques can be used to create variants which include, e.g., deletions, insertions, or sl~hstihltions~ of residues of the known amino acid sequence of a protein. The sites for mutation can be modified individually or in series, 30 e.g., by (1) substituting first with conserved amino acids and then with more radical choices depending upon results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class ~ nt to the located site, or combinations of options 1-3.
(A) Alanine Sczlnning Muta~enesis Alanine sc~nning mutagenesis is a useful method for identification of certain 35 residues or regions of the desired protein that are p.ere~l~d locations or domains for mutagenesis, Cnnningh~m and Wells (Science 244:1081-1085, 1989). In alanine sC~nning, a residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine). Replacement of an arnino acid can affect the interaction SUBSTITUTE SHEET (RULE 26~

CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 of the amino acids with the surrounding aqueous environrnent in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions are then refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined. the nature of the 5 mutation per se need not be predetermined. For example, to optimize the p~lrol~ ce of a mutation at a given site, alanine sc~nning or random mutagenesis may be conducted at the target codon or region and the expressed desired protein subunit variants are screened for the optimal combination of desired activity.
(B) Oli~onucleotide-Mediated Muta~enesis Oligonucleotide-mediated mutagenesis is a useful method for ~lel,~h1g substitution, deletion, and insertion variants of DNA, see, e.g., Adelman et al., (DNA 2: 183, 1983). Briefly, the desired DNA is altered by hybridizing an oligonucleotide encoding a mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage co..l;1i . .i..g the unaltered or native DNA sequence of the desired protein.
After hybridization, a DNA polymerase is used to synthe~i7P an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the desired protein DNA. Generally,oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complement~ry to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthPsi7P~ using techniques known in the art such as that described by Crea et al. (Proc. Natl. Acad. Sci. USA, 75: 5765[1978]).
(C) (~csette Muta~enesis Another method for ~l~,p~illg variants, cassette mutagenesis, is based on the technique described by Wells et al. (Gene, 34:315[1985]). The starting material is a plasmid (or other vector) which includes the protein subunit DNA to be mutated. The codon(s) in the protein subunit DNA to be m~lt~tPtl are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mer1i~ted mutagenesis method to introduce them at a~ pllate locations in the desired protein subunit DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but cont~ining the desired mutation(s) is synthe~i7P-l using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the c~csette. This cassette is designed to have 3' and 5' ends that are colllpal~ble with the ends of the linearized plasmid? such that it can be directly ligated to SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 the plasmid. This plasmid now contains the mutated desired protein subunit DNA
sequence.
(D) Combinatorial Muta~enesis Combinatorial mutagenesis can also be used to generate mutants (Ladner et al., WO
88/06630). In this method, the amino acid sequences for a group of homologs or other related proteins are ~ n~-1 preferably to promote the highest homology possible. All of the amino acids which appear at a given position of the aligned sequences can be selected to create a degenerate set of combinatorial sequences. The variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library. For example, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degen~ldl~ set of potential sequences are expressible as individual peptides, or alternatively, as a set of larger fusion proteins cont~ining the set of degenerate sequences.

Other Modifications of H. pvlori Nucleic Acids and Polypeptides It is possible to modify the structure of an H. pylori polypeptide for such purposes as increasing solubility, enhancing stability (e.g., shelf life ex vivo and resi~t~nce to proteolytic degradation in vivo). A modified H. pylori p~otein or peptide can be produced in which the amino acid sequence has been altered, such as by amino acid substitution, deletion, or addition as described herein.
An H. pylori peptide can also be modified by s~lbstihltion of cysteine residues preferably with ~l~nin~?, serine, threonine, leucine or glutamic acid residues to minimi71o dimerization via ~ llficle linkages. In addition, amino acid side chains of fragments of the protein of the invention can be chemically modified. Another modification is cyclization of the peptide.
In order to enhance stability and/or reactivity, an H. pylori polypeptide can bemodified to incorporate one or more polymorphisms in tl1e amino acid sequence of the protein resl-ltin~ from any natural allelic variation. Additionally, D-amino acids, non-natural amino acids, or non-amino acid analogs can be substituted or added to produce a modified protein within the scope of this invention. Furthermore, an H. pylori polypeptide can be modified using polyethylene glycol (PEG) according to the method of A. Sehon and co-workers (Wie et al., supra) to produce a protein conjugated with PEG. In addition, PEG
can be added during chemical synthesis of the protein. Other modifications of H. pylori proteins include reduction/alkylation (Tarr, Methods of Protein Microcharacterization, J. E.
Silver ed., Humana Press, Clifton NJ 155-194 (1986)); acylation (Tarr, supra); chemical coupling to an ~lo~liate carrier (Mishell and Shiigi, eds, Selected Methods in Cellular Immunology, WH Freeman, San Francisco, CA (1980), U.S. Patent 4,939,239; or mildformalin treatment (Marsh, (1971) Int. Arch. of Allergy and Appl. Immunol., 41: 199 - 215).

SUBSTITUTE SHEFT (RULE ~6,~1 CA 0222339~ 1997-12-03 To facilitate purification and potentially increase solubility of an H. pylori protein or peptide. it is possible to add an amino acid fusion moiety to the peptide backbone. For example, hexa-histidine can be added to the protein for purification by immobilized metal ion affinity chromatography (Hochuli, E. et al., (1988) Bio/Technology, 6: 1321 - 1325). In S addition. to facilitate isolation of peptides free of irrelevant sequences, specific endoplotease cleavage sites can be introduced between the sequences of the fusion moiety and the peptide.
To potentially aid proper antigen proces~ing of epitopes within an H. pylori polypeptide, canonical protease sensitive sites can be engineered between regions~ each 10 comprising at least one epitope via recombinant or synthetic methods. For example, charged amino acid pairs, such as KK or RR, can be introduced between regions within a protein or fragment during recombinant construction thereof. The resulting peptide can be rendered sensitive to cleavage by cathepsin and/or other trypsin-like enzvmes which would generate portions of the protein co.~ i..g one or more epitopes. In addition, such charged amino acid residues can result in an increase in the solubility of the peptide.

Primarv Methods for Screenin~ PolYpePtides and Analo~s Various techniques are known in the art for screening generated mutant gene products. Techniques for screening large gene libraries often include cloning the gene library into replicable e~ ion vectors, transforming a~pru~liate cells with the resulting library of vectors, and exl,lessillg the genes under conditions in which detection of a desired activity, e.g., in this case, binding to H. pylori polypeptide or an interacting protein, facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the techniques described below is amenable to high through-put analysis for screening large numbers of sequences created, e.g., by random mutagenesis techniques.
(A) Two Hvbrid Svstems Two hybrid assays such as the system described above (as with the other screening methods described herein), can be used to identify polypeptides, e.g., fr~gment~ or analogs of a naturally-occurring H. pylori polypeptide, e.g., of cellular proteins, or of randomly generated polypeptides which bind to an H. pylori protein. (The H. pylori domain is used as the bait protein and the library of variants are expressed as fish fusion proteins.) In an analogous fashion, a two hybrid assay (as with the other screening methods described herein), can be used to find polypeptides which bind a H. pylori polypeptide.
(B) Displav Libraries In one approach to screening assays, the candidate peptides are displayed on thesurface of a cell or viral particle, and the ability of particular cells or viral particles to bind an ~plupliate receptor protein via the displayed product is ~1etected in a "panning assay".
For example~ the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein ~letected by panning (Ladner et al.~ WO

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 . PCTrUS96/09122 88t06630; Fuchs et al. (1991) Bio/Technology 9:1370-1371; and Goward et al. (1992) TIBS
18: 136- 140). In a similar fashion, a detectably labeled ligand can be used to score for potentially functional peptide homologs. Fluorescently labeled li~;~n~c, e.g., receptors. can be used to detect homologs which retain ligand-binding activity. The use of fluorescently labeled li~7/ntlc, allows cells to be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell perrnits, to be separated by a fluorescence-activated cell sorter.
A gene library can be expressed as a fusion protein on the surface of a viral particle.
For inct~nf e, in the fil~mentQus phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at concentrations well over 1013 phage per milliliter, a large number of phage can be screened at one time. Second, since each infectious phage displays a gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical E. coli fil~nnentous phages M13, fd., and fl are most often used in phage display libraries. Either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate p~ck~gin~ of the viral particle. Foreign epitopes can be expressed at the NH2-termin~l end of pIII and phage bearing such epitopes recovered from a large excess of phage lacking this epitope (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) J. Biol. Chem. 267:16007-16010; Griffiths et al. (1993) EMBO J 12:725-734;
Clackson et al. (1991) Nature 352:624-628; and Barbas et al. (1992) PNAS 89:4457-4461).
A common approach uses the maltose receptor of E. coli (the outer membrane protein, LamB) as a peptide fusion partner (Charbit et al. (1986) EMBO 5, 3029-3037).
Oligonucleotides have been inserted into plasmids encoding the LamB gene to produce peptides fused into one of the extracellular loops of the protein. These peptides are available for binding to lig~ntlc, e.g., to antibodies, and can elicit an immllnt? response when the cells are ~llmini~tered to ~nim~l~ Other cell surface proteins, e.g., OmpA (Schorr et al.
(1991) Vaccines 91, pp. 387-392), PhoE (Agterberg, et al. (1990) Gene 88, 37-45), and PAL (Fuchs et al. (1991) Bio/Tech 9, 1369-1372), as well as large bacterial surface structures have served as vehicles for peptide display. Peptides can be fused to pilin, a protein which polymerizes to form the pilus-a conduit for interb~ctt~ri~l exchange of genetic information (Thiry et al. (1989) Appl. Environ. Microbiol. 55, 984-993). Because of its role in interacting with other cells, the pilus provides a useful support for the presentation of peptides to the extracellular environment. Another large surface structure used for peptide display is the bacterial motive organ, the flagellum. Fusion of peptides to the subunit protein flagellin offers a dense array of many peptide copies on the host cells (Kuwajima et al. (1988) Bio/Tech. 6, 1080-1083). Surface proteins of other b~ctt?ri~l species have also served as peptide fusion partners. Examples include the Staphylococcus SUBSTITUTE SHEET (RULE 263 CA 0222339~ 1997-12-03 W O 96/1~93 PCT~US96/09122 protein A and the outer membrane IgA protease of Neisseria (Hansson et al. (1992) J.
Bacteriol. 1747 4239-4245 and Klauser et al. (1990) EMBO J. 9, 1991-1999).
In the fil~mentous phage systems and the LamB system described above, the physical link between the peptide and its encoding DNA occurs by the co~ i l 1" ,ent of the 5 DNA within a particle (cell or phage) that carries the peptide on its surface. Capturing the peptide ca~LLI,eS the particle and the DNA within. An alternative scheme uses the DNA-binding protein LacI to form a link between peptide and DNA (Cull et al. ( 1992) PNAS
USA 89: 1865- 1869). This system uses a plasmid cont~ining the LacI gene with anoligonucleotide cloning site at its 3'-end. Under the controlled induction by arabinose, a 10 LacI-peptide fusion protein is produced. This fusion retains the natural ability of LacI to bind to a short DNA sequence known as LacO operator (LacO). By in~t~lling two copies of LacO on the ~ es~ion plasmid, the LacI-peptide fusion binds tightly to the plasmid that encoded it. Because the plasmids in each cell contain only a single oligonucleotide sequence and each cell expresses only a single peptide sequence, the peptides become 15 specifically and stably associated with the DNA sequence that directed its synthesis. The cells of the library are gently lysed and the peptide-DNA complexes are exposed to a matrix of immobilized receptor to recover the complexes COI~t~i~,;,.g active peptides. The associated plasmid DNA is then reintroduced into cells for amplification and DNAsequencing to ~letermine the identity of the peptide lig~n-lc As a demonstration of the 20 practical utility of the method, a large random library of dodecapeptides was made and selected on a monoclonal antibody raised against the opioid peptide dynorphin B. A cohort of peptides was recovered, all related by a co~çn~ sequence corresponding to a six-residue portion of dynorphin B. (Cull et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89- 1869) This scheme, somçtimes referred to as peptides-on-plasmids, differs in two 25 hll,oul~lt ways from the phage display methods. First, the peptides are ~tt~ch~?d to the C-tPrminll~ of the fusion protein, reclllting in the display of the library members as peptides having free carboxy termini Both of the fil~mentous phage coat proteins, pIII and pVIII, are anchored to the phage through their C-tt~rmini, and the guest peptides are placed into the outward-~xten.ling N-termin~l clom~in~ In some (lecipn~, the phage-displayed peptides are 30 presented right at the amino terrninll~ of the fusion protein. (Cwirla, et al. (1990) Proc.
Natl. Acad. Sci. U.S.A. 87, 6378-6382) A second difference is the set of biological biases affecting the population of peptides actually present in the libraries. The LacI fusion molecules are confined to the cytoplasm of the host cells. The phage coat fusions are exposed briefly to the cytoplasm during translation but are rapidly secreted through the 35 inner membrane into the periplasmic culllpa~L.,lent, rem~ining anchored in the membrane by their C-terminal hydrophobic domains, with the N-termini, cont~ining the peptides, protruding into the periplasm while awaiting assembly into phage particles. The peptides in the LacI and phage libraries may differ significantly as a result of their exposure to different proteolytic activities. The phage coat proteins requye transport across the inner SUBSTITUTE SHEET (RULE 26) , CA 0222339~ 1997-12-03 membrane and signal peptidase processing as a prelude to incol~ul~Lion into phage.
Certain peptides exert a deleterious effect on these processes and are undclleplesented in the libraries (Gallop et al. (1994) ~ Med. Chem. 37(9):17.33-1251). These particular biases are not a factor in the LacI display system.
The number of small peptides available in recombinant random libraries is enormous. Libraries of 107-109 independent clones are routinely ~l~;paled. Libraries as large as 1011 recombinants have been created, but this size approaches the practical limit for clone libraries. This limitation in library size occurs at the step of transforming the DNA co~ g randomized segmentc into the host bacterial cells. To circumvent this limitation, an in vitro system based on the display of nascent peptides in polysome complexes has recently been developed. This display library method has the potential of producing libraries 3-6 orders of m~gnit~lcle larger than the currently available phage/phagemid or plasmid libraries. Furtherrnore, the construction of the libraries, ~x~l~s~ion of the peptides, and screening, is done in an entirely cell-free format.
In one application of this me~hod (Gallop et al. (1994) J. Med. Chem. 37(9): 1233-1251), a molecular DNA library encoding 1012 decapeptides was constructed and the library expressed in an E. coli S30 in vitro coupled lldnsc.;~lion/translation system.
Conditions were chosen to stall the ribosomes on the mRNA, causing the accumulation of a substantial proportion of the RNA in polysomes and yielding complexes cont~inin~ nascent peptides still linked to their encoding RNA. The polysomes are sufficiently robust to be affinity purified on immobilized receptors in much the same way as the more conventional recombinant peptide display libraries are screened. RNA from the bound complexes is recovered, converted to cDNA, and amplified by PCR to produce a template for the next round of synthesis and screening. The polysome display method can be coupled to the phage display system. Following several rounds of screening, cDNA from the enriched pool of polysomes was cloned into a phagemid vector. This vector serves as both a peptide expression vector, displaying peptides fused to the coat proteins, and as a DNA sequencing ' vector for peptide identification. By t;~ressillg the polysome-derived peptides on phage, one can either continue the affinity selection procedure in this format or assay the peptides on individual clones for binding activity in a phage ELISA, or for binding specificity in a completion phage ELISA (Barret, et al. (1992) Anal. Biochem 204,357-364). To identify the sequences of the active peptides one sequences the DNA produced by the phagemid host.

., 35 Secondarv Screenin~ of PolYpeptides and Analo~s The high through-put assays described above can be followed by secondary screensin order to identify further biological activities which will, e.g., allow one skilled in the art to differentiate agonists from antagonists. The type of a secondary screen used will depend on the desired activity that needs to be tested. For example, an assay can be developed in SUBSTITUTE 5HEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 which the ability to inhibit an interaction between a protein of interest and its respective ligand can be used to identify antagonists from a group of peptide fr~gment~ isolated though one of the primary screens described above.
Therefore, methods for generating fr~ment~ and analogs and testing them for activity are known in the art. Once the core sequence of interest is identified, it is routine for one skilled in the art to obtain analogs and fr~gment~

Peptide Mimetics of H. pvlori PolvpePtides The invention also provides for reduction of the protein binding domains of the subject H. pylori polypeptides to generate mimetics, e.g. peptide or non-peptide agents.
The peptide mimetics are able to disrupt binding of a polypeptide to its counter ligand, e.g., in the case of an H. pylori polypeptide binding to a naturally occurring ligand. The critical residues of a subject H. pylori polypeptide which are involved in molecular recognition of a polypeptide can be determined and used to generate H. pylori-derived peptidomimetics which competitively or noncompetitively inhibit binding of the H. pylori polypeptide with an interacting polypeptide (see, for example, European patent applications EP-412,762A
and EP-B31,080A).
For example, sç~nning mutagenesis can be used to map the amino acid residues of a particular H. pylori polypeptide involved in binding an interacting polypeptide,peptidomimetic compounds (e.g. diazepine or isoquinoline derivatives) can be generated which mimic those residues in binding to an interacting polypeptide, and which therefore can inhibit binding of an H. pylori polypeptide to an interacting polypeptide and thereby interfere with the function of H. pylori polypeptide. For in~t~n~e, non-hydrolyzable peptide analogs of such residues can be generated using benzodiazepine (e.g., see Freidinger et al.
in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands. 1988), azepine (e.g., see Huffman et al. in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Nethçrl~ntl~, 1988), substituted gama lactam rings (Garvey et al. in Peptides: Chemistry and Biolo~y, G.R. Marshall ed., ESCOM
Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al.
(1986) J Med Chem 29:295; and Ewenson et al. in Peptides: Structure and Function(ProceeAing~ of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), ~-turn dipeptide cores (Nagai et al. (1985) Tetrahedron Lett 26:647; and Sato et al.
(1986) J Chem Soc Perkin Trans 1: 1231), and ~-aminoalcohols (Gordon et al. (1985) Biochem Biophys Res Communl26:419; and Dann et al. (1986) Biochem Biophys Res Commun 134:71).

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 VI. Vaccine Formulations for H. pvlori Nucleic Acids and Polvpeptides This invention also features vaccine compositions for protection against infection by H. pylori or for tre~fnnent of H. pylori infection, a gram-negative spiral microaerophilic bacterium. In one embodiment, the vaccine compositions contain one or mor 5 immlm~genic components such as a surface protein from H. pylori, or portion thereof, and a ph~rrn~relltically acceptable carrier. Nucleic acids within the scope of the invention are exemplified by the nucleic acids of the invention contained in the Sequence Listing which encode H. pylori surface proteins. For example, the preferred nucleic acid for a vaccine composition of the invention is isolated from the group of nucleic acids which encode cell 10 envelope prot~ s as outlined in Table l . More specifically, the amino acids of SEQ ID
NO:812, SEQ ID NO:820, SEQ ID NO:880, SEQID NO:658, SEQID NO:865, SEQID
NO:1729, SEQID NO:1861, or fr~gment~ thereof, can be used alone or in combination for the formulation of vaccine compositions of the invention, as well as, their corresponding nucleic acids of SEQID NO:977, SEQID NO:978, SE(~ID NO:994, SEQID NO:215, SEQID NO:989, SEQID NO:1278, and SEQID NO:1410. However, any nucleic acid encoding an immlmogenic H. pylori protein, or portion thereof, which is capable of expression in a cell, can be used in the present invention. These vaccines have therapeutic and prophylactic utilities.
One aspect of the invention provides a vaccine composition for protection against 20 infection by H. pylori which contains at least one immlmt~genic fragment of an H. pylori protein and a ph~rm~eutically acceptable carrier. Preferred fr7~gm~nt~ include peptides of at least about 10 amino acid residues in length, preferably about 10-20 amino acid residues in length, and more preferably about 12-16 amino acid residues in length.
Immunogenic components of the invention can be obtained, for example, by 25 screening polypeptides recombinantly produced from the corresponding fragment of the nucleic acid encoding the full-length H. pylori protein. In addition, fr~gment~ can be chemically synthl-~i7Pcl using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemi~try.
In one embodiment, immunogenic components are identified by the ability of the 30 peptide to stimul~te T cells. Peptides which stimlll~t~ T cells, as ~ettormined by, for example, T cell proliferation or cytokine secretion are defined herein as comprising at least one T cell epitope. T cell e~iLopes are believed to be involved in initiation and perpetuation of the immune .e~ollse to the protein allergen which is responsible for the clinical symptoms of allergy. These T cell epitopes are thought to trigger early events at the level 35 of the T helper cell by binding to an ~plup~iate HLA molecule on the surface of an antigen presenting cell, thereby stimulating the T cell subpopulation with the relevant T cell receptor for the epitope. These events lead to T cell proliferation, lymphokine secretion, local infl~mm~t~-ry reactions, ~ iLInent of additional immune cells to the site of antigen/T cell interaction, and activation of the B cell c~cc~le, Ieading to the production of SUBSTITUTE 5H EET (RULE 26) -CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 antibodies. A T cell epitope is the basic element, or smallest unit of recognition by a T cell receptor, where the epitope comprises amino acids escPnti~l to receptor recognition (e.g., approximately 6 or 7 amino acid residues). Amino acid sequences which mimic those of the T cell epitopes are within the scope of this invention.
Screening immunogenic components can be accomplished using one or more of several different assays. For example, in vitro, peptide T cell stim~ tory activity is assayed by cont~rtinF a peptide known or suspected of being immnnogenic with an antigen presçntin~ cell which presents a~.u~-iate MHC molecules in a T cell culture. Presentation of an immunogenic H. pylori peptide in association with ~p.op.iate MHC molecules to T
cells in conjunction with the necessary costimulation has the effect of transmitting a signal to the T cell that induces the production of increased levels of cytokines, particularly of interleukin-2 and interleukin-4. The culture supern~t~nt can be obtained and assayed for interleukin-2 or other known cytokines. For example, any one of several conventional assays for interleukin-2 can be employed. such as the assay described in Proc. Natl. Acad.
SCi USA, 86:1333(1989) the pertinent portions of which are incorporated herein by reference. A kit for an assay for the production of h.l~.reroll is also available from Genzyme Corporation (Cambridge, MA).
Alternatively, a common assay for T cell proliferation entails measuring tritiated thymidine incorporation. The proliferation of T cells can be measured in vitro by cletermining the amount of 3H-labeled thymidine incorporated into the replicating DNA of cultured cells. Therefore, the rate of DNA synthesis and, in turn, the rate of cell division can be quantified.
Vaccine compositions of the invention cont~inin~ immunogenic components (e.g., H. pylori polypeptide or fragment thereof or nucleic acid encoding an H. pylori polypeptide or fragment thereof) preferably include a ph~rm~t~eutically acceptable carrier. The terrn "pharmaceutically acceptable carrier" refers to a carrier that does not cause an allergic reaction or other untoward effect in patients to whom it is ~lmini~tered. Suitable ph~rm~celltically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline. dextrose, glycerol, ethanol and the like, as well as combinations thereof. Ph~rm~centically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody. For vaccines of the invention cont~ining H. pylori polypeptides~ the polypeptide is co~mini~tered with a suitable adjuvant.
It will be a~alGl,t to those of skill in the art that the therapeutically effective amount of DNA or protein of this invention will depend, inter alia, upon the ~timini~tration schedule, the unit dose of antibody ~lminictered, whether the protein or DNA is ~mini~tered in combination with other therapeutic agents, the imrnune status and health of the patient, and the therapeutic activity of the particular protein or DNA.

SUBSTITUTE SHEET (RULE 26) , CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/O91z2 Vaccine compositions are conventionally ~(lmini~tered parenterally, e.g., by injection, either subcutaneously or intramuscularly. Methods for intramuscular immlmi7~tion are described by Wolff et al. (1990) Science 247: 1465-1468 and by Sedegah - et al. (1994) Immunology 91: 9866-9870. Other modes of ~irninistration include oral and 5 pulmonary formulations, suppositories, and tr~nc(1erm~l applications. Oral jmml-ni7~tion is ~rere-l~ed over ~elllel~l methods for inducing protection against infection by H. pylori.
Czinn et. al. (1993) Vaccine 11: 637-6~2. Oral formulations include such normally employed excipients as, for example, ph~rm~ceutical grades of lllanllilol~ lactose, starch, m~gn~ium stearate, sodium saccharine, cellulose, m~gne~ium carbonate, and the like.
The vaccine compositions of the invention can include an adjuvant, including, but not limited to all-mim-m hydroxide; N-acetyl-muramyl--L-threonyl-D-isoglllt~min~ (thr-MDP); N-acetyl-nor-muramyl-L-alanyl-D-iso~lu~nille (CGP 11637, referred to as nor-MDP); N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-~lir~lmitoyl-sn-glycero-3-hydroxyphos-phoryloxy)-ethylamine (CGP 19835A, referred to a MTP-PE);
RIBI, which contains three components from bacteria; monophosphoryl lipid A; trehalose dimycoloate; cell wall skeleton (MPL + TDM + CWS) in a 2% squalene/Tween 80 emulsion; and cholera toxin. Others which may be used are non-toxic derivatives of cholera toxin, int~hl~lin~ its B subunit, and/or conjugates or genetically engineered fusions of the H. pylori polypeptide with cholera toxin or its B subunit, procholeragenoid, fungal polysaccharides, including schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin of E. coli, non-H. pylori bacterial lysates, block polymers or saponins.
Other suitable delivery methods include biodegradable microcapsules or immllnt~-stim~ ting complexes (ISCOMs), cochle~te.~, or liposomes, genetically ~nginePred~ttenll~te~l live vectors such as viruses or bacteria, and recombinant (chimeric) virus-like particles, e.g., bluetongue. The amount of adjuvant employed will depend on the type of adjuvant used. For example, when the mucosal adjuvant is cholera toxin, it is suitably used in an amount of 5 ~lg to 50 ~g, for example 10 ,ug to 35 ~Lg. When used in the form of microcapsules, the amount used will depend on the amount employed in the matrix of the microcapsule to achieve the desired dosage. The ~letermin~tion of this amount is within the skill of a person of oldill~y skill in the art.
Carrier systems in h~lm~ns may include enteric release capsules protecting the antigen from the acidic environment of the stomach? and including H. pylori polypeptide in an insoluble form as fusion proteins. Suitable carriers for the vaccines of the invention are " 35 enteric coated capsules and polylactide-glycolide microspheres. Suitable diluents are 0.2 N
NaHCO3 and/or saline.
Vaccines of the invention can be ~-lministered as a primary prophylactic agent in adults or in children, as a secondary prevention, after sllcce~sful eradication of H. pylori in an infected host, or as a therapeutic agent in the aim to induce an immlme response in a SU13STITUTE SHEET (RULE 26~,1 CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 susceptible host to prevent infection by H pylori. The vaccines of the invention are 2~1minictered in amounts readily cletermined by persons of ordinary skill in the art. Thus, for adults a suitable dosage will be in the range of 10 ~lg to 10 g, preferably 10 ,ug to 100 mg, for example 50 ~g to 50 mg. A suitable dosage for adults will also be in the range of 5 S ~g to 500 mg. Similar dosage ranges will be applicable for children. Those skilled in the art will recognize that the optimal dose may be more or less depending upon the patient's body weight, (1i~e~e7 the route of ~lmini~tration~ and other factors. Those skilled in the art will also recognize that a~pru~l;ate dosage levels can be obtained based on results with known oral vaccines such as, for example, a vaccine based on an E. coli lysate (6 mg dose 10 daily up to total of 540 mg) and with an enterotoxigenic E. coli purified antigen (4 doses of 1 mg) (Schlllm~n et al., J. Urol. 150:917-921( 1993); Boedecker et al., AmericanGastroenterological Assoc. 999:A-222 (1993)). The number of doses will depend upon the ~licezl~c, the formulation, and efficacy data from clinical trials. Without inten~ling any limitation as to the course of trç~tment the tre~tment can be ~lmini~tt~red over 3 to 8 doses 15 for a primary immllni7~tion schedule over 1 month (Boedeker, American Gastroenterological Assoc. 888:A-222 (1993)).
In a preferred embodiment, a vaccine composition of the invention can be based on a killed whole E. coli ple~ ion with an immllnogenic fragment of an H. pylori protein of the invention expressed on its surface or it can be based on an E. coli lysate, wherein the 20 killed E. coli acts as a carrier or an adjuvant.
It will be ~,p~ to those skilled in the art that some of the vaccine compositions of the invention are useful only for preventing H. pylori infection, some are useful only for treating H. pylori infection, and some are useful for both preventing and treating H. pylori infection. In a preferred embodiment, the vaccine composition of the invention provides 25 protection against H. pylori infection by stimlll~ting humoral and/or cell-mediated immunity against H. pylori. It should be understood that amelioration of any of the symptoms of H. pylori infection is a desirable clinical goal, including a lessening of the dosage of medication used to treat H. pylori-caused fii~e~e7 or an increase in the production of antibodies in the serum or mucous of patients.
VII. Antibodies Reactive With H. ~vlori Polypeptides The invention also includes antibodies specifically reactive with the subject H.pylori polypeptide. Anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard protocols (See, for example, Antibodies: A Laboratory Manual ed. by 35 Harlow and Lane (Cold Spring Harbor Press: 1988)). A m~mm~l such as a mouse, a h~m~ter or rabbit can be immunized with an immunogenic form of the peptide. Techniques for conferring immllnogenicit,v on a protein or peptide include conjugation to carriers or other techniques well known in the art. An immunogenic portion of the subject H. pylori polypeptide can be ~mini~t~red in the presence of adjuvant. The progress of immnni7~tion SUBSTITUTE SH EET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies.
In a plc~re~-~d embodiment, the subject antibodies are immlmospecific for antigenic S deterrnin~nt~ of the H. pylori polypeptides of the invention, e.g. antigenic det-~rmin~nt~ of a - polypeptide of the invention contained in the Sequence Listing, or a closely related human or non-human m~mm~ n homolog (e.g., 90% homologous, more preferably at least 95%homologous). In yet a further preferred embodiment of the invention~ the anti-H. pylori antibodies do not substantially cross react (i.e., react specifically) with a protein which is for example, less than 80% percent homologous to a sequence of the invention contained in the Sequence Listing. By "not substantially cross react", it is meant that the antibody has a binding affinity for a non-homologous protein which is less than 10 percent, more preferably less than 5 percent? and even more preferably less than 1 percent. of the binding affinity for a protein of the invention contained in the Sequence Listing. In a most pLer~--ed embodiment, there is no crossreactivity between bacterial and m~mm~ n antigens.
The terrn antibody as used herein is inten~A to include fr~gment.~ thereof which are also specifically reactive with H. pylori polypeptides. Antibodies can be fr~gmentecl using conventional techniques and the fragments screened for ~tility in the same manner as described above for whole antibodies. For example, F(ab')2 fr~gm~nt~ can be generated by treating antibody with pepsin. The resulting F(ab')2 fragment can be treated to reduce disulfide bridges to produce Fab' fr~gment~ The antibody of the invention is further inten~led to include bispecific and chimeric molecules having an anti-H. pylori portion.
Both monoclonal and polyclonal antibodies (Ab) directed against H. pylori polypeptides or H. pylori polypeptide variants, and antibody fragments such as Fab' and F(ab')2, can be used to block the action of H. pylori polypeptide and allow the study of the role of a particular H. pylori polypeptide of the invention in aberrant or unwanted intracellular sign~lin?~, as well as the normal cellular function of the H. pylori and by microinjection of anti-H. pylori polypeptide antibodies of the present invention.
Antibodies which specifically bind H. pylori epitapes can also be used in immunohistochemical staining of tissue samples in order to evaluate the abl-n-l~n~e and pattern of expression of H. pylori antigens. Anti H. pylori polypeptide antibodies can be used diagnostically in immuno-precipitation and immuno-blotting to detect and evaluate H.
pylori levels in tissue or bodily fluid as part of a clinical testing procedure. Likewise, the ability to monitor H. pylori polypeptide levels in an individual can allow determination of the efficacy of a given tre~tment regimen for an individual afflicted with such a disorder.
The level of an H. pylori polypeptide can be measured in cells found in bodily fluid, such as in urine samples or can be measured in tissue, such as produced by gastric biopsy.
Diagnostic assays using anti-H. pylori antibodies can include, for example, immunoassays SUBSTITUTE Sl IEET (RULE 26) CA 0222339~ 1997-12-03 ~leci~ne~ to aid in early rlizl~nosie of H. pylori infections. The present invention can also be used as a method of detecting antibodies contained in samples from individuals infected by this bacterium using specific H. pylori antigens.
Another application of anti-H. pylori polypeptide antibodies of the invention is in 5 the immlml~logical screening of cDNA libraries constructed in ~x~l~s~ion vectors such as ~gtl 1, ~gtl 8-23, ~ZAP, and ~0RF8. Messenger libraries of this type, having coding sequences inserted in the correct reading frame and orientation, can produce fusion proteins. For instance, ~gtl 1 will produce fusion proteins whose amino termini consist of ~3-galactosidase amino acid sequences and whose carboxy termini consist of a foreign 10 polypeptide. Antigenic epitopes of a subject H. pylori polypeptide can then be detectec~
with antibodies, as, for example, reacting nitrocellulose filters lifted from infected plates with anti-H. pylori polypeptide antibodies. Phage, scored by this assay, can then be isolated from the infected plate. Thus, the presence of H. pylori gene homologs can be detected and cloned from other species, and ~ltPrn~te isoforms (including splicing variants) 15 can be detected and cloned.

VIII. Kits Cont~ining Nucleic Acids. Polypeptides or Antibodies of the InventionThe nucleic acid, polypeptides and antibodies of the invention can be combined with other reagents and articles to form kits. Kits for diagnostic purposes typically 20 comprise the nucleic acid, polypeptides or antibodies in vials or other suitable vessels. Kits typically comprise other reagents for performing hybridization reactions, polymerase chain reactions (PCR), or for recon~tih~tion of lyophilized components, such as aqueous media, salts, buffers, and the like. Kits may also comprise reagents for sample processing such as dt:L~lge~ chaotropic salts and the like. Kits may also comprise immobilization means 25 such as particles, supports~ wells, dipsticks and the like. Kits may also comprise labeling means such as dyes, developing reagents, radioisotopes, fluorescent agents, lllmin~scent or chemilllminPscent agents, enzymes, interr~l~ting agents and the like. With the nucleic acid and amino acid sequence information provided herein, individuals skilled in art can readily assemble kits to serve their particular purpose. Kits further can include instructions for use.
IX. Dru~ Screening Assays Usin~ H. pvlori PolYpeptides By making available purified and recombinant H. pylori polypeptides~ the presentinvention provides assays which can be used to screen for drugs which are either agonists or antagonists of the normal cellular function, in this case, of the subject H. pylori 35 polypeptides~ or of their role in intracellular sign~ling Such inhibitors or potentiators may be useful as new therapeutic agents to combat H. pylori infections in hnm~ns. A variety of assay formats will suffice and, in light of the present inventions, will be comprehen~ecl by the skilled artisan.

SUBSTITUTE SH EET (RULE 26) CA 0222339~ 1997-12-03 In many drug screening programs which test libraries of compounds and natural extracts, high throughput assays are desirable in order to m~ximiZl~ the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins~ are often preferred 5 as t'~lh~ /" screens in that they can be generated to per nit rapid development and . relatively easy detection of an alteration in a molecular target which is mçdi~fP~1 by a test compound. Moreover, the effects of cellular toxicity and/or bioavailability of the test compound can be generally ignored in the in vitro system, the assay instead being focused primarily on the effect of the drug on the molecular target as may be manifest in an 10 alteration of binding affinity with other proteins or change in enzymatic plo~ Lies of the molecular target. Accordingly, in an exemplary screening assay of the present invention, the compound of interest is contacted with an isolated and purified H. pylori polypeptide.
Screening assays can be constructed in vitro with a purified H. pylori polypeptide or fragment thereof, such as an H. pylori polypeptide having enzymatic activity, such that the 15 activity of the polypeptide produces a (l~tect~ble reaction product. The efficacy of the compound can be assessed by gener~tin~ dose response curves from data obtained using various concentrations of the test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. Suitable products include those with distinctive absorption, fluorescence, or chemi~ min.oscl n~e ~ clLies, for example, 20 because detection may be easily automated. A variety of synthetic or naturally occurring compounds can be tested in the assay to identify those which inhibit or potentiate the activity of the H. pylori polypeptide. Some of these acti~e compounds may directly, or with chemical alterations to promote membrane perrneability or solubility, also inhibit or potentiate the same activity (e.g., enzymatic activity) in whole, live H. pylori cells.
EXEMPLIFICATION

I. Clonin~e and Sequencin~ of H. ,nylori DNA
H. pylori chromosomal DNA was isolated according to a basic DNA protocol 30 outlined in Schleif R.F. and Wensink P.C., Practical Methods in Molecular Biology, p.98, Springer-Verlag, NY., 1981, with minor modifications. Briefly, cells were pelleted, resuspended in TE (10 mM Tris, I mM EDTA, pH 7.6) and GES Iysis buffer (5.1 M
guanidium thiocyanate, 0.1 M EDTA, pH 8.0, 0.5% N-laurylsarcosine) was added.
Suspension was chilled and ammoniurn acetate (NH4Ac) was added to final concentration 35 of 2.0 M. DNA was exkacted~ first with chloroform, then with phenol-chloroform, and reexkacted with chloroform. DNA was ple-;ipiL~ted with isopropanol. washed twice with 70% EtOH~ dried and resuspended in TE.
Following isolation whole genomic H. pylori DNA was nebulized (Bodenteich et al., Automated DNA Sequencing and Analysis (J.C. Venter, ed.), Ac ~-lemic Press, 1994) to SUBSTITUTE SH EET (RULE 26) CA 0222339~ 1997-12-03 a median size of 2000 bp. After nebulization, the DNA was concentrated and separated on a standard 1% agarose gel. Several fractions, corresponding to approximate sizes 900-1300 bp, 1300-1700 bp, 1700-2200 bp, 2200-2700 bp, were excised from the gel and purified by the GeneClean procedure (BiolO1, Inc.).
S The purified DNA fragments were then blunt-ended using T4 DNA polymerase.
The healed DNA was then ligated to unique BstXI-linker adapters (5' TCTAGACCACCTGC and 5' GTGGTCTAGA in 100-1000 fold molar excess). These linkers are complimentary to the BstXI-cut pMPX vectors, while the overhang is not self-compliment~ry. Therefore, the linkers will not concatemerize nor will the cut-vector religate itself easily. The linker-adopted inserts were separated from the unincorporated linkers on a 1% agarose gel and purified using GeneClean. The linker-adopted inserts were then ligated to each of the 20 pMPX vectors to construct a series of "shotgun" subclone libraries. The vectors contain an out-of-frame lacZ gene at the cloning site which becomes in-frame in the event that an adapter-dimer is cloned. allowing these to be avoided by their blue-color.
All subsequent steps were based on the multiplex DNA sequencing protocols outlined in Church G.M. and Kieffer-Higgins S., Science 240:185-188, 1988. Only major modifications to the protocols are hiphlight~ Briefly, each of the 20 vectors was then transformed into DH5a competent cells (Gibco/BRL, DH5a transformation protocol). The libraries were a~sessecl by plating onto antibiotic plates co~ ampicillin~ methicillin and IPTGtXgal. The plates were inr~b~ted overnight at 37~C. Successful transformants were then used for plating of clones and pooling into the multiplex pools. The clones were picked and pooled into 40 ml growth medium cultures. The cultures were grown overnight at 37~C. DNA was purified using the Qiagen Midi-prep kits and Tip-100 columns (Qiagen. Inc.). In this manner, 100 ,ug of DNA was obtained per pool. Fifteen 96-well plates of DNA were generated to obtain a 5-10 fold sequence rec~llnt1~nry ~cllming 250-300 base average read-lengths.
These purified DNA samples were then sequenced using the multiplex DNA
sequencing based on chemical degradation methods (Church G.M. and Kieffer-Higgins S., Science 240:185-188, 1988) or by Se4uiLl~ l (Epicenter Technologies) dideoxy sequencing protocols. The sequencing reactions were electrophoresed and L~ r~ d onto nylon membranes by direct transfer electrophoresis from 40 cm gels (Richterich P. and Church G.M., Methods in Enzymology 218:187-222, 1993) or by electroblotting (Church, supra). 24 samples were run per gel. 45 succes~ful membranes were produced by ~h~rnic~l sequencing and 8 were produced by dideoxy sequencing. The DNA was covalently bound to the membranes by exposure to ultraviolet light, and hybridized with labeled oligonucleotides complimentary to tag sequences on the vectors (Church, supra). The membranes were washed to rinse off non-specifically bound probe, and exposed to X-ray film to visualize individual sequence ladders. After autoradiography, the hybridized probe SUBSTITUTE SH EFT (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 . PCT~US96/09122 was removed by incubation at 65~ C, and the hybridization cycle repeated with another tag sequence until the membrane had been probed 38 times for chemical sequencing membranes and 10 times for the dideoxy sequencing membranes. Thus, each gel produced a large number of films, each COllt;~ new sequencing information. Whenever a new5 blot was processed, it was initially probed for an internal standard sequence added to each of the pools.
Digital images of the films were generated using a laser-sc~nning densitometer (Molecular Dynamics, Sunnyvale, CA). The digitized images were processed on computer ~..h~Lions (VaxStation 4000's) using the program REPLICATM (Church et al., 10 Automated DNA Sequencing and Analysis (J.C. Venter, ed.), ~c~ mic Press, 1994).
Image processing included lane str~ight~ning, contrast adjustment to smooth out intensity differences, and resolution enhancement by iterative g~llcci~n deconvolution. The sequences were then automatically picked in REPLICATM and displayed for interactive proofreading before being stored in a project rl~t~b~ce The proofreading was accomplished 15 by a quick visual scan of the film image followed by mouse clicks on the bands of the displayed image to modify the base calls. Many of the sequence errors could be detectcd and corrected because multiple sequence reads covering the same portion of the genomic DNA provide adequate sequence re~l--n~l~ncy for editing. Each sequence automatically received an identification number (co~ ollding to microtiter plate, probe information, 20 and lane set number). This number serves as a perrn~nlont identifier of the sequence so it is always possible to identify the original of any particular sequence without recourse to a specialized rl~t~h~ce Routine assembly of H. pylori sequences was done using the program FALCON
(Church, Church et al., Automated DNA Sequenicng and Analysis (J.C. Venter, ed.), 25 Academic Press, 1994). This program has proven to be fast and reliable for most sequences. The assembled contigs were displayed using a modified version of GelAssemble, developed by the Genetics Computer Group (GCG) (Devereux et al., Nucleic Acid Res. 12:387-95, 1984) that interacts with REPLICATM. This provided for an integrated editor that allows multiple sequence gel images to be inct~nt~neously called up 30 from the REPLICATM ~l~t~b~ce and displayed to allow rapid sc~nninp of contigs and proofreading of gel traces where discrepancies occurred between different sequence reads in the assembly.

II. Identification~ clonin~ and ~x~ ion of recombinant H. pvlori DNA sequences To facilitate the cloning, ~xl~lession and purification of membrane and secretedproteins from H. pylori a powerful gene ~x~lession system, the pET System (Novagen), for cloning and expression of recombinant proteins in E. coli, was selected. Also, a DNA
sequence encoding a peptide tag, the His-Tag, was fused to the 3' end of DNA sequences of interest in order to f~ilit:~te purification of the recombinant protein products. The 3' end SUBSTITUTE SHEFT (RULE 26,) CA 0222339~ 1997-12-03 W O 96/40893 PC~US96/09122 was selected for fusion in order to avoid alteration of any 5' termin~l signal sequence. The exception to the above was ppiB, a gene cloned for use as a control in the expression studies. In this study, the sequence for H. pylori ppiB contains a DNA sequence encoding a His-Tag fused to the 5' end of the full length gene, because the protein product of this gene 5 does not contain a signal sequence and is expressed as a cytosolic protein.

PCR Amplification and cloning of DNA sequences containing ORF's for membrane andsecreted proteins from the J99 Strain of Helicobacter pylori.
Sequences chosen (from the list of the DNA sequences of the invention) for cloning 10 from the J99 strain of H. pylori were prepared for amplification cloning by polymerase chain reaction (PCR). Synthetic oligonucleotide primers (Table 4) specific for the 5' and 3' ends of open reading frames (ORFs) were designed and purchased (GibcoBRL Life Technologies, Gaithersburg, MD, USA). All forward primers (specific for the 5' end of the sequence) were designed to include an NcoI cloning site at the extreme 5' terminus, except for HpSeq. 4821082 (SEQ ID NO: 820) where NdeI was used. These primers were dt?signed to permit initiation of protein translation at a methionine residue followed by a valine residue and the coding sequence for the rem~in~ler of the native H. pylori DNA
sequence. An exception is H. pylori sequence 4821082 (SEQ ID NO: 820) where the initiator methionine is immediately followed by the remS~in~ler of the native H. pylori DNA
20 sequence. All reverse primers (specific for the 3' end of any H. pylori OR~) included a EcoRI site at the extreme 5' terrninl-s to permit cloning of each H. pylori sequence into the reading frame of the pET-28b. The pET-28b vector provides sequence encoding an additional 20 carboxy-termin~l amino acids (only 19 amino acids in HpSeq. 26380318 (SEQ ID NO: 658)and HpSeq.14640637 (SEQ ID NO: 447)) including six histidine 25 residues (at the extreme C-termin--s), which comprise the His-Tag. An exception to the above, as noted earlier, is the vector construction for the ppiB gene. A synthetic oligonucleotide primer specific for the 5 ' end of ppiB gene encoded a BamHI site at its extreme 5' te~ninl-s and the primer for the 3' end of the ppiB gene encoded a XhoI site at its extreme 5' terminl~s SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 Oli~onucleotide primers used for PCR amplificatioll of H. pvlori DNA sequences Outer membrane Protel~s Forward primer 5' to 3' Reverse Primer 5' to 3' 16225006(SEQID NO: 5'-TATACCATGGTGGG 5'-ATGAATTCGAGTAAG
465) CGCTAA-3'(SEQID GATTTTTG-3'(SEQID
NO:1897) NO:1898) 26054702(SEQ ID NO: 5'-TTAACCATGGTGAAA 5'-TAGAATTCGCATAAC
649) AGCGATA-3'(SEQ ID GATCAATC-3'(SEQID
NO:1899) NO:l900) 7116626(SEQ ID NO:865) 5'-ATATCCATGGTGAGT 5'-ATGAATTCAAlllll TTGATGA-3'(SEQID TATTTTGCCA-3'(SEQ ID
NO:1901) NO:1902) 29479681(SEQIDNO: 5'-AATTCCATGGTGGC~G 5'-ATGAATTCTCGATAG
677) GCTATG-3'(SEQ ID CCAAAATC-3'(SEQ ID
NO:1903) NO:1904) 14640637(SEQ ID NO: 5'-AATTCCATGGTGCAT 5'-AAGAATTCTCTAGCA
447) AACTTCCATT-3'(SE(~ID TCCAAATGGA-3'(SEQ
NO:1905) ID NO:1906) Periplasmic/ Secreted Protei~s 30100332(SEQ ID NO: 5'-ATTTCCATGGTCATG 5'-ATGAATTCCATCTTT
685) TCTCATATT-3'(SEQID TATTCCAC-3'(SEQID
NO:1907) NO:1908) 4721061(SEQ ID NO:812) 5'-AACCATGGTGATTT 5'-AAGAATTCCACTCA
TAAGCATTGAAAG-3' AAAllllllAACAG-3' (SEQID NO:l909) (SEQID NO:l910) Other Surface Proteins 4821082(SEQID NO:820) 5'-GATCATCCATATGTT 5'-TGAATTCAACCATTT
ATCTTCTAAT-3'(SEQID TAACCCTG-3'(SEQ ID
NO:l911) NO:1912) 978477(SEQIDNO:880) 5'-TATACCATGGTGAA 5'-AGAATTCAATTGCG
AllllllCTTTTA-3' TCTTGTAAAAG-3'(SEQ
(SEQID NO:1913) ID NO:1914) Inner Membrane Protein 26380318(SEQID NO: 5'-TATACCATGGTGAT 5'-ATGAATTCCCACTT
658) GGACAAACTC-3'(SEQ GGGGCGATA-3'(SEQ ID
ID NO:1915) NO:1916) Cytoplasmic Protein ppi 5'-TTATGGATCCAAAC 5'-TATCTCGAGTTATA
CAATTAAAACT-3'(SEQ GAGAAGGGC-3'(SEQ ID
ID NO:1917) NO:1918) SUBSTITUTE SH EET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 Genomic DNA prepared from the J99 strain of H. pylori (ATCC #55679) was used as the source of template DNA for PCR amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). To amplify a DNA sequence contzlininP: an H. pylori ORF, genomic DNA (50 nanograms) was S introduced into a reaction vial cont~inin~V 2 mM MgC12, 1 micromolar synthetic oligonucleotide primers (forward and reverse primers) complementary to and fl~nkin~ a defined H. pylori ORF, 0.2 mM of each deoxynucleotide triphosphate; dATP, dGTP, dCTP, dTTP and 2.5 units of heat stable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ, USA) in a final volume of 100 microliters. The following thermal cycling conditions were used to obtain amplified DNA products for each ORF
using a Perkin Elmer Cetus/ GeneAmp PCR System 9600 thermal cycler:

Sequences 26054702 (SEQ ID NO: 649), 7116626 (SEQ ID NO: 865), 29479681 (SEQ
ID NO: 677), 30100332 (SEQ ID NO: 685), 4821082 (SEQ ID NO: 820) and 978477 (SEQ ID NO: 880);
Denaturation at 94~C for 2 min, 2 cycles at 94~C for 15 sec, 30~C for 15 sec and 72~C for 1.5 min 23 cycles at 94~C for 15 sec, 55~C for 15 sec and 72~C for 1.5 min Reactions were concluded at 72~C for 6 minutes.
Sequence 16225006 (SEQ ID NO: 465);
Denaturation at 94~C for 2 min, 25 cycles at 95~C for 15 sec, 55~C for 15 sec and 72~C for 1.5 min Reaction was concluded at 72~C for 6 minutes.
Sequence 4721061 (SEQ ID NO: 812);
Denaturation at 94~C for 2 min, 2 cycles at 94~C for 15 sec, 36~C for 15 sec and 72~C for 1.5 min 23 cycles at 94~C for 15 sec. 60~C for 15 sec and 72~C for 1.5 min Reactions were concluded at 72~C for 6 minutes.

Sequence 26380318 (SEQ ID NO: 658), Denaturation at 94~C for 2 min, 2 cycles at 94~C for 15 sec, 38~C for 15 sec and 72~C for 1.5 min 23 cycles at 94~C for 15 sec, 62~C for 15 sec and 72~C for 1.5 min Reactions were concluded at 72~C for 6 minutes.

SUBSTITUTE SHEET (RULE 26) , CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 Sequence14640637(SE Q ID N 0:447);
Denaturation at 94~C for 2 min, 2 cycles at 94~C for 15 sec, 33~C for 15 sec and 72~C for 1.5 min 30 cycles at 94~C for 15 sec, 55~C for 15 sec and 72~C for 1.5 min 5 Reactions were concluded at 72~C for 6 minllt~
qi Conditions for amplification of H. pylori ppiB;
Denaturation at 94~C for 2 min, 2 cycles at 94~C for 15 sec, 32~C for 15 sec and 72~C for 1.5 min 25 cycles at 94~C for 15 sec, 56~C for 15 sec and 72~C for 1.5 min Reactions were concluded at 72~C for 6 minlltes Upon completion of thermal cycling reactions, each sample of amplified DNA was washed and purified using the Qiaquick Spin PCR purification kit (Qiagen, Gaithersburg, MD, USA). All amplified DNA samples were subjected to digestion with the restriction endonucleases, NcoI and EcoRI (New F.ngl~n~l BioLabs, Beverly, MA, USA), or in the case of HpSeq. 4821082 (SEQ ID NO: 820), with NdeI and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). DNA
samples were then subjected to electrophoresis on 1.0 % NuSeive (FMC BioProducts, Rockland, ME USA) agarose gels. DNA was visualized by exposure to ethidium bromide and long wave uv irradiation. DNA contained in slices isolated from the agarose gel was purified using the Bio 101 GeneClean Kit protocol (Bio 101 Vista, CA, USA) Cloning of H. pylori DNA sequences into the pET-28b prokaryotic expression vector.
The pET-28b vector was ~re~,al~ed for cloning by digestion with NcoI and EcoRI, or in the case of H. pylori sequence 4821082 (SEQ ID NO: 820) with NdeI and EcoRI
(Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). In the case of cloning ppiB, the pET-28a vector, which encodes a His-Tag that can be fused to the 5' end of an inserted gene, was used and the cloning site prepared for cloning with the ppiB gene by digestion with BamH1 and XhoI restriction endonucleases.
Following digestion, DNA inserts were cloned (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994) into the previously digested pET-28b expression vector, except for the amplified insert for ppiB, which was cloned into the pET-28a expression vector. Products of lhe ligation reaction were then used to transform the BL21 strain of E. coli (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994) as described below.

Transformation of competent bacteria with recombinant plasmids Competent bacteria, E coli strain BL21 or E. coli strain BL21(DE3), were transforrned with recombinant pET e~lession plasmids carrying the cloned H. pylori SUBSTITUTE SHEET (RULE 26)1 CA 0222339~ 1997-12-03 W O 96/4089~ PCTAUS96/09122 sequences according to standard methods (Current Protocols in Molecular. John Wiley and Sons, Inc., F. Ausubel et al., eds., l 994). Briefly, 1 microliter of ligation reaction was mixed with 50 microliters of electrocompetent cells and subjected to a high voltage pulse, after which, samples were incubated in 0.45 millilit~rs SOc medium (0.5% yeast extract, 2.0 % tryptone, 10 mM NaCI, 2.5 mM KCI, 10 mM MgC12, 10 mM MgSO4 and 20, mM
glucose) at 37~C with ~h~king for 1 hour. Samples were then spread on LB agar plates r cu~ 25 microgram/ml kanamycin sulfate for growth overnight. Transformed colonies of BL21 were then picked and analyzed to evaluate cloned inserts as described below.
Identification of recombinant pET expression plasmids carrying H. pylori sequences Individual BL21 clones L~ srol.lled with recombinant pET-28b-H.pylori ORFs were analyzed by PCR amplification of the cloned inserts using the same forward and reverse primers, specific for each H. pylori sequence, that were used in the original PCR
amplification cloning reactions. Successful amplification verified the integration of the H.
pylori sequences in the ~x~l~s~ion vector (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994).

Isolation and Preparation of plasmid DNA from BL21 tru~ or".ants Individual clones of recombinant pET-28b vectors carrying prol)e~ly cloned H.
pylori ORFs were picked and incubated in 5 mls of LB broth plus 25 microgram/ml kanamycin sulfate overnight. The following day plasmid DNA was isolated and purified using the Qiagen plasmid purification protocol (Qiagen Inc., Chatsworth, CA, USA).

Expression of recombinant H. pylori sequences in E coli The pET vector can be propagated in any E. coli K-12 strain e.g. HMS174, HB101, JM 109, DH5, etc. for the purpose of cloning or plasmid preparation. Hosts for expression include E. coli strains co..l~i..i..g a chromosomal copy ofthe gene for T7 RNA polymerase.
These hosts are Iysogens of bacteriophage DE3, a lambda derivative that carries the lacI
gene, the lacW5 promoter and the gene for T7 RNA polymerase. T7 RNA polymerase is in~ ce~ by addition of isopropyl-B-D-thiogalactoside (IPTG), and the T7 RNA polymerase transcribes any target plasmid, such as pET-28b, carrying a T7 promoter and a gene of interest. Strains used include: BL21(DE3) (Studier, F.W., Rosenberg, A.H., Dunn, J.J., and Dubendorff, J.W. (1990) Meth. Enzymol. 185, 60-89).
To express recombinant H. pylori sequences, 50 nanograms of plasmid DNA
isolated as described above was used to transform competent BL21(DE3) bacteria as described above (provided by Novagen as part of the pET ~ ession system kit). The lacZ
gene (beta-galactosidase) was expressed in the pET-System as described for the H. pylori recombinant constructions. Transformed cells were cultured in SOC medium for 1 hour, SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O ~C/S~33 PCT~US96/09122 -97-and the culture was then plated on LB plates co~ 25 micrograms/ml kanamycin sulfate. The following day, bacterial colonies were pooled and grown in LB medium cont~ining kanamycin sulfate (25 micrograms/ml) to an optical density at 600 nM of 0.5 to 1.0 O.D. units, at which point, 1 mil1im~ 1ar IPTG was added to the culture for 3 hours to 5 induce gene expression of the H. pylori recombinant DNA constructions .
After induction of gene ex~ s~ion with IPTG, bacteria were pelleted by centrifugation in a Sorvall RC-3B centrifuge at 3500 x g for 15 minlltes at 4~C. Pellets were resuspended in 50 milliliters of cold l O mM Tris-HCl, pH 8.0, O. l M NaCl and 0.1 mM EDTA (STE buffer). Cells were then centrifuged at 2000 x g for 20 min at 4~C. Wet l O pellets were weighed and frozen at -80~C until ready for protein purification.
i III. Purification of recombinant proteins from E coli Analytical Methods The concentrations of purified protein ~lc~ ions were quantified spectrophotometrically using absorbance coefficients calculated from amino acid content (Perkins, S.J. 1986 Eur. J. Biochem. 157, 169-180). Protein concentrations were also measured by the method of Bradford, M.M. (1976) Anal Biochem. 72, 248-254, and Lowry, O.H., Rosebrough, N., Farr, A.L. & Randall, R.J. (1951) J. Biol. Chem. 193, pages 1 265-275, using bovine serum albumin as a standard.
SDS-polyacrylamide gels (12% or 4.0 to 25 % acrylamide gradient gels) were purchased from BioRad (Hercules, CA, USA), and stained with Coomassie blue.
Molecular weight markers included rabbit skeletal muscle myosin (200 kDa), E. coli (-galactosidase (116 kDa), rabbit muscle phosphorylase B (97.4 kDa), bovine serum albumin (66.2 kDa), ovalbumin (45 kDa), bovine carbonic anhydrase (31 kDa), soybean trypsin inhibitor (21.5 kDa), egg white lysozyme (14.4 kDa) and bovine aprotinin (6.5 kDa).

1. Purification of soluble proteins All steps were carried out at 4~C. Frozen cells were thawed, resuspended in 5 volumes of lysis buffer (20 mM Tris, pH 7.9, 0.5 M NaCl, S mM imidazole with 10%glycerol, 0.1 % 2-mercaptoethanol, 200 ~lg/ ml Iysozyme, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 10 ug/ml each of leupeptin, aprotinin, pepstatin, L-1-chloro-3-[4-tosylamido]-7-amino-2-heptanone (TLCK), L-1-chloro-3-[4-tosylamido]-4-phenyl-2-butanone (TPCK), and soybean trypsin inhibitor, and ruptured by several passages through a small volume microfluidizer (Model M-110S, Microfluidics Tntern~tional Corporation, 35 I Newton, MA). The resultant homogenate was made 0.1 % Brij 35, and centrifuged at 100,000 x g for 1 hour to yield a clear supernatant (crude extract).
Following filtration through a 0.8 ,~Lm Supor filter (Gelman Sciences, FRG) the crude extract was loaded directly onto a Ni2+- nitrilotriacetate-agarose (NTA) with a S
milliliter bed volume (Hochuli, E., Dbeli, H., and Sch~htoer, A. (1987) J. Chromatography SUBSTITUTE SHEET (RULE 26~

CA 0222339~ 1997-12-03 W O 9G/lC~93 PCTAUS96/09122 411, 177-184) pre-equilibrated in lysis buffer co.~ 10 % glycerol, 0.1 % Brij 35 and 1 mM PMSF. The column was washed with 250 ml (50 bed volumes) of Iysis buffer col-t~; - - i - .g 10 % glycerol, 0.1 % Brij 35, and was eluted with sequential steps of lysis buffer cont~inin~ 10 % glycerol, 0.05 % Brij 35, 1 mM PMSF, and 20, 100, 200, and 500 S mM imid~ole in s-lcces~i~ n. Fractions were monitored by absorbance at ~D280 nm, and peak fractions were analyzed by SDS-PAGE. Fractions CO~ the recombinant protein eluted at 100 mM imidazole.

Recombinant protein 14640637 (SEQ ID NO: 447) andproteins, beta-galactosidase (lacZ) 0 andpeptidyl-prolyl cis-trans isomerase (ppiB) Fractions co~ i..g the recombinant proteins from the Ni2+-NTA-agarose columns were pooled and then concentrated to approximately 5 ml by centrifugal filtration (Centriprep-10, Amicon, MA), and loaded directly onto a 180-ml column (1.6 X 91 cm) of Sephacryl S-100 HR gel filtration medium equilibrated in Buffer A(10 mM Hepes, pH 7.5, 150 mM NaCl, 0.1 mM EGTA) and run in Buffer A at 18 mllh. Fractions co~ the recombinant protein were identified by absorbance at 280 nm and analyzed by SDS-PAGE.
Fractions were pooled and concentrated by centrifugal filtration.

Recombinant protein 7116626 (SEQ ID NO: 865) Fractions cont~ining the recombinant protein from the Ni2+ -NTA-agarose column were pooled and dialyzed overnight against 1 liter of dialysis buffer (10 mM MOPS, pH
6.5, 50 mM NaCl, 0.1 mM EGTA, 0.02% Brij 35 and 1 mM PMSF). In the morning, a fine white p~ i~te was removed by centrifugation and the reslllting ~;ul,c ..~ l was loaded onto an 8 ml (8 x 75 mrn) MonoS high performance liquid chromatography column (Pharmacia Biotechnology, Inc., Piscataway, NJ, USA) equilibrated in buffer B (10 mM
MOPS, pH 6.5, 0.1 mM EGTA) cont~ininp SO mM NaCl. The column was washed with 10 bed volurnes of buffer B cont~ining 50 mM NaCl, and developed with a 50-ml linear gradient of increasing NaCl (50 to 500 mM). Recombinant protein 7116626 (SEQ ID NO:
865) eluted as a sharp peak at 300 mM NaCl.
2. Purification of insoluble proteins from inclusion bodies The following steps were carried out at 4~C. Cell pellets were resuspended in Iysis buffer with 10% glycerol 200 ~Lg/ ml Iysozyme, S mM EDTA, lmM PMSF and 0.1 % -mercaptoethanol. After passage through the cell disrupter, the rçs-llting homogenate was made 0.2 % deoxycholate, stirred 10 minnte~ then centrifuged at 20,000 ~ g, for 30 min.
The pellets were washed with lysis buffer conSzlining 10 % glycerol, 10 mM EDTA, 1%
Triton X-100, 1 mM PMSF and 0.1% -mercaptoethanol, followed by several washes with Iysis buffer cont~ining 1 M urea, 1 mM PMSF and 0.1 % 2-mercaptoethanol. The resulting SUBSTITUTE SHEET (RULE 26) -CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 white pellet was composed primarily of inclusion bodies, free of unbroken cells and membranous materials..

- Recombinant proteins 26054702 (SEQ ID NO: 649), 16225006 (SEQ ID NO: 465), 30100332 (SEQ ID NO: 685), 4721061 (SEQ ID NO: 8~2) The following steps were carried out at room te~ cl~Lul~. Purified inclusion bodies were dissolved in 20 ml 8.0 M urea in lysis buffer with I mM PMSF and 0.1 % 2-mercaptoethanol, and incubated at room temperature for 1 hour. Materials that did not dissolve were removed by centrifugation. The clear sup~rn~t~nt was filtered, then loaded onto a Ni2+ -NTA agarose column pre-equilibrated in 8.0 M urea in Lysis Buffer. The column was washed with 250 ml (50 bed volumes) of Iysis buffer containing 8 M urea, 1.0 mM PMSF and 0. l % 2-mercaptoethanol, and developed with sequential steps of lysis buffer cont~inin~ 8M urea, 1 mM PMSF, 0.1 % 2-melc~loethanol and 20, l00, 200, and 500 mM imid~ole in succession. Fractions were monitored by absorbance at ~D280 nm, and peak fractions were analyzed by SDS-PAGE. Fractions cont~ining the recombinant protein eluted at l 00 mM imidazole.

Recombinant proteins 29479681 (SEQ ID NO: 677), 978477 (SEQ ID NO: 880J, 26380318 (SEQ ID NO: 658) The pellet co~ E the inclusion bodies was solubilized in buffer B cont~ininf~ 8 M urea, 1 mM PMSF and 0.1 % 2-mercaptoethanol, and incubated for 1 hour at room le~ dl~. Insoluble materials were removed by centrifugation at 20,000 x g for 30 min, and the cleared supPrn~t~nt was loaded onto a 15 ml ( 1.6 x 7.5 cm ) SP-Sepharose column pre-equilibrated in buffer B, 6 M urea, l mM PMSF, 0.1 % 2-mercaptoethanol. After washing the column with 10 bed volumes, the column was developed with a linear gradient from 0 to 500 mM NaCI.

Dialysis and concentration of protein samples Urea was removed slowly from the protein samples by dialysis against Tris-buffered saline (TBS; 10 mM Tris pH 8.0, 150 mM NaC1) cont~ining 0.5 % deoxycholate (DOC) with sequential reduction in urea concentration as follows; 6M, 4M, 3M, 2M, lM, 0.5 M and finally TBS without any urea. Each dialysis step was conducted for a minimllm of 4 hours at room temperature.
After dialysis, samples were concentrated by p,es~ule filtration using Amicon stirred-cells. Protein concentrations were measured using the methods of Perkins (1986 Eur. J. Biochem. 157, 169-180), Bradford ((1976) Anal. Biochem. 72, 248-254) and Lowry ((1951) J. Biol. Chem. 193, pages 265-275).
The recombinant proteins purified by the methods described above are summarized in Table 5 below.

SUBSTITUTE SHEFT (RULE 26) , W O 96/40893 PCT~US96/09122 o t~ t~ t~ tD

~ E E ! E E E E ! E
. _ C_ o ~~ ~ o ~
~LL ~o r~

~ y tY O o ~ . O~oa oO to ~o ~ ~
T T C oo V~

_ w C D_O C~ D ,~
r~ ~ ~ _o ~ o t ~ 2' ~ cr~

o ~ E ~ ~ c ~ ~
'':

o ~ _ ~o~ ~' ~ ~o -- D ~ ~ ~ C ~

- o ~ " ~~ z cr~ Z O Z
'~ a o ~

SUBSTITUTE SHEET (RULE 26) W O 96/40893 . PCTAUS96/09122 m ~ a: ~ m ~ ~ ~c E ~ E E E E

oo ~~ _ ~ ~ ~ o o ~ _ ~ ~ a ~ ~, T T
,~ r -- = g ~ g O .0 T ~ C; ~, T ~ T ~

. _ _ ,3 Q' _ " o o C~ _ ,D D _0 ~ c~ --. . . . . ~ C~
,0 D

~C ~ ~ C ~ C o V~ ~
_ ~ t-- -- ~ ca ('~ E ~ E
e ~~ ~ ~ ~' ~ ~ o o E g ~ V~ ~ O O oo ~ C ~

~ Z ~ Z . o Z ~ ~ , ~,, O C "~ O
O a ~ ~ ~ E E

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 IV. AnalYsis of H ~vlori proteins as Vaccine candidates To investigate the immunomodulatory effect of H. pylori proteins. a mouse/H.
pylori model was used. This model mimics the human H. pylori infection in many respects. The focus is on the effect of oral immlmi7~tion in H. pylori infected ~nim~l~ in S order to test the concept of the-dl~eulic oral immunotherapy.

~nimals Female SPF BALB/c mice were purchased from Bomholt Breeding center (Denmark). They were kept in ordinary makrolon cages with free supply of water and food.
10 The ~nim~l~ were 4-6 weeks old at arrival.

lnfection After a minimllm of one week of acclim~ti7~tion, the z-nimz~l~ were infected with a type 2 strain (VacA negative) of H. pylori (strain 244, originally isolated from an ulcer 15 patient). In our hands, this skain has earlier proven to be a good colonizer of the mouse stomach. The bacteria were grown overnight in Brucella broth supplemented with 10 %
fetal calf serum, at 37~C in a microaerophilic atmosphere (10% CO2,5% ~2)- The ~nim~l.c were given an oral dose of omeprazole (400 llmol/kg) and 3-5 h after this an oral inoculation of H. pylori in broth (approximately 108 cfu/animal). Positive take of the 20 infection was checked in some ~nim~l~ 2-3 weeks after the inoculation.

Antigens Recombinant H. pylori antigens were chosen based on their association with externally exposed H. pylori cell membrane. These antigens were selected from the 25 following groups: (1.) Outer Membrane Proteins; (2.) Periplastic/Secreted proteins; (3.) Outer Surface proteins; and (4.) Inner Membrane proteins. ~11 recombinant proteins were constructed with a hexa-HIS tag for purification reasons and the non-Helicobacter pylori control protein (,~-galactosidase from E. coli; LacZ), was constructed in the same way.
All antigens were given in a soluble form, i.e. dissolved in either a HEPES buffer or 30 in a buffer cont~ining 0.5% Deoxycholate (DOC).
The antigens are listed in Table 6 below.
Table 6 Helicobacter pvlori proteins Outer membrane Proteins SEQ ID NO:447 SEQ ID NO:677 SEQ ID NO:865 40 SEQ ID NO:812 SEQ ID NO:465 SUBSTITUTE SHEET (RULE 26) WO 96/40893 PCT~US96/09122 Periplastic/Secreted proteins SEQ ID NO:685 Other cell envelope proteins SEQ ID N 0:820 SEQ ID NO:880 Flagella-~csociqte~l proteins SEQ ID NO:658 Control proteins ,B-galactosidase (LacZ) 1 5 Immunizations Ten ~nim~l~ in each group were irnmunized 4 times over a 34 day period (day 1, 15, 25 and 35). Purified antigens in solution or suspension were given at a dose of 100 ~g/mouse. As an adjuvant, the ~nim~l~ were also given 10 llg/mouse of Cholera toxin (CT) with each immllni7~tion. Omeprazole (400 ~mol/kg) was given orally to the ~nim~l~ 3-5 h 20 prior to i " " ",., 1i7~fion as a way of protecting the antigens from acid degradation. Infected control ~nim~l~ received HEPES buffer + CT or DOC buffer + CT. Animals were sacrificed 2-4 weeks after final immunization. A general outline of the study is shown in Table 7 below.
25 Table 7 Studv outline. therapeutic imm1lni7sltion:
Mice were all infected with H. pylori strain Ah244 at day 30. Proteins are listed by their SeqID #'s.
Mouse strain Dates for Substance n= 10 Dose/mouse ~g 1. Controls, PBS Balb/c 0,3 ml 0, 14, 24, 34 2. Choleratoxin, 10 llg Balb/c 0,3 ml 0, 14, 24, 34 35 3. Protein 447, 100 llg +CT 10 ~lg Balb/c 0,3 ml 0, 14, 24, 34 4. Protein 465, 100 ~lg + CT 10 ~lg Balb/c 0,3 ml 0, 14, 24, 34 5. Protein 649, 100 llg + CT 10 llg Balb/c 0,3 ml 0, 14, 24, 34 6. Protein 658, 100 ,ug + CT 10 llg Balb/c 0,3 ml 0, 14, 24, 34 7. Protein 677, 100 ~lg + CT 10 tlg Balb/c 0,3 ml 0, 14, 24, 34 - 40 8. Protein 685, 100 llg+CT 10 ~g Balb/c 0,3 ml 0, 14, 24, 34
9. Protein 812, 100 llg + CT 10 ~ug Balb/c 0,3 ml 0, 14, 24, 34
10. Protein 820, 100 llg + CT 10 llg Balb/c 0,3 ml 0, 14, 24, 34 I l. Protein 880, 100 llg + CT 10 !lg Balb/c 0,3 ml 0, 14, 24, 34 12. Protein 865, 100 ~lg + CT 10 !lg Balb/c 0,3 ml 0, 14, 24, 34 SUBSTITUTE SHEET (RULE 26i) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 Analysis oSinfection Mucosal infection: The mice were sacrificed by CO2 and cervical dislocation. Theabdomen was opened and the stomach removed. After cutting the stomach along the greater curvature, it was rinsed in saline. The mucosa from the antrum and corpus of an S area of 25mm2 was scraped separately with a surgical scalpel. The mucosa scraping was suspended in Brucella broth and plated onto Blood Skirrow selective plates. The plates were inellb~te(l under microaerophilic conditions for 3-5 days and the number of colonies was counted. The identity of H. pylori was ascertained by urease and c~t~l~ce test and by direct microscopy or Gram st~ining-The urease test was performed escenti~lly as follows. The reagent, Urea Agar Base Concentrate. was purchased from DIFCO Laboratories, Detroit, MI (Catalog # 0284-61-3).
Urea agar base concentrate was diluted 1: 10 with water. 1 ml of if the diluted concentrate was mixed with 100-200 ~11 of actively growing H. pylori cells. Color change to magenta indicated that cells were urease positive.
The c~t~l~ee test was p~.ro-llled çcc.?nti~lly as follows. The reagent, N,N,N',N'-Tetramethyl-p-Phenylen~ rnine7 was purchased from Sigma, St. Louis, MO (Catalog #
T3134). A solution of the regent (1 % w/v in water) was prepared. H. pylori cells were swabbed onto Whatman filter paper and overlaid with the 1 % solution. Color change to dark blue indicated that the cells were c~t~l~ce positive.
Serum antibodies: From all mice serum was ~ al~d from blood drawn by heart puncture. Serum antibodies were identified by regular ELISA techniques, where the specific antigens of Helicobacter pylori were plated.
Mucosal antibodies: Gentle scrapings of a defined part of the corpus and of 4 cm of duodenum were p~,~rolllled in 50% of the mice in order to detect the presence of antibodies in the mucous. The antibody titers were determined by regular ELISA technique as for serum antibodies.
Statistical analysis: Wilcoxon-Mann-Whitney sign rank test was used for dete., .,i~ ion of significant effects of the antigens on Helicobacterpylori colonization.
P<0.05 was considered significant. Because the antrum is the major colonization site for Helicobacter most emph~cic was put upon changes in the antral colonization.

Results Antibodies in sera: All antigens tested given together with CT gave rise to a measurable specific titer in serum. The highest responses were seen with SEQ ID
NOs:865, 812, 658, 447, and 820 (see Figure 1).
Antibodies in mucus: In the mucus scrapings, specific antibodies against all antigens tested were seen. By far the strongest response was seen with SEQ ID NOs:685, followed by 447, 865, and 658 (see Figure 2).

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 WO 96140893 PCT~US96/09122 The.d!)~uLic immunization effects:
All control ~nim~l~ (BALB/c mice) were well colonized with H. pylori (strain AH244) in both antrum and corpus of the stomach. Of the antigens tested 3 proteins (SEQ
ID NOs: 812? 820, and 447) gave a good and significant reduction and/or eradication of the H. pylori infection. The degree of colonization of the antrum was lower following immlmi7~tion with SEQ ID NOs: 880, 6~8, and 865 compared to control. The effect of SEQ ID NOs:465, 677, and 685 did not differ from control. The control protein lacZ, i.e.
the non-H. pylori protein, had no eradication effect and in fact had higher Helicobacter colonization compared to the HEPES + CT control. A11 data are shown in Figures 3 and 4 for proteins dissolved in HEPES and DOC respectively. Data is shown as geometric mean values. n=8-10 Wilcoxon-Mann-Whitney sign rank test * = p<0.05; x/10 = number of mice showing eradication of H. pylori over the total number of mice ex~mine~l The data presented indicate that all of the H. pylori associated proteins included in this study, when used as oral imrnunogens in conjunction with the oral adjuvant CT, resulted in stim~ tion of an immllne response as measured by specific serum and mucosal antibodies. A majority of the proteins led to a reduction., and in some cases complete clearance of the colonization of H. pylori in this animal model. It should be noted that the reduction or clearance was due to heterologous protection rather than homologousprotection (the polypeptides were based on the H. pylori J99 strain sequence and used in the therapeutic immllni7~tion studies against a different (AH244) ch~llen~e strain), indicating the vaccine potential against a wide variety of H. pylori strains.
The highest colonization in the antrum was seen in ~nim~l~ treated with the non-Helicobacter protein LacZ? indicating that the effects seen with the Helicobacter pylori antigens were specific.
Taken together these data strongly support the use of these H. pylori proteins in a pharmaceutical formulation for the use in hnmz~n~ to treat and/or prevent H. pylori infections.

V. Sequence Variance Analvsis of ~enes in Helicobacter pvlori strains Four genes were cloned and sequenced from several strains of H. pylori to compare the DNA and deduced amino acid sequences. This information was used to determine the sequence variation between the H. pylori strain, J99, and other H. pylori strains isolated from human patients.

Preparation of Chromosomal DNA.
Cultures of H. pylori strains (as listed in Table 10) were grown in BLBB (1%
Tr~vptone, 1% Peptamin 0.1% Glucose, 0.2% Yeast Extract 0.5% Sodium Chloride, 5%Fetal Bovine Serum) to an OD600 of 0.2. Cells were centrifuged in a Sorvall RC-3B at 3500 x g at 4~C for 15 min~ltes and the pellet resuspended in 0.95 mls of 10 mM Tris-HCl, SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 0.1 mM EDTA (TE). Lysozyme was added to a final concentration of 1 mg/ml along witn, SDS to 1% and RNAse A + Tl to 0.5mg/ml and 5 ~mits/ml respectively, and incubated at 37~C for one hour. Proteinase K was tnen added to a final concentration of 0.4mg/ml and t'ne sample was incllh~tPcl at 55 C for more than one hour. NaCl was added to the sample to a concentration of 0.65 M, mixed carefully, and 0.15 ml of 10% CTAB in 0.7M NaCL
(final is 1% CTAB/70mM NaCL) was added followed by incubation at 65~C for 20 minlltes At this point, tne samples were extracted with cnloroform:isoamyl alcohol, extracted witn phenol, and extracted again witn cnloroform:isoamyl alcohol. DNA was ~l~ci~iL~Ied witn either EtOH (1.5 x volumes) or iSOplO~ lO1 (0.6 x volumes) at -70~C for 1 Ominutes, washed in 70% EtOH and resuspended in TE.

PCR Amplification and cloning.
Genomic DNA prepared from twelve strains of Helicobacter pylori was used as tne source of template DNA for PCR amplification reactions (Current Protocols in Molecular Biology, Jonn Wiley and Sons, Inc., F. Ausubel et al., editors, 1994). To amplify a DNA
sequence co.,~ an H. pylori ORF, genomic DNA (10 nanograms) was introduced into a reaction vial cont~inin~ 2 mM MgC12, 1 micromolar syntnetic oligonucleotide primers (forward and reverse primers, see Table 8) complçment~ry to and fl~nkin~ a defined H.
pylori ORF, 0.2 mM of each deoxynucleotide triphosphate; dATP, dGTP, dCTP, dTTP and 0.5 units of heat stable DNA polymerase (Arnplitaq, Roche Molecular Systems, Inc., Branchburg, NJ, USA) in a final volume of 20 microliters in duplicate reactions.
Table 8 Oli~onucleotide primers used for PCR amplification of H. Pvlori DNA sequences.
Outer membrane Proteins Forward primer 5' to 3' Reverse Primer 5' to 3' SEQ ID NO:649 5'-TTAACCATGGTGAAAAGC 5'-TAGAATTCGCCTCTAAAACT
(for strains AH4, GATA-3' (SEQ ID NO:1919) TTAG-3' (SEQ ID NO:1920) AHI5,AH61,5294, 5640,AH18, and AH244) SEQ ID NO:649 5'-TTAACCATGGTGAAAAGC 5'-TAGAATTCGCATAACGATCA
(for strains AH5, GATA-3' (SEQ ID NO:1921) ATC-3' (SEQ ID NO:1922) 5155,7958,AH24, and J99) SEQ ID NO:865 5'-ATATCCATGGTGAGTTTGA 5'-ATGAATTCAAI-lllllATTTT
TGA-3' (SEQ ID NO:1923) GCCA-3' (SEQ ID NO:1924) SEQ ID NO:677 5'-AATTCCATGGCTATCCAAA 5'-ATGAATTCGCCAAAATCGTA
TCCG-3' (SEQ ID NO:1925) GTATT-3' (SEQ ID NO:1926) SEQ ID NO:764 5'-GATACCATGGAAl-l-lATGA 5'-TGAATTCGAAAAAGTGTAGT
AAAAG-3' (SEQ ID NO:1927) TATAC-3' (SEQ ID NO:1928) SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 . PCTAUS96/09122 The following thermal cycling conditions were used to obtain amplified DNA
products for each ORF using a Perkin Elmer Cetus/ GeneAmp PCR System 9600 thermal cycler:
, Sequences (by SEQ ID NO:) 865 and 764;
De~ ion at 94~C for 2 min, 2 cycles at 94~C for 15 sec, 30~C for 15 sec and 72~C for 1.5 min 23 cycles at 94~C for 15 sec, 55~C for 15 sec and 72~C for 1.5 min Reactions were concluded at 72~C for 6 minlltes Sequence (by SEQ ID NO:) 649 for strains AH5, 5155, 7958, AH24,and J99;
Denaturation at 94~C for 2 min, 2 cycles at 94~C for 15 sec, 30~C for 15 sec and 72~C for 1.5 min 25 cycles at 94~C for 15 sec. 55~C for 15 sec and 72~C for 1.5 min Reaction was concluded at 72~C for 6 minllt~s-Sequences (by SEQ ID NO:) 677 and 649 for strains AH4, AH15, AH61, 5294, 5640, AH18, and Hp244;
Denaturation at 94~C for 2 min, 2 cycles at 94~C for 15 sec, 30~C for 20 sec and 72~C for 2 min 25 cycles at 94~C for 15 sec, 55~C for 20 sec and 72~C for 2 min Reactions were concluded at 72~C for 8 minlltec Upon completion of thermal cycling reactions, each pair of samples were combinedand used directly for cloning into the pCR cloning vector as described below.

Cloning of H. pylori DNA sequences into the pCR T~ cloning vector.
All amplified inserts were cloned into the pCR 2.1 (pCRII in the case of H. pylori sequence 865) vector by the method described in the Original TA cloning kit (Invitrogen, San Diego, CA). Products of the ligation reaction were then used to transform the TOPl OF' (INVaF' in the case of H. pylori sequence 865) strain of E. coli as described below.

Transformation of competent bacteria with recombinant plasmids Competent bacteria, E coli strain TOPlOF' or E. coli strain INVaF' were transformed with recombinant pCR ~x~ie~,~ion plasmids carrying the cloned H. pylori sequences according to standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994). Briefly, 2 microliters of 0.5 micromolar BME was added to each vial of 50 microliters of competent cells.

SUBSTITUTE 5HEET (RULE 26~

CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 Subsequently, 2 microliters of ligation reaction was mixed with the colllpe~ l cells and inc~lb~te~ on ice for 30 minl~tec. The cells and ligation mi~lu,e were then subjected to a "heat shock" at 42~C for 30 seconds, and were subsequently placed on ice for an additional 2 minl-t~s, after which, samples were incubated in 0.45 milliliters SOC medium (0.5%
yeast extract, 2.0 % tryptone, 10 rnM NaCl, 2.5 mM KCl, 10 mM MgC12, 10 mM MgSO4and 20, mM glucose) at 37~C with ~h~kinp for 1 hour. Samples were then spread on LB
agar plates CO~ i"il~p 25 microgram/ml kanamycin sulfate or 100 micrograms/ml ampicillan for growth overnight. Transformed colonies of TOP 1 OF' or INVaF' were then picked and analyzed to evaluate cloned inserts as described below.
0 Identification of recombinant PCR plasmids carrying H. pylori sequences Individual TOPlOF' or rNVaF' clones transformed with recombinant pCR-H.pylori ORFs were analyzed by PCR amplification of the cloned inserts using the same forward and reverse primers, specific for each H. pylori sequence, that were used in the original PCR amplification cloning reactions. Successful amplification verified the integration of the H. pylori sequences in the cloning vector (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994).
Individual clones of recombinant pCR vectors carrying properly cloned H. pylori ORFs were picked for sequence analysis. Sequence analysis was performed on ABI
Sequencers using standard protocols (Perkin Elmer) using vector-specific primers (as found in PCRII or pCR2. 1, Invitrogen, San Diego, CA) and sequencing primers specific to the ORF as listed in Table 9 below.

SUBSTITUTE SHEET (RULE 26) PCT~US96/09122 Table 9 -Oli~onucleotide primers used for sequencin~ of H pvlori DNA seguences.
Outer Forward p.;,.~e.~ 5' to 3~ Reverse rr- ~ ' to 3' membrane P~ i~s SEQ ~1) NO:649 5'-CCCI~CAl~l~TAGAAATCG-3' 5'-CTTTGGGTAAAAACGCATC-3' (SEQ ID NO:1929) (SEQ ID NO:1936) 5'-Al-I-rCAACCAATTCAATGCG- 5'-CGATCTTTGATCCTAAl~CA-3' (SEQ ID NO:1930) 3' (SEQ IDNO:1937) 5'-GCCCCTlTI'GATTTGAAGCT- 5'-ATCAAGTTGCCTATGCTGA-3' 3' (SEQ ID NO:1931) (SEQ ID NO:1938) 5'-TCGCTCCAAGATACCAAGA
AGT-3' (SEQ ID NO:1932) 5'-CTTGAATTAGGGGCAAAGA
TCG-3' (SEQ ID NO:1933) 5'-ATGC(~ l-llACCCAAAGA
AGT-3' (SEQ ID NO:1934) 5'-ATAACGCCACl~CCTTATT
GGT-3' (SEQ ID NO:1935) SEQ ID NO:865 5'-l~GAACACTTTTGATTATG 5'-GTCl~AGCAAAAATGGC
CGG-3' (SEQ IDNO:1939) GTC-3' (SEQ IDNO:1941) 5'-GGAl-rATGCGAl-rGl-I'TTAC ~'-AATGAGCGTAAGAGAGCC
AAG-3' (SEQ ID NO: 1940) 1-rC-3' (SEQ ID NO:1942) SEQ ~D NO:677 5'-Cl-rATGGGGGTAlTGTCA-3' 5'-AGGl-rGl~GCCTAAAGACT-3' (SEQ ID NO: 1943) (SEQ ID NO:1945) 5'-AGCATGTGGGTATCCAGC-3' 5'-CTGCCTCCACCl~GATC-3' (SEQ ID NO:1944) (SEQ ID NO:1946) SEQ ID NO:764 5'-ACCAATATCAATTGGCACT-3' 5'-CTTGCTTGTCATATCTAGC-3' (SEQ ID NO:1947) (SEQ ID NO:1949) 5'-ACrrGGAAAAGCTCTGCA-3' 5'-Gl~GAAGTGl-rGGTGCTA-3' (SEQ ID NO:1948) (SEQ ID NO:1950) 5'-CAAGCAAGTGGmGGm 5'-GCCCATAATCAAAAAGCC
TAG-3' (SEQ ID NO:1951) CAT-3' (SEQ ID NO:1953) 5'-TGGAAAGAGCAAATCATTG 5'-CTAAAACCAAACCACl~GC
AAG-3' (SEQ ID NO:1952) TTGTC-3' (SEQ ID NO:1954) VectorP~ -1, 5'-GTAAAACGACGGCCAG-3' 5'-CAGGAAACAGCTATGAC-3' (SEQ ID NO:1955) (SEQ ID NO:1956) 5 Results To establish the PCR error rate in these ex~ nt.~, five individual clones of SEQID NO:649, prepared from five separate PCR reaction mixtures from H. pylori strain J99, were sequenced over a total length of 897 nucleotides for a cumulative total of 4485 bases of DNA sequence. DNA sequence for the five clones was compared to the DNA sequence 10 of SEQ ID NO:649 obtained previously by a different method, i.e., random shotgun cloning and sequencinp. The PCR error rate for the experiments described herein was deterrnin~l to be 2 base changes outof4485 bases, which is equivalent to an estimated error rate of less than or equal to 0.04%.

SUBSTITUTE SHEFT (RUEE 26) CA 0222339~ 1997-12-03 DNA sequence analysis was ~ rolll,ed on four different open reading frames identified as genes and amplified by PCR methods from a dozen diLr~ t strains of the bacterium Helicobacter pylori. The ~le.1uce(1 arnino acid sequences of three of the four open reading frames that were selected for this study showed statistically significant S BLAST homology to defined proteins present in other bacterial species. Those ORFs included: SEQ ID NO:649, homologous to the val A & B genes encoding an ABC
transporter in F. novicida; SEQ ID NO:865, homologous to lipoprotein e (P4) present in the outer membrane of H. influenzae; SEQ ID NO:677, homologous to fecA, an outer membrane receptor in iron (III) dicitrate transport in E. coli. SEQ ID NO:764 was 10 identified as an unknown open reading frame, because it showed low homology with sequences in the public ~t~b~ees To assess the extent of conservation or variance in the ORFs across various strains of H. pylori, changes in DNA sequence and the decl-lced protein sequence were compared to the DNA and deduced protein sequences found in the J99 strain of H. pylori (see Table 15 10 below). Results are ples~ ed as percent identity to the J99 strain of H. pylori sequenced by random shotgun cloning. To control for any variations in the J99 sequence each of the four open reading frames were cloned and sequenced again from the J99 bacterial strain and that sequence information was colllpalt;d to the sequence information that had been collected from inserts cloned by random shotgun sequencing of the J99 strain. The data 20 demonstrate that there is variation in the DNA sequence ranging from as little as 0.12 %
difference (SEQ ID NO:764, J99 strain) to approximately 7% change (SEQ ID NO:649, strain AH5). The ~educec7 protein sequences show either no variation (SEQ ID NO:764, strains AH18 and AH24) or up to as much as 7.66% amino acid changes (SEQ ID NO:649, Strain AH5).

SUBSTITUTE SHEET (RULE 26) CA 0222339~ l997-l2-03 WO 9611~9~ PcTrus96/o9l22 Table 10 Multipie Strain DNA Sequence analysis of H. pylori Vaccine Can~ dL~:s J99 Seq. ID #: 649 649 865 866 677 677 764 764 Length of248 a.a. 746 nt.232 a.a. 696 nt.182 a.a.548 nt.273 a.a. 819 nt.
Region Sequenced:

Strain Tested AA Nuc. AA Nuc. AA Nuc. AA Nuc.
identityidentityiderltityidentityidentityidentityidentityidentity J99 100.00%100.00% 100.00% 100.00% 100.00% 100.00%99.63% 99.88%
AH244 95.16% 95.04% n.d. n.d. 99.09% 96.71% 98.90% 96.45%
AH4 95.97% 95.98% 97.84% 95.83% n.d. n.d. 97.80% 95.73%
AH5 92.34% 93.03% 98.28% 96.12% 98.!31% 96.90% 98.53% 95.73%
AH15 95.16% 94.91% 97.41% 95.98% 99.~2% 97.99% 99.63% 96.09%
AH61 n.d. n.d. 97.84% 95.98% 99.27% 97.44% n.d. n.d.
5155 n.d. n.d. n.d. n.d. 99.45% 97.08% 98.53% 95.60%
5294 94.35% 94.37% 98.28% 95.40% 99.64% 97.26% 97.07% 95.48%
7958 94.35% 94.10% 97.84% 95.40% n.d. n.d. 99.63% 96.46%
5640 95.16% 94.37% 97.41% 95.69% 99.09% 97.63% 98.53% 95.48%
AH18 n.d. n.d. 98.71% 95.69% 99.64% 97.44% 100.00% 95.97%
AH24 94.75% 95.04% 97.84% 95.40% 99.27% 96.71% 100.00% 96.46%
n.d. = not done 5 VI. ExPerimental Knock-Out Protocol for the Determination of Essential H. I7vlori Genes as Potential The;ld~JcuLic Tar~ets Therapeutic targets are chosen from genes whose protein products appear to play key roles in es~enti~l cell pathways such as cell envelope synthesis, DNA synthesis, transcription, tr~n~l~tion, regulation and colonization/virulence.
The protocol for the deletion of portions of H. pylori genes/ORFs and the insertional mutagenesis of a kanamycin-rçcict~nt~e cassette in order to identify genes which are e~Pnti~l to the cell is modified from previously publ;shed methods (Labigne-Roussel et al., 1988, J. Bacteriology 170, pp. 1704-1708; Cover et al.,l994, J. Biological Chemistry 269, pp. 10566-10573; Reyrat et al., 1995, Proc. Natl. Acad. Sci. 92, pp 8768-8772). The 15 result is a gene "knock-out."

Identification and Cloning of H. pylori Gene Sequences The sequences of the genes or ORFs (open reading frames) selected as knock-out targets are identified from the H. pylori genomic sequence and used to design primers to 20 specifically amplify the genes/ORFs. All synthetic oligonucleotide primers are designed with the aid of the OLIGO program (National Biosciences, Inc., Plymouth, MN 55447, USA), and can be purchased from Gibco/BRL Life Technologies (Gaithersburg, MD, USA). If the ORF is smaller than 800 to 1000 base pairs, fl~nking primers are chosen outside of the open reading frame.

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 Genomic DNA prepared from the Helicobacter pylori HpJ99 strain (ATCC 55679) is used as the source of template DNA for amplification of the ORFs by PCR (polymerase chain reaction) (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F.
Ausubel et al., editors, 1994). For the p~ ion of genomic DNA from H. pylori, see 5 Example I. PCR amplification is carried out by introducing 10 nanograms of genomic HpJ99 DNA into a reaction vial co..l;.il.;..g 10 mM Tris pH 8.3, 50 mM KCl. 2 mM MgCl2, 2 microMolar synthetic oligonucleotide primers (forward=Fl and reverse=Rl), 0.2 mM of each deoxynucleotide triphosphate (dATP,dGTP, dCTP, dTTP), and 1.25 units of heat stable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ, USA) 10 in a final volume of 40 microliters. The PCR is carried out with Perkin Elmer Cetus/GeneArnp PCR System 9600 thermal cyclers.
Upon completion of thermal cycling reactions, each sample of amplified DNA is visualized on a 2% TAE agarose gel stained with Ethidium Bromide (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994) to 15 detP~nine that a single product of the expected size had resulted from the reaction.
Amplified DNA is then washed and purified using the Qiaquick Spin PCR purification kit (Qiagen, Gaithersburg, MD, USA).
PCR products are cloned into the pT7Blue T-Vector (catalog#69820-1, Novagen, Inc., Madison, WI, USA) using the TA cloning strategy (Current Protocols in Molecular 20 Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994). The ligation of the PCR product into the vector is accompli~hPd by mixing a 6 fold molar excess of the PCR
product, 10 ng of pT7Blue-T vector (Novagen), 1 microliter of T4 DNA Ligase Buffer (New Fngl~n-l Biolabs, Beverly, MA, USA), and 200 units of T4 DNA Ligase (New Fn~l~n~l Biolabs) into a final reaction volume of 10 microliters. Ligation is allowed to 25 proceed for 16 hours at 16~C.
Ligation products are electroporated (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994) into electroporation-competent XL-l Blue or DH5-a E.coli cells (Clontech Lab., Inc. Palo Alto, CA, USA). Briefly, 1 microliter of ligation reaction is mixed with 40 microliters of electrocompetent cells and subjected to 30 a high voltage pulse (25 microFarads, 2.5 kV, 200 ohms) after which the samples are incubated in 0.~5 ml SOC medium (0.5% yeast extract, 2% tryptone, 10 mM NaCI, 2.5 mM
KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 mM glucose) at 37~C with ~h~king for 1 hour.
Sarnples are then spread onto LB (10 g/l bacto tryptone, 5 g/l bacto yeast extract, 10 g/l sodium chloride) plates cont~ining 100 microgram/ml of Ampicillin, 0.3% X-gal, and 100 35 microgram/ml IPTG. These plates are in~lb~ted overnight at 37~C. Ampicillin-resistant colonies with white color are selected, grown in S ml of liquid LB cont~ining 100 microgram/ml of Ampicillin. and plasmid DNA is isolated using the Qiagen miniprep protocol (Qiagen, Gaithersburg, MD, USA).

SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 To verify that the correct H.pylori DNA inserts had been cloned, these pT7Blue plasmid DNAs are used as templates for PCR amplification of the cloned inserts, using the same forward and reverse primers used for the initial arnplification of the J99 H.pylori sequence. Recognition of the primers and a PCR product of the correct size as vicll~li7~1 S on a 2% TAE, ethidium bromide stained agarose gel are confirrn~tion that the correct inserts had been cloned. Two to six such verified clones are obtained for each knock-out target, and frozen at -70~C for storage. To minimi7t~ errors due to PCR, plasmid DNA from these verified clones are pooled, and used in subsequent cloning steps.
The sequences of the genes/ORFs are again used to design a second pair of primers which flank the region of H. pylori DNA to be either i~ u~led or deleted (up to 250 basepairs) within the ORFs but are oriented away from each other. The pool of circular plasmid DNAs of the previously isolated clones are used as templates for this round of PCR. Since the orientation of amplification of this pair of deletion primers is away from each other, the portion of the ORF between the primers is not included in the rçslllt~nt PCR
product. The PCR product is a linear piece of DNA with H. pylori DNA at each end and the pT7Blue vector backbone between them which, in Ç~cPn, e, resultes in the deletion of a portion of the ORFs. The PCR product is vicll~li7~1 on a 1% TAE, ethidium bromide stained agarose gel to confirm that only a single product of the correct size has been amplified.
A Kanamycin-rçcict~n-e Ç~csette (Labigne-Roussel et al., 1988 J. Bacteriology 170, 1704-1708) is ligated to this PCR product by the TA clGning method used previously (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994). The Kanamycin cassette c~ g a Campylobacter kanamycin recict~nregene is obtained by carrying out an EcoRI digestion of the recombinant plasmid pCTB8:kan (Cover et al.,1994, J. Biological Chemistry 269, pp. 10566-10573). The proper fragment (1.4 kb) is isolated on a 1 % TAE gel, and isolated using the QIAquick gel extraction kit (Qiagen, Gaithersburg, MD, USA). The fragment is end repaired using the Klenow fill-in protocol, which involved rnixing 4ug of the DNA fr~gment, 1 microliter of dATP,dGTP, dCTP, dTTP at 0.5 mM, 2 microliter of Klenow Buffer (New Fngl~nrl Biolabs) and 5 units of Klenow DNA Polymerase I Large (Klenow) Fragment (New Fngl~n~l Biolabs) into a 20 microliter reaction, incubating at 30~C for 15 min, and inactivating the enzyme by heating to 75~C for 10 minn1e~ This blunt-ended Kanamycin cassette is then purified through a Qiaquick column (Qiagen, Gaithersburg, MD, USA) to elimin~te nucleotides. The "T" overhang is then generated by mixing 5 micrograms of the blunt-ended kanamycin c~sett~' 10 mM Tris pH 8.3, 50 mM KCl, 2 mM MgCl2, 5 units of DNA Polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ, USA), 20 microliters of 5 mM dTTP, in a 100 microliter reaction and incl-kating the reaction for 2 hours at 37~C. The "Kan-T" c~csette is purified using a QIAquick column (Qiagen,Gaithe.~bulg, MD, USA). The PCR product of the deletion primers (F2 and R2) is ligated SU13STITUTE SHEFT (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCT/U~3~ 5122 -l 14-to the Kan-T c~ceettt? by mixing 10 to 25 ng of deletion primer PCR product, 50 - 75 ng Kan-T cassette DNA, 1 microliter l 0x T4 DNA Lig~e reaction mixture, 0.5 microliter T4 DNA Ligase (New Fngl~n-l Biolabs, Beverly, MA, USA) in a 10 microliter reaction and incubating for 16 hours at 16~C.
The ligation products are transformed into XL-1 Blue or DH5-a E.coli cells by electroporation as described previously. After recovery in SOC, cells are plated onto LB
plates cont~inin~ 100 microgram/ml Ampicillin and grown overnight at 37~C. These plates are then replica plated onto plates C~ ;l.i..g 25 microgram/ml Kanamycin and allowed to grow overnight. ~t?s~l1t~nt colonies have both the Ampicillin resistance gene present in the 10 pT7Blue vector, and the newly introduced Kanamycin resistance gene. Colonies are picked into LB cont~ining 25 microgram/ml Kanamycin and plasmid DNA is isolated from the cultured cells using the Qiagen miniprep protocol (Qiagen, Gaithersburg, MD, USA).
Several tests by PCR amplification are con~ ctc~l on these plasmids to verify that the Kanamycin is inserted in the H. pylori gene/ORF, and to ~letennine the orientation of 15 the insertion ofthe Kanamycin-r~?eiet~nce gene relative to the H. pylori gene/ORF. To verify that the Kanamycin cassette is inserted into the H. pylori sequence, the plasmid DNAs are used as templates for PCR amplification with the set of primers originally used to clone the H. pylori gene/ORFs. The correct PCR product is the size of the deleted gene/ORF but increased in size by the addition of a 1.4 kilobase Kanamycin s~esette To 20 avoid potential polar effects of the kanamycin reciet~nce cassette on H. pylori gene c;ssion, the orientation of the Kanamycin rçsiet~nce gene with respect to the knock-out gene/ORF is ~leterrnin~ and both orientations are eventually used in H. pylori transformations (see below). To ~lett?rrnine the orientation of insertion of the kanamycin resistance gene, primers are ~leeign~-l from the ends of the kanamycin resi~t~n~e gene 25 ("Kan-l" 5'-ATCTTACCTATCACCTCAAAT-3', and "Kan-2" 5'-AGACAGCAACATCTTTGTGAA-3'). By using each of the cloning primers in conjunction with each of the Kan primers (4 combinations of primers), the orientation of the Kanamycin ~~esette relative to the H.pylori sequence is ~let~nnined. Positive clones are classified as either in the "A" orientation (the same direction of transcription is present 30 for both the H. pylori gene and the Kanamycin re~iet~nce gene), or in the "B" orient~tion (the direction of transcription for the H.pylori gene is opposite to that of the Kanamycin reeiet~n~e gene). Clones which share the same orientation (A or B) are pooled for subsequent t;x~.;...ents and independently transformed into H. pylori.

35 Transformation of Plasmid DNA into H. pylori cells Two strains of H. pylori are used for transformation: ATCC 55679, the clinical isolate which provided the DNA from which the H. pylori sequence ~l~t~b~ee is obtained, and AH244, an isolate which had been passaged in, and has the ability to colonize the mouse stom~h Cells for transformation are grown at 37~C, 10% CO2, 100% humidity, SUBSTITUTE SHEET (RULE 26) CA 0222339~ 1997-12-03 WO ~G/ ~h 33 PCTnUS96/09122 either on Sheep-Blood agar plates or in Brucella Broth liquid. Cells are grown to exponential phase, and e~nnin~d microscopically to ~leterrnine that the cells are "healthy"
(actively moving cells) and not cont~min~tP~l If grown on plates, cells are harvested by - scraping cells from the plate with a sterile loop, su~p~?n~ 1 in 1 ml of Brucella Broth, spun 5 down (1 minute, top speed in eppendorf microfuge) and resuspended in 200 microliters Brucella Broth. If grown in Brucella Broth liquid, cells are centrifuged (15 minllt~s at 3000 rpm in a Be~ m~n TJ6 centrifuge) and the cell pellet resuspended in 200 microliters of Brucella broth. An aliquot of cells is taken to ~letprrnin~ the optical density at 600 nm, in order to calculate the concentration of cells. An aliquot ( 1 to 5 OD600 units/25 microliter) 10 of the resuspended cells is placed onto a prewarmed Sheep-Blood agar plate, and the plate is further incubated at 37~C, 6% CO2,100% humidity for 4 hours. After this incubation, 10 microliters of plasmid DNA (100 micrograms per microliter) is spotted onto these cells.
A positive control (plasmid DNA with the ribonuclease H gene disrupted by kanamycin re~i~t~n- e gene) and a negative control (no plasmid DNA) are done in parallel. The plates are returned to 37~C, 6% CO2 for an additional 4 hours of in~ h~tion. Cells are then spread onto that plate using a swab wetted in Brucella broth, and grown for 20 hours at 37~C, 6% CO2. Cells are then tr~n~f~rred to a Sheep-Blood agar plate cont~inin~ 25 micrograms/ml Kanamycin, and allowed to grow for 3 ta, 5 days at 37~C, 6% CO2, 100%
humidity. If colonies appear, they are picked and regro~n as patches on a fresh Sheep-20 Blood agar plate co~ g 25 micrograms/ml Kanamycin.
Three sets of PCR tests are done to verify that the colonies of tran~ro~ have arisen from homologous recombination at the proper chromosomal location. The template for PCR (DNA from the colony) is obtained by a rapid boiling DNA pLe~ lion method as follows. An aliquot of the colony (stab of the colony with a toothpick) is introduced into 100 microliters of 1% Triton X-100, 20 mM Tris, pH 8.5, and boiled for 6 minllt~s An equal volume of phenol: chloroform ( 1:1) is added and vortexed. The mixture is microfuged for 5 minutes and the supe. ..~ls..ll is used as DNA template for PCR with combinations of the following primers to verify homologous recombination at the proper chromosomal location.
TEST 1. PCR with cloning primers originally used to amplify the gene/ORF. A
positive result of homologous recombination at the correct chromosomal location should show a single PCR product whose size is expected to be the size of the deleted gene/ORF
but increased in size by the addition of a 1.4 kilobase Kanamycin cassette. A PCR product of just the size of the gene/ORF is proof that the gene had not been knocked out and that the transformant is not the result of homologous recombination at the correct chromosome location.
TEST 2. PCR with F3 (primer designed from sequences ~llc~ll of the gene/ORF
and not present on the plasmid), and either primer Kan-1 or Kan-2 (primers decignPd from the ends of the kanamycin resistance gene), depending on whether the plasmid DNA used SUBSTITUTE S~ EET (RULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 was of "A" or "B" orientation. Homologous recombination at the correct chromosomal location will result in a single PCR product of the expected size (i.e., from the location of F3 to the insertion site of kanamycin reci~t~nce gene). No PCR product or PCR product(s) of incorrect size(s) will prove that the plasmid had not integrated at the correct site and that 5 the gene had not been knocked out.
TEST 3 . PCR with R3 (primer clesipnçcl from sequences dov~l"ll~ a,ll of the gene/ORF and not present on the plasmid) and either primer Kan- 1 or Kan-2, depending on whether the plasmid DNA used was of "A" or "B" orientation. Homologous recombination at the correct chromosomal location will result in a single PCR product of the expected size 10 (i.e., from the insertion site of kallallly~hl rç~i~t~nce gene to the dov~ ,L-~:alll location of R3). Again, no PCR product or PCR product(s) of incorrect size(s) will prove that the plasmid had not hll~7ldled at the correct site and that the gene had not been knocked out.
Transformants showing positive results for all three tests above indicate that the gene is not essçnti~l for survival in vitro.
A negative result in any of the three above tests for each kan~rollllant indicates that the gene had not been disrupted, and that the gene is es~çnti~l for survival in vitro.
In the event that no colonies result from two independent transformations while the positive control with the disrupted ribonuclease H plasmid DNA produces transfol-ll~t "
the plasmid DNA is further analyzed by PCR on DNA from tran~rolllla~lt populations prior 20 to plating for colony formation. This will verify that the plasmid can enter the cells and undergo homologous recombination at the correct site. Briefly, plasmid DNA is incubated according to the transformation protocol described above. DNA is extracted from the H.
pylori cells immt~ tely after inrllh~tion with the plasmid DNAs and the DNA is used as template for the above TEST 2 and TEST 3. Positive results in TEST 2 and TEST 3 would 25 verify that the plasmid DNA could enter the cells and undergo homologous recombination at the correct chromosomal location. If TEST 2 and TEST 3 are positive, then failure to obtain viable transfolm~ll~ indicates that the gene is ec~Pnti~l, and cells suffering a disruption in that gene are incapable of colony formation 30 VII. Hi~h-throughput dru~ screen assay Cloning, expression and protein purification Cloning, transformation, c;~les~ion and purification of the H. pylori target gene and its protein product,e.g., an H. pylori enzyme, to be used in a high-throughput drug screen 35 assay, is carried out ~çnti~lly as described in Examples II and III above. Development and application of a screening assay for a particular H. pylori gene product, peptidyl-propyl cis-trans isomerase, is described below as a specific example.

SUBSTITUTE SH EET (RULE 26) W O ~ 3 PCT~US96/09122 Enymatic Assay The assay is e~enti~lly as described by Fisher (Fischer, G., et.al. (1984) Biomed.
Biochim.Acta43:1101-1111). Theassaymeasuresthecis-transi~om.-ri7~tionoftheAla-Pro bond in the test peptide N-succinyl-Ala-Ala-Pro-Phe-p-nitro~nili~le (Sigma # S-7388, lot # 84H5805). The assay is coupled with a-chymotrypsin, where the ability of the protease to cleave the test peptide occurs only when the Ala-Pro bond is in trans. The conversion of the test peptide to the trans isomer in the assay is followed at 390 mn on a Bec~m~n Model DU-650 spectophotometer. The data are collected every second with an average sc~nning of time of 0.5 second. Assays are carried out in 35 mM Hepes, pH 8.0, in a final volume of 400 ul, with 10 ~lM a-chymotrypsin (t~ype l -5 from bovine Pancreas, Sigma # C-7762, lot 23H7020) and 10 nM PPIase. To initiate the reaction, 10 ~11 of the substrate ( 2 mM N-Succinyl-Ala-Ala-Pro-Phe-p-nitro~nilide in DMSO) is added to 390 ,ul of reaction lllixLu-e at room l~ln~ dlule.

Enzymatic assay in crude bacterial extract.
A 50 ml culture of Helicobacter pylori (strain J99) in Brucella broth is harvested at mid-log phase (OD 600nm ~ 1) and resuspended in lysis buffer with the following protease inhibitors: 1 mM PMSF, and 10 ~lg/ml of each of ~r ~ hl, lt;u~ hl, ~ f 7 TLCK, TPCK, and soybean trypsin inhibitor. The suspension is subjected to 3 cycles of freeze-thaw (15 mimlt~c at -70 ~ C, then 30 minlltes at room tell.~ e), followed by soni~ ~ti~ n (three 20 second bursts). The lysate is centrifuged (12,000 g x 30 mimlt~s) and the ~u~ l lt is assayed for el~;ylll~lic activity as described above.
Many H. pylori enzymes can be ex~ sed at high levels and in an active form in E.coli. Such high yields of purified proteins provide for the design o f various high throughput drug scl~ g assays.

EQUIVALENTS
Those skilled in the art will recognize, or be able to ascertain using no more than routine ~x~-hllentation, many equivalents to the specific embo-limPnt~ and methods described herein. Such equivalents are int~nr1~cl to be encompassed by the scope of the following claims.

SUBSTITUTE SHEET (RULE 26) CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 SEQUENCE LISTING

(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Astra Aktiebolag (B) STREET: S-151 85 (C) CITY: Sodertalje (D) STATE:
(E) COUNTRY: Sweden (F) POSTAL CODE (ZIP):
(ii) TITLE OF lNV~NllON: NUCLEIC ACID AND AMINO ACID SEQUENCES
RELATING TO HELICOBACTER PYLORI FOR
DIAGNOSTICS AND THERAPEUTICS
(iii) NUMBER OF ~QUr:N~S: 1956 (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 8-mm cartridge tape (B) COMPUTER: SPARC station LX
(C) OPERATING SYSTEM: SunOS Release 4.1.3 (D) SOFTWARE: tar (v) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: PCT/US96/09122 (B) FILING DATE: June 6, 1996 (vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/630,405 (B) FILING DATE: 01-APR-1996 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/561,469 (B) FILING DATE: 17-NOV-1995 (viii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/487,032 (B) FILING DATE: 07-JUNE-1995 (ix) CORRESPON~N~ ADDRESS:
(A) ADDRESSEE: LAHIVE ~ COCKFIELD
(B) STREET: 60 State Street, Suite 510 (C) CITY: Boston (D) STATE: Massachusetts (E) COUNTRY: USA
(F) ZIP: 02109-1875 (x) ATTORNEY/AGENT INFORMATION:
(A) NAME: Mandragouras, A~y E.
(B) REGISTRATION NUMBER: 36,207 (C) REFERENCE/DOCKET NUMBER: GTN-00lC5PC
(xi) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617)227-7400 (B) TELEFAX: (617)227-5941 SUB~ ul~SHEE~ (RUIE26) CA 0222339~ l997-l2-03 W O 96l40893 PCTrUS96/09122 (2) INFORMATION FOR SEQ ID NO:1:
(i~ SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1527 base p~irs (B) TYPE: nucleic acid (C) STRA~ S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...1527 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 A~ ~T~ ~ AGGAAATTTT ATCAAGCTTG CAAACCATTA TTGCCGAACA A~ ATA 60 AATATCATCA CTCAGCTTGC TAATAAACTC ACACAAGTTA AAAATCTAAA ~ L~ ~AG 120 AATTATGTCA GTAATCTTTT TTTCAATCTA CAACGCATTA TA~G~~ AT CA~~ 240 GA~ AA TCACCACTCT AAGTATTGCA CTA~ l~ TAA~ ll TATTATCCTT 600 TCAAAATTAA ~ll~l~l~GG AGCAATTGCT GGGTATATCC AAGCATTTAG CTCTACCCAA 660 rAA~ArTAC AAGATTTATC ATTTTATGGA AA~lG~l"ll"l' TTGCTATCAA TAAATACTTT 720 GAAGAAAAAA TCCATAGCAT TACATTTGAA AATATTAGTT ~ ATCC TAATTCAAAA 840 CTTATTTTTG AAAACTTTAA ~ A CACTCTAATA AAATTTATGC ATTAGTCGGC 900 AAGAATGCTA GCGGAAAAAG CACGCTGATT AATTTATTAT TAG~~ A TACCCCAAAT 960 CATCAACAAA TGAGTGCCAT ATTTCAAGAT ~ ATG~l~l~A TAGCATTGAT 1080 CTAAAATCTT TTGATGAGAA TTTTCAAAAT ~ AATG ATTGCAACAA CACACTATTT 1200 GGAGCGCAAT ATAATGGGGT AGA'll~ l TTAGGTCAAA AGCAACGCAT AGCTACCATG 1260 (2) INFORMATION FOR SEQ ID NO:2:
(i) ~Q~N~ CHARACTERISTICS:
(A) LENGTH: 399 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: dou~le (D) TOPOLOGY: circular (ii) MOLECU~E TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

SUB~ Jlt SllEE~ E 2~) CA 0222339~ l997-l2-03 , 120 (vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...399 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 AAAGGTATTC TAATGAATTG TTGCAGGSCT TGGAAACACC AG~ AA GCAAAGCACG 120 ACAGGTTTAG ~ ~AG CATTATCTCT TCTACAGCCC CCTTTATTGG 'l"l~ ~GG 180 ACGGTAGTTG AAATTTTAGA AGC~l~'l'lAAC AATTTGGGCG CGTTAGGTCA AG~ 240 GCCATTCCAG CCTATTCTTT TTACTTGATC TTAA~AGCGCA AGGTGTATGA TTTATCGGTT 360 TATGTGCAGA TGCAAGTGGA TA~l~lll~l~'l' TCTAAAAAA 399 (2) INFORMATION FOR SEQ ID NO:3 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 474 base pairs (B) TYPE: nucleic acid (C) STRANu~UN~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...474 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 GAGGAACAAT TCCGTGGAAG TGTAGGAAAA AATATTGAAC AACTTGAAGA AAGAGTTA~A 180 GA~ lAG CGATTATAAA ACGCATCAAT AACCTTGGTC TTAATCCTAA TTCTAATTTT 240 AATATGGATA GCGGCATTGA TACAATAGGC TTATTTAGTT CAATAGGAGG 'l"l"l'~ ~ 300 CTTCTATTGA CGC~~ AGT AGGTGAGTTT GCGTTAATTG CAGGAGTGGG TTTAGCATTA 360 A,r~A~A~.AA~ TGGATAAGAA TTTACATCAA ATTTGCGAAA AATTGTGCAG GATG 474 (2) INFORMATION FOR SEQ ID NO:4:
(i) ~:Qu ~:N-~ ~' CHARACTERISTICS:
(A) LENGTH: 336 base pairs (B) TYPE: nucleic acid (C) STRANu:UN~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPO~ lCAL: NO
(iv) ANTI-SENSE: NO

SU~illu~ kk I ~BULE 26) CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 (~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...336 (xi) ~yukNLk DESCRIPTION: SEQ ID NO:4 A'l'~CLl'L-GCG TGTATCAAAT GAGTATAGAG ~ AA AAGAATGCGA AGAATTAGTG 60 TTTAAGGATT TGATCGTTAT AGCGGATTTG ~l~LllL~ GCG AATACACCGA CCATGGGCAT 240 TGCGGGATTT TAGAAAACGC 'l"l'L'l'L'l'L'l'L''l' AACGATAAAA CGCTAAAGAT TTTAAATCTT 300 CAAGGGCTTA TTTTGCTGAA AGCG~'l'~l'~G ATATTC 336 (2) INFORMATION FOR SEQ ID NO:5:
( i ) ~k~U ~:N'~ CHARACTERISTICS:
(A) LENGTH: l9S base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1. .195 (Xi) ~:~Uk'NL'k DESCRIPTION: SEQ ID NO:5 GAGTTTCATT TGCGAGAGCT TTTCGGGGGG AAlLl~ A AAAGCAGCAT TAAAACCCAT 120 GGL Y 'lcAATA TSATA 195 (2) INFORMATION FOR SEQ ID NO:6:
( i ) ~kQUk~C~' CHARACTERISTICS:
(A) LENGTH: 1857 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ny~L)~lnk~ cAL: NO

(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
ul~ SHEE~ (RIIJI ~ 26) w o ~c/1a893 , PCT~US96/09122 (A) NAME/KEY misc_feature (B) LOCATION 1 1857 (xi) SEQUENCE DESCRIPTION SEQ ID NO 6 "l"l~l~GG CAAGCAAACA AGCTGACGAA CAAAAAAAGC TAGTTATAGA GCAAGAGGTT 60 CAAAAGCGGC AGTTTCAAAA AATAGAAGAA CTTAAAGCAG ACATGCAAAA GG~l~lCAAT 120 CC~"l"l"l"l~l"l'A AA~ TGATGGGGGG AATAGGTTGT '~ C TGAAACTTTT 180 AATTTATTCTT CTATATTTAT A~ A ACAATTGTAT TA~ AT '~ ~AA 240 GCCTATGAAC ~~ GAT TGTAGCGATT GTTATTGTGC TTGTAGCTCT TGGATTCAAG 300 AAAGATTACA GGCTTTATCA AAGAATGGAG CGAGCGATGA AATTTAAAAA AC~ ~ 360 TA~ Ll~ TAGGCACAAT CAAATTGGGG GGCATTGATT TTTTAACCAC TTCCAAAAAA 600 GATCTCATAG AGTTACACGC TTCTATTTAT AG~ A GGAATTTTGT TACCCCTGAA 660 TA~l~Gl~ A ~ l-l'AA TGATTTCATG CGAGCCTATA ATGAGAAGCA AAAGAGAGAA 780 A~~ ATG ATATTAGTTT TTATCTCACC ATAGAGCAAG ATTTATTAGA CACTCTCAAT 840 GAACCCGTTA TGAATAA~AA GCATTTTGCA GACAATAATT TTGAAGAGTT TCAAAGGATT 900 GACTTGTATC TCAAGGAAAA AATGCATGGT GGGGTGAAAG AAGTTTATTT TGcrAAT~ 1140 r~T~rGCcC CTAAATCACA GAGCGATTTG TTTGATAAAA TCAACGCTCT AGACAGCGAA 1260 TTCACCTCTA GAAGGATTAT TATTAGTGGA GGCTCCAAAG AGCAAGGCAT GA~ ~G~l~ 1380 TGCTTGAGCG AATTAGTGGG TAATGGTGAT ATTACGCTAG GCAGTTATGG TAA~ A 1440 GTG~l~ G CTGATAGCTT TGAAAAAATG AAAr~A~GCG TTAAGGAATG C~'l'~'l'~'l'AGT 1500 CTTAACGCTA AAG~ l"l' AGCCAACGCA GCGACTTTCT CTATGGAAAA TTA~ 1560 GCCAAACATT G~lC~ AT CACG~ C~l~ TTTATTTTTG ATGTAACTTC TAACAATTTT 1620 GGCAATAGCG TGATGACGTT AAAAAGCGAG ATCAATTCGC ~~ ATTT GAACTTCCAC 1740 TCAGGTAAGA ACA~~ lA TGTCCATGAC TCTAAACGCT A~l~GGGCAAT TTGCCTA 1857 (2) INFORMATION FOR SEQ ID NO 7 U~N~ CHARACTERISTICS
(A) LENGTH 330 base pairs (B) TYPE nucleic acid (C) STRANV~V~SS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (~enomic) (iii) ~Y~O~ ICAL NO
(iv) ANTI-SENSE NO
~vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 330 (xi) ~yu~N~ DESCRIPTION SEQ ID NO 7 GTr~ r~ C~l~l"l~lG~l~ TACAATAGGG AGGATCCGGG ~C~l~ AT CATTAAGGCG 60 CA~ GC 'l"l'~'l'~AGGG A~ ATG AATTTTACCG CTTATAACAC GAAGACGCCA 120 ATTAAAACTT TATCCATGAA ATTAGCGCAA GG~l~ ~C~ A AAGAATGGAG G~~ l~CCT 240 SUB~ SHEE~ (RUlE 26) , -CA 0222339~ 1997-12-03 W O 96/40893 ~ PCTrUS96/09122 GAGCGCGGGA GCl~-l~l~C GAAGCATTTA 330 r (2) INFORMATION FOR SEQ ID NO:8:
i ~ ~kyU~W~ ~' CHARACTERISTICS:
(A) LENGTH: 204 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA ( genomic) (iii) HYPO~l~b:'l'lCAL: NO
(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...204 txi) ~yu~w~: DESCRIPTION: SEQ ID NO:8 ~l~G~ AAAG ACATCATCAG CGAGTCTCAA AACCTTTGCG CAAGAAAATT CCGCCGTTTG 60 TA'l~C~lAT TGAAAGAAAA TGAAATGCTC ATTCGCATCG GATCTTATCA AATGGGGAAC 120 GATAAAGAGC TTGATGAAGC GATTAAGAAA AAGG~l~ AA TGGAGCAATT TTTAGTGCAA 180 GATr-AAAA~G CTTTACYAGC CTTT 204 (2) INFORMATION FOR SEQ ID NO:9:
(i) ~Uu~N~ CHARACTERISTICS:
(A) LENGTH: 1338 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA ( genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...1338 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9 ~''l"l"l"l"l"l'AG AAACCATTTT AGTGGAAAAC GAGCAAGACG CTTTGATTTT GGAAAATTCT 120 TTGATCAAGC AGCTCAAGCC TAAATACAAC A~ AA ~Ar'ACr~TAA AACTTACCCT 180 AAACAGCCTG GCGTTAAATA TTTTGGCCCT TTTACGAGCG GGGCTAAGGA TAl~ l~GAC 300 A~ ATG AATTGCTCCC TTTGGTTCAA AAGAAAAATT GCATCAAGGA TAAAAAGGCA 360 TGCATGTTTT ATCAAATAGA G~ l'AAA GCCCCATGCG AGGATAAAAT CAcTAAAGAA 420 GAATATTTAA 'AAATCGCTAA AGAATGTTTA GAAATGATTG AAAATAAAGA CAGGCTCATC 480 AAArAr-CTTG AATTGAAAAT GGAGCGCCTT TCTAGTAACT TG~ll"l"l'~A AGAAGCCTTA 540 SU~lllll~ SHE~ (RULE 26) CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 , 124 GCCAAACTCT ACGATTTGGA TATTTTTGCT TTTTATGGTG GGAACAACAA GGC~ rA 660 GTGAAAATGT TCATGCGTGG GGGTAAAATC A~ lCAG CGTTTGAAAA AATCCACTCT 720 AAGGGTGATA AG~l~CGc~ AATAGAAATC GCTATGAAAA ACGCTCAAGA GATTTTTAGC 960 CAAGAAAAAA CCTCTAATGA AGATCGGATC T~r-AA~G CGCGATCGCT CTTCAATTTA 1020 GA~l~C~l~C CTTATAGGGT AGAAATCTTT r-~rAr~AGCC ACCATTCAAA CAGCCAATGC 1080 GTGGGGGGAA ~l~l'~l'~l~A TGAAAACAAT GCATTTCAAA AAGACTCTTA TCGGCGCTAC 1140 A~Ar~AAAAA GGGGATTC 1338 (2) INFORMATION FOR SEQ ID NO:10:
QU~ CHARACTERISTICS:
(A) LENGTH: 252 base pairs (B) TYPE: nucleic acid (C) sTRA-Nn~nN~c~ double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) oRr-ANTsM Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...252 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10 GTGAGTTTGG GG~C~lll~A GGGGTATTAT GGAGGGCTAG TGGATTTAGT GGGGCAAAGG 60 TTGAGCGAAA TTTGGAGCGC GATCCCCATG c~llllll-l~AC TCATTGTGAT TTCTAGCGCG 120 TTCAATTCTA A~ llGGAT CAl~c~ TTAGTCTTGC TCTTTAGCTG GATGGGGCTT 180 TCTCAAGTCG TGCGCACGGA ~~ AAAA GCAAGGAATA TGGACTACAC CAAAGCCGCT 240 (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 120 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature S~ tt~ ~BUIE26) CA 0222339~ l997-l2-03 W O 96/40893 PCTfUS96/09122 (B) LOCATION 1...120 (xi~ s~:~u~:N~E DESCRIPTION: SEQ ID NO:ll ~ ATGAGTGAAG CCTATTTTTT ArAr~ATAAA AACGCTTCTC AA~l~r~r~l~ TAATGAACAA 60 GTTTTAAACG TTATGAAACA AGTTCAATTG GATGAAAATT TTTGGAATGT rl~l~lrATG 120 (2) INFORMATION FOR SEQ ID NO:12:
'Qu~:N~' CHARACTERISTICS:
(A) LENGTH: 900 base pairs (B~ TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANIS~: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...900 (xi) ~:~u~' DESCRIPTION: SEQ ID NO:12 GTGATCCTGA TATTTATCAT C~l~l~AA GATCAGA~AG GCAT~l"l"l~CC TATCGCAGCG 60 TCAAAAAGAA AAAGCCAAAG ~~ ~ATC ATTGAAGACG ~ ~AG CAAAGAGGAT 120 GGCATTATTT TTGGGCATGC GTTAAGCGGG AATTTGCACT 'l"l'~'l'C~'l"l'AC GCCGATTCTA 240 AGCAAAAGCT ~l~G~l~l~AT TAAAGCCGAA CATGGCACAG GCAGGATGGT AGCCCCTTTT 360 ~r~ l~AAA GGAT~lGCCC CAGTAAAGAT TTATCCTTAA CGCCACGACA ACGCATCGTC 600 ATCr~r~r-~G AGGTAGAGCG TTTGAAAGAA AGGGTAAGTC ATGGTCATGA TGAAGATCAG 660 GTTTTACTAG ATGAGCTTTT AAAAGAGTCT GAATACTTAG CGCATGCCAC TTGC'GCG~l~ 720 CATTATCAAA AAAACCCTAA AGGCGAAAAG A'lCG~ AA AGATTCTTAA ATCACATGCA 840 AACGACCACA AGCGTGGCTC ~'l"l"l"l"l'~"l"l"l' AAAARGCGCT TTCGTGGTTT CAAAAACTCA 900 (2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 642 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) A~TI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori ~U~IIu~ IE~(Rl~LE26) CA 0222339~ l997-l2-03 W O 96/40893 , PCT~US96/09122 , 126 (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...642 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13 A~L~~ L~L TTTTAGTGGT GTTTGCCCTA AAAAATTCGC CTAAAAATGA TTTAGTGTAT 120 TTTAAATCCA ATTATCGTTT TTCAGTGGGT TTAAAGCCTC TTACCGAAAG CCCTA~AAACC 240 AAACCCGCTT TAGATTCGCC AAATATTCAA GTGTATTTAG ~~lL~LATCC CAGCCAATCC 420 TCAATTTTAA AAAACGCTAA AGCATTTTTT AAATA~AAAA TA 642 (2) INFORMATION FOR SEQ ID NO:14:
QU~:N~: CHARACTERISTICS:
(A) LENGTH: 411 base pairs (B) TYPE: nucleic acid (C) STRANvE~N~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOL~LlCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...411 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14 ATGCCCATTA AAGG~'l'~"l"l"l' TTTAGCCAGA AACCGCCTGG TGA'l'CG~L~lL AACCGATGCG 60 AAATACCAAA AACCCTTGTT ~ L~ LACCC CAACGCCTGA ATGAGAGCGA CGGCACTAAT 180 GA~L~ LAG AAAAAGGGCA GGCTCAAGGG ATATTTAATA TTCAAAATTT TATAAA~CC 240 TACGAGCTGT TGGGTAAGAT TAAGCGCATC AATCATCTCG 'LW'L~'l"l'AGC A 411 (2) INFORMATION FOR SEQ ID NO:15:
(i~ SEQUENCE CHARACTERISTICS:
(A) LENGTH: 816 base pairs (B) TYPE: nucleic acid (C) sTRANn~n~s double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

SII~ SH~E~ (RUIE 26) W~ ~G14D3~3 PCTAUS96/09l22 (vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 816 (Xi) ~U~'N~k DESCRIPTION SEQ ID NO 15 GGGAAATCCA CGCTCATTCG CTTGATcAAT TGTTTAGAGC GCCCCAGTTC TGGCGAAGTT 180 ~ G~ G CTCTAGAAAT CGCCCGATGG GAAAAAACTA AGATTAAATC AAGGGTGCAT 360 GAA~ ~G AATTAGTGGG GTTAGAAGAT AAAGTGCATT TTTATCCTAA ACAGCTCAGC 420 GGCGGGCAAA AACAACGAGT GGCGATCGCT AGGAGTTTAG CGAATTGCCC TAAl~ l~ 480 GG~lcG~l~G AAGAAATTTT TGCTAACCCT AAACATGCTG TTACTAAAGA A'l"l~ ~GC 720 ATCAAAAACG AACATGCGGA TCA~AAATCG CAAGACATTT ATCGCATCGT ~~ AGGG 780 (2) INFORMATION FOR SEQ ID NO 16 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 318 base pairs (B) TYPE nucleic acid (C) STRAN~sS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 318 (xi) SEQUENCE DESCRIPTION SEQ ID NO 16 ATGGGGGCTT TGATAGCCAT ~l"l"l"l"l"l"l"l~A ATGCTCATTA AAAAGACTAT CGCTTATAAA 60 ATCCAGCTCG CTTGCGGTTG TGTCCTTGCG CTTTTGATTT TTA~l~C~llll~ TAAAAGATTT 240 GTGTTAAAAA AAGCCCCGCA ATTAGAAAAT AGCCACGAAA GCGTCAATGA G~l~ AAT 300 GTCCCTTTGA ~l"l"l"l"l~GCC 318 (2) INFOR~ATION FOR SEQ ID NO 17 ( i ) ~k~Uk'N-'~' CHARACTERISTICS
(A) LENGTH 471 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) SU~ ult~ RWIE26) CA 0222339~ l997-l2-03 W O 96/40893 PCT~us96/09122 (iii) HYPOTHETICAL: NO
~iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...471 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17 GTAGGCTTTG CCAATAAATG L-~ l~GGLl~ AGGGTGTATG GL~ lAGA 'l"l'~L-'l"l"l'AAC 240ACTTCAGGGA CTGAACACAC CAAAACCAAT ~ ~Ll~CACCT ATGGCGGCGG TGGCGATTTG 300 ATTGTCAATC TCAl~l'L~l"l"l' GGATAAATTC GCTCTAGGTC TCATTGGTGG CGTTCAATTA 360 GCCGGAAACA CTTGGATGTT CCCTTATGAT GTCAATCAAA CCAGATTCCA ~~ Ll~ ATGG 420 AATTTAGGCG GAAGAATGCG l~Ll~L-GGGAT RCAGTGCGTT TGAAGCGGGC G 471 (2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 834 base pairs (B) TYPE: nucleic acid (C) STRAN~ SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...834 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18 ATGTATCGCC A~l~L-~ AA AGATTTCTCC CTAGATTTTA GCAAA~.~AA~. CGTTCAAGAG 60 L~ AACC AGCTGGCTAA AGACACTTTT TTA~ ~L~ TGCLl~L-l~ AATCATTTTA 120 ATGL-l~L-~lL-G CL-'1"1"1"1"1'L-'1'L TAA~lL-~l~L~ G CAA~ ~L"l' GGLl~L~ ~c CCCTAAAGTC 180 ATTGAGCCTA AA~ "l"l'L"l'AA AATCAACCCT ATCAATGGCG TCAAAAACCT 'l"l"l"l"l'~'l"l"l'A 240 AAAAAGATCC TTGATGGGAG TTTGATCACT TTAAAAGTTT TTTTAGCTTT ~ L~I~LGGG 300 TTTTTCATCT TTTCCTTATT TTTAGGGGAA TTAAACCATG CGGLl~Ll~ GAATTTGCAA 360 GGCCAGTTGT ~lL-TGL-l~ AA AAGCAAGGCG TTATGGCTCA ~ Ll~lLGCT TTTATTTTTA 420 'l"l"l"l"l"l'L-'l'L'l' TGGLl"l"l"l~'l' GGATTTAATC ATCAAACGCC GCCAATACAC TAAL~l~L~ A 480 CCCAAATCCA A'1'L-'1'C~'1'~'1' GACTAACCCT ACCCATTATG CCGTCGCTCT CAAATTTGAT 660 GAA~-~A~C CTGTGCCTGT GGTAGTGGCT AAAGGCACGG ATTATTTAGC CATTAGGATT 720 CTTTATAGAG ACGTGAAATT GAACGCCACC ATACCAGAAG AA~ L-l~ l~A GCGG 834 (2) INFORMATION FOR SEQ ID NO:l9:

Sl~ Jlt Sht~ (RUI ~ 26) CA 0222339~ l997-l2-03 W O ~Gl~93 PCT~US96/09122 ( i ) S ~ yU ~'N~ ~: CHARACTERISTICS:
(A) LENGTH: 360 base pairs (B) TYPE: nucleic acid (C) sTRANn~n-N~ss double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
tiv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...360 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19 AT~AATACA~ GSCCCTTAAT CGCTACGCTT TTGCAAGCGC CTTTGCATGT TTTAGGGATT 60 AGAGAGCCAG 'l"l"l'~"l"l"l"l'LA GC~ l"l"l'l'AC CCCAAAACAG AAAAGCCTAA TCGCCCTCAA 120 AAGTTCGcGC Al~lll~l~AG CATGCCCAGT TTGGAATTTT TAGAAAAATT GGTGATCCGC 180 TAC~~ AG AAGA~A~-AA~- CCTATTGGAT TTAGCGGTGG GTTATATCCA TAGTGGGGTA 240 TTA~lr~C~l~ TATTATTAGA TGCGAATTTA CCCCTAAAAA AAGGGGGTTT TGAAAAGGAA 360 (2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 678 base pairs (B) TYPE: nucleic acid (C) STRAN~k~hkSS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...678 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20 ATGGGGCAGG CA~ lAA AAAAATTGTT GGL~ A TTTATTTTTA 60 ~ ~AATA AGAAGATTGC TTATTTGGGA GATGAAAAAC CTATTACGAT TTGGACTTCA 180 TTA~-A~AATG TTACCGTGAT CCAACTTGAA AAAGATGAAA CTAT~ A CATCACAACA 240 TCGGTAAAAA GTAATCTCAT GTTTGAAAAA GAAGCAGTGA AT~ ~CC~l~ AATGACAAGA 360 GCACAAAAAG ATAAA~AGAGA AA~AAGAAAG GAGGAGCGTG CAAAAAATAG AGCCAATTTA 540 Sl~ UI~S~EE3 ~P~UL~26) CA 0222339~ l997-l2-03 WO 96/40893 PCTAUS96/09l22 (2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
tA) LENGTH: 150 base pairs (B) TYPE: nucleic acid (C) STRANn~nN~5S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...150 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21 ATGAATACAG AAATTTTAAC CATCATGTTA ~~ CCG TGCTTATGGG ATTGGTAGGC 60 (2) INFORMATION FOR SEQ ID No:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 390 base pairs (B) TYPE: nucleic acid (C) STRANn~n~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...390 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22 A~ AG CGGCCGGGCT TGGGGCTTAT GCGATCGCGC ~ ACCT CTTTACGCAT 60 GCGl~ CA AATCCCTCCT 'l"l"l'~'l"l'AGGC TCAGGCAATG TCATGCATGC GATGGAAGAC 120 AATCTGGATA TTACTAAAAT GGGCGCTTTA TACAAGCCTA TGAGGATCAC AG~~ 180 ATGATTATAG GGTCAGTGGC ~ ~G~ ATCTACCCCT ~l"l~CGGGCTA ~ ~CAAA 240 GACAAGATTT TAGAGGTCGC ~ ~ATG CACCACCACA TTTTATGGTT ~ C"l"l"l"l~ 300 A~ ~GGGCGA TCTTTACCGC TTTTTATAGC TTCAGACTCA TCA~ ~CA 360 (2~ INFORMATION FOR SEQ ID NG:23:
Qu ~:N~: CHARACTERISTICS:
(A~ LENGTH: 549 base pairs ~In~ltlU~ ~LE26) CA 0222339~ l997-l2-03 W O~C/~3 PCT/U~,G~122 (B) TYPE nucleic acid (C) STRAN~N~SS double tD) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SEWSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_~eature (B) LOCATION 1 549 (xi) SEQUENCE DESCRIPTION SEQ ID NO 23 ATGTTTATAT ~''l"l'~-l"l'~'l"l'A CACGCTGAGT TTTGTATGGC ~ AAT 'l"L'l'~'l"l"l"l"l"l' 60 TTCAAAAATA AGCCATTGGG TTTGAGGTTT TCG~~ ~lu~ TGATAAGCGT GATTTTAAGc 120 TTAAGCCCCT TTAGCTGTCT TTTGATCCTT GCTTATGCAA G~ T~ ~ CCATATACTC 240 AAAAAGCCCC CTTTAGAAAC CTTGCAATCT TATAGCGTCA 'l'~''l'~'l"l"l"l"l' CAAT~TG~l'~ 300 CTTTTGACAG ATATTTTAGG ~l~lllu~C~CT TTTTCAATCT ACCATCATTT CA~ 360 CTGATTTTTA GCGCGCTTTT TTGCAGCAGT ll~l~llll~A GTAGCCCCTT ATTAGGCGTG 420 TCTTTATTGG ATTTCCCATT A~ ''l"l"l"l"l"l'A AGACTTTATA TCTTGCTAAA 540 (2) INFORMATION FOR SEQ ID NO 24 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 705 base pairs (B) TYPE nucleic acid (C) STRAN~N~SS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 705 (xi) SEQUENCE DESCRIPTION SEQ ID NO 24 GC~ll~l~ TAAAAAAACA G~l~ lAGTC AATAAAATGG 'l'~ AA ACC~ 120 ATCGTTAAAG AGGGCGATCA AATTGAACTC Al~G~l~C~CA ATCTATTCGT TAGCAGGGCT 180 GGGGAAAAAT TAGGGGCTTT TTTAGAAGAT CATTTTATAG ATTTTAAAGA AAAG~ T 240 TTAGATGTGG GAGCGAGTAA GGGAGGCTTT AGTCAAGTGG ~l~ AA AGGGGCTAAA 300 CG~TAA~A AGGGGGTGGT GATGGATAAA GAAGCCATTT TGAACGCTTT AGAAAACTTT 600 SNEEr (RULE 26) CA 0222339~ 1997-12-03 WO 96/40893 PCT~US96/09122 GGGAAAAACG GGAATGTTGA A~L~ LATC CATTTCAAGC GAGCC 705 (2) INFORMATION FOR SEQ ID No:25:
ti) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 264 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori ~ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION l...264 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25 ATGAGCCTAC CACC~ ~ CATTTTGAAA GATGTGAATC ACCTTTTACA AGTCTTRCAT 60 ~ ~1~ CGTTAGGCAA TTCCATGCTA GTGATTGAGC ATAATTTAGA CATCATCAAA 120 AACGCTGACT ACATTATAGA CATGGGGCCT GATGGGGGGG ATAAGGGCGG GAAAGTCATT l80 (2) INFORMATION FOR SEQ ID N5 26:
(i) ~Q~:N~ CHARACTERISTICS:
(A) LENGTH: 444 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA tgenomic) (iii) ~Y~~ CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Heliccbacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION l...444 (xi) ~Qu~w~ DESCRIPTION: SEQ ID NO:26 GC~1"L1"1"1~1' GGCTCAAAAT CGTAGCCATA GGTTTAGAGT TGGGCGAAGA CGATCCGCAA l80 ~L~ ~ AGAGCATCAA CGCTACAGGC GTGCAATTAA AAGGGCTGGA TCTCATCCGC 240 AACTATTTGA TGATGGGGGA AAATYCTGAC AACCAGAATC ~L~L~LLATAA TACTTATTGG 300 AGCCCACCAC Ar-~r-ArAATT TCCC 444 SU~IIlul~ SHEEr (RUIE26) CA 0222339~ l997-l2-03 W O 96/40893 , PCT~US96/09122 , 133 (2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 321 base pairs (B) TYPE: nucleic acid (C) STRA~ s double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) tiii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...321 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27 AAA'l'~l'~'l"l'~ TGTTGGCATC AATTACAGTG CTATTTGTCG GCATTCTTYC ATCTCTGAAT 120 A~ TA TGATAAAATT GATTGATATT GTGGTGAATC TATTACAAAA GCATACGCAT 180 TTTGAATACA G~l~ l' ACCAACTTTA CTACTATGGG GAGCCTTGCT ~l"l"l"l"l~AACG 240 CA~ ~l CAGGAAATTT TATCAAGCTT GCAAACCATT ATTGCCGAAC AA~ AT 300 (2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 408 base pairs tB) TYPE: nucleic acid (C) STRAN~N~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (8) LOCATION 1..,.408 (xi) ~Qu~:N~ DESCRIPTION: SEQ ID NO:28 GGCA AGATCAAGCC 'l"L~'l"l~C~l~ TTAGAGTCTC TAAAATCATG ~ CAA 120 ACCTATTCTT ~ AAC GCGAAAACAA GATTTCAAAT CGCATTTGCG CCATTTCATT 180 ATTAGCGGGT TTCA~l~TTAGG GATTTTGAGC GCGAGCGTGT A~ c~ 360 (2) INFORMATION FOR SEQ ID No : 29:

Sl~ SH~E~ (RULE 26) CA 0222339~ l997-l2-03 W O 96/40893 PCT~US96/09122 , 134 (it SEQUENCE CHARACTERISTICS
(A) LENGTH 162 base pairs (B) TYPE nucleic acid (C) STRAN~w~SS double (D) TOPOLOGY circular (ii~ MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (iX) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 162 (xi) ~U~w~ DESCRIPTION SEQ ID NO 29 TGr~Ar-~A~- CAlC~lllCG TCTAATCGTT ATGGAGCCAT TT 162 (2) INFORMATION FOR SEQ ID NO 30 (i) ~Q~WL~ CHARACTERISTICS
(A) LENGTH 37S base pairs (B) TYPE nucleic acid (C) STRAN~ ~:~N ~:S S: double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 375 (xi) ~k~U~w~ DESCRIPTION SEQ ID NO 30 A'l~GCGGLll~ GGAACACTTT AGTAGAAAAA ATCATCGCTC CTAAACACAA GGTCAAAATT 60 ~'lll"l'L-'l~ GCAAGTATTT AAGCTTAAAA GAATCTTATA AATCCTTGAT TGAAGCCCTA 120 ATCCATGCGG GGGCGCATCT GGATACGCAA GTCAATATTG AA~l~L-G~'l~GA TAGCGAGAAT 180 TTTAATGAAA AGACTGATTT AGAGGGCGTT GATGCGATTT TAGTGCCGGG GGG~ lwA 240 GAAAGGwGA TTGAGGGCAA AATTTGCGCC ATTCAAAGGG CTAGGTTAGA AAAACTCCCC 300 TTTTTAGGGA ~l"l"l'~ll~l'~GG CATGCAATTA GCGATCGTTG AA~ L-lLL CAAATGTTTT 360 AGGLll~AAA GGGGC 375 (2~ INFORMATION FOR SEQ ID NO 31 (i) ~'~UbWL~ CHARACTERISTICS
(A) LENGTH 747 base pairs (B) TYPE nucleic acid (C) STRAN~w~S double SU~51~u~k~ tl ~RIILE26) -W 096l~0893 PCT~US9~/09122 (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_~eature (B) LOCATION l 747 (xi) SEQUENCE DESCRIPTION SEQ ID NO 3l ATGACTAAAG C~'l''L''l'~'l'~cc TTTAAGTTTG TTAGTGAGCG CGATTTTATT AGC~ G 60 CTCATCTTAA TCCCCACTTC TAAGAGCGCT TATTACGGGT TTTTGCGTCA AAAAAAAGAC lZ0 AAGATTGACA TTAACATCAG AGCGGGTGAA TTCGGGCAAA AATTAGGCGA TTGGCTCGTG l80 TATGTGGATA AGACTGAAAA CAATTCCTAT GATAATTTGG TG~ TAATAAAAGT 240 ~ AAG AAAGCTTTAT TTTGGCTCAA AAAGGCAATA TCAACAATCA AAACGGCGTG 300 AATAAAAATC AAAAACGCCG ~ AA GCGATCTTAG TTTCCTTGTT CCCTTTAGCG 540 AGC~l~llll TAATCCCCTT ATTTGGCATC GCCAACCCGC GATTCAAAAC GAATTGGAGT 600 TATTTCYAWG ~l~C~-~l~lGGAGC GGTTGGGGTW TA~ llllAA TGGTGCATGT GATTTCTACG 660 GA~ TGATGACCTT ~ lCCCC TTTATTTGGG CGTTTATTTC TTATTTATTG 720 IT~A~AAAT TCATTTTAAA GCGTTAT 747 (2) INFORMATION FOR SEQ ID NO 32 (i) ~Q~ CHARACTERISTICS
(A) LENGTH 258 base pairs (B) TYPE nucleic acid (C) STRA~nFnN~ double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION l 258 (xi) SEQUENCE DESCRIPTION SEQ ID NO 32 ATGAGTAAGA GCGCGATTTT ~ GG~~ lLl~AG C~ll~ ~CT CTA~ ~ 60 TTATTATATG ~1~ l~ll AGAAAGGCAT AATAAAGAAG CAGAGAAAAT CCTTTTAGAT 120 TTAAATAAAA A~A~AACA AGCCATTGAC TTGAATTTAG AAGATCTGCC AAGCGAGAAA 180 AAGAATGAAA AAATTRAAAA AGTAACGGAA AAACAGGACG A~ AGA GCCTAAAAGA 240 (2) INFORMATION FOR SEQ ID NO 33 ( i ) ~ ~:Q~k'~'k CHARACTERISTICS

SU~~ E~EE~ l.E26) CA 0222339~ l997-l2-03 (A) LENGTH: 384 base pairs (B) TYPE: nucleic acid (C) STRANIJ~l~N~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(ivt ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAMEJKEY: misc_feature (B) LOCATION 1...384 (xi) ~ J~ DESCRIPTION: SEQ ID NO:33 GTGATGGCTC AA~l~CLl~lGLl' TGTYCATGCC ~ L-CCG CL~l~lL~Ll~:GC CcTAGccTTT 60 TA~ ilLA TGCCAGCGAT TTATATTCTT TTAAGCATCG L'l'L'l"l"l"l'~AG TGGG~ L 180 AAAGAAAGGA TGAA~AGCCTA TATCAA~AAA GCTAAAATCC TGTATTTTTT AGAAACGATT 360 (2) INFORMATION FOR SEQ ID NO 34 i r Q U ~ CHARACTERISTICS:
(A) LENGTH: 306 base pairs (B) TYPE: nucleic acid (C) STRAN~ : double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~r) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...306 (xi) SEQUENCE DESCRIPTION: SEQ ID No:34 C~ AATG ~ ATT CATTTTAACA GCGATCTTTT TAGCGTTCAT GCTTTTAGTG 60 AGTTATTGCA TGCCCCATTA TAGCGTGGCT GTCATTAGCG GGGTGGAAGT ~'AAAAr-AATG 120 }~ATGA~AATG AAAACACGCC CAATAATAAG GAAGTA~AA~A CCCTTGCTAG AGATGTCTAT 180 ;lGCA~A CTTACGACCC TAAGGATCAA AAAAGCGTGA CCGTCTATCG TAACGAAGAC 240 ACG~GLll~lG GL'1"1'CCL"1"1"1' TTATTTTAAG TTTAATTCGG CTGATATTTC AGCTCTCGCC 300 ~2) INFORMATION FOR SEQ ID NO:35:
(i) S'k~U~ Lb: CHARACTERISTICS:
(A) LENGTH: 264 base pairs (B) TYPE: nucleic acid SU~ ulkSHEEl (RULE26) CA 0222339~ 1997-12-03 W 0 96/40893 , PCT~US96/0912Z

(C) STRAN~N~5S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii~ HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION l...264 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:35 ATGTTTA~AA AAATCATTTT TTTGTGCGTT TTTTTGATAG GGGGATTTGT CATTCCACCC 60 GAAAAGCTCT ATAGAAGCAT CATTAACCGC CAAAASSTCA CGCGTAAAAA AA~CG~lGG l80 TA~ Tl~ AG GG~G~l"l'~G CGCTGTAGAA GCCATTAAGG ACTATCAAGG CAAGGAAATG 240 (2) IN~ORMATION FOR SEQ ID NO:36:
(i~ SEQUENCE CHARACTERISTICS:
(A) LENGTH: 384 base pairs (B) TYPE: nucleic acid (C) sT~ANnFnNEss double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix~ FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION l...384 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36 CAGGCGTGCA AAAAGGCCAC CAACCAGATC CATTCAAGGY YTGCAAAACA TCCAGCAAAA l20 TATCCCCCCT CAAGTATTAA CCCCTCAATC CAAGCGGGTA TACAAGGGGT GATGCAAGGT l80 'l"l-l~GGGCTT TGAGCAGCAY YTTAGAAGYC CCCYTATTTG T~ YYAAGC AAAATGTGGG 240 G~~ L~Ac CTTTCAAGGG GCTG 384 (2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 324 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular SU~IIIul~SHEE~ (RUIE26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv~ ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION l...324 (xi) ~kyuk~k DESCRIPTION: SEQ ID NO:37 ATGCAGAAGT ~ vl~G TTTTAGAAGG TGGGCGTTGC CCTTTTATTT TGTGAGCGCT 60 TTAGCAGCGA TTGATATTGA TGAAGTAACA GAAGCTCAAG CTAATAGCAT TAAATTAAGC l20 GATCAGTTAG TGAGCCTGAG CGATAAGCTT TTAGAAAAAG CGGTGGATAG GGGGCGCAAT l80 TTAGAGCCTA AGCCTAAGGG CA~AGAAGAT AGTCCTAACT TGGGAGGTAA TAAGGATATG 300 A~GTTG AAATCGGAAG CGGT 324 (2) INFORMATION FOR SEQ ID NO:38:
(i) ~bVUkN-k CHARACTERISTICS:
~A) LENGTH: 354 base pairs (B~ TYPE: nucleic acid (C) STR~NnFnN~S: double (D) TOPOLOGY: circular tii~ MOLECULE TYPE: DNA (genomict iii) nY~Oln~:llCAL: NO
~iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANIS~: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (3) LOCATION l...354 (xi) ~k~U~k DESCRIPTION: SEQ ID NO:38 GTGATTTTAG C~ll~GC~ll~ TGGCATGAGT ~~ vl~ ~AT TAGCGGGCAT GTTCATTGAT 60 Al~lC~l~ TATCCACAGG CGTTCATATC CCTAGAAAAG AGGATATTTT ATGGATTTCT 120 TTAATAGGGA TTAGCGGGAC TTTAGGGCAG TA~ *~ AA CCTATGCTTA CATGAACGCT l80 CCTGCTGGGA TCATCGCCCC CATTGAATAC ACCCGCATTG TTTGGGGGCT A~ lGGG 240 (2) lN~oKMATIoN FOR SEQ ID NO:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 162 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

S~ t~ht~o (R~E26) , CA 0222339~ l997-l2-03 W O 9C/1~_,3 , PCT,~US96/09122 (iv) A~TI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
~A) NAME/KEY misc_feature (B) LOCATION 1 162 (xi) SkyukN~k DESCRIPTION SEQ ID W0 39 GAGCATTTTA GA~ACGCCCC TTTTGAAAGC AATTTACCCG TTTTAATGGG ATTAATCTGG 120 C~l~lG~lAT ATCTAACTTT TTTTCCAATC CAAAAAGCCA CT 162 (2) INFORMATION FOR SEQ ID NO 40 (i) ~kyukN~ CHARACTERISTICS
(A) LENGTH 864 base pairs (B) TYPE nucleic acid (C) STRAWDEDNESS double tD) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) ' (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(~i) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_~eature (B) LOCATION 1 864 (xi) ~kQukN-k DESCRIPTION SEQ ID NO 40 A~l~GCCGCCA AATCCAAAGC GYAAACGCTT AAA~l~ ll CAAAATTTTT CAGCAATTTC 60 AAAATCACTA AACTCAAAGA CAAccAcGAA GAAGCCCACA AA-~ ll~ AGAAAATAGC 120 ATAGAAACCG TGGGCTTTAG ~ ~ATT TTAGCGGTCG CTTACATCTT ATTCAAATAC 240 ACCAATGTTG TTTTTAAAAG C~ AAG ACCATCGTTG AAGAGGATTT AGTCCCTTTA 420 AGCGG~l~CG GAAAATCCAC GCTGGCGGAT ATTATTATGG GGCTTACCTA CCCTAAAAGT 600 AAAATAGGCT ATATCCCCCA AAATATTTAC ~'l"l"l"l"l'~ATG GCA~ ~l~GG GGATAATATC 720 G~ l~G~A GTGCTATAGA TGAAAAACGC TTGATTAAGG TGTGCAAAAT GGCTCATATC 780 TTAGCGGCGG Tr~ G CGCA 864 (2) INFORMATION- FOR SEQ ID NO 41 (i) ~kyukN~k CHARACTERISTICS
(A) LENGTH 576 base pairs (B) TYPE nucleic acid tC) STRANDEDNESS double (D) TOPOLOGY circular Sht~l ~BU~26) CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(vit ORIGINAL SOURCE:
(A) oRr~NT~M Helicobacter pylori (iX) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...576 (Xi) ~:~U~:N~: DESCRIPTION: SEQ ID NO:41 ATGCTTGATA TATGGATAGA TATGATAATC TGTATTTTTT A~ TTTTACGACT 60 C~''l'~'l"l"l"l'AC TCCCACAAAA GGATTATGAA GAAGCGGGAA ATTATGCTAT TAGGAAAATG 180 CAATTATCCA TTATTTCTCA AATTTTAGAT GGGGTGATCT TTGCTGGTTG G~ 240 G~ ~ACGC ATTTAGAAGA TCTCACGCAT TATTTAAACC TTCCTGAAAC GCTAGGTTAC 300 ~ ~ C~~ l~ll TTTAGCGATT CAAAGCGTTT TAGCTTTACC CATTAGCTAC 360 TATACTACCA TGCATTTGGA TAAGGAATTT GG~~ A AGGTGAGTTT A~ 420 TTTAAGGATT TTTTCAAAGG ATTATTGCTC ACTTTAGGCG TGGG~ GTTGATTTAC 480 ACTCTCATAA TGATCATTGA ACATGTGGAG CATTGGGAGA TCAGCTCGTT ~l"l"l"l~l~l~ 540 ~l"l"l~l"l"l"l~C~A TGATTTTGGC TAA~ TTACCC576 (2) INFORMATION FOR SEQ ID NO:42:
( i ) ~ ~:~ U ~:N~ ~: CHARACTERISTICS:
(A) LENGTH: 504 base pairs (B) TYPE: nucleic acid (C) STR~NnF'nN~Cc:: double (D) TOPOLOGY: circular (ii) ~OLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori ~ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...504 (xi) ~Qu~:N~b: DESCRIPTION: SEQ ID NO:42 ATGCTAAAAA AAATATTTTT AACCAACAGC TTAGGGATTT TATGCTCTAG GA~ l~GC 60 ~ LG~ r TCAAATTGCC TAATCTATTC AGGCGTATTT TTGCGGAGGG ~"l'~'l"l"l"l"l'~''l' 180 CAAAGCTTTT TACCGAGCTT CATACGGAGT TCCATTAAGG GGG~'l"l"l"l'GC GA~ ~ 240 ~G~~ ATTT ~ l~GC~l~ TTTATTCATG ~l~G~l~ AT TAGTAGCGCT CAA~ C~l~ A 300 ATTGTAGCGA TCAATTTTTG GTA~ A ~lG~ A TCACCACTTT TTTAGGCGCG 420 CTTTTACAAT ACA~ ~l"l"l"l"l"l~CC GCGCTTATGC GCAAGCTTAC TCAATTTATG 480 CATGATTTTA GCC~ ll"l~A TTTC 504 (2) INFORNATION FOR SEQ ID NO:43:
U~N~: CHARACTERISTICS:
(A) LENGTH: 459 base pairs SU~IllUl~SHEEl (RUIE26) CA 0222339~ l997-l2-03 W O 96l40893 PCTAUS96/09122 (B) TYPE: nucleic acid (C) STRA~ S: double tD) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...459 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43 ATTTTAATAG Al~lG~GGCA TAACCCCCAT AGCGCTAAAG CCTTAAAAGA AGAAATCAAA 180 TTGGTGCTAG AAATTTTAAA ~'l'~'l'~'L~'l"l' AAAAAGGTTT TGATTTTAGA ATTGCATAAT 300 GAAAGAATTA TCCAATTAGA AAAACTTA~A GGGATTTTAG AAACTTTAGG GTTAGAACAC 360 GC~ l~ AAGAACTGAA AGAAAATGAA AATTATTTGG TGTATGGCTC A'1L"1'~1'~1'A 420 GCCAACGCTT TTTATGAACG CTATCCAAAG AAGAGGGATg5g (2) INFORMATION FOR SEQ ID No:44:
(i) ~:~u~ : CHARACTERISTICS:
(A) LENGTH: 177 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...177 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44 ATGGCTATCG GGTTTCCGTT A~l~ ~GG ATTTTACTCA CC~~ AG C~ AT 60 TGGCGTGAGT ~l-l~GG~GC~l~ TTCAGGGGTA TTATGGAGGG CTAGTGGATT TAGTGGGGCA 120 (2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 666 base pairs (B) TYPE: nucleic acid (C) sTR~Nn~nNFss double (D) TOPOLOGY: circular SU~91111~ SHEEr (RIJIE26) -CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION l...666 (Xi) ~:QU~:N-~' DESCRIPTION: SEQ ID NO:45 ATGAAGAAAA AAGCAAAAGT ~ AAAA TGAl~l~C~l~ ~ GTTGTATTTG 60 GCG~l~ l'~AG CGTATCAGAC GCTAAAGAAA TCGCTATGCA ACGATTTGAC l20 AAACAAAACC ATAAGATTTT TGAAATCCTT GCGGATAAAG TGAGCGCCAA AGACAATGTG l80 GGCGAGGGCT ~ C~l~ AA AACCGATTAT GTGAAATTGA GTTTGAACGA AAAATATGAG 360 ATCATTTTCC C~l~ ATGT CCAAGACAGC GTGAGCGGGA ~ll~G~lGAG CGCGGATATT 420 ATTTTCATGT CCACGAGCAA TAAAAGAACT ACC~G~l~ r TATACCCTGA ~l~l~l~CACT 660 (2) INFORMATION FOR SEQ ID NO:46:
:yu~:N~: CHARACTERISTICS:
(A) LENGTH: 159 base pairs (B) TYPE: nucleic acid (C) STRAN~ )N~:~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (iX) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION l...159 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46 ATGCTGGATT TTGATTTGGT ~l~ll"l"l~l~GGC GCGACTGGGG ATTTAGCCAT GCGAAAGCTC 60 ~ ~GC TTTATGAAAT TTATATTTCA TTTATGGTTT TAAAAACGAT TCTAGGATTA 120 TCGCATCGGG GCGTAA~-A~- CTATCCAATG AAGAGTTTT159 (2~ I~'FORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 327 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular SUB~ SHEEl (RULE26) CA 0222339~ l997-l2-03 W 0 96/40893 PCT~U~,G~'~3122 (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANIS~: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...327 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47 CA~l~l~lll~ GCTCTAGCTG TTTGTATGAA TGGAATGGAA ATGAAATTAG TAATGAAGAA 120 AAAGATTTAA AGGTTAAAGG CTCATCTTTG ~ AAAA AAGGCACTAA AATCAAAAAT 240 ATCAAGCTTG TCAATAGCGA TCACAATGTG GATTGTAAAG TGGAAGGGCA GAG~ c~l~ 300 TTAAAATCTG AA'l"l'C~"l"l'AA AAAAGCT 327 (2) INFORMATION FOR SEQ ID NO:48:
(i) ~'kQ~k~k CHARACTERISTICS:
~A) LENGTH: 219 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...219 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48 TTTTCAGAAG ATAAGGACTC GCCTTATGCT AA~l~l"l~l~AG Ccl~c-lC~l~A GGATAATGCG 120 All~ G~ATA CCTATAAGGG GGCGATTATC C~Gc~ 219 (2) INFORMATION FOR SEQ ID NO:49:
QU~:N~ CHARACTERISTICS:
(A) LENGTH: 711 base pairs (B) TYPE: nucleic acid (C) ST~AN~NESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

SU~ Sht~l (R~1~26) CA 0222339~ l997-l2-03 W O 96/40893 PCT~US96/09122 (vi) ORIGINAL SOURCE
(A) ORGANISM Helicob~cter pylori (ix) FEATURE
(A) NAME/KEY misc_feature ( B ) LOCATION 1 711 (xi) SEQUENCE DESCRIPTION SEQ ID NO 4g ~l~G~ YCCA TG~l'~'l'~'l"l' G~l~ ~AGC GATAATTTTT TAGGG~ CATTGGCTGG 60 GAAGGGGTGG GGCTATGCTC TTA-~ ' A'l~ GGTATCATAA AAAAAGCGCG 120 AATAACGCTT CTATTGAAGC ~ ~l~ATG AATCGAATCA CGGATTTAGG CATGCTCATG 180 GGGATTATTT TGA~ ~ GAATTTTGGC ACCCTCCAGT ATAAAGAAGT CTTTAGCATG 240 CTCAATAACG CCGATTATTC CATGCTCTTT TACATTAGCG ~l~l"l"l~l"l"l"l~ TATTGGCGCT 300 ATCAGAGCCA ATC~l'l~l'~lA TAGTGCGGTG TTTGAAGTGG GTTATTTTAT CGCATGCTTA 480 GGAGCGTTTG TGG~l'-~l"l"l"l' TGGAGCGAGC ATGGCTTTAG TCAATAAGGA TTTAAAACGC 540 A~lC~l~Y~l~ ATTCCACGCT TTCTCAATTA GGGCTATATG TTTGTAGCGG CCGGGCTTGG 600 GGCTTATGCG ATC~CG-"l"l"l' TCCACCTCTT TACGCATGCG ~ ~AAAT CC-'1'~L'1"1"1"1' 660CTTAGGCTCA GGCAATGTCA TGCATGCGAT GGAAGACAAT CTGGATATTA C 711 (2) INFORMATION FOR SEQ ID NO 50 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 291 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature ( B ) LOCATION 1 291 (xi) SEQUENCE DESCRIPTION SEQ ID NO 50 ATGATGATAA CCAAACAATC GTATCAAAGA ~ ~G~l~ AA TGCGG~l~ ~ 60 l~G~l~ATT GCCCTTGATG CTGCTTAGCG CTAAAATTGA AAGGAAACGC 240 TTA~ lCGC ~ ATT TTCAGCCATA 'l~C~ll~ CGCG T 291 (2) INFORMATION FOR SEQ ID NO 51 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 840 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO

Sll~ tSh~5 ~RU~F76) CA 0222339~ l997-l2-03 WO 9~ X~3 PCI~/US96/091~2 (iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...840 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51 ATGAAACTGA ~.A~AA~TGT TTTAATCGGT GTGGCAATTC TGTGCTTAAT TTTAAGTGCG 60 TGCAGTAACT ATGCGAAAAA A~l~G~T~AAA CAAAAGAACC ATGTTTATAC Gcc~ Gl~AT 120 TACTTGCAAC CCACTTTGAA TCAAAAGGGT ~ L~ATGA TAGCGAGTAA CTACAATGAT 420 A~ ~C AAGACAAGGA ACAAGAATAT ACCACTAGGA AAAATAACCA ACGAGAAATT 660 CAAGAAGAAA GAGAGAATGA ATACTTGCGC AATCAAATCA GAA~~ ~L CAGTGGTAAG 840 (2) INFORMATION FOR SEQ ID NO:52:
(i) ~yu~ : CHARACTERISTICS:
(A) LENGTH: 174 base pairs (B) TYPE: nucleic acid (C) STRA~N~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...174 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52 A'~ AG ATCACATCGC TAAAGAGATC AGAAGTTTAG TGGAAAACGA TATTGAAGTG 60 GGTATTGTGA ~ GGAGG CAATATCATT AGG~G~ A GCGCGGCTCT AGGGGGGATC 120 (2) INFORMATION FOR SEQ ID NO:53:

u~:~cE CHARACTERISTICS:
(A) LENGTH: 372 base pairs (B) TYPE: nucleic acid _ (C) sTRANn~nNF~s double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) S1~ 3~k S~EEr (~I~E 26t CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...372 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53 GAAGAAATTT ATGAAGGGTT TGCGGACATG TTTGATGATC l~G~l~AAAG GATCGTTCAA 120 CACCTAGAAA AAGAATTTAA AGAG~ AACACCGCCG AAAAAGAAGG CGATAAAGTT 300 (2) INFORMATION FOR SEQ ID No:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 270 base pairs (B) TYPE: nucleic acid (C) STR~iJ~ S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...270 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54 TACGATATAG CG~l~ C TAACCCCATG ~"l'~'l'~ATT C~l~ AAA GGTGGAATTA 180 GACTGCGCGA TACCTGAAGA ATTGTATGAA AGC~ l~C AA~ Al~G~l~AAC 240 (2) INFORMATION FOR SEQ ID NO:55:
(i) ~Qu~:N~: CHARACTERISTICS:
(A) LENGTH: 633 base pairs (B) TYPE: nucleic acid (C) STRANDEDNEss: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

SUBSi~ S~EEr (RULE2~) -CA 0222339~ 1997-12-03 WO 96/40893 PCT/u:~,6/031ZZ

(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
tA) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION l...633 (xi) ~'kOUkN~ DESCRIPTION: SEQ ID NO:55 CTTTTAGCTT ~ TATT AAAGCATGCG AACGAAAAAA CTAAACCCAT ~ AGAA 120 TTGCAAAAAG C'l'TTATGGCG CGTAGAAAGG ATCATTAAAG CCACCTTGCT 'l"l"l"l"l'~:'l'AAA l80 GAAGGGTTTT TTGACTTTGA TTTAATGGGG A'1"1'~ '1"1'AC AAAATTTCTT GT~T;~t't--CC 360ATTGATGCGA TTGAAGCCTT A~'-AA~A~'.AC,C GAACAAGGTC AGGTCA~AAT TGAAGCGTTC 420 ~ c~ ;C AA~ C~ AA AGCCCATGAA GGGAGCATTG CGCTATTAGA AAATCAAGAA 600 (2) INFORMATION FOR SEQ ID NO:56:
;QUI~'N~ I~' CHARACTERISTICS:
(A) LENGTH: 636 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double tD) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
~vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION l...636 (Xi) ~ Qul-:N(~: DESCRIPTION: SEQ ID NO:56 GTGTCAGAAT TTCATCAAGT TTATGACCCT Ll~wl~AATA TTTGGCTGAG CG~ ~ 60 GCCTTATTGC CGA~ A'1"1"1"1"1'(_:'1"1'A TCTTTAATGG TTTTTAAACT CAAAGGTTAT 120 ACAGCGGCCT TTTTGAGCGT GGCCTTATCA GCCATTATTG CG~l~ AGT GTATAAAATG l80 CCTGTTAGCA ~ ~G~ AAGCTTCCTT TATGGCTTTC TTTATGGCCT ATGGCTATTC 240 GCTTGGATCA TTATTGCCGC GA~ A TAt'plAA~TCA GCGTTAAATC CGGCTATTTT 300 A~ lGGcic ATTTTTAGAA ~:GC~iATCG GCTTTGGAGG GCCTATTGCC 420 ATCACAGCGG CGATTTTAGT GGG~l~ GGiiG TTAAGCCCTT TGTATTCTGC TGGGTTATGT 480 iAGCT TGTTAGTGCC ~ ATT GTGTKT 636 t2) INFORMATION FOR SEQ ID NO:57:
,2U~ CHARACTERISTICS:
(A) LENGTH: 546 base pairs (B) TYPE: nucleic acid SU~lllult SHEEr (RUIE26) -_ CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 (C) STRA~~ N~ double (D~ TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi~ ORIGINAL SOURCE
(A) OR~-~NT~M Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 546 (xi) ~QU~N~ DESCRIPTION SEQ ID NO 57 ATGGAAATTA A~ATGGCTAA GGATTATGGT 'l"l"l"l'~'l"l"l"l~ GCGTCAAAAG AGCGATACAA 60 ATTGTGGAAT CCATGAGTAA AGAAGGGTAT CAAATCGTGC ~ ~G~A CATTAACCAC 360 CCTGAAGTCA AGGGCGTGAT CAGCTATGCC ACTAACCAGG CTTTAGTCGG CAA~ A 420 GAAGAATTGC AAGAAAAAAA ATTGCAACGG A~A~l'~G~-l~l TA~~ ~l~A AACCACCCAA 480 GCAAACCCCA AAA~ ~C AAATCGCTTC TTA~ ~ GARGRTGCAC TGAAGTGCGT 540 (2) INFORMATION FOR SEQ ID NO 58 (i) SkQU ~N~ CHARACTERISTICS
(A) LENGTH 672 base pairs (B) TYPE nucleic acid (C) sTRA-NnFnNF~s double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
tiv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 672 (xi) ~'QU~N~ DESCRIPTION SEQ ID NO 58 ATGGATCATG A~ll~ l~AT TACCATGCGT TTGAGCTTTT CTTTAGCTTT GATTACCACC 60 CTTATTTTAC TCCCTATAGG GA~ A GGcTATTTTT TAAGCCTTAA ACGCAATCTT 120 TT~r~GCT TAACAGAAAC G~~ AT ATGCCTTTAG TTTTACCCCC AAG~l~lA 180 GG~~ ATC 'l~ l"l'AAT ~l~L~ CG--~ -"l"l-"l"l"l"l"l' TGGGAGCGTT TTTACAAGAT 240 GTGTTAAATG TGAAACTCGT TTTTAGTTTC CAA~GG~ A TCTTAGGGAG CGTGATTTTT 300 ~CCCT TTATGGTAAG CCCTATTAAA AGCGCGTTAA TTTCCTTGCC CA~ A 360 ~ ~CCA GTTATAGCTT GGGTAAAGGG GAATACTACA CC~~ ACTC 420 GAA~ l~GCG TGGTGATGAT G~ GGGG~l~ GATATATTAG GGGA~ACAAG A~l~GLlAGC 540 ACGCTCACGC TTATTAGTTT TAGC~l~ll~ l'ACCC TATTTTTAAA TAAAAAACAA 660 AGLl~l~ TA 672 SU~ U1~26~

CA 0222339~ l997-l2-03 W O 96/40893 , PCTAUS96/0912Z

(2) INFORMATION FOR SEQ ID NO:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 420 base pairs (B) TYPE: nucleic acid (C) STRANV:~N~'SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...420 (xi) ~:QU~N~: DESCRIPTION: SEQ ID NO:59 ATGCATCCTA TAA~ L~C CTATATCGCT AACGC~cl~ CTCAAGCTAG AAAGATCAAC 60 GGAACACTTT GCA~l~GC~l~ TCAAAAAATA TCTCAAGTCA AAGAATTAGG CATTGATAAA 120 GCAAAGAGTT TGATAGGCAA C~ AA GTGATTATCT ACCCCACAAA AGATACTGAT 180 GAATTAATAG AA'l~'l'~GC~'l' CCCATTAAGC GATAGTGAAA TCAATTTCTT Ar~r~r~cG 240 GAAATTGATT TAAAAAAGAT TTGCAAGAAC TACTTTATAT TCTTGATAGC AAl~cl~lA 360 ATAr~A~A~T CCTCAATGAT CTTAAAAAAG CAAACCAAGA AACTTATAAG GAAGAGTATT 420 ~2) INFORMATION FOR SEQ ID NO:60:
(i) ~y~'N~: CHARACTERISTICS:
(A) LENGTH: 219 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
tA) NAME/KEY: misc_feature (B) LOCATION 1...219 (xi) ~yu~N~ DESCRIPTION: SEQ ID No:60 F
A'l~l~C~l~A CAGGCGGCTT GATGCGTTGG CTCAAATCGG TAAAGCCTGA ACGAATCTTG 60 CA~lcl~l~G TGGAATTTGT GGATATTGCC GGATTGATTA AGGGGGC~AG CAAGGGGGAG 120 CG~ ~ AAGATGACAA TYATCACGCA TGTGAACGA 219 -(2~ INFORMATION FOR SEQ ID NO:61:

SU~lllu~t SHEE~ (RULE26) CA 0222339~ l997-l2-03 wo~/sa~,3 PCTrUS96/09122 (i) ~:Qu~N~: CHARACTERISTICS: -(A) LENGTH: 276 base pairs (B) TYPE: nucleic acid ~C) STRAN~ SS: double f (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ~iii) hY~O~ CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...276 (xi) ~:~u~:N~: DESCRIPTION: SEQ ID NO:61 ATGCATGTTG ~l"l~l~l"l"l"l~ GGCTTTAGGG GATAACCTCA TCACGCTTAG CCTTTTAAAA 60 ATCGCCAAGC TTTTAGAATG CGAMAACAT TTTGAAATCA TTC~ TGAAAATATC 180 C~~ ATGACCTTAA AAAACAAGGC ~ll~ ~G~ CGATGAAGGA '~ ATGG 240 (2) INFORMATION FOR SEQ ID NO:62:
(i) ~:yu~:N~E CHARACTERISTICS:
(A) LENGTH: 615 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...615 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62 ~r.~rAr~ GAGAGTTATT AAGCTTCG-T AAACATTGGA ATATCCCAAC GA~ C~l~ 120 TTC~r~r~ CTCAAGCCGA AGCCGGCGAT GC~ CC AAGAAACTAA AGGGATCATA 180 GACGAAGAAT GGGGGTTTAA AG~l~ AGAGCCTATG TGAGGGTCAA 'l"l~ l"lGCC 240 TTTTCATTTA GGGG~l~l~AA A~lCC~l~ll~ GAAGGTTTAG AAGAATTGGT AGATGAAACG 300 A~ ATGCC TTTCAGACGC TGAAAAAAAT AAGAMAGGC A~ ~AG TATTCAAAGA 360 GCATCAGGCG CTGCAGGAGT TGCTGGGCTT ATCCCCATAC CTTTTAGCGA TGCGCl~CG~l~ 480 ATCGCACCCA TTCAAGCAGG GATGATCTAT AAAATGAATG ACG~ ~ AATGGATTTG 540 r~ ~CTG TGGGCGCGAG ~ l~lCGCA GGATTGTTAG GCGTAAACTG TCGCGCAAGT 600 ~GG~r-r-~cT CTCGT 615 (2) INFORMATION FOR SEQ ID NO 63 SU~ltu~ Shtt~ (~LE26) CA 0222339~ l997-l2-03 W O 96/40893 , PCTrUS96/09122 1~1 ~i) ~ky~kN-k CHARACTERISTICS:
(A) LENGTH: 123 base pairs (B) TYPE: nucleic acid ~C) STRAN~ )N~:.c.S: double ~ ID) TOPOLOGY: circular (ii~ MOLECULE TYPE: DNA (genomic) (iii~ HYPOTHETICAL: NO
(iv~ ANTI-SENSE: NO
(Vi~ ORIGINAL SOURCE:
(A~ ORGANISM: Helicobacter pylori (ix~ FEATURE:
(A~ NAME/KEY: misc_feature (B~ LOCATION 1...123 (xi~ yUkN~k DESCRIPTION: SEQ ID NO:63 ~GCG TGTTYAATTT AAGGGGCAAT ~~ lCCCTT TGATCAGTTT GCGTTTAAAG 60 TTTGGCTTGA AAGCCGAAAA ACAAAACAAA GACACTCGTT A~L~ G~ ACGCCATAAC 120 (2~ INFORMATION FOR SEQ ID No:64:
(i~ ~kQu~N~k CHARACTERISTICS:
(A~ LENGTH: 657 b~se pairs (B~ TYPE: nucleic acid (C~ STRAN~kUNkSS: double (D) TOPOLOGY: circular (ii~ MOLECULE TYPE: DNA (genomic) (iii~ HYPOTHETICAL: NO
(iv~ ANTI-SENSE: NO
(vi~ ORIGINAL SOURCE:
(A~ ORGANISM: Helicobacter pylori (ix~ FEATURE:
(A) NAME/KEY: misc_feature (B~ LOCATION 1...657 (xi~ ~:QukN~: DESCRIPTION: SEQ ID NO:64 GTGAAAAGCG TTTTTAGCGA AGAAAAAGAA ACGCCTGTTA CTAAAGAAAA C~G~~ AT 60 ACGATTATAG GG~l~ ATGA AAAGGATTAT AAGGCGCAAA ATTTAGTTGC AAGCCTTTAT 180 ~'l'~'l"l"l"l"l'~ GGCATAAAAT AGAATTGGTG GTGGCTTTAG AAGAAGTTTA TCGTTACGCT 240 ATCGCTAGCG GAGGCAATCA AAA~-~TTTT 'L~Y~ll~GG-L TAAAAAAGGC TTTAGAAGGG 360 ~'l~'l~l'~'l"l'A AAAAGGGCGG AA'l'~L"lll'~C TACCCGCAAA AGAAATTGCG AAAGCTTTTT 480 GAA~L~ll~lC CTTTAGCCTT GATGGTTGAA AAAGCTAAAG GGGAAGCGTT TTATTTTGAT 540 AA~GGG~ A AAAAGCGTTT GCTAGATCAA AGCGTAGAAA GCTACCATGA AAAAAGCGAA 600 -(2~ INFOR~ATIoN FOR SEQ ID NO:6S:

S15~ t ~F~ 1 E 26) , -CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 (i) ~yu~L~ CHARACTERISTICS
(A) LENGTH 564 base pairs (B) TYPE nucleic acid (C) STRAN~ ~N~SS double (D) TOPOLOGY circular (ii~ MOLECULE TYPE DNA tgenomic) (iii) ~Y~O1~ 1CAL NO
(i~) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature tB) LOCATION l 564 ~xi) ~Qu~ DESCRIPTION SEQ ID NO 65 ATGA~AAGCA TTGGAGAAGT GATGGCGATA GGGGGCAATT TCTTAGAAGC CTTACAAAAA 60 GCGTTATGCT CTTTGGAAAA CAATTGGCTA ~G~1~ 7AAT CGTTAAGCAA AGATTTAGAG l20 GCGATAAAAA AGGAAATCCG CCGGCCCAAT CCCAAACGCT TGCTCTATAT TGCTGATGCG l80 TTCAGGTTGG GC~1"1"1~-"1'~'1' GGATGAAGTG TTTGAATTAT GCCAGATTGA CAG~ Z40 TTATCTCAAA TTCAAAAACT AGTCAAAGCA GAAGAGGGCA TCAATTCTAG C~~ L~1~AACG 300 AATTTACAAA TCGCGCCCCA TTTTGAAGAA GTGGACACTT GCGCGGCGGA ~11~ ATCG 480 r~AA~Ar~ AGAAAAGAAA ATCC 564 2) 1N~uK~ATIoN FOR SEQ ID NO 66 (i) ~:y~'N~' CHARACTERISTICS
(A) LENGTH 693 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) ~OLECULE TYPE DNA (genomic) (iii~ HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) F ATURE
(A) NAME/KEY misc_feature (B) LOCATION l 693 (Xi) ~:yU~'N~: DESCRIPTION SEQ ID NO 66 A'1'~'1"1"1'~A ATAAGCAGTT ACAGCTTCAA ATCAGTCAAA AAGATTCTGA GATTGCGGAG 60 TTA~A~AAAr AAGTCAATCT CTATCAAAGC CTTTTAAATT ~ ~CA TGAGGG~ 120 GTAGGTATTA AAAACAATAA A~7~ AAAAGCGGGA ATCTTGCAAG CTTAAACAAT l80 TCTTATTCTT TGAAAAGCCA AAATATTGAC GGCGTGCAGT A~ *~ATT GGCTAAAAAA 300 Ar~ 7~l~GG~AAT~ CCATAAAAAT GA~ A AGA~ G CACGAGCTTA 360 ~ ~AATG CGGCTAAAAA TGGCGAAGAG CATTCTAATG AAGGATTAAT AACCGTTAAT 480 A~A~rr7GrTc A~r~r~TGA A~1~G-1~u~1'AT GAAAAGATGC AAAACGCCAC ~ C~1~1~AGCG 540 SU~il~ul~nP~ LE2~) WO ~c/~a~33 , PCT~US96/09122 GA~-lcCLlLA ACCAACGGAG CAATGAAATC ACTCAAGTCA 'l~ L~ ~AT TGATGATATT 600 ATGGCAGAGG Lll~l~CG~l~ GTGGCTGATG AGG 693 ., ~ (2) INFORl~ATION FOR SEQ ID NO:67:
(i) ~'~NL~' CHARACTERISTICS:
(A) LENGTH: 189 base pairs ~ (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~Ol~ lCAL: NO
(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORr-ANT-~M: Helicobact~r pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature ~B) LOCATION 1...189 (xi) ~:yU~NL~: DESCRIPTION: SEQ ID No:67 ATGTGGATTA ~ LlLLACT TTCTAGTTCA ~ L~ LATT CG~lL~CATCAAATCA 60 AACCCTGGCC AACTCTTAAA AGLl~l~GG~l TCAAAAATCT TTTTCATAAA TAGAAAGTTT 120 GTTTTAGCAC AGTATAATCC TAGCGTTTCA ATTTTTATTT TACTCAATAG G~'1'L-'1"1"1'~L-'1' 180 L~ ~GC~l~l 189 (2) INFORNATION FOR SEQ ID NO:68:
(i) ~:yU~NL~: CHARACTERISTICS:
(A) LENGTH: 459 base pairs (B) TYPE: nucleic acid (C) STRAN~ )h~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii~ HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(-~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NA~E/KEY: misc_feature (B) LOCATION 1...459 ~xi) ~r:yu NL DESCRIPTION: SEQ ID NO:68 ~GGCGLlA ACC~l~l~CC GCATGCGCAA A~ AAT CAGTTGTGGA TGATTTGAAA 60 GAGAAAGGGA TCAAATTAGT GA~l~L~l~L-l~L~l~ TTTACGGATT A'1'~'1'L-'1"1'~CC TAATTTAGCG 120 CTCAATGACG GLlLl~ AGA CGCGAATTAC TTCCAGCACC GCCCTTATTT GGA~l~LG~l~ 180 AATTTGGACA rAAAAATGCA C~ lG~l~ Tl'GGCCAATA TCCATGTGGA GCL~ AAGA 240 TTTTATTCTC AAAAAATCAC AGACATTA~A AACCTTAAAA AAGGCTCAGT GATTGCTGTG 300 CCAAATGATC CGGCCAATCA AGGCAGGGCG TTGATTTTAC TCCATAAACA A~GCL~ ATC 360 GLlLl~AAAG Arc~AA~-~A TCTATACGCT ACGGAGTTTG ATATTGTCAA AAATCCTTAC 420 SUB~ ult SHE~ (RUI~E2-6) CA 0222339~ l997-l2-03 W O 9G/S~9~3 , PCT,~us96/09122 (2) INFORMATION FOR SEQ ID NO:69:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 216 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME~KEY: misc_~eature (B) LOCATION 1...216 ~xi) ~U N~: DESCRIPTION: SEQ ID NO:69 Al~GGCl~l~ TTGCGAGCGG CATTAACGAT GAAGAGCTTT TAAAATGGCT TCAGG~ 60 GGGTTAAAAA TG~l~ ~ TTTTCAAGTG CTAGATGATA TTATAGACGT TA~A~AA~ 120 (2) INFORMATION FOR SEQ ID NO:70:
(i) ~:yu~:N~ CHARACTERISTICS:
(A) LENGT~: 627 base pairs (B) TYPE: nucleic acid (C) STRANn~NF~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~A~T~M: Helicobacter pylori (ix) FEATURE:
(A) NAME~KEY: misc_feature (B) LOCATION 1...627 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70 A~l~G~ A ACCG~l~l~l' GGATAGAGAC ATTGATAAGG ATAACCCAAG GACGAAAAAC 60 GCl~ C~l~GGAGT GAGTTATTTC ATCAACCCTT TAGCTTTCAA G~ A 180 C~ l~A TCATTTTAGG GGGTTATTCG TATTTCAAGC G~l~ GGCGCAT 240 t l"l"l~l~l~G ~ll~l~G~ r GGGTTTAGCC CCCATTGCAG GAAGCGTGGC G~l~ AGGG 300 GATATTCCTT TATGGAATGT ~l"l"l"l"l~Y TTAGGGGTGA 'l~ l~G~l~ GGCTGGGTTT 360 GA~ A'll~lllACA GGATATGGAG TTTGATAAAG AAAGGGGCTT GTTTTCCATT 420 CCTAGCCAAT TAGGGGAAAA AT~'l~'l"l~ AA'~ AA ~G~ ~GCA ~ ~GCA 480 CTGATCTGCT GG~l~l"l'~l"l"l' TGTGAAATGC TATCATGGGG GG~ ~C GTATTTGGGC 540 TTA~ll~ CAGCCTTGAT CTTACTCTAT GAGCAGATTT TAGTGGCCAG AGATTATAAA 600 AACATTCCTA AAA~C~ll"lRl' TTGTGAG 627 SU~Illul~Sllttl (RUlE26) CA 0222339~ l997-l2-03 W O 96/40893 PCT/U~,G/09122 (2) INFORMATION FOR SEQ ID NO:71:
(i) ~u~N~ CHARACTERISTICS:
(A) LENGTH: 285 base pairs (B~ TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAWE/KEY: misc_feature (B) LOCATION 1...285 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71 ACATTGATTG GcAcGATTwA TGGCATGAAT TTTAAATTCA TGCCGGAGTT AGAATGGCAA 120 TACGGGTATC 'l''l''l''l-l~CLL''l' GATTGTCATG GCGATTTCTA CGATTTTGCC GGTGATTTAT 180 TTCAAAAAGA AAGG~l~l~G~l~ TGTAGCCTTT CATGGAATTT TTATCCTCAC TCTTAGACGC 240 AcA CCGCATGGCA TA~l~'l~C~l~ GGCTACGCCA CGCTT 285 (2) INFORMATION FOR SEQ ID No:72:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 276 base pairs (B) TYPE: nucleic acid (C) STRA~h~Ss: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAWE/KEY: misc_feature (B) LOCATION 1...276 (xi) ~uU~-~ DESCRIPTION: SEQ ID NO:72 A~ C~ATT CAA~l~cLl~l"lA ~ CAAT AAGAGCGGGT TTGTTACCAC G~~ ~L~ A 60 ~ ~ATTT CG~ ATTT GGTGATGACT TTA~l~G~l~ ATAA AAGCATTGTA 120 y TTAAAGATTG AACTCAGGCG CGAGATGCAA ~l~c~l l"l'~'l'C'l'A ACATTCTTAA TGGAGCGCAA 180 GACGCTCCAG AGCATTTTAT GTTTAATAAA AAAAGA~ATG ATGAGACCAA AAGGTATTCT 240 ~ATGAATTGT TGCAGGSCTT GGAAACACCA GGTTCT 276 (2) INFORMATION FOR SEQ ID No:73 (i) ~u~c~ CHARACTERISTICS:

S~ u~S~ (MilE2'G) CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 tA) LENGTH 375 base pairs (B) TYPE nucleic acid (C) STR~NI)I~ NI'~ S: double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) HYPOTHETICAL NO
(i~) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A~ ORGANISM Helicobacter pylori (ix~ FEATURE
(A) NAME/KEY misc_feature (B~ LOCATION 1 375 (xi) ~yuk~L~ DESCRIPTION SEQ ID NO 73 GATATTGGCG AA'l~L~ lLCC TGATAATGAC CCCAAATACA AAAACGCCTC TTCTAAAGAG 120 CTTTTAA~AA ~l~C'~l~L-l~l~LA ~ lL~lCAA AGCATTGGGT TTGAATTGCT TGAAATGGGA 180 TTGAGCCAAC ~ ~G~l"ll~ AGAAAAATCT CAAATCAGCT TGAAAGCCAC TACAATGGAA 300 TATAAArpAA AACTT

~2) INFORMATION FOR SEQ ID NO 74 ( i ) ~kyU~N~ ~' CHARACTERISTICS
(A) LENGTH 3534 base pairs (B) TYPE nucleic acid (C~ STRA~ N~ S double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPO~ CAL NO
(i~) ANTI-SENSE NO
(~i) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 3534 (xi) ~u~ DESCRIPTION SEQ ID NO 74 ATr-ATArrAA ATI~-ArATAT AGAAGGAGAA ACAATGACTA ACGAAGCCAT TAACCAACAA 60 CrArAAACCG AAGCGGL~ r TAACCCGCAG CAA~l~TATCA ATAATCTTCA AL-'1'~L'1"1"1"1' 120 AATGATAGGG ATAATArrCA AG~ ll~AG AAAATCTCGC AGCTAAGGGA GGAATTCGCT 240 AATAAAGCGA TrAAAAATcc TACCAAAAAG AATCAGTATT TTTCAAGCTT TATCAGTAAG 300 AGCAATGATT TAATCGACAA AGACAATCTC ATTGATACAG ~l~ --CAT AAAGAGCTTT 360 rA~AAATT,TG GGACTCAGCG TTACCAAATT TTTATGAATT ~G~l~ LCCA TCAAAACGAT 420 CC~l~L~l~AAAA TCAACACCCA AAAAATCCGA GL~ ATGG AAAATATCAT ACAACCCCCT 480 A~l~Ll~ ~ATG ATAAArA~A~ AGCGGAGTTT TTGAGGTCTG CCAAACAAGC TTTTGCAGGA 540 ATTATCATAG rA~Ar~AAAT CCGATCGGAT CAAAAATTCA ~l~GGGC~l~l~ TGATGAATCT 600 TTr-AAAr-Ar-A GGCAAGAAGC AGAAAAAAAT GGAGAGCCTA ATGGAGATCC TAL~l~lL~G 660 GA~l~GL~ ~ ATA~ ATCATTTGTG TTTAACAAAA AACAATCTTC CGATCTCAAA 720 GAAACGCTCA ATrAAr~Arc AGTTCCTCAT GTCCAACCAG ATGTAGCCAC TACCACCACT 780 SUBSIIlul~ ~HEE~ (RUIE2~) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 , 157 ~ ~ ~ ~
GACATACAAA GCTTACCGCC TGAAGCTAGG GA111~..11~ ATGAAAGGGG TAA'1"1"1"1"1'~'1' 840 AAATTCACTC 11~.C.C~.ATAT GAACATGTTA GATGTTGAGG GA~ .~1~A CATTGATCCT 900 AATTACAAGT TCAACCAATT ATTGATCCAC AATAACGCTC ~ U~ U~1~1 GTTAATGGGG 9 60 AGTCATAATG GrAT~r-AArC TGAAAAAGTT TCA11~11~1 ATGGAAACAA TGGTGGTCCT 1020 GCTACACTCA TTAATGTGCA TATGAAAAAT GGCAGTGGGT TAGTCATAGC AG~1~1~AG 1140 Cr-Ar-rA'rTGA GTCAAr-AAr-A GATCCAAAAC AAAGTGGATT TCATGGAATT TCTTGCACAA 1260 AATAATGCTA AATTA~ArAA CTTGAGCAAG AAAGAGAAAG AAAAATTCCA AAATGAGATT 1320 '1"1"1'~'1"1"1'~'1'A AAAAAGACAA AAAACATTTA GCTTTAGTTG CTGAGTTTGG TAATGGGGAA 1440 AAAACCACTC TTCAAGGTAG CCTAAAACAT GATGGCGTGA 'l'~'l"l"l'~'l"l'~.A TTATTCTAAT 1560 TCCCATTTAG AAGCAGGCTT TAGCAAGGTA G~"1'~'1'~'1"1"1'A A~ 1~CU~1~AA TTTAAATAAT 1680 CTCGCTATCA CTA~.'1'~'1'C~'1' AAGGCAGGAT TTAGAGGATA AACTAATCGC TAAAGGATTG 1740 TCCCCACAAG AAGCTAATAA GCTTGTCAAA GA111111~A GCAGCAACAA AGAATTGGTT 1800 GAGGTGAAAC AAGCTCAGAA AGATCTTGAA AAATCTCTAA AGAr'~ACGAGA GC~111~AG 1920 AAAGATGTAG CGAAAAATTT GGAGAGCAAA AGCGGCAACA AAAATA~AAT GGAAGCAAAA 1980 GATGCAAGAG CAATCGCTTA CGCTCAGAAT CTTAAAGGCA TCAAAAGGGA A'L'1'~'1'~"1'GAT 2100 AAACTTGAAA ATATCAACAA GGATTTGAAA GACTTTAGTA AA1~1111~A TGAATTCAAA 2160 AATGGCAAAA ATAAGGATTT rArrAArGCA GAAGAAACAC TAAAAGCCCT TAAAGGCTCG 2220 GAAGATTTCA ATACTGGAAA AAATTCTGCA CTATACCAAT CCGTTAAGAA 1~G~1~ AAAC 2580 GGAACCCTAG TCGGTAATGG GTTATCTAAA GCAGAAGCCA CAA~1~111. TAAAAACTTT 2640 TCGGACATCA Ar-AAAr-Ar.TT GAATGCAAAA CTTGGAAATT TCAATAACAA TAACAATAAT 2700 ATTGACCGAC TCGATCAAAT AGCAAGTGGT 11GG~1~ATG TAGGGCAAGC AGCGAGCTTC 2820 ~ AAAA GGCATGATAA AGTTGATGAT CTCAGTAAGG TAGGGCTTTC AGCTAACCAT 2880 AAAGTTGATG ATCTCAGTAA GGTAGGGCTT TCAAGGGAGC AAAAATTGAC TCAGA,AAATT 3000 GCAAAAAAAG TGCCTACTAG TTTGTCAGCG A~ATTGGACA ATTACGCTAC TAACAGCCAC 3180 ACACGCATTA ATAGCAATGT CAA~AATGGA ACAATCAATG AAAAAGCGAC CGGCATGCTA 3240 ACGCAA~AAA ATTCTGAGTG GCTCAAGCTC GTGAATGATA AGATAGTTGC GCATAATGTG 3300 GGAAGTGCTC ~ UAGC GTATGATAA~A ATTGGATTCA ACCAA~AGAA TATGAAAGAT 3360 GG~111~1GC AATTTTTAAC CAATATATTT TCTATGGGAT CTTACAGCTT GATGAAAGCA 3480 (2) INFORMATION FOR SEQ ID NO:75:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH 1398 base pairs (B) TYPE nucleic acid (C) S~RANn~nNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE DNA (genomic) (iii) ~Y~U1~11CAL: NU
(iV) ANTI-SENSE: NO
(Vi) ORIGINAL SOURCE:
(A) ORGANIS~: Helicobacter pylori SU~ S~EE~ (RULE 26) CA 0222339~ l997-l2-03 W O 96/40893 . PCT~US96/09122 (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...1398 (xi) ~:uU~w~ DESCRIPTION: SEQ ID NO:75 ATGAAAGCGT TGAAGACTTT TTTAAAAAAA l~CC~l~'l'ATTC TGTTACTAGC AA~ G~l~l~A 60 AACCACTTAA ACG~ l~GC TATGATTGTG GATAATCCTA CGCAGAACGC TTGGAATGGT 120 ATCAAGCTCG CT~A~-A~r ATTAGATAGG GCTAATCAGA CGCTTAATTC CATCAACAAA 240 GAAAGGATCA AA~-AAA~TGC ACAAAACTAT GATATACGCA ATCAAATTGC AGCCAAACGC 420 A~ ~AAA AATGCCCTGA ACTCAATTGG GATGTCAGTC AAGACGCGAG CCCTACAGAG 480 GTGTATGCGA AAGTCAAACA G~ G~l~A GCTTCCCAAG ATAGAGCGTT TAGTCAAATG 840 GATAATGAGT TGGGCGTTAA AA~ ll~GG TTCAACGATG AGAATGTTAA AAAAGGTTAT 900 CGCTTAAAAG CGCAATTTGA TGAGCTTAAT TTAGATTATA GTAGGGATAT 'l~ AAA 1020 AAAGGTGAAG CAGCCG~l'AA AGTGTTCAAT GACTACAAAC ACCGATTCCA ACAATTAAGC 1080 C~ ~ACG CCCTAAAAGA TGACAAAGAG CATCAAGAAA ATCTTGAACA AAAACAACAA 1260 GAAA~ AAGTCTATAG GGCTAAATTA GACGCTTATG GTTTCCCTAA TGGTAGTGTA 1320 Q~ A ATCCGTAT 1398 (23 INFORMATION FOR SEQ ID No:76:
( i ) ~kyUkN~ ~ CHARACTERISTICS:
(A) LENGTH: 189 base pairs (B) TYPE: nucleic acid (C) STRAN~ SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...189 (xi) ~yU~ : DESCRIPTION: SEQ ID NO:76 GTGATGGATG ~A~GG GGAATTGCTC GTTGCAGGAA GTTACCCTGA ATACAATTTG 60 AAcc~ll-lAT TAAACCGCTT CGCAATGCCT TGTATCCGCC GGGATCTGTG GTTAAAATGG 180 G~l~GG~l~ 189 (2) INFORMATION FOR SEQ ID NO:77:
(i) ~:~U~N~' CHARACTERISTICS:
(A) LENGTH: 1263 base pairs S~ Ul~ SHEEr (RU~E ~6) CA 0222339~ l997-l2-03 W O 96/~ 3 PCTIUS96/09122 ~ ~159 (B) TYPE: nucleic acid ~C) sTRA~n~n-N~-çs double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAB: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) O~ANT.ÇM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...1263 (xi) ~Qu~.N~r DESCRIPTION: SEQ ID NO:77 ATGAATTTTT TTGACACCCT TATGGGTATG ~ ~AGC CATCTCAAAA AGTAGCCAAA 60 A~l~ l'G AACATGTGGG TAG~ CATGCACAAC TCATTTTAAA CACAATTATT 120 AAAACCGCTA TGG~l~l~l TGTATTTATA GC~l~ ~lAG GATTTATCAA TTGGGGGATT 240 AAAAATCCTA ATGATTTTAA CACTTATTTT AT~AA~A~A TATTCTACCC ATCTGAAAAA 300 CTAGCCATAC TTA~L~C~l'~A AAGCCTAAAT GAl~G~ AG AAATCCCCAC TAACACTAAT 360 CCTAAAATAA TTA~L~l"llll TTTAGTGATT TTAGGGGAAT TAll~lLll~l~ AGGCTTATTG 540 GTA~ ~C~ TAGGTTTAAT CCCCCAAACC AAAGGCATGT TATTTAGCTA TCTTAAAAAG 660 CTCATTTCCC TTA~l~clll~A TAAACCTTGT ATGATGTTAG TAG~ Tl~ T TAATTATGGA 720 ATAATCTATA AAGTCAATAC TTTAATCCCC ACTAAACACG AAGTCACACA AG~-l~Lll~AT 780 GGCAATGCGG ATAAAATGGC AAATGAGGGA AAAATTATTG A~ ~G CAA~ A 840 GTTTTAGGTT CTGTGATTTG ~ A GTCAAACGAG TGCCTGATTT TATCAATAAT 960 A~ CA CAAGTGGAGG C~l~GGGCA GTAACAGAAA TGATGCAAAA AATTGGCATG 1020 GCCTAT QGA GTG~l~GG~G CGGACTAGCA GGACTTCAAG CTGGAGCTAA AGCTTTTGGG 1140 GT~-AAArA~T TTGTAGCAAG TGTTAAAAGT GG~ll~ ~GAT TTGATAATGA TAAAAATAAT 1260 (2) INFORMATION FOR SEQ ID NO:78:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 267 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) OP~ANT-ÇM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...267 (xi) ~ kN~ DESCRIPTION: SEQ ID NO:78 SUBSTITUTE SHEET (RULE 26) CA 0222339~ l997-l2-03 ATGGATGAAC CAGAAACCAG TTTAGAGCAA AACG--~ A TAAGACTATC AAATCTCATA 60 AGCTTGCGCA ACACCCAACA ACTTACAAGT ATCATCGCCA CTCATGATCC TAll~l~ll~A 120 GATAGTTGCG AATGGGTATT GCTCCTTAAG AATGGCAACA TTGCTCAATA CAAACCTTTA 180 r (2) INFORMATION FOR SEQ ID NO 79 (i) ~i~;yU~N~ CHARACTERISTICS
(A) LENGTH 711 base pairs (B~ TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii~ MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 711 (Xi ) ~h~U l-:N~; DESCRIPTION SEQ ID NO 79 TTTGTATTTT TTACAAGTAT CATTGCCAAA CA~ CC CAAACACGCT TAGCCCTATC 120 'lwl~ AAA TCAACACTTA TGGGATCTTT GCTGCAGGTT ATCTGGCGCG CCCG~ 180 GGCATAGTGA TGGCCCACTT TGGGGATAAA ~ C~ A AAAACATGTT CATGCTCTCT 240 GTGG~ i GCGTGGATAG CATGwGCTT ACCCCTAAAA ACGCTCATTA ~ AC 360 ATAG~l~C~ lKGT R~~ llAGG ATTTGTCAAG GC~l~G~ GGGTGGTGAA 420 TTGC--"l'~iGCG ~-l"l~Giilll"l' TGTCCATGAA CATGCCCCAC AAGGACAAAA AAACACTTAT 480A~ G~ TAACCGCTTC CGTAGTTTCT GGGATTTTGC TTGGGAGTTT GGTTTATATC 540 GGGATTTACA ~l~iGl~ iA CAAGCCTGTT GTTGAAGATT GGG~l~l~GCG GGTTGCCTTT 600 GGGCTTGGAG GAA'~ G TATCATTTCT GTGTATTTGA GGC'G~l~ A~ A~ AACT 660 CCC~l~ l'C AGCAAATGAA GCAGGGACGA TGCCTTAGTC A~ATTCCCGC T 711 (2) INFORMATION FOR SEQ ID NO 80 QU~N~ CHARACTERISTICS
(A) LENGTH 1413 base pairs (B) TYPE nucleic acld (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) liY~O~ CAL NO
~iv) ANTI-SENSE NO

(vi) ORIGINAL SOURCE
(A) O~ AMTcM Helicobacter pylori ~iX) FEAI'URE
(A) NAME/KEY misc_feature ~B) LOCATION 1 1413 SU~lll31~ SHEEI (BV~E 26) CA 0222339~ l997-l2-03 , 161 ~ ~ ~
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80 ATGCGCAAAT TTTTGGATGG GGCAAAAAGT GAG~l~Ll~l~AA AATACGATGT GAll~ 60 GATATTTTTG ATACCCTCCT TCTAAGACCT TTCATTAAAC CCACAGATTT A~lllll~l~T 120 ATTGAGACTA A~TACAATAT TAAAGGTTTT CATCAAGCAA GGATCCTGGC AGAAATGCAA 180 AAAGAGTTTC ATTCATATAA GGGAGTAGAA ATCGCTACTG AAAAAGAGGT G~l~ CCA 300 AACTTGGAGA TGTTAGAACT CTA~ l~ GCTAAAGAGA A~AT~A~-~G AGTGATTATT 360 GTATCAGATA TGTATTTACC TTTAGAGGTT CTTGAAGATA TTTTAATTTC TAAG~ll~ll 420 ~l~AAGC A'l'~ AAA ACAAGAAAAT ATTACTAATA CGCAGATATT GCATATCGGT 540 A~l'~l"l'~CGC AAAGTTTTAT TTTAGGATCT TTA~l~C~l~ TTTATAAAAA TTATATTCAA 720 AAACATGAAA AATTTGATTA ~l"l'G~ l"l' TTAGGAGCGA TGCAGGCAGG AATTGCAGCC 780 TT GCCAGTTTAT CTATAAGGAG ATTCACA~AA GAAATATTGA TACTTTAGTG 840 ~ ~C~c GAGATGGTTA TTTATTGCAA AAAATTTTTA ATATTTTATA TCCAAATTCA 900 CGCCATTTAG CGTTAAAATG TTTAGATAAT TACAGAAAAT A~l"l'~'l"l"l''l'~ ATCAAATTTA 1140 GAAGGAAATA TCGCTATTGT AGATACGATT ACTTTAGGCT A~ l~CA AGGGTTAATC 1200 CAAAAAGCTT TAAATAAAGA A~~ ll~G TGCTATGTGG A~ C~ AAG AATTTTAAAT 1260 TATGATTGCG TGA~ AC~ l"lCA CACCCTAAAC CCGTTTATTT TCATAATTGG 1320 GATTTTATGG A~l~ G~l~ AACAAGCCCT GAATACCCTA TTTTAAATGT AGAAAATGGC 1380 GTTCCAATCT TATCAAAAAG AC~ lCATC TTG 1413 (2) INFORMATION FOR SEQ ID NO:81:
( i ) ~kQ~ ~:N~ ~: CHARACTERISTICS:
(A) LENGTH: 369 base pairs (B) TYPE: nucleic acid (C) STRAN~nN~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~O~ CAL: NO
(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...369 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81 GAAAT ~ ll~AAGA TTCCAAACAG CTTAGCACGC CTATGGGAAA GAGCGCGGTG 60 GGCAGTAAGG ATTCTCATGT CAA'l~ l~ ATTCTTAAAA CCCTTATTTC AGCGGGGATT 180 AAAGACACGC GCTTGCCTGA AATCTTTATA GGr~G~-~TT TTAGTGATTG TTTGCAGCGC 300 GGCG~G~ ~ AGCCATTTTT TTGGGTTTTC TAl~ l~ GGGGCGTTCA l~ ~GCAT 360 (2) INFORMATION FOR SEQ ID NO:82:
(i) ~yU~N~ CHARACTERISTICS:
(A) I~ENGTH; 777 b~se pairs S~ S0E~1 (~i~26) CA 0222339~ l997-l2-03 W O 96/40893 PCT~US96/09122 , 162 (B) TYPE nucleic acid (C) sTRANnEnN~s double (D~ TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 777 (xi) ~Qu~ DESCRIPTION SEQ ID NO 82 ATGATTTTAG CCC~ l~AT TTCTAAAGAA AAAACGCATT TAGAAGCGTT GTATTATTTG 60 AGCTATGGCG TGCTTTTAGG GGGC'~l~GCT CAAATCTTAT TACACTTTTA ~ lAGTA 120 AAATTAGGCT TATGGGATTT ATTATTTAAA GGGl~ ~G GTTTTAAGAC TAAAAATACA 180 ~ CC~A G~~ AGG CAATTCTAGC GCTCAGATCG ~ AGACACCACA 300 A~l~CG~ l~GCGAG CGGGAGCGTG TCTTATTTGT ATTACGCCAA TAGAGTCTTC 360 CAGC~l~C~ TAGCCTTATT CGCTATCGCT ATCTCCACAG ~'l'~'l"l"l"l'~CC TAGCATTGCG 420 A'lCGCG-~ A AAAACAACCA GCAGGATTTA ATCTTACAAC GCTTGCAAAA GGC~ 480 'lll"l"l'~'l'~ ~G~l"l"l"l~l TCTTTGCAGC Al~ ~GGGA TAATGTTAAG CAAAGAAATC 540 ~l~l"l"l"l~GC TCTATCTTTT AGG~~ C ~'-~ ~G~C TAACCAAACT ~l"l"l"l~l"l"l~A 660 ~l~G~ l'ATG CGAAATTAGA GCAAAAAAAA GCGG~ AAAA '~ AAT TTCGCTTTTT 720 TTAGGTTTAG CGG~ll~ GAGTTTAATG C-~AG GG~ll~ ~GG ~ ~C~l~ 777 (2) INFORMATION FOR SEQ ID NO 83 Ou~-~ CHARACTERISTICS
(A) LENGTH 231 base pairs (B) TYPE nucleic acid (C) STRAN~ N~ double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(~i) ORIGINAL SOURCE
(A) OR~ANI~M Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 231 (xi) SEQUENCE DESCRIPTION SEQ ID NO 83 ATGATTGAAG TGTTTAATTT TA~G~l~ CAAGTCAAAG AAGACATGCA AAAATTAAAG 120 CCTGAAGCGC CCA~ll~ll"ll"l~ AATGAGCTCC AAAGACCCTA AAAGCTTGGA AGATTTTAAA 180 AA~ C~l~ TA~AAAAAAA GCGTGA~AAT TACCAATCCA CGCATTCGTT T 231 (2) INFORMATION FOR SEQ ID NO 84 S~ h~ 26) , CA 0222339~ l997-l2-03 WO 96/40893 PCTrUS96/091Z2 (i) SEQUENCE CHARACTERISTICS: ~
(A) LENGTH: 540 base pairs (B) TYPE: nucleic acid (C) STRAN~k~N~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi3 ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...540 (xi) ~k~uk~N~k DESCRIPTION: SEQ ID NO:84 ATGc~ GCGCGGGAAG GAATGAGACT TTAAAAAAAG CGGTGCCTAT l~l~l~GGC 60 CTTATTTTTA TAGGGAGCGC GGGGAGTTAT AGCCCAGAAA CGGAGATTTT GAGC~ 180 TTGGATAATT TCATTCACAT AGAAACTAAA GAGCAGGCTC TTTTTGA,AAG GGTGCGTGTG 300 AATAGCAGTA ACTACATCCA CACCAGCGAA A~ r~l~A AAAAAATGGT TCAAAAGGGC 360 GTTTTATTAG AAAACATGGA ~l"l"l"l"l"l~AGC GTCTTAAGCG TGGCTAAAAT 'l"l"l"l"l'~'l"l"l'A 420 AAGGCTAAAG GGA~ l*ll~ CGTGAGCAAT CATGTAGGGC TTAACGCGCA TAAGGAATTT 480 AAAGAAAACC ACGCCAAAGT rAAArA~ATT CTAGAAAACA TCATTGATAG TTTGATAGTT 540 (2) INFORMATION FOR SEQ ID NO:85:
Q~kN~k CHARACTERISTICS:
(A) LENGTH: 639 base pairs (B) TYPE: nucleic acid (C) sTRANn~nN~Cs: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...639 (xi) ~kQukN~k~ DESCRIPTION: SEQ ID NO:85 GTGTATGAAG AAAGGATCAC TCTGGCTTCT CAAGGGATCC CTAAAAC~A~ TAAAGTGGGC 60 TTTGAAATCT TTGACACTAA AGA~l~ ~GG GCGACTGATT TTGATCAAAA CATCAAACTC 120 GCCAATGTGC ATATTGCAAT CCCTAAAGAC AG~ ~ TGGCTAAAGA AGTCCCTCCT 240 GTGAATGAAA ATGGCGAATC AATAGGCGAG GGC~-~T~TAC TAGAAAACTC CAAAGAATTA 420 GCCTTAGAGC AATTGCGCTA CAAACAAAAT TTT~-A~AA~A TTTTAGAAAA TAAGATCGTC 480 AATATCTTAG CCCCTATTGT GGGGRGTAAA AACAARGTRG T~R~AARRGT CAATRCGGAG 540 TTTRATTTCA RCCAAAAGAA AAGCACCAAA GAGACTTTTG ATCCCAATAA ~ CG~rAAG 600 SU~u~ ttl (RUL~2-6) CA 0222339~ l997-l2-03 W O 96/~0893 PCTrUS96/09l22 GAGCGAGCAA AATTTAGAAG A~A~AA~AGA AGGCGCTCC 639 (2) INFORMATION FOR SEQ ID NO:86:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 444 base pairs (B) TYPE: nucleic acid (C) STRP~ S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAMEJKEY: misc_feature (B) LOCATION 1...444 (xi) ~QurN~: DESCRIPTION: SEQ ID NO:86 GTA~lC~ll~l~ TGGCGTATAG TAGTGCGTTC GCAGCGGATT TAGAAACCGG AACCAAAAAC 120 ACTAAAAA~G ATAAAAAGCT TTATGATTTC ACTAAAAATA GCGGATTAGA AGGCGTGGAT 240 ~ CG~l~AAAA ACAATATCGC TGAAGGGGTG AGCATGCCGA TTGTGAATTT CAATAAAGCC 360 CTA~ ~ GGCCTTATTT TGAAAGGACT AAAAGCAAAA AAACCCAATA CATGGACGGC 420 GG~llGATGA TGCACATCCG TTTT 444 (2) INFORMATION FOR SEQ ID NO:87:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 843 base pairs (B) TYPE: nucleic acid (C) STRAMnFnNF~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~Ol'~l'lCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...843 (xi) ~U~N-~: DESCRIPTION: SEQ ID NO:87 ACGCCCATTA TCACTGACCC TAAAAAAGCT A~l~CG~GG~l~ TGCAAAGCGT GGCTAAAGAA 120 GAACAAGCCC AAAGTAACGR CGTTGAAGCG ~l~CC~l~ATT TGA~ GATTGATGAA 240 CAAATGGGGC GAGCGAGCGG CTTGCACCTC All~l~CGA CCCAACGCCC GAGCGTGGAT 360 SU~llultSHEEr (RU~E26) _ CA 0222339~ l997-l2-03 , 165 GATATGCTCT TTACCCCCCC AGr-AArAAAr GGGTTAGTGC GCTTGCATGC CCCCTTTGCC 540 ~ ACTGAAGATG AAATCAAAAA AATCGTGGAT TTTATTAAAG CCCAAAAAGA GGTGGAATAC 600 ~ GATAAAGATT TCTTGCTAGA AGAATCGCGC ATGCCTTTAG ACACCCCTAA CTATCAAGGC 660 GATGACATTC TAGAAAGGGC TAAAGCGGTG ATTTTAGAAA A~AAGATCAC TTCTACGAGC 720 GAAGCTCAAG G~lll~lATC CCCAAGAAAC GCCAAAGGCA ACAGAGAGAT TTTGCAAAAT 840 (2) INFORMATION FOR SEQ ID NO:88:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 432 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...432 (xi) ~:yu~N~ DESCRIPTION: SEQ ID NO:88 ATGAATTTTT TTAAAATCCT TTTAATGGAG TTAAGAGCCA ~~A TAAGGGCGTT 60 TTATTGATCC TTATAGGCGC ~lC~ AATC TAi~ll~l~ TATACCCTTT GCCTTATTTG 120 AAAGACATCG TAACGCAGCA AAAAATCGCC CTTGTAGATG AAGACAATTC CTTccTTTcT 180 TCTATGCTGG AAGCCAAAAA GCTTTTAAAA GAAGAAAAAA TTTATGGGAT CTTArArA~T 300 GAACGCCAAT TA~ l~A TTTATGGTGC GTTAGCGAAT GCG~~ ~ GGAGCATCAA 420 (2) INFORMATION FOR SEQ ID NO:89:
.(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 219 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...219 SU~IIluc~ SHEE~ l~ULE 26) CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 (xi) ~kyUkN~: DESCRIPTION: SEQ ID NO:89 ~ ~GGLl~ TAGCCATGCT GGG~~ ~TAATATTG AAAAAATTTC GCTCGCCACA 60 GCGACGGCTT TCTCGCAATG CGCGCCTAWT TATACGGTGC ~ CCCC ~l"l"l~"l"l"l"l~ 120 (2) INFORMATION FOR SEQ ID NO:90:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 933 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) F-r-ATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...933 (xi) Sky~r~N~k DESCRIPTION: SEQ ID NO:90 ~ ~A CGGATTTGAT TCAAGGGCTT TTGATGATGA GCGCTTTAAT C~ ~CCG 60 GCTTGGGGGT TAGGCTATTT TGGGCAACCC CATATTTTAG ~l~GCG~l~L~AT GTCTATCCGC 240 TCCATTAGAG ATGTGCCTAA AGCGACCACT ATTGGGATTT CTTGGATGGT TA~ A 300 A~ ~GGGCAT GCGTTATGGG GCTTTTAGGC ~~ ATG TACATAAATY TGACTTGAGT 360 T~Ar-A~r-Acc cTrAAAAr-AT TTTCATTGTA ATGAGTCAAT TG~l~ AA CCCTTGGATC 420 CTTGTAAGCT CTTCTACCAT TGCTGAAGAT TTCTATGCGA CGATTTTCAA TAA~AACGCC 540 CCCCAA~AAT TAGTGATGAC GATTTCTAGG ~ CG~lll~ TAGGGGTGGC TTGCATCGCT 600 GGCTTTGGCG CGA~~ ~G ~ ~ATT ~ CAC ~ C AAGAATGACG 72C
CGCATTGGCG CGATTGCTGG CA~ l GGGGCTAGCA CGGTGATTTT ATACGATAAA 780 TTTGGCAAAA G~~ ~GA TATTTATGAA ATCGTTCCGG GCTTTATTGT AGCGAGCGTA 840 GCTATTGTTG CGTTTAGTTT ~ AGC GTGCGATCAG GCACTAAAGA GGCCTTTGAA 900 (2) INFORMATION FOR SEQ ID NO:91:
(i) skQ~kN~k CHARACTERISTICS:
(A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori ~U~~ SHEE~ gR~lLE26) CA 0222339~ l997-l2-03 W O ~6/l~ PCTAUS96/09122 ~
~ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...345 (xiJ SEQUENCE DESCRIPTION: SEQ ID NO:91 ~l~GGG~ TTATCGTTTT ~~ lAATT ~TAATGAAGC ACCAAACCTC CCCCTATGCT 60 AA'l~ l~A G~ ATTT TAGCGGCACT AAAGAAGGGG CAAGGGATGT GAAAATCAGC 240 (2) INFORMATION FOR SEQ ID NO:92:
(i) SEQUENCE CHARAcTERIsTIcs:
(A) LENGTH: 600 base pairs (B) TYPE: nucleic acid (C) STR~ )~r:~S: double (D) TOPOLOGY: circular (ii3 MOLECULE TYpE: DNA (genomic) (iii) ~Y~~ CAL: NO
(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...600 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92 A~ l~lAG GGCCAACAGG CGTGGGGAAA ACGACGACTT TGGCTAAATT AGCCGCACGC 60 TATTCTAGAA ~ l~G~lAA AAAATACAAG ~l~GGCATTA TCACTTTAGA CAATTATCGC 120 ATTGGGGCTT TGGAGCAATT GA~ll~l~AT GCTAATAAAA TGAAAATGAG TATAGAAGCG 180 TTAGTGGATA CGACAGGGCA TTCGr~TAr GATAAGGAAA AAATTGCCGG TTTGAAAGAG 300 TTTATAGATG GGG~ll~ATAA TATTGATGTA TCCTTAGTGC 'l"l"lC~l'l'AC CACTAAGTAT 360 GAAGACATGA AAGATATTTA TGA~ GGG~l~ AG GGATTGACAC TTTAATCTTT 420 ACGAAATTAG ATGAGAGTAG GGGGTTAGGG AA~ CTTTAGTGCA TGAAAGCCAA 480 AAGCCTATCA GTTATCTTTC ~ ~GGC~AA GAA~l~C~l~A TGGATTTGAA AGTGGCTACT 540 AATGAGTATT TAGTGGATTG CATGCTAGAT ~G~~ AGTA ACCCTAATAA GGAACAAGCA 600 (2) INFORMATION FOR SEQ ID NO:93:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 792 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double -(D) TOPOLOGY: circular (ii) ~OLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:

Sl~ EE~U~~26) CA 0222339~ l997-l2-03 W O 96/40893 , PCTrUS96/09122 , 168 (A) o~rANT.~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...792 (xi) ~u~ DESCRIPTION: SEQ ID NO:93 GTGGGAGGAG CGAGCTTTAT ~ ~l~GGGGC AATGGCACGC TTTATGGCTT GAATGTGGGC 60 TATGACCGAT TGGTTAAAAG CGTGATCCTT GG~ ATG TGGCTTATGG CTATAGCGGT 120 TTTAACGGGA ACATCATGCA ll~l~ ~GCT AATAATGTGG A~ ~G~AT GTATGCGAGG 180 G~ llll~A AA~r-~AArr-~A ATTCACTTTG AGCGCGAATG AAACTTATGG AGGCAATGCG 240 AGTCATATCA A~ lAA ~ GCTC l~ ~A ACCAACGCTA CAACTACAAC 300 ~l~GlG~ AA AACCTCAAGT GGGCTTGAGC TATCATTTCA TAGGCTTGAG CGGGATGAAA 420 GGTAAAATGC AAAATCCAGC TTACCAACAA ~ ~ATGC ATTCAAACCC TTCTAACGAA 480 ~lCG~ AA CGCTCAACAT GGGGTTAGAG AGCCGTAAAT A~ AA AAATTCCTAT 540 TA~ AA CGGCGAGGTT GGGTAGGGAT CTTTTGATCA AAGCTAAAGG CGACAATGTG 600 ~'l'~'l"l"l"l'~ TGGGTGAAAA CACTTTATTG TACCGCAAGG GGGAAATTTT TAACACTTTT 660 GCGAGCGTGA TCACAGGAGG CGA~ATGCAT TTGTGGCGTT TGATGTATGT GAATGCGGGG 720 ~l~GGG-l"lA AAATGGGCTT GCAATACCAA GATCTTAATA TCACTGGGAA TGTGGGCATG 780 (2) INFORMATION FOR SEQ ID NO:94:
(i) ~:O~:N-'~' CHARACTERISTICS:
(A) LENGTH: 1017 base pairs (B) TYPE: nucleic acid (C) STRAN~N~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~l~ lCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORr-ANT-~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...1017 (xi) ~:yU~:N~: DESCRIPTION: SEQ ID NO:94 ATGGACGGCT A~ AA AATGCAAGAC TTGGGCCAAA AAACTCAAGT TATCCAACAC 60 A~ lll~CCG GGGATGATGT GAGCGCTTTA GAAGTCAAAG AAAATGAATG CGTTAAAATC 120 rAAAAr-GGcG AGAACGCTTC TTTAAACAGC GTTTTAGTCC CTAAAAATAC CCGTTTGAAT 300 T~AA~AATCG ~l~ l"l'AG TAGCGGCGAT GAATTAGTGC CTTTAGGGCA AAACGCCCTA 420 GAGTGCCAGG TTTATGATGT TAATTCAGTG ~l~l"l"l"l"l~A ACATGCTTAA AAACTACAAC 480 ACGCATTTTC TAGGG~l"l"l~l~ AAAAGATGAT AAAAATTTAC AGCTTAAAAT ACTTGAATTG 540 CAAGGCTATG ATGTCATCCT TTCAAGTGCG GGGGTGAGCG TAGGGGATAA AGA~~ 600 AAA~A~GCTT TGAAAGAAAG AAACGCCCTT TTTTATTACG AAAAAGTCAA TCTCAAACCT 660 AATAArAAAc GGACGCATTT AATCTTAGGC AACTATTCAA ACCACCAATT CATTCCTTAC 900 AArAArrr~CT ATGAATCAGG AGCGATTCAA GCC~ ~CGC AAGTGGATTC TATCRCTTTA 960 ~ tkll ~LE~) CA 0222339~ l997-l2-03 W O 96/40893 , PCTAUS96/09122 L
(2) INFORMATION FOR SEQ ID NO:95:
( i ) ~ ~ UU ~'N~ ~' CHARACTERISTICS:
(A) LENGTH: 438 base pairs (B) TYPE: nucleic acid (C) sTRANnFnM~c.~: double (D) TOPOLOGY: circular (ii) MOLECU~E TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-sENsE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANIS~: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...438 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95 ATGCCATACG CCTTAAGAAA AAGATTTTTC A~ACGCCTTT TA~TTTAATTGTT 60 TGTATGATAA ATTTGcATGC CAAAAGCTAT C'L'~'l"l"l"l' - ''l'C CTTTGCCCCC AGCGCACCAG 120 CAAATCATTA AGACAGAGCC TTG~ G GA~~ l~A AAGACTTGAT GCTGCAAAAT 180 CAAATCTTTT ~ r~ ATc CCAATACGAT GATAACAACC AAGATGAGAG CCTTAAAACT 240 AAAGAAAGCT ATGAGCCTAA GATTGAATTA GCGATTTTAC TGCCTAAAAA G~lG~l~GGC 360 (2) INFORMATION FOR SEQ ID NO:96:
(i) ~uU~NC~: CHARACTERISTICS:
(A) LENGTH: 180 base pairs ~B) TYPE: nucleic acid (C) STR~Nn~nN~: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
tA) ORGANIS~: Helicob~cter pylori ~ (ix) FEATURE:
~ (A) NA~E/KEY: misc_feature tB) LOCATION 1...180 (xi) ~rQ~N~ DESCRIPTION: SEQ ID NO:96 4 ATGCCTATTA A~C~l~-l~l~A ~l~Cl"l"l"l~CCC AA'l'~'l"l"l"l"l'A CCGCTAGCAG TA~ A 60 GGCATGATGA GTA~ A CG~llCCAGT TACCAATTTG TCATGGCGTG TTGGTTAGTG 120 G~CGAGTC TTATTTTAGA TGGGCTTGAT GGGCGTGTCG CAAGGCTTAC CAAACACCAC 180 (2) INFORMATION FOR SEQ ID NO:97:
(i) ~yu~u~ CHARACTERISTICS:
SU~ LII~SHE~(RULE~-6) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 (A) LENGTH 699 base pairs (B) TYPE nucleic acid (C) STR ANnFnN~.~.~: double ID~ TOPOLOGY circular ~ii) MOLECULE TYPE DNA (genomic) ~iii) HYPOTHETICAL NO
(iV~ ANTI-SENSE: NO
(Vi) ORIGINAL SOURCE
IA) ORGANISM Helicobacter pylori ~iX) FEATURE
(A) NAME/KEY: misc_feature (3) LOCATION 1... 699 (Xi) SEQUENCE DESCRIPTION SEQ ID NO:97 A'1~L'1"1"1'LAG CCTTGCTTTC TAAAATGGGG ACTTACGCCT TATTACGCTT CTTGCTCCCG 60 L1~ CCTG AACTTTCAGA AATTTATTTA ACCCCCATAG CCATTGTGGC GCTGTGCATG 120 ATCATTTATG GAG~'1"1"1"1'~'1' AGCCTACGCT CAAAA~AGATT TAAAAACCCT CA'1'LG~'1"1'AT 180 A~l~lll~l CGCACATGGG A~1~C~ ~ CTTGGGGTTT '1"1"1'~'1"1"1'~'AA TGTTGAAGGG 240 GTTTCAGGGG CG~'1'~'1"1"1'AT GATGTTTGCG CA'1'GGCL'1"1'A TCGTCATGGG ATTATTTTTA 300 ~1LGL1~ A '1'L"1~1'~AAGA ACGCGCCAGC AGTTTAGAAA TCGCTCGCTT TGGATCGATC 360 GCTAAAAGCG CTC~~ TGCAGCCTTT TTTATGATCG TTTTAATGGC GAATGTGGGC 420 A~1~CL~1"1"1~AA GCA~ TGTGGGAGAG TTTTTGARCT TGTTAGGGTT TTTTGCCACT 4 80 TA-'CL'1'~'1"1"1' TGGCTATCAT TGCCGGGACA AGCCTCATTC TATCAGCGGT TTACATRCTC 540 AATTTTAGGG ATTTATYCYA AA~CG~ AAAA~C~AT 699 (2) INFORMATION FOR SEQ ID NO g 8 (i) ~UU~NL~ CHARACTERI STICS:
(A) LENGTH: 9 6 base pairs (B) TYPE nucleic acid (C) STRAN~ S double (D) TOPOLOGY circular ~ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~O1~ 11CAL NO
(iV) ANTI-SENSE: NO
(Vi~ ORIGINAL SOURCE
(A) OR~ANT.~M Helicobacter pylori (iX) FEATURE
(A) NAMEt~ Y: misc_feature (B) LOCATION 1...9 6 (Xi) ~UU~N~ DESCRIPTION SEQ ID NO 98 GTGGAATTGA TTAGCAATAA CCCTAACGCC AGCCAACAAT CTATCGTTAT '1'~'1"1"1'~GAG 60 AL'1"11"1'L-CL'1' TGGCGCGAGC GTTAAAGGGA ATCTTT9 6 (2) INFORMATION FOR SEQ ID NO 99 (i) ~k~U~: CHARACTERISTICS
(A) LENGTH 513 base pairs SUBSlllultS~EEr (RUIE~G) CA 0222339~ l997-l2-03 W O ~ D9,3 PCT~US96/09122 ~B) TYPE: nucleic acid (C) sTR~Nn~nN~5c double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ~iii) HYPOTHETICAL: NO
_ (iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~ANTCM: Helicobacter pylori (iX) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...513 (Xi) SFQUENCE DESCRlPTION: SEQ ID NO:99 ATGAAAATTT TTGGGACTGA ~l~GGC~l~AGG GGTAAAGCAG GGGTGAAACT CACCCCCATG 60 ~ lL-ATGC GTTTAGGCAT TGCTGCCGGA TTGTATTTTA AAAAACATTC TCAAACGAAT 120 AALO~ ~ AAGACAATGG CATCAAGTTT TTCAATTCCT ATGGTTATAA ACTCAAAGAA 360 ~AA~A~A GAGCGATTGA AGAAATCTTT CATGATGAAG AATTACTGCA TTCTAGCTAT 420 AAA~l~GGGCG AGAGCGTCGG TAGCGCTAAA AGGATAGACG ATGTGATAGG GCCGCTATAT 480 (2) INFORMATION FOR SEQ ID NO:100:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 99 base pairs (B) TYPE: nucleic acid (C) STRANn~N~SS double (D) TOPOLOGY: circular (ii) ~OLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NA~E~KEY: misc_feature (B) LOCATION 1...99 (Xi ) ~k~NL~: DESCRIPTION: SEQ ID NO:100 GTGCGAGCCG 'l'L-'l"l"~'l'L'l"l' ~ ~AAA GCGGCGTTTT GTATAGGGAT ~ L~l~AT 60 ~CGL~ ATT ATTTCCTAGA TGA~~ A ATCAAGCTC 99 -(2) INFOR~ATION FOR SEQ ID NO:101:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 210 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular SUBS~ SHEEr (RUIE26) CA 0222339~ 1997-12-03 WO 96/40893 , PCT~US96/09122 (ii) MOLECULE TYPE: DNA (genomic) (iii) ~YPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vit ORIGINAL SOURCE:
(A) ~Rr-ANT.CM: Helicobacter pylori (ix) FEATURE:
~A) NAME/KEY: misc_feature (B) LOCATION 1...210 (xi) ~:yU~ DESCRIPTION: SEQ ID NO:101 GGTATTGGGG GGTCAGATTT AGGCGCTTTA A~ ~l~CA CCGCCCTAAA ACGCTACGGC 120 CACCCAAGAT TARRAATGCA ~ AATGTGGAAT GGCACGCAGA TTTTAGACGT 180 TTTGr-AA~AA ATrAACCCGG CCAGCGCGCT 210 l2) INFORMATION FOR SEQ ID NO:102:
yu~ t~ CHA-R~AcTERIsTIcs:
(A) LENGTH: 390 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) tiii) HYP~ CAL: NO
(iv) ANTI-SENSE: NO
(vit oRTrTN~T. SOURCE:
(A) o~r~NT.cM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...390 (xi) ~yU~-NL~ DESCRIPTION: SEQ ID NO:102 ATGAATCTTG '1~ ~ GGCCGCTCTA GGAGGGGCTA TAGGGAGCTC GTTAAGGTAT 60 TTTGTGGGCA AAATGATGCC CAGTAAATTT TTAATGTTTG AAA~l~llCC'C' TTTAGGGACT 120 TTTAGCGTGA ATCTCATAGG ~ ATC ATCGGCTTTA TGGGGCATTT GGCCGCTAAA 180 AAA~l'~ l~ GTGATGATTT TGGGATTTTC TTTGTAACCG GAGTTTTAGG ~G~ ACG 240 AC~"1"1"1"1'L'1"1' CTTATGGGTT AGACACTTTA AAACTCTTGC AAAAATCCCA ATACCTTGAA 300 GCCATTTCTT A~ AGG CACTAACCTT TTAGGGCTTA TTGGGGTAGC TATCGGTTGG 360 ~GLl~A AGAATTTTGT AG~C~l~l~AAT 390 (2) INFORMATION FOR SEQ ID NO:103:
(i) ~yU~N~: CHARACTERISTICS:
(A) LENGTH: 237 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double ~D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomict (iii) ~Y~l~"l'lCAL: NO

SUBSIIlultSHEEl (RUIE~6) CA 02223395 l997-l2-03 W O 96/40893 ~ PCTAUS96/09122 ~iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~A~TsM: Helicobacter pylori ~ix) FEATURE:
(A) NAMEJKEY: misc_feature (;3) LOCATION 1...237 (xi) ~:yukN~: DESCRIPTION: SEQ ID NO:103 A~ ~GAAA AACTGATTGA AAGAGTGTTG TTTGCCACTC ~ll~GCT AGCCCCTTTA 60 TGCATTGCCA 'l~Tc~T~l~AGT ~ G~l~GGTT TTAGGCTATG TGTTCATGAA AGA~ ~G 120 TTAGTGGATT TGTTGGTTCA TGGCCGGGCT 'l'~'l"l"l"l'~ATG GTGCTGCTCG CCAGTTA 237 (2) INFORMATION FOR SEQ ID NO:104:
( i ) ~ h ~U ~ CHARACTERISTICS:
(A) LENGTH: 306 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPO~ CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_featuxe (B) LOCATION 1...306 (Xi~ U~'N~: DESCRIPTION: SEQ ID NO:104 ATGCACTATC AATT~r~A~- TTTCAATATA ATACAAGATC TTTTTATAAC TTGTCATGTG 60 TTAAGGATCA A~ATGCGCGT ~'l"l"l'~'l"l"l'~C TTTTTAGGGG ~ ATC TAAC~G~~ ~ 120 G~ C~l~ ~ GCTATGTGGT TTTAATCCCC CTACTCATTT TATCAGGGAG TTTAACCCCA 180 CACCAAAGCT TCCAACTGGG TATTGCGGTG CTAATGGGCT A~ ll~ GAG~ A 240 ATCCAATTTT TAAGCCC~~ AATGTCATTA SAAAGCATCG CTAAAATCAG TTTTAAATTA 300 (2) INFORMATION FOR SEQ ID NO:105:
( i ) ~ ~:~U ~:N~ CHARACTERISTICS:
(A) LENGTH: 45 base pairs - (B) TYPE: nucleic acid (C) STRA~~ S: dou~le (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv~ ANTI-SENSE: NO
(vi~ ORIGINAL SOURCE:
(A) ORr-~NT-~M: Helico~acter pylori SUBSIllul~Sh~tl (RUIE2'6) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 (ix) FEATURE:
(A) NAME/gEY: misc_feature (B~ LOCATION 1...45 (xi) ~:~U~:NV~: DESCRIPTION: SEQ ID NO:105 (2) lN~v~MATION FOR SEQ ID NO:106:
( i ) ~:y U ~:N~ ~: CHARACTERISTICS:
(A) LENGTH: 3081 base pairs (B) TYPE: nucleic ~cid (C) STRAN~:~h~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii~ HYPOTHETICAL: NO
(iv~ A-NTI-SENSE: NO
(vi~ ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix~ FEATURE:
(A) NAMEtgEY: misc_feature (B) LOCATION 1...3081 -(Xi) ~:~U~N~: DESCRIPTION: SEQ ID NO:106 GAPrAAAAAr GCATGGGATT AGTGAATAAA ACGCTCATTG C~ AA CCATTTAACC 120 AArrAATGGG GCGATGAATT TTATAAGGCT TACCCTAACG CTAATGTGTT A~~ ~AT 180 AGCAAr-r.ArA CCACTGAAAA AGAAAGAGAA CTTTTATTCA ATCAAATCGC TAACAACAAT 240 ATArAArAAT TGAAAGAAGA AGAGCTAGTG AATGCTGAAA AAAACTTTGA AAGGCAAGAA 360 TTAGCTTATA AAAATAArCC TAr-Ar-A~ACT AAAAAACCCA ATGAAAGAGC CTTTAAAAAC 420 AAGTTGGATA AAA~lvC~l~C TAAATACGAT GCGATTTTAG AAAAACAAGG CTCTCATATT 480 CGCGCTAGAG Al~ AT TAAAACGCGC TACTTGCATC AAAArrATAA GAAAATCATG 660 TTAACCCCTG A'l~ AAA AGAP,AGAGGG TTAGAATTCT TTGATGATTG GGCTAAGACT 780 AA~l~CG~lll~ CTAAATTTAG CGATGTGCAA GGCTTAAGCA CCATGTATAG AG~lll~ GCG 900 GATATTGTCT CTAATGATGA TATTTTAAAG CATAACCCCC A~l~ l~lGCC TAAAGTGTAT 960 GGGr-ATAAAr CTATCAATGT G~lG~l~AAA AGAAGCGAAG AA~l~GvlCA ATTCATTGGA 1020 ~G~ AG AAAATGGAAA ATATAATGAA GGCTCTATCA TTGATAGGAT GCAAAAATGC 1080 GGrArArAAr ~l~lllvAT AGGGCTATCC ACACCCAAAA CCCATAGCCA AAAAGTCAGT 1320 TTAGAAGCGC TArATAACGC TCACGAAACT GAAAATAAAA ATCCCCTAGA TAAAGCTCAA 1380 GAACTTTTAG AAAG~l~l~ TAGTTATGAT GAAAAGGGCA ATCTTATCGC TCCTAGCAAG 1440 AA,ArAATTAG AGAACGAGCT CAAAGAGAAA GAAGCTAAAA GCGTCAATTT AGATGAAGAG 1500 ATAGCTAAAG Gv~ C~l~l~ TGATGTTTAT AGCGATGTTT TAAGGCATTT AGTCCAAATG 1560 GGTATCCCAC AAAATGAAAT CG~l~ CATC CATGACGCTA AAACCGAAGA GCAAAAGCAG 1620 GA~ A AA~AGCTCAA TCGTGGCGGA GTCAGGGTAT TATTGGGCAG TCCTGCTAAA 1680 A~l~GC'C~l~AG G QCTAATGT GCAAGAAAGA TTAGTCGCTA TGCATGAATT AGATTGCCCA 1740 TGGAGACCTG ATGAATTGTT GCAAATGGAA ~GGC~l~G~A TAAGGCAAGG CAATATTTTA 1800 rAcrAAAATG ATCCTGAAAA CTTTAGAATG AAAATCTATC GTTACGCCAC TGAAAAGACT 1860 AArGrGrArA AATTAGGCTT GAATGAATTA GAAGAcTTTA ATATGGGTAG CTCTAATGCG 1980 SUBS~ lt SHEEI (RUiE 26) ; ~ ;
CA 0222339~ l997-l2-03 W O 96/40893 PCTAUS96/09lZ2 GAAGAAAGCT TAAAAAACAA C~c~ AA,A TTGGATTATC TAAAACAGGA ATTGAAAGAT 2160 TTAGAAACGC TTr~AA~-ATC CGTAATAATC CCCACTCATA CAGAGATcAA GCTCTATGAT 2220 AAAGAAAACG CCTCTATGAG TGAAGAATTA ACGCACAAGA AACTCAAAGA ACAAAACAAG 23~0 TTGAACACCT l~l~l~l~l~AA TGAAGAAGAA GATTATAAGC TTTTAGAATA CAAGGGCTTT 2460 CCCAATATTG CCTATAGCCC TAGCAATATG GTTTATA~AA ACGATACTAT CAACATGTTT 2580 A~ ATA ATTTCTGCGC TGAGATCAAG TTTGATGGGT TTTTAAAAAG GTTGGATAAC 2640 AAAAATATCG CTAAATACAC AAGATTAGTG GAGCAAAAAC ~'l"l'~"l"l'ACCC ACGACTAGAA 2760 AAA~ A ATTATAAGCC l~C~~ C-AAC CCTAAATCTA AAG~AGTCTT AAAGAATTTG 2880 (2~ INFORMATION FOR SEQ ID NO:107:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 186 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_fea~ure (B) LOCATION 1...186 (xi) ~kQUk~k DESCRIPTION: SEQ ID NO:107 AATGAGTATT 'l"l"l'~'l"l"l"l"l"l' TTATATGGTG G~l~GGATGG CTTTAGCGAG ATGTATCGCC 180 (2) INFORMATION FOR SEQ ID NO:108:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 711 base pairs (B) TYPE: nucleic acid (C) sTR~Nn~nN~-~s double _ (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOl~ l~-AL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:

SUBSil~ult SHEEI (RULE 26) CA 0222339~ l997-l2-03 , 176 (A) ORGANISM: Helicobacter pylori tix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...711 (Xi) ~:yu 'N~' DESCRIPTION: SEQ ID NO:108 ATGAAAACAC TCGTGAAAAA TACCATATAT ~l~u~ ~C TA~ TTTGATGGCA 60 rAAr.ATATAA CAAGCGGul~ AAAGCAACTG GATAACACCT ACrAAr-ArAr rAArrA~rAA 120 GTGCTCAAAA ACCTAGATGA GA~ CA ACCACTAGCC CTAGCGCTAA TAATAAAATA 180 GGTCAAGAAG A~ AAA CATCAAAAAA GCGGCCATTG CTTTGAGAGG AGATTTAGCG 240 TTATTGAAAG CCAATTTTGA AGCGAATGAG TTA~ CA TCTCAGAAGA TGTGATTTTT 300 AAGACTTATA TGTCTAGCCC TGAACTTTTA TTAACCTATA TGAAAATCAA ~l~CCul~lAGAC 360 GGGAAGCTGA AAATCGAGCA AGAAAAACAA AATATAAGAG AGC~ AGA AA~ A 480 (2) INFORMATION FOR SEQ ID NO:109:
( i ) ~k~U ~'N~ ' CHARACTERISTICS:
(A) LENGTH: 249 base pairs (B) TYPE: nucleic acid (C) STRAN~:~N~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORr-A~T-~M: Helicobacter pylori (ix) FEATURE:
(A) NAMEtKEY: misc_feature (B) LOCATION 1...249 (Xi) ~-UU~'N~'~ DESCRIPTION: SEQ ID NO:109 GTGAGCGAAA AAr-A~Ar-GGC ~ l"l"l"l'A GCGAGCTTGT CTTGCGTGGA TTA~ ~l~ 60 ~'l'~'l"l"l'WAG AAGACACGCC CATAAAATTG ATTCAAGCCC TAAAGCCTGA TATTTTAGTC 120 AAGGGAGCGG ACTACCTCAA TAAAGAAGTC ATAGGGAGCG A~~ ~Gul~AA AGAAACCCGT 180 TTGATAGAAT TTrAArAArG TTATTCCACA AGCGCTATCA TAr-AAAP~AT TAAAAGGACA 240 (2) INFORMATION FOR SEQ ID NO:110:
:Qu N~: CHARACTERISTICS:
(A) LENGTH: 192 base pairs (B) TYPE: nucleic acid (C) STRAN~ l)N~:~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~O'l'~:'l'lCAL: NO
(iv) ANTI-SENSE: NO

SU~ Shttl (RllLE26) -CA 0222339~ l997-l2-03 WO 96~40893 PCTAUS96/09122 ~ ..
(Vi) ORIGINAL SOURCE
(A) ORGANISM: Helieobaeter pylori (iX) FEATURE
(A) NAME/KEY: mise_feature (B) LOCATION 1...192 (X~ QU~ DESCRIPTION SEQ ID NO 110 GTGTATGACA AAT~ G TAAGACCATG GCGCTAGCGT TGAAGGCTTT AGGCGTTAAA 60 GCGTGCGAAT TGAAAAATAA CGAAATTTTA GAGTATGATT TGAGCGCTAA AGA~ ~R~1~ 180 (2) INFORMATION FOR SEQ ID NO:111:
(i) ~QU~E CHARACTERISTICS
(A) LENGTH: 684 base pairs (B) TYPE: nueleic aeid (C) STRANDEDNESS: double (D) TOPOLOGY eircular (ii) MOLECULE TYPE DNA (genomie) (iii) ~Y~O1~ CAL NO
(iV) ANTI-SENSE NO
(Vi) ORIGINAL SOURCE:
(A) ORGANISM: Helieobaeter pylori (iX) FEATURE
(A) NAME/KEY: misc_feature (B) LOCATION 1... 684 (Xi) ~YU~N.~- DESCRIPTION SEQ ID NO 111 ATTTTAAACC AAAAGATTGG TATAGAGACT AAAAAAAGCG TGG~ AAGCGATGGC 240 GA~ AG ATCCTAAATT AACGCCTTTA AAAGCGATCG ~ ATAA GGA~ 300 AGAGAGTTCA AAGCCC~ ~ AAAAGGCATG AGGGAAAAAT TGCAGCTGAT TTTAACCCTA 420 TCACGAAACG ~ A ~ 1~AT GAGCCGGTGG CTGGGATTGA CCCTATTGCA 480 AGAGAAGAGA 111~11~AGTT AATCG_TAAG GAGTTTAGCC AAAACGCAAG C1~1~1AGTC 540 GCTAAAGTGG TGGCTTTTGG GGA1~1~GGG GAATTAAAAA AAGGGTATAG CA~lll~AG 660 ,.
(2) INFORMATION FOR SEQ ID NO:112:
(i) SEQUENCE CHARACTERISTICS
~ (A) LENGTH 819 base pairs _ (B) TYPE nueleic aeid (C) STRANDEDNESS: double (D) TOPOLOGY: cireular (ii) ~OLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO

SUB~ ul!~ S~EEr (WL~ 26) , CA 0222339~ 1997-12-03 WO 96/40893 PCTrUS96tO9122 (iv) ANTI-SENSE NO
(vi~ ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 819 (xi) SEQUENCE DESCRIPTION SEQ ID NO 112 ATGAACAAGC ~ AGC TTTTATTGTT GGGGGAATGC TTTTAAGTGC TGATGCTTTA 60 AACGATAAGA TTGAGAATTT AATGGGGGAG CGATCCTACC ACATGAACAA G~~ A 120 GAGC~l~ l TTAAAAATCG TAAGGATTTC TATGAAATGG GG~~ G~A l~lC~l~l'AAAA 180 CTACTCAACA CTCTCAAAGA AAACGGG~ TTA~lC~lll~A ATTTTGACAA ACCAAGCGTG 240 TCTTTGAATA TGA~l~GG~l'A TTCGTATGTT ~ ~C~l~ATTA GAATGCAAAG ~~ AGGC 360 GAGACGATGA AAAGGCATGG TTTTGATTTT ATGGATATTA GACGG~~ ~ TTTAAAGGAG 480 TGGGAATACG A~lll~C~ ACAAAAGATC AAGCTCCCTA ACGCGAGAGC CTTAGTTTTG 540 AACGCGTATT TAAAAATAAG CTCCAATAAC C~l~ ~GC AACCrAAAAT CA~ AT 660 CTTAACTTGC TTGATGGCGT GCGTTTTATC CATATCACTG ArGrAAAA~A CCCTATCATT 780 TTAAAAAATG GGATTAGCGT G~~ l~AT GCGATGCCT819 (2) INFORMATION FOR SEQ ID NO 113 (i) SkQUkN~I-: CHA-R~AcTERIsTIcs:
(A) LENGTH 45 base pairs (B) TYPE nucleic acid (C) STRA~~ ss double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
~A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 45 (xi) ~kQ~kN~ DESCRIPTIOW SEQ ID NO 113 GCC CGTTCAAAAC GATCAAAAAA CCCCrAC~Ar CCCCT 45 (2) INFORMATION FOR SEQ ID NO 114 (i) SkQ~kNCk CHARACTERISTICS
(A) LENGTH 201 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) ~Y~O~l~k~l~lCAL NO

S~ e~n~ IL~2~) CA 0222339~ l997-l2-03 WO gG/10~33 PcTtus96/o9l22 (iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 201 (Xi) ~'OU~N~ DESCRIPTION SEQ ID NO 114 ATGATCGCTG TATTACCGCC ~~l"l~'l"l"l"l~l' ATGGGGAGCT TTGATGAGTG GATTTATAGG 60 GG~L~ ~G CTTTAATGGT GAGCTGTCCT TGCGCGTTAG TGA~ GCCTTTAGGG 120 TATTTTGGAG GCGTGGGAGC GGCGAGCCGA A~GGGGATTT TAATGAAAGG AGTGCATGTT 180 (2) INFORMATION FOR SEQ ID NO 115 (i) ~kQU~c~ CHARACTERISTICS
(A) LENGTH 969 base pairs (B) TYPE nucleic acid (C) STRAN~'~N~SS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (iX) FEATURE
(A) NAME/REY misc_feature (B) LOCATION 1 969 (xi) s~yu~Nc~ DESCRIPTION SEQ ID NO 115 GTGCAACACT TCAATTTCCT CTATAAAGAT TCTTTATTTT CTA~l~cG~ ATTCACTTTC 60 GACGAGCTTT TAAAGCATGC TAA~ATTTCC AGTTTGATGT TTTTAGCTAG GGCGTATTCT 240 AAAGCGGATG TGGAAATGAG CATTGAAATC TTAAAAGGGC TTTTGAATCG CCCCTTAAA~A 300 GATGAAGAA,A AAA'l'CG~'l~'l' TTTAGATTTA TTGGCTAAAA ATTATTTTAG CGTGGGGTAT 360 TTGCAGAAAA CAAAA~A~AC CGTGAAAGAA A~ ~CG~l~ TTTCCCCAAG GAATGTGGAA 420 GC~ll~ll~A A~-l~ll"l~CA TGCGTATGAA TTAGAAAAAG ATTATTCAAA GGCTTTAGAA 480 ~C~'l'-'~'l"l'AG ATTTGAAAAA AATCGCTCTG AATCACTTAA AATCGCATGA TGAAAATCTT 660 TTTTGGCAAG AAATTGATAC AACCGAACGG CTA~-~AATG TGATCGATCT TTTATGGGAT 720 ATGAATATCC cl~cl~ AT TTTAGAAAAA CA'l~CCc~Ll~ TGCAGGACAT CGCGCGATCT 780 CAAGGGTTGC ~ l~ATCA CAAACCTTGC CAAATTTTTG AATTAGAGGT TTTACGCGCT 840 CTATTGCATA GCCCTATAAA AGCGAGTCTG A~~ l~AAT ACCGCTGCAA GCATTGCAAA 900 CAAATCTTTC CTTTTGAAAG CCATAGGTGT C~ACCAGTTAGC GTTTATGGAT 960 Al~lGG~l 969 (2) INFORMATION FOR SEQ ID NO 116 (i) s~QurN~ CHARACTERISTICS
(A) LENGTH 30 base pairs (B) TYPE nucleic acid (C) sTRANnFn~s double SU~I~ SHEr (RUlE26) CA 0222339~ l997-l2-03 , 180 (Dt TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
tA) NAME/KEY: misc_feature (B) LOCATION 1...30 (xi) ~U~:N-~ DESCRIPTION: SEQ ID NO:116 ATGr~ArArc TTACAAGGGG AATTAAGCAC 30 (2) INFORMATION FOR SEQ ID NO:117:
(i) ~:yu~:N~-~ CHARACTERISTICS:
(A) LENGTH: 153 base pairs (B) TYPE: nucleic acid (C) STRAN~N~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) H~O~ lCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...153 (xi) ~U~:Nc~: DESCRIPTION: SEQ ID NO:117 ~ ATCT TAGGCTCRCA TGGCAAGGAA GAGTATTACG CTAGCAAGAT TGCAGCCCCC 60 ATTrAAAACG CTTTGGAAAA AAACCGCTTA AAA lS3 (2) INFORMATION FOR SEQ ID NO:118:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 237 base pairs (B) TYPE: nucleic acid (C) STRAN~:~N~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori SUBSIIlul~ SHEE~ (RULE 26) CA 02223395 l997-l2-03 WO 96/408g3 , PcT~/us96/o9l22 f (ixt FEATURE: -(A) NAME/KEY: misc_feature (B) LOCATION 1...237 (xi) ~ U~NL~ DESCRIPTION: SEQ ID NO:118 AT~AAAAAr-G TTA'l"l'~'l'~GC TTTAGGCGTT TTGGCGTTCG CAAATGTTTT AATGGCAACC 60 GATGTTAAGG ~ L'l'AAA AG~l"l'~l~GCC GCTTGCCATG GGGTTAAGTT TrAAAArAAA- 120 GCTTTAGGTA AAAGCAAAAT CGTTAACATG ATGAGCGAAA AAGAGAl'TGA AGAGGATCTT 180 ATGGCTTTTA AAAGCGGTGC CAACAAGAAT CCTGTCATGA CCCGCAAGCT AAA~AAT 237 (2) INFORMATION FOR SEQ ID NO:ll9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 285 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAMEJKEY: misc_feature (B) LOCATION 1...285 (xi) ~:~U~NL~' DESCRIPTION: SEQ ID NO:ll9 ATGGGGATTG rAACrAr.TCT CATCAGTGAG ~ll"rLrAAGT TTTATTACGC TTT ~AATAC 60 CATGCGAAAT TTATGAGCTT GGGGGAGCTT GL~l~LLlATG CGAGCCATTA 'l"l'C~l"l~l'~ 120 CAAAAATGCA TAGAGCTCAA TGAAGCGATC TGTATTTTAG AArAcrATA~ AACCTTGAAA 180 GAGGATTTTA AAr~rGGcTT GGAll~ A GAAAAACACA TCCAAGAGTT AGGCTATGCG 240 CL~ LATGC ATTTATTGTA TGATGCCAGC GTGAAAAGTG AGCCT 285 (2) INFORMATION FOR SEQ ID NO:120:
(i) ~:Q~bNL~ CHARACTERISTICS:
(A) LENGTH: 462 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular ~ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
-- (vi) ORIGINAL SOURCE:
_ (A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...462 (xi) x~u NL~ DESCRIPTION: SEO ID NO:120 SUBSl~lUl~ SHEEr (RUIE26) CA 0222339~ l997-l2-03 W O 96/40893 , PCT,rUS96/09122 , 182 ATGCACCTTA AAAGTGGGGC ~ ATC TCTGATGCGC A~ ll"ll~cc CAAAAGCCCT 60 CATTTAATCC ATACGCTTAA AGAACTTTTA AGCGCCAAAC CCCCGCAAGT ~ll~l"ll~ATG 120 GGCGATATTT TCCATGTTCT TGTGGGCTAT ~TACCCCTAG ATAAAGAGCA GCAAAAAATC 180 GATTTTTCCA ~l~C~ ATTCAATTCC AAAGTAATGG 'l"lnl"l"l'~AGCG CCAAAACCAA 30~
CCCGCATTAT TCCAGTATGA TAACAAACGC ~ AG CCCATGGGGA TTTATTCATC 360 ACTAAAGCGT ATGAATTTTA CATCACGCAG CTCACTTCCA CTTGGGCTAG A~ A 420 A~ AA ATTTATTAAG TTTT,AAAACC TTATACCCTT TT 462 (2) INFORMATION FOR SEQ ID NO:121:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 939 base pairs (B) TYPE: nucleic acid (C) sTRANn~nN~: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1 939 (xi) ~yu~N~ DESCRIPTION: SEQ ID NO:121 GTGrAArCr.~ TGAAATCTAA AAAACTTTAT TTAGCTTTAA TCATAGGGGT TTTATTAGCG 60 TTTTTAACCC TATCTTCATG GCTAGGTAAT AG~G~l~llAG TG~GGC~ ~l~l~G 120 TTTGCCGCAA TCAATAAAAA ATATTTTGGG TA~ AT TGATTAATTT ACCCTATTTG 180 GC~l~G~ TA~ C~l~ ATACAGGGCT AAAAACCCTT TTACAGAAAT C~ AGAA 240 AAAACTTTAG GGCATCTATT AGGCATTTTA TCTTTACTCT TTTTGCAATC TAGC~l~ l~ 300 AATCAAGGGG AAATCGGCAA CAGCGCGCGT ~ AC ACC'~ AT AGGGGACTTT 360 CCCCCTAAAA GC'~~ A CCCTTATATG AACAAAACAC AAAGCCTTTT AAAAGAGATT 480 TACAAACAAT G~ ~AGGC CTTTAGCCCT AATTTTAGCC T~AAAAA~-A GG~~ l~AA 540 AACACCCCAT CAGATTCTCA AAAAAAAGAA A~A~A~CG ACAAAGAAAA AGAAAACCTC 600 ACTAACCCCA CTTTAAAAGA ACCTAAGCAA GAAACCAAAG AAA~A~.~ACC CACGCTAAAA 840 AT~ArAAAA~ RGAAAACCAC AAAACCCCTA ACCACCCCA 939 (2) INFORMATION FOR SEQ ID NO:122:
(i) ~kVU~N~' CHARACTERISTICS:
(A) LENGTH: 957 base pairs (B) TYPE: nucleic acid (C) STRANU~N~'SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

SUE~ k ~HEEr (RULE ~6) CA 0222339~ l997-l2-03 WO 96/~D~93 PCTAUS96/09122 i (vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori --(ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 957 (xi) ~k~UkNc~ DESCRIPTION SEQ ID NO 122 GTGATGTTAA GTAGAGACAT TGTCCAATAT TCCAAGATCC Gr~rCr-Ar-TT ATACGCCTAC 60 CTCACTTATT 'l'~l"l"l"l'-G~'A CAATATCCGC AACCACCTTC CTGAAATCAC TTTGGATTAT 120 TTAAACAGGC AAATCAGTAA GATGCAAGCT GAAATCAAAA TGGCA~A~AAG 'l"l"l"l"ll"l'~'l"l' 180 TTAGACGCTA AGGGCATGCT CATGCTTAAG CCAAGCCAAT TTA~AGAGCA GGGGCATAAG 240 TAl~ A AAAAAGGGAA CCA~l"l~'l'A GTGAGCGCGT CTTACCCGGT GTATGATCAA 420 AATAACGATC TAGC~lll~l~ GGTGTGCTTG CAAATCCCTT TGAGGGTGGC GATTGAAATC 480 AG~l--GC~ CAAAGTATTT TAAAACTTTT AGCGAAGGGA GCATGGTCAT GTATTTTATG 540 TGGACAGCGA T~ ATTT TAGCAGTTTT GACATTAAAG AA~ A CCCCATTGTG 660 ~ll~G~lAAAA ATAGCGGGGA cAAcrArrAT GCGATCCACC GCACCATGAT CAG~ A 780 GG~ ATCA TTATCGCATT AGCCATTGAA GCGTTAATGC ~ AA ATTCAGCGTG 840 AGCGAGCCGG ATAAAATCAC TTA~l~CG~l~G TATTTGGCTA TCGGCGTGGC G~lG~ll~ l~ 900 (2) INFORMATION FOR SEQ ID NO 123 (i) ~kOu~N~k CHARACTERISTICS
(A) LENGTH 354 base pairs (B) TYPE nucleic acid (C) STRA-N~ Nrcs double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(i~) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_~eature (B) LOCATION 1 354 (xi) ~UkN-~k DESCRIPTION SEQ ID NO 123 ATGGTTATAC ATGA,AAAAAT CAAAAGCCGC 'll"ll'~"l'AGGA A~ cll~l~ AAGGAATAGG 60 GGCAGGCATT TTGCATCTTC AAGCGTGTAT 'l"l"ll"l'~'l'CAC ~ cl~ ~AT TACAGCGGTT 120 AATAGAAGTA GTGCAGTTGC ~ W l~ ATTG ATGCCTGAAC ATTTGATTGG ~'l'~'l"l''l"l"l'~ 180 A~ A GTGGGGAATT TGTAGCAGAC A~l~GC~ l~ GCAAAAAAAG TAAGATTTTT 240 AAAACCCGCT TTGGAATTTC TATTGTGAGC GGC~ ~AC TA~ ~G CGCTTACCAG 300 CG~ ATT ~ ATGG ~ ~G~ll~ A TTAATTGGTG GG~-l~l~ l TTTA 354 -(2) INFORMATION FOR SEQ ID NO 124 (i) ~yukN~k CHARACTERISTICS
(A) LENGTH 276 base pairs (B) TYPE nucleic acid (C) STRAN~k~NkSS double (D) TOPOLOGY circular Sl~ SHEEF(~26) CA 0222339~ l997-l2-03 WO ~C/~8~3 , PCT~US96/09122 .L
(ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~O~ CAL: NO
(iv~ ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
~A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...276 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124 ~ l~GG ATGTCATAAA ATACAAAATA GAAGATTTGC AACATGATCA TTATCTATCA 120 CAAGTGAAAG AAAGGGAAGA ATATTATAAA AACrAr~TA~- AAGAAGCTTT GAAAAAGGAT 180 Gu~ ~AAA ~AAATA~-AA~ AATGTTAGAG ATTAAA 276 (2) INFORMATION FOR SEQ ID NO:125:
( i ) ~ ~:U U ~:N~ CHARACTERISTICS:
(A) LENGTH: 414 base pairs (B) TYPE: nucleic acid (C) STRA~ JNI~ ,S: double (D) TOPOLOGY: circular (ii~ MOLECULE TYPE: DNA (genomic) ~iii) ~Y~u~ lCAL: NO
(iv~ ANTI-SENSE: h-O
(vit ORIGINAL SOURCE:
(A) OR~-ANT~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...414 (xi) ~kyu~:Nu~ DESCRIPTION: SEQ ID NO:125 ATGGTATTTT GGGGCGu~ A TGGGATCGAA CGGCATGGAA GCGCTTAATG 60 ~A ACAGCTTGAW TTYCATGCTT GCGGCCTTGA GTTTGGGGTC ~ AGGG 120 GCATGGATCA AAAATGAAGC CCACACCACT CAAATCGTTT TGA~ ~ TTTGCCCTTG 180 ATTTTTATGA l~G~l~ GTGGCCTTTT GAAlCul~ ~C CCTCTTATTT GCAAGTCTTC 240 GTT~AAATAr~ ~c~ A TCATGGGATC A~ uG GGCGATTGAA TCAAATGCAT 300 GCGGAATTTA TAGATGTTTC TATCCATTTT TACGCGulu~A TTGCGATTTT TATCGTGAGT 360 TT~TA~GT GC~ CAA ACTCAGCTCT TTAAAGAAAG CTTGTGAAAA CGCT 414 ~2) INFORMATION FOR SEQ ID NO:126:

(i) ~:yU N~ CHARACTERISTICS:
(A) LENGTH: 762 base pairs (B) TYPE: nucleic acid (C) STRAN~N~:~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) Ul~nk~ (RlJlE2-6) CA 0222339~ l997-l2-03 W O96l40893 PCTAJS96/09122 (iii) ~YPOl~llCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~ANT.CM: Helicobacter pylori (i~) FEATURE:
(A) NAMEJKEY: misc_feature (B~ LOCATION 1...762 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126 ATGCATGAGC AAG~ll-lAT AAG~lllKlA GGCGKACAGG GAGCTAAAAG ATTATTATAC 60 A~-ArAATTCT TTGATTATTT G~-A'rA~-AAAA AGGC~l'l'ATG GCTTTGATTT TACGCTTAAA 360 AAGAGT'm T TAAAAACACT CTTAGACTAT AAGCCAGCTA CAAGCTTTGA AAAACGCAAT 480 AGAAAAGAGA GAAAAGCTTA TATTAAAAAG A~lllrllAG AACCAAGCTT GAATGCTTGG 660 ATTAGTGATG ATTACAGACT AAAATATTTC AATGGAGCAT A~ AA AAAGGATAAG 720 ~AAAAA'rQC AAAATTCTTT AACGCTTTAT AATTTATCCC CT 762 (2) INFORMATION FOR SEQ ID NO:127:
( i ) ~h~ U ~:N~: CHARACTERISTICS:
(A) LENGTH: 555 base pairs (B) TYPE: nucleic acid (C) STRAN~ N~:cS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~ANT.'~: Helicob~cter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...555 (Xi) ~ U~N~: DESCRIPTION: SEQ ID NO:127 C:~'1W'1'~'1-11'A AAATTTTAAG TTTATGGTTA GGG~l~ lll GTTTCCTTAG GGCTACGCAT 60 TTATACTTAG GC~AA~A~CC CAAArrArrAAA GACAATTTCA CGCATTTTGA ATACGCTAAC 120 CCTAACGCTA ~AAAA~GCGG l~llll~AGA AATGACGCTA 'rA~-Gr-~TTT TGATAGCCTT 180 AACC~ , CGCTTAAAGG CACTAAAGCC GAAGGCTTGG ATCTCATTTA TGACACTTTA 240 Al~ ,~AAA GCT'rA~Ar~-~ AC~llllC:,CA GAATACCCCT TAATCGCTAA AGACGCCGAA 300 ~,l~lAAGG A'rAA~A~CTA TGTGATTTTT ACCCTAGATA AAAGAGCGAG ATTCAGCAAT 360 AACG~-l~C~A TTTTAGCGAG CGATGTGAAG TTTAGCTTTG ATACGATAAT GAAATTAGGA 420 ~l~C~C'C~lll ATAGGCAGTA TTACCAAGAT GTTAAAAAGG CGGTTATCTT AGACAAGCAC 480 CATGT~AAT TCATTTYCAA AACCACTGAA AATAAAGAAT TGCCCCTCAT TTTAGGGCAG 540 TT~QGATCT TTTCC 555 ~, (2~ INFORMATION FOR SEQ ID NO:128:

SUBSIIlult SHEEr (RUIE26) CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 , 186 (i) ~N~ CHARACTERISTICS
(A) LENGTH 198 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double ~D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPu~ CAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 198 (xi) ~yU~N~ DESCRIPTION SEQ ID NO 128 TATGCCACTA GAGGCG~ TAAAAACGCC GTTTTATTTG AAAAAGGAAT GCCTGGGGGG 120 (2) INFO~M~ATION FOR SEQ ID NO 129 (i) ~U~'N~ CHARACTERISTICS
(A) LENGTH 546 base pairs (B) TYPE nucleic acid (C) STR~N~ N~S double ~D) TOPOLOGY circular ~ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
~A) OR~-~NTCM Helicobacter pylori (ix) FEATURE
~A) NAME/KEY misc_feature (B) LOCATION 1 546 (xi) ~kyu~ DESCRIPTION SEQ ID NO 129 ~l~r~;AA~A GCTTGAGATA CAGCTTGAAT TTAGATCTCA ATCAAAAAGC CGA~ 60 A~AGGCGATT TTGATTCAGG GCTAAAATCC TATGACATGA GCTACATGTA TGCGAGCCTT 180 CATGGCATAG GCATTGAAGG GTGGTGGCAA CAAAACGGGA A'l"l~ ~ GGCGATGGAA 360 TTGGA~AAAA GAGCGTTATT CATTGTGCTC ATGCTCATTA TTTTAATGGC ~ ll~AAT 420 ATCATCAGCT CG~ AAT GGTGGTGATG AACAGGCGTA AAGAAATCGC CCTACTCTTT ~80 (23 INFORMATION FOR SEQ ID NO 130 (i) ~uu N~ CHARACTERISTICS

SllBSlllultSHEEF (RULE26) CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 (A) LENGTH: 741 base pairs (B) TYPE: nucleic acid ~C) sTRA~n~nM~cs double .~ (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NA~E/KEY: misc_feature (B) LOCATION 1...741 (xi) ~r~UkNL~: DESCRIPTION: SEQ ID NO:130 ATGAAAAAAA ~'L'l~ ~AT CGCTTTAGCG CTTACGGCTT CTCTTATAGG CGCTGAAAAC 60 TTTTTCACCC ACCATACTTT AAAGGLl~ CG TTTGAGCCGA CTAACCACAT CAATTATAGA 300 GGGCATGACT A~lL~lLl~lL;LA TAATGTGCAT TTCCACGCCC CTATGGAGTT TTTAATCAAT 360 A~TA~A~CCA GGCCTTTGAG CGCGCATTTC GTGCATAAAG ACGCTAAAGG LCL~ l~ 420 GTGTTAGCGA ~ LL~ L-A AGAAGGGAAA GAAAACCCCA ACCTTGATCC TATTTTAGAA 480 GGCATTCAAA AGAAACAAAA TCTTAAAGAG GTGGCTTTAG ACGL~ L~ GCCTAAAAGC 540 ATCAATTACT ACCATTTTAA cGGLrLlL~lc ACCGCTCCTC CTTGCACAGA GGGGLrGGCA 600 ~l~L-L~l"l"l~L~l~LA TAGAAGAACC TTTGGAAGTT TCTGCCAAAC AATTGGCTGA AATCAAAAAA 660 AAAAGCTCGG cTr-ar-~rccr~ C 741 (Z) lN~ATION FOR SEQ ID NO:131:
(i) ~:yuk~L~ CHARACTERISTICS:
(A) LENGT~: 1266 base pairs (B) TYPE: nucleic acid (C~ STRAN~N~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) XYPOTHETICAL: NO
(iv) ANTI-SFNSE: NO
(vi) ORIGINAL SOURCE:
(A~ ORr~NT~M: Helicobacter pylori (ix) FEATURE:
(A) NAMEJREY: misc_feature ~ (B) LOCATION 1... 1266 ; (xi) ~:yU~L~: DESCRIPTION: SEQ ID NO:131 ATGAAAATTT CTTTATTGGG GCATGGAAAA ACCACTCTAG CCCTAGGGCG '~ AAA 60 AAAAACCATA ATGAAGTCAA A~ "l"l"l"l'LAT GATAAATTCC CTGCATTTTT TAAGGATAGC 120 GAGL-Ll~ lL 'l"l"l'LL'l'ACCC TAGTAAGGAT TTTAACCCTA ATGATTCCCA ACTAGAAATC 180 GAAT~rr-~TT ATATTGATAG ~l~l~l'~'ll~l'~AT CAs~l~L~ lLA CGCCTACGAT GATAAGTATT 300 AAGGCTGTGA ~l~G~G~AA TATCGGCACG CCCTTGATTG AA'l"l'~Tl"l~GA AAAACGATCG 420 SU~ll~ultSHEEl ~JIE26) CA 0222339~ l997-l2-03 W O 91/~993 PCTAUs96/09122 CC~ ~l~G TGCTAGAAAC AAGul~ TCTTTGCATT ACACTAATAA GGCTTACCCT 480 AATTATTTGA ACGCTAAACT CAAG~~ A ACATTGATGC CTAAAACTTC GCTCGCTATC 600 ~l~C~ll~ AA AATTCAAAGA ACACCCTATT GTTCAAAACT CGCAAGCGCA AAAAATCTTT 660 TTTGACAAAA GCGAAGAGGT TTTAGAGTGT TTAAAAATCC CTTCTAACGC CC~ 720 AAGGGAGCGT TTTTATTAGA CGCGGu~ A GCCCTTTTAG TTTATGAGCA ATTTTTAAAA 780 AAAATCGGCT CGrATAAAAT G~-AA~-AATTT AGGGATAAAC AA~GGC~rlr ~l'~l~AGAT 900 GACAGCAAAG CCA~r-AATAT TGATGCCACC TTACAAGCCC TAAAAACCTT TAAAAACCAA 960 AAAATCCATT TGATTTTAGG GGGCGATATT AAAGGGGTCA ATTTAACCCC C~ r~l~AA 1020 GAGTTTAAAA ACTATAAAAT AAGCCTTTAT GcrATArr,AT CAAGCGCTTC TATCATACAA 1080 GCCTTAGCGT TAGAATTTAA 'l'~l"l"l'~'L'l'~'l' CAG~l~ TGAAGTTAGA AAAAGCGGTT 1140 CAAGAAATTA AAAGCGTTTT ATTACAAAAT GAA~~ TGCTTTCACC TAGCGCGGCC 1200 A~ GGATC AA~ u~ C GTATAAAGAA AGGGGTGAAA AATTCAAAGC ~l"ll~l"l"l-l~A 1260 A~AGAT 1266 t2) INFORMATION FOR SEQ ID NO:132:
(i) ~UU~'N~k' CHARACTERISTICS:
(A~ LENGTH: 162 base pairs (B) TYPE: nucleic acid (C) sTRANn~nN~-cs double (D) TOPOLOGY: circular (ii~ MOLECULE TYPE: DNA (genomic) (iii) HYPO~ lCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ~R~ANT.cM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...162 (Xi) ~'~:UU~NU~' DESCRIPTION: SEQ ID NO:132 ATGAAAGAAA TCA~l~l~l~GC C~~ ~GGC CAGCCTAATG TGGGGAAATC ~l~uul~l~AATC 60 AACG~ll~l~A GTAACSCCCA TTTRAAAGTG GGGAATTTTA CCGRGGTTAC CGTGGATAAA 120 (2) INFO~MATION FOR SEQ ID NO:133:
(i) ~:QU~N~' CHARACTERIS~ICS:
(A) LENGTH: 333 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular ~ii) MOLECULE TYPE: DNA ~genomic) (iii) HYPOl~l~lCAL: NO
(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) OR~ANT~M: Helicobacter pylori t (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...333 SUB~59~ S~EEl (~g~~26) CA 0222339~ l997-l2-03 ,. .
(xi) ~:~u~ DESCRIPTION: SEQ ID NO:133 GTGCATCGTT TTTCTAGAAA CCCATGCGCA TCTTGCAATC GCGCTCGCTC '~ CGAGA 60 CTA~ uGLl~ CATTAGTGAG LGCG~LAACT ~l~l'G~l"l'~A GL~ T~l~C~L~l~L;~ 120 A~~ AT ~lLl~ AGT CAGL~l~lG ATTTTATGGG TTAGCTCGGT L~l"l"l"l~l~Ll~l~ 180 TTTAGCCTTT L'l"l"l"l"l'~"l'L'l' TGTCAATTCT L"l"ll"l"l"l'L'l"l' CAGTCAGCCG A~l~L~lu~l~GGL~l~ 240 GCTAATAAGC ~'l~'l'L'l"l"l"l'C TTTAGCTAAA A~ u~ ll CCGTTTTCAG ~ ~U~l"l"l"l~ 300 TCTTTAGTGA Gu~ L~ ATT GTTTTGCCAT AAT 333 (2) INFORMATION FOR SEQ ID NO:134:
U~N~: CHARACTERISTICS:
(A) LENGTH: 411 base pairs ~B) TYPE: nucleic acid (C) sTRANn~nN~ss double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv~ ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A~ OR~-ANTCM: Helicobacter pylori (ix~ FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...411 (xi) ~kUUr'N~' DESCRIPTION: SEQ ID NO:134 ATGCAAAAAA ~l~GGCLll~l CTCTTATTCC L~ CAAG CGTTTGAAAA GGCTTTGAGT 60 CGGTTTAAAG AGGGCL~ TTTGATTGTG GA~ L~ AA GGCGTTl'GAT TATGGGGAGC 120 GCTTCAGTTA AAGAATTGAG lL~GL'~l~AATA GGCATTGTGG GGGCGTTAAG CCATGCCAAT 180 AGCGTGAGCA ~l~"l"l"l-l~l"l~ GTTTGGGGCG TTTTTATCTA TCAATCl'AGG GATTTTAAAT 240 TTATTACCCA TTCCAGCCTT AGA~lLLGGCG CAAATGCTAG GGL;l~LLl~ TAAAAATATT 300 ~l"l~l"l"l"l"l~G TCA~ l AGGGCTTTTT AATGACATTA L~lC'L-ll~l~CT A 411 (2) INFORMATION FOR SEQ ID NO:135:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 372 base pairs (B) TYPE: nucleic acid (C) sTRANn~nN~.ss: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) OR~ANI.~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...372 (xi) ~yukN~-~ DESCRIPTION: SEQ ID NO:135 ~ ~EE~ 26) CA 0222339~ l997-l2-03 GTGATGGCTT TGTTGAAAAT TA~ lA ~illC~-l~AGG GGGAAGTTTA TACAGGAGAG 60 GTTAAAAGCG ~ GCC AGGAGTGGAA GGGGAATTTG GG~ '1"1'1'A TGGGCATAGC 120 AAAAAGCTTT TAGAGGACGC AAG~ AC AGGTTAGCGG TCTCTAGCGT G~l~c~G~ AAG 360 (2~ INFORMATION FOR SEQ ID NO:136:
(i) ~QIJ~ CHARACTERISTICS:
~A) LENGTH: 258 base pairs (B) TYPE: nucleic acid (C) STRANv~ N~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORt~NTCM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...258 (xi) ~yu'-:N---~:DESCRIPTION: SEQ ID NO:136 ATGTATTCCT ~ AGA TTTGAATAAA AA~ rCGCTC TTTTAGGCAC AAGAGGGTTT 60 TTTATCGACG ACAAACACAT CAAAGAAAAG GG~ iACCA CGCCCACTCT TTTAGAGCTT 120 TATAGCGATT TGt'~ A~'-C GA~ A AAATGCGAAT ACTTCATTAT GGAGGTGAGC 180 TCCCATGCGA TTGTCCAAAA CGCATCGCTG GG~iATTT CGCTCTTAAA ATTCTCACCA 240 (2) INFORMATION FOR SEQ ID NO:137:
(i) ~:yU~:N~:~. CHARACTERISTICS:
(A) LENGTH: 324 base pairs (B) TYPE: nucleic acid (C) STRANnFnN~C:S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~Ol~r:llCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...324 (xi) ~:yU~:N~:~ DESCRIPTION: SEQ ID NO:137 ATGAAAACGA ACTTTTATAA AATTAAATTA CTA~ G~ AT CATTGGCATG 60 TTTAACGCTC CGCTTAACGC T~ CrAAA;~(- ACGGATATAA AAGATATTAG TCCTGAAGAT 120 SUg~ ultSHEEr (RULE~6) CA 0222339~ l997-l2-03 W O 96/40893 , PCT~US96/09122 i.
A~l~GCG~l~AA ATAGCGTGGG G~ll~lll-l AGAGATCAGC TAAAAATAGA GATCCCTAAA 180 A~l~l~G~A TTCAAAATCT TCTM 324 (2) INFORMATION FOR SEQ ID NO 138 (i) ~'yu~ CHARACTERISTICS
(A3 LENGTH 720 b~se pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 720 (xi) ~kyu~N~ DESCRIPTION SEQ ID NO 138 ~ AG GAGGCGATGG CACGATTTTA GGGGCTTTAA GAATGACGCA TGCTCACAAT 120 AAGCCATGCT TTGGGGTGAG GATTGGGAAT TTAGG~ l"L' TGAGCGCGGT TGAATTGAAC 180 ~llGAAAG A'll~ l"l'ACA AGATCTCAAG CAAAACAGGA TCAAATTAGA AGAGCATTTG 240 G~lllG~AGG GCCGTATTGG AAACACTTCT TTTTATGCGA TCAATGA~AT CGTGATCGCT 300 AGCG-~l~ATG GGCCCATTGT GCA~lG~ A AGCCAAAGCT ATATTTTAAC GC~-l~ ~C 480 GAl~ TAACGrAArG CCCTTTAGTG TTAGGGGCGG AAl~ GA~ll~ ~C 540 GCTCATGAAG ACG~ GGTTATTGAT GGGCAAGCCA CCTACGATTT AAAAGCCAAC 600 GATTATTTTA AA~l'~L~ AA AGAAAAGCTG TTATGGGGGG AAAGCCCTAA CAAAAAAAGA 720 (2) INFORMATION FOR SEQ ID NO 139 (i~ SEQUENCE CHARACTERISTICS
(A) LENGTH 549 base pairs (B) TYPE nucleic acid (C) STRA~nN~CS double (D) TOPOLOGY circular (ii) M~T~cur~ TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(i~) ANTI-SENSE NO

~ (~i) ORIGINAL SOURCE
(A) oRr-A~TSM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 549 (Xi) ~yU~ DESCRIPTION SEQ ID NO 139 SU~I~u~ SHEE~ (RUILE2-6) CA 0222339~ l997-l2-03 W O 9C/~ 3 , PCTAJS96/09122 ATGATAGTGG GTTTGATAGG G~ ~l~AA AAAATCTCTG CTTTAGAAGc GrATATAr-A~ 60 GTGCAAGGGG ~ ATGG GGTGCAAGTT TCTATGCGAA CGG~ ~C~ GcT~rAAArr, 120 GGCrAAAAA~i CGC~l~ ~AA AATCTTACAA GTGATTAAAG AAGATGCGCA 'l~ ATAc 180 ~G~l~ AG AAGAGAGCGA AAAAATTCTC TTTGAAAGGC TTTTGAAAAT CAA~l~GG~l~A 240 GGGGGGCGTA ~lCG~~ AGC CA~ ~A AGCTTTTCGC CGAATGAATT TGAAAACATT 300 GATAAGATCA TGGTGGATTT GATTGGCTTT TTCATTCAAG ATGAAAACAG ACCCG~GCGC 420 AATGAAGTCT TTTTAGCCCT AGAGAGTTTG ~G~l~ LAAAA GCGCTGAAAT CAATCCAGTT 480 (2) INFORMATION FOR SEQ ID NO 140 ( i ) ~h~ N~ CHARACTERISTICS
(A) LENGTH 462 base pairs (B) TYPE nucleic acid (C) sTRANn~N~s double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 462 (xi) ~U~N~ DESCRIPTION SEQ ID NO 140 ~l~G~G~llT TGTTRGCGTT ~ "l"r TATGCGAAAA ATAACCTTTT GriAAAA~ACC 60 CAAATACGCA TGCAATACAC CGCTGATGCG ATCGCTAAAA GC~ Ll~AGA ATTAAATAAT 120 GC~-~ l TAGAGCCTTT AAAAATCTTA GAAGAACGAT TCAAAAACAC CCC~ 180 ~ ~ACG CAGACAACAG AGTCAAGTTT TCTAATATCG GG~ GGC~-~ 240 ACAGACAGCG CCCCAACTAA CCGCTTAGGG ~ AAAA TCATTATTGC AGAAGAAGAA 360 ATTCAAAAAA TCTTTATCCC CCTTTATAAA ATGATAGGCT A~ GGGCGCGAGT 420 (2) INFORMATION FOR SEQ ID NO 141 (i) ~QU~N~ CHARACTERISTICS
(A) LENGTH 864 base pairs (B) TYPE nucleic acid (C) STRAN~N~SS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO

(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM HelicobaCter pylori (ix) FEATURE
(A) NAME/KEY mis~_feature U1~5~ 3a~26) , CA 0222339~ 1997-12-03 w 096140893 PCTrUS96/091Z2 , 193 (B) LOCATION 1 864 (xi~ SEQUENCE DESCRIPTION SEQ ID NO 141 GTGGTAATAA TGATTTTAGT CTG~ l"l'A GCTTGCTCGC AAGAGAGCTT TATCAAAATG 60 CAAA~AAAAG CCCAAGAGCA AGAAAATGAC GGCTCTAAAC GCCCCAGCTA TGTGGATTCG 120 GATTATGAAG TCTTTAGCGA AACGATTTTT TTACAAAACA ~ ATCA GCCTATAGAG 180 GAAAGAAACG ~ CCA ACTGACTAAA GATGAAGACA A~ll~llll~AA CCCTGAAAAT 240 r TCCGTGATTT TACTGAATGA GCCAAGCGAT AATAGTGAAA AAAACCrAcT CTCATACCCA 300 AACGATCCCA ATAACAATGA AGACAACGCT AATAATAGTC AAAAAAATCC ~l~TC~ AC 360 CAATCCAAAG CCTTGAAGCG ~ llAAAA GATCAAAACG ATAAAGATCG CCAGATCCAA 540 ACTTTCACTT TTAATGACAC TAAAACGCAA ATCGCGCAAA TTAAGGGCAA AA~s~ ~ 600 TATGTTTATA CCACCAATAA CGGTAGCTTG AGTTTAAGGC ~y~ ATGA ATC~ ~ 660 (2) INFORMATION FOR SEQ ID NO 142 (i) SEQUENCE CHARACTERISTICS
(A) ~ENGTH 1260 base pairs (B) TYPE nucleic acid (C) STRAN~DN~SS double (D) TOPOLOGY circular (ii) MOLECU~E TYPE DNA (genomic) (iii) ~Y~O~ llCAL NO
(iv) ANTI-SENSE NO
(~i) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 1260 (xi) SEQUENCE DESCRIPTION SEQ ID NO 142 ATGGCCGCTC CACTACTTGC TCTGCCCTTT ~ AACC CTTTAGTGCT ~ A 60 GCTGTCATAG GA~l~G~l~C TTACTTGTAT CCCAATAAGC AAGATTCTTT A~~ G~AA 120 GCAGATGGGC TTTATAGTGA AAll-l~l~GG '~ CATTT C~'l"l"l"l'~'l'AG CAAGATCTTG 180 CTTTTAATCC ~ ATTC CTTTAAACGC TATCA~AACA ATGATTTATT TGAAATCAAA 300 AC~~ llAA TG~ l~lAGGA TACc~ l TGTACCATTA ~ AAA 360 TCTGATGGTT CTAGTAGCGG TAAl~sCG~ TCCAGTTTTG C~'l"l"l'-'AAAA TCATGTAACA 420 GAAATTTTTG ACACGCCTGC TAA~~ A AATGCTGGGA TTTCTAATGT GGTTAAGGAA 480 TTCAAAATTA ATAATGGACT ATCGCTAAAA ACCCTTATTG CAG~ GTTATTAGTT 660 ATTTTAGGAT TAGAATTGTT TTTATTGTTC AAA~llll~l GTTATGTTTT TATGACTTAT 720 - TTAGAAAAAA TTATTTACTT ~ ATTTTCATGC TACTGCTAGG ~'l"l"l"l"l"l'~'AG 780 CAGACTAGAG ~l"l"l"l"l"l~AGT GTCTTATGTG AAAAAAATTA TTTCATTGAC TTTTTACATG 840 C~ TGCTATTAGT GTTATTCAAC '~ AT TACAATACGC AATCAAAGTG 900 C~l~l~ll~A GA~l~GG~l~l~ GGAGACGATT GAACTTCCCA AGTCTCATAG AGCTAGCAAA 1260 lk S~IEE~ 26) CA 0222339~ l997-l2-03 W O 96/40893 PCT~US96/0912Z

, 194 (2) INFORMATION FOR SEQ ID NO 143 ( i ) ~QU ~:N~ b CHARACTERISTICS
(A) LENGTH 216 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 216 (xi) ~QU~ DESCRIPTION SEQ ID NO 143 GTGTTAAAAT TTCAAAAATT ACCCTTATTG ~L"Ll~ll;l~CA L~ lLATAA TCAAAGCCCT 60 TTATTGGCTT TTGATTATAA GTTTAGTGGG GTAGCGGAAT ~L~l"l"l-"l~AA AGTGGGGTTT 120 ~2) INFORMATION FOR SEQ ID NO 144 (i) ~bQu~:N-~: CHARACTERISTICS
(A) LENGTH 615 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(~i) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 615 (xi) ~bQ~N~ DESCRIPTION SEQ ID NO 144 ATGGGTAATC ALl~LL~ AA ATTAGGATTT GTTTTAGCGG CTTTAGGGAG CGCGATAGGT 60 TTAGGGCATA TCTGGCGCTT CCCCTATATG A~LGGG~l~A ~~ L~GGGG 'L~'l~l"l"l'~'l"l' 120 TTA~LL'~L~L~L TATTTTTATC CTTAAGCGTT GGTGCGGCGA TGTTTATCGC TGAAATGCTA 180 TTAGGACAAA GCACGCAA~A AAATGTAACA GAAGCTTTTA AAGAGCTTGA CATTAACCCT 240 TATGGCACTA TTTTAGGTTG G~~ lAT TATTTGGTGA GTATTAGTTT TAATTTGCCT 360 TCCATAGGGC TTTTTAGCGT TTTATTCATA A~CG~GGA L"l~l"l"l~lAG GGGGATTAAA 480 ~A~Gr~TTG AAAAACTCAA 'l"l"l'~'l"l"l"l'A ATGCCCTTAC TCTTTGCCAC 'l"l"L'l"l"l"l'~'L' 540 ~L"L~l"Ll"l"l"l~ ATGCGATGAG CATGGATTCT ~ AAAG ~ CCATTT CATGTTGATT 600 SU~~ t~h~ RULE26) CA 0222339~ l997-l2-03 WO 96/40893 PCT~US96/09122 (2~ INFORMATION FOR SEQ ID NO:145:
U~NC~ CHARACTERISTICS:
(A) LENGTH: 984 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii~ MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINA~ SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NA~E/KEY: misc_~eature (B) LOCATION 1 984 (Xi) ~U~N~r: DESCRIPTION: SEQ ID NO:145 CTCAATGGAT TTTTAAAAAA A~1"1'~1"1"1'A AAAAAGCGTG ATATGTTACA AAGCACTATG 240 TTATTTGATG AAGTCAAAGA AGCTGATGTG ~'lll"l'l~AAG CAGAGCGTAA AATTGGCGAT 300 TGGATTTTTA GCAGTGCGGT ~l"l~lll"l"l"l~ GCTCTAGCCC TTATAGAAGC CATTATTATT 360 GTATGCTTAT TGCCGTTAAA AGAAAAAGTG CCTTATTTAG TAAC~~ l~ AAACGCTACA 420 CAAAATTTTG CCATAGTCCA AAGAGCAGAC AAGAGCATCC GTGCTAATCA AGCG~ ~ 480 AGACAATTGG TAGC~l~ A TGTTAATAAT AGAGAAAATA TTTCAAGTAT AAAAGAGCAA 540 A~rrA~T~G CCCACGAAAC CATTAGGTTG CAAAGCGCAT TTGAAGTGTG GGA~ 600 GAAAAACTGG ~ lATGA GCATAGCATT TACACTAATA TAAATCTAAC ACGAA~AAATT 660 AGCATTATCA ATA~l~G~ll AATCAGTAAA ACCCAAGCCA ATATTGAAAT ATCCGCACAA 720 ~ LATA AAGAAAAGTT AGAAAGCGAA AAGCGTTATA GAATAATTAT GACCTTTGAA 780 CAG~ATAAAr- ATGTTAAGGA GCAA 984 (2) INFORMATION FOR SEQ ID NO:146:
QU~N~ CHARACTERISTICS:
(A) LENGTH: 228 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

(~i~ ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1 .228 S13~ H~ ILI~ 26) CA 0222339~ l997-l2-03 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146 ATGCTGCATA AGGCTAAGGT GGGCATCGTG TTTCAGGCGC TTTTAGGGAT ~l"l"l"l"l~C~l~ 60 TTTTTATTGT ~l~l"l"l"l~ACTT GAGCGCGTTT TTAATGGTGG CTTTTAAAGA CACTAAA~GC 120 ATGTTTATAA GC~l~ AAT AGGGAGCGTG GTGTTCCTTT GGAGCGATCT A~ 180 GTAGG~l~ A AAAATATCAG ~l"l"l~l"l"l"lG GATATTGGTT ATGAAATC 228 (2) INFORMATION FOR SEQ ID NO:147:
'Q U ~'N ~' ~' CHARACTERISTICS:
(A) LENGTH: 420 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...420 (Xi) ~:Q~:N~ ' DESCRIPTION: SEQ ID NO:147 GCTAGTGGGG TGGGGAAAAG C~ ATT GCGAGCCTTT TAGGG~C~~ TGGGCTTAAA 120 GAGAGCAACG CTTrAAA~AT TGAAGTGGAA TTGATCGCGC ~'l"ll"l"l"l'AGA CACGGAAGAA 180 TACGGCATTT TTAr-Ar-AAr-A TGAGCATGAA CCCTTAGTTA TTAGCGTGAT TAAAAAAGAA 240 AAAACACGCT A~ AAA CCAAA~AAr-C CTATCTAAAA ACACGCTCAA AGCGTTATTA 300 AAGGGGCTTA TTAAACGCTT ATCTAArr-Ar AGATTCAGCC AGAATGAACT CAACGATATT 360 (2) INFORMATION FOR SEQ ID NO:148:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 924 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORrANT.~M: Helicobacter pylori (ix) FEATURE:
(A) NAMEtKEY: misc_feature (B) LOCATION 1...924 (xi) ~:yu~:N~: DESCRIPTION: SEQ ID NO:148 ATGCCACAAA ACCAGCTTGT GATCACCATC ATTGATGAAT CAGG~~ AA GCAACTCAAA 60 ~ ~lAAAA ATTTAAAACG CAACCTCATC A~ ~ TCAl~ ATTGATCGTG 120 Sl~~lllultSht~l (RULE26) CA 0222339~ l997-l2-03 W O 96~40893 PCT~US96/09122 , 197 GGG~ l~GC~ ~ G~ AAAATTTTTA ATCGCTAAAA TGGATACGAT GACAAGCGAG 180 GAGATTAAAA ACAAGCGAGA AGAGCTTTTT A~ ~GGGC AAAAGATCCG TGGGCTAGAA 300 TCCTTGATTG AAATCAA~AA GGGGGCTAAT GGGGGAGGGC ATCTCTATGA TGAAGTGGAT 360 TTA~-AAAATT TGAGCTTAAA TCAAAAACAT TTAGCACTCA TGCTCA,TTCC TAATGGCATG 420 AGCGCTGATG GGA~ll~l~A ~ ~l'~AAG A-"1'C~'1"1'~''1'A ATGCGGGGTA TGGGAACTTG 600 G~TAAA~A~A CCTTAAAAGG TCAG 924 (2) INFORMATION FOR SEQ ID NO 149 (i) ~kQukN-k CHARACTERISTICS
(A) LENGTH 1017 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY ~ircular (ii) MOLECULE TYPE DNA (genomic) ~iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
- (vi) ORIGINAL SOURCE
(A) OR~ANI~M Helicobacter pylori (ix~ FEATURE
(A) NAME/KEY misc_~eature (B) LOCATION 1 1017 (xi) ~Qu~N-k DESCRIPTION SEQ ID NO 149 AACCC~ll~ ATGGCAAGGA CATTCAGGCT TTAAAAAACA CGCTTTTAAA CGCAAAGCAT 120 AGCAGCCTTT ATAGCGATCC TGATGGGGAT TTTCCTAACC ACCACCCAGA CccTAGcGAA 360 G~~ ll~ATG GCGATGCGGA TAGGATTGCG ATGCTAAGCT CTCATCATAT CTATGCGGGC 480 GATGAATTAG CGATTTTATT CGCTAAACGC TTGCATGCTC AAGGCATCAC CC~ G 540 A~l~GG~AAG TCAAATGCTC TCAAGTGATG TATAACGCAA TCAATACTTT TGGTAAGACG 600 G~l~ ACG CATGTTTAAG GGCTTTGGAG TTATTGCTTG AACA~AGTCC AAGCGACTTG 780 AGCCATTTCC CTACAATCAA AGAAATCATC AGCATTGATG GCGTGAGAGT G~ ~AA 960 CA'l~G~lll~ GGCTTATTCG CGCAAGCAAC ACCCACCCCC TATTTAGTCA GCCGCTT 1017 (2) INFORMATION FOR SEQ ID NO 150 (i) ~kQ~kN~ CHARACTERISTICS
(A) LENGTH 621 base pairs (B) TYPE nucleic acid (C) STRAN~k~NkSS double (D) TOPOLOGY circular SU~ UltSHFE~(RULE26) CA 0222339~ 1997-12-03 W O 96/40893 , PCT~US96/09122 , 198 (ii) MOLECULE TYPE: DNA (genomic) ~iii) HYPOTHETICAL: NO
(iv~ ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...621 (xi) ~:QU~NL~: DESCRIPTION: SEQ ID NO:150 ATAAGGGAGA TGAAAATGTT TGAAACCATT G~y~ ATT TCTTTGCGAT CCTTACTTTA 120 AGCATGGCGT TA~l~L~ ~AT CACAACCACA AATATCCTCT ATGCCATTAC CGL~ GCT 180 AGTAGCATGG TTTTTATTTC ~lGL~ L TTTTTACTGG ACGCTGAGTT TTTGGGCGTG 240 GTGCAAATCA C~ ATGT GGGTGCGGTC ATTGTGATGT ATGC~~ GG CATGATGTTT 300 TTCAACTCCG CTGCAGAAGT AGTTGAACGC AAGCAAAGCC CTAAAATCTT GTGC~ Ll~ 360 TCATTTGGCG TGGCGLl'~l"l' GCTCACCTTG ATTTTAAGCG CTCCTAGCAT TGSSGAAAAC 420 ~ L~l~AAGC AAGTCAATTC CAACGCTATT GATGCGCAAA TYCCYAACAT TAAAGCGATT 480 GGTTATGTGC TTTTCACCAA TTACCTCATT CCCTTTGAAG CGGCGGCTTT AA'l'L-L'~ l'A 540 GL~l~ATGG TTGGAGGCAT CGCTACAGGG ATTCAAAAAA TCCATGGGAA AAATCACACG 600 (2) INFORMATION FOR SEQ ID NO:151:
U ~'N L~: CHARACTERISTICS:
(A) LENGTH: 753 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...753 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151 Al~l~CAA TTTTATCTAT TTTAAAACTT GAAATCAAAT CTTATCTCAC CAATACAAGC 60 GCGCTATTTT GGACTTTTAT TTATCCTATT TTAATGCTCC TATTACTAAT ~ 120 Tr~AAAT~ CCACTGAAAT TTTTTACTTT AATAACATTA TAGGTCTAAT GGGACTTCTT 180 ATATTCTTAT TCTACATGCT ATCACCAGCA ACTTTCAAAC A~ATAACTCT AGCATTAATC 300 GCTTCAAGAC TAA'lL~'l~lL-l' AATCCTATAT ~L~ "l"l'ATCT TTA~l'L-'l"lLl' Ll~L~ AT 360 GCGL~l~CAATA TCATCACTAT TCTTAATTTT AAAGCGCTTA TTTTGGGGTT TATTAGCATT 420 TTTTCAAGCG CA'l~ l'~ TTTTTGCTTG GCAATTTTTG TAGCTAGAAT TTTTCAAAAC 480 GAACAAAGCA TCTTAGGATT TTGTAATATC ATCAATCTCT Al~L-CGLl~AAT ~'l'L'll~l~AAT 540 ~ L CTTTAGAATA CCTACCTAAT ATTGGTCAAT TATTTATCAA AACATCTATT 600 TTTTACTACC TTAATCAACT TCTAATCA~A GL~ lCAAG GGATTGATAC TATACTGGTT 660 SU~ u~ Sk~ RIIaE26) CA 02223395 l997-l2-03 W O 96/40893 . PCTrUS96/09122 , 199 t2) INFO~MATION FOR SEQ ID NO:152:
(i) ~:yukN~: CHARACTERISTICS:
(A) LENGTH: 207 base pairs (B) TYPE: nucleic acid (C) STRA~ : double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i~ ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori ~ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...207 (xi) ~yU~: DESCRIPTION: SEQ ID NO:152 ATGGCAGGCA CACAAGCTAT ATATGAATCA ~ ~i~CAG GATTCTTATC GCAAGTCTCC 60 TCAATCATCT CAAGCACAAG ~ CGCA GGGCCATTTG CAGGAATAGT AGCGGGCGCT 120 ATGACAGCAG CGATTATTCC TA~ l'~T~ GGATTTACTA ATCCGCAAAT GACCGYTATY 180 (2) INFORMATION FOR SEQ ID NO:153:
(i) ~kyu~N~ CHARACTERISTICS:
(A) LENGTH: 336 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular ~ii) ~OLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) OR~ANT~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...336 (xi) ~kyu~N~: DESCRIPTION: SEQ ID NO:153 CGCATTCAAG CCCCTATCAA AGGTAAAGAT ~'l'~'l"l~'l'A TTGAAATCCC TAACAGCCAA 120 AGCCAAATTA TTTATTTAAG AGAAATTTTA GAAAGCGAAT TGTTTCA~AA ATCCAGCTCG 180 CCTCTAACCC TAGCTTTAGG CAAAGACATT ~l~GG~l~AACC CTTTCATCAC GGATTTAAAA 240 ~AG~lCCCCC A~l~l~Ll~AT CGCCGGCACG ACAGGGAGCG GTAAGAGCGT GGGCGTGAAT 300 GCGATGATTT TATCCTTACT TTATAAAAA~ CCCCCC336 ., (2) INFO~MATION FOR SEQ ID NO:154:
(i) ~:yu~N~: CHARACTERISTICS:

SLi~l~UI~ ~HE~ ~ JLE 26) CA 0222339~ l997-l2-03 , 200 (A) LENGTH: 456 base pairs (B) TYPE: nucleic acid (C) sTRANn~nNE-~s double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ~iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...456 (Xi) ~kyU N - ~' DESCRIPTION: SEQ ID NO:154 ATGGATGAAA GS~ llA TGGGGTGATT TGCATGCCCA GTCAGGTTTT TGCCAACACC 60 GGCACTAACG TGAGCATCAT ~ -AA AAAACGCCAA GCGCAAAGGA AGTGATCTTG 120 ATTGACGCTT CCAAACTCGG CGAAGAATAC ACCGAAAACA AAAACAAAAA AACGCG~~ A 180 ~ -GCTC ~l~lll~'l-ll' TGATGAAATT ACAGAAAAAA ATTATTCTCT AAA~CC~GGG 300 ATG~AA~AAT ATTCAAGCGA ACTAGCGAGC ~ll"l~ l~ATG AAAGCCAAAA TTTGCAACAA 420 GAGATTTTAG AAACTTTAAA A~G~l'~l~AGG TTTGAG 456 ~2) INFORMATION FOR SEQ ID NO:155:
( i ) ~y U ~:N~ ~' CHARACTERISTICS:
(A) LENGTH: 339 base pairs ~B) TYPE: nucleic acid (C) STRAN~ S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~-ANI~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...339 (xi) ~kyu~N~ DESCRIPTION: SEQ ID NO:155 ATr.~AA~A~ TTATTAAAAA CACACTTTCA CGCTTAGGCT ATGAAGATGT TTTAGAAGCT 60 GAGCATGGGG TGGAAGCTTG GGAAAAACTA GACGCTAATG CGGACACTAA G~l~l~lATT 120 ACGGATTGGA ACA~l~CLl~A AATGAACGGG TTGGATCTCG TTAAAAAGGT GCGTGCGGAT 180 r AACCGATTTA A~AAATCCC TATCATTATG ATCACCACAG AGGGCGGTAA AGCTGAGGTC 240 TTGAAAGAAA AATTAGAGGT ~ AGGG ACAAACGAT339 (2) INFORMATION FOR SEQ ID NO:156:
( i ) ~ ~:y U ~:~ ~ r' CHARACTERISTICS:
(A) LENGTH: 549 base pairs S~l~llllll~BEE~ (RULE26) -W O 96l40893 PCTAUS96/09122 , 201 (B) TYPE: nucleic acid (C) STRAN~r~N~:~S: double (D) TOPOLOGY: circular - (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~ANT~M: Helicobacter pylori (ix) ~EATURE:
(A) NAME/KEY: misc_fea~ure (B) LOCATION 1...549 (xi) ~:yubN~: DESCRIPTION: SEQ ID NO:156 -ATTA TTGGAAGCGT GCTAGTGATG CTTTTATTGG ~l~G~l~AT TATCATGCTG 120 ~ ~ GGC~~ ~lA TGCGATTGAT GCGC~l~ l~ CGGTGAATTT G~l~l~clcAA 300 AATGGCAGAC GCTACCTTAA GGCTTCTATT TCGCTA,GAAT TGAGCAATGA AAAGc~ ~ 360 AGCCATTTGA A~ GATTGATGGC TTTATTAAAA A~CACTGATTTC 540 (2) INFORMATION FOR SEQ ID NO:157:
(i) ~:yu~N~: CHARACTERISTICS:
(A) LENGTH: 105 base pairs (B) TYPE: nucleic acid (C) STRAN~:~N ~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGAMJ.CM: Helicobacter pylori (ix) EEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...105 (xi) ~u N~: DESCRIPTION: SEQ ID NO:157 A~ TTAGCACCAT 'l"l'~'l"l'~'l'AAG GGTTTAACGC TTAGCGTTGG TGGATTTTTG 60 (2) INFORMATION FOR SEQ ID NO:158:
(i) ~Qu N~ CHARACTERISTICS:
(A) LENGTH: 2106 base pairs (B) TYPE: nucleic acid (C) STRANn~nNEss: double (D) TOPOLOGY: ~ircular lUltSHEEl (RULE2'6) CA 0222339~ l997-l2-03 WO 96/40893 , PCT!U~3G~5122 , 202 (ii~ MOLECULE TYPE: DNA (genomic) ~iii) hY~O~l~kl~LCAL: NO
( iY) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A~ ~RrANTcM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature ~B) LOCATION 1 2106 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158 ~l~GCGC~ lAA AAGGCGTAAA ATTGATTATA AACAAAGCAT TCAATCTGAC 60 TA'l~ AG TTTTAGAAAG CACTCACTCT TTGCATGGCG TTTTGGAGCA TAAGAAAAAA 180 ~ l'-ATGC ACGCTAATAG AGAAAATTTT AAGGATATTC ~ ATAA AGCGCATTTT 240 AACTCTAAAG AG~l~ ll~AA TTTTTATGCA GAATATATTA ATGGGTTTGA ACTCCCTTTA 360 AAACCCCTAG TAGGGGG~ A TTTGAGCGAT AGCTATATCG CTAGTTCTAT CA~~ l~AA 420 AAAGCTTATG AGAGCGAAAG GATCACTTCT ATAGCGGTGG GAGCG~~ ATACCAAGAG 540 ACGC~ll~l~G ATATTATCTT TTCCATAGAG CCTATGAGCG TCAATAAAAC GCTGAGTTTT 600 TT~AAAr-A~ GGGCCAAGTT TAGCATGTCT AA~ A AAAACGAGCT ATTAGAATAC 660 CAAGAATTAG TCAAAACCAA ACGATTATCC ATGCAAAAAT TCGCCCTAAA C~l~ "lATC 720 AAArAAAArT TA~l~GGC~'l' TATAGAAACT TTTGGCTTGA AAGGGGGGTA TTTTTCCTTT 840 ~C~l~AAC GCATCCATTT AAACCACCGC TTGC~l~ TAACCTCTAA AGCCCTAGCG 900 ~lvl"l~ ~ATGG TGTTTGAAAG GCAAAATTTA GGTTTTAAGG CTAATTCATG GGG~AATAGC 960 C~ l~AGCG TGTTTAAAAA TTTGGATTAT ~ CC~l~ TATTCAATTT CrArAArCAA 1020 TACrAAAArA TGCGCCTTTT A~-llll~AC AGGATGCAAG GGTTGTATTC TTTCACCGAA 1200 AAG GGCATTACCA TGACGGCCAA ~ AGTA TCAACCCCTT ~ llAGAG 1260 CCTAATTTGC AGAATTTAGA ATTTTTGCAA ~l~l"ll"ll"l"l~ TGAGCATGTT GGA~ l~CC 1320 CCTTCAAGGG ATAAA~A~r-C CTTAGAAGAC ATGAATGCGA ~ ~CGC GATTAAGAGC 1380 CTTTATGAGA CCTTATACCC CAAAGATTTT A~ll~ l~ ATTTTAAAGA AACGCTTAAA 1440 AGAACCTCAT CTAArrAATT GGGCTTGAGT TTAGAGCCGT ATTTGAATAA CCCC~ 1500 AACGCTTTGA ATGACGCGTT CAACTCCAAC G~lllll~ AA ATGTGATAAA CCTAGATGCG 1560 ATCACCCAAA ACCCTAAAGA CTTAGGGCTT TTAGCCTATT A~ A TAAGATCTTA 162G
GAAGAGTCTA GG~AAAA~A CAGCGG~l~ TAGACGAATT TAAATCCTAT 1680 GTGr-AAAArr. A~ AAA CACTAAAATC AACGCTTTAA TCACGCAAGC CAGGAAAGCT 1740 AA~l~GC.C~l~G ~ l~GC CTTGCAAGAC ATTTACCAAC TTAGCGGGGT TAAAAACGCC 1800 CATAGTTTTT TAAGCAACAT GGGGACTCTC A~ ATC CGCAAi~AAAA CGCTAGGGAA 1860 TTGAAACACA ATTTCAATGT GCCTTTGAGC GAAACTGAAA 'l"l"l'L'l"l"l"l"l"l' AGAAAACACC 1920 C~l~ ATG CCAGGCAGGT TTTAGTCAAA AAT~l~G~l~A ACGGGAGTTC CAACATGATT 1980 GATGTGAGTT TGGAGGGCTT GGG~ lAT TTGAAAATCT TTAATTCAGA TTCCAGTCAT 2040 GTrAATAAA~ TGAAAGCGTT ACAAAAAGAC TACCCTACAG AGTGGCGTGA GAAACTTTTG 2100 (2~ INFORMATION FOR SEQ ID NO:159:
(i) S'~yukN~ CHARACTERISTICS
(A) LENGTH: 879 base pairs (B) TYPE: nucleic acid (C) STRA~r~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~O~ CAL: NO

~IIIUIt SHEEl ~RULE 26) CA 0222339~ l997-l2-03 . 203 (iv) ANTI-SEWSE: NO
, (vi) ORIGINAL SOURCE:
_ (A) oRr~ANT-~M Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...879 (Xi) ~:~U~N~'~: DESCRIPTION: SEQ ID NO:159 ATGCAAGAAG ACTGGCAAGC CGTccAAGAc ACCATTAAAG ~ cAGA TGTGAAAGCG 60 ATTTTCAAAA TCTTTGAA,AG CTATTCTGGC TTGGATTTTA GAGGGCGGAT CCAAAACGCT 240 ~l~c~G~l~AGGG TGGAATTGGT TACTAACGCT TTAGGGCAAG A,AATCCA~A~A AATGCTAGAA 300 A~ C~l~cl~A ATTTTGCCAA AGATCTAGCG AACGATAGCG CGAATTTAAA AGAATGCGTG 360 CAAAATTTAG AA~AGGCTTC AAACTCCCAA CACAAAAGCC TGATGGAAAC TTCCAAAACG 420 GCG~l~ ~G CTGATGAGGT GAGGAAGCTC GCTGAAAGGA CGCAAAAATC CCTCAGTGAG 660 AACCAGGTTA AAGAAGTAGA AGAGATCAAC GCTTCTATTG AAGCCTTAAG A~l~CG~ ACT 780 TCTAArr-ATA TTTTAr.AAr-A TGTGAATAAA AAGCAGTTT 879 (2) INFORMATION FOR SEQ ID NO:160:
(i) ~QU N~' CHARACTERISTICS:
(A) LENGTH: 156 base pairs (B) TYPE: nucleic acid (C) STRA~~ N~'SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORr-ANT-~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...156 (Xi) ~'~U~'NC~- DESCRIPTION: SEQ ID NO:160 ATGCCTAAAA GTTTCACCTT ACCGACTTTC ~L~GG GGTTATCTTA 60 Ar~rAArGcTT ~ C~ l' TAAAATCCAT AGC~~ ACAGAGAGGT TTCAGTTATA 120 GGGAATGTGA GCTTGAGCCT ~'l"l"l"l"l'AGCT TACGCT 156 (2~ INFORMATION FOR SEQ ID NO:161:

(i) ~kyU N~'~: CHARACTERISTICS:
(A) LENGTH: 546 base pairs (B) TYPE: nucleic acid (C) sTRANnFnNEss double (D) TOPOLOGY: circular SU~llult SHE~ (~UILE 26) CA 0222339~ l997-l2-03 W O 96/40893 PCT~US96/09122 (ii) MOLECULE TYPE: DNA (genomic)' (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...546 (xi) ~:QD~:N~: DESCRIPTION: SEQ ID NO:161 ~l~GGG~l~ TAAATTCTAA GGCGTTCAAA CCCTACCGCA AGA~ ~CA AA~ 60 TTAGAAGAAG ~ AAA CCCTGAATTG CTTAACTTTT ACGCTTATGA GCTCAGCGGA 240 TTGAATTTAC AAGAAAAGCA GGATTTGAGC TA~ A TCAGCCATGA TTTAGATGTG 420 GCTATTGAAG AG~ ~A CAACCCCAAA CACGCTTATA CCAAGCGTTT GTTGGAATCC 540 (2) INFORMATION FOR SEQ ID NO:162:
(i) ~:Q~N~: CHARACTERISTICS:
(A) LENGTH: 753 base pairs (B) TYPE: nucleic acid (C) STRANIJ~:l)N~:~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...753 (xi) ~QU~:N~b: DESCRIPTION: SEQ ID NO:162 GTGAGTTTGA TTAAAGTTAG TGGTGATAAA AAAGTGATTG AG~~ AT TCCTTTAACT 60 ACAGCGACTA GAAAAATCCC TTTTAGTTTA AAGCATTATG TAGAGTGGCA GA~l~CG~l~ AT 180 GAl~l~CCCCA TTA~A~AT~A AGAAAAATTT GAACTCACTA CTTTAAAAGA TGAAAAATAT 240 CA~ AG GGGCTAATAA TAAAGTAAAA A~l~ ATG AATTGAGCGA AATGATTTAT 300 TACGCTAAGC GA~l~G~lll~ AATCAGTTTA GAAAATTTAG AAAATACTTT AAAATTTTTA 360 CATCAAlll~ GTGGCATGGA TTTTGAACTC TCACGCATTT CTTATCCTTT GCTCATTCAT 480 ~ l"l"l"l~ATG ATAATGAGTT GAGCGAAATA GTTATTAAGG AACAACAATA TGGCTCTAAA 540 ACCr~A~.crA ~lG~ ATTT 'l"l'~''l"l"l"l'~"l' ATTTTGGAGT TAAAAACCGC TACCCCCTTA 600 ~'l"l~'l'~'l~l"L"l' TAGAAATGCT TAAAATTTTT GGACTTTTAA GCCAAGTGCA CCATAACGAT 720 SU~S911ult SHEE~ (~U~E 2~) CA 0222339~ l997-l2-03 W O ~f'1D~3 PCTAUS96/09122 . 205 (2) INFORMATION FOR SEQ ID NO:163:
(i) ~yu~N~: CHARACTERISTICS:
_ (A) LENGTH: 120 base pairs - (B) TYPE: nucleic acid (C) STRA~I~ : double (D) TOPOLOGY: circular ~ (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1.,.120 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163 GTGATCACGG C~'l'~'l"l"l"l'AA TAGYGA~AAA ACCATTGAAG ACACCATTCT TTCCGTGCTT 60 AATCAAACTT ATAAAAArAT TGAATACATC ATTATAGATG GGGCTAGCGC GATAGCACTT 120 (2) INFORMATION FOR SEQ ID NO:164:
(i) ~:yU~ : CHARACTERISTICS:
(A) LENGTH: 366 base pairs (B) TYPE: nucleic acid (C) STRA~~ S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORr-~NT~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...366 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164 ~ l~lAG GGCTTTATCA TGGGGCAAGC ATCTTTGATT TAAAATTTGA AGTCTATCTT 60 ACTATGCTAA ~ c~ AAT GCCcl~ ~ GCTACGATTT ATATCAATTT CCCAAAAACC 120 Ar~r~ArTT CGCATGGCTA TGCGAGATGG GCTAATGTTA AAGATATAGA ATGCTTTAAA 180 ATTTTTAGCA AAGAGGGCTT TTGT~AAGTG GTGCATAGAT TA~GG~l~CA ATTTGATAAT 240 ~G~~ ATTC TAGGTAAATT ~l~G~llllCCA AAGCTTAGAA ATGTGTGCTA TGACAAGCCC 300 TTAGGAACGA TGAll~l~l~ ACCCC~l~l GCGGAAAAAC TGCATGTGTG GCTTTGCCAA 360 (2) INFORMATION FOR SEQ ID NO:165:
(i) ~yu~: CHARACTERISTICS:
(A) LENGTH: 339 base pairs (B) TYPE: nucleic acid (C) STR~NDEDNESS: double SU~l~lul~Sht~l (R11~26~

CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 . 206 tD) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...339 (xi) ~ u~:N~: DESCRIPTION: SEQ ID NO:165 ATGAAACGCC 'l"l'~'l'~'l"l'~C GCTTATTTTG ~L~ ~GGAG ~lw l~l~GGG GAAATCCTTG 60 GAAAAAATTT TA~l~ GG GATGAGCGAT ATA'l'~ CAGATATGGA TTATAGCTTG 180 GAGATTAAGG CTGGTGAGCT AAAGGCCACT TTTATTGATA CGr-A~AAAr.T TTATGTGCTT 300 CTAAGAATCA CTAAGAAGcA TGTCGCTTTA ATGAATGAG339 (2) INFORMATION FOR SEQ ID NO:166:
(i) ~'QU~:N~'~: CHARACTERISTICS:
(A) LENGTH: 1311 base pairs (B) TYPE: nucleic acid (C) STRAN~N~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) AN-TI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...1311 (xi) SEQUENCE DESCRIPTIO~: SEQ ID NO:166 ATGAACCCCC AGATTCAACC CGCCACTAAA AAACCCTTAA AA~l~C~l~ AGCCGCTAGT 60 TCAGGCAATT TAGTGGAATG GTATGATT~T TACGCTTATG ~l"l'C~ ~C TCCTTATTTC 120 GcTAAGGAAT TTACCCACAC CAATGACCCT ACTCTAGCGC TCATCTCAGC '~ AGTT 180 TTTATGCTAG G~ l~AT GCGCC~~ ~ GGGAGTTTGT ~l"l"l"l"l~l~AA ATTGGGGGAT 240 AAAAAGGGGC GTAAAACTTC CATGGTGTAT TCCATTATCC TTATGGCGCT AGG~l~l~ ~ 300 ATGCTCGCAT TGCTCCCCAC TAAAGAAATC GTAGGGGAAT GGGC~ll~ ATTG 360 TTAGCCAwC TTTTACAGGG CTTTAGCGTG GGAGGAGAAT A~l~GC~l~G~l~ CGCCACTTAT 420 ~ Ll~l~AAT TAGGCAAGAA TGGTAAAAAA ~'l"l-l~l"l'ATG G~~ ~CA ATATGTAACT 480 TTAGTGGGAG GGCAACTCTT AGCTATTTTT ~l~CG~l'~ll~l~A TCGTTGAAAA CGTTTACACG 540 CTACTCTCGC ~L~l~ ~AG AAATATCATG GAAGAAACTA TGGATAATGA AGCGACTCCT 660 AGTTTAAAGG AATTGCTCAA CCATAAAAAA GCCTTAATGA TA~ l~G GCTAACTATG 780 GGAGGGAGTT ~ GC'l"l"l"l'A CACTTTTACG GTGTATTTAA AAA~ AACCAACAGC 840 TCA~l~C~ A GCCCTAAAGA AAGCAGTTTT ATCATGCTTT TAGCG~l~lC TTATTTCATC 900 TTCTTACAAC CCTTATGCGG GATGCTTGCG GATA~A~ATCA AACGCACCCA AATGCTGATG 960 ~l~l"lll~CGA TCACAGGGCT TATTGTAACG CCTATTGTCT TTTATGGTAT rAAr-rATGCC 1020 SII~ lUltSHEEr(RULE26) CA 0222339~ 1997-12-03 WO ~)G/1D~3 PCI'/US96/09122 ACTAGCGTGT ATGAAGCCCT ATTTTATGAA ATACTCGCAT TGAGCAGCAT GA~ AC 1080 ACTTGCATTG clG~G~ lAT TAAGGCGGAA TTATTCCCTG AACATGTGCG AGCG~ l'~GC 1140 ~l~G~ AG CCTATGCGAT CGCCAATGCG clll~ GAG GGAGCGCGAG TTATATAGCG 1200 TTAGAGTTCA AACAGCATGG TTTTGAAGAG GGc~ G GCTATGTCAT GTTGAGTATT 1260 (2) INFORMATION FOR SEQ ID NO 167 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 285 base pairs (B) TYPE nucleic acid ( C ) STR ANnF~nNF.CS: double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii~ HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature ( B ) LOCATION 1 285 (xi) SEQUENCE DESCRIPTION SEQ ID NO 167 GAAAATACGG CTTTTAGTAT CGGCGTGGAG TTGGGAAAAA TCATGCGAGA AT;~rt'-~TAAA 120 AGC~ i TAGGGCATGA CGCAAGGGTG CA~l~GGC~ l(iA AGTTTTGAGC 180 GCGGGG~ iC AATCAAGCGG CTTGAAAGTG TATGATTTAG GGCTAATCCC CACACCGGTA 240 (2) INFORMATION FOR SEQ ID NO 168 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 306 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature , (B) LOCATION 1 306 (xi) SEQUENCE DESCRIPTION SEQ ID NO 168 GTGTGCGACA ~ ~A l~GGC~ A TTGGACAAAG CGTTAGTGAT TTATTTCAAA 60 TTAGCGCAAR ATATCCTTCA AG~ G~l"l~ AATTTAGGGG CTAGGCTCGC TAAAGCGGGG 180 GTTCARCTCA ~l~CC~ ciA AGRTGAAAGC GTTTTAAACG CTCTAGCCAG GCAGCTTCAA 300 SUBSIllUl~ SNEEr (RULE 26) CA 0222339~ l997-l2-03 W O 96/40893 PCTAus96/09122 , 208 (2) INFORMATION FOR SEQ ID NO:169:
Q~:N~: CHARACTERISTICS:
(A) LENGTH: 381 base pairs (B) TYPE: nucleic acid (C) STRAN~ S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) AWTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...381 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169 ATGTTTAAAA AAA~ GAGCCTGCTA ATGATAAGCG ~l~'l"l"l~'l'~l' GGGGGCAAAG 60 GACTCTAGTC TTTTAAGTAT CACTTCTATG AACGATGAAC CG~~ ~AT TAAAAACCTT 180 TATTACCATA AA~ lC~AA A 381 (2) INFORMATION FOR SEQ ID NO:170:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1506 base pairs (B) TYPE: nucleic acid (C) STRANn~nNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA tgenomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION l...lS06 (xi) ~:Q~N~: DESCRIPTION: SEQ ID NO:170 ATGACCTTGA AGCCATATCC AACCAAAGAG A~l~l~ ~ CTAGCCAATT ATCTGGGCAC 60 ~l~'l"l"l"l"ll~ AG~ ATTTAATAAA ACAAACTTTA ATCCTAATAA AATTTGGATT 120 GATAGTCATG AA~ ~AA TATCTCTAAA AAATACTTGC AAGAAATAGA TCAAGAATCA 240 GATAATAACG ATATACTGCA ACTTGAATTT TTTGAGAATG ATACAAGTTT ~ ~CT 360 AAA~-~AA~TT TTGrA~AA~T TTTAGAATAC AACATGCAAT TAAAAATAGA 'l~ AATT 420 SU~ SHEEl (RU~ ?6) CA 0222339~ l997-l2-03 WO ~G/~8~3 , PCTrUS96/09l22 ACAAAAGAAT TTAATAAGCT TTTAGCGATc GTTCAAGATA GTCCCCAAGA TAGTTACCAA 480 TTAAAAATTC GTGTCCGACA TAACAATAAG ~l"l'~'l'AGAG AGAAATATAC GGAACATGAA 540 AATCATGTTA ~l"l"l"l~l"l"l~ AGCCACCCAT GACCCCTTTT TAGTGGATAC GGATCATTTA 840 GATGAAATAA GGATTGTGGA AAAGGAAACA GAA~G~ ~ TAATTAAGAA TCACTTTAAC 900 TATCCCCTAA ATAATGCAAG CAAAGACTCC GACG~ ~G ACA~AATCAA ACG~ A 960 GACAACCCCA TTCCTTTCAC ~ ACCC ATTTCAGGGC TTAAAAACGA TTCAAACGAT 1140 GATGACAGAA AA'l'~C~'l"l"l"l' TAACCAACAA GCAACGAGCG AACGATTTAA AAGAGCTAAT 1260 GAAGAAATGC ATGATCCCAT CACCATCCTA CAACTCTCAG ACTGCGATAG GCATTTCA~A 1320 CAAATTGAAG A~ l~AG CGCAAACGAT AGAAACAAAT ACGCTAAAAA TAAGCAAATG 1380 GAATTGAGCA TGGCTTTTAA AACAAGGCTT TTGTATGGCG GAGAAGATGC GATA~-AAAAA 1440 (2) INFORMATION FOR SEQ ID NO:171:
(i) ~kyukN-~k CHARACTERISTICS:
(A) LENGTH: 126 base pairs (B) TYPE: nucleic acid (C) sTR~Nn~n~ double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...126 (xi) ~kQukN~ DESCRIPTION: SEQ ID NO:171 GTGTATTTTT TTCTGGCATT GAGCGGGGAA AAAGTCTTAC TGCCCGTCAT TGGCG~l~ A 60 GA~A~AA~CG CGCTAGAAGC CGGGCTGTTA AAGGGGGATA GAA~ ATCAACCATC 120 (2) INFORMATION FOR SEQ ID NO:172:
(i) ~kQu~N~k CHARACTERISTICS:
(A) LENGTH: 1050 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~O'l'~k'l'lCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori S~ u~tSHE~ (~ULE26) CA 0222339~ l997-l2-03 WO 96/~B93 PCTrUS96/09l22 , 210 ¦ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1 1050 (xi) ~Ou~N~ DESCRIPTION: SEQ ID NO:172 ATGGAAAATT TTAAACTCAT CAA~ ACCGGTCAAA ACGATGCGGG TAAAACCAAT 60 CTTTTAGAAG ~l~~ ATAC CAACACAGGC ~ lGl~ATC CTACTGCCAA TCAAGTCAGT 120 ~ c~l~CTG AACATGCCGT GAATATTAGT GAATTCAGAA AAATCAAACT CGATGCCGAC 180 AACCTAAAAA C~"l"l"l"l"l"l"l'A TCAAGGAAAC ACCGCTAATC CCATTAGTAT CcGcAcTGAA 240 AAGCCACAGC TCCAATTTTC CTACAATCCA 'l'CC~'l"l"l'~CC CCATGACAAT GACTTATGAA 420 AAAGAAAATG CGATGTTTAT TCCTATAGAA TTATcTATTG TTAATTcTcT TAAAGCATTG 540 CCTAATATTT TAAATGCTAA TACAATAAGA AA~ ATATCCAAAT CAAAGATGAA 660 AACACACCGC TAGAAGAAAG TCCCAAAAGG CTTTTAAATT ~l~l"l"l~l"l~ GGGTTTTATC 720 AAA~ A TTATGGTGAG CATTCTTATA GACAATCGTG TCAAGTATCT TTTTATTGAT 780 GAAATAGAAA GCG~ ~CA CCATACAAAA ATGCAAGAGT TTTTAAAAGC ~ ~lllAAG 840 AACGCCATCA ACACGATATC CGATAATGAA ACGGGAGTTT TTAAAGACAT AGC~ 960 (2) INFOR~ATION FOR SEQ ID NO:173:
(i~ SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1395 base pairs (B) TYPE: nucleic acid (C) STRANnFnN~S-s double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORr-ANI~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1 1395 (xi) ~h'~U~ DESCRIPTION: SEQ ID NO:173 ATGGATTTTA AAAAATGCCC TAATTTTGAA AAAAAATGTG C~ ~ TTTCTCAAAT 60 'l"l'~'l"l"l"l'AC TTATTGAAAT CCACTCTAAA GGACTACACA TGCAAAAAAA GAAACCCAAG 120AACCCGCAAC CGAATTTATT TAGCATCTTA GATAAGGGCG ATGTTGCAAC AAACAATCCT 180 GTTGAAGAGT rAr.ArAA~C CAATAAAATA CAAGAGCCAC ~l~CCcl~rATGT CGTGAAAACG 240 I55G~AAAAC GAGTCTATAA Gr-ATAATAr-T AAAr-AAr-ATG TCAATTTCTT TGCCAATGGT 360 GAGATAAAAr. AAAGTTCTCG TGTTTATGAA GCGAATAAAG AAGG~ ~A AAGGCGCATC 420 ACTAAAAGAT ACGATCTGAT TGATAGAAAT ATTGATAGAA ATAr.Ar.AATT TTTTATAAAA 480 GTTAAArAAT ACGACCATCT TAAAGATATT TACCAAGAAG TAGAAAGAAC AAAAGATGGT 660 GGATTGGTAA GA~-AAATAAT CCCCAGTATT TCTAGCGCTG AGTATTTCAA GCTTTACAAC 720 AAA~lGC~ll~ TTGAATCAAT AAACAATGAA AATACCA~AC TGAATACTAA CGACAATGAA 780 CAA~ rArrAArAA~ TTATTATTCT TGGATAGATA AA~.AT~AT~A TGCGAATTTT 900 S~ t~ t~ (R~26) CA 0222339~ l997-l2-03 WO 9G/~Cq93 PCT~US96/09l22 , 211 G~-l~l~AAAA TGCATAGGCT TATCAATGAA ~ATAAA~TCA AAGAAAAccA TCTCAGCGCC 960 AAAGAAGAAC AAAGCGCTAT ACAAGAAAAC AGAGATTATT CTTTAAGAAG CGc~ llA 1080 AGTTTAGAAG AAAl~G~ A AG~AAAAATT GAATTGCAA~A AATACTATGA AAGC~ 'AT 1140 GTTAATGGTG ATGGGAATAA AAGAGAAATC AA~C~ Ll~A AAGAAATTTT AAGAGACACC 1200 (2) INFORMATION FOR SEQ ID NO:174:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 579 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL sOURCE:
(A) ORGANISM: Helicobaeter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...579 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:174 A~l~G~G~~ ~ AA~l~'llll' ATGGGATTTT GATGGCGTGA 'l"l"l"l"l'~ACAG CATGCATTTA 60 AAATATGAAG GGTTTAAGGC ~~ lCAA AAGCATGGCA ACGATAGTAA AGAGG~ ~ 120 AAA~AA~Ll~ AAGTTTATCA CTATCAAAGT ~G~GGATTT CAAGGAATGA AAAGATCCAA 180 TATTTTTATA ACGAGATTTT AA~AACCCCT A~l~CG~l~AAG AAGAAATAGA TGCATTAGCC 240 CTAGAGTTTG GCGCTATCAT AGAGCAAAAG ~~ GATA GGGGGCATTT GAATAGCGAR 300 TAT~.A~C~AA GCCGTATGCT AATGATAGCG ATAGCGTCAA TGATTATGAA AGCGCTAAGG 540 CTAATAAAGT GGC~~ l~ GGCTATAACA GCAAGGTTT 573 (2) INFORMATION FOR SEQ ID NO:175:
(i) ~:OU~'N~: CHARACTERISTICS:
(A) LENGTH: 423 base pairs (B) TYPE: nueleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature SUP~ 9~ SHEE~ (RULE~6) W O 96/40893 PCT~US96/09122 ~B) LOCATION 1...423 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:175 ATGCTCAAAA AAAAGATTGA TTTGCATAAA GATTCTATTA GGAAGcTcTT TTTTTATTAC 60 TTCATCCCTT TA~l~ l"l~ TATGATCTCA ~ ACTT ACTCTATGGT AGATGACATG 120 ~l"l"l~l'~GGLA AAAAACTGGG TAAAGAAGCT ATCGCTGCGG TCAATATCGC ATGGCCTATT 180 TTTCCAGGAC TCAll~L~lA TGAATTGCTT ~ G~ ~ GGGCAGCGAG CA~ GGGG 240 TA~ AG GTCAAAATAA AACCCATAGG GCTAGGCTTG TGTTTAGCAG L~l'~l"l"l"l~AT 300 'l"l"l~lLGLlL TAAGCGCCTT TATTTTGAGC ATGGCGTTAT TGCLl~ AG CGAAAATATC 360 ~2) INFORMATION FOR SEQ ID NO:176:
yu~:N~: CHARACTERISTICS:
(AJ LENGTH: 477 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~Ol~ CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) O~NTSM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...477 (xi) ~:yukN~- DESCRIPTION: SEQ ID NO:176 A~AACGACTA CCCCTATTTT AGCGCCTATG AGCL-l~lGG CTGGGAGGTT GRCTSCSCAT 120 TTAGTCCAGC ATTATTTACT GGCTTTAGAG CATGTTAAAG GGTTTATGGG TAAGGGG~l- 180 ATACTAGGGG ~~ L-~l~CGGG TGCSCAAAGG GCTAAAATCG TCGTAATTGG AGGC~l~l~ 240 ~l~l~GcATGG AGAGCGCGAA AGTCTTAARC CA~ATGGGGR CTAAAGTAAC GATTTTAGAA 300 AGCGTGAATG AAGCCAATAT CATTCAAGCC TTAAACGGGR CG~l~LGGGL~l AGTGGGAGCG 420 GTRL~ A r~R~CCA AACCCCTAAA ~l~Kl~ AA GAAGGCATTT AAAATAC 477 (2) INFORMATION FOR SEQ ID NO:177:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1128 base pairs (B) TYPE: nucleic acid (C) STR~r'~ 5s: double (D) TOPOLOGY: circular (ii) M~r.~TTr.~ TYPE: DNA (genomic) (iii) ~Y~Ol~hl~lCAL: NO

(iv) ANTI-SENSE: NO
~vi) ORIGINAL SOURCE:
(A) OR~NI.~M: Helicobacter pylori (ix) FEATURE:

Sl~ t SHEElr (RIJLE 26) CA 0222339~ l997-l2-03 W O 96/40893 PCT~US96/09122 (A) NAME/KEY misc_feature (B) LOCATION 1 1128 ~xi) SEQUENCE DESCRIPTION SEQ ID NO 177 A~ ~-AA AAAl~lll~l TAGCTCATTG GTTGCGTTTG GA~~ L~l~ GGCTAATGTG 60 rAArACGCTC TTAAAGCTCG CAAGAAGCTC TTAAACAATA CGCATGATTT CTTAGAAGAC 180 l"l~G~l"l"l"l"l~A GAAAACAAAA AATCAAAGAG ~ ~GATT ACAGAGCTAA A~'1"1'~'1"1"1"1'A 240 GATTTAGAAA ACAAGTACAA A~AAGAAAAA GAGGCTCTAG AGAAAGAGAC AAGAGGTAAA 300 CTTTATAAGA AAC~ CC TAACCCTTAT GCTTATGTTT TAAACCAAGA AACATTCACG 420 AAAAAAArTA CCGCTACCAC TAAAGATAAG GCTCAGGCTT TGCTTCAAAT GG~ l 540 AAGATCAATG AGAAATACTT AA~GG~lAT GAAGCTTTTT CTAACTTGTT GAAAAATGTC 840 GcArAAAAAc AAAAATTGTG ~ TTAGACAGCT TCAATTTTGA TACCCAATCC 960 AAAAAATCTA TATTAAA~AA GACTAATGAA TACAATATCT TCGTAGATAG CGATCCTATG 1020 ATGAGCGACA A~ACAACTAT GCAAAAAGAA CACTACAAGA TATTTAATTT CTTCA~AACA 1080 G~lll~C~lG CATACCGGAA CAATGTTGCC AAGAATAACC CCTTTGAA 1128 (2) INFORMATION FOR SEQ ID NO 178 (i) ~kQU~:~ CHARACTERISTICS
(A) LENGTH 1056 base pairs (B) TYPE nucleic acid (C) STRAN~ S double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 1056 (xi) ~ u~-~ DESCRIPTION SEQ ID NO 178 l~l~ATCC GTAACGATAA GTTAGGCGAT TTTATTTTAG YGATTCCCGC TTTAATCGCT 120 CTCAAGCATG ~"l"l"l"l"l"l'AGA AAAAGGCGTA GAAGTGTATT TGGGCGTGGT TGTGCCTAGC 180 TATACCACCC CAAll~--ll~l~ AGAATTCCCT TTCATTGATG AAGTTATCAT AGAAGACAAC 240 CATTTAGCCA CCACCCYCAA AAACCGCTCC ATTGACGCTC TTA~ A~ AAT 300 AAr-ArrAAA~ TCTATTCTTG GCTTTATCAA AAGAGAGTGC GCCAAAACCG ~ ATGC 420 TTAAAAArrG AATACGAATA CAATTTGGAC TTAATCCATG ~l"l"l"l'~'l'AA AGACTACGAT 480 ~-lCC~l~AACG CTCAACTTAA AAAAATCGCA TGGAAGCTTA AAGACAAATC CAAAGAGCGA 540 ArArA7~7AAr TCCTTAAAGA AGTCCCTTTC GCTCACCTCT ATGATACGAG CCATAGTTTA 780 GTGGATTTAG CCAAATTGTG CGCGAATTTA AG~l~l'~lA TCGGGAACGC TTCAGGCCCT 840 TTGCATGTGA ACG~l~ ATT TGACAACCAA TCTATCGGGT TTTACCCTAA CGAACTCACC 900 ~C~l~l~ATTG CCAGATGGCG GC~ll~l~AAC r'A~AATTTT TAGGCATCAC CCCGCCTAAT 960 SUBSlllult SEEr ~RllLE26) CA 0222339~ l997-l2-03 W O 96/~ 3 PCTrUS96/09122 AT~A~AAAAA A~l~c~ LCA TCACATGCAA GAAAGA1056 (2~ INFDRMATION FOR SEQ ID NO:179:
Qu~ CHARACTERISTICS:
(A) LENGTH: 264 base pairs (B) TYPE: nucleic acid ~C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii~ HYPOTHETICAL: NO
~i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...264 (xi) ~:~u~N~ DESCRIPTION: SEQ ID NO:179 ~G~l~l~l~ TAl~CC~l~AA AATAGAGGCA ATTTCTAATT TTTATGGGTT ATGC~ A 60 ~GGGl~ll~l TAGCATGTTT TTA~ lA GACGCTTATT ATCTCATGCA AGAAAGGCTG 120 TTTAGGGAGC AATACCAATG GCTAATAAAA AACCGACTTA AAACCGATGA AAGG-l'~l 1"1' 180 GAAGTCTTCC CTATTCATCA AACTTGCCAA TCAACGCAAT TCTTATCGCC ATG~l~lC~l~ 240 TTA~ CCCCTATTGG GCGT 264 (2) INFORMATION FOR SEQ ID NO:180:
~N~: CHARACTERISTICS:
(A) LENGTH: 315 base pairs (B) TYPE: nucleic acid (C) srR~Nn~n~ double (D) TOPOLOGY: circular (ii~ MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...315 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180 A~l~l~LL~LAG GGGCAGTGGT CAGCTCACTC CTTTGCCATA AGTTAGAGGG GGCAATATTA 60 AAAGGCA~AA AACGCCTTCT TTACAATTAT ATTAAAGCCC ATA~ ~Yl~ AAA-~ A 180 ~U~ Ult St9~tl ~RULE 26) CA 02223395 l997-l2-03 wo 96/40893 PCT/US96/09122 ~2l INFORMATION FOR SEQ ID NO:181:
(i) ~yu~ CHARACTERISTICS:
_ (A) LENGTH: 228 base pairs lB) TYPE: nucleic acid ~C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ~iii) ~Y~O'l'~llCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix~ FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...228 (xi) ~QU~N~-~ DESCRIPTION: SEQ ID NO:181 ATGA~AAAAA CAACCCTCTT TGTATTGGGC TTATTATTCA ATAGCTCTTT AAGCG~~ 60 GATGGGATTT CTCA~ACCGA GC~l~ TTGAATTTGG CTGAAGATAG C~l~C~ 120 AACCATTCTA ACGCCCAAAA A~ A AAAAACGCAT GGAATAGGGT ~l~ AAT 180 (2) INFORMATION FOR SEQ ID NO:182:
(i) ~Qu~N~ CHARACTERISTICS:
(A) LENGTH: 294 base pairs (B) TYPE: nucleic acid (C) STR~N~ xS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...294 (xi) ~QU~r DESCRIPTION: SEQ ID NO:182 GTGAAAAAAr~ TAGAATCCAT GAA~ i~ CCTTTCATTG ACATCATGCT ~ A 60 GTGATCGTGC TCACAACGGC ~l~l"l"ll~lG CAAACTTCAA AGCTTCCTAT TAGCATTCCT 120 CAAGTGGATA ArrATArCAC TGATTCTAAA GA'l~l~ ~G ACAA~AAACA AGTTACGATC 180 GCTATTTCTA ATAArr~rTTc TTTTTATTTT GACGATAAAG AAATCAGCTT TGAAAATTTA 240 r~r~ArG TTTCCACTTT GGCTAAAGAC ACCCCTATTG TCTTTGCAAG GCGA 294 (2) INFORMATION FOR SEQ ID NO:183:
_ (i) ~yu~ CHARACTERISTICS:
(A) LENGTH: 486 base pairs (B) TYPE: nucleic acid (C) STRAN~ S: double ~u~~ SHEE~ (RIILE 2-6) CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv~ AWTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 486 (xi) SEQUENCE DESCRIPTION SEQ ID NO 183 ATGGGATCTT ACACATTCCC TCTCATTTTG AAGCCAATAT TTATAAACAA A~'1'GC~'1'~'1'A 60 ~l~l~GGGA GCATCAACGC CTTAAACGAT GAAATCAGGT TcAAAcGcAA CGCCCAAATA 180 GAAGAAGCTG AATTAGGGAC AGACGGGATT AAGATTAAGC CTA~l~G~lnl~l~ GTATAACCCT 240 AGTGAGGGGT ATTTGAATTA CGC~l~ 'L AGC~ A TTTTCATCTT ACACCAGGTG 300 AAGAAACAAA ~l~G~l"l"l~AAG GCTGTGCGCA AGA~l~llGG TGTTCATGGG GGC~ll~ AGC 420 ~l"l"l"l"l~l-l"l~ TATGGTATTT TGGGGCGCTG ~l"l"l"l~l"l"l"l"l~ ATGGGATCGA ACGGCATGGA 480 (2) INFORMATION FOR SEQ ID NO 184 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 174 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature ~B) LOCATION 1 174 (xi) ~Q~N~ DESCRIPTIO,~ SEQ ID NO 184 GTGATTATGA CTAAGCTTGA TGGCACTT-T AAGGGCGGAG CGATTTTARG C~L~ AT 60 GAGTTGAAAT TACCCATTCT TTATTTAG~A ATGGGCGAAA AAGAAGACGA TTTGATCGCT 120 TTTGATGAAG AACGCTTTAT AGAAGATTTG GTTGATGCGG ~~GA ACAA 174 (2) INFORMATION FOR SEQ ID NO 185 QU~N~ CHARACTERISTICS
(A) LENGTH 198 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) S~ ultSHEEr(RU~E26) CA 0222339~ l997-l2-03 WO 96/40893 , PCT~US96/091Z2 , 217 ~2 (iii) HYPOTHETICAL: NO
_ (iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori ~ (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...198 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:185 ~l~l'~l~GGG CTCATGGAAA GAGCAGTATC ACGGYCATGT TGAGCGCGAT ll~CCCCG~l~ 60 GATATGAGTT TG~'ll~l"ll~A ASCCGATGAA AGTGATTCAA ~'l"l"l"l"l"l"l'AT TTTCCAACCC 180 (2J INFORMATION FOR SEQ ID NO:186:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 231 base pairs (B) TYPE: nucleic acid (C) STRA~~ S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...231 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186 ACAGAAAAAA CAGAATTAAA TAACAAGATT A~ AG CCACAGA~AA AGAAAGGTTA 180 (2) INFORMATION FOR SEQ ID NO:187:
(i) ~Qu~ CHARACTERISTICS:
(A) LENGTH: 555 base pairs (B) TYPE: nucleic acid (C) STR~N~N~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori S~ ult SHEEI (RULE 26) , CA 0222339~ l997-l2-03 W O 96/40893 PCT~US96/09122 , 218 (ix) FEATURE:
(A) NAME/KEY: misc_feature ~B) LOCATION 1...555 (xi) ~QU~:N~: DESCRIPTION: SEQ ID NO:187 ~AA~ATA~CC CCCTAAAA~A AGAGCCTAGC ACAAAGGAAG TAAAAATCCC TAAAAAAAGG 120 C~~ ~A TAAAAGAACT TAATGAATTT TTGCTAGAAT TTGGCTCATT TAAAGAGACA 240 GAGCAA~AGC TTTTAAAGCA ACTAGAAAGA TTACAAAACA AAGAAAAGGG AATAATGAAA 360 GCTAATATCT TAGCCAATAT G~l~ lGCT AAGATAAGCA ATGAGAATGC CCCTAAAATT 540 (2~ INFORMATION FOR SEQ ID NO:188:
(i) ~:Q~N~: CHARACTERISTICS:
(A) LENGTH: 432 base pairs (B) TYPE: nucleic acid (C) STR~N~nN~S double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...432 ~xi) SEQUENCE DESCRIPTION: SEQ ID NO:188 Al~G~'l~l' ATGGGATAGG CATTAGCCGG TTGCTCAGCG TGATTTTAGA GCAAAAAAGC 60 GATGATCTAG R~~ ~l~l~ GACGAAAAAT ACCG~lC~l~l~ TTGATGTGGT GATCGTGGTT 120 CAAAAGGGCG TTGATGCGCT GTTAGATGAC AGAGACGCTC ~~ l~GGC GAAGATGAGG 240 ATTA~-AA~-~A AAAATTTTAG AAATGTTAGC GAGCGAATAA GGGGAGGGAA TGGAAAAAYT 420 (2) INFORMATION FOR SEQ ID NO:189:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 270 base pairs (B) TYPE: nucleic acid (C) STRAN~N~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

ultSHEET (RUL~26) CA 0222339~ l997-l2-03 WO 96/40893 PCT!U~,C/~3l22 .. .
(~i) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 270 (Xi) ~ N~' DESCRIPTION SEQ ID NO 189 ATGGAAATAC AACA~ACACA CCGCAAAATC AATCGCCCTT TA~l~ L CGTTTTAGCA 60 GGAGCGTTGA TTAGCGCCAT ACCGCAAGAG AGTCATGCCG CL~ LAC GACCGTGATC 120 ATTCCAGCCA ~ GGGGG TATCGCCACA GGCACTGCTG TAGGAACGGT CTCAGGGCTT 180 CTTAGTTGGG GACTCAAACA AGCCGAAGAA GCrAATAAAA CCCCAGA~AA ACCCGATAAA 240 (2~ INFOR~ATION FOR SEQ ID NO 190 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 804 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii~ ~OLECULE TYPE DNA (genomic~
(iii) HYPOTHETICAL NO
(i~) ANTI-SENSE NO
(~i) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 804 (xi) SEQUENCE DESCRIPTION SEQ ID NO 190 ATGTCAGAAA AA~AA~CT GAATGAAGTG ATCTTAGAAG AAGAGAATAA TGGGAGTGGT 60 ACTAA~AAGG ~ LAT CGTGGCCATA GCCATTATCA TTTTGGCGGT GCTTTTAATG 120 L~ L-GA AAAGCACCAG A~'1'L'GL'1'C'~"1' AAAGAGACTT TTTTACA~AC CGATAGTGGC 180 ATGGATTCTC CCAAACAAGA AGACAAGTTA ~-ArAAA~-TGG TGGATAATAT TAAAAAACAA 300 rA~AAAA~AC AAGAATCTCA AAAAGAATTA AAAGCTGTTG AGCCTATTCC CATGAGCACT 420 CAAAAAGAAT CTCAGGCTGT GGCTAAAAAA GA~ACCCCCC ATAAAAAGCC TAAAGTAGCG 480 CCAAA~TA AAGAAGCGCA TAAAGRTAAA GCTAAGCATG CAGCTAARGA GCCAAAAGTC 540 AA~AAArAAG CTCGTAAAGA AL-~lll'LlAAG AAAGCTAATT CTAAAACCAA TCTTACTAAA 600 GGGCATTATT TGCAAGTGGG G~ L-CG CACACGCCCA ACAAAGCCTT TTTACAAGAG 660 CCTTATAAr-A GCAAGCAAGA AGCCTTAATG CATGCCGATG AAGTCAGCAA GAAGATGACT 780 AA~rr~llG TCATAGAAGT GCGG 804 (2) INFORMATION FOR SEQ ID NO l91 (i) ~QU~'~L~ CHARACTERISTICS
(A) LENGTH 513 base pairs (B) TYPE nucleic acid (C) sT~ANn~nNEss double (D) TOPOLOGY circular (ii) ~OLECULE TYPE: DNA (genomic) SUBS~ Ul~SHEEr~MIIE2'6) CA 0222339~ 1997-12-03 W O 96/40893 , PCT~US96/09122 ~iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...513 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l91 CATTTGAATC TGTTCGCTAT GCCTAAAGCT AAGCACATTA AAGAAGCCAC GAGC~ A 120 GAGCGCTTGG ATTTAGAGTC CTTAAAAGAT CAAGGCATTA ACGATTTGTC C~G~l~AA 180 GAGCCTACGA GTGCGTTAGA TTTAAl~AAC CAAGCCCTTT TTTTTGATGC GATTAAAGAT 300 GAGATGAAAA AACGAGAATT GAG~l'l~ A GTCAATATCC ATGATCCCAA 'l"l"l'~'l"l'~C 360 AGGCACTCCA CGCATGTGGT CATGCTCAAA GATAAAAAAC ~ L~ ~CA AGCTTCCACG 420 (2) INFORMATION FOR SEQ ID NO:192:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 306 base pairs (B) TYPE: nucleic acid (C) STRAN~r~N~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA ( genomic) (iii~ HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...306 (Xi) ~'~U~:NC'~' DESCRIPTION: SEQ ID NO:192 ATGATGGCAC ATTCACTTAT ~ A AAAACATCAC TCTCCAACCT GCTTATTTTT 60 ~ wll~CAAC CTGATGGGAA ATTGAGCATG ACTGATGCCG CCATTGATCC TAACATGACT 120 rArAAArCCC TTGTAACAGT GATCAATAAA GGCTATGGGA AAAATCCATT GACAAAAAAT 240 TACAATATCA AAAACTATGG TGAATTGGAG C~ ~ATTA AAAAGCTCCC ~ l"l~lCAGA 300 (2) INFORMATION FOR SEQ ID NO:193:

(i) ~:uU~:N~'~: CHARACTERISTICS:
(A) LENGTH: 711 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) ~OLECULE TYPE: DNA (genomic) SU~Il~ulkSHEEl (RUL~26) CA 0222339~ l997-l2-03 W O 9~ ,3 PCT~US96/09122 ~ 221 (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
tA) ORr~ sM: Helicobacter pylori (ix) FEATURE:
lA) NAME/KEY: misc_feature (B) LOCATION 1...711 (Xi) ~'~U~ DESCRIPTION: SEQ ID NO:193 GTGCTGAATG AAGAGCAAAA TTCATTAGAA GAAAAAGGGG GcGAAAAcAA AAACGAAAAA 60 ACrAATA~rG AAACGCCTAA CGACACCAAT AACGCAGAAG CCGAAGGGCA AATAGAAAAT 360 TTAGACTTGC CTGATTTAAT CGGCAAAGAC 'l'~'l"l"l~AAAA GAAACGATGA AAGCCAAGTG 420 GATGCGATGA TGCAAAAAGC GA~C~l~L~ ~ TATGAGCAAG GGCAAAAAGA TGAAGCCTTG 480 CA~l~ll~lll~ ATAAGATCGC ~l"l~l"l"l~l~G CAAGGGATTG CGAGCCATAA TCTAGGGGTG 540 GATGCGGATT TGTATTATCA TTATCTAAAA ATTGTRAAGA GACAcTrrTGT A 711 (2) INFORMATION FOR SEQ ID NO:194:
(i) SEQUENCE CHARACTERISTICS:
(A) ~ENGTH: 675 base pairs (B) TYPE: nucleic acid (C) STRAN~:~N~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...615 (xi) ~b-Qu~:N~-~ DESCRIPTION: SEQ ID NO:194 ATG~PTArA~ GCTTATTGAC CCAAGCACAG GTTTTAAGCT CTAAAGAAAA TCAAATCCAT 60 CGC~l~ TAGAGCTTTT AGAAGAGGCT AAGCTTCATT TTGAGCCTAA GCTTTATATC 120 ATTAACGCCC CTTACATGAA CG~-L~ l~CG AGCGG~l~GG ATGAATCTAA TTCCCTTATC 180 G~ ACAA GCGClll~AAT AGAGAGGTTA rATArAr~rG AATTAAAAGC CGTGATCGCT 240 CATGAGCTCA GCrArAT~rG GCACAACGAC ATCCGCTTGA CCA~ GC~l~ GGGGATTTTG 300 AATAGCGGGG CGAATTTAGC CCGAATGATT TTA'l~l~ TACAGATCAT CTTGCCTTTT 420 ~CG~C~l l~ TAATGCATGA CAATAAGCCC ATGATCAGAG CCTTACAAAA GATTTCTAAC 540 SU~slu~ SHEE~ tRllLE26) CA 0222339~ l997-l2-03 . 222 (2) INFORMATION FOR SEQ ID NO:195:
( i ) ~ ~:y U kNL~: CHARACTERISTICS:
(A) LENGTH: 1605 base pairs (B) TYPE: nucleic acid (C) STRA~IJ~ S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...1605 (xi) ~uu~N~ DESCRIPTION: SEQ ID NO:195 ATGTTTAATA TTAAAAGGAC ~ AATA ACGATCATAA ~'l"l"l"l"l"l"l'~"l' CA~lu~ l 60 AA~l~lG~l~l~A AAGCTATTGA TTTGCCCATT GTTTCAAATC TCAA~ATTTA CCAAACAGTT 120 TATTGCATGC TGATACCGAG TTA~ A ACCAACAAAA ~~ GCAGA TATTTTGACA 180 ~CG~ll~AGCA CACCATTAGC CACAAGTTTA GCCGCTAGCA Al~l~l~AA ATATTTGAAT 300 ~G~G~l~ll~ AGGACAATGT GAAAGGCAAT A'1"1'~'1"1"1"1'AC A~ATAATTGG CTCAATAACC 540 GCTCAAGCTT CT~rr.AATAT TACAGCTGAT GGTTTAATTT GGCTGATTGG TAAArAATTC 600 ACTGCAAATA AACTGCAAAA CAACACTATA GCCATGCTTG ~~ GCCGC ATTAGAATCT 660 ~ ~l~AAAG GAGCGGACGC ~ CCTGCATATG GTGTAGTCAA TCTGCCTGAT 720 ATTATCATAG GGCAAGGGTC ATATCTTGAT 'l"l"l'~-l"l"l'~''l"l' ACCTAATTTA TA~ 780 GGGATTTTTG TTTTTATTTC TTTTATGAAA TTr-Ar-Ar-AT~ TTTCAAACGG CATTCAGATT 840 AArATAr.r.TT TTrA~TArAT GCGATTTGTT GGGGGGACAT TATTCAAAAT GGCGATGGTC 900 ~ ATCG CCTATGCAGG TTTTGGTTAT CTTTATAAAA ~ ATTC TATTTATTTT 960 GGTTTAGCAG ~'l'~''L'l"l l~G GCTGAATCAA ~'l"l'~'l"l"l"l"l"l' GGGCTTTAGA TTTAGTGCTG 1020 AATTACACTG TTAATTCAAT TTTACCTGCG GTAAGAGCTG 'l"l"l"l"l"l'~"l'AA TGTTGGCAAC 1080 AAL~lC~-l~A ~~ l~llACA AGGCTTGCAA GTGGCAGGTA 'l"l"l'~"l"l"l'ATT CGcTATTTTT 1140ATGCAAGTAA CTATCATTAT GAGAATAAGC AC~ l~ TGAAACCTTT GATAGCGGGG 1200 GCTTTTAGCG GTA~ CCCTATTGCA GTATGTTTGA ~ AGA TTGGTTCAAA 1260 GATTCTATGA A~AArATATT GATATGGTTT ATTAATAATC TGTTTATCTT GGTTCTAGCT 1320 ATTCCTATTT ~ l~CA TTATTGGCAT TCAATTTGAC CATAACGCCC 1380 ~ A TACA~AACAT CAATCAAGGG GGATTGGGTA TCGATTCAAC TATTGCGAGT 1440 ATCGTTAACA CCATTTTCAG ~"l'~'l'~'l'~''l'~'l' ATGGATGGTA GCAGAATGGA TAGAGAAAGA 1560 GA~l~C~ AA ~ GG~AAG A~l~l~l~GA TCTATGTTTA AAGGA1605 (2) INFORMATION FOR SEQ ID NO:196:
( i ) ~ ~yu ~'N~: CHARACTERISTICS:
(A) LENGTH: 426 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOhOGY: circular (ii) MnD~CUT~F TYPE: DNA (genomic) (iii) ~Y~O~l~b~l~lCAL: NO
(iv~ ANTI-SENSE: NO

S~ u~t SHEEr (RULE26) CA 0222339~ l997-l2-03 tvi) ORIGINAL SOURCE:
~A) oRr~NTcM Helicobacter pylori - Six) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...426 ~ (Xi~ ~yU~N~ DESCRIPTION: SEQ ID NO:196 Al~G-~llll GGCAGGCTAT CC~l~l~G ATTTTAAAGT TACCCTTTAT GATGGGAGCT 60 ACCATGATGT GGA~ll'~l~ll~ AGAAATGGCG TTTAAAATCG CTGGYTyTAT GGCGTTTAAA 120 GAAGCGAGTC GTGCGGCTAA CCcG~l"l"~ A CTAGAGCCTA TGATGAAAGT GGAAGTGGAA 180 GTCCCTGAAG AATACATGGG CGATGTGATT GGCGATTTAA ~rAArAAr AGGGCAAATC 240 AATTCTATGG Ac~-~T~ATT AGGTTTGAAA ATCGTGAATG ~l"l"l~'l'~CC GTTAGTGGAA 300 A~ l~ll ATTCTACGGA TTTGCGATCA GCCACTCAAG GGCGTGGGAC TTACTCTATG 360 GAGTTTGACC ACTATGGCGA A~l~Ccl~AGC AATATCGCTA AGGAAATCGT GGAAAAACGC 420 (2) lN~ukhATION FOR SEQ ID NO:197:
(i) SEQUENCE CHARACTERISTICS:
~A) LENGTH: 459 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ~iii) ~Y~O~ lCAL: NO
~iv) ANTI-SENSE: NO
~vi) ORIGINAL SOURCE:
~A) O~T~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature ~B) LOCATION 1...459 ~xi~ ~kyu~N~ DESCRIPTION: SEQ ID NO:197 ATGCAGAATT ~l~CCG~l~AT GGCGAGAGCG GCGATGCTAA CCACATCATC AGCCCCAGCC 60 CCTGAGGGTG AA~G~G~l~ TAGAGCCATG AAAATGGCTT CAGAAATGGC GAAAGTGGAA 120 GTAGGCTATG T~-~ACG~CCA TGGGACAAGC ACGCATTATA ACGATTGGTA TGAAAGCATT 180 GCGTTAAAAA A~ ~GC TCTAAAGAAA AAGTCCCTCC TGTTAGCTCC ACTAAAGGGC 240 AGATTGGGCT ~l~llGG~l~ CTGCGGGGTT AGAAGCCGTT ATTCTATCAT GGCCATGAAY 300 CAAGGGATCT TACLl~l~AC CATTAATCAA GAAACGCCTG ACCCAGAATG CGAYCTGGAT 360 ~ ~lG~LA CTAATGGTGT TGTGATTTTC AAAAAAGCC459 -(2) INFORMATION FOR SEQ ID NO:198:
:yU~N~ CHARACTERISTICS:
(A) LENGTH: 279 base pairs (B) TYPE: nucleic acid (C) sTR~Nn~nNEss double (D) TOPOLOGY: circular - ~iit MOLECULE TYPE: DNA (genomic) (iii) ~Y~Ol~llCAL: NO

SU~Il lul~ SHEEr (~U3lE 26) CA 0222339~ l997-l2-03 W O 96/40893 PCT~US96/09122 ~iv~ ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ~R~NT.~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature . --(B) LOCATION 1...279 (xi) ~r:~U~ DESCRIPTION: SEQ ID NO:198 ATGATACTAA AAAATTTGAT ~ lATTT TTAGCAAAGA GAAAACTTAT TTTCATAGAA 60 (2) INFORMATION FOR SEQ ID NO:l99:
(i) ~:VU~NV~: CHARACTERISTICS:
(A) LENGTH: 264 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ~iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
~A) OR~-~NT~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...264 (xi) ~u N~: DESCRIPTION: SEQ ID NO:l99 TTACCGGTAT TATTAGCGGG CTTAGTGGTG GGG~ AG TCAGTATTTT TCAAGCGACC 120 ACCCA~ATCA ATGAAATGAC ~l"l"l~l~v~l"l"l"l~ ~l~C~l~AAGA TTTTAGCCGT GATTGGGGTG 180 CTGATTTTAA CCA~l~CC~l~ GATGACGAAC ATGCTTTTAG ATTACACCAA AACCTTAATC 240 AAGCTCATTC CT~TCAT AGGC 264 (2) INFORMATION- FOR SEQ ID NO:200:
v~ CHARACTERI STICS:
(A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori SUBS~ Shttl (RIIL~26) CA 0222339~ 1997-12-03 WO 96/qO893 PCTfUS96/09122 ~ 225 (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...345 ~ (xi) ~u~C~ DESCRIPTION: SEQ ID NO:200 GTGGTAACAA CCAATCCTTT AA'l'~G~G~'l'~' ACCAGTCCTG CAACAGGCGT TACTGAGACT 120 A~AAGTTTGG TTATTCAGAT CA$~ ~L~ CTAGCGATCG TAG~ ~ CGCTTTAGGG 180 GTCAAAGGCA TAGrAr-ATAT TTGGAAAATC TCTGATGACA TCAAAAGAGG TCAGGCGACT 240 ~ ~CTT ACGCGCAACC CATAGCTATG TTAGCGGTGG CAGGTGGCAT TATCTATTTG 300 t2) INFORMATION FOR SEQ ID NO:201:
(i) ~'~N~' CHARACTERISTICS:
(A) LENGTH: 573 base pairs (B) TYPE: nucleic acid ( C ) STR ANn~nNEss: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...573 (xi) ~:~u N~r: DESCRIPTION: SEQ ID NO:201 ATrAAAA~TC CCCAAGCTAA ~ AAAA ~ llAA ATCAAGTGGC TGACCAAAAA 60 TACATAr-ATA TGAATGATGA AAAAAACTAT GACCCAAGAG AACCTGAACC CCCTTATGGA 120 GATGATGAAT TTGGGAGCAT TA~ Cll~ TTTAAGCGTT TTATGTATGT CTATAAAGAC 240 AATATCAGTA TTTACATTGT AA'l~CG~l~c-AA ATTGATATAG GCACACTTTC ~ cl"llAGTA 360 AGAGCCTTTT TAr-Ar-Ar-TAT TGCTAAAAAC CTTATGGTCA AAGAAAGCTC TAAACCTGAA 420 GAGCGTATTT TTATCATTGC TGATGAATTT GTTAGATTTG GTAAGTTGCC 'l"l"l'~'l"l'~'l"l'A 480 GAAATGCCAG CA~l~ ~lCG CTCTTATAAT ~ll~l'~CCCT TATTCATCAC GCAAGATTAT 540 ~2) INFORMATION FOR SEQ ID NO:202:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1053 base pairs (B) TYPE: nucleic acid (C) STR~NnEn~CS double (D) TOPOLOGY: circular ~ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~ CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANI~M: HeIicobacter pyIori ~IIIUI~ SHEEl (RIILE26) CA 0222339~ l997-l2-03 WO 96/40893 , PCTfUS96/09122 (ix) FEATURE
(A~ NAME/KEY misc_feature (B) LOCATION 1 1053 (Xi) ~yU~:N~-' DESCRIPTION SEQ ID NO 202 TTGAATAAAA CTT~AAAAAr AAGCTTATTA GCTGGGGTTT TACTAGGTGC TA~~ ~CC 120 A~lG~l~l~GA ATTTATCTAA AGAATTTCCG CAAGAATATA GAGAAAAGAT TTTTGAATGC 300 AAATTTATGG ~ l~AAAT GAAAGAACAC TCTAAAGAAT TCCCAAATAA AAAGCAACTT 480 GAAC~~ ~ GGGGTATAAG TAGAGAGAAT ACTTATAAAG CA~ ~G~AT TAAAGAATAT 600 AGTGATGAAG GAAAGATATT AGC~lll~GC GAAAGAAGTT ATATTAGACA ATATAAAAAA 660 AAAGATTGGG GA~ l"lGG TAAGGCAAAA GTCCCAGAAA CTTGGAGAAA TAAGATTTGG 960 GAATGTATTA AGAATAAAGT AAAGTCCTAT GACAACACTA CCGCTGAAAT AGr-AA~Ar-TT 1020 TGrAAAAAAA ATACTTATTC TA~ CAT CAC , 1053 t2) INFORMATION FOR SEQ ID NO 203 ( i ) ~kyU ~:N~ ~ CHARACTERISTICS
(A) LENGTH 1053 base pairs (B) TYPE nucleic acid (C) STRA~ )~:lJNr:.~S: double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) oRrA~T~M Helicobacter pylori ~ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 1053 (xi) ~yu N~r DESCRIPTION SEQ ID NO 203 A~l~G~l~ATA TTTTAAGCCA AGAAGAAATT GAL~CG~ TAGAAGTCGT TGATGAGAAT 60 GATTTCAAGC GCCCTAATCG TGTGAGTAAG GAGCAATTGC G~ AG GAGCATCCAT 180 ~A~A~AA~GG CTAGGAATCT TTCCAGTCAA ~ A TCA~l~C'~l~ TATTGTAGAA 240 ATCCAGCTTC ATAGC~l~GA TCAAATGACT TATGGCGAAT TTTTGATGAG TTTGCCTAGC 300 AATCCTAGCA ~lCG~l~ CCC TATGATTGAC AGACTATTAG GGGGTAAGGG GAGCGCGTAT 420 GTGATGCAAA TTTTAAAAGA A~l~'l'~'l'~G CCTGTGGTGG AGATGTATCC TACCATTGAC 540 GCTAAAGAAT CCAGCGCGAA TGTGGTCCAA A'lC~'l-~-l~ AAAATGAAAT TTCTATCATG 600 ~ AG AGATTATCAT TGGGCATAGC CGTGGGATGA TGAATATTTG TTACCCGGTG 660 ATGATGGTGT ~l"l"ll~GGCGC GGTGGAATTG AGTTTGAAAG AAATGTTGGA TTTAGATGTG 8 40 GGGrATArTA ~l~C~G~ ~AA TAAAGTCGCT AACGATGAAG TGAGCGTGTA TGTACATAAG 900 SUBS~ tSHEEl (RUIE26) CA 0222339~ 1997-12-03 WO ~ 9,3 PCT~US96/09122 ' 227 AAAAAGCGTT ATTTAGCGAG CGTGGGGTTT CAAGGGTATA GGAAA~CCAT TCAAATTAAA 9 60 GAA~ ATAGCGAAAA AGAACGCACT AAAGAAATTT TAGAAWTGCT WGAAGAACAG 1020 CGCAGGAGGC AAAL11~L~GC GR1~11ATGG AGC 1053 (2) INFORMATION FOR SEQ ID NO 204 QUkNL~ CHARACTERISTICS
(A) LENGTH 570 base pairs (B) TYPE: nucleic acid (C) STRA~ )Nb:~.~: double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iV) ANTI-SENSE NO
(Vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori tiX) FEATURE
(A) NA~E/REY misc_~eature (B) LOCATION 1 570 (Xi) SEQUENCE DESCRIPTION SEQ ID NO 204 ATGCCCACGA TGTTAGCGGT TG~'1"1"1"1"1'~G ~'l'~'l"l'W'l"l"l' TTTTATCCAC GAGCAATGCG 60 GTGAATTTAA CCGACGGGTT AGACGGATTA GCGAGTGTGC CTAGCATTTT CACC~'1'~'1"1'A 120 AGC~ L~1~A ~ L~1~A TGTGGCAGGG AATGCGGAAT TTTCTAAATA .1~ ~1AT l80 TTTGGCTTTT ~ ~1ATAA CTGCAACCCG GCAAGCGTGT TTATGGGCGA TAGCGGGAGT 300 TTGGCAATAG GAGGGTTTAT CGCTTATAAC GCTATTGTTT CGCATAATGA AA~ 1~ 360 GTTTTAATGG GGTCTATTTT TGTAATAGAA A~'1'~'1'~'1'~'1'~ TGATCTTGCA AGTAGGGAGC 420 TATAAAACCC GTAAAAAACG CL''1"1"1"1"1"L'1'A ATGGCACCCA TCCATCATCA TTTTGAACAA 480 AAGWGTTGGG C~-A~ATAA GGTGATCGTG C~1~ ~A TCATTTCTAT GCTGAGTAAT 540 TTA~1~-~1~C TTTTGAGCTT GAAG~1~1~ 570 (2) INFORMATION FOR SEQ ID NO 205 (i) ~YU~ CHARACTERISTICS
(A) LENGTH 1467 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA ( genomic) (iii) HYPOTHETICAL NO
(iV) ANTI-SENSE NO
(Vi) ORIGINAL SOURCE
(A) OR~ANT~M Helicobacter pylori (iX) FEATURE
(A) NAME~REY misc_~eature (B) LOCATION 1 1467 (Xi) ~Y~N~ DESCRIPTION SEQ ID NO 205 ~l~C~ ~ AAAATTTCAT CAACCGCCTA GCCTTTTACA TGGCCACAGG GAGCGGTAAA 60 SlJB~ JltSHEEl (RULE26) CA 0222339~ 1997-12-03 W O 96/40893 PcTAJs96/o9l22 GAAATTGAAA AATArAArCG CAATAAGGAC TATTCCAAAC AAATTGATTT CAAAAACCTT 240 AAAAGCGTTA AGAATAAGGA TTTTTATCGT GCTCCA~AAG A'L"1'~'1"1"1'AAT GAAAGAAATC 300 G.1-111111 ATTACCGCGC AGATTTAATG AGCGATGAAG AAAGCAAGGA AAAC~1111A 3 60 AATTATAAGG A~ 1~GGA TAATGGGGAA AATTATGTGA TTTTAGATGA AGCGCATAAG 420 GGGAATAAGA CTGAAAGCAA AAGACAGGCG ATTTTTAGCC '1'~'1'~'1'~'1"1"1' AAAAGGGTTT 480 TTGAGCGTGG GCGAGTGGGT GAAACTTGGC TATGGTAAAG A~'1'~''1'~'1"1"1"1' ATTGAAGAAA 600 AACAACTTAA A~G~1"1"11AA GGAATTGAAA GATTTAAACG ACAGGGAAAA AGAAATCGCT 660 CATGACCCTT TAATGCTCGT GTTCACGCAT ~ ~AACA TGGAAAACAG CGATGCGRAA 780 A'1'-"1"1"1"1"1"1'A AAACTTTAGC GCGCGTGATT GAAAATGATG ATGAGAGCGA '1"1"1"1"1'~'AAAA 840 GCTAAAGACG ATTTATTAGA GGAATTAAAG AATCCGGAAT TC~'1"1"1"1"1'AG CGATGGCAAA 900 ATTAGAATAG GCGATATTAC AGAATGGATC CGTGAAAAAT TAAAGAGCGT GAAG~1~1~ 1140 AG~AAr~AATT TGAGCTTCAA AGAAGAGAGC TATTTCAGCC AGATTGATAA GAGCAGTATC 1200 AATATCTTAG 1~G~1.1~ 1~1~111GAC A~T~G~1~GG ATAGCACAAG GCCTAGCGTG 1260 (2) INFORMATION FOR SEQ ID NO 206 O~N~ CHARACTERISTI CS:
(A) LENGTH 639 base pairs (B) TYPE nucleic acid (C) STRAN~ S: double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iV) ANTI-SENSE NO
(Vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (iX) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 639 (Xi ) ~ ~ QU ~ N - ~ DESCRIPTION SEQ ID NO 206 ~1~111AAAA ATTCCCTCTT TGGTATATCA ATCTCCATGC TTATCACTTG G~llllAACC 60 GCTTGTATTT TGATTTTTAT C~1~ 1~1'C CCGAATTTTA CCCTTACGCA TCCCAATTTT 120 CATTTCACTC CGTTTGAAAA AACCTATTTT CAAATTCTAG GA~11~11GG TATTGTAAGT 180 TTTAGCSCGA C~"l"ll'~W'l"l' TTTTGGCTTT TTA11~111A AGGAATTTTA TTCTAACGCG 300 CCAAGTTTAG TCAATACTAT AATTTTATAC TTTTTAGCTT G~1111~CGC GGGCATTATG 3 60 AA'1"1"1 l"l~CC CCATTTTCAT GAGCGATGTG TTTAGCGCTA RAATCCGTTT TAGCGGGATT 420 1~.111~11 ATAArATAr-C CTATGCTATA ACCGCTGGCT TTACCCCTCA ACTTTCAAGC 480 TATATCCTTA TA~11~1-111 AA11~.1111~ ATTACATCGC TTTTAATGGC GCCAATTTAT 600 rPr~AATCTA ATACCCAACA CGAAGTGTCG CCCACGGCA 639 (2) INFORMATION FOR SEQ ID NO 207 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 936 base pairs SU~ ult S~EEr (RU~26) CA 0222339~ l997-l2-03 WO ~G/~fi~3 . PCT~US96/09122 ~ 229 (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular - (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) AWTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...936 (xi) ~kQu:Nck DESCRIPTION: SEQ ID No:207 GG~l"l'~ATTT TCGCGCTCTA TC~ T~l~ TTAATCTATC AATGTATTGC CACAATTAAA 120 G~l~w ~AA GCGGTAAAAC GCCCTTCATT TTAGAAATCG CTCCAAGATA CCAAGAAGTG 240 GCG~l~ CTAGAGGGTA TCAACGGGAT TCTAAAGGTT TAGTGGTGGT GAGCGTTAAA 300 GGAAACATTT TA~l~lC~l-A AAAAACAGCG GGCGATGAAG CCTATCTTTT AGCCTTAAAT 360 GAATTAGGAT CAAAGATCGT ~ AGAC GATGGTTTTA GGTTTAATTT CAACCAATTC 480 AATGCGCTTT TAAAACCCAA AGTCCCCCCC TACTACCCTT 'l"l-l~-l"l"l'~CC TA~CG~l~l~ 540 TATArAr~AA ATATTA~AAG CTATAAAGAA GCCCATTTAG TCATTACAGA AGATAAGGAT 600 TATCAAAGAA TCACCTCTAT CACTAACCCC ACCA~ACGCA TGCTTTTAGT AACGGCTATC 660 GCTAACCCTA GCAGGCTTGA TGC~l~ A CCCAAAGAAG TGGTTAAAAA ATTGTATTTT 720 AGAGACCATG CCC~ll~ ~A TTTGAAGCTT TTAGAAAAAG AGTTTTATCA AAATAACGCC 780 A'l-~l"l'~ A~lC~ AA TATAAAAGAA CATCTA 936 (2) INFORMATION FOR SEQ ID NO:208:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 168 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...168 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:208 Al~lcl~llAG GGGCAGTGAT CAGGCTTATT ~ ATA AGTTAGAGGG GGTAATATTA 60 AAr~ Ar~ AAAATCCATT ATCTAGTRCT TCAAAGTTCA TATTGCTT 168 SU~lllult SHEE~ (~IULE24) CA 0222339~ l997-l2-03 ~ 230 (2) INFORMATION FOR SEQ ID NO:209:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 684 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) tiii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...684 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:209 ATGCTAGA~A CCACTATTGA ~l"ll"l"l~l~l~ TACAGCAGCG TGAAAATCGG ~l~CGC~l~ A 60 AAAGTGAGCG TTTTAGAAAA C~TAATGAA A~ ~AAG AACACCAGAT CATAGGATTA 120 GATTATATTT GCGATAAGGG TGA~l~G~l~ GAGGTAGGGG GAGCGGCCAA TGCGTCTAAA 240 ATTTTTAATT ATTTTAGGGC GAATGATTTA GAGGGTTTAG A~lll~ AGG GCAATTGCCT 300 GGCACTTTAG GGGCGTTAGT TAAAATGAAT G~l~GCATGA AAGAATTTGA AATAAAAAAT 360 GTTTTAGAAA GC~l~l~C~l~ TAATGGCGAA TGGCTAGAAA AAGAAGCTTT GGGG~lAGAT 420 TATCGCAGCA GCGGGTTTAA TGGC~ TTGAGGGCTA GGTTTAAAAA GACGCATGGT 480 TTTAGAGAAG GG~~ AAA AGCGTGTAAA AGCATGCGCA AAAGCCACCC CAAATTGCCT 540 AA~ ll~GGA G~~ ~AA AAACCCGC~l~AACGATTATG CGGGCAGGCT TTTAGAGGGC 600 GTGGGCTTAA ~ ATTG TCTAAAAGAG l~G~l"l"l~C CAAAGAACAT GCGAATTTTT 660 (2) INFORMATION FOR SEQ ID NO:210:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 267 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~Ol~:llCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...267 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:210 ATGGATGGCT ACA~ll~lC~C CTCTGAAGTG CGTAAATACA ATAAATTCAA AAACCTGCCC 120 TTGATCGCCG TTACCAGTCG GGTAACTAAA ~Gr-A~ A TGCGCG~C~l~ TGAATCCGGC 180 AGCATTA~AT TAGAAGGAGA CCAATCG 267 SU~ ul~ SHEEI (RULE2-6) CA 02223395 l997-l2-03 (2~ INFORMATION FOR SEQ ID NO:211:
( i ) ~ l~yu ~:NI_ 1~' CHARACTERISTICS:
(A) LENGTH: 333 base pairs ~B) TYPE: nucleic acid (C) STRA~m~nN~S double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ~iii) HYPOTHETICAL: NO
(i~r) ANTI-SENSE: NO
(~ri) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...333 (Xi) ~l~:yurN~;~: DESCRIPTION: SEQ ID NO:211 ATTGAAACTT TAACGACTAA Al(iC(~ GAA GGCATCACGG CTAATGAAAA GATTTGCCAC 120 GATTATGTTT TTAACAGCAT TGGCATTGTT AC-:GCG~ l~A ACCCTCATAT CGGCTATGAA 180 AAATCCGCTA TGATCGCCAA AGAAGCCTTA A~AGCGATC GCTCTATCTA TGATATCGCT 240 (2) INFORMATION FOR SEQ ID NO:212:
yU~N~: r' CHARACTERISTICS:
(A) LENGTH: 195 base pairs (B) TYPE: nucleic acid (C) STRAhL~EL)N~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...195 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:212 A~ C~ll~ TATTAGCCCA AAAAAGCGCT ATTAAACTCA TTCTTATCCC CCCAAGCGCG 60 AACGCTTTAG GCATCGCTTC TATTTGCGAA TTGAGCGAAG AA~ ~A ACATGAAAAA 120 ATCGTAGGCA TTCGCGCTCA AGGGGATTTC ACTATCAATA GCGACGATAG GG~ iG 180 (2) INFORMATION FOR SEQ ID NO:213:
NL~: CHARACTERISTICS:

SU~lIIUlE SHEEI (RlllE 26) CA 0222339~ l997-l2-03 W O 96/40893 PCTnJS96/09lZ2 (A) LENGTH: 804 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...804 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:213 ATGAAAAAAC ~ LL~ ACT CTTAGAGCAT AAGATCGTAA AAATTGGCTT AATTATTGTG 60 A~ll~l~l~l~AG TGG~l~ Ll~l~lL~LAT GAACAAGAAA TCAAAGAAAA AGCTGTTAAT 120 ~llL~lCAAG GTAAATTCCC CACTTCATCT TAl~Ll~ lC AAGCTTACGA AGGCATTAAG 180 AATACCGCTA ACGAAGATGA AAAAAACCGC CTGGTGATTT TAGC~L~LCG TATTAGCAGC 420 CAAAAAGAAA CGCAACCTCC CATTTCTATA AAAAATAGCG ~ lCACAT AAAATCCAAA 480 GAAAAACGAG AACTTGAAAA AGAATGGGCA AAACCTAGTG ~L~ l~G 'l"l'~ll"l"llCC 540 TTGCTTTCCA ~LL~l"l'~l"l'C 'l"ll"ll~'l"l~l' TTTGAAGTTT ~l~ l'ATC AAGGGGAATA 600 TTATTATCTT CA~L~ l~ CCATCCACTT ~l~l~l"l"ll"l"l~ ~'L~l~l'AAT AGGATTAATC 720 ~l"l"l"l~l"l"l"l"l~ CTAAGTTTTC TAGAGAGCTA GTGAATGCGT CTAACAATTC GCTTGAGTTT 780 (2) INFORMATION FOR SEQ ID NO:214:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 300 base pairs (B) TYPE: nucleic acid (C) STRA~ SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...300 (xi) S~:~u~:N~: DESCRIPTION: SEQ ID NO:214 AGCr.~AAA~G AAGAAGACAT CATTAAGGAT ATTTTAAAAG GCATCAATAA ~ L~ l'AAA 120 SU~l~lul~Shtt~ (~VI~E2'6) CA 0222339~ l997-l2-03 W O ~6/1~93 PCTAUS96/09122 . 233 (2) INFORMATION FOR SEQ ID NO:215:
(i) S~:yU~:N~ CHARACTERISTICS:
(A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C) STRA~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iV) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (iX) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...240 (Xi) ~:~U~'N~' DESCRIPTION: SEQ ID NO:215 GTGATGGACA AACTCACTAA AAGCTTGCAA ACGCA~AAA ACTTCGCTTA TTTAGGCAAA 60 (2) INFORMATION FOR SEQ ID NO:216:
(i) ~QU ~:N~ ~ CH~RACTERISTICS:
(A) LENGTH: 615 base pairs (B) TYPE: nucleic acid (C) ST~ANn~nNFcc double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
( iY) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_~eature (B) LOCATION 1...615 (Xi) ~:QU~N~-~: DESCRIPTIG~: SEQ ID NO:216 ATGCGGTATT TTAGAAGCGC l"l"l"l"l-lATTA l~ ATGA CG~l~ ~C 60 TCTAAGCACC ~ AA GCAAACCCCT AAGACTAAGG AGCGGATCCG ACAAGAAGAA 120 GCCAATAAAA AAA~ArAA~A GACTTTGAAT GCCTTGCGCC AATTCAGACT CATTTACATT 180 AACACGCCGG ~ CG~ TTATGATTAC GGCACGATCA AAACCGATAA AGACCACAAT 240 AGCATTTGTT TTAGCCAAAA ATGTTCGGCC AAATGGATTG CTGCAAGGGA ~ ~GC 360 AAGGTGAGCT ATGGGGATTT GTTTGATGAT A'~ AG GGAGGGATAT TTTTAAAGGT 420 TTArGrAAAC GCCACCTAAC CCCTGAATAT GTGATCCAAA GGTTTCAAAA AAGCGGGGAA 480 ATTATCCTTT ATGAAAGAAA AAATGGCCTG A~ TCC AAAACTTGAC TCAAAAAATT 540 GCTATTAGGA TTGAACCCTA TGAGCCTTCT TTGCAAGATT TAr-AAr-ArAA TGAAAACGCT 600 SlJ~Il~ultSlltt~ (RU5LE26) _ CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 ~ 234 (2~ INFORMATION FOR SEQ ID NO:217:
QU~N~ h CHARACTERISTICS:
(A) LENGTH: 372 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) AWTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_fea~ure (B) LOCATION 1...372 (xi) ~Q~N~ DESCRIPTION: SEQ ID NO:217 ATGCGCATTG AAGAAAATGG CGTGATTTCT CTA~C~ A GTAACGGGGT GGTAGAGCCG 60 ~ ~G~lCGCA TCGGTATTTW AGCTTTCACT AACGATCAAG GCTTAAGGAA AATCGGCGGT 120 (2) INFORMATION FOR SEQ ID NO:218:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 279 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicob~cter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...279 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:218 CAAGAGTTCG CTCACTTTGG ATCGAATGAT ~l~GC~ TAAACACCTT TAAAATCAAT 120 GCC~l~GCA ~L~C~L~l~AAG CACCTATGCA AGAGCGATGA ~l~G~l~GA ATTGCAATTG 180 GCT~ G ~ GAA TTTGGGCGTG GTTTATTTGC ACAATTTGAT TTCCAACGCA 240 (2) INFORMATION FOR SEQ ID NO:219:

Sh~k~ ~BIILE26) CA 02223395 l997-l2-03 ~i) S~:~U~N~: CHARACTERISTICS:
(A) LENGTH: 642 base pairs (B) TYPE: nucleic acid (C) STRAN~N~SS: double (D) TOPOLOGY: circular ~ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...642 (Xi) ~'k~U 'N~: DESCRIPTION: SEQ ID NO:219 ~ GAAAG ~ llAAG l'~l'~l"l'~'l"l' TTCAGTTCGT ATGGGTCAGC AAATGACGAT 120 AAAGAAGCCA AAAAAGAAGC GCTAGAAAAA GAAAAAAACA CTCCCAATGG ~ AT 180 AATAGAGTCC TTA~AA~AAT AAAGGATTTG AAGcATTAcG ATCCAGTTAT TGAAAAAATC 360 AAAGACTTTT TTACTTTCAA AAGCATCAGC ACGACCAACA AACAACGCTG ~~ lATCA 480 TTG~CGr-~G AA~r~ A~A AATTTTATGC GATGATAAGC TATATAATGT TTTATTGGCC 540 GTATTCAATT CTTATGATCC TAATGATCTT TTGAAACACA TTAGCACCAT AGA~l~l-lC 600 AAAAA~ATCT TTTATArrAT TACATGTGAA GCGGTATATC TA 642 (2) INFORMATION FOR SEQ ID No:220 ¦ i J ~ ~ yu ~:N~ ~ CHARACTERISTICS:
(A) LENGTH: 234 base pairs (B) TYPE: nucleic acid tc) STr~Nnr~'m~F~S: double (D) TOPOLOGY: circular ( ii J M~T r~rur~r~ TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~-~NT~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...234 (Xi) ~:yu N~ DESCRIPTION: SEQ ID No:220 ~l~GGGG~CA ll~l~LAAA CATGAACGAT CTTTCAACTT ACATGGTTGA GAATTTACTC 60 A'l~G~ll~ A~ ~ TAGCGCTTTA GA~ l~G~C~ TGAAi~AAAGC CATTAATCTA 120 GCGAGCTCTT ~CG~l~ ATCC TAAATACGCC CCTAACCCTT TAAAAGAGAG CGATTTATTG 180 ~A~GG~ILll~ TAGAACCAAC GAATGAAGGC TACGCTTTGC CAAACTCTCT GTRR 234 -(2) INFORMATION FOR SEQ ID NO:221:

SU~ lt SHEE~ (~LE 26) CA 0222339~ l997-l2-03 W O 96/40893 . PCTrUS96/09122 ~ 236 (i) ~:yu~N~ CHARACTERISTICS:
(A) LENGTH: 531 base pairs (B) TYPE: nucleic acid (C) STRANn~n~: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
~vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...531 (Xi) ~:QU~:N~ DESCRIPTION: SEQ ID NO:221 AT~rA~A~ GAAAACATGT ATCCAAGAAA ~ AATG TCATTATCTT ~~ ~GCA 60 TTAAAAATTG GAAAACTTGG CATTTCTGAA TTATACTTAA AACTCAATAA CAAG~lll~ 180 TTGGAAGTTG AG~-GG~ll~A ~ ~CATC AAAAACCCAC TAAAAAGCGT 240 GAAAAACTTA AAGTCAAAGA AATCATTTTA GACGATAAAA ATAAAGCCAA TA~ 360 GATGGGAATA AATAcr~GTT WAGAATTTCC AGGAATCAAA GGGGAATTTT CCCTAGAAGA 420 CGATTAAAAA TATCAAGCTT AAAATCATCA A~ 'l"l' TAAAGATGTT AAAGTCCAAG 480 TGGATGGCAA CGCCCACTAT TCRCCCAAAG rr~r~r~ AT GGCGTTCAAT T 531 (2) INFORMATION FOR SEQ ID NO:222:
(i) ~:QU~'N~: CHARACTERISTICS:
(A) LENGTH: 774 base pairs (B) TYPE: nucleic acid (C) STRAN~:~hhSS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...774 (xi) ~kyu~:N--k DESCRIPTION: SEQ ID NO:222 GTGTCATGTT GGGGAGCGTC AAAAAAGCGG TTTTTAGGGT ~l"l"l~l~l"l"l~ G~GGC~ 60 GTTTATGCGG ~4~ wl~l~AAT GGCAGAGCAA GATCCTAAAG AGCTTATATT TTCAGGTATA 120 ACTATTTACA CGGATAA~AA TTTCACTAGA GCTAAGAAAT ATTTTGAAAA AGCTTGCAAA 180 Grr.~ r-~A ACGr~Ar~ GAGCATTGAA AAAGCTCTTG AACACACCGC TAcTGcTAAA 300 ~ AAAT TAAACGATGC TGAAAAAATGC AAGGACTTAG CAGAGTTTTA TTTTAATGTA 360 Gw~ ATGC TGTCAGCAAC TTTTTATAAC GATATGATAA AGG~~ l~AA AAAAGATAAA 480 AAAGATCTAG AATATTATTC TAAAGCTTGC GAGTTAAATA ACGGTGGAGG ~l~ lAAA 540 TTA~-~r~-rG ATTATTTTTT TGGTGAAGGC GTAAr~A~G ATTTCAAAAA AG~ l~AA 600 SUBSIIlul~ ~n~tl (~ULE 26) CA 02223395 l997-l2-03 W O 96/40893 , PCTAUS96/09122 , TA~ u~l~u-A AAGul~l~l~A GTTGAACGAT GCTAAAGGGT GTTACGCTCT AGCAGCGTTT 660 ~.
(2) INFO~MATION FOR SEQ ID NO 223 (i) ~QU~N~' CHARACTERISTICS
(A~ LENGTH 225 base pairs (B) TYPE nucleic acid (C) STRAhJ~rSS double (D) TOPOLOGY circular ~ii) MOLECULE TYPE DNA (genomic) (iii) ~Y~Ol~kl~lCAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATUKE
(A) NAME/KEY misc_feature (B) LOCATION 1 225 (xi) SEQUENCE DESCRIPTION SEQ ID NO 223 ~'l'~U'l'L'l'-A ull~ ~GGGGC TAGAGGGGGG GTGTATTTGT GTGGGGGGAT TATCCCACGA 60 TTCATTGATT ATTTTAAAAC TTCGCCCTTT AGAGC~C~ll~ TTGAAACGAA AGGGCGCATG 120 GGAGCGTTTC ~l~CG~l~lCCAT CCCTGTGCAT ~~ ~ATGA AAAAAACTCC CGGACTTGAT 180 G~GGC~GGCA '~ AGA AAATTATTTA CTGCATGATA GAATA 225 ~2) lN~uK~ATION FOR SEQ ID NO 224 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 1263 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) ~YPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 1263 (xi) ~U~NC~' DESCRIPTION SEQ ID NO 224 CAAGCTCAAG TCAATCAGTT ACAAAAAGTC AATAACATGA TAA~T~rr-~r TAA~ l"l~ 240 r~A~r~r~ GCATTAGATA CAACTATGAG AATTTAAAGC AAAGCATAGA AAATTGGAAC 360 rr~r~A~T TGTTAAGAAA CAAATACTTA CAGCAACAAT GCCul~l~G~l TAATGTCAAT 420 GcTcTTAcTA ArAA~AAr-~T TGTCAATCTT AAAGATCTCA ATAACCTAAT CACCAAAAAT 480 SUBSIIlul~ SHEEr (RUlE26) CA 0222339~ l997-l2-03 W O 96/40893 , PCTAJS96/09122 ~ 238 GGCTATGGAA ACATGCAATC ACTTGCTGGG GAATTGAGTG GTAGAGcGTG GGGGGAAATG 600 ~ ~lAAAA TGGTAAACGA TAGTAATTAT GAAAGCGAGC AAG~ AGCAACAGGC 660 AATAACCCAG AAGAGCAAAA ACGAAGATTT ~l"l~l"l~AGAG TAAAGAAAAA GGTTAATGAT 720 AATAAGCAGT TA~AAGATAA ACTTGACCCA TTTCTAAAAA GACTTGATGT CCTACAAACT 780 GA~ l~ TAACTGACCC TACAGCTAAC CATAATAAGC AAGGGATACA TTATTGCACA 840 GATAACGAAT TAGAAr~Ar.~ AATCCAAACG CTCACACTTG ATTTAATCAA AGCCTCCAAT 960 AAAGACGCTC A~AGCCAAGC CTACGCAAAT TTCAATCAAA GGATTAAATT ACTTACTCTA 1020 AAATATTTAA AAGAAATTAC CAATCAAATG ~"l'~'l"l"l"l"l'AA ATCAAACAAT GGCAATGCAA 1080 AGCGAGATTA TGACAGATGA TTATTTTAGG CAAAATAATG A~ ~G GGAAAAAGAA 1140 AACCATATAG ACr-A~rAATT AACGCAAAAA AGAATA,AACG A~AAGAGAAAG AGCTAGAATA 1200 (2) INFORMATION FOR SEQ ID N3:225:
(i) ~yu~N~: CHARACTERISTICS:
(A) LENGTH: 330 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) .
(iii) ~Y~O~ lCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORrA~T.~M: Helicobacter pylori ~ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...330 (xi) ~:~u~ : DESCRIPTION: SEQ ID NO:225 GTTCAAGTGG CGGTTATGAT CCTTTATGTG ~l~G~ AA CCTTTAGGGT ATGCGGGAAG 120 GATTATGATG ~GGCG~ l"l' GTGCGCGGGG CATTGCGGTT TTGGGCTTGG AGCGACCCCA 180 ACGGCTATGG TGAATATGCA AACCATCACC AACCACTATG GGCCATCGCA ~ ~G~ll~ 240 A~l~C~l~l~C CTTTAGTGGG AGC~llllll~ GTTGATATTA TTAACGCTTT AGCGATTAAA 300 GG~l~ ~C TTTTGCCTTT TTTCCCTAGT 330 (~) INFORMATION FOR SEQ ID NO:226:
(i) ~:QU~N~: CHARACTERI ST I CS:
(A) LENGTH: 336 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORr-~l.CM: Helicobacter pylori (iX) FEATURE:

SW~ tSh~tl (Rl~lE26) CA 02223395 l997-l2-03 W O 96/40893 , PCT~US96/09122 . 239 (A) NAME/KEY: misc_feature (B) LOCATION 1...336 ~xi) ~kyu~NL~: DESCRIPTION: SEQ ID NO:226 ATGCAACTAA GCCC~ ACA AAGCGCGCTG TTATATTTCC GTTACTTTAT TTATCCGGAA 60 AAAAAAACAA GGA~L'l"l"l'~A TTTAAGCGAT TTAATTTTTA TTGTCATGGT 'l"l"l"l"l"l'AGTC 120 CTA~~ l~ GG~l~l~l~AT GAGCGAAGAA ATTTCTATCA GCTACA~ATGA AGCGAAAGAC 180 TA GCGATGCGTG ~l~ll~l~AAA ATCGCTCA~A AAAGCGTAGC CATTTTAAGG 240 Cr~AAA~-~T TTGGCTTTAA GA~l~C~-llu~ TTTGATCGCT CACGTCATCA ACA~l~llull 300 (2) INFORMATION FOR SEQ ID NO 227 (i) ~yu~:N~ CHARACTERISTICS:
(A) LENGTH: 261 base pairs (B) TYPE: nucleic acid (C) sTRANn~nNEss double (D) TOPOLOGY: circular (ii~ MOLECULE TYPE: DNA (genomic) (iii) ~Y~O~ luCAL: N3 (iv) ANTI-SENSE: NO
t~i) ORIGINAL SOURCE:
(A) ~R~ANT.~M: Helicobacter pylori (ixJ FEATURE:
(A~ NAME/REY: misc_feature (B) LOCATION 1...261 (xi) ~yU~N~ DESCRIPTION: SEQ ID No:227 GTGTATGCGC TCATGGTGGC ~l"l"l"l"l"l~"l' TACATGAGTT All~ ~GG GTATCAATTC 60 TCCAAATTCG TTTCTAAAAA CAACATTTCA TCGCTCTCAT CGCTTTTATC AAG~l~l~l~ 120 CGC~ L~ lG~l~AAT ~~ lCGCTC AGTAGCCTAG AGTTGCGTTA CTTCTCACCC 180 CTAACTATCA TAACCATGCA TTTTGCCCTA ACGCTTATCA TC~'l"l"l"l"l'~'l'AT 240 AAGGCTAAGC C~llL~ATGA G 261 (2) INFORMATION FOR SEQ ID NO:228:
(i) ~:yu~N~: CHARACTERISTICS:
(A) LENGTH: 1257 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTXETICAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...1257 (xi) ~ U~N~ DESCRIPTIOW: SEQ ID NO:228 SUB~ u~SNEEI (RUIE26) CA 0222339~ l997-l2-03 ATGAGGTCTT GGATGAAGAA AAAATACTTC ACG~ l"l'AT TGCAAAGTAG ~ G~l~ATTA 60 G~G~'l"l"l"l'l'A TAG~l~llC' TTCTACCAGG AATCATACTT TTTCAGCCCT TAGTAATCAA 120 GA~AAT~A~- ArrATAA~cT CCCAGTGGTC CATTCCATTA AAACGATTAA CGATGTGAGT 180 TCA~~ TTGAATGGTC TAAAGTCGCT GACACTTATG ACATTGACGG ~l"l"l~l"l"l"lG 240 TA~ GA AAAAAGACTC CAAGCTTAAA AGAATCGCCA CCATTAAAAA CCCTTATGCG 300 TACAAGGGCG ATAAAATTTC CAAACTTTCA GAACCCATTT TAGTAAAAAC ~l~C~ll~ ATC 420 AA~ AG AAAGC~~ TGCAAGCCTT GAATACCCTA AAAGCGTGAA A~ ll~G 480 AGCCCG~ACC CAAATCCCAG ~ ~AAA TACATCATTC AAAGGCAGAA TAAAGACGGC 540 AAATTTTTAA A~ ~GGGGC TGTAAAAAAC CGCTTATTCG TGGAGTTTTT TGATAAAGAT 600 GTTAGAGTGA GTCAAAACCT CACACGACAA ATTGAATTGA ~ll~ATAA ATCCCCAGAA 780 TATTATAAAG ~l~C~l~GCC~'l' AGATAAAACG CATCTTGAAG GGGCGTTACC CAAAGAGCCT 960 CAGll~ ~G ATAAGGACAT GAAAGTGGGC ~'l'~G~'l"l'ATC GCTATCAGGT GGTGAGCGTG 1200 rATAAArATG GTTTAGAGTC GCACCCAAGC AAAGAAGTGC ~'l"l"l'~'l"l"l"l"l' AGAGCGC 1257 (2) INFOR~ATION FOR SEQ ID NO:229:
( i ) ~ ~ y~ ~ ~ L- CHARACTERISTICS:
(A) LENGTH: 378 base pairs (B) TYPE: nucleic acid (C) STRA~ lJN~:cS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~Ol~ CAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A~ oRr.AMT.~M: Helicob~cter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...378 (xi) ~:yu~: DESCRIPTION: SEQ ID NO:229 A'1~'1"1'~'1'A CTAAAACACG CATTAGAGAT CCGAACAAGC AAGAACTTAC ACAACCAAAA 60 ATAAAAGGAT TGAGTATGGG AAAAATTTTA G~~ l~G~l~GCGG AACAAATCTT 120 TTTACAGGTT TATCCAGTGA 'l"l"l'~'l"l"l"l'~'l' ATGATATTAA A~ C~l~ATG 180 G~~ lG GTAATGGTTT TGGTAGCAGC AAATCAGACA AAACCACTAA TAAAATGAGT 360 GTccr~r~Ar- TAAGACTC 378 (2) INFORMATION FOR SEQ ID NO:230:

(i) ~:~u~ : CHARACTERISTICS:
(A) LENGTH: 216 base pairs (B) TYPE: nucleic acid (C) STRANI~:l7N~S: double (D) TOPOLOGY: circular ¦ ii ) MnT~T~ruT~ TYPE: DNA (genomic) SU~ U~tSNE~ IE26) W O 96140893 PCT~US96/09122 ~ 241 (iii) HYPOTHETICAL: NO
(iv~ ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME~KEY: misc_feature (B) LOCATION 1...216 (xi) ~:~U~IN~I DESCRIPTION: SEQ ID NO:230 TATGATCAAG AA~AAGTGGA GGCTTATTTA GAGGAA~AAG GCTATCTAAA CACGGCAGAA 120 TTTGGCGTGT CGGTAATGGC CA~ TATCGTAACC AAGAGATTAC CCCTA~AACC 180 CG~l~AAGA CAGAAGTTAT TTATGAAGTG ATTGAA 216 (2) INFORMATION FOR SEQ ID NO:231:
(i) ~:~U~'NC'~' CHARACTERISTICS:
(A) LENGTH: 333 base pairs (B) TYPE: nucleic acid (C) STRAN~ ~S: dou~le (D) TOPOLOGY: circular (ii) ~OLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) AhTI-SEN-SE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...333 (xi) ~k~U~:N~ DESCRIPTION: SEQ ID NO:231 Al~GCC-GGGC ~ lGAT GGTGCTGCTC GCCAGTTATG AAAG~l~L~ TTCTA~ATTA 60 TTAAAGGTTT CC~ C~AT TGTAGCCATT TCGGCGATTT TCTTGCTCAA ACGCTACATG 180 AGTTTAGAAG AC'~~ lATC CAGTATTCCT AAAGACACGC CCCTATCGCA TAACCCTATT 240 TTTTGGCAAG TGGTGATCCA ~ CAG CGCTGTTAAC CGCTGTTACC 300 A~T~ TCG ~ ~G~A GAAAGAAAGG CAT 333 (2) INFORMATION FOR SEQ ID NO:232:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 426 base pairs (B) TYPE: nucleic acid O (C) STR~Nl~ : double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~l~ CAL: NO
(i~) ANTI-SENSE: NO

SUBSlllultSHEEl (RUIE26) CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 ~vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...426 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:232 A

ATTAGCGATA TTAAAATGGG GCTTATTA~A GGAGGTCAAT GGGGGGTTAT ~ AGGC 120 lGCC~l~AAAG ATAAAAAAGA AGAATACGAG CGCTTGAGTT TAGAGGAATT GCT~AAA~rA 240 AAAGAATTGC AAAGCTTAAA AGA~l~GGGCG ATTTTAATCA ATGTGGGGCG TGGGGGCATT 360 GTGAATGAAA AG~'l"l"l'~GC TTTRRTTTTA GAAACCACAG ATTTGTATTA CGCGAGCGAT 420 (2) INFORMATION FOR SEQ ID NO:233:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 189 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORr-ANT'~M: Helicobacter pylori (ix) FEATURE:
(A) NA~E/KEY: misc_feature (B) LOCATION 1...189 (xi) ~yU~N~' DESCRIPTION: SEQ ID NO:233 GTGAATTTCA ACGCTAAAAA TATTTCAATT GATAATTTGG TAGAAATCAA TAA~ ~ 60 G~~ ~GAG CCGGGAGAAA AGCCAGCTCT ACG~~ ~A ~~ ~AAGC TTCAGAAGGG 120 r~A~r~rMr- 189 (2) INFORMATION FOR SEQ ID NO:234:
(i) ~yUhN~ CHARACTERISTICS:
(A) LENGTH: 930 base pairs t (B) TYPE: nucleic acid (C) STRAN~h~NhSS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~O~l~h~llCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: HelicobaCter pylori S~ tShttl (R~L~26) CA 0222339~ l997-l2-03 W O 96t40893 PCTAUS96/09122 ' 243 (iX) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 930 (xi) ~Q~N~h DESCRIPTION SEQ ID NO 234 ATGCGAACGC TcA~ r~lc G~ AAAA CATGCGATTT TAATGGGCAT GCTTTTAAAA 60 GAATGCCAAG AAAAGTTAAA G~l"l~"l"l"l~A AATTTGAGTG CTAATCATTG ~~l~ l~AGC 120 GCGGGGTATG GGGCGAGTTC AGCGATTAAG AAATTTCAAG AAATTTTAGG G~l~l~l~ATC 180 CCTTCAAAAA CGAAGAAAAA TTTAGAGCCG TATTTGAAAG ATA~l~G~ AAA~C~l~l~ 240 ATTGTAGGGC CTTATGAGCA TCATTCTAAT GAAGTTAGCT GGCGTGAAGG ~ AA 300 GTGGTGCGTA ~ C~ AAA TGAACATGGT TTATTGGATT TAGAAATTTT AGAGCAAACT 360 TT~A~AAAA CCCCTAACAG ~'l"l'~'l"l"l'~"l' GTGAGCGCGG CTTCTAATGT AACGGGAATT 420 GATTTAGCGA ATTTTAGCGC GCATGCTAAC CCTAAAGATT GCGAATACCA AACCG~ 540 TATGCGCCTC ATAAGCTTTT AGGGGGCGTT GGAG~l~CG ~'l'~l"l"l"l~AGG CATTTCTAAA 600 GATTTGATTG ACACGCAAAT YCCTYCGAGT TTTAGCGCAG GGGGC~l~AT TAAATACGCT 660 GGA~ ~ll~C AATTTTACAG GAGCG~l~-lA GCGTATCAAT TAAGAGATGA ATG~ l~ 780 GATTTTATCC ATAAGAAAGA AAACAACCTT TTAAGGGTGC 'l"l~ ATGG CTTAAAAGAC 840 TTGCCCGCTA TTAATATTTA TGGGAATTTA ACGGCGAGTC ~ ~GGGGT AGTGRCTTTT 900 (2) INFORMATION FOR SEQ ID NO 235 (i) ~;kQUh'N~ ' CHARACTERISTICS:
(A) LENGTH 564 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOlnhllCAL NO
(iv) ANTI-SENSE NO
~vi) ORIGINAL SOURCE
(A) OR~NT~M Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 564 (xi) SEQUENCE DESCRIPTION SEQ ID NO 235' AACGCCC--l~A TTTTAGTGCT AGGGACAAAA GCGACGATTC AATCCAACGC CTATGACAAC 180 GCC~l~AAAC AACAAGGCTA TTTGAACATT TCGCATTTAG CTA~~ l~CCT 240 A~l~C~ AG AGATTTTACC CGAAGTGATC ATTTTAGGTT GCACGCATTT TCCCTTAATC 360 GCT~PA TTGAGGGCTA TTTCATGGGG CATTTTGCCC TTCCAACGCC CCCCCTACTC 420 CAAGCTAAAG AA~l~G~ -AA ATTG 564 (2) INFORMATION FOR SEQ ID NO 236 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 426 base pairs (B) TYPE nucleic acid ~C) sTR~n~n~s double SlJ~ ultSnttl (RVLE26) CA 0222339~ l997-l2-03 W O 96/40893 , PCTrUS96/09122 ~ a44 (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) AWTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...426 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:236 ~ l"1~l~GG TGCTATATTT TTTAACCAGT TTATTTATTT G~ ~AT ~ ~G 60 TCTA~AAAAT CCA~L~l~l"l~ TGTGGATAAC GCTAATAAAA TCCAAGGCTT CCATCATGCA 120 AGAACCCCAC GAGCCGGGGG GCTTGGGATC 'l"l"l'~ l"l' TTGCGTTGGC TTGTTATCTT 180 GAACCTTTTG AGATGCCTTT TAAGGGGCCT 'l"l"l'~'l"l~l"l'~'l' TAGGGCTATC GCTAGTGTTT 240 CAAGCTGTAG GG~'l'C~'l"l"l'~ CATCATTTCA TCAACGCCTT TAGTGGTGAG CGA~ ~G 360CCC-"l"l"l"l"l'A GCTTGCCTTA TTTCATCGCT TTTTTATTCG CTA~ A ~l~'l'~'l'~GG 420 (2) INFORMATION FOR SEQ ID NO:237:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 258 base pairs (B) TYPE: nucleic acid (C) STRAN~:~N~:~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...258 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:237 AlGGC~ A AAl~l"ll'~-CC TAAGATCAGA AAAACAGATT GGATTTTTAT TTTAATCGCC 60 CCAAAATCTT CACGCCCTCT TTCACGCCCT ATTGAAAAGC CTAA~AAT~T GACTGAAGAA 180 GAAAGGA,AAA AGC~ AT AGAGTTGCAA AAAGCATGCT TACTTCATAA AGACAAAAAG 240 GCATGCGAAG A~ll~l"l"l' ~ 258 (2) INFORMATION FOR SEQ ID NO:238:

QUk~: CHARACTERISTICS:
(A) LENGTH: 363 base pairs (B) TYPE: nucleic acid (C) STRANn~nN~.cs double (D) TOPOLOGY: circular SU~ Sl~t~ ~RI~LE26) CA 0222339~ 1997-12-03 W O 9t'S~9~ PCTAUS96/09122 ~ 245 (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...363 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:238 GTGGATTCCA TTTTAATTGA TGAAGCGAGA SCTCCTTTAA TCATTTCAGG Gcc~l~l~AT 60 GCCGAAAATC 'l'-"L'l"l'~C~'l' GGATAATTTA TACAAAATTG AAAACGCCGC CCTATCGCAC 240 CATTTAGACC AAGCCTTGAA AGCGAATTAC ~ C"l"l~l"L'l"l'A TTGRTAAAGA TTATATTGTA 300 GC~ATAATG AAGTGGTGAT TGTAGATRRA TTTACCGRCC ~lll~rYl~A AGGGGAGGCG 360 (2) INFORMATION FOR SEQ ID NO:239:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 177 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...177 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:239 ATGACGATCA CCACCCTATC 'l"l"l"l"l"l~ATTc ACAACGCCAG AA~l~ CAATCAGGAT 60 TTCCCATGGC TTTCTGGGGC TGGAAGGCTA ~l~G~l~ AAAG ACTTGGCGTT ATTTGCTGGA 120 GGCll~ l~ TGGCCGGATT TGATCGAAAC GCTATTTGGA GGGTAAAGGG TTTTGCT 177 .~ (2) INFORMATION FOR SEQ ID NO:240:
(i) ~yU~:N~ CHARACTERISTICS:
(A) LENGTH: 426 base pairs (B) TYPE: nucleic acid (C) STRAN~:~N~'~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
S~ ultSEEl (RUILE26) CA 0222339~ l997-l2-03 WO g6!1~E33 PCT~US96/09122 ~ 246 (vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...426 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:240 ~r~l"ll~ ~ GCAATAAAAG GGCTATAAAT TATCGCACGA TTGTCAGCGC ~~ ~l~ATT 60 CAA~l~G~ TAGGGGCGTT GGCTTTATAT GTGC~ GG GCAGAGA~AT ACTGCAGGGT 120 TTAGCTAGCG GC~TA~AAA~- CGTGATTGGT TACGGCTATG AGGGGGTACG ~~ ATTT 180 AAC~l~lllAG CGATCATTAT ~ ~CT AGCTTGATTT CACTTCTATA TTATTTAAA~A 300 AAAGCAGAAA GCATGAGCGC AGCGGCTAAT AY'1'Y'1"1~'1'~G CGCACACCGA AGACRCCCTT 420 (2) INFORMATION FOR SEQ ID NO:241:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...240 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:241 A~l~l~l~ GTATCAGTAA CGCTATTAAT ATCATTGACG GGTTTAACGG GCTTGCATCT 60 GGGATTTGCG CGATCGCGCT TTTAGTCATT CATTATATAG ACCSTAGCAG ~ ~l 120 TTGCTCGCTT ACATGGTGCT TGGGGTTTAT ~~ AAAW TTCCCTTCAG GAAAGATTTT 180 TTAGGWCGAT CGGGGGGGCG TA~ l~G ~ lG~l~R CGGRATTTCT CTCTTGCATT 240 (2) INFORMATION FOR SEQ ID NO:242:
(i) ~r~ N~ CHARACTERISTICS:
(A) LENGTH: 225 base pairs (B) TYPE: nucleic acid (C) STR~N~ ss: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori SUB~ ult SHEEr (RULE26) CA 02223395 l997-l2-03 W ~96/40893 PCTAUS96/09122 ~ 247 (ix) FEATURE:
(A~ NAME/KEY: misc_feature (B) LOCATION 1...225 (Xi) ~:QU~N~ DESCRIPTION: SEQ ID NO:242 ATGCTACATA AAAAATATCG TCCTAATGTT GCGGCCATTA TCA~ ~C~ AGACTACCCT 60 AAr~rA~GcG AA~ AT CGCTGAGCGC ATA~TTG AAGGGGCGTG GCAGTTCCCC 120 (2) INFORMATION FOR SEQ ID NO:243:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 354 base pairs (B) TYPE: nucleic ~cid (C) STR~nFn~CS double (D) TOPOLOGY: circular (ii) ~OLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...354 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:243 TTAAATGATT ~ ~l"l"l"l"lGG TATAGAAGTG GGGCTTGATA GCAATGCGAG AAAAAATCGT 180 AGCAGAAAGG CTATGGAAAA TCATCITATC G~ l~ TCCAAGCTCA ATTAAATTTT 240 A~ AG TAGATATTAG AGAATTTGAG GATTTACGCC AGG~ l~ AAATGATACT 300 AAAAAATTTG A~ ll'~l"l'AT TTl-lAGCAAA GAGAAAACTT ATTTTCATAG AAGC 354 (2) INFORMATION FOR SEQ ID ~ 244:
(i) ~k~U~ CHARACTEP.IC~ICs:
(A) LENGTH: 627 ~ase pairs (B) TYPE: nucle~c ac~d (C) STRANDEDNESS: aouble (D) TOPOLOGY: c~rcular (ii) MOLECULE TYPE: D~;A ~e~omic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...627 SllBSlllult SHEE~ (~UE 26) CA 0222339~ l997-l2-03 WO 9.'s&e93 PCT~US96/09122 ~ 248 (Xi) ~:QU~:N~' DESCRIPTION: SEQ ID NO:244 ATGATCCGTC TAGCCGC~ AGCT CTCGCTTGCG CGATTACGCC AAAAAGCCGC 60 ~ llAA AAAATGTCTT GCTCAACCCC ACTCGCATAG AAGCTTTTGA G~ll~ ~AAA 120 ATTTArATAr- AGCATGCCCC TTTAAAAGCG ATCAGTATTG ATCAGAATAT CGCCAGCCTT 240 ATTGATGA~A ~lCCCCG~~ AAGCATCGCT ATG~ l~ CAAAAGGCAA AAGCATGGTG 300 Ar~AAArGcTA AAGATTTACG AGCCAAAGAA AGCGATAGGA TTAAAGCGGT ~ ~lAAT 360 TTCAATGATC ACAGGATTGC GATGAGTTTC ~ AA CTTTAGCGTT GCCTTTAGAA 540 TTrAAAAAAA GGAGTCTCAA TGGAAAT 627 (2) INFORWATION FOR SEQ ID NO:245:
( i ) ~ ~:yU ~'N~' ~' CHARACTERISTICS:
tA) LENGTH: 225 base pairs (B) TYPE: nucleic acid (C) sTRA~n~NEss: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~l~:llCAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix~ FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...225 (Xi) ~'~U N~: DESCRIPTION: SEQ ID NO:245 ~lw~AGTT TGAAATTTTT AAACGCTATG GGG~ll~ATT TAAAGGTTAA AGAGAGCGCT 60 (2) INFORWATION FOR SEQ ID No:246:
(i) ~:yukN~ CHARACTERISTICS:
(A) LENGTH: 363 base pairs (B) TYPE: nucleic acid (C) STRAN~NESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ( iii ) hY ~Ol~kllCAL: NO
(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori v (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...363 SUB~ ul~ Sh~t~ (RULE 2~) CA 02223395 l997-l2-03 W O 96/40893 , PCTAUS96/09122 (xi) ~kyu~N~-~ DESCRIPTION SEQ ID NO 246 'l"l"l~L~'l"l'~'l' TGCAAATCTT AGAGCCTATG ATCCCGCACA CGGCATGGGA ATTGAGCGAG 120 A~l~lll"lA AAAGAGAGAA TTTCAAGCCT ATAGAAGTAG ATGAAAGCGC TTTGATAGAA 180 ATTAACGCTA GCAAAGAAGA GATTATTATT TTGGCTAAAA AAGAATTAGA ~AA~T~TTTA 300 ~AAACGCGA GCGTTAAAAA AGAAATTTAT ~l~GC~ AATA AA~ AA 'l"l"l"l'~'l"l'ACC 360 (2) INFORWATION FOR SEQ ID NO 247 (i) ~'~yU~N~ CHARACTERISTICS
(A) LENGTH 306 base pairs (B) TYPE nucleic acid (C) sTRANnFnN~ double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPO~ lCAL NO
~iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 306 (xi) ~QU~N~ DESCRIPTION SEQ ID NO 247 ATGAAAGAAA GTATTAAATA cll~clAGAA AG~l~Gc TA~~ AATGAGCGTG 60 AA'l~CCGGG~l''ll~GCGGGCA GAA~l~l-Ll~ A GATCTAGTGC TAGAAAAGTG CTTGAAAGTT 120 AAAGAACTGA TCAAACGCTA CAACCCTAGC ~ l'AG AAGTGGATGG GGGC~l~GAAT 180 GATAAAAATA TCTTTGAACT CCAACAAGCG GGC~l~GATG ~ AGGGAGTTAT 240 A~ ll~AAT C~AAA~ATYG TAAGCTGGCT ATTGAAGGCT TACAGAATGT CAGACAACCT 300 (2) INFORMATION FOR SEQ ID NO 248 (i~ SEQUENCE CHARACTERISTICS
(A) LENGTH 393 base pairs (B) TYPE nucleic acid (C) STRAN~ ~N~SS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix~ FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 393 (xi) ~yukN~ DESCRIPTION SEQ ID NO 248 SUESlllult SHEEr (@ULE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 ~ 2S0 GTGCATGACG GL~'1'~-'1"1~ ~'1'~G~'1'AGGC TTCACTTTGA TTGCGAGCAT GTATCACATG 60 ACCCCTAGGC TTTT QAAAG AGAGATCTAT TCAGGAAGAC '1"1'~'1'~ATTT CCAATTTTGG 120 GGGATGATGT GrArr,rATGT GGATCAATAC GGGAATCTCA CTTACCAATT CATTGACACG 240 GTTAAGGCGC TAA'1'LCL'1"1'A TTA~ATATT AGAGGCGTTG GGG~1~L1"1AT GTATTTTATT 300 GGATTTATTA 'l"l"l"l"l'~L'l"l'A CAATATCTTT ATGACAATCA CGGCAGGCAA AAAATTAGAG 360 (2) INFORMATION FOR SEQ ID NO 249 (i) ~kQ~kNLk CHARACTERISTICS
(A) LENGTH 1323 base pairs (B) TYPE nucleic acid (C) STRA~I)FI~kS~ double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYP~'1'~"1'1CAL NO
(iV) ANTI-SENSE NO
(Vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (iX) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 1323 (Xi) ~YU~'NL~ DESCRIPTION SEQ ID NO 249 ATrATAArGC TCTTTAGTTT TGGAGCGTTC GCTTACTATT ~L TCAAATCAGT 60 TTAAATAArT ACTCTGATTA TAGAGCCATA GAAGATTACC TCTATAAA~AT '1'~GL'1"1"1'AGA 180 AGAAATATTT GGTATGCTGA AG'1~'1"1"1'AAA TTCAGCGATA l~lllllAT CCTTTTAAAA 300 AAGGATGAGC A~1"1"1"1~1~-"1~ TTATAAAGAT TTGCATTCGG ~ L~ ATAG GAATTATTTC 360 TTAGCCATTA LG~l~G~lll ATTATTGATT TTA'1"1'CL'1'L'1' TTTTATTTGT TTTGCAGAGT 420 TTA'1"1'~CC'1"1' TAAGAGAGTT AAGATCTCAA GTGAAACGCT '1LGL1LAAGG GGATAAAAGC 480 TGCATCCAA~A AAATCAATGC GATGAATGAA '1'L'1'CGG~'1"1"1' TA'1"1~1"1"1'GCG CTCTATCATG 600 L'1'~'1'~"1"1'LCA AACGCTTTTC ATCTATATTT GATCACTTGA ACATGTTGAT TGAGCAATTT 7 20 ATCCATGTAT CL'1'L'1"1'~'AAA TTACATCATT GAAGCGGATT TTGAATTGTT TGCTATAGCG 900 T~AAAAAACA T~T~r~rA~ TGCGATCAAA TACAGCGATG ACAAACAGGT ~ ~AT 960 TTCATAGGGA ATAATTTAGT ~'1'~'1'-'CAAT AAAAGCAAAC CTTTAAAAGA AGATTTTGAA 1020 AAGTATTTGC AACCCTACTT TAAATCTTCT AACCCCAGCC AAGCCCATGG ~'1"1"1'~G~'1"1'A 1080 AGCAATGGAA GAA'1'L'1'~'1"1"1' CACTATCCAT GA'1"1'~C~'1"1"1' TTAATAGTTT TTACGATTTA 1200 Gr~Ar~rAA~ AAGCCAATTG '1'G~G~'1"1'AAA GA~AAACAAA AAGAGAGAAC ATGTTCAAAC 1320 (2) INFORMATION FOR SEQ ID NO 250 (i) ~yU~NL~ CHARACTERISTICS
- (A) LENGTH 381 base pairs (B) TYPE nucleic acid (C) STRA~(~ S: double (D) TOPOLOGY circular S~ Ult~HEEr~RUI~26) CA 0222339~ l997-l2-03 WO 96l40893 , PCT/U59C~122 ~ 251 ~ .
(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
tA) ORr-A~T~M: Helicobacter pylori (ix) FEATURE:
(At NAME/KEY: misc_feature (B) LOCATION 1...381 (xi ) ~ ~ Qu r ~ DESCRIPTION: SEQ ID NO:250 ~'l'~'l"l'C''l'~C ~lll~lC~lAT GGGTATCGCT TTTGCCCACT CTA~ L~ GTCCATCACG 60 G~~ l~G TCA~sl~C~l~l~ CGCGCCAAGA AACAAAAAAC AACAGGCCTT A~GG~l~ll~A 120 GCGTTAGGGA ~l~TC~l~ AGC GATGATTTTA GGGTTGCCGC TTGGGAGGAT CATTGGGCAA 180 CCTATATTAA TGAAACGCCC GCTTTTAGTG GGGATTTATT ~l~G~Yl~l~AA TCATGGTTAT 360 (2) INFORMATION FOR SEQ ID NO:251:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) STRANv~N~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPulh~ lCAL: NO
~iv) ANTI-SENSE: NO
t~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...345 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:251 ATGCGCATTA TCATAAGGTT ACTTTCATTT AAAATGAACG ~'l"l"l"l~l"l'AAA ACTCGCGCTC 60 G~llc~ l~A TGGGGGGGCT TTGGTATGCT TTCAATGGCG AA~-~l'~"l~A GA~ CG~l 120 A~ArG~ATTT ~ ll~AT ~'l"l'~'l"l"l'~'l"l''l"l"l"l"l"l'ATCC GCCCTGTGAG TTTCCAAGAC 180 CrAr-AAAAAC GAGAAGAATA CATAGAACGG CTTAAAAAAA ACCATGAGAG GAAAATGATC 240 T~ArAAr-ArA AGCAAAAAGA AGAGCAAATG CGCCTCTATC AAGCCAAAAA ~rArrrAr.Ar. 300 AG QGGCAAA AArAAr-ArCT TAAAGAACAA ATGAAAAAAT ACTCA 345 (2) INFORMATION FOR SEQ ID NO:252:

(i) ~yuk~ CHARACTERISTICS:
(A) LENGTH: 258 base pairs (B) TYPE: nucleic acid (C) STRA~I]~ c: double (D) TOPOLOGY: circular (ii) Mnr~FcTJr~ TYPE: DNA (genomic) ullt SHEEr ~RULE 26) CA 02223395 l997-l2-03 ' 252 ( i i i ) ~i Y ~O'l'~lk'l'l CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ~R~-~NT'CM: Helicobacter pylori (ix) FEATURE:
(A) NAMEtKEY: misc_feature (B) LOCATION 1...258 (Xi) ~:yU~'N~' DESCRIPTION: SEQ ID NO:252 GTGCGATCTT GCAAACAGAT TTTTGATAAG GGTTTAAAGC CCTATTATAA ACA~ ~rl~ 60 TGCTTAAAGC ~'l"l"l'-l"l"l~l'AG ~'l"l"l"l'~'l"l"l"l' CTCAAAATTC ATGCTTATCA ACAGCGTTAT 120 AGAGCGTTTG CTCTAACGCT ~ c~ AA~ A ACGCTTGTAA GATTTTTATT 180 CCCATAATTG ATTTTAAAAT C~ll~ ATC CCTATTCTAA AACACCAAGC CAAGCTAAAA 240 AGA~l~ A ATGCCTAT 258 (2) INFORMATION FOR SEQ ID No:253:
( i ) ~kQU ~:N~ ~: CHARACTERISTICS:
(A) LENGTH: 132 base pairs (8) TYPE: nucleic acid (C) STR~Nn~nN~.CS double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~Ol~kl~lCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...132 (xi) ~k~urN~k DESCRIPTION: SEQ ID No:253 A~l~l~l~GAA ~ AT TGGCTTCAAA ACAAAACTTA CTCAAACAAA GGCATTTATT 60 ATATTGATCC CAA~ ll~A GGACAGAGCG GTCAAAGCGG CAACACGCTC AGCACCTATA 120 ~-~T~TT GT 132 (2) INFORMATION FOR SEQ ID NO:254:
U~N~k CHARACTERISTICS:
(A) LENGT~: 1680 base pairs (B) TYPE: nucleic acid ( C ) STR ~Nn~n~.c~ double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~YPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORr-~T~M: Helicobacter pylori SU~lllult SHEEI (RUIE26) CA 0222339~ l997-l2-03 WO 9G/~ 3 PCTrUS96/09122 ~ 253 .. .
(ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1 1680 -~ (xi) ~y~NL~ DESCRIPTION: SEQ ID NO:254 ATGGGGAATT TTAATAGCTA TGGCGATTTG ~lL-illAACC TCAGTCATTC AGTTAGTCAT 60 TTCAACGCTT CTTCA~AAGA AGTGGGTACT TACACGCTGA TTGATAGCGC TAAAGCCATT 180 AACGGGCAAG CCGTGAGCGT TAAAGATGGC GGTTTAGTTG TAL~Ll~ AA GGACTCTCAA 360 AATCAATACA TTTACACTTC CA~ AT AATAAAGTGA AAATCGCTGT TTCTAATGAT 420 ATCTTTGAAA CTAAAGGAAG LcLl~ ATTc GCTCCCTATT ATCTAGAGAG CCACTCCACA 600 AATTTTAAAA ATGACGCCAC TAATATTTTA CAGATCAACA CCTACACGCA GcAAATGAGT 720 CGTTTAGCCA A~l~Ll~L~l~GA CACTTCAACT TTCGCCCGTT CTGATTTCTT AGAACGCTTA 780 AAATACTCTC AAArr-~TAG AGTTAAAAAT AA'l~l'~'l'GL-G CGACAGGAGT TGGAGGGGCT 900 AGAAGCGAGC TAACCATGAG CTTGAATGAG A~'l"l~LL-G~AT ACAATAAAAC TTTCATCAAC 1140 CCCCAAGTAG GCTTAAGCTA TTATTACATT G~'1"1"1L-'1L1'~ GTTTAAGGGG CATTATGGAT 1320 ATCAATTTTG CCCTAGAAAG TCGGCATTAT TTCAATAAAA ACTCTTATTA ~ ~ATT 1440 GCGGATGTGG GrAr~r~ArTT ATTCATTAAT TCTATGGGGG ATAAAATGGT GCGTTTCATC 1500 GGTAATAACA CCCTAAGCTA ~ArArA~GGT GGCAGATACA ACACTTl'TGC TAGCATTATC lS60 ACAGGCGGL-G ArA~ArATT GTTCAAAACC TTTTATGTGA ATGCGGGCAT AGGGGCTAGG 1620 lL-GGLl~l~ ATTATAAAGA TATTAATATT ACCGGAAATA TTGGTATGCW SYATRCTTTT 1680 (2) lNlukMATIoN FOR SEQ ID NO:255:
(i~ S~yu N~ CHARACTERISTICS:
(A) LENGTH: 423 base pairs (B) TYPE: nucleic acid (C) STRAN~N~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
~iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) nRr~A~T~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1 423 (Xi) ~yU~NL~ DESCRIPTION: SEQ ID NO:255 Gcr~r~ArA~TA AaGGCTATAA CGGCTTAGTG GGGGAATTGA TTGAAAGGAA TTTCCAACGC 120 TA'l~C~l~C CGTTACTGCT TTCTACGCTC ACTAACGGCC TATTGATTGG GATCACTTCG 180 GCTTTAAACA ArAr-Ar~r~A TAAAGAAGAG GTGACTAATT lL~ lGGGGA TTA~ A 240 rAr~Ar~rcA AGAl~CCCC CAll~l~L-l~ ATTAGAGAGG GGAGTAGGGT CTTCATTTCG 360 SUBSIllul~ SHEEr (RULE21~) CA 02223395 l997-l2-03 W O 96/40893 ~ PCT~US96/09122 ' 254 CCrAAT~rTG ACA~ lLl"l~ CCCTATACCC AGAGAGAATG AAGTCATCGC TGA~ l"llG 420 (2) lN~vKMATIoN FOR SEQ ID NO 256 (i~ ~hyu~ CHARACTERISTICS
(A) LENGTH 153 base pairs (B) TYPE nucleic acid (C) S~N~ ;: double (D) TOPOLOGY circular (ii) ~T~FrUT~P TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(Yi ) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 153 (Xi) ~YU N~: DESCRIPTION SEQ ID NO 256 GTGAATTTTT AC~ CGCC CAAAGATTAC CACCACTACC ACGCCCCTTG CGATTTAGAA 60 ATTTTAGAGG ~lC~l~l~ATTT TGCGGGGAAA TTACTACCAG TrAATAArcc CTCATTACAC 120 AAAAAArAA~ A'l'--l~l"l"l'~l' GGGCAATGAA AGG153 (2) INFORMATION FOR SEQ ID NO 257 (i) ~yu~N~ CHARACTERISTICS
(A) LENGTH 699 base pairs (B) TYPE nucleic acid (C) STRANl~ 5 double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
( iY) ANTI-SENSE NO
(Yi ) ORIGINAL SOURCE
(A) ORr-ANT5M Helicobacter pylori (ix) FEATURE
~A) NAME/REY misc_feature (B) LOCATION 1 699 (Xi) ~U N~: DESCRIPTION SEQ ID NO 257 ATGGATATTT TAAAAGCAGA GCATTTAAAC AAACAGATTA AAAAAACCAA AA~lC~l~ ~A 60 GA~ TAGAAGTGAA AAGCGGCGAA ~~ l~GGGC TTTTAGGGCC TAATGGGGCG 120 GGTAAAACCA CCAC~ l l"l'A CATGATATGC GGGCTTTTAG AGCCTAGTGG GGGGAGCGTT 180 TATTTAAACG ATGTGGATTT AGCTAAATAC CCCTTACACA AGC~ LAA CTTGGGCATA 240 GGCTACTTGC CCrAAr-AATC CAGTATTTTT AAAGAATTGA GCGTGGAAGA GAATTTGGCC 300 CTAGCAGGGG Ar-Ar-rArTTT TAAAAACTCT AAAGAGAGCG AAGAAAAAAT GGAAAGCTTG 360 CTTGATGCTT TTAATATCCA AGCCATAAGA GAGCGCAAGG GCATGAGCTT GA~l~GGGGA 420 r~AArAArGC GcGTArAAA~ CGCTAGGGCT TTAATGAAAA ACCCTAAATT C~'l~-''l'~'l"l'A 480 GATGAGCCTT ~l~l~C~GGC~l GGATCCGATT GC~l~ATTG ACATTCAAAG AATCATTGAA 540 AGCTTGATTG GATTAAArAT ~l~G~ lG ATTACTGATC ACAATGTGCG AGAGACCTTG 600 SU~Illul~SHEEl (RIJLE26) CA 02223395 l997-l2-03 W O 96~4a8~3 . PCT~US96/09122 ~ 255 AGC~l~l~CC ATA~GG~-~lA TGTGATCAAA AGCGGCACGC ~l"lnrTAGCGGC GGGAACGCTA 660 ATGAAATTTA Tr-AAAAc~cT ll~l~C~l~A AGTATTATT 699 (2) INFOR~ATION FOR SEQ ID NO:258:
(i) ~:Qu ~N~ ~: CHARACTERISTICS:
(A) LENGTH: 474 base pairs (B) TYPE: nucleic acid (Ct STRAh~:~N~ss: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~-ANT.sM Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...474 (xi) S~yU~N-~: DESCRIPTION: SEQ ID No:258 ATGAAAGAAA TCGTTACAAT AGAGAATGTG ~ AACT ACcAcAA~rcG CGCTATTTTT 60 AAGGATTTTA ATTTAAGCAT TCAAGAAGGG GA~ l'AT GCGTTTTAGG GGAGAGCGGG 120 AGCGGTAAAA GCAC'G~ll"l"l~ AGGCTTGATT TTAGGGCTTT TAAAACCCAG TCTGGGGAGC 180 GTTAAAATCT TTAATGAGAC CCTTTCAAAC AACG~ lll TACGCCAAAA AATAGGCTAT 240 ATCGCTCAGG GCAATTCCTT ATTCCCTCAT TTAAACGCCT TACAAAACAT GA~~ ll~C 300 CTTAATTTAC AAGGCATAAA CAAAr~A~-CC GCTCAAAAAG AAGCCAAAGC CTTAGCGTTA 360 AAAATGGGGT TA~.Arr.A~A~ CCTTATGGAT AAATTCCCTA ATGAATTGAG TGGGGGGCAA 420 GCrAAAr-Ar-T GGGCATTATT AGGGGGATTA TrrArA~CC AGAACTCATT TTAT 474 (2~ lN~MATION FOR SEQ ID NO:259:
(i) ~kQU~:N~' CHARACTERISTICS:
(A~ LENGTH: 573 base pairs (B) TYPE: nucleic acid (C) STRANl)~l)Nh:~s double (D) TOPOLOGY: circular (ii) MnT.F~'.~IJTF TYPE: DNA (genomic) (iii) hY~ul~llCAL: NO
(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~ANT-sM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...573 (Xi) ~yU~'N~: DESCRIPTION: SEQ ID NO:259 ATGATTTTCC ~Cr-A~-CGCTT TCAAAACGCC TTTTTAGGGT TAAGCGAATT GTTTTACTAC 60 G~ll~AGCT TGA~l~l~lL~l~A TACGATTTTG TCTTTATCGC CTAl~ GTTCGTGTTC 120 A~ CATTA CTTGCAAGCG CACAGCGGTG AAATGGAAGC CTTGATTTTC 180 CCTAACGCTC CTAAACTCAT l~GCGC~ATT AAGGATTTTT TAGAAAATTT TAAAAAAACA 240 GACATGACCT TAGGCACGCT TGAAGAGGTG TCTATTGTGG TGGC~ll~l G~ 300 SU~IllulkSHEEr (RUlE21i) CA 0222339~ l997-l2-03 W O 96/40893 , PCT~US96/09122 ' 256 GAAAACTACC GCTCCATCGC GTCAAAAATT TTTGACGCAA AGcccAGAGA TTATGCGCAT 360 TTTAAGGGTA AAGAAATCTT TTTATTTTGG GG~L~LL~G~A CGACTTTAGT ~Lll"lLATTC 420 G~~ 1~C~ L~L~L~L TTTTGATATT AAGATCCAAG ~L~1L11~1GA A~ATAAA~AT 480 TCAAGCTTGT TGCATGTTTT AAGATGGATA GGCACTTACG C~'l"ll"l"l"l"l"l' GA~l~C~ ll"l 540 ACCATTCCCA C~-AATAA~T GTTTAAACTA YYA 573 (2) INFORMATION FOR SEQ ID NO:260:
( i t ~yU ~ N~ ~ CHARACTERISTICS:
(A) LENGTH: 729 base pairs (B) TYPE: nucleic acid (C) sTR~Nn~n~s double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...729 (Xi) ~:yU N~: D~rRTPTION: SEQ ID NO:260 A'1~'1"1"1"1'~A TGATTTTCAC AAGCATCTTG AAGATAGCGT TAAAAGTTTT ATCAGAGCGA 60 A~AAAAAATC GTTATGGTTT TCCTAGAATC TTTGATGTTG ~-A~AT~GA A~AAGA~GAG 120 AGGGAAGTCA TTGAATGGCG AGAAAP~AAG AAAGCGTCAA AACAAAGCTA TAAA~AAAA~ 180 A~ AAGCG T~ATA~-A~GC TGATATAGAG C~'L~'ll"l"l'A TCCCGCCTAA AGAlll~l"l~A 300 AAACAATTAG AAAAAATTAG ~G~l"l~l~"l"l~ TCTAAAGACA TCGTAATAAC GATAAAGCAA 360 GTAGAAAAAT TAGAGCTTAA CTATGCGCTA AT~-A~AATA TC~AArATAA CACG~ll~AT 420 GACACGCTTG ATTTTACCTT TAl"l~ll~GG GAll~ l~A GCGTTCAGTC GCTTTATGTT 480 GGGAAATTGG GGA~ l~A ATCTAGAGAG CAAGCGTTAG A~L~L~CG ATTATCGCAA 600 rAA~AAATAT TGACCGG~L~ TATTTTTAAT GGCG~LlACC GCCTTCAAAA CGATCTTAAG 720 (2) INFORMATION FOR SEQ ID NO:261:
( i ) S ~ yU ~'N~ ~' CHARACTERISTICS:
(A) LENGTH: 708 base pairs (B) TYPE: nucleic acid (C) sTRANn~nNEss double (D) TOPOLOGY: circular (ii) ~OLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) A~TI-SENSE: NO
~vi) ORIGINAL SOURCE:
(A) nR~-ANT-CM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...708 SUB~ ult SHEEI (RULE 26) -CA 0222339~ 1997-12-03 WO 9C'459~3 PCTAUS96/09122 ~ 2S7 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:261 GA~L~r~ r~l~A TCCGTTATAA CTTGAGTTTA r-AA~A~-TCG CTAACGCGAT TAAAAATTCC 120 AATAACGATA CCG~l~GGG CGTTATTTTA GAAAACGGGT TTGAAAAAAT TATAAGATCG 180 CATGGCTATA TCCAATCTTT AAACGATTTA GAAGAAATTG TGGTTA~AA A~-AA~-GGGCT 240 GCGG~lAATC TCAACGGCGA TAAGGAAGTG ~l~G-~GGA TTGTTATGGT GCGCTATCAC 360 ATCAGTTTCT TGCTCATGSG TTATTTCRAT ATTGAAGCGA GCATCATGAG l~ ~G~GGC 660 (2) INFORMATION FOR SEQ ID NO:262:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 525 base pairs (B) TYPE: nucleic acid (C) STRAN~E~N~3S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ~iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...525 (xi) ~Q~N~ DESCRIPTION: SEQ ID NO:262 GTCATTAACG CTACTGAGGG GGGG~l~AGG ATTAAAGGGA CTAAAGAAAT GCCCTTTAAA 120 A~TTCGTATT TTATGGATGC GATACAATCT TACATTTTCC ACCAGGAATT GCATATCGCT 480 (2) INFORMATION FOR SEQ ID NO:263:
Q~N~: CHARACTERISTICS:
(A) LENGTH: 678 base pairs (B) TYPE: nucleic acid (C) sTRANnFnN~c~ double ~ (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

SUB~ ultSHEEl (RULE2-6) -CA 0222339~ l997-l2-03 WO 96/40893 PCT~US96/09122 ~ 258 (vi) ORIGINAL SOURCE
~A) OR~-~NT~M Helicobacter pylori (ix) FEATURE
(A) NAME/REY misc_feature (B) LOCATION 1 678 (xi) SEQUENCE DESCRIPTION SEQ ID NO 263 ATGAAAACGC CTTGCAACGC CTA~ AAAACGCCAC CCAAAAACAA AAAAAGAAGA 60 GTTTATGTTA ATTTAGCGGT ~l"l"l'-"l"l"l"l"l' TTATTGCTAG CGAGCGCTTT ATGGCTCATT 120 CCTAGAAGTG CCATAGAAGR AAAGCCCTTA ~~ ~GCGA CAAAACCTAG CAGCGAGCAG 180 GC~ll~ ~GCA ~ ~GGGG GACGATGAAT ATCCATCCGG CATTGATTAG GGGCGATTTT 300 GATTTGTATG TGGAATATAC CGGCACCGCT ~l~GGGl~AACA CGCTCAAAAA CCCTTTGACT 360 CAAAAAGTGG ATTTTGAAAC GATTAAAAAG CGTTATGAGA AGGAATTTAA ~ l~l~G 420 GTGGGACTTT TGGGCTTTAA TAACACCTAT TCTTTAGCGA TTTCTA~AGA AGACGCTCAA 480 GCGGAGYTTG A~ l~A AAGAGAGGAC GCTTTTAAGG GCTTAATCAA AGCTTATCGC 600 TTTCATTTTA GAAGTTTGCA TGA~ATGGAY ATTAATTTGC GTTATAAAAG TTTTGAATCC 660 (2) INFORMATION FOR SEQ ID NO 264 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 237 base pairs (B) TYPE nucleic acid (C) STRA~N~S double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAMEtREY misc_feature (B) LOCATION 1 237 (xi) SEQUENCE DESCRIPTION SEQ ID NO 264 GTGATGGTTT ATAAACTCCC CAAACACCAG CAAAATAAGG TCATGATTTT AGG-~ ~G~C 60 TTAGCGATGA TCACTCGTAT AG~ A GGGAGCTTGT TTTTCATCAG CCATTTGCAA 120 AAGC~ AT TCGCTATAGC GGGCATGAGC TTTTCATGGC GTGATGTGGT GCTGCTTTTA 180 ~GG~GGGC~l~ TTTTGGCTTT TAAGGCGTTA GTGGAATTAA AAAGAGCAGA TCTATCC 237 (2) INFORMATION FOR SEQ ID NO 265 ( i ) ~ r ~U ~:N~ ~ CHARACTERISTICS
(A) LENGTH 630 base pairs (B) TYPE nucleic acid (C) STRA~ N~:~S: double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) ~Y~O~ CAL NO
(iv~ ANTI-SENSE NO

SUB~ ul~Sht~(~lE26) _ CA 0222339~ l997-l2-03 W O9C~1~893 PCTAUS96/091Z2 .; ' 259 (vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...630 (xi) ~Q~ c~ DESCRIPTION: SEQ ID NO:265 AT~ GG TTTTTATAGA AG~ TTAGCGATTT ~~CGC GGCGGTGGGG 60 GCcl~ TTATGTGCGA TAll~ A ATGAGCATGG G~ Ll~G CGTGGGGGCT 180 TA~ c~cl~A AAAACCTTTA TTTGAGCTTG TTTTTGAATT TAlll~GC A~ll~ lACC 240 GGATTTTACG ~ l~GC TTTAAAAACC c~ CAAA CCTTTAAAAA AAAGCAAGTC 300 CTCAATCCTC AAGTGTATTT GGAAATGGTG TTTTTAATTG GCGCGAGCGC TA'l'~'l~ 420 AACCTAGTGC AAAAATTCGT ~~ AGCT GGCACTTTAT CGGCTGCCTT 'l"l'~'l"l'~GCTT 480 (2) INFORMATION FOR SEQ ID No:266:
(i) ~Q~h'N~'~' CHARACTERISTICS:
(A) LENGTH: 888 base pairs (B) TYPE: nucleic acid (C) STRAN~NF~S: double (D) TOPOLOGY: circular (ii) ~OLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv~ ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NA~E/REY: misc_feature (B) LOCATION 1...888 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:266 AAAATGATTG AAATAAGCGA A~ lGCAA AAACTAGACG ATGCCTTAGA TAAAGTTGTT 120 GCTAAAAAAG AGCCAGAGAG ~ ~l~-AAG CCGATCATTT CACCAATAGA GGACTACCAA 180 GCTTACCCTC AATTTTTAAG ~'l'~'l'~'l"l"l'A TTGCAAGTTA GGGGCAAAAA TGGTGCTAAC 300 ATGGAATTTT TATTGCCTAA AGTTTATCCT ~ CCCCC~l~A AAA~-~ lA TATAGAGCAT 360 A~rr-~AAT~G AAGAAGCCCT AAAGCATTTG CATGAATATT TAAAGGTTAA TTTGCAAGAA 600 7 AAATTAGCCG GTTTTAGAGA ~ l~l~CAT TATAATGAAA ACGCCAAAGA CTCCTTGCCT 660 TTAAAAGCGC ~ AAG CGGG~l~GAT Gcl~ l~AGTA AAGACGCGCT TTATTATCTA 720 GAAAAGATCA TGC~ GG CTCT~AAAAT GGG~ ~A G~ CAA TTTGGAGAGC 780 ..
(2) INFORMATION FOR SEQ ID NO:267:

Sll&~ ult SHEEr (RULE26) CA 0222339~ l997-l2-03 i ) ~yU ~:N~'~: CHARACTERISTICS
(A) LENGTH 282 base pairs (B) TYPE nucleic acid (C) STRANI~l)N~ double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi~ ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 282 (Xi) ~:yU~:N - '~: DESCRIPTION SEQ ID NO 267 AAGCAAGAAT TA~l-~l~A TTTCATTGTC CCAAGCGCTG A~ATCAACAT AGGCRRTCAA 120 GTGYTAACGA GCGGG--l'AGA TGGGATTTTT GGAGCGGGGG ~ ~GG TGAAGTTTCA 180 AGCGTTGAAG ATCATTACAC TTATAAAAGC GCG~ ~A AAAACGCTTT TTTAAGCGAA 240 GCCAAACTTT TAAGGCATGT ~ AAGC GGTGTGA~A~A AC 282 (2) INFORMATION FOR SEQ ID NO 268 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 249 base pairs (B) TYPE nucleic acid (C) STRAN~ :~N~:SS: double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) OR~-ANJ~M Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 249 (xi) ~QU N~: DESCRIPTION SEQ ID NO 268 ATGGAAGCGC AATTACGATT TACGGGTGTT GGAGGGCAAG GC~ AGCGGGAGAG 60 TCGCAAGTGC GTGGAGGTCC CACTAAAGTG GATATTTTGT T~A~AAA~A TGAAATTATT 180 TTCCCTTATG CTAAA~-Ar-GG CGAGATTGAT TTCATGCTTT CA~l~G~lCA AATCAGCTAC 240 ~2) INFORMATION FOR SEQ ID N3 269 (i) ~kyU 'N~: CHARACTERISTICS
(A) LENGTH 609 base pairs (B) TYPE nucleic acid (C) STRANnFnN~s double (D) TOPOLOGY circular SU~lll~lt SHEE~ (RUl~ 26) CA 0222339~ l997-l2-03 W O 9~ PCTrUS96/09l22 . 261 (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOl~kl~lCAL: NO
(iv) ANTI-SENSE: NO
(vi~ ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...609 (Xi) ~k~N~: DESCRIPTION: SEQ ID NO:269 ATGCAAGCTT GGGTGGATAA GCCGGTATTG TTAGAGCCAG ATAGTA~CGC CCAATACGCC 60 GCTGTCATTG AAATTGATGT GGrA~.AAATC ACGGAGCCTA TTTTGGCATG CCCTAATGAC 120 GCTATTGATG AA~ AT TGGCTCTTGC ATGACGAATA TTGGGCATTT CAGAGCCTTT 240 GGTGAAATCG TTAAAAACGC CCCTCCCAGT CAAGCACGCC ~ GG~l~AGT GCCACCCAGT 300 AAAATGGACG AACAAGAGCT TATTAATGAG GGCTATTATG CGA'l"l"l"l"l'~G GGCTGCCGGG ~60 AAl~G~l~G 'l"l"ll"l"l'~'l'AC TTCCACACGG AATTTTGATA ATCGTATGGG TAGAGGGGCT 480 ACTAA,AGAAG AATACATGAA TTTAGTGAGT GAAAAGCTAG AGAGCCAAAA AGACAAGATC 600 (2) INFORMATION FOR SEQ ID NO:270:
(i) ~hyukN~k CHARACTERISTICS:
(A) LENGTH: 660 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...660 (xi) ~kyu~:~k DESCRIPTION: SEQ ID NO:270 ~GG~AATG CCGGG~l~GC TTTAGCGGGT TTGATGAGCG ATGAAATTTA TTTGTGCGCT 60 ACTTTTAGCG A~l~G~ll~ ~c~ AAAGAAAGGA TTGAAGAAGC CCTTCATTAT 240 TACCAGCCTA AAAAAGTCTA TAATTTAAGC TATGGGGCGA AAATCAAGCA CGCC~~ AGC 300 CTGATTCGTT TTAAA~-~GA ~ CACG CATTTAAACA CGC~ ~A AACCAAGCAA 480 GAAGCATTTG AA~l~G~l~GA TAGCTTGAGT GGATTTTGCC AAACAGCCAG CGCTAAAACC 540 GTTTCATTGC ATCTTAAAGA AAATGAGCTG ACG~~ llAT CAAATTCTCT CAAAACGCCT 660 SU~~ SHE~ (RUlE 2~i) CA 0222339~ l997-l2-03 ~ 262 (2) INFORMATION FOR SEQ ID NO:271:
(i) ~:Qu r:N~ ~: CHARACTERISTICS:
(A) LENGTH: 744 base pairs (B) TYPE: nucleic acid (C) STRAN~ :x~: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~O~ CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...744 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:271 ATGCAAAAAA GTATATTCAA AATAACTCTG TTGTTGGTTT ~l~C~ AAGGAATGCT 60 ~ AG ACGATAAAAA AGCAGCTCCT AAAAGCGTTC AAAATACCCC TAAAAATTTA 120 CCCCCTATCC AGTTAAGGCT CGATCAAGCC TATGAAGACC TTATCA~AAT GTTAGACAAT 180 GAGGAATGGC TAGGAGTCGC CCATGAAGAA ~ ~C~l~ TAGTCATGTT AATAAGCCCT 300 A~AGCCCATG AGCATGAAAT GGCCCTCAAC AAATCCCAAC CCTTAAAAAA GGAACCGCCT 480 GGGTATTACT TGCAAATTGG GG~ll~llllA AATTCGCCCA GTAAGGATTT TTTGCAAACG 600 CCTTATAAAA CCAAAGAAGA AGCCCTAAAA CAGCTTGAAA Al~CGG~l~AA AAGCTTTAAA 720 AATAAGCCTG C~ll~l~AGA GAAG 744 (2) INFORMATION FOR SEQ ID ~:272:
u~N~ CHARACTERISTICS:
(A) LENGTH: 450 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: à~uble (D) TOPOLOGY: c~rcular (ii) MOLECULE TYPE: ~ enomic) (iii) HYPOTHETICAL: N~
(iv) AWTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Hel~-obacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...450 (Xi) ~U~N~' DESCRIPTION: SEQ ID NO:272 ATGCAAGAAA TCTTAATCCC TTTAAAAGAA AAAAGCTATA AA~ GGGGGAACTG 60 CCTGAAATAA AATTGAAACA AAAAGCGCTC ATCATTAGCG ATAGCATCGT GGCCGW~ ~ 120 CATTTGCCCT A~l"l"l~l"l~AGA GCGCTTGAAC GCCTTAGAAG TCAGAGTGTG CGTGATAGAG 180 'l'~CGGG~A~A AATA~A~AA TTTTCATTCA TTAGAGCGGA TTTTAAACAA CGCCTTTGAA 240 Su~ Ultsn~tl (RULE26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 ~ 63 ATGCAATTAA ACCGCCATTC TTTAATGATA GCC~l~ G GGGGAGTGAT AAGCGATATG 300 rAA~AA~CTA ATCGGATCGT TCCACCAGCC 450 ~, (2) INFORMATION FOR SEQ ID NO:273:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 561 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helico~acter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION l...S61 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:273 ATGCGAATAC TTCATTATGG AGGTGAGCTC CCATGCGATT GTCCAAAACG CA~l~CG~L~G~ 60 CTTGATTTCG CTCTTAAAAT TCTCACCAAT ATCACAAGCG ATCATTTAGA TTTCCATCAA l20 AATATAGAAA ATTACAGGGA CGCTAAAAAC AG~l~ llA AAGATGAGGG CTTAAAAGTC l80 ATCAACAGAG ATGAAACAAA CGCCc~ L~ AACCCCATTA ACGCGCGCAC TTACGCACTG 240 TTATGCTACC AACACGATTT AAGAGATCCC AATCTTAAAG A~ACCGCCCT GATCCATTCC 360 CCC~~ lAG ~GC~llACAA CCTTTATAAT ATTTTAGCGG ~C~llllAGG GGTTAAATTG 420 GGGC~~ ~G AAATTGTACA TTCTAAACCT TTA~l~lCG TGGATTI'TGC CCACACAACA 540 GACGGCATGC AACAAGTTTT T 56l (2) INFORMATION FOR SEQ ID NO:274:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 594 base pairs (B) TYPE: nucleic acid (C) STRA~E~N~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOl~ CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
r (A) ORGANIS~: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION l...594 (xi) ~:yu~:N~ DESCRIPTION: SEQ ID NO:274 S~ ultSHEEl (RUI~Ea6) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 ~ 264 A~l~llll~lA AACTTTCAGG CATGACAGGC ACGGCTCAAA CcGAAGccAc AGAATTTTTA 120 GAAATCTACA ATTTAGAAGT GGTGTCCATC CCTACTAATC TAGcGATcAA GCGAAAAGAT 180 AAAGAATTAC ACGATAAGGG TCAGCCCGTT TTAGTCGGCA CGGCTAGCAT TGAAaAGAGT 300 GAAACCTTGC AC~~ ACT CAAAAAAGAG CGCATCCCTC ACACCGTTTT AAACGCCAAG 360 rAArArArTA AAGAAGCTGA AATCATCAAA GACGCCGGGC TTAAAGGGGC GGTTACGATT 420 A~:G~(;AA GCGGGCGTCA AGGCGATCCG GGAGTGAGTC AGTTTTATTT GAGC 594 (2) INFORMATION FOR SEQ ID NO:27S:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 624 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) oRr-ANT~M: Helicobacter pylori (iX) FEATURE:
(A) NAM.E/KEY: misc_feature (B) LOCATION 1...624 (xi) ~:~ukN~ DESCRIPTION: SEQ ID NO:275 ~l~l~G~l~ ATGAGGTGAG AAAGCTCGCT GAAAAAACCC AAAAAGCCAC TAAAGAAATC 60 G~l~lC~l~ TTAAAAGCAT GCAACAAGAA GCGAACGATA TTCAAACCAA CACCCACGAT 120 AATAACATGA ~ CGCGCA AGCCGCAAAA TACACCATCT ACAATATCAA TAACCGGGTG 240 ~CG~l~Y TGGCTAAACT CGATCATGTG ~ llAAAA ACAATCTTTA TGGCATGGTG 300 C~ll~l~l~r CAATTCCTTT GACATTACCA GCCrATAAr-A GTTSCCGTTT AGGCAAATGG 360 (2) INFORMATION FOR SEQ ID No:276:
(i) ~:Qu~c~: CHARACTERISTICS:
(A) LENGTH: 603 base pairs (B) TYPE: nucleic acid (C) STRA~n~n~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~Ol~ lCAL: NO

(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORr-ANT-~M Helicobacter pylori (ix) FEATURE:
SUB~ ul~SHEEr(RULEa6) CA 0222339~ l997-l2-03 W O 9~ 3 PCTAUS96/09122 ' 265 (A) NAME/KEY: misc_feature (B) LOCATION 1...603 (xi) SEQUENCE DESCRIPTIOW: SEQ ID NO:276 ATGAATACAT CAAAAAAATT AGGTAACCCC TTG~ L TGCATGATAA TAAAATTTTG 60 ~ G TAGGG~l~AG CATGGGcGGG ~l~c~ACTT CTAAAATCTA TCAATTTGAA 120 AGCGCTTTAG AGCCGATTCA TTTTAAGTTT GCGC~A~ llAAG CC~'l"l"l"l"l"l'A 180 AATTTGAGCC ATTTAGTAAG GAATAAGCCT TTA,AACACCA CTGATGGCGG GTTTATGCTA 240 CCACTCTATC ACGAATTAGC CACCCAATAC CC~ ~T TGAAATTTGA CCAACAAAAT 300 AACCCAAGAG AG~l~l'L'l'AAG GCCTAATACC TTAA,ACCACC AGCTCCAACC AAGCTTAACC 360 CCCTTTAAAG A~l~C~~ CATGGCGTTT AGAAACCATT CTTTT~AAGA TAGCCTCATG 420 TTAGATGATT CTTTAAATTT ACTCAATTTA AATGGAATAT TGTATTTGAT C~AA~CCT 540 AGCGATTTAT CACTGCGTCG TAAAGAACTT TGG~ lA AATTAGA~AA CCYYCAACTC 600 (2) INFORMATION FOR SEQ ID NO:277:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 381 base pairs (B) TYPE: nucleic acid (C) STRAWDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HypoT~ cAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...381 (xi) ~kyu~N~ DESCRIPTION: SEQ ID NO:277 ATGAGTATTC AACATTTCCG TGTCGCCCTT A~ ~C~ TTGCGGCATT ~ GC~ll~CCT 60 ~l"l"l"l"l~l~C ACCCAGAAAC Gu-~ GAAA GTAAAAGATG CTGAAGATCA ~ ~G~l~CA 120 CGA~l~G~l~ ACATCGAACT GGA~-T_~AC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC 180 GAAGAAcGTT TTCCAATGAT GAG_~-~TT AAAGTTCTGC TA~ ~Gu~C GGTATTATCC 240 CGTATTGACG CCGGGCAAGA G~ _~GT CGCCGCATAC ACTATTCTCA GAATGAcTTG 300 GTTGAGTACT CACCAGTCAC AG~A~__AT CTT~Gr-ATG GCATGACAGT AAGAGAATTA 360 (2) INFORMATION FOR SEQ '~ ~ 278:
yU~N~ CHARA_~EP~-STICS:
(A) LENGTH: 237 ~ase pairs (B) TYPE: nucleic ~cid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
~vi) ORIGINAL SOURCE:

SUBSIllult SHEEr (BULE 26~

CA 0222339~ l997-l2-03 W O 96/40893 PCT~US96/09122 ' 266 (A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...237 (xi~ ~kyu~N~ DESCRIPTION: SEQ ID NO:278 GCGAATAAAA TCGCGGATAT ~ AAA GCG~l~ TTTTAGCCTT TGTGAGCTTT 180 TTATTGTGGC AATTTGGTTT GG~l~AAT TTTGAAAAAS GCTTTAATGG TGTGTAT 237 (2~ INFORMATION FOR SEQ ID NO:279:
( i ) ~ ~ QU ~N~ CHARACTERISTICS:
(A) LENGTH: 147 base pairs (B) TYPE: nucleic acid (C) sTRANnFnNF~: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~YPOTHETICAL: NO
(i~) A'NTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...147 (xi) ~:~U~:N~: DESCRIPTION: SEQ ID No:279 ATGCTAATGG TTAATGGCTA TCAAATCACG ATG~TAA~-G GTTATAAGGT AGG~ 60 A~A~GTT ACAACCCTGA ~ ~G~l~AA ACCATTCAAA ATAGAAGCTA TTTGATGAGC 120 TCTTATGAGT TAl~C~l"l~ AAGAAAT 147 (2) INFO~ATION FOR SEQ ID NO:280:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1236 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) hY~O~ CAL: NO
(i~) ANTI-SENSE: NO
(vi~ ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...1236 (xi) ~:Uu~NC~ DESCRIPTION: SEQ ID NO:280 SU~llultSHEEr (RULE2~) CA 0222339~ l997-l2-03 W O ~/t~ 93 PCTrUS96/09122 ~ 267 A~ ~AAT TTCAAAACAC GCTTAATA~AA TTCCATGCCC TA~ lAA AAACGCAAAT 60 TTAATTTATA ATGCAAAATT A~ACAAAACA TGCTATAAAG AAAATTCAAA TACTATCATT 120 TTAAGGATTA AAATGCTCAC CCAAGAAGAT GTCTTA~ACG CGTTA~AAAC GATCATCTAC 180 CCTAATTTTG AAAAGGATAT TGTCAGCTTT ~l"l"l"l~l"l~A AAAACATCAC CTTGCATGAC 240 A~rr~ATTAG GG~ AAT AGAAATcccc TCAAGCTCTG AGGAAAcGAG TGCGATTTTA 300 AGGr~ T~ TCTCCAAAGC GATGCAAGAA AAAGGCGTGA AA~L~ l~AA TTTGGATATT 360 AAGCATGTGG TCATGATAAG CTCAGGCAAG ~GC~ ~ GTAAAAGCAC CACCAGCGTG 480 AATTTAAGCA ~l~CG~lllAGC GAATTTAAAC CAAAAAGTGG GGCTACTAGA CGCTGATGTG 540 TA~l~GCC~-l~A ATATCCCTAG AATGATGGGC TTGCAAAACG CTGATGTGAT CATGGATCCT 600 AGGAACAGGC GATGCGCAGC TCACGCAGCc CAAGCCGTGC CACTCAGCGC AGGAATCACC 840 AAACTACACA TTCCTATTGC GGGCATTGTA GAAAATATGG GGA~l~ GTGCGAGCAT 960 AACACGCAGA TTTTAGCCAA GCTCCCTTTA GAGCCTAAAG 'l'~-'~'l'-''l'AGG GGGGGATAAG 1080 G~Gr-~TT TGAGTGCTTT TTTAGACAAG GTGGAAAGGG AAAAACTAGC CGATAATAAG 1200 ~2) INFORMATION FOR SEQ ID NO 281 (i) ~yU~ CHARACTERISTICS
(A) LENGTH 267 base pairs (B~ TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) ~OLECULE TYPE DNA (genomic) (iii) ~YPOTHETICAL NO
( iY) ANTI-SENSE NO
(Yi ) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/REY misc_feature (B) LOCATION 1 267 (xi) ~Qu~N~-~ DESCRIPTION SEQ ID NO 281 Al~G~l~l~ TGA~ ~A GACCACAGAG ATTGGAGATG ATGTTACCAT TTATCATGGC 60 G~AACTCTGG GGGGTACGGG CAAGTTTAAG GGCAAACGCC ACCCTACTTT AGGCAACCGA 120 GTGGTAGTTG GGGCAGGGGC TAAG~~ ~ GGCGCGATTT GCGTGGGCGA TGATGTGAGG 180 ATTGGGGCTA ATGC~l~l~ GCTTTCAGAT TTACCCACGG GTTCTACGGC TGTAGGTGCT 240 (2) INFORMATION FOR SEQ ID NO 282 (i) ~yu~ CHARACTERISTICS
, (A) LENGTH 576 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) ~Y~ CAL NO

SU~ SNEEr(~ILE2~

~ 268 (i~) AWTI-SENSE: NO
(~i~ ORIGINAL SOURCE:
(A) OR~NT~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION l...576 (Xi) ~:~U~-N~' DESCRIPTION: SEQ ID No:282 TTGTTACTGC TTTTTAGTTT GG~ l AAAGATTTAG AAATCCAAAC ~ ~L~GCT 120 AAATACCTTT CTAAAAATCA AAAAATACAA GCCCTACAGG AGCAAATTGA CGCTTTAGAT l80 TCTCAAGAAA AA~l~l~ AG CAAATGGGAT AACCCTATTT TGTATTTAGG CTATAACAAC 240 GCTAACGTGA GCGATTTTTT CAG~l~AT AGCACCTTAA TGCAAAACAT GAGCTTGGGT 300 ~l~l~luliuAAA AAGTGGATTT AAATGGTAAA AAACTCACGC AGTCTAAAAT GATCAATTTA 360 ATGATAAACG GcATTGA-A-AA CTATAAAAAC CAACAAGAAA TAGAGCTTTT AAACACAGCG 480 GYGATYGYCA AGTTRr-~AA~ TTTAAAAATC GCCAWT576 t2) INFORMATION FOR SEQ ID NO:283:
(i~ ~k~ CHARACTERISTICS:
(A) LENGTH: 348 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~u~ CAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature lB) LOCATION l...348 (xi) ~:~UkN~: DESCRIPTION: SEQ ID NO:283 GTGCCGGCTG ll~GGGGGGC TTTGATTTGG ATYCYTATAG YGATTTATGA GCTTTATCAT 60 GGGYATGTGA ATGAGGYTAT TTTTAYYGTT TTGTATTCCA ~ AAT TG~l~ l"l~ 120 ATTGATAGCG TGATCAAGCC AATTTTAATC ~~ ATCA AAAAAAGAAT CTTTAAAACC l80 ACCCTTAAAA TCAATGAAAT ATTGATTTTC 'l"l~ ATGA TTGCTGGGAT TTCTCAATTT 240 ~ l~GG GGATTATCGT AGGGCCTACC ATCACGGCGT TTTTTATCGC GTTACTGCGA 300 (2) INFORMATION FOR SEQ ID NO:284:
(i) ~'~UkN~'~' CHARACTERISTICS:
(A) LENGTH: 489 base pairs (B) TYPE: nucleic acid (C) sqR~Nn~nN~.cs double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~YYU~ lCAL: NO

~U~IIlult SHE~ (~IJLE 26) CA 02223395 l997-l2-03 W O ~6/~n3 PCTrUS96/091Z2 ~ 269 (iv) ANTI-SENSE: NO
~vi~ ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature _ (B) LOCATION 1.. 489 (xi~ U N~'~' DESCRIPTION: SEQ ID NO:284 ~ A TTATTTTAGT G~lC~l~ ATC ATTCAAAACA G~ AAAAGAAGAG 60 AGAGAGCAAG AACGCGCTAT TAAGCCCGAC ACCAAAAATA AllclllCAA TGAAACTAAT 120 GACAAGCAAG GCAAA~AA~C GATCAAAGAA AATCCTAATA CCATTTACAT TATCCCTAAA 240 TTTAAAA~AA GTTATCCTTT AGAGGCTAAA AACCACCGCT ~ ACG CTTTGGGCAT 360 CG~l~ AT ACGAGCCAAA TAAAGGTTTA ACGCTCATCA ATGAGGCCCA ATACAAAGCG 480 (2) INFORMATION FOR SEQ ID NO:285:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 120 base pairs (B) TYPE: nucleic acid (C~ sTRANn~nN~s double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~O~ l'lCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORr-ANI-~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/~EY: misc_feature (B) LOCATION 1...120 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:285 Ar-rArr~ATTG AACG~l~l~A AGTCATCATT GACATGAGCC AACACAAAGA CAAl~lCG~C 120 (2) INFORMATION FOR SEQ ID NO:286:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 135 base pairs (B) TYPE: nucleic acid (C) STRAN~ N~:~S: double (D) TOPOLOGY: circular ~ii) ~OLECULE TYPE: DNA (genomic) iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:

SU~IIlul~ SHEEr (RIILE26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 ~ 270 (A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...135 (Xit ~:QU~:N-~' DESCRIPTION: SEQ ID NO:286 ~l~GC~G~CA GCTTTATTAT ~ 1"1"1"1"1' AG~AG CGGATCAATT TGTGAGCGTG 60 TTTCAGCATG AAAACGCCTT GCAACGCCTA ~l~AAA ACGCCACCCA AAAACAAAAA 120 AAr~rAr-TT TATGT 135 (2) INFORMATION FOR SEQ ID No:287:
( i ) ~ ~ ~U ~:N~ ~' CHARACTERISTICS:
(A) LENGTH: 354 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...354 (Xi) ~:QU~-k DESCRIPTION: SEQ ID NO:287 ATGGTAGCTT TAAGCAACGC TCTTTCAAGG ~ ~GTT ~l~l~G~l~G CTATAAATTC 60 C~ A TCCA~AAAAG CATCAACGCT CTTTATGTTA AGATCTTTAA AATTGATTTG 120 AGCGAGTTTG AGCCTTTAGA AAATTATAAG AGTTTGAACG ~ l'~AT GCGu~ A 180 ATCACTGAAT GLG~'1"1"1"1"1-1' AGACAACGAT AGCGCTTTAC AAATTAAAGG CATGCCCTAT 300 AAAGCGCATG AATTAGTGGG CGAAATCAAC CCCTTAAGCC ~'l'~'l-l"l"l"l"l'C TATG 354 (2) INFORMATION FOR SEQ ID NO:288:
(i) ~QU~:N-~: CHARACTERI STICS:
(A) LENGTH: 600 base pairs (B) TYPE: nucleic acid ( c t sTRANn~nN~.~s: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) r (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORr-~NT~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...600 SUI~ SHEE~ (RUI F 26) CA 0222339~ l997-l2-03 W O 96l40893 PCTrUS96/09122 ' 271 (xi) ~ u~N~ DESCRIPTION: SEQ ID NO:288 ATGGCAGTGT TAAAAAAGAT GATAGGTTTG ~l~GCG~~ TAAGCGTTTT ATTAGCCAGA 60 AAAATCACGC TCACTTACCA AGATATTGAT GGCTCTATCC ATTCTAAAGT C~l~l~ATT 240 GATAAAAGCA TTGATTGGCA CTACCCCTTA AAA~lll~CCC AACACACCCT TAATCAAGAC 300 ATTTTGCGTT CCCCTTATAA AATTTTGCGC 'l'~l"l"l"l'~l~l~ TAGTCAATCC TTATAGAATC 420 GTGTTAGACA CGCAAAAAGG CC~ l"l'~GAT ATTTATCAAA ACATGGATTT AAACCAGAAG 480 ~l"l"l"L"~ ACATTAAAGT CGGCACGCAC AAAGATTATT ACCGCATCAC GCTCATTTTA 540 (2) INFORMATION FOR SEQ ID NO:289:
(i) ~:Qu~N~: CHARACTERISTICS:
(A) LENGTH: 237 base pairs (B) TYPE: nucleic acid (C) STRANu~DN~:~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...237 (xi) ~:yu~ DESCRIPTION: SEQ ID NO:289 A~l~GCG~AT TCACAAGCAT ATGGCATTGG GTCATTGTTT TATTAGTGAT ~ L~ A 60 TTTGGGGCTA AAAAGATCCC AGAATTGGCT A~AGGTTTAG GCAGTGGGAT TAAGAATTTC 120 (2) INFORMATION FOR SEQ ID NO:290:
:Qu~:N~ CHARACTERISTICS:
(A) LENGTH: 618 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...618 (xi) ~:yu N~ DESCRIPTION: SEQ ID NO:290 SUBSlllult SHEEr (Rl~IE26) CA 0222339~ l997-l2-03 W O 96/40893 PCT~US96/09122 ~ 272 GTGCGTTTGA ATGCGGCGGT l~lG~l~AT GGCAAGTATA AAATcGcGcT CGAAGACGGG 60 GCAAACGCTT TArAATAr~ GCCTTTAAGC GATGAATSGS TTAAAAAAAT CAACGYCCTA 120 GTCAAACAAG CCA~llG~l~A TAACCAAAAT AGAGGCGATG AC~l~GCG~l~ GAGTAATTTT 180 GAGTTTAACC CTA~ ~CC TATGATTGAC AACGCCACCT TGAGTGAAAA AATCATCTAT 240 AAAACCCAAA AAATTTTAGG TTTATTTATG TTTTTAATCA AGGTATATTT G~~ ATA 300 GTGTTATTCA ~ ATAA AAAAGTGATC GTGCCTTTCA GCGAACGCAT GCTGGAAGTG 360 GAGTTGAACA AA~l~GGCGA TTTGAGGAAA AAAGTAGAAG ATCAATTAGG GCTTAATGCA 480 AAAGAGCGTC CTGATGAAAT CGCCACGCTC TTTAAACTCT TAATCAAAGA TGA~ATCTCT 600 Tr~r-ArArCG CGAAAGGT 618 (2) INFORWATION FOR SEQ ID NO:291:
(i) ~Qu ~:N~ ~: CHARACTERISTICS:
(A) LENGTH: 294 base pairs (B) TYPE: nucleic acid (C) sTR~Nn~nN~s double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) oRr-ANT-~M Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...294 (Xi) ~:~U N - ~' DESCRIPTION: SEQ ID NO:291 ~ A TATTGCCTTT 'll~-l-l-l'AGGG GTTTTAGGCA CGCAAATCTT TAAACAAGAG 60 ACCCCAAGAC AG~l~C~lAT C~l~~ ~ GATTTGGATA AGACCACTAC AAGCCATCAA 120 GATTTGGAGA GAAAAATCAA AAl~GGGCGA AAAGTGGSAT TTGCCCTTTT ATTA 294 (2) INFORWATION FOR SEQ ID ~3:292:
(i) SEQUENCE CHARAC_ERI_TICS:
(A) LENGTH: 5gl base pairs (B) TYPE: nucle~c ac~d (C) STRANDEDNES~. ~uble (D) TOPOLOGY: c:rcu1a-(ii) MOLECULE TYPE: D~ enomic) t (iii) ~Y~Ol~ lCAL: N3 (iv) ANTI-SENSE: NO

(~i) ORIGINAL SOURCE:
(A) OR~ANI-~M: Helico~acter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...591 SUBSlllult SHEE~ (~ILE 26) CA 0222339~ l997-l2-03 WO 9G/1~93 PCT~US96/09122 , 273 ~xi) SEQUENCE DESCRIPTION: SEQ ID NO:292 ATGAAAGGCT TAl~G~ AA~ A ~l"l"l"l"l~l"l~ ~l~l"l"l"l"l~l~ GGCTAATGAA 60 GGC~ l'A AAGAGCTTTA TCTTAAAACC GGCGTGCGTT TTGCGATTGA TATGACGGAT 180 TTTTTAAAGc AGCTCAAACc ~'~'i"l"l"l'~'l'~ GTA~ TCTACCATGA CGCTCAAAAA 300 ATAGAATTAG TGGCTAACCC TAAAGATTTG cTAGACACTG ATAAAATCTT TTTTGAAAAA 360 ATCGCTCCCT TACTCCCCAC A~ACGCTAAA ~A~A~A~C CCCAAAGAAT TTCAGCCATG 420 ACGCAAAATT TTAGCGCTCC TAAGGGAGTA A~ AA AGGTGGTTAT TTATATTTTG 540 TTATTGACGc TTTTGGGCGC ~l~llll~GG CTTTATTTTT TTAAAAAATC T 591 (2) INFORMATION FOR SEQ ID NO:293:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 204 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...204 (xi) ~:QU~:N~: DESCRIPTION: SEQ ID NO:293 A'i'~'1'~'1"1'~'1'A AAAAAATAAG AAATCTCATT TTATGCTTTG GTTTTATTTT AAG~ ~C 60 CCTAAAGACG CTCCCATTCT TTTGGAAGAA AAACGCGCCC AAACTCTAGA GCTTA~AGAA 180 (2) INFORMATION FOR SEQ ID NO:294:
(i) ~y~NC~ CHARACTERISTICS:
(A) LENGTH: 279 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/XEY: misc_feature (B) LOCATION 1...279 (xi) ~:yu~N~ DESCRIPTION: SEQ ID NO:294 SU~ ultSHEE~(Rlll~26) CA 0222339~ l997-l2-03 W O 96/40893 , PCTrUS96/09122 a74 AGATCCACTA AACTTAAAAA CATGAAACAA A~l~CG~l~ l"l' TAAAAGAAAA GGGCATAGGA 180 GAAGCCAGCG TGAAAAAATT GTTGGATTAT l~ll~G~AGTT TTGAAGCGAT Ar.~AAA~.cG 240 AGCGATCAGG AAAAAAACGC C~~ AAAA AAAcr-~AAA279 (2) INFORMATION FOR SEQ ID NO:295:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 219 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~O~ CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1 219 (Xi) ~k~N~ DESCRIPTION: SEQ ID NO:295 GTGGGCATTA TTAGGGGGAT TATCCACAGG CCAGAACTCA TTTTATTAGA TGAGC~~ 60 AA'l~ G CTACTTTCAT TATGGTAACG CATGATGAAA ACGAGGCGCA AAAGTTAGCC 180 ACAAAAACCC TAr.~AATCAA AGCCCTTAAA CAAGAGCAG 219 (2) INFORMATION FOR SEQ ID NO:296:
Qu~ CHARACTERISTICS:
(A) LENGTH: 804 base pairs (B) TYPE: nucleic acid (C) STRAWDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1 804 (xi) ~Qu~ DESCRIPTION: SEQ ID NO:296 GTGATTTTTA TCGCTACCGC TAAT~AT~TT GACAGGATCC CAG~l~-~-ll~l~ AAGAGACAGA 60 ATGGAATTTA TCAGCGTGTC CAGCTACACG CCTAGCGAAA A~Ar~GAT CGCTAAAAAC 120 CATGAATGTT TGAAACTCAT TATTGAAAAA TACACCAGAG AAGCG~GC~l~ TAGGGATTTA 240 rr~AAr~c~GA TCGCAACGAT TATGCGTAAA GCGGCTTTAA AATACCTAGA ~.ATAA~CCG 300 hetl (RULE26) CA 0222339~ 1997-12-03 W ~ 96/40893 , PCT~US96/09122 ~ 275 CACAA~AAAG GGCGGACCAA AAAAAGCGAA GACAAAGATA AAAAAGGCGG AAATGAAGAA 360 AACGAAAAAA GAGGTGAGAG TAAAGATTTT ~l~C~ A TcAcGccTGA TAACCTTAAA 420 AAGATTAGAG GCAAGGGGGA ATTGAAACTC ACCGGGAGTT TGGGcGAcGT GATGAAAGAA 600 TCCGCCATTA ~ ~C~ll~ lC ~ CAAA ~lcl~ ~llGG ATAACGAAAC CTTAAAAGTG 660 GCG~l~AT CGCTATGGCG AGCG 804 (2) INFORMATION FOR SEQ ID No:297:
( i ) ~kQUkN~k CHARACTERISTICS:
(A) LENGTH: 498 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...498 (xi) ~kyukN~k DESCRIPTION: SEQ ID NO:297 A'l~G~ CGTTTATCTT TAAAAAAGTT AGGGTTTATT CTAAAATGTT G~~ l~ 60 GGGCTTTCAA GC~~ L~AT CGGTTGCGCG ATGAATCCAA GCGCTGAGAC AAAAAAACCA 120 CATGTTACGC CACTAGATTT TAATTACCCG GTGCATATTG TTCAAGCCCC ArAAAArr~T 240 CA~ AG GTATTTTAAT GCCACGCATT CAAGTGAGCG ATAATCTAAA ACCCTATATT 300 CAAGTGTTGC GTTTTCAAGA TGAAAA~GCT TTGAATGTGC AAGATAAGAA AAAGATTTTT 420 l~C~l~llGG ATTTGAAAGG GTGG~TAGGA ATCTTAGAAG ATTTGAAAAT GAATTTAAAA 480 (2) INFORMATION FOR SEQ ;~ r~~ 298 (i) SEQUENCE CHARACTEF.'S-~CS:
(A) LENGTH: 43 base pairs (B) TYPE: nucle:- a-,a (C) STRANDEDNEC' a~uble (D) TOPOLOGY: c:rc~la-(ii) MOLECULE TYPE: DNA ~ enomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_fe2ture (B) LOCATION 1...432 Sll~lllult SHEEr (RUIE26) CA 0222339~ l997-l2-03 . 276 (xi) ~kyukN~k DESCRIPTION: SEQ ID NO:298 'l~GCll~l"l"l"l' TATACGATTT TTCACGCCCT TTTATCAAAA ATAGCGGCGC GATTTTAGAC 120 ATAGGCTCAG G~ ~GG~l~ TCTAGGCTTG CTCTGCGCTA GAGACAACCC GCTAGCGAGC 180 GTTCATTTAG TGGAAAAGGA TAGCAAAATG GC~l"l~ CCCAAAAAAA CGCCCTTAAA 240 TTCCCTAACG CTCAAGTGTT TGAGAGCGAT TTTTTAGATT TTAACCCTCC GA'Ll~L~l~AT 300 GATGCGATTG TGTGCAACCC TC~~ AT GCTTTAGGAT CTATTAAATC TCAAATTAAA 360 (2) INFORMATION FOR SEQ ID NO:299:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 141 base pairs (B) TYPE: nucleic acid (C) STRA~k~k~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...141 (xi) ~-kQ~kN~k DESCRIPTION: SEQ ID NO:299 ATGTTGAGTG C~l~lG~l~AT GCTGCCTTTT ATGGAGGTTT TTTATTATTT CAA~ CCG 60 ~ l~G~l~A A~ AGGGCAAACC ATTGGAGCGG TGAllull~ CAAGTTGGAT 120 (2) INFORMATION FOR SEQ ID NO:300:
(i) ~kyukN~k CHARACTERISTICS:
(A) LENGTH: 387 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...387 (xi) ~k~UkN~k DESCRIPTION: SEQ ID NO:300 ATGAATACTA TTATAAr.~TA TGCGAGTTTA ~l~GGG~ GTATTACTCT AACTCTAGCG 60 ult SHEEr (RVLE26) CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 ~ 277 CAAACCCCCT CTAAAACCCC TGATGAAATC AAGCAAATCC TTAAcAATTA TAGCcATAAG 120 AA~l"l"l~AAAGC TCATTGATYC GCCGACAAGT TCTTTARRAG CGAcAccGGG TTTTTWWCCC 180 TCGCCTAAAG AAACAGCGAC CACGATCAAT CAAGAGATCG CTA~ATACCA TGAAAAAAGC 240 GATAAAGCCG c~ ~G~ - ''l' TTATGAATTG CTAAAGGGGG CTACCACCAA TCTCAGTTTG 300 ~ 1 l~CCT ACTTTGAACG CGAGTTA 387 F (2) INFORMATION FOR SEQ ID NO 301 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 726 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 726 (Xi) ~k~ W~: DESCRIPTION SEQ ID NO 301 Al~l~ l~l TTCTATCCAT TTTTAAAAAA AGCTTTAATG A~ AAG CGCTAGAATG 60 CTTTTAATCA A~l~ll~c-CC TATCCTTTTG AGTTTGGCGT TTTTTGGAGC TA~lcl~ AT 120 TACGCTCATT CTCAAGGCTT ~ l~CCG~l~ G~ CGCAT G~l"l"l"l"l~AA AGCGTTAGTG 240 TA~ lrA '1"1 l~r~ll~GAT CGTAATTCTT TTGAGTTTAG TCATCAATAT TTTTGCGTCT 300 A~ ACA CCC~~ AGT ~~ ~llAT TTGCACCAAA AATATTATCC CCATGTCGTT 360 TTA~AAr-AA~ TTGGCTCTAT C~~ lcl ATTAAATATT TTTTAAAATC GCTCACTTTT 420 A'~ lAT TCTTAGCGGT TTTAACGCCC CTTTATTTCA ~ CC~ AT AGGGGTCTTT 480 GGG~lc~ TTTCTATAGT CCCGCATTTC CY~ CA AAAACACCAT GAGTTTGGAT 540 AAGCATTATC ~'1"1"1"1"1' - '~'1"1' 'l"l"l"l"l'~"l'AT c~ l~CT TGATTCCTTT TTTTAATTTT 660 (2) INFORMATION FOR SEQ ID NO 302 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 378 base pairs (B) TYPE nucleic acid (C) STRANn~nN~SS double c (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO

(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
_ (A) ORr-ANISM Helicobacter pylori (ix) FEATURE , tA) NAME/REY misc_feature SU~ ul~Shttl (RUL~26) CA 0222339~ 1997-12-03 W O 96/~0893 PCT~US96/09122 ~ 278 (B) LOCATION 1...378 (xi) ~QUkN~k DESCRIPTION: SEQ ID NO:302 ATG~AATArG CTAACGCTTA TCAAGCCTAC CAGCATAACC GAGTGAGTGT GGAATCCCCG 60 GCAAAACTCA TTGAAATGCT TTATGAAGGG ATTTTAAGAT ~ llCGCA AGCCAAACGC 120 TGTATTGAGA ATGAAGACAT TGAAAAGAAG ATCTATTATA TTAATAGGGT T~CGr.ATATT 180 AGTAAGATTG ATTTGGTGTT GAA~ ~G~l~ AGGGGGTTGT TAGAGGCATG GAGGGAAATC 360 (2~ INFORMATION FOR SEQ ID NO:303:
(i) ~kyukNLk CHARACTERISTICS:
(A) LENGTH: 429 base pairs (B) TYPE: nucleic acid (C) STRAN~k~NkSS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...429 (xi) SEQUEN OE DESCRIPTION: SEQ ID NO:303 ATGATGTTTG ATAACACGCT TATCAATTTA TTT~-A~-A~Ar- CGC'Cl~ll~ AACYTCGCTT 60 TTAGCTGGGA TTTTAACTTT TTTAAGCCCT ~ ~l"lGC CTTTGATCCC GGCGTATATG 120 TCTTATATTT CGCAAATTTC TTTAGAGGAT ATTAAAGATG GTAAGGCTAA AAGG~ l~G 180 ~ AA AATCCTTGAT ~ l~ GG~l~lllCGC ~lC~l~ ll GG~C~lGG~C 240 ATGTCTATGG CCAAGCTTAT CCATAGCTTT ~lC~l~ ~CT GGGTGAATTA TATCGCTGGG 300 GGGATTGTGA TC~l~ ~G TTTGCATTTT TTAGGCGTGT 'l'l~l"ll"l~C A~ AT 360 AAAACCCAAA GC~~ AGCGAGCAAA TCTAACAGCA TGCAGCGCTT TACCCCTTTC 420 ~GCA 429 (2) INFORMATION FOR SEQ ID NO:304:
(i) ~kQukNCk CHARACTERISTICS:
(A) LENGTH: 252 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~O~l~k~l~lCAL: NO
(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAMk-/KEY: misc_~eature Sll~ll~ul~SHEEl (RUL~26) CA 02223395 l997-l2-03 W O 96/40893 PCT~US96/09122 c ~ 279 (B) LOCATION 1252 (xi) ~k~N~ DESCRIPTION: SEQ ID NO:304 G~l~G TGGGCAAACC CAACGAAAGC TATGCAGATA CCCACGCCCG CATTGAGCAT 60 TTTATCAAGC TTGTAGATTT TAAGGGCGAA A'l~ llA TcAATGAAGA TAATTCTAGC 120 GTA~AA~-CTT ATGA~AATTT AGAGCATTTG GGTAAGAAAA ATAAGCGGAT CGCTACCAAA 180 GA~l~GCCG~l~ TAGACTCTTT GAGCGCTTGT AGGATTTTAG AGCGCTATTG CCAGCAGGTT 240 TTAA~AAA~G GC 252 (2) INFORMATION FOR SEQ ID NO:305:
(i) ~:yU~:N~: CHARACTERISTICS:
(A) LENGTH: 465 base pairs (B) TYPE: nucleic acid (C) STRA~ N~ : double ~D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANTCM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...465 (Xi) ~:~U~:N~: DESCRIPTION: SEQ ID NO:305 TCTTGGGGTA TCAATTTTTC TTTGAAAAAC ACTTTGGCTT ACGC'~lll~AT GGG~ 120 GACTACGCTC ATGCCAATTC TATTAAGCTT A~AAACCCTA ACTATAAT~. CGAAGCGGCG 180 CAA~l~G~l~A GTCAAATTCT TGGGAAACAA GAAATCAATC GTTTAACAAA CATTGCCGAT 240 CCCAGAACTT TTGAGCCGAA CATGCTCACT TA~l~GGGGGG CTATGGACGT GATGGTTAAT 300 GTCATCAATA ACGGCATCAT GAGTTTGGGG G~ll~ l~GCG GGATACAATT GGCCGGCAAT 350 TCATGGCTTA TGGCGASACC GAGCTTTGAG GGCATTTTAG GGGAACAAGC C~~ ~l~AGC 420 AGA~AGCCAC ~ -CAA TTTTTATTCA A~ ~GGGC TCGCM 465 (2) INFORMATION FOR SEQ ID NO:306:
(i) ~hyU N~h CHARACTERISTICS:
(A) LENGTH: 513 base pairs (B) TYPE: nucleic acid (C) STRAh~h~h~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~l~h~l~lCAL: NO
(i~) ANTI-SENSE: NO

(~i) ORIGINAL SOURCE:
(A) OR~ANT~M: Helicobacter pylori _ (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1513 S~ ult SHEE~ (~ILE 26) CA 0222339~ l997-l2-03 W O 96/40893 , PCTrUS96/09122 ~ 280 (Xi~ U~:N~' DESCRIPTION SEQ ID NO 306 ATGAATGTCA AAAAAAAGGA AAAGCCACAA AGTGGAAAGA TTGATAGGGT GGA~rl~ ~ 60 GAGAAACTTG GGAAAGAMA CACTACTTTT TTAAGCAGTA TAGCTATGGG GAGCATTGGT 120 t CAATTAGCGA TCCCCATTCC TGGAGTTGGA GTGCTCATTG GG~lll~l~ G~l~G~lG 180 ATGAGTA~AA c~l"l"l"l"l~ATGA ~ CG~l'A ACGATTTTCA AAGAGGCTAA ATTAGCGCGT 240 CAAAATCAAT TTAATGAAGT GTTTGAGCGG TATTTTCATG GGACTATAAA A~ llAAT 360 GAAAGTTTTG ATGAGCTGGR GAG~GCG~l"l' TGTGCGGGCG ATGCGGATTT GGCTATAGCA 420 GTr~AT~A~ AGATCCAAGA GGGGATGGGT CAAGAGTTGC TGTTTGACAA TAAGCAAGAG 480 'l~lGGGAAT TTATCACTAG CCGTAAAGAG GGT 513 (2) INFORMATION FOR SEQ ID NO 307 (i~ ~QU~NC~: CHARACTERISTICS
(A) LENGTH 423 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iv) ANTI-SENSE NO
(vi~ ORIGINAL SOURCE
(A) OR~-ANI~M Helicobacter pylori ~ix) FEATURE
(A) NAME/KEY misc_feature (B) LOCATION 1 423 (Xi) ~:yU~N~: DESCRIPTION SEQ ID NO 307 A~ l~CC~r RMAGCTTTT TCTAAAACCC CTAAAAGAAA CGAGCCTTGC C~lr~lGGGA 60 GTGGCAMAA ATATAAAGAT ~r~r~l~GCGCTA AAAGCGGGCC TAMAAGGGC TTA~ r~C~A 120 AATAGATCCT TAAl~-lll~ll~ CCTTATCAAG CGTTATTTGC ~~ l~ATAA AAGCCAGCCT 180 TTCATTAGTA TCA-"l~l"ll GTTAGCCTTT TTTGGCGTGG CGGTTGGCGT GATGGTTTTA 240 ATTGTGGCTA TGGCGATCAT GAACGGCATG AGTAAGGAAT TTGAAAAAAA Gc~ ~ 300 ATGAACTACC CCTTAACGCT CTATACCACA AGCCc~ ATG GGATCAGCGA AGAAGTGGTT 360 CAAGCTTTAG AAAAMAGTT CCCTAATTTG C~AG YCCCTATTTG CAAACCCAAA 420 (2) INFORMATION FOR SEQ ID NO 308 (i) SEQUENCE CHARACTERISTICS
(A) LENGTH 210 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO

(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) OR~ANI~M Helicobacter pylori (ix) FEATURE
(A) NAME~REY misc_feature t SHEEI (RUI E 26) CA 02223395 l997-l2-03 WO 96/40893 PCTrUS96/09122 ~B) LOCATION 1...210 (xi) ~yU~N~ DESCRIPTION: SEQ ID NO:308 ATGGTATCGT TGCTTGGCGC GCTTAAACGC A~C'C~ll~CA CTAATCGCTT TTATCTTAAA 60 CCATGCGCCC ~ C~ A AAACGCGCTC 210 (2) INFORNATION FOR SEQ ID NO:309:
U r:N~: CHARACTERISTICS:
(A) LENGTH: 459 base pairs (B) TYPE: nucleic acid (C) sTRANr)F~nN~c~s: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv~ ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) oRr-~T~M Helicob~cter pylori (ix) FEATURE:
(A) NA~E/KEY: misc_feature (B) LOCATION 1...459 (xi) ~:yU~N~ DESCRIPTION: SEQ ID NO:309 GTGCATCATT TGYAACGGCT TTTAGACTCA GGCTCTGAAA GGTGTATAGG ~l~l~G~l~ 60 TGCr-~AAr-~ TTTGCACGAG CAACTGCATA AGGATCATCA CGCATAAGGG CGAAGACAAC 120 CGCAAAAAGA TCGATTCTTA CACGATCAAT TTGGGGCGTT GCATTTATTG CGG~r~ Gl 180 CAAC-~l~-CC AATACGGCTC TAAAAGCGAG TTTCTAACGA GCGAACAAGA CGCTAAAAAC 300 TGCTCGCATG CCGAATTTTT AGG~ 'L~l~ GCGGTAAGCC CTAATTATAA CGAACGCATG 360 CAAGCCACCC CTTTAGATTA TGTCCAAGAA CCTTCAAA~AG AAGAATCCAA AGAAGAGTTT 420 YCrAr~r-CC rAr.~AAr.CCA TAAGGGAGAT GAAAATGTT 459 (2) INFORMATION FOR SEQ ID NO:310:
(i) ~:yU~:N~: CHARACTERISTICS:
(A) LENGTH: 549 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
3 (~i) ORIGINAL SOURCE:
(A) OR~AMTSM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_~eature (B) LOCATION 1...549 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:310 SUB~ SHEEr lRUlE 26) CA 0222339~ 1997-12-03 W O ~6/~93 PCTrUS96/09122 . 282 ATGGCTATTT GGGG~l~l~ ~llllllATTT TTAl~l~C~l TGAl~l~GGG TTCAAGCATG 60 CATGAGTTGG TTTTAAGATC CCAAGCTTTA GGGTTTGAAA C~CG~ll~AGT CCAGTGCGAT 120 TTA~ CTTATGAAAG GTTTATTTCT AAAACCAAAC G~~ AGc ~ L~l~AGAA 180 CTGGAATTAC TCAAAGCGCT GTATTTTAAA TTAGAAAAAT TAGAGAGCCT ~l~lllAAAA 300 TGCCTAAAAA AArA~Ar-CCT GATAGCGCCT CAAACTTACT ATGGGCGTTG C~'l'~'l"l'AGAG 420 GGr~ ATCC TAGCCTTTTT ~l~GC~l~GCA AGGGATAAAG A~ AGA AATCACTCGC 480 ATGCACGCCT TAr.ArATTAA GCGTTATGAT TCCTTCATTG TTGATAGCGA AAGA~AAGGC 540 (2) INFORMATION FOR SEQ ID NO:311:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 201 base pairs (B) TYPE: nucleic acid (C) STRAN~:~N~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~~ lCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...201 (xi) ~ky~ N~ DESCRIPTION: SEQ ID NO:311 ATGCCGGAAA ATTCTAAACT ACAACCTGCT AAGTTAGGGA AAAATTTTGA CC~ ~GAT 60 CATTCTAA Q GGAATTTTTT ~ A'l~ ~ TATTGTTACA ~ ~ATT 120 TA~ AT TTGAACACAG AGAAGATTTT TTTCCTTCAA AACCCAAGCT CGTTAAATTA 180 ~2) INFORMATION FOR SEQ ID NO:312:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 519 base pairs (B) TYPE: nucleic acid (C) STRA~ : double (D) TOPOLOGY: circular (ii) M~T~T~rUT~T~' TYPE: DNA (genomic) (iii) ~YPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
tA) ORr-~NT-~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...519 (Xi ) ~kyUkN~k' DESCRIPTION: SEQ ID NO:312 SU~ UI~ SHEEr (B~l F 26) CA 02223395 l997-l2-03 WO 9C/~0~~3 Pcl'/u~jGl~o3l22 ~ 283 GL~llll"lAG TTCAATCGTG GGCTTTGAGC TTGAAAATAG ACAGcc~rGTT 'l"l'~l'~''ll"l~ll' 60 AG~l~G~lA AAATCCCTAG CGGATCTAAA GATCCCTTTG CGTTAAGGCG TTTGAGTTTT 120 AAC~'l-lll'~ AAAAAGTGGG CGTTTATCAA AGCTTTGATT TAGAGGTTTT AGAAAAGTTT 240 TTACTGGAGC GCTTTCATAA TTTAATAGAT TGTAACCTCT CTATTATAAG AA~ A 300 AArArr7~ACG AGcr7Ar-Ar~T TGTTAAAATC ATTCA,AAAAG TCAAAGCCTT AAAACGCTTT 360 TTAGACAATC CTAAr-AArGC TC~iA~AA~A GAGTTGCTTT TTAGCGCTTT CAAACGATTA 420 GCTAATATCA ATAAAGACAG A,AACCCTAAC GAATCAAGCG G~'1"1"1"1'~"LAC GA~~ l~ 480 AAArAATTAC AAGAGCATGC CCll"l'~ '~AA GCGTTCAAC 519 (2) INFO~M,ATION FOR SEQ ID NO 313 'N~' CHARACTERISTICS
(A) LENGTH 777 base pairs ~B~ TYPE nucleic acid (C) sTRANnFnNEss double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) ~Y~Ol~ ICAL NO
(iv) ANTI-SENSE NO
(vi) ORIGINAL SOURCE
(A) ~Rr7~T~M Helicobacter pylori (ix) r'EATURE
(A) NAME/REY misc_feature tB) LOCATION 1 777 ~xi) ~U~L~ DESCRIPTION SEQ ID NO 313 ATGAGTCTTG CTCCAAGCGT TATGGCGGGC ~l"l~l"l~l"l"l"l~ GTGCCGGCTC TTG~l~G-l~l 60 CG~ll~C~l~A ATTATTCTAA AATCATTTCC ATAGATGTGG ATAC~l~ll~ TTTAGGCGAT 120 GAcAcTTTTT CCCACCTTCC TTTTGAAGCC ~ ~l~ATT TTTGCGAACG CACATGCAAG 240 TTTAACATGG G~~ ~l GGCGAATTTA GATTTATGGC GCGAAAATGG GTTTGAAAA~A 360 ATCGCTTTAG A~lll"ll~AA AACTAGGGGA AAGGATCTTT TCTACCCTGA GCA~l~l~llA 420 ATCAATATGG ~ lAGA GCGTATTTTA GAATTGCCTA TTCATTATAA TTGCTATTCT 480 GA~ A AAGAGCACTA CCCTAAAAGT ATCATCATGC TCCATTTCAT CAAATACAAG 540 CC~l~GGC~l~ CTGTCAGTTC TTTGAACGGG CGTTTGATTT GCTATGAAGC TGAAGCGAGT 600 TTTTGGCTCG CCAACCTTTT TTGCACCCCT TTTAAAAACG A~ AA AGAACGCCTT 660 GAAATGGCTA AArArrAAr~ AATGCAATCT TTTAAAACCC ACATCCGATC AAAAACGATT 720 AGGGATTATT TTTATTTTAG ~ATAAAAAAT ATTTTGAAAA AA~ ~A ACTCTCT 777 (2) INFORMATION FOR SEQ ID NO 314 (i) ~'U~N-'~ CHARACTERISTICS
(A) LENGTH 582 base pairs (B) TYP~ nucleic acid (C) sTRANn~n~s double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) ~Y~O'l'H~'l'lCAL NO
_ (iv) ANTI-SENSE NO
(Yi ) ORIGINAL SOURCE
~A) o~r~NT~M Helicobacter pylori 5~ ul~SHEEI (RUlLE26) , CA 0222339~ 1997-12-03 W O 96/40893 PCTrUS96/09122 . 284 (iX~ FEATURE:
(A) NAME/REY misc_feature (B) LOCATION 1... 582 (Xi) ~:yU N~' DESCRIPTION SEQ ID NO:314 GTGATTGTTT GCAGCGCGGC GGG~'1"1'GAGC CA'1"1"1"1"1"1"1'~ ~'1"1"1"1'~'1'AT ~'1'~'1"1"1'~GGG 60 ~1"1CGCGCAAT TAAAAAACCT ~'1"1"1"1"1'~GCC ~'1"1"1"1"1"1"1'~'A TTACGATAGG GATGCAGATT 180 AGTTTTAAGA CTTTTATCAT TTA'1'~CG~'1'A TTG~'~'1"1"1"1"1' TTAGAGACGC TAAAACCGCC 300 ATCAAAACCG C~ GGCGCAAATT GGGGAGTTTT ~1"~ C~1~AT ~ AAAT 360 TCAGGCTCGC ACCAGCTCTT TAATTTGCAA GAAAAAAAAG GGA~ ~G ~ ACAC 4 20 ~'1'C'1"1"1"1'~'1'A TGTTAGCAAC CCCTTTTATT TTAAAATACC TAGAATCTAT CGCTCAATTT 540 ATTTTGCACC AAAAGAGCCA AGAAAACGAG CCGGCTAA~A AA 582 ~2) INFOR~ATION FOR SEQ ID NO:315:
( i ) ~ ~:y U ~'N~' ~: CHARACTERISTICS
(A) LENGTH: 396 base pairs (B) TYPE nucleic acid (C) STR~N~ cS: double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) HYPOTHETICAL NO
(iV) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE
(A) OR~A~T.~M Helicobacter pylori (iX) FEATURE:
(A) NAME/KEY misc_feature (3) LOCATION 1...396 (Xi) ~'yU~N~: DESCRIPTION SEQ ID NO:315 A'1'~'1"1'~'1'ATC TTATCAATAC AGGAGTGCCT CATTTAGTGG GATTTGTGAA AAATAAAGGG 60 GTTGAAGATT TCACGCTAGC TTGCGG~-A~A GGCATGGCAG CG~'1"1"1"1"1'AT CGCCGCGCGC 240 ~'11"1"1"1'~'ATA ACACCCCTAA AAAAGCCACT CTCATCCCTA AAAGCAACGA ATTTTTAGAG 300 ~ AA AAAATGATGG AA~1"1"1"1"1"1~AT ~AA~A~TCG CGC~ ATAT CGGCATGAGC 360 G'1"1"1"1'AGGCA '1'~G~'1'~'1"11"1' TAAAAATGGG TGTTTT396 (2) INFORMATION FOR SEQ ID NO 316 ( i ) ~UU N~' ~: CHARACTERISTICS
(A) LENGTH 639 base pairs (B) TYPE nucleic acid (C) STRPNn~nN~-~S: double S
(D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) ~Y~O1~ 1CAL NO
(iV) ANTI-SENSE: NO

SU~lllult SllEEr (RULE 26) CA 02223395 l997-l2-03 W O9G/~ ,3 PCTAUS96/09122 ~ 285 (~i) ORIGINAL SOURCE:
~A) OR~A~T.SM: Helicobacter pylori (ix) FEATURE:
tA) NAME/REY: misc_feature tB) LOCATION 1...639 (xi) ~:yu~N~ DESCRIPTION: SEQ ID NO:316 ATGATTAAAG CGATTGATAT TTCTCATGST TTTGAAAARC ~ luKl~A TGGCGTGAAT 60 TTGCGCATTA AACCCA~AGA AAG~Y~l~YG ATTTTAGGCG TGAGCGGGAG CGGTAAAAGC 120 ACG~llYlAA GCCATTTGGC CACCATGCTA AAACCGGATA GCGGAACAGT CA~ A 180 GAACACcAAG ATATTTATGC cCTAAATTCC AAAAAGCTTT TGGAATTGCG GCGCTTA,A~A 240 CAAGTCGCTT CAATCCTAGC CAAGCAAGAA ATAAATCATT CCClr~l"lAGA ACAATTAGGC 360 ATAGCCCACA CCCTAAAACA AGGC~ GC GAATTGAGCG GCGGCCAGCA ACAACGCTTA 420 AGCATCGCCA GA~~ TAA~AAACCC CAAATCATTA TCGCTGATGA ACCCACCGGG 480 GTCTATCGCC ~A~AAAA~ ATCTTTGATT AAGGAAAAA 639 (2) INFORMATION FOR SEQ ID NO:317:
(i) ~:uu~:N~ CHARACTERISTICS:
~A) LENGTH: 228 base pairs (B) TYPE: nucleic acid (C) STR~N~ )N~ S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~~ CAL: NO
(i~r) ANTI-SENSE: NO
(~r.i) ORIGINAL SOURCE:
(A) OR~-~T-~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...228 (xi) ~h:~U~: DESCRIPTION: SEQ ID NO:317 Al~ll~ATA AACGCATTAA AACGCTTTTA ~'l"l"l"l"l"l"l"l'~ GTCTTAATAT G~l~l~lll~ 60 AGCGTGI~GTT TTACCAATAA GCCTCATTTG 'l'~'l"l"l"l"l'~'l' TTTTAGTGTT A~~ AT 120 TTAGTT'.rATG AGTGGCAAAA GAAACAAAAA AAAGATTTTC AAAGCGCTAA AAGTTTGAAA 180 TTTr-~'A~CG TTAGCGAATT AGA~AAGGAT TTTGAACATG GAAGTAAC 228 (2) I~'O~MATION FOR SEQ ID NO:318:
(i) ~U N~'~ CHARACTERISTICS:
(A) LENGTH: 207 base pairs (B) TYPE: nucleic acid (C) STRAN~ s double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ) ~Y~O~l~l~lCAL: NO
(i~r) ANTI-SENSE: NO

SU~ ultSHEEl (RULE26) , CA 0222339~ l997-l2-03 W O 96/40893 , PCTAUS96/09122 ' 286 (vi~ ORIGINAL SOURCE:
(A) OR~-~NI~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION l...Z07 (Xi) ~'QU~'N~' DESCRIPTION: SEQ ID NO:318 ATGA~AACAA TTAAAAATGG TATTATGATC GGCACACTCG GTGC~ ATTGAGCGGT 60 ~ AGCT TTGATGCTCA GC~ll~l~CGCT TGTCTCCCTA AAGACCATTC TTCAAAAGAC 120 GCTTCTACCA AAAAAGAAGC GCAATACATT CCTAAGGGCT TTTTTGACCC TTA~ 180 (2) INFORMATION FOR SEQ ID NO:319:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 570 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...570 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:319 ATGGAGCTTA TTTTAGGCTC TCAATCCAGC GCTAGGGCGA A~ AAA AGAGCATGGG 60 AGGGAGTTTG TCTATTTGGC GTGCAAGGGG AAATTAGA~A AAGCTAAAGA GTTACTTGCG 180 AATAATTGCG CTA~lC~l~l GGCTGATAGC ~ GAGCG TGGGTAATCG CATGCAACGA 240 GAGGTTTTAA ~l"l~ ~C ATTGATTTCT C~ ~llGG AATGGCTGGA TCTATCGGTT 360 TTTAGAGCGC GTTTAAAGGC GTTTGATTGC AGCGAAATAG AAA~ATATTT AGAGAGCGGT 420 TTATGGCAAG GAAGTGCGGG ~ l'~'l'~C~l~ TTAGAGGACT TTCATAAGCC TTATATTAAA 480 (2) INFORMATION FOR SEQ ID NO:320:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 405 base pairs (B) TYPE: nucleic acid (C) STRANv~:v~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~Ol~ CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:

SUI~ ultSHEEr(RULE26) CA 0222339~ l997-l2-03 W O 96/40893 , PCTAUS96/091Z2 ' 287 (A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1.. 405 (xi) ~Q~hN~ DESCRIPTION: SEQ ID NO:320 _ ATGCTTATTT ~A~ArAccc TTTAATCCCT AG~G~l~ll r~ AT TAAAAACACC 60 GATGCTATTC ATTCCAGCGC CAA~AAr~AT ATA~ TTGAAGCA~AA CCCAAAAAAT 120 TTGGAATTAG CCCAATATTG CTGTGA~AAT GGCGTCCATT TTAGCGTGAT ~ ATCG 180 CACAAGATAG AGACGGACAC ~'l"l"l"l"l"l"L'l'A TTCAACGCTT TCAAACCGCT CTATTGTATT 240 TTTAAGGATA TTAAGCAAGC CATACTCGCC CAACAACACG CCACTAATTA ~ AGAT 300 AGCAAAATCT ~ AT GGATTTTAAC GATACAGAGT CATGGGAGAT TTGCGCTAAA 360 AATCAAATAG A~l~w~ CAT TTCTAAAGAT TCACTCCTTT TGAAA 405 (2) INFOR~ATION FOR SEQ ID NO:321:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 765 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
~A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...765 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:321 ATGAP~AAA GATTGAATAT AGGGCTTGTG GGTTTAGGGT GC~l~GGAG CACGGTCGCT 60 AAAATCTTAC AAGAAAATCA AGAAATCATT AAAGACAGAG CCGGCGTGGA AATTAA~ATT 120 AAAAAAGCGG ~ ~C~AGA CGTGAAAAAA CACAAGwCT ATGCTTTTGA AATCAGTGAT 180 GATTTAGAAA GCGTGATAGA AGATAAAGGG ATTGATATTG TCGTGGAGCT TA~ ~GG 240 GTGGAAGCGC CTTATCTTTT AGCTAAAAAA ACTTTAGCCA AACAAAARGC ~ C~ ACA 300 GC~AAT~AAG CCATGTTAGC GTACCACCGC TATGAATTAG AACAAATCGC TAAAAACACC 360 CCCATAGGCT TTGAAGCGAG C~~ ~l~GG GGTATCCCCA TTATCAAGGC TTTAAAAGAC 420 GGCTTGAGCG CTAATCACAT C~ ll AAAGwATTT TAAACGGCAC GAGCAATTAC 480 AT~ AAGCC AGATGTTTAA AAATCAAGCG AGCTTTAAGG ACGCTTTGAA AGACGCGCAG 540 CATTTAGGCT ATGCGGAATT GAACCCTGAA TTTGACATTA AGGGCATTGA ~l~GCGGCGCAC 600 AGCATCA~AC TTTTAGGCAT CGCTAAAAAA CACCAGGGAT TGCAT 765 (2) INFORMATION FOR SEQ ID NO:322:
: CHARACTERISTICS:
(A) LENGTH: 729 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double - (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) SU~ ul~ SHEEr (~ILE26) CA 0222339~ 1997-12-03 W O 96/40893 , PCTrUS96/09122 ' 288 (iii~ HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...729 (xi) ~QU~N~ DESCRIPTION: SEQ ID No:322 ATGCAAGAAA AACGACTTAA AGCCATTCAA AACAAAATCG ~ ~AT CAAGGAAATT 60 GAAAGCGGCT TTATAGATGC A~ AAGATTGGCC CTTCAAAGAT GCTGCGCTCC 120 AAACTCATGC TCG~ AGACGAAAAA ACAGACGCTA TTTTATTAGA TAAAGCGCTC 180 AA~lll~l~l~ CGATTGTGGA AATGATACAG ACCGCTTCTT TATTGCATGA TGATGTGATT 240 GACAAGGCGA CCATGCGCCG AAAGCTCCCT AGCATTAACG ~~ ll~G GAATTTTAAC 300 GAC~l~lll~ TGGGGGAATG TTTTAATAGC r-ArAAArAAA AATACTGGCG TATTTTAGAA 480 GACGCCAAAA TGTATGCGGA TTTTGGGTTG CA~ lGGCA TGGCGTTTCA AATCATTGAT 600 GA~ AG ACATCACTCA AGACGCCAAC ACTCTAGGTA AGCCCAATTT TAGCGATTTT 660 (2) INFORMATION FOR SEQ ID NO:323:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 756 base pairs (B) TYPE: nucleic acid (C) STRAN~ ~N~SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPO~ llCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...756 (xi) ~ryu~:N~ DESCRIPTION: SEQ ID No:323 ATGTTAGGGA AAAAAAACGA AGAAGTCTTG ATTGATGAAA ATTTGGTTGG GG~~ ~ATA 60 GCC~l~l~ATA GATTGGCAAA ACTCAATAAG GCrAATAr-GA CTTTCAAAAG GG~l~ AT 120 ~ ATGG TGCTCAATGT CGCCG~l~ A ACGAGTATTG TGATGATGAT GCCTTTGAAG 180 AAAArArATA TA~ A TGGCATTGAT CGATACACAG GAGAATTTAA AATCGTCAAA 240 CG~l~CC~ATG CTAGGCAAAT CGTCAATTCT GAAGCC~ll~ TGGATAGTGC AACTTCAAAA 300 ~ CAT TG~~ l~G TTATAGCAAA AAl~ l~A GGGATCGCAA GGATCAACTA 360 S
ATGCAGTATT GCGATGTGAG TTTCCAAACC CAAGCAATGA GAATGTTCAA T~-AAAATATC 420 AA~AGTCAAAA ATAGTCCCTT AACGAGATTA ACA~ ~A TTACCATCAA AATCACGCCT 540 GCTAGAGGTA A~ lCA AGAAAATCTT ATCATCAACC ~ ~GCTT CAAAGTGTTT 660 GACATTCAAA TCACGGATTT ACAAAACGAA rAr-~rAr-TAA GCGAAATTTT GAGAAAGATT 720 AAArAArTGG AATCAAAAAA TAAGGCATTA AATAAA756 Ult SNEEr(RlllF2S) CA 0222339~ l997-l2-03 W O ~6~IC~93 PCTAUS96/09122 . 289 (2) INFORMATION FOR SEQ ID No:324:
(i3 ~kQ~kN~k CHARACTERISTICS:
(A) LENGTH: 495 base pairs (B) TYPE: nucleic acid (C) STRANV~:VN~:~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOT~ETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...495 (xi) ~kyukN~k DESCRIPTION: SEQ ID NO:324 ATGATTGATT TTTTCAATAA ACCCATGCTC GCTTACCCTA TTGAAACAGC ACTA~ATTCC 120 AAGclclll~ AAAAAGTGTT TATCTCTAGC GATAGCATGG AGTATGTCAA TTTAGCCAAA 180 AATTATGGGG CGA~~ lllr GAATTTACGC CCTAAAAATT TAr-cAr-AC~-A CAGGGCCACG 240 'l~'l"l'~'l"l"l'~l' ATGGCGTTTC AGTATTTTTA CAAGAAAAGC ATTTACAAAA CG~ ~AA 360 ACTTTAAAAC AAAATCAAAA TACGGATTAT ~ ll~ACAT G~l~l~ TAGCGCTTCG 420 (2) INFORMATION FOR SEQ ID NO:325:
(i) ~kyUkN~k CHARACTERISTICS:
(A) LENGTH: 513 base pairs (B) TYPE: nucleic acid (C) STRAh~k~hkSS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORr.ANT.~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...513 (xi) ~y~:N~k DESCRIPTION: SEQ ID NO:325 ATGAGTAATC AAGCGAGCCA TTTGGATAAT TTTATGAACG CTAAA~ATCC CAAAAGTTTT 60 TTT~-ATAATA AGGGGAATAC CAAATTCATC GCTATCACAA GCGGTAAGGG GGGCGTGGGG 120 GTATTTGATG Cr-RATATTGG TTTAGCGAAT TTAGATGTCA ll~lrl~GG~l GAAAACCCAY 240 A~AAATATCT TGCATGYCTT AAAAGGCGAA GYCAAATTGY AAGAAATCAT TTGCGAGATT 300 GAACCCGGGC '~ AAT CC~l~GGGAT AGCGGCGAAG AAATTTTAAA ATACATCAGC 360 GSSGCGGAAG Yl-l-l~ATTC ATTCTTAGAT r-AAr-Ar-GGGG TTCTAAGCGC TTTAATTTAT 420 SU6~ ult SHEEr (RUIE 26) CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 ATTTTAATTA ATACATTTTC TAAAAATTTG GGTCCACTAT CTcAAAcTTT TCTTAATTTT 480 (2) INFORMATION FOR SEQ ID NO:326:
~N~: CHARACTERISTICS:
(A) LENGTH: 186 base pairs (B) TYPE: nucleic acid (C) sTRANn~nN~s double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...186 (xi) ~:yu~:N~: DESCRIPTION: SEQ ID NO:326 TTGGGGCTGG CTTTGAAATT AGAAGTGCTG GATA~G~ATA TGATCATTAG CGAGAGGGTG 120 GGCTTGAGCG TGAGAGGGAT TTTTGAAGAG ~ ~C~AAG ACAATTTCAG GATGTTTGAA 180 (2) INFORMATION FOR SEQ ID NO:327:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 65Ç base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: HelL_obacter pylori (ix) FEATURE:
(A) NAME/KEY: ~s-_~eature (B) LOCATION 1...65 (xi) ~:Q~ : DESCRIPTIOri: SEQ ID NO:327 TTAGAAGGAG CGTTTAGATT AGAAAAGTTT TTCAAACGCT ACAAGTGGGT ~ 120 A~ ~G CTTTTATCGC TTATTTAGGG GATA~A~AAT TACAAGATTA TAAGCATGAG 180 ATCGTTAAAG C~llCGCCAA ATATTCTTAC GCAlCG~l~ CTAGAGATAA AAACCTGCTT 420 GAAA~AAGCC CCATTCTTAA AGAAATGAGC GCTTTACAAG AAGTGAACTT GTTGTATGAA 480 GAAAATTCTA A-A~-AcGrAAT CAAAAAAGCG CATCAAAGTT TATCAACTAT CCCTCTAAGT 540 SU~ ul~ SHEEr (RUlE a6) CA 0222339~ l997-l2-03 W O 96/40893 , PCTrUS96/09122 TCTTCACTCT ATGCTATAAT ~'l~T~'l"l"l"l'A AAACATTATG GAATGTTAGA AGATATTCAG 600 rA~AA~CCTT CCAAACCAAC CAATCTAAAG AAAGAAACCA TTCAAGGAAC GCAT 654 (2) INFORMATION FOR SEQ ID No:328:
U~'NL'b CHARACTERISTICS:
(A) LENGTH: 303 base pairs _ (B) TYPE: nucleic acid (C) STRAMn~nNESS: double (D~ TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori ~ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...303 (xi) ~k~kN~ DESCRIPTION: SEQ ID NO:328 GTGCATTTCA ATCAGGTTGT TCTCCCAAAA GGL~lLGGCG CGATTTTAGT CGCACCAAAA 60 GGGCCCGGGA GCGCTTTAAG AGAAGAATAC CTTAAAAATA GGGL~ ATA CCATCTAATC 120 GCGATGGGTG GGGGGAGAAT GGG~l~lllA GAAACGAGTT TTAAAGAAGA ATGCGAGAGC 240 GATTTATTCG GCGAGCAAGC GL-'1'L'1"1'L'1'LC GGGGGGTTAG AAGTCGATCG TAAGAATGGG 300 GTT

(2) INFORMATION FOR SEQ ID No 329:
(i) ~u NL~ CHARACTERISTICS:
(A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C) sTRANn~nNEss: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv), ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) oRr~ANTcM Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...240 (xi) ~QU~N~ DESCRIPTION: SEQ ID NO:329 ATGAAAAAAT ~ lLl~-A A'1'L'1"1"1'L-'1"1'A GL~lL~ ATTA TCTCTATGAA 'lLCG~l'ATCT 60 GGCATGGATG GTAATGGCGT ~ AGGG GCGGGTTATT TGCAAGGACA GGCGCAAATG 120 cATGcGr-~T~ TTAATTCTCA AAAACAAGCC ACCAACGCTA CGATCAAAGG CTTTGACGCG 180 _ LlLl~l~LGGLl~ ATCAATTTTT CTTTGAAAAA CAL'l''l''l'L-GL'l' TACGCCTTTA TGGGGTTTTT 240 (2) INFORMATION FOR SEQ ID NO:330:

SU~ ultSHEEr (RUlE26~

CA 0222339~ l997-l2-03 W O 96/40893 PCTrUS96/09122 ~ 292 ( i ) S ~:Q U ~:N~ ~: CHARAcTERIsTIcs:
(A) LENGTH: 1341 base pairs (B) TYPE: nucleic acid (C) STRANv~N~:SS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...1341 (xi) s~Qu~:NL~: DESCRIPTION: SEQ ID NO:330 ATGCTAAAAA AGA~Ll~L~ A ~l~LL~l"l"l"l~ATC GTTTTATTTT TGATTATCGT AGGL~ ~ 60 GCCL1~ ~ TCGCTCAAGT 'l~ AAcT ACGGATAAGG ATATTGCTAA AATTAAAGAT 120 TATCGCCCCA LlLl~GLl~lC ACAGATTTTA GACAGAAAAG ~GC~~ ~AT CGCTAATATT 180 TATGATAAGG AA~ C~ll~l~ TTATGCGCGT TTTGAAGAAA TCCCCCCACG Al~ l~AA 240 AGCCTTCTAG CGGTAGAAGA CACCLl~Ll~ TTTGAGCATG GGGGGATCAA TTTAGACGCT 300 CTAACCCAAC AA~l~C~l~l~AA AAACATGGTG CTCACACGGG AAAAAACCCT AACCAGAAAA 420 GAGCGTTATT TGAACCAAAC ~ L-G~ CATGGGTATT A~l~GC~lGAA AACCGCAAGT 540 AGGGCTAATG ATATTTTAAG ~CG~l~ AT TCTTTAGGCY GGA~ l~ TAACGAGCTC 720 AAAl~-CGLl- TCAATGAAGT GCCAATCGTC TATAACCAAA CTTCCACGCA AAATATCGCT 780 GGCTATACCA TAAAACTCAC GATAGATTTG GATTACCAAC GCTTAGCGTT GGA~~ l~ 900 C~lll~GGC ATCAAAAAAT CTTAGAAAAA ATCGCTAAAG AGAAGCCAAA AACTAACGCT 960 ACGCAAGCCA AACGGCAGTT TGGGAGCGCR ATCAAGCCTT ~ LilATCA AATCGCTTTT 1140 AATTTAGCGA TCGLll~L~l~ A 1341 (2) INFORMATION FOR SEQ ID NO:331:
(i) s~Q~ ~:N-~: CHARACTERISTICS:
(A) LENGTH: 654 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:

SU~ ul~ SHEE~ (RULE 26) CA 02223395 l997-l2-03 W O ~C~993 PCT~Us96/09122 ~ 293 (A) NAME/KEY: misc_feature tB) LOCATION 1 654 Ixi) ~kyu~N--~ DESCRIPTION: SEQ ID NO 331 AT~-~ArrA~A CAACAGAGCA CCATGGATCC AATCCGCTAA ACGCCCCACC ACCTAGCAAC 60 TrArA~-Ar-rA ACGATCTCTT A~ATTTGCTA GACl~LL~ AT ATCCTAAAGG GAGTTTAGGG 120 ~AArA~A~AT TTCACGAAGC TTTAAAGAAT CAAGAAGAGT TGAAAAATAT CCTAATAGAA 180 A~A~A,A~AGC TACCGCAAGA AAAAAGGTAT GAACTTCTGA TGCAGATAGG ACAAGCCAAA 240 rA~AATAA TGGAAGCATA CGCTCATTCA TTCTTAGGAT ATATAGGGGG ACTAGAGCAT 300 CTGTTAGGAT TGTGTATGGG TGGGATATTT L-'l"l"l"l'L'l"l"l'~ CAATCTATTT TGTATTTTTA 360 AGAACTAGCA AAAACACAGA GCTAGTGGAA AGTCTAAAAA CAAAAl'TAAA ACTTCAGTAT 420 TTTTACTATG CL''1"11'LL-'1'~'1' GG~L~LG~ ~l"l"l"l"l"lG GATTAGAAAC AATTAGATCG 480 ATTTATGAAC TATATATCTT AGGAATTGGT AGCACTAACG ACAAGGTGCT L'l"l"l'L'l"l"l"l'~ 540 ATAAAAAATT TTATCAATGG ~l~L~ lCGCT TCAAAGAAAC AAGGCGGTGC AGAA 654 (2) INFORMATION FOR SEQ ID NO 332 (i) S~y~NL~ CHARACTERISTICS
(A) LENGTH 576 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) ~iii) HYPO~ lCAL NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE
(A) ORGANISM Helicobacter pylori (ix~ FEATURE:
(A) NAME/KEY misc_feature (B) LOCATION 1 576 (xi) SEQUENCE DESCRIPTIO;~ SEQ ID NO:332 ATGATGGATA AG~l~GLlll TAAATCTCAA GGCATCTTTG TGATGGACGC TAGCAAGAGG 60 GA~l~L-GGCG~l TGAACGCGTA TTTI~GAGGC TTGGGTAAAA ACAAGCGGGT G~lLl~l~Ll~ll 120 GACACTTTGA TCTCTAAAGT TGw A~AGAA SGGCTTTTAG CCATTTTAGG GCATGAGTTA 180 GGGCATTTTA AAAATAAGGA 'l~ ~A AATTTAGGGA TTATGGGAGG L~ L-LrL~GCT 240 U'l"l'~'l"l"l"l"l'~ CTTTGATCGC TCA. .___G CCGTTGGTTT TTGAAGGCTT TAA~ Ll~LG 300 CAAACGCCAG CGAGTTTGAT CA_GA~ A L'l'L''l"l'L'l"l"l"l' TGCCGL~lLl~ l"lLLLl"l"lAC 360 GCCATGCCTT TGATTGGGTT ~.~ - .A_ - C__ AAGAACGAAT ACAATGCGGA CAA~l~llL~G 420 GCGAGTTTAA GCTCTAAAGA GA_ .~___ AAAGCGTTAG TGTCCATTGT GAATGAAAAT 480 AAAGCGTTCC CCTATTCGCA C_~ ~~ Ll"l"l"l'L"l"l~C ATTTCACGCA CCCGCCGCTA 540 TTA~-AA~GCC TAAAAGCTTT GGA.. A._~ ATTGAA 576 (2) INFORMATION FOR SEQ I~ t:~ 333 (i~ SkyU~WL~ CHARACTERISTICS
(A) LENGTH 603 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY circular (ii) MOLECULE TYPE DNA (genomic) (iii) ~Y~ul~ lCAL NO

SU~Il~lllt SHEEF (RULE26) CA 0222339~ l997-l2-03 ' 294 (iv~ ANTI-SENSE: NO
(vi~ ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix~ FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1 603 (xi~ SEQUENCE DESCRIPTION: SEQ ID NO:333 ATGAATATTT ATCAAAAAAA CTTGCAAGCT ~ CAAAA AAGACCCTCT ~ ~G~A 60 TTTGGCTTGG GTAATGGGGT GTTTTATCGC ~ AG GCAATGAAAA TTTAAAACGC 300 ~ A TTGAGCCTGA AATA~A~GTG ATTTTCATTG TGCTGAATCT TTTGGATTTT 360 TCCACTGAGA TTTTAGAAAA ~ l~ATT TTATTGCATG CAA~l~ r~ CAATTACAAC 420 ATGATTGCTT CATTATTTGA TATGGATAAA AA~l~'l~l~l' TATACGCAAG AATGTATGAT 480 (2) INFORMATION FOR SEQ ID No:334 (i) ~kQukN~k CHARACTERISTICS:
(A) LENGTH: 390 base pairs (B) TYPE: nucleic acid (C) sTRANn~nN~: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPO~ CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori tix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1 390 txi) ~kuukN~k DESCRIPTION: SEQ ID NO 334 ATGAAAAAGA TTATTCTTGC ATGCCTTGTG G~l~ ~l~G GTGCCAATTT AAGCGCAGAG 60 AGTGGTTCAG CCACTTCTAA AGAGG-ll~l~ AAACAAAAAG CGTTAGCGGA TTTAGTGGCG 180 TCTATTAGCG ~ G~l~-AA TTCACAAATC CACATTCAAA AAAGTCGTGT GGATAATAAG 240 GTAGAAATTG TCAATCAAGA AGCGCAAAAA GGGATCTACT ACACCAGAGT ~G~.~ATCAA 360 r t2) INFORMATION FOR SEQ ID NO:335: 5 (i~ ~kQ~kN~ CHARACTERISTICS:
(A) LENGTH: ~32 base pairs (B) TYPE: nucleic acid (C) STRA~~ s: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ~U~ lllt SHEET (RIILE 26) CA 0222339~ l997-l2-03 wo~cl~a~ PcT/us96/o9l22 ' 295 ic .
(iii) ~Y~l~k~ CAL: NO
(i~) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~ANT-~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...432 (xi) ~yuk~k DESCRIPTION: SEQ ID NO:335 A~ll~ll~GCA AAATTTCACC CCACAAAACC GCAGAAGAAT TCACYAATTT AATGTTGAAC 120 ATGATCGCTG TTTTAGACTC CCAATCTTGG GGCGATGCGA TCTTAAACGC ~lC-''l"l"ll'~AG 180 AATAAATTTA AAAACAAAGC RGATCTTGAT GTAATTGTTT TAAAGGATTC AGGG~ A 360 (2) INFORMATION FOR SEQ ID NO:336:
( i ) ~ r Qu ~-Nck CHARACTERISTICS:
(A) LENGTH: 927 base pairs (B) TYPE: nucleic acid (C) STRANn~nN~.~S: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...927 (xi) ~Qu~N~ DESCRIPTION: SEQ ID NO:336 TA~ CTGTTAGCGA ~ ~ATT TGCAAGGAAA GATTTATGGA TGAAATTAAA 120 Arll~ll~l~l~ TTTGTATAGG TTTTTATTTT ~l~C~l"l"l"l"lcl~ TArGr.~ArAA AACCATGAAA 240 CTCTTATCCA AAA~r-r.ATGA GATTTTGGCG AAlu"l~ lC~ CGCAGGTTAC TTTTATCTTA 300 ATCACTGTTT TAGGAACGGT GGGGATTGCG GTGGCGTTGG CTTTAAAAGA TTA~ u~l~A 420 AGCATTGCTG GAGGGATAAT CCTTATTATT TTACACCCTT TrAAA~AAr-G AGACATCATT 480 GAAATCTCTG GCCTAGAGGG CAAAGTAGAA GCGCTTAATT TTTTTAATAC ~ ACGC 540 TTGCATGACG GGCGC~ ~GC GGTTTTGCCT AATAGAAGTG TCGCTAATTC TAATATTATC 600 AATAGCAATA ACACTGCGTG TCGGCGCATT GAA'l'~G~ GGG~l~AGG GTATGGGAGC 660 ~AAAArATGc CCACTTTCAT TGGAATCACG GATTTTGGAC AAA~l~G~l' GAACTTCACC 780 TCTATCAACA AAr~r-~rTC TTCTAAG 927 SUBS~ Sh~tl (RUIE26) CA 0222339~ l997-l2-03 W O 96/40893 PCT~US96/09122 ' 296 (2) INFORMATION FOR SEQ ID No:337:
(i) ~'yU~'N~' CHARACTERISTICS:
(A) LENGTH: 491 base pairs t (B) TYPE: nucleic acid (C) sTRANn~n~cs: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
~iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NA~E/KEY: misc_feature (B) LOCATION 1...491 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:337 AT~ ~T TTTCCCCACT CTA~ AAAARGCTCA AAAAACGCCA TTTAATCGCT 60 CTGAGTCTGC C~l~ TTATGCGAAT GGCTTTAAAA TCCAAGAGCA AAGCTTGAAT 120 GGCACGGCTT TAGGCTCGGC GTATGTCGCT GGGGCTAGGG GTGCTGACGC ~l"l~l"l"l"l"l~AC 180 (2) INFORMATION FOR SEQ ID NO:338:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 162 base pairs (B) TYPE: nucleic acid (C) sTR~NnFn~cs double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) A-NTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...162 (xi) ~:yu~: DESCRIPTION: SEQ ID NO:338 A~l~L~ AG CGATCCCCTC TAAAGTCATA GCCATTAACG ATAATGTGGC ACTCTTAGAG 60 A~ll~GGCG TTCAAAGAGA AGCGAGCTTG GATTTAATGG GCGAGTCCGT TAAAGTGGGC 120 (2) INFORMATION FOR SEQ ID No:339:
( i ) ~ r:yuk~ CHARACTERISTICS:

SUBSIllUlt SHEET (RUI~ 26) CA 0222339~ l997-l2-03 w o ~cJ~e93 , PCT~US96/09122 ~ 297 (A) LENGTH: 606 base pairs (B) TYPE: nucleic Acid (C) sTRANn~n~ss double ; (D) TOPOLOGY: circular (iit MO~ECULE TYPE: DNA (genomic) (iii) HYPOT3',~ETICAL: NO
(i~) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix3 FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...606 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:339 AT~A~ATT TA~l~G~ l TTTAATATAC GCTATAGGGC ~~CAAC AGATAAAACG 60 CTAGATATTA TTA~AACCAT TCAAAAACTT CCTAAGATTG AAGTGCGCTA CTCCATAGAT 120 CAGCATTTTG A'l~ A AAACAAAGAG CAAGGTGCTA TCAATTACGC AGAACTCAAG 240 ATTGTAAGTT TAGATCTATA CC~~ l~CA GCGCACAACA TGGCCATTGT GGTGAATGAT 420 TATTTAAAAG CCC~l~ AT GG~l~ GGATG AAGCGCCTGA ~l"l~l"l"l"l"l"l~ TAAATACATT 480 (2) INFORMATION FOR SEQ ID NO:340:
(i) ~yukN~- CHARACTERISTICS:
(A) LENGTH: 615 base pairs (B) TYPE: nucleic acid (C) s~RANn~nNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii3 HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) O~NT.sM: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...615 ~xi) ~yukN~ DESCRIPTION: SEQ ID NO:340 ~l~Gl~AGCG GG~l~l~AT CATTATTGTG ~l"l"l"l"l"l~l~GC CGATTCTAAC CTTACAGGGG 60 TTAGTTCTAT CCATCACTAT CATTCCTGTA GTGAGCTCTC ~l~*~l~ AAA AGCCACGCCC 180 CATAGCGAAA C~~ AAC GAG~l"l"l"l"l~A AACAGAATCT ACGCCCCTTT ATTGGAATTT 240 Tll~l~CATA ACCCTAAAAA AGTGATTTTA GGAGCG~ ~ 'l"l"l"ll"l"l'AAT CGCAAGCCTT 300 TCTTTATTCC ~ l~G GAAGAATTTC ATGCCTGCTT TAGATGAGGG CGA~ ~Gl~ 360 AGCGATGAAT l~l~A TTTAGGGGGT TTGAATCAAA CrGATACTTT TA~ 540 SUB~ UliSHEE~(gUlE26) CA 02223395 l997-l2-03 ' 298 '~''l"l"l'AAAA GACTT 615 (2) INFORMATION FOR SEQ ID NO:341:
( i ) ~ ~ ~u r:N~ ~ CHARACTERISTICS:
(A) LENGTH: 216 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~NT~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION 1...216 (Xi) ~:Q~'N~ DESCRIPTION: SEQ ID NO:341 GTGGr.~T~T~ TCCCTARGGA AAAGATTGTA GGCATTAGCG CGATCGCTAA ACTCATTGAA 60 ATTTATAGCA AACGC~ A AATCCAAGAA AGGCTGACCA CTCAAATTGC AGAAACTTTT 120 GATGAAATCA TAGAGCCAAG G~GC~l~ATC ~~ AAGCCAAGCC ACTTGTGCAT 180 GAGCATGCAA G~G~l~AAA AGCAAAATGC GATCAT 216 (2) INFORMATION FOR SEQ ID NO:342:
QU ~ N~ ~' CHARACTERISTICS:
(A) r~GTH: 39 base pairs (B) TYPE: nucleic acid (C) STRz~NnF~nNF~c~s: double (D) TOPOLOGY: circular ~ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~l~kl~lCAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~NI~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...39 (Xi) ~'~U~NL~: DESCRIPTION: SEQ ID NO:342 ~G~ l~ATAG TTTGATAGAG AACAAGAAG 39 5 (2) lN~MATION FOR SEQ ID NO:343:
(i) ~kyU N~ CHARACTERISTICS:
(A) LENGTH: 297 base pairs (B) TYPE: nucleic acid (C) STRi~ J~ : double Su~lllul~Sht~l ~RU~E26) W O ~SL_~ PCTAUS96/09122 ' 299 ~D) TOPOLOGY: circular (ii~ MOLECULE TYPE: DNA (genomic) (iii) ~Y~~ CAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) OR~.AMT-~M: Helicobacter pylori (ix) FEATURE:
(A) NAME/REY: misc_feature (B) LOCATION 1...297 (xi) ~UkN~ DESCRIPTION: SEQ ID NO:343 ATGAAAAAAA 'l~ l~AG ~l"l'~'l'~'l"l"l'~ GTTTTGAGTT TGG~l~r~ AAAAGCCCAT 60 ATGAAAATCA ACCACACGAA GGG~l~lll~C GCTAAAGGCG l~l~ CC TAACCCGCAA 180 GC~Ar7~A~ ATTTAGAGGT GCCACTACTC AATGAAAAAG AAATCCCTGC ~lcl~lAAGG 240 TA~ l~G GGGGCGTGGT CGATTGGACG ATAAAAGCAA GGTTAGGGGA ATGGCGT 297 (2) INFOR~ATION FOR SEQ ID No:344:
~k CHARACTERISTICS:
(A) LENGTH: 300 base pairs (B) TYPE: nucleic acid (C) STR~N~ N~: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(~i) ORIGINAL SOURCE:
(A) OR~NT~M: Helicobacter pylori (ix) FEATU~E:
(A) NAME/KEY: misc_feature (B) LOCATION 1...300 (xi) ~QUrN~ DESCRIPTION: SEQ ID NO:344 GTGATCAAAC CTCATAGCGT GGGATTGGTA AGGATTGGGA 'l"l~ l~lC TTTAGAAGTG 60 GGGTATGAAC TGCAGGTACG CACCCGTAGC GG~l~G~ll~ TGAATCATCA GGTGATGGTG 120 AATTTGAGCG ATAAAGATTT TAAAGTTCAA GTAGGGGATA GGATcGcTcA AGGG~ r 240 ~A~AA~TT ATAAAGCCGA ATTTATAGAA TGCGAACAAT TAGATGAAAC CTTCAAGGGG 300 (2) lN~k~ATION FOR SEQ ID NO:345:
ukN~k CHARACTERISTICS:
(A) LENGTH: 765 base pairs (B) TYPE: nucleic acid (C) STRA~I~ c: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) (iii) ~Y~ kllcAL: NO

SI~ ul~SHEE~ (~IE26) _ CA 0222339~ 1997-12-03 W O 96/40893 PCT~US96/09122 ~ 300 (iv~ ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helicobacter pylori (ix) FEATURE:
(A) NAME/XEY: misc_feature (B) LOCATION 1...765 (xi) ~Q~rNC~: DESCRIPTION: SEQ ID NO:345 ATGGAAATCA TTTTATTAAT TGTTGCGGCG ~ TTTATTTTTA CAACACCCTC 60 AATGACCCCT A~ GCAATCTAGC CCCCTAGACA AATTCAAGCA AACCCAAATA 180 GGCGCGTATA TGC~ AAAATTTTTA GACATTCAAA AAAACGCCTT GGATAACGCT 240 ATGCTATTAG CCTATGCTGA TGGGATTTTG GACAGCAAAG AAAAAGAATT ~ AGAT 480 GTGGGGGCGT ~lllG~AGAT AGACAATCAA GATTTTAACG AGCTTTATGA CAATTTTGAA 540 (2~ INFORMATION FOR SEQ ID NO:346:
(i) ~Q~ ~:N~ ~: CHARACTERISTICS:
(A) LENGTH: 318 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic) ~iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Helic~bacter pylori (ix) FEATURE:
(A) NAME/XEY: m~ 'eature (B) LOCATION 1.. 31&
(Xi) ~U N~- DESCRIP-'-~: SEQ ID NO:3~6 ATGGAAGTAG AGCATGGCAA GA~ _C ACTTTAAGCT TGGGGGCGTC TCATTTGGAA 60 GTCATTAAAA TGA~lG~ l' AGA~ .~ C~ AG TGAATAATAT CACCATCACT 120 TTAATTTCTC TAATAGGCTA TT~ .A.:~ GCYGGAGCGT TAGGG~l~G GGGATTGGGG 180 GATTTAGCCA TTAGGATTGG CTATC~A~T TATAGGGGCG ATGTGCTTTT TTA~l~CG~l~ 240 ~ C~l~ATCA 'l'~'~'l"l"l"l'AGT GCA~TCA-~ CAAAGCGCGG GGGATTATGT GGTGAAACGC 300 TTr.~A~ ATAAGTAT 318 (2) INFORMATION FOR SEQ ID NO:347:
(i) ~Qu ~:N~ ~- CHARACTERISTICS:
(A) LENGTH: 1581 base pairs (B) TYPE: nucleic acid (C) STR~Nn~n~Fss double (D) TOPOLOGY: circular ~U~ ul~H~ IILE26) ~CA 02223395 1997-12-03 DEMANDES OU BR~VE~S VOLU~VllNElJX

~A P~ÉSE~YTE PARTIE DE CEl~E DENIANDE C)U CE BR~VFI
COMPREND PLUS D'U~I TOME - - -C~CI EST LE T~ME / - -DE_S _ -- NOl~: Pc~ur les tomes additionels, veuillez c~ntacter le E3ureau canadien ~es brevets ~

i JUMBO APPL~CATIONS/PATENTS - .

.
THIS SECTION OF THE APPI ICATION/PATENT CONTAINS MORE
~HAN ONE VOLUME

THIS IS VO~IJME I O~

NO~E: E~r addi~ional ~rci~tmes-p~ease c~ntac~~~he Canadian Patent ~ff~c~ -

Claims (108)

1. An isolated nucleic acid comprising a nucleotide sequence encoding an H.
pylori cell envelope polypeptide or a fragment thereof, said nucleic acid selected from the group consisting of SEQ ID NO: 1020, SEQ ID NO: 1021, SEQ ID NO 1036, SEQ ID
NO: 1050, SEQ ID NO: 1071, SEQ ID NO: 1101, SEQ ID NO: 1135, SEQ ID NO: 1276, SEQ ID NO: 1150, SEQ ID NO: 1187, SEQ ID NO: 1192, SEQ ID NO: 1361, SEQ ID
NO: 1379, SEQ ID NO: 1399, SEQ ID NO: 1403, SEQ ID NO: 1400, SEQ ID NO: 1189, SEQ ID NO: 1002, SEQ ID NO: 1213, SEQ ID NO: 1214, SEQ ID NO: 1215, SEQ ID
NO: 1234, SEQ ID NO: 1236, SEQ ID NO: 1237, SEQ ID NO: 1224, SEQ ID NO: 1251, SEQ ID NO: 1262, SEQ ID NO: 1149, SEQ ID NO: 1220, SEQ ID NO: 1240, SEQ ID
NO: 1164, SEQ ID NO: 1165, SEQ ID NO: 1404, SEQ ID NO: 1144, SEQ ID NO: 1182, SEQ ID NO: 1157, SEQ ID NO: 1160, SEQ ID NO: 1300, SEQ ID NO: 1321, SEQ ID
NO: 1323, SEQ ID NO: 1329, SEQ ID NO: 1332, SEQ ID NO: 1345, SEQ ID NO: 1358, SEQ ID NO: 1375, SEQ ID NO: 1417, SEQ ID NO: 1283, SEQ ID NO: 1335, SEQ ID
NO: 1368, SEQ ID NO: 1179, SEQ ID NO: 1255, SEQ ID NO: 1258, SEQ ID NO: 1044, SEQ ID NO: 1273, SEQ ID NO: 1219, SEQ ID NO: 1274, SEQ ID NO: 1210, SEQ ID
NO: 1422, SEQ ID NO: 1302, SEQ ID NO: 1308, SEQ ID NO: 1310, SEQ ID NO: 1331, SEQ ID NO: 1432, SEQ ID NO: 1052, SEQ ID NO: 1091, SEQ ID NO: 1421, SEQ ID
NO: 1069, SEQ ID NO: 1005, SEQ ID NO: 1007, SEQ ID NO: 1166, SEQ ID NO: 1177, SEQ ID NO: 1193, SEQ ID NO: 1206, SEQ ID NO: 1207, SEQ ID NO: 1304, SEQ ID
NO: 1305, SEQ ID NO: 1346, SEQ ID NO: 1348, SEQ ID NO: 1350, SEQ ID NO: 1032, SEQ ID NO: 1053, SEQ ID NO: 1081, SEQ ID NO: 1124, SEQ ID NO: 1382, SEQ ID
NO: 1437, SEQ ID NO: 1263, SEQ ID NO: 1173, SEQ ID NO: 1405, SEQ ID NO: 1406, SEQ ID NO: 1410, SEQ ID NO: 1086, SEQ ID NO: 1322, SEQ ID NO: 1266, SEQ ID
NO: 1282, SEQ ID NO: 1271, SEQ ID NO: 1208, SEQ ID NO: 1126, SEQ ID NO: 1270, SEQ ID NO: 1278, SEQ ID NO: 1419, SEQ ID NO: 1125, SEQ ID NO: 1181, SEQ ID
NO: 1416, SEQ ID NO: 1096, SEQ ID NO: 1082, SEQ ID NO: 1146, SEQ ID NO: 1145, SEQ ID NO: 1108, SEQ ID NO: 1148, SEQ ID NO: 1337, SEQ ID NO: 1338, SEQ ID
NO: 1424, SEQ ID NO: 1000, SEQ ID NO: 1027, SEQ ID NO: 1175, SEQ ID NO: 1330, SEQ ID NO: 217, SEQ ID NO: 217, SEQ ID NO: 367, SEQ ID NO: 911, SEQ ID NO: 944, SEQ ID NO: 18, SEQ ID NO: 107, SEQ ID NO: 894, SEQ ID NO: 943, SEQ ID NO: 203, SEQ ID NO: 85, SEQ ID NO: 290, SEQ ID NO: 5, SEQ ID NO: 199, SEQ ID NO: 992, SEQ ID NO: 934, SEQ ID NO: 899, SEQ ID NO: 302, SEQ ID NO: 215, SEQ ID NO:
893, SEQ ID NO: 984, SEQ ID NO: 97, SEQ ID NO: 22, SEQ ID NO: 49, SEQ ID NO:
309, SEQ ID NO: 150, SEQ ID NO: 240, SEQ ID NO: 957, SEQ ID NO: 57, SEQ ID NO:
2, SEQ ID NO: 92, SEQ ID NO: 255, SEQ ID NO: 164, SEQ ID NO: 201, SEQ ID NO:
278, SEQ ID NO: 245, SEQ ID NO: 921, SEQ ID NO: 896, SEQ ID NO: 248, SEQ ID
NO: 159, SEQ ID NO: 979, SEQ ID NO: 194, SEQ ID NO: 194, SEQ ID NO: 946, SEQ

ID NO: 916, SEQ ID NO: 76, SEQ ID NO: 905, SEQ ID NO: 914, SEQ ID NO: 931, SEQ
ID NO: 50, SEQ ID NO: 250, SEQ ID NO: 969, SEQ ID NO: 66, SEQ ID NO: 275, SEQ
ID NO: 330, SEQ ID NO: 204, SEQ ID NO: 383, SEQ ID NO: 303, SEQ ID NO: 70, SEQ
ID NO: 983, SEQ ID NO: 972, SEQ ID NO: 929, SEQ ID NO: 972, SEQ ID NO: 936, SEQ ID NO: 267, SEQ ID NO: 197, SEQ ID NO: 55, SEQ ID NO: 54, SEQ ID NO: 210, SEQ ID NO: 90, SEQ ID NO: 15, SEQ ID NO: 913, SEQ ID NO: 227, SEQ ID NO: 79, SEQ ID NO: 191, SEQ ID NO: 238, SEQ ID NO: 274, SEQ ID NO: 27, SEQ ID NO: 258, SEQ ID NO: 295, SEQ ID NO: 10, SEQ ID NO: 160, SEQ ID NO: 225, SEQ ID NO: 964, SEQ ID NO: 166, SEQ ID NO: 56, SEQ ID NO: 980, SEQ ID NO: 903, SEQ ID NO: 261, SEQ ID NO: 71, SEQ ID NO: 955, SEQ ID NO: 361, SEQ ID NO: 58, SEQ ID NO: 114, SEQ ID NO: 940, SEQ ID NO: 960, SEQ ID NO: 144, SEQ ID NO: 362, SEQ ID NO: 40, SEQ ID NO: 285, SEQ ID NO: 11, SEQ ID NO: 161, SEQ ID NO: 974, SEQ ID NO: 111, SEQ ID NO: 316, SEQ ID NO: 257, SEQ ID NO: 78, SEQ ID NO: 966, SEQ ID NO: 352, SEQ ID NO: 981, SEQ ID NO: 158, SEQ ID NO: 989, SEQ ID NO: 963, SEQ ID NO: 48, SEQ ID NO: 68, SEQ ID NO: 135, SEQ ID NO: 910, SEQ ID NO: 236, SEQ ID NO: 241, SEQ ID NO: 949, SEQ ID NO: 945, SEQ ID NO: 207, SEQ ID NO: 977, SEQ ID NO:
978, SEQ ID NO: 994, SEQ ID NO: 163, SEQ ID NO: 256, SEQ ID NO: 287, SEQ ID
NO: 184, SEQ ID NO: 45, SEQ ID NO: 136, SEQ ID NO: 214, SEQ ID NO: 16, SEQ ID
NO: 192, SEQ ID NO: 373, SEQ ID NO: 892, SEQ ID NO: 239, SEQ ID NO: 34, SEQ ID
NO: 340, SEQ ID NO: 41, SEQ ID NO: 332, SEQ ID NO: 134, and SEQ ID NO: 330.
2. The purified nucleic acid of claim 1, wherein said H. pylori cell envelope polypeptide or a fragment thereof is an H. pylori flagella-associated polypeptide or a fragment thereof encoded by the nucleic acid selected from the group consisting of SEQ ID
NO: 1020, SEQ ID NO: 1021, SEQ ID NO: 1036, SEQ ID NO: 1050, SEQ ID NO: 1071, SEQ ID NO: 1101, SEQ ID NO: 1135, SEQ ID NO: 1276, SEQ ID NO: 1150, SEQ ID
NO: 1187, SEQ ID NO: 1192, SEQ ID NO: 1361, SEQ ID NO: 1379, SEQ ID NO: 1399, SEQ ID NO: 1403, SEQ ID NO: 1400, SEQ ID NO: 1189, SEQ ID NO: 217, SEQ ID NO:
367, SEQ ID NO: 911, SEQ ID NO: 944, SEQ ID NO: 18, SEQ ID NO: 107, SEQ ID NO:
894, SEQ ID NO: 943, SEQ ID NO: 203, SEQ ID NO: 85, SEQ ID NO: 290, SEQ ID NO:
5, SEQ ID NO: 199, SEQ ID NO: 992, SEQ ID NO: 934, SEQ ID NO: 899, SEQ ID NO:
302, and SEQ ID NO: 215.
3. The purified nucleic acid of claim 1, wherein said H. pylori cell envelope polypeptide or a fragment thereof is an H. pylori inner membrane polypeptide or a fragment thereof encoded by the nucleic acid selected from the group consisting of SEQ ID NO:
1002, SEQ ID NO: 1213, SEQ ID NO: 1214, SEQ ID NO: 1215, SEQ ID NO: 1234, SEQ
ID NO: 1236, SEQ ID NO: 1237, SEQ ID NO: 1224. SEQ ID NO: 1251, SEQ ID NO:
1262, SEQ ID NO: 1149, SEQ ID NO: 1220. SEQ ID NO: 1240, SEQ ID NO: 1164, SEQ
ID NO: 1165, SEQ ID NO: 1404, SEQ ID NO: 1144. SEQ ID NO: 1182. SEQ ID NO:

1157, SEQ ID NO: 1160, SEQ ID NO: 1300, SEQ ID NO:1321,SEQ ID NO:1323, SEQ
ID NO:1329, SEQ ID NO: 1332, SEQ ID NO: 1345, SEQ ID NO: 1358, SEQ ID NO:
1375, SEQ ID NO: 1417, SEQ ID NO: 1283, SEQ ID NO: 1335, SEQ ID NO: 1368, SEQ
ID NO: 1179, SEQ ID NO: 1255, SEQ ID NO:1258, SEQ ID NO: 1044, SEQ ID NO:
1273, SEQ ID NO: 893, SEQ ID NO: 984, SEQ ID NO: 97, SEQ ID NO: 22, SEQ ID NO:
49, SEQ ID NO: 309, SEQ ID NO: 150, SEQ ID NO:240, SEQ ID NO: 957, SEQ ID NO:
57,SEQ ID NO: 2, SEQ ID NO: 92, SEQ ID NO:255, SEQ ID NO: 164, SEQ ID NO:
201, SEQ ID NO: 278, SEQ ID NO: 245, SEQ ID NO: 921, SEQ ID NO:896, SEQ ID
NO: 248, SEQ ID NO: 159, SEQ ID NO: 979, SEQ ID NO:194, SEQ ID NO: 194, SEQ
ID NO: 946, SEQ ID NO: 916, SEQ ID NO: 76, SEQ ID NO: 905, SEQ ID NO: 914,SEQ
ID NO: 931, SEQ ID NO: 50, SEQ ID NO: 250, SEQ ID NO: 969, SEQ ID NO:66,SEQ
ID NO: 275, SEQ ID NO: 330, SEQ ID NO: 204, SEQ ID NO: 383, SEQ ID NO: 303, SEQ ID NO: 70, SEQ ID NO: 983, SEQ ID NO: 972, SEQ ID NO: 929, SEQ ID NO: 972, SEQ ID NO: 936, SEQ ID NO: 267, SEQ ID NO: 197, SEQ ID NO: 55, SEQ ID NO: 54, and SEQ ID NO: 210.
4. The purified nucleic acid of claim 1, wherein said H. pylori cell envelopepolypeptide or a fragment thereof is an H. pylori transporter polypeptide or a fragment thereof encoded by the nucleic acid selected from the group consisting of SEQ ID NO:
1219, SEQ ID NO: 1274, SEQ ID NO: 1210, SEQ ID NO: 1422, SEQ ID NO: 1302, SEQ
ID NO: 1308, SEQ ID NO: 1310, SEQ ID NO: 1331, SEQ ID NO: 1432, SEQ ID NO:
1052, SEQ ID NO: 1091, SEQ ID NO:1421, SEQ ID NO: 1069, SEQ ID NO: 1005, SEQ
ID NO: 1007, SEQ ID NO: 1166, SEQ ID NO: 1177, SEQ ID NO: 1193, SEQ ID NO:
1206, SEQ ID NO: 1207, SEQ ID NO: 1304, SEQ ID NO: 1305, SEQ ID NO: 1346, SEQ
ID NO: 1348, SEQ ID NO: 1350, SEQ ID NO: 1032, SEQ ID NO: 1053, SEQ ID NO:
1081, SEQ ID NO: 1124, SEQ ID NO: 1382, SEQ ID NO: 1437, SEQ ID NO: 1263, SEQ
ID NO: 90, SEQ ID NO: 15, SEQ ID NO: 913, SEQ ID NO: 227, SEQ ID NO: 79,SEQ ID
NO: 191, SEQ ID NO: 238, SEQ ID NO: 274, SEQ ID NO: 27, SEQ ID NO: 258, SEQ ID
NO: 295, SEQ ID NO: 10, SEQ ID NO: 160, SEQ ID NO: 225, SEQ ID NO: 964, SEQ ID
NO: 166, SEQ ID NO: 56, SEQ ID NO: 980,SEQ ID NO: 903, SEQ ID NO: 261, SEQ ID
NO:71, SEQ ID NO: 955, SEQ ID NO:361, SEQ ID NO: 58, SEQ ID NO: 114, SEQ ID
NO: 940, SEQ ID NO: 960, SEQ ID NO: 144, SEQ ID NO: 362, SEQ ID NO: 40, SEQ ID
NO: 285, SEQ ID NO: 11, SEQ ID NO: 161, SEQ ID NO: 974, SEQ ID NO: 111. SEQ ID
NO: 316, SEQ ID NO: 257, SEQ ID NO: 78, and SEQ ID NO: 966.
5. The purified nucleic acid of claim 1, wherein said H. pylori cell envelope polypeptide or a fragment thereof is an H. pylori outer membrane polypeptide or a fragment thereof encoded by the nucleic acid selected from the group consisting of SEQ ID NO.
1173, SEQ ID NO: 1405, SEQ ID NO: 1406, SEQ ID NO: 1410, SEQ ID NO: 1086. SEQ
ID NO: 1322. SEQ ID NO: 1266, SEQ ID NO: 1282, SEQ ID NO: 1271. SEQ ID NO:

1208, SEQ ID NO: 1126, SEQ ID NO: 1270, SEQ ID NO: 1278, SEQ ID NO: 1419, SEQ
ID NO: 1125, SEQ ID NO: 1181, SEQ ID NO: 1416, SEQ ID NO: 1096, SEQ ID NO:
1082, SEQ ID NO: 1146, SEQ ID NO: 1145, SEQ ID NO: 1108, SEQ ID NO: 1148, SEQ
ID NO: 1337, SEQ ID NO: 1338, SEQ ID NO: 1424, SEQ ID NO: 1000, SEQ ID NO:
1027, SEQ ID NO: 1175, SEQ ID NO: 1330, SEQ ID NO: 352, SEQ ID NO: 981, SEQ ID
NO: 158, SEQ ID NO: 989, SEQ ID NO: 963, SEQ ID NO: 48, SEQ ID NO: 68, SEQ ID
NO: 135, SEQ ID NO: 910, SEQ ID NO: 236, SEQ ID NO: 241, SEQ ID NO: 949, SEQ
ID NO: 945, SEQ ID NO: 207, and SEQ ID NO: 977.
6. A recombinant expression vector comprising the nucleic acid of claim 1 operably linked to a transcription regulatory element.
7. A cell comprising a recombinant expression vector of claim 6.
8. A method for producing an H. pylori polypeptide comprising culturing a cell of claim 7 under conditions that permit expression of the polypeptide.
9. An isolated nucleic acid comprising a nucleotide sequence encoding an H.
pylori cytoplasmic polypeptide or a fragment thereof, said nucleic acid selected from the group consisting of SEQ ID NO: 1147, SEQ ID NO: 1288, SEQ ID NO: 1324, SEQ ID
NO: 1363, SEQ ID NO: 997, SEQ ID NO: 1015, SEQ ID NO: 1084, SEQ ID NO: 1094, SEQ ID NO: 1099, SEQ ID NO: 1229, SEQ ID NO: 1250, SEQ ID NO: 1268, SEQ ID
NO: 1293, SEQ ID NO: 1339, SEQ ID NO: 1408, SEQ ID NO: 1429, SEQ ID NO: 1434, SEQ ID NO: 1228, SEQ ID NO: 1031, SEQ ID NO: 1034, SEQ ID NO: 1008, SEQ ID
NO: 1061, SEQ ID NO: 1064, SEQ ID NO: 1191, SEQ ID NO: 1217, SEQ ID NO: 1365, SEQ ID NO: 1394, SEQ ID NO: 1414, SEQ ID NO: 1415, SEQ ID NO: 1435, SEQ ID
NO: 1058, SEQ ID NO: 1059, SEQ ID NO: 1080, SEQ ID NO: 1128, SEQ ID NO: 1133, SEQ ID NO: 1211, SEQ ID NO: 1252, SEQ ID NO: 1253, SEQ ID NO: 1286, SEQ ID
NO: 1289, SEQ ID NO: 1291, SEQ ID NO: 1303, SEQ ID NO: 1396, SEQ ID NO: 996, SEQ ID NO: 1095, SEQ ID NO: 1156, SEQ ID NO: 1158, SEQ ID NO: 1159, SEQ ID
NO: 1277, SEQ ID NO: 1038, SEQ ID NO: 1257, SEQ ID NO: 1357, SEQ ID NO: 1436, SEQ ID NO: 1047, SEQ ID NO: 1055, SEQ ID NO: SEQ ID NO: 1141, SEQ ID NO:
1227, SEQ ID NO: 1327, SEQ ID NO: 1412, SEQ ID NO: 1003, SEQ ID NO: 1087, SEQ
ID NO: 1116, SEQ ID NO: 1130, SEQ ID NO: 1132, SEQ ID NO: 1185, SEQ ID NO:
1188, SEQ ID NO: 1198, SEQ ID NO: 1218, SEQ ID NO: 1244, SEQ ID NO: 1306, SEQ
ID NO: 1325, SEQ ID NO: 1397, SEQ ID NO: 1398, SEQ ID NO: 1407, SEQ ID NO:
1433, SEQ ID NO: 1216, SEQ ID NO: 1239, SEQ ID NO: 1362, SEQ ID NO: 1017, SEQ
ID NO: 1019, SEQ ID NO: 1360, SEQ ID NO: 1423, SEQ ID NO: 1425, SEQ ID NO:
1374, SEQ ID NO: 1028, SEQ ID NO: 1037, SEQ ID NO: 1077, SEQ ID NO: 1115, SEQ
ID NO: 1232, SEQ ID NO: 1241, SEQ ID NO: 1267, SEQ ID NO: 1163, SEQ ID NO:

1068,SEQ ID NO:1025, SEQ ID NO:1042, SEQ ID NO: 1046, SEQ ID NO: 1056, SEQ
ID NO: 1039, SEQ ID NO: 1072, SEQ ID NO: 1073, SEQ ID NO: 1092, SEQ ID NO:
1100, SEQ ID NO: 1102, SEQ ID NO: 1103, SEQ ID NO: 1104, SEQ ID NO: 1111, SEQ
ID NO: 1119, SEQ ID NO: 1136, SEQ ID NO: 1137, SEQ ID NO: 1140, SEQ ID NO:
1142, SEQ ID NO: 1233, SEQ ID NO: 1238, SEQ ID NO: 1243, SEQ ID NO: 1245, SEQ
ID NO: 1247, SEQ ID NO: 1249, SEQ ID NO: 1261, SEQ ID NO: 1269, SEQ ID NO:
1279,SEQ ID NO: 1284, SEQ ID NO: 1290, SEQ ID NO:1297, SEQ ID NO: 1328, SEQ
ID NO: 1370, SEQ ID NO: 1372, SEQ ID NO: 1377, SEQ ID NO: 1383, SEQ ID NO:
1384, SEQ ID NO: 1385, SEQ ID NO: 1388, SEQ ID NO: 1401, SEQ ID NO: 1402, SEQ
ID NO:1418, SEQ ID NO: 1420, SEQ ID NO: 1427, SEQ ID NO: 1070, SEQ ID NO:
1151, SEQ ID NO: 1176, SEQ ID NO: 999, SEQ ID NO: 1006, SEQ ID NO: 1012, SEQ
ID NO: 1018, SEQ ID NO: 1030, SEQ ID NO: 1033, SEQ ID NO: 1041, SEQ ID NO:
1049, SEQ ID NO: 1054, SEQ ID NO: 1057, SEQ ID NO: 1090, SEQ ID NO: 1097, SEQ
ID NO: 1129, SEQ ID NO: 1139, SEQ ID NO: 1143, SEQ ID NO: 1152, SEQ ID NO:
1153, SEQ ID NO: 1155, SEQ ID NO: 1161, SEQ ID NO: 1162, SEQ ID NO: 1169, SEQ
ID NO: 1170, SEQ ID NO: 1171, SEQ ID NO: 1180, SEQ ID NO: 1194, SEQ ID NO:
1195, SEQ ID NO: 1199, SEQ ID NO: 1200, SEQ ID NO: 1201, SEQ ID NO: 1202, SEQ
ID NO: 1205, SEQ ID NO: 1312, SEQ ID NO: 1336, SEQ ID NO: 1349, SEQ ID NO:
1355, SEQ ID NO: 1359, SEQ ID NO: 1413, SEQ ID NO: 1426, SEQ ID NO: 1430, SEQ
ID NO: 882, SEQ ID NO: 382, SEQ ID NO: 130, SEQ ID NO: 230, SEQ ID NO: 269, SEQ ID NO: 312, SEQ ID NO: 211, SEQ ID NO: 959, SEQ ID NO: 938, SEQ ID NO:
110, SEQ ID NO:244, SEQ ID NO:328, SEQ ID NO: 235, SEQ ID NO: 315, SEQ ID
NO: 296, SEQ ID NO: 976, SEQ ID NO: 321, SEQ ID NO: 43, SEQ ID NO: 281, SEQ ID
NO: 326, SEQ ID NO: 272, SEQ ID NO: 344, SEQ ID NO: 139, SEQ ID NO: 30, SEQ ID
NO: 220, SEQ ID NO: 364, SEQ ID NO: 369, SEQ ID NO: 372, SEQ ID NO: 991, SEQ
ID NO: 128, SEQ ID NO: 347, SEQ ID NO: 52, SEQ ID NO: 12, SEQ ID NO: 247, SEQ
ID NO: 64, SEQ ID NO: 101, SEQ ID NO: 338, SEQ ID NO: 83, SEQ ID NO: 46, SEQ ID
NO:348, SEQ ID NO: 223, SEQ ID NO: 39, SEQ ID NO: 232, SEQ ID NO: 168, SEQ ID
NO: 65, SEQ ID NO: 952, SEQ ID NO: 341, SEQ ID NO: 69, SEQ ID NO: 924, SEQ ID
NO:4, SEQ ID NO: 197, SEQ ID NO: 313, SEQ ID NO: 119, SEQ ID NO: 188, SEQ ID
NO: 956, SEQ ID NO: 935, SEQ ID NO: 246, SEQ ID NO: 196, SEQ ID NO: 376, SEQ
ID NO: 172, SEQ ID NO: 25, SEQ ID NO: 126, SEQ ID NO: 951, SEQ ID NO: 147, SEQ
ID NO: 895, SEQ ID NO: 14, SEQ ID NO: 154, SEQ ID NO: 277, SEQ ID NO: 363, SEQ
ID NO: 342, SEQ ID NO: 378, SEQ ID NO: 130, SEQ ID NO: 198, SEQ ID NO: 243, SEQ ID NO: 19, SEQ ID NO:9,SEQ ID NO: 149, SEQ ID NO: 167, SEQ ID NO: 349, SEQ ID NO: 209, SEQ ID NO: 990, SEQ ID NO: 185, SEQ ID NO: 883, SEQ ID NO: 8, SEQ ID NO: 887, SEQ ID NO: 350, SEQ ID NO: 987, SEQ ID NO: 63, SEQ ID NO: 249, SEQ ID NO: 118, SEQ ID NO: 132, SEQ ID NO: 47, SEQ ID NO: 106, SEQ ID NO: 324, SEQ ID NO: 155, SEQ ID NO: 121, SEQ ID NO: 153, SEQ ID NO: 87, SEQ ID NO: 986, SEQ ID NO: 262, SEQ ID NO: 333, SEQ ID NO: 36, SEQ ID NO: 982, SEQ ID NO: 180, SEQ ID NO: 84,SEQ ID NO: 900, SEQ ID NO:20, SEQ ID NO:7, SEQ ID NO: 61, SEQ
ID NO: 253, SEQ ID NO: 120, SEQ ID NO: 268, SEQ ID NO: 299, SEQ ID NO: 942, SEQ ID NO: 173, SEQ ID NO: 187, SEQ ID NO: 187, SEQ ID NO: 234,SEQ ID NO:
112, SEQ ID NO: 324, SEQ ID NO: 971, SEQ ID NO: 62, SEQ ID NO: 308, SEQ ID NO:
74, SEQ ID NO: 1, SEQ ID NO: 266, SEQ ID NO: 337, SEQ ID NO: 93, SEQ ID NO: 44, SEQ ID NO: 335, SEQ ID NO: 368, SEQ ID NO: 208, SEQ ID NO: 358,SEQ ID NO:
923, SEQ ID NO: 310, SEQ ID NO: 26, SEQ ID NO: 279, SEQ ID NO: 890, SEQ ID NO:
325, SEQ ID NO: 109, SEQ ID NO: 143, SEQ ID NO: 918, SEQ ID NO: 252, SEQ ID
NO: 953, SEQ ID NO: 902, SEQ ID NO: 174, SEQ ID NO: 73, SEQ ID NO: 898, SEQ ID
NO: 300, SEQ ID NO: 356, SEQ ID NO: 298, SEQ ID NO: 354, SEQ ID NO: 138, SEQ
ID NO: 319, SEQ ID NO: 80, SEQ ID NO: 933, SEQ ID NO: 891, SEQ ID NO: 366, SEQ
ID NO: 113, SEQ ID NO: 320, SEQ ID NO: 915, SEQ ID NO: 351, SEQ ID NO: 162, SEQ ID NO: 965, SEQ ID NO: 67, SEQ ID NO: 314, SEQ ID NO: 904, SEQ ID NO: 345, SEQ ID NO: 374, SEQ ID NO: 962, SEQ ID NO: 270, SEQ ID NO: 186, SEQ ID NO: 60, SEQ ID NO: 379, SEQ ID NO: 889, SEQ ID NO: 967, SEQ ID NO: 973, SEQ ID NO:
280, SEQ ID NO: 170, SEQ ID NO: 985, and SEQ ID NO: 932.
10. The purified nucleic acid of claim 9, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in energy conversion encoded by the nucleic acid selected from the group consisting of SEQ ID NO:1147, SEQ ID NO: 1288, SEQ ID NO: 1324, SEQ ID NO: 1363,SEQ ID NO: 882, SEQ ID NO: 382, SEQ ID NO: 130, and SEQ ID NO: 230.
11. The purified nucleic acid of claim 9, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in amino acid metabolism encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 997, SEQ ID NO: 1015, SEQ ID NO: 1084, SEQ ID NO: 1094,SEQ ID NO: 1099, SEQ ID NO: 1229, SEQ ID NO: 1250, SEQ ID NO: 1268, SEQ ID
NO: 1293, SEQ ID NO: 1339, SEQ ID NO: 1408, SEQ ID NO: 1429, SEQ ID NO: 1434, SEQ ID NO: 1228, SEQ ID NO: 1031, SEQ ID NO: 1034, SEQ ID NO: 1008,SEQ ID
NO: 269, SEQ ID NO: 312, SEQ ID NO: 211, SEQ ID NO: 959, SEQ ID NO: 938, SEQ
ID NO: 110, SEQ ID NO: 244, SEQ ID NO: 328, SEQ ID NO: 235, SEQ ID NO: 315, SEQ ID NO: 296, SEQ ID NO: 976, SEQ ID NO: 321, SEQ ID NO: 43, SEQ ID NO: 281, SEQ ID NO: 326, and SEQ ID NO: 272.
12. The purified nucleic acid of claim 9, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in nucleotide metabolism encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1061, SEQ ID NO: 1064, SEQ ID NO: 1191. SEQ ID NO: 1217, SEQ ID NO: 1365, SEQ ID NO: 1394, SEQ ID NO: 1414, SEQ ID NO: 1415, SEQ ID
NO: 1435, SEQ ID NO: 1058, SEQ ID NO: 1059, SEQ ID NO: 344, SEQ ID NO: 139, SEQ ID NO: 30, SEQ ID NO: 220, SEQ ID NO: 364, SEQ ID NO: 369, SEQ ID NO: 372, SEQ ID NO: 991, SEQ ID NO: 128, SEQ ID NO: 347, and SEQ ID NO: 52.
13. The purified nucleic acid of claim 9, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in carbohydrate metabolism encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1080, SEQ ID NO: 1128, SEQ ID NO: 1133, SEQ ID NO: 1211, SEQ ID NO: 1252, SEQ ID NO: 1253, SEQ ID NO: 1286, SEQ ID NO: 1289, SEQ ID
NO: 1291, SEQ ID NO: 1303, SEQ ID NO: 1396, SEQ ID NO: 996, SEQ ID NO: 12, SEQ
ID NO: 247, SEQ ID NO: 64, SEQ ID NO: 101, SEQ ID NO: 338, SEQ ID NO: 83, SEQ
ID NO: 46, SEQ ID NO: 348, SEQ ID NO: 223, SEQ ID NO: 39, SEQ ID NO: 232, and SEQ ID NO: 168.
14. The purified nucleic acid of claim 9, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in cofactor metabolism encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1095, SEQ ID NO: 1156, SEQ ID NO: 1158, SEQ ID NO: 1159, SEQ ID NO: 1277, SEQ ID NO: 1038, SEQ ID NO: 65, SEQ ID NO: 952, SEQ ID NO:
341, SEQ ID NO: 69, SEQ ID NO: 924, and SEQ ID NO: 4.
15. The purified nucleic acid of claim 9, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in lipid metabolism encoded by the nucleic acid selected from the groupconsisting of SEQ ID NO: 1257, SEQ ID NO: 1357, SEQ ID NO: 1436, SEQ ID NO: 197,SEQ ID NO: 313, and SEQ ID NO: 119.
16. The purified nucleic acid of claim 9, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in mRNA translation and ribosome biogenesis encoded by the nucleic acidselected from the group consisting of SEQ ID NO: 1047, SEQ ID NO: 1055, SEQ ID NO:
SEQ ID NO: 1141, SEQ ID NO: 1227, SEQ ID NO: 1327, SEQ ID NO: 1412, SEQ ID
NO: 188, SEQ ID NO: 956, SEQ ID NO: 935, SEQ ID NO: 246, SEQ ID NO: 196, and SEQ ID NO: 376.
17. The purified nucleic acid of claim 9, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in genome replication, transcription. recombination and repair encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1003. SEQ ID NO: 1087.

SEQ ID NO: 1116, SEQ ID NO: 1130, SEQ ID NO: 1132, SEQ ID NO: 1185, SEQ ID
NO: 1188, SEQ ID NO: 1198, SEQ ID NO: 1218, SEQ ID NO: 1244, SEQ ID NO: 1306, SEQ ID NO: 1325, SEQ ID NO: 1397, SEQ ID NO: 1398, SEQ ID NO: 1407, SEQ ID
NO: 1433, SEQ ID NO: 172, SEQ ID NO: 25, SEQ ID NO: 126, SEQ ID NO: 951, SEQ
ID NO: 147, SEQ ID NO: 895, SEQ ID NO:14, SEQ ID NO: 154, SEQ ID NO: 277, SEQ
ID NO: 363, SEQ ID NO: 342, SEQ ID NO: 378, SEQ ID NO: 130, SEQ ID NO: 198,.
SEQ ID NO: 243, SEQ ID NO: 19, and SEQ ID NO: 9.
18. The purified nucleic acid of claim 9, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in outer membrane or cell wall biosynthesis encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1216, SEQ ID NO: 1239, SEQ ID NO: 1362, SEQ ID NO: 1017, SEQ ID NO:1019, SEQ ID NO: 1360, SEQ ID NO: 149, SEQ ID NO:
167, SEQ ID NO: 349, SEQ ID NO: 209, SEQ ID NO: 990, SEQ ID NO: 185, SEQ ID
NO: 883, and SEQ ID NO: 8.
19. The purified nucleic acid of claim 9, wherein said H. pylori cytoplasmic polypeptide is an H. pylori chaperone polypeptide or a fragment thereof encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1423, SEQ ID NO: 1425, SEQ ID NO: 1374, SEQ ID NO: 887, SEQ ID NO:
350, and SEQ ID NO: 987.
20. A recombinant expression vector comprising the nucleic acid of claim 9 operably linked to a transcription regulatory element.
21. A cell comprising a recombinant expression vector of claim 20.
22. A method for producing an H. pylori polypeptide comprising culturing a cell of claim 21 under conditions that permit expression of the polypeptide.
23. An isolated nucleic acid comprising a nucleotide sequence encoding an H.
pylori secreted or periplasmic polypeptide or a fragment thereof, said nucleic acid selected from the group consisting of SEQ ID NO:1004, SEQ ID NO: 1138, SEQ ID NO: 1067, SEQ ID NO: 1078, SEQ ID NO: 1314, SEQ ID NO: 1319, SEQ ID NO: 1378, SEQ ID
NO: 1105, SEQ ID NO: 1114, SEQ ID NO: 1118, SEQ ID NO: 1120, SEQ ID NO: 1123, SEQ ID NO: 1127, SEQ ID NO: 1212, SEQ ID NO: 1223, SEQ ID NO: 1225. SEQ ID
NO: 1246, SEQ ID NO: 1248, SEQ ID NO: 1259, SEQ ID NO: 1264, SEQ ID NO: 1265, SEQ ID NO: 1281, SEQ ID NO: 1285, SEQ ID NO: 1294, SEQ ID NO: 1298. SEQ ID
NO: 1299. SEQ ID NO: 1315, SEQ ID NO: 1316. SEQ ID NO: 1317, SEQ ID NO: 1318.
SEQ ID NO: 1344, SEQ ID NO: 1351, SEQ ID NO: 1353, SEQ ID NO: 1373. SEQ ID

NO: 1380, SEQ ID NO: 1387, SEQ ID NO: 1389, SEQ ID NO: 1393, SEQ ID NO: 1411, SEQ ID NO: 1428, SEQ ID NO: 1431, SEQ ID NO: 1439, SEQ ID NO: 1043, SEQ ID
NO: 1183, SEQ ID NO: 1184, SEQ ID NO: 1196, SEQ ID NO: 1197, SEQ ID NO: 1203, SEQ ID NO: 995, SEQ ID NO: 998, SEQ ID NO: 1001, SEQ ID NO: 1022, SEQ ID NO:
1023, SEQ ID NO: 1029, SEQ ID NO: 1040, SEQ ID NO: 1051, SEQ ID NO: 1062, SEQ
ID NO: 1154, SEQ ID NO: 1320, SEQ ID NO: 1075, SEQ ID NO: 1106, SEQ ID NO:
1109, SEQ ID NO: 1134, SEQ ID NO: 1221, SEQ ID NO: 1226, SEQ ID NO: 1235, SEQ
ID NO: 1301, SEQ ID NO: 1311, SEQ ID NO: 1326, SEQ ID NO: 1341, SEQ ID NO:
1354, SEQ ID NO: 1364, SEQ ID NO: 1366, SEQ ID NO: 1376, SEQ ID NO: 1391, SEQ
ID NO: 1395, SEQ ID NO: 1445, SEQ ID NO: 1079, SEQ ID NO: 1186, SEQ ID NO:
1010, SEQ ID NO: 1016, SEQ ID NO: 1172, SEQ ID NO: 1174, SEQ ID NO: 117, SEQ
ID NO: 254, SEQ ID NO: 24, SEQ ID NO: 242, SEQ ID NO: 950, SEQ ID NO: 263, SEQ
ID NO: 286, SEQ ID NO: 947, SEQ ID NO: 51, SEQ ID NO: 177, SEQ ID NO: 156, SEQ
ID NO: 190, SEQ ID NO: 375, SEQ ID NO: 222, SEQ ID NO: 21, SEQ ID NO: 912, SEQ
ID NO: 148, SEQ ID NO: 202, SEQ ID NO: 224, SEQ ID NO: 112, SEQ ID NO: 32, SEQ
ID NO: 339, SEQ ID NO: 182, SEQ ID NO: 228, SEQ ID NO: 152, SEQ ID NO: 219, SEQ ID NO: 137, SEQ ID NO: 318, SEQ ID NO: 141, SEQ ID NO: 165, SEQ ID NO:
334, SEQ ID NO: 13, SEQ ID NO: 297, SEQ ID NO: 35, SEQ ID NO: 216, SEQ ID NO:
908, SEQ ID NO: 124, SEQ ID NO: 75, SEQ ID NO: 927, SEQ ID NO: 221, SEQ ID NO:
178, SEQ ID NO: 169, SEQ ID NO: 293, SEQ ID NO: 289, SEQ ID NO: 926, SEQ ID
NO: 948, SEQ ID NO: 115, SEQ ID NO: 251, SEQ ID NO: 345, SEQ ID NO: 17, SEQ ID
NO: 920, SEQ ID NO: 95, SEQ ID NO: 86, SEQ ID NO: 360, SEQ ID NO: 271, SEQ ID
NO: 970, SEQ ID NO: 288, SEQ ID NO: 282, SEQ ID NO: 98, SEQ ID NO: 29, SEQ ID
NO: 317, SEQ ID NO: 343, SEQ ID NO: 291, SEQ ID NO: 108, SEQ ID NO: 377, SEQ
ID NO: 305, SEQ ID NO: 305, SEQ ID NO: 100, SEQ ID NO: 988, SEQ ID NO: 212, SEQ ID NO: 884, SEQ ID NO: 37, SEQ ID NO: 968, SEQ ID NO: 975, SEQ ID NO: 237, SEQ ID NO: 335, SEQ ID NO: 260, SEQ ID NO: 370, SEQ ID NO: 91, SEQ ID NO: 276, SEQ ID NO: 311, SEQ ID NO: 173, SEQ ID NO: 102, SEQ ID NO: 304, SEQ ID NO:
380, SEQ ID NO: 127, SEQ ID NO: 993, SEQ ID NO: 925, SEQ ID NO: 181, and SEQ ID
NO: 171.
24. A recombinant expression vector comprising the nucleic acid of claim 23 operably linked to a transcription regulatory element.
25. A cell comprising a recombinant expression vector of claim 24.
26. A method for producing an H. pylori polypeptide comprising culturing a cell of claim 25 under conditions that permit expression of the polypeptide.
27. An isolated nucleic acid comprising a nucleotide sequence encoding an H.
pylori surface or membrane polypeptide or a fragment thereof, said nucleic acid selected from the group consisting of SEQ ID NO: 1060, SEQ ID NO: 1110, SEQ ID NO: 1112, SEQ ID NO: 1230, SEQ ID NO: 1260, SEQ ID NO: 1280, SEQ ID NO: 1292, SEQ ID
NO: 1296, SEQ ID NO: 1307, SEQ ID NO: 1442, SEQ ID NO: 1444, SEQ ID NO: 1122, SEQ ID NO: 1254, SEQ ID NO: 1256, SEQ ID NO: 1272, SEQ ID NO: 1275, SEQ ID
NO: 1309, SEQ ID NO: 1313, SEQ ID NO: 1347, SEQ ID NO: 1352, SEQ ID NO: 1356, SEQ ID NO: 1438, SEQ ID NO: 1441, SEQ ID NO: 1009, SEQ ID NO: 1026, SEQ ID
NO: 1048, SEQ ID NO: 1063, SEQ ID NO: 1190, SEQ ID NO: 1083, SEQ ID NO: 1113, SEQ ID NO: 1222, SEQ ID NO: 1295, SEQ ID NO: 1343, SEQ ID NO: 1392, SEQ ID
NO: 1443, SEQ ID NO: 1085, SEQ ID NO: 1093, SEQ ID NO: 1117, SEQ ID NO: 1121, SEQ ID NO: 1131, SEQ ID NO: 1287, SEQ ID NO: 1440, SEQ ID NO: 1209, SEQ ID
NO: 1342, SEQ ID NO: 1381, SEQ ID NO: 1390, SEQ ID NO: 1409, SEQ ID NO: 1035, SEQ ID NO: 1014, SEQ ID NO: 1088, SEQ ID NO: 1242, SEQ ID NO: 1178, SEQ ID
NO: 1089, SEQ ID NO: 1340, SEQ ID NO: 1074, SEQ ID NO: 1107, SEQ ID NO: 1204, SEQ ID NO:1066, SEQ ID NO: 381, SEQ ID NO: 229, SEQ ID NO: 323, SEQ ID NO:
371, SEQ ID NO: 284, SEQ ID NO: 116, SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO:
907, SEQ ID NO: 193, SEQ ID NO: 145, SEQ ID NO: 59, SEQ ID NO: 322, SEQ ID NO:
94, SEQ ID NO: 306, SEQ ID NO: 939, SEQ ID NO: 205, SEQ ID NO: 123, SEQ ID NO:
906, SEQ ID NO: 928, SEQ ID NO: 346, SEQ ID NO: 129, SEQ ID NO: 307, SEQ ID
NO: 133, SEQ ID NO: 131, SEQ ID NO: 886, SEQ ID NO: 179, SEQ ID NO:104, SEQ
ID NO: 213, SEQ ID NO: 359, SEQ ID NO: 140, SEQ ID NO: 146, SEQ ID NO: 327, SEQ ID NO: 365, SEQ ID NO: 33, SEQ ID NO: 331, SEQ ID NO: 175, SEQ ID NO: 200, SEQ ID NO: 292, SEQ ID NO: 23, SEQ ID NO: 336, SEQ ID NO: 301, SEQ ID NO: 28, SEQ ID NO: 941, SEQ ID NO: 103, SEQ ID NO: 231, SEQ ID NO: 176, SEQ ID NO: 31, SEQ ID NO: 917, SEQ ID NO: 151, SEQ ID NO: 922, SEQ ID NO: 265, SEQ ID NO:
142, SEQ ID NO: 259, SEQ ID NO: 122, SEQ ID NO: 206, SEQ ID NO: 96, SEQ ID NO:
353, SEQ ID NO: 38, SEQ ID NO: 89, SEQ ID NO: 77, SEQ ID NO:954, SEQ ID NO:
264, SEQ ID NO: 937, SEQ ID NO: 226, SEQ ID NO: 283, SEQ ID NO: 88, SEQ ID NO:
125, SEQ ID NO: 183, SEQ ID NO: 195, SEQ ID NO: 81, SEQ ID NO: 901, SEQ ID NO:
82, SEQ ID NO: 42, SEQ ID NO: 881, and SEQ ID NO: 885.
28. The purified nucleic acid of claim 27, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least one membrane spanning region encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1060, SEQ ID NO: 1110, SEQ ID NO: 1112, SEQ ID NO: 1230, SEQ ID NO: 1260, SEQ ID NO: 1280, SEQ ID NO: 1292, SEQ ID
NO: 1296, SEQ ID NO: 1307, SEQ ID NO: 1442, SEQ ID NO: 1444, SEQ ID NO: 381, SEQ ID NO: 229, SEQ ID NO: 323, SEQ ID NO: 371, SEQ ID NO; 284, SEQ ID NO:

116, SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 907, SEQ ID NO: 193, SEQ ID NO:
145, SEQ ID NO: 59, SEQ ID NO: 322, SEQ ID NO: 94, SEQ ID NO: 306, and SEQ ID
NO: 881.
29. The purified nucleic acid of claim 27, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least two membrane spanning regions encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1122, SEQ ID NO: 1254, SEQ ID NO:
1256, SEQ ID NO: 1272, SEQ ID NO: 1275, SEQ ID NO: 1309, SEQ ID NO: 1313, SEQ
ID NO: 1347, SEQ ID NO: 1352, SEQ ID NO: 1356, SEQ ID NO: 1438, SEQ ID NO:
1441, SEQ ID NO: 1009, SEQ ID NO: 1026, SEQ ID NO: 1048, SEQ ID NO: 1063, SEQ
ID NO: 1190, SEQ ID NO: 939, SEQ ID NO: 205, SEQ ID NO: 123, SEQ ID NO: 906, SEQ ID NO: 928, SEQ ID NO: 346, SEQ ID NO: 129, SEQ ID NO: 307, SEQ ID NO:
133, SEQ ID NO: 131, SEQ ID NO: 886, SEQ ID NO: 179, SEQ ID NO: 104, SEQ ID
NO: 213, SEQ ID NO: 359, SEQ ID NO: 140, SEQ ID NO: 146, SEQ ID NO: 327, and SEQ ID NO: 365.
30. The purified nucleic acid of claim 27, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least three membrane spanning regions encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1083, SEQ ID NO: 1113, SEQ ID NO:
1222, SEQ ID NO: 1295, SEQ ID NO: 1343, SEQ ID NO: 1392, SEQ ID NO: 1443, SEQ
ID NO: 33, SEQ ID NO: 331, SEQ ID NO: 175, SEQ ID NO: 200, SEQ ID NO: 292, SEQ
ID NO: 23, and SEQ ID NO: 336.
31. The purified nucleic acid of claim 27, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least four membrane spanning regions encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1085, SEQ ID NO: 1093, SEQ ID NO:
1117, SEQ ID NO: 1121, SEQ ID NO: 1131, SEQ ID NO: 1287, SEQ ID NO: 1440, SEQ
ID NO: 1209, SEQ ID NO: 301, SEQ ID NO: 28, SEQ ID NO: 941, SEQ ID NO: 103, SEQ ID NO: 231, SEQ ID NO: 176, SEQ ID NO: 31, SEQ ID NO: 917, SEQ ID NO: 151, and SEQ ID NO: 922.
32. The purified nucleic acid of claim 27, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least five membrane spanning regions encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1342. SEQ ID NO: 1381. SEQ ID NO:
1390, SEQ ID NO: 1409, SEQ ID NO: 1035. SEQ ID NO: 265. SEQ ID NO: 142, SEQ ID
NO: 259, SEQ ID NO: 122, SEQ ID NO: 206. and SEQ ID NO: 885.
33. The purified nucleic acid of claim 27, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least six membrane spanning regions encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1014, SEQ ID NO: 1088, SEQ ID NO: 1242, SEQ ID NO: 1178, SEQ ID NO: 96, SEQ ID NO: 353, SEQ ID NO: 38, SEQ ID NO: 89, SEQ ID NO: 77, SEQ ID NO: 954, and SEQ ID NO: 264.
34. The purified nucleic acid of claim 27, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least seven membrane spanning regions encoded by the nucleic acid selected from the group consisting of SEQ ID NO: 1089, SEQ ID NO: 1340, SEQ ID NO:
1074, SEQ ID NO: 1107, SEQ ID NO: 1204, SEQ ID NO: 1066, SEQ ID NO: 937, SEQ
ID NO: 226, SEQ ID NO: 283, SEQ ID NO: 88, SEQ ID NO: 125, SEQ ID NO: 183, SEQ
ID NO: 195, SEQ ID NO: 81, SEQ ID NO: 901, SEQ ID NO: 82, and SEQ ID NO: 42.
35. A recombinant expression vector comprising the nucleic acid of claim 27 operably linked to a transcription regulatory element.
36. A cell comprising a recombinant expression vector of claim 35.
37. A method for producing an H. pylori polypeptide comprising culturing a cell of claim 36 under conditions that permit expression of the polypeptide.
38. A vaccine composition for prevention or treatment of an H. pylori infection comprising an effective amount of a nucleic acid of claim 1.
39. A vaccine composition of claim 38, further comprising a pharmaceutically acceptable carrier.
40. A vaccine composition of claim 39, wherein the pharmaceutically acceptable carrier is an adjuvant.
41. A method of treating a subject for H. pylori infection comprising administering to a subject a vaccine composition of claim 38, such that treatment of H.
pylori infection occurs.
42. A method of claim 41, wherein the treatment is a prophylactic treatment.
43. A method of claim 41, wherein the treatment is a therapeutic treatment.
44. A vaccine composition for prevention or treatment of an H. pylori infection comprising an effective amount of a nucleic acid of claim 9.
45. A vaccine composition of claim 44, further comprising a pharmaceutically acceptable carrier.
46. A vaccine composition of claim 45, wherein the pharmaceutically acceptable carrier is an adjuvant.
47. A method of treating a subject for H. pylori infection comprising administering to a subject a vaccine composition of claim 44, such that treatment of H.
pylori infection occurs.
48. A method of claim 47, wherein the treatment is a prophylactic treatment.
49. A method of claim 47, wherein the treatment is a therapeutic treatment.
50. A vaccine composition for prevention or treatment of an H. pylori infection comprising an effective amount of a nucleic acid of claim 23.
511. A vaccine composition of claim 50, further comprising a pharmaceutically acceptable carrier.
52. A vaccine composition of claim 51, wherein the pharmaceutically acceptable carrier is an adjuvant.
53. A method of treating a subject for H. pylori infection comprising administering to a subject a vaccine composition of claim 50, such that treatment of H.
pylori infection occurs.
54. A method of claim 53, wherein the treatment is a prophylactic treatment
55. A method of claim 53, wherein the treatment is a therapeutic treatment.
56. A purified H. pylori cell envelope polypeptide or a fragment thereof, wherein said polypeptide is selected from the group consisting of SEQ ID NO: 1471, SEQ
ID NO: 1472, SEQ ID NO: 1487, SEQ ID NO: 1501, SEQ ID NO: 1522, SEQ ID NO:
1552, SEQ ID NO: 1586, SEQ ID NO: 1727, SEQ ID NO: 1601, SEQ ID NO: 1638, SEQ
ID NO: 1643, SEQ ID NO: 1812, SEQ ID NO: 1830, SEQ ID NO: 1850, SEQ ID NO:
1854, SEQ ID NO: 1851, SEQ ID NO: 1640, SEQ ID NO: 1453, SEQ ID NO: 1664, SEQ
ID NO: 1665, SEQ ID NO: 1666, SEQ ID NO: 1685, SEQ ID NO: 1687, SEQ ID NO:
1688, SEQ ID NO: 1675, SEQ ID NO: 1702, SEQ ID NO: 1713, SEQ ID NO: 1600, SEQ
ID NO: 1671, SEQ ID NO: 1691, SEQ ID NO: 1615, SEQ ID NO: 1616, SEQ ID NO:
1855, SEQ ID NO: 1595, SEQ ID NO: 1633, SEQ ID NO: 1608, SEQ ID NO: 1611, SEQ
ID NO: 1751, SEQ ID NO: 1772, SEQ ID NO: 1774, SEQ ID NO: 1780, SEQ ID NO:
1783, SEQ ID NO: 1796, SEQ ID NO: 1809, SEQ ID NO: 1826, SEQ ID NO: 1868, SEQ
ID NO: 1734, SEQ ID NO: 1786, SEQ ID NO: 1819, SEQ ID NO: 1630, SEQ ID NO:
1706, SEQ ID NO: 1709, SEQ ID NO: 1495, SEQ ID NO: 1724, SEQ ID NO: 1670, SEQ
ID NO: 1725, SEQ ID NO: 1661, SEQ ID NO: 1873, SEQ ID NO: 1753, SEQ ID NO:
1759, SEQ ID NO: 1761, SEQ ID NO: 1782, SEQ ID NO: 1883, SEQ ID NO: 1503, SEQ
ID NO: 1542, SEQ ID NO: 1872, SEQ ID NO: 1520, SEQ ID NO: 1456, SEQ ID NO:
1458, SEQ ID NO: 1617, SEQ ID NO: 1628, SEQ ID NO: 1644, SEQ ID NO: 1657, SEQ
ID NO: 1658, SEQ ID NO: 1755, SEQ ID NO: 1756, SEQ ID NO: 1797, SEQ ID NO:
1799, SEQ ID NO: 1801, SEQ ID NO: 1483, SEQ ID NO: 1504, SEQ ID NO: 1532, SEQ
ID NO: 1575, SEQ ID NO: 1833, SEQ ID NO: 1888, SEQ ID NO: 1714, SEQ ID NO:
1624, SEQ ID NO: 1856, SEQ ID NO: 1857, SEQ ID NO: 1861, SEQ ID NO: 1537, SEQ
ID NO: 1773, SEQ ID NO: 1717, SEQ ID NO: 1733, SEQ ID NO: 1722, SEQ ID NO:
1659, SEQ ID NO: 1577, SEQ ID NO: 1721, SEQ ID NO: 1729, SEQ ID NO: 1870, SEQ
ID NO: 1576, SEQ ID NO: 1632, SEQ ID NO: 1867, SEQ ID NO: 1547, SEQ ID NO:
1533, SEQ ID NO: 1597, SEQ ID NO: 1596, SEQ ID NO: 1559, SEQ ID NO: 1599, SEQ
ID NO: 1788, SEQ ID NO: 1789, SEQ ID NO: 1875, SEQ ID NO: 1451, SEQ ID NO:
1478, SEQ ID NO: 1626, SEQ ID NO: 1781, SEQ ID NO: 660, SEQ ID NO: 660, SEQ ID
NO: 855, SEQ ID NO: 534, SEQ ID NO: 675, SEQ ID NO: 404, SEQ ID NO: 518, SEQ
ID NO: 464, SEQ ID NO: 672, SEQ ID NO: 640, SEQ ID NO: 490, SEQ ID NO: 755, SEQ ID NO: 389, SEQ ID NO: 635, SEQ ID NO: 877, SEQ ID NO: 637, SEQ ID NO:
477, SEQ ID NO: 772, SEQ ID NO: 658, SEQ ID NO: 463, SEQ ID NO: 852, SEQ ID
NO: 503, SEQ ID NO:411, SEQ ID NO: 441, SEQ ID NO: 782, SEQ ID NO: 575, SEQ
ID NO: 691, SEQ ID NO: 724, SEQ ID NO: 452, SEQ ID NO: 386, SEQ ID NO: 497, SEQ ID NO: 712, SEQ ID NO: 591, SEQ ID NO: 638, SEQ ID NO: 740, SEQ ID NO:
697, SEQ ID NO: 569, SEQ ID NO: 470, SEQ ID NO: 700, SEQ ID NO: 586, SEQ ID
NO: 823, SEQ ID NO: 627, SEQ ID NO: 627, SEQ ID NO: 684, SEQ ID NO: 551, SEQ
ID NO: 478, SEQ ID NO: 508, SEQ ID NO: 545, SEQ ID NO: 628, SEQ ID NO: 443, SEQ ID NO: 702, SEQ ID NO: 776, SEQ ID NO: 461. SEQ ID NO: 737, SEQ ID NO:

809, SEQ ID NO: 642, SEQ ID NO: 879, SEQ ID NO: 773, SEQ ID NO: 468, SEQ ID
NO: 842, SEQ ID NO: 788, SEQ ID NO: 624, SEQ ID NO: 788, SEQ ID NO: 644, SEQ
ID NO: 727, SEQ ID NO: 631, SEQ ID NO: 450, SEQ ID NO: 448, SEQ ID NO: 653, SEQ ID NO: 495, SEQ ID NO: 400, SEQ ID NO: 541, SEQ ID NO: 673, SEQ ID NO:
482, SEQ ID NO: 622, SEQ ID NO: 689, SEQ ID NO: 736, SEQ ID NO: 417, SEQ ID
NO: 716, SEQ ID NO: 762, SEQ ID NO: 395, SEQ ID NO: 587, SEQ ID NO: 669, SEQ
ID NO: 758, SEQ ID NO: 593, SEQ ID NO: 451, SEQ ID NO: 827, SEQ ID NO: 502, SEQ ID NO: 719, SEQ ID NO: 469, SEQ ID NO: 715, SEQ ID NO: 847, SEQ ID NO:
453, SEQ ID NO: 527, SEQ ID NO: 652, SEQ ID NO: 745, SEQ ID NO: 567, SEQ ID
NO: 848, SEQ ID NO: 430, SEQ ID NO: 748, SEQ ID NO: 396, SEQ ID NO: 588, SEQ
ID NO: 795, SEQ ID NO: 523, SEQ ID NO: 791, SEQ ID NO: 714, SEQ ID NO: 481, SEQ ID NO: 765, SEQ ID NO: 837, SEQ ID NO: 833, SEQ ID NO: 585, SEQ ID NO:
865, SEQ ID NO: 764, SEQ ID NO: 440, SEQ ID NO: 465, SEQ ID NO: 555, SEQ ID
NO: 526, SEQ ID NO: 687, SEQ ID NO: 692, SEQ ID NO: 693, SEQ ID NO: 677, SEQ
ID NO: 649, SEQ ID NO: 812, SEQ ID NO: 820, SEQ ID NO: 880, SEQ ID NO: 590, SEQ ID NO: 713, SEQ ID NO: 750, SEQ ID NO: 613, SEQ ID NO: 437, SEQ ID NO:
556, SEQ ID NO: 657, SEQ ID NO: 402, SEQ ID NO: 623, SEQ ID NO: 862, SEQ ID
NO: 449, SEQ ID NO: 690, SEQ ID NO: 424, SEQ ID NO: 821, SEQ ID NO: 432, SEQ
ID NO: 811, SEQ ID NO: 554, and SEQ ID NO: 809.
57. The purified polypeptide of claim 56, wherein said H. pylori cell envelopepolypeptide or a fragment thereof is an H. pylori flagella-associated polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 1471, SEQ ID NO:
1472, SEQ ID NO: 1487, SEQ ID NO: 1501, SEQ ID NO: 1522, SEQ ID NO: 1552, SEQ
ID NO: 1586, SEQ ID NO: 1727, SEQ ID NO: 1601, SEQ ID NO: 1638, SEQ ID NO:
1643, SEQ ID NO: 1812, SEQ ID NO: 1830, SEQ ID NO: 1850, SEQ ID NO: 1854, SEQ
ID NO: 1851, SEQ ID NO: 1640, SEQ ID NO: 660, SEQ ID NO: 660, SEQ ID NO: 855, SEQ ID NO: 534, SEQ ID NO: 675, SEQ ID NO: 404, SEQ ID NO: 518, SEQ ID NO:
464, SEQ ID NO: 672, SEQ ID NO: 640, SEQ ID NO: 490, SEQ ID NO: 755, SEQ ID
NO: 389, SEQ ID NO: 635, SEQ ID NO: 877, SEQ ID NO: 637, SEQ ID NO: 477, SEQ
ID NO: 772, and SEQ ID NO: 658.
58. The purified polypeptide of claim 56, wherein said H. pylori cell envelopepolypeptide or a fragment thereof is an H. pylori inner membrane polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 1453, SEQ ID NO: 1664, SEQ
ID NO: 1665, SEQ ID NO: 1666, SEQ ID NO: 1685, SEQ ID NO: 1687, SEQ ID NO:
1688, SEQ ID NO: 1675, SEQ ID NO: 1702, SEQ ID NO: 1713, SEQ ID NO: 1600, SEQ
ID NO: 1671, SEQ ID NO: 1691, SEQ ID NO: 1615, SEQ ID NO: 1616, SEQ ID NO:
1855, SEQ ID NO: 1595, SEQ ID NO: 1633. SEQ ID NO: 1608, SEQ ID NO: 1611. SEQ

ID NO: 1751, SEQ ID NO: 1772, SEQ ID NO: 1774,SEQ ID NO: 1780, SEQ ID NO:
1783, SEQ ID NO: 1796, SEQ ID NO: 1809, SEQ ID NO: 1826, SEQ ID NO: 1868, SEQ
ID NO: 1734, SEQ ID NO: 1786, SEQ ID NO: 1819, SEQ ID NO: 1630,SEQ ID NO:
1706, SEQ ID NO: 1709, SEQ ID NO: 1495, SEQ ID NO: 1724, SEQ ID NO: 463, SEQ
ID NO: 852, SEQ ID NO: 503, SEQ ID NO: 411, SEQ ID NO: 441, SEQ ID NO: 782, SEQ ID NO: 575, SEQ ID NO: 691, SEQ ID NO: 724, SEQ ID NO: 452, SEQ ID NO:
386,SEQ ID NO: 497, SEQ ID NO: 712, SEQ ID NO: 591, SEQ ID NO: 638, SEQ ID
NO: 740, SEQ ID NO: 697, SEQ ID NO: 569, SEQ ID NO: 470, SEQ ID NO: 700, SEQ
ID NO: 586, SEQ ID NO: 823, SEQ ID NO:627,SEQ ID NO: 627, SEQ ID NO: 684, SEQ ID NO: 551, SEQ ID NO: 478, SEQ ID NO: 508, SEQ ID NO: 545, SEQ ID NO:
628, SEQ ID NO: 443, SEQ ID NO: 702, SEQ ID NO: 776, SEQ ID NO: 461,SEQ ID
NO: 737, SEQ ID NO: 809, SEQ ID NO: 642, SEQ ID NO: 879, SEQ ID NO: 773, SEQ
ID NO: 468, SEQ ID NO: 842, SEQ ID NO: 788, SEQ ID NO: 624, SEQ ID NO: 788, SEQ ID NO: 644, SEQ ID NO: 727, SEQ ID NO: 631, SEQ ID NO: 450, SEQ ID NO:
448, and SEQ ID NO: 653.
59. The purified polypeptide of claim 56, wherein said H. pylori cell envelope polypeptide or a fragment thereof is an H. pylori transporter polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 1670, SEQ ID NO: 1725, SEQ
ID NO: 1661, SEQ ID NO: 1873, SEQ ID NO: 1753, SEQ ID NO: 1759, SEQ ID NO:
1761, SEQ ID NO: 1782, SEQ ID NO: 1883, SEQ ID NO: 1503, SEQ ID NO: 1542, SEQ
ID NO: 1872, SEQ ID NO: 1520, SEQ ID NO: 1456, SEQ ID NO: 1458, SEQ ID NO:
1617, SEQ ID NO: 1628, SEQ ID NO: 1644, SEQ ID NO: 1657, SEQ ID NO: 1658, SEQ
ID NO: 1755, SEQ ID NO: 1756, SEQ ID NO: 1797, SEQ ID NO: 1799, SEQ ID NO:
1801, SEQ ID NO: 1483, SEQ ID NO: 1504, SEQ ID NO: 1532, SEQ ID NO: 1575, SEQ
ID NO: 1833, SEQ ID NO: 1888, SEQ ID NO: 1714, SEQ ID NO: 495, SEQ ID NO: 400, SEQ ID NO: 541, SEQ ID NO: 673, SEQ ID NO: 482, SEQ ID NO: 622, SEQ ID NO:
689, SEQ ID NO: 736, SEQ ID NO: 417, SEQ ID NO: 716, SEQ ID NO: 762, SEQ ID
NO: 395, SEQ ID NO: 587, SEQ ID NO: 669, SEQ ID NO: 758, SEQ ID NO: 593, SEQ
ID NO:451, SEQ ID NO: 827, SEQ ID NO: 502, SEQ ID NO: 719, SEQ ID NO: 469, SEQ ID NO: 715, SEQ ID NO: 847, SEQ ID NO: 453, SEQ ID NO: 527, SEQ ID NO:
652, SEQ ID NO: 745, SEQ ID NO: 567, SEQ ID NO: 848, SEQ ID NO: 430, SEQ ID
NO: 748, SEQ ID NO: 396, SEQ ID NO: 588, SEQ ID NO: 795, SEQ ID NO: 523, SEQ
ID NO: 791, SEQ ID NO: 714,SEQ ID NO: 481, and SEQ ID NO: 765.
60. The purified polypeptide of claim 56, wherein said H. pylori cell envelope polypeptide or a fragment thereof is an H. pylori outer membrane polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 1624. SEQ ID NO: 1856, SEQ
ID NO: 1857, SEQ ID NO: 1861, SEQ ID NO: 1537, SEQ ID NO: 1773, SEQ ID NO:

1717, SEQ ID NO: 1733, SEQ ID NO: 1722, SEQ ID NO: 1659, SEQ ID NO: 1577, SEQ
ID NO: 1721, SEQ ID NO: 1729, SEQ ID NO: 1870,SEQ ID NO: 1576, SEQ ID NO:
1632, SEQ ID NO: 1867, SEQ ID NO: 1547, SEQ ID NO: 1533, SEQ ID NO: 1597, SEQ
ID NO: 1596, SEQ ID NO: 1559, SEQ ID NO: 1599, SEQ ID NO: 1788, SEQ ID NO:
1789, SEQ ID NO: 1875, SEQ ID NO: 1451, SEQ ID NO: 1478, SEQ ID NO: 1626, SEQ
ID NO: 1781, SEQ ID NO: 837, SEQ ID NO: 833, SEQ ID NO: 585, SEQ ID NO: 865, SEQ ID NO: 764, SEQ ID NO: 440, SEQ ID NO: 465, SEQ ID NO: 555, SEQ ID NO:
526, SEQ ID NO: 687, SEQ ID NO: 692, SEQ ID NO: 693, SEQ ID NO: 677, SEQ ID
NO: 649, and SEQ ID NO: 812.
61. A purified H. pylori cytoplasmic polypeptide or a fragment thereof, wherein said polypeptide is selected from the group consisting of SEQ ID NO: 1598, SEQ ID NO:
1739, SEQ ID NO: 1775, SEQ ID NO: 1814, SEQ ID NO: 1448, SEQ ID NO: 1466, SEQ
ID NO: 1535, SEQ ID NO: 1545, SEQ ID NO: 1550, SEQ ID NO: 1680, SEQ ID NO:
1701, SEQ ID NO: 1719, SEQ ID NO: 1744, SEQ ID NO: 1790, SEQ ID NO: 1859, SEQ
ID NO: 1880, SEQ ID NO: 1885, SEQ ID NO: 1679, SEQ ID NO: 1482, SEQ ID NO:
1485, SEQ ID NO: 1459, SEQ ID NO: 1512, SEQ ID NO: 1515, SEQ ID NO: 1642, SEQ
ID NO: 1668, SEQ ID NO: 1816, SEQ ID NO: 1845, SEQ ID NO: 1865, SEQ ID NO:
1866, SEQ ID NO: 1886, SEQ ID NO: 1509, SEQ ID NO: 1510, SEQ ID NO: 1531, SEQ
ID NO: 1579, SEQ ID NO: 1584, SEQ ID NO: 1662, SEQ ID NO: 1703, SEQ ID NO:
1704, SEQ ID NO: 1737, SEQ ID NO: 1740, SEQ ID NO: 1742, SEQ ID NO: 1754, SEQ
ID NO: 1847, SEQ ID NO: 1447, SEQ ID NO: 1546, SEQ ID NO: 1607, SEQ ID NO:
1609, SEQ ID NO: 1610, SEQ ID NO: 1728, SEQ ID NO: 1489, SEQ ID NO: 1708, SEQ
ID NO: 1808, SEQ ID NO: 1887, SEQ ID NO: 1498, SEQ ID NO: 1506, SEQ ID NO:
1592, SEQ ID NO: 1678, SEQ ID NO: 1778, SEQ ID NO: 1863, SEQ ID NO: 1454, SEQ
ID NO: 1538, SEQ ID NO: 1567, SEQ ID NO: 1581, SEQ ID NO: 1583, SEQ ID NO:
1636, SEQ ID NO: 1639, SEQ ID NO: 1649, SEQ ID NO: 1669, SEQ ID NO: 1695, SEQ
ID NO: 1757,SEQ ID NO: 1776, SEQ ID NO: 1848, SEQ ID NO: 1849, SEQ ID NO:
1858, SEQ ID NO: 1884, SEQ ID NO: 1667, SEQ ID NO: 1690, SEQ ID NO: 1813, SEQ
ID NO: 1468, SEQ ID NO: 1470, SEQ ID NO: 1811, SEQ ID NO: 1874, SEQ ID NO:
1876, SEQ ID NO: 1825, SEQ ID NO: 1479, SEQ ID NO: 1488, SEQ ID NO: 1528, SEQ
ID NO: 1566, SEQ ID NO: 1683, SEQ ID NO: 1692, SEQ ID NO: 1718, SEQ ID NO:
1614, SEQ ID NO: 1519, SEQ ID NO: 1476, SEQ ID NO: 1493, SEQ ID NO: 1497, SEQ
ID NO: 1507, SEQ ID NO: 1490, SEQ ID NO: 1523, SEQ ID NO: 1524, SEQ ID NO:
1543, SEQ ID NO: 1551, SEQ ID NO: 1553, SEQ ID NO: 1554, SEQ ID NO: 1555, SEQ
ID NO: 1562, SEQ ID NO: 1570, SEQ ID NO: 1587, SEQ ID NO: 1588, SEQ ID NO:
1591, SEQ ID NO: 1593, SEQ ID NO: 1684, SEQ ID NO: 1689, SEQ ID NO: 1694, SEQ
ID NO: 1696, SEQ ID NO: 1698, SEQ ID NO: 1700, SEQ ID NO: 1712, SEQ ID NO:
1720, SEQ ID NO: 1730. SEQ ID NO: 1735, SEQ ID NO: 1741, SEQ ID NO: 1748, SEQ

ID NO: 1779, SEQ ID NO: 1821, SEQ ID NO: 1823, SEQ ID NO: 1828, SEQ ID NO:
1834, SEQ ID NO: 1835, SEQ ID NO: 1836, SEQ ID NO: 1839, SEQ ID NO: 1852, SEQ
ID NO: 1853, SEQ ID NO: 1869, SEQ ID NO: 1871, SEQ ID NO: 1878, SEQ ID NO:
1521, SEQ ID NO: 1602, SEQ ID NO: 1627, SEQ ID NO: 1450, SEQ ID NO: 1457, SEQ
ID NO: 1463, SEQ ID NO: 1469, SEQ ID NO: 1481, SEQ ID NO: 1484, SEQ ID NO:
1492, SEQ ID NO: 1500, SEQ ID NO: 1505, SEQ ID NO: 1508, SEQ ID NO: 1541, SEQ
ID NO: 1548, SEQ ID NO: 1580, SEQ ID NO: 1590, SEQ ID NO: 1594, SEQ ID NO:
1603, SEQ ID NO: 1604, SEQ ID NO: 1606, SEQ ID NO: 1612, SEQ ID NO: 1613, SEQ
ID NO: 1620, SEQ ID NO: 1621, SEQ ID NO: 1622, SEQ ID NO:1631, SEQ ID NO:
1645, SEQ ID NO: 1646, SEQ ID NO: 1650, SEQ ID NO: 1651, SEQ ID NO: 1652, SEQ
ID NO: 1653, SEQ ID NO: 1656, SEQ ID NO: 1763, SEQ ID NO: 1787, SEQ ID NO:
1800, SEQ ID NO: 1806, SEQ ID NO: 1810, SEQ ID NO: 1864, SEQ ID NO: 1877, SEQ
ID NO: 1881, SEQ ID NO: 390, SEQ ID NO: 876, SEQ ID NO: 547, SEQ ID NO: 678, SEQ ID NO: 729, SEQ ID NO: 786, SEQ ID NO: 654, SEQ ID NO: 734, SEQ ID NO:
646, SEQ ID NO: 522, SEQ ID NO: 696, SEQ ID NO: 807, SEQ ID NO: 683, SEQ ID
NO: 790, SEQ ID NO: 763, SEQ ID NO: 806, SEQ ID NO: 799, SEQ ID NO: 434, SEQ
ID NO: 743, SEQ ID NO: 804, SEQ ID NO: 733, SEQ ID NO: 826, SEQ ID NO: 562, SEQ ID NO: 420, SEQ ID NO: 664, SEQ ID NO: 850, SEQ ID NO: 857, SEQ ID NO:
861,SEQ ID NO: 872, SEQ ID NO: 544, SEQ ID NO: 830, SEQ ID NO: 446, SEQ ID
NO: 397, SEQ ID NO: 699, SEQ ID NO: 459, SEQ ID NO: 509, SEQ ID NO: 818, SEQ
ID NO: 488, SEQ ID NO: 438, SEQ ID NO: 831, SEQ ID NO: 667, SEQ ID NO: 429, SEQ ID NO: 680, SEQ ID NO: 597, SEQ ID NO: 460, SEQ ID NO: 709, SEQ ID NO:
822, SEQ ID NO: 466, SEQ ID NO: 584, SEQ ID NO: 388, SEQ ID NO: 631, SEQ ID
NO: 787, SEQ ID NO: 532, SEQ IDNO: 619, SEQ ID NO: 723, SEQ ID NO: 641, SEQ
ID NO: 698, SEQ ID NO: 630, SEQ ID NO: 869, SEQ ID NO: 601, SEQ ID NO: 415, SEQ ID NO: 542, SEQ ID NO: 704, SEQ ID NO: 572, SEQ ID NO: 467, SEQ ID NO:
399, SEQ ID NO: 579, SEQ ID NO: 739, SEQ ID NO: 849, SEQ ID NO: 824, SEQ ID
NO: 871, SEQ ID NO: 547, SEQ ID NO: 633, SEQ ID NO: 695, SEQ ID NO: 405, SEQ
ID NO: 394, SEQ ID NO: 761, SEQ ID NO: 574, SEQ ID NO: 596, SEQ ID NO: 832, SEQ ID NO: 651, SEQ ID NO: 867, SEQ ID NO: 614, SEQ ID NO: 401, SEQ ID NO:
393, SEQ ID NO: 413, SEQ ID NO: 835, SEQ ID NO: 863, SEQ ID NO: 458, SEQ ID
NO: 701, SEQ ID NO: 531, SEQ ID NO: 550, SEQ ID NO: 439, SEQ ID NO: 516, SEQ
ID NO: 802, SEQ ID NO: 581, SEQ ID NO: 535, SEQ ID NO: 578, SEQ ID NO: 492, SEQ ID NO: 858, SEQ ID NO: 720, SEQ ID NO: 813, SEQ ID NO: 426, SEQ ID NO:
834, SEQ ID NO: 609, SEQ ID NO: 489, SEQ ID NO: 480, SEQ ID NO: 406, SEQ ID
NO: 392, SEQ ID NO: 456, SEQ ID NO: 707, SEQ ID NO: 533, SEQ ID NO: 728, SEQ
ID NO: 769, SEQ ID NO: 671, SEQ ID NO: 602, SEQ ID NO: 618, SEQ ID NO: 618, SEQ ID NO: 682, SEQ ID NO: 524,SEQ ID NO: 802, SEQ ID NO: 785, SEQ ID NO:
457, SEQ ID NO: 781, SEQ ID NO: 473, SEQ ID NO: 384, SEQ ID NO: 726, SEQ ID

NO: 817, SEQ ID NO: 498, SEQ ID NO: 436, SEQ ID NO: 815, SEQ IDNO: 856, SEQ
ID NO: 650, SEQ ID NO: 844, SEQ ID NO: 580, SEQ ID NO: 783, SEQ ID NO: 416, SEQ ID NO: 741, SEQ ID NO: 442, SEQ ID NO: 803, SEQ ID NO: 520, SEQ ID NO:
566, SEQ ID NO: 557, SEQ ID NO: 706, SEQ ID NO: 710, SEQ ID NO: 487, SEQ ID
NO: 603, SEQ ID NO: 472, SEQ ID NO: 476, SEQ ID NO: 770, SEQ ID NO: 841, SEQ
ID NO: 768, SEQ ID NO: 839, SEQ ID NO: 560, SEQ ID NO: 796, SEQ ID NO: 483, SEQ ID NO: 634, SEQ ID NO: 445, SEQ ID NO: 853, SEQ ID NO: 525, SEQ ID NO:
798, SEQ ID NO: 549, SEQ ID NO: 836, SEQ ID NO: 589, SEQ ID NO: 760, SEQ ID
NO: 462, SEQ ID NO: 789, SEQ ID NO: 507, SEQ ID NO: 828, SEQ ID NO: 866, SEQ
ID NO: 754, SEQ ID NO: 730, SEQ ID NO: 617, SEQ ID NO: 455, SEQ ID NO: 873, SEQ ID NO: 435, SEQ ID NO: 766, SEQ ID NO: 793, SEQ ID NO: 742, SEQ ID NO:
599, SEQ ID NO: 854, and SEQ ID NO: 632.
62. The punfied polypeptide of claim 61, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in energy conversion selected from the group consisting of SEQ ID NO: 1598, SEQ ID NO:1739, SEQ ID NO: 1775, SEQ ID NO: 1814, SEQ ID NO: 390, SEQ ID NO:
876, SEQ ID NO: 547, SEQ ID NO: 678.
63. The purified polypeptide of claim 61, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in amino acid metabolism selected from the group consisting of SEQ ID NO:
1448, SEQ ID NO: 1466, SEQ ID NO: 1535, SEQ ID NO: 1545, SEQ ID NO: 1550, SEQ
ID NO: 1680, SEQ ID NO: 1701, SEQ ID NO: 1719, SEQ ID NO: 1744, SEQ ID NO:
1790, SEQ ID NO: 1859, SEQ ID NO:1 880, SEQ ID NO: 1885, SEQ ID NO: 1679, SEQ
ID NO: 1482, SEQ ID NO: 1485, SEQ ID NO: 1459, SEQ ID NO: 729, SEQ ID NO: 786, SEQ ID NO: 654, SEQ ID NO: 734, SEQ ID NO: 646, SEQ ID NO: 522, SEQ ID NO:
696, SEQ ID NO: 807, SEQ ID NO: 683, SEQ ID NO: 790, SEQ ID NO: 763, SEQ ID
NO: 806, SEQ ID NO: 799, SEQ ID NO: 434, SEQ ID NO: 743, SEQ ID NO: 804, SEQ
ID NO: 733.
64. The purified polypeptide of claim 61, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in nucleotide metabolism selected from the group consisting of SEQ ID NO:
1512, SEQ ID NO: 1515, SEQ ID NO: 1642, SEQ ID NO: 1668, SEQ ID NO: 1816, SEQ
ID NO: 1845, SEQ ID NO: 1865, SEQ ID NO: 1866, SEQ ID NO: 1886, SEQ ID NO:
1509, SEQ ID NO: 1510, SEQ ID NO: 826, SEQ ID NO: 562, SEQ ID NO: 420, SEQ ID
NO: 664, SEQ ID NO: 850, SEQ ID NO: 857, SEQ ID NO: 861, SEQ ID NO: 872, SEQ
ID NO: 544. SEQ ID NO: 830, and SEQ ID NO: 446.
65. The purified polypeptide of claim 61, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in carbohydrate metabolism selected from the group consisting of SEQ ID NO:
1531, SEQ ID NO: 1579, SEQ ID NO: 1584, SEQ ID NO: 1662, SEQ ID NO: 1703, SEQ
ID NO: 1704, SEQ ID NO: 1737, SEQ ID NO: 1740, SEQ ID NO: 1742, SEQ ID NO:
1754, SEQ ID NO: 1847, SEQ ID NO: 1447, SEQ ID NO: 397, SEQ ID NO: 699, SEQ ID
NO: 459, SEQ ID NO: 509, SEQ ID NO: 818, SEQ ID NO: 488, SEQ ID NO: 438, SEQ
ID NO: 831, SEQ ID NO: 667, SEQ ID NO: 429, SEQ ID NO: 680, and SEQ ID NO: 597.
66. The purified polypeptide of claim 61, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in cofactor metabolism selected from the group consisting of SEQ ID NO: 1546, SEQ ID NO: 1607, SEQ ID NO: 1609, SEQ ID NO: 1610, SEQ ID NO: 1728, SEQ ID
NO: 1489, SEQ ID NO: 460, SEQ ID NO: 709, SEQ ID NO: 822, SEQ ID NO: 466, SEQ
ID NO: 584, and SEQ ID NO: 388.
67. The purified polypeptide of claim 61, wherein said H. pylori cytoplasmic polypeptide or a fragment tnereof is an H. pylori polypeptide or a fragment thereof involved in lipid metabolism selected from the group consisting of SEQ ID NO: 1708, SEQ
ID NO: 1808, SEQ ID NO: 1887, SEQ ID NO: 631, SEQ ID NO: 787, and SEQ ID NO:
532.
68. The purified polypeptide of claim 61, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in rnRNA translation and ribosome biogenesis selected from the group consisting of SEQ ID NO: 1498, SEQ ID NO: 1506, SEQ ID NO: 1592, SEQ ID NO: 1678, SEQ ID
NO: 1778, SEQ ID NO: 1863, SEQ ID NO: 619, SEQ ID NO: 723, SEQ ID NO: 641, SEQ
ID NO: 698, SEQ ID NO: 630, and SEQ ID NO: 869.
69. The purified polypeptide of claim 61, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in genome replication, transcription, recombination and repair selected from the group consisting of SEQ ID NO: 1454, SEQ ID NO: 1538, SEQ ID NO: 1567, SEQ ID
NO: 1581, SEQ ID NO: 1583, SEQ ID NO: 1636, SEQ ID NO: 1639, SEQ ID NO: 1649, SEQ ID NO: 1669, SEQ ID NO: 1695, SEQ ID NO: 1757, SEQ ID NO: 1776, SEQ ID
NO: 1848, SEQ ID NO: 1849, SEQ ID NO: 1858, SEQ ID NO: 1884, SEQ ID NO: 601, SEQ ID NO: 415, SEQ ID NO: 542, SEQ ID NO: 704, SEQ ID NO: 572, SEQ ID NO:
467, SEQ ID NO: 399, SEQ ID NO: 579, SEQ ID NO: 739, SEQ ID NO: 849, SEQ ID
NO: 824, SEQ ID NO: 871, SEQ ID NO: 547. SEQ ID NO: 633, SEQ ID NO: 695, SEQ
ID NO: 405, SEQ ID NO: 394, and SEQ ID NO: 761.
70. The purified polypeptide of claim 61, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof involved in outer membrane or cell wall biosynthesis selected from the group consisting of SEQ ID NO: 1667, SEQ ID NO: 1690, SEQ ID NO: 1813, SEQ ID NO: 1468, SEQ ID
NO: 1470, SEQ ID NO: 1811, SEQ ID NO: 574, SEQ ID NO: 596, SEQ ID NO: 832, SEQ
ID NO: 651, SEQ ID NO: 867, SEQ ID NO: 614, SEQ ID NO: 401, and SEQ ID NO: 393.
71. The purified polypeptide of claim 61, wherein said H. pylori cytoplasmic polypeptide or a fragment thereof is an H. pylori chaperone polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 1874, SEQ ID NO: 1876, SEQ
ID NO: 1825, SEQ ID NO: 413, SEQ ID NO: 835, and SEQ ID NO: 863.
72. A purified H. pylori secreted or periplasmic polypeptide or a fragment thereof, wherein said polypeptide is selected from the group consisting of SEQ ID NO:
1455, SEQ ID NO: 1589, SEQ ID NO: 1518, SEQ ID NO: 1529, SEQ ID NO: 1765, SEQ
ID NO: 1770, SEQ ID NO: 1829, SEQ ID NO: 1556, SEQ ID NO: 1565, SEQ ID NO:
1569, SEQ ID NO: 1571, SEQ ID NO: 1574, SEQ ID NO: 1578, SEQ ID NO: 1663, SEQ
ID NO: 1674, SEQ ID NO: 1676, SEQ ID NO: 1697, SEQ ID NO: 1699, SEQ ID NO:
1710, SEQ ID NO: 1715, SEQ ID NO: 1716, SEQ ID NO: 1732, SEQ ID NO: 1736, SEQ
ID NO: 1745, SEQ ID NO: 1749, SEQ ID NO: 1750, SEQ ID NO: 1766, SEQ ID NO:
1767, SEQ ID NO: 1768, SEQ ID NO: 1769, SEQ ID NO: 1795, SEQ ID NO: 1802, SEQ
ID NO: 1804, SEQ ID NO: 1824, SEQ ID NO: 1831, SEQ ID NO: 1838, SEQ ID NO:
1840, SEQ ID NO: 1844, SEQ ID NO: 1862, SEQ ID NO: 1879, SEQ ID NO: 1882, SEQ
ID NO: 1890, SEQ ID NO: 1494, SEQ ID NO: 1634, SEQ ID NO: 1635, SEQ ID NO:
1647, SEQ ID NO: 1648, SEQ ID NO: 1654, SEQ ID NO: 1446, SEQ ID NO: 1449, SEQ
ID NO: 1452, SEQ ID NO: 1473, SEQ ID NO: 1474, SEQ ID NO: 1480, SEQ ID NO:
1491, SEQ ID NO: 1502, SEQ ID NO: 1513, SEQ ID NO: 1605, SEQ ID NO: 1771, SEQ
ID NO: 1526, SEQ ID NO: 1557, SEQ ID NO: 1560, SEQ ID NO: 1585, SEQ ID NO:
1672, SEQ ID NO: 1677, SEQ ID NO: 1686, SEQ ID NO: 1752, SEQ ID NO: 1762, SEQ
ID NO: 1777, SEQ ID NO: 1792, SEQ ID NO: 1805, SEQ ID NO: 1815, SEQ ID NO:
1817, SEQ ID NO: 1827, SEQ ID NO: 1842, SEQ ID NO: 1846, SEQ ID NO: 1896, SEQ
ID NO: 1530, SEQ ID NO: 1637, SEQ ID NO: 1461, SEQ ID NO: 1467, SEQ ID NO:
1623,SEQ ID NO: 1625, SEQ ID NO: 530, SEQ ID NO: 708, SEQ ID NO: 414, SEQ ID
NO: 694, SEQ ID NO: 703, SEQ ID NO:721, SEQ ID NO: 749, SEQ ID NO: 685, SEQ
ID NO: 444, SEQ ID NO: 606, SEQ ID NO: 582, SEQ ID NO: 621, SEQ ID NO: 868, SEQ ID NO: 666, SEQ ID NO: 408, SEQ ID NO: 538, SEQ ID NO: 573, SEQ ID NO:
639, SEQ ID NO: 668,SEQ ID NO: 524, SEQ ID NO: 422, SEQ ID NO: 819, SEQ ID
NO: 611, SEQ ID NO: 674, SEQ ID NO: 577, SEQ ID NO: 663, SEQ ID NO: 558, SEQ

ID NO: 794, SEQ ID NO: 564, SEQ ID NO: 592, SEQ ID NO: 814, SEQ ID NO: 398, SEQ ID NO: 767, SEQ ID NO: 425, SEQ ID NO: 659, SEQ ID NO: 517, SEQ ID NO:
539, SEQ ID NO: 475, SEQ ID NO: 615, SEQ ID NO: 665, SEQ ID NO: 607, SEQ ID
NO: 598, SEQ ID NO: 759, SEQ ID NO: 752, SEQ ID NO: 595, SEQ ID NO: 686, SEQ
ID NO: 528, SEQ ID NO: 705, SEQ ID NO: 828, SEQ ID NO: 403, SEQ ID NO: 561, SEQ ID NO: 500, SEQ ID NO: 491, SEQ ID NO: 846, SEQ ID NO: 732, SEQ ID NO:
778, SEQ ID NO: 751, SEQ ID NO: 744, SEQ ID NO: 504, SEQ ID NO: 419, SEQ ID
NO: 792, SEQ ID NO: 825, SEQ ID NO: 756, SEQ ID NO: 519, SEQ ID NO: 870, SEQ
ID NO: 777, SEQ ID NO: 808, SEQ ID NO: 506, SEQ ID NO: 864, SEQ ID NO: 655, SEQ ID NO: 407, SEQ ID NO: 427, SEQ ID NO: 774, SEQ ID NO: 797, SEQ ID NO:
688, SEQ ID NO: 815, SEQ ID NO: 718, SEQ ID NO: 859, SEQ ID NO: 775, SEQ ID
NO: 874, SEQ ID NO: 543, SEQ ID NO: 878, SEQ ID NO: 594, SEQ ID NO: 610, and SEQ ID NO: 600.
73. A purified H. pylori surface or membrane polypeptide or a fragment thereofwherein said polypeptide is selected from the group consisting of SEQ ID NO: 1511, SEQ
ID NO: 1561, SEQ ID NO: 1563, SEQ ID NO: 1681, SEQ ID NO: 1711, SEQ ID NO:
1731, SEQ ID NO: 1743, SEQ ID NO: 1747, SEQ ID NO: 1758, SEQ ID NO: 1893, SEQ
ID NO: 1895, SEQ ID NO: 1573, SEQ ID NO: 1705, SEQ ID NO: 1707, SEQ ID NO:
1723, SEQ ID NO: 1726, SEQ ID NO: 1760, SEQ ID NO: 1764, SEQ ID NO: 1798, SEQ
ID NO: 1803, SEQ ID NO: 1807, SEQ ID NO: 1889, SEQ ID NO: 1892, SEQ ID NO:
1460, SEQ ID NO: 1477, SEQ ID NO: 1499, SEQ ID NO: 1514, SEQ ID NO: 1641, SEQ
ID NO: 1534, SEQ ID NO: 1564, SEQ ID NO: 1673, SEQ ID NO: 1746, SEQ ID NO:
1794, SEQ ID NO: 1843, SEQ ID NO: 1894, SEQ ID NO: 1536, SEQ ID NO: 1544, SEQ
ID NO: 1568, SEQ ID NO: 1572, SEQ ID NO: 1582, SEQ ID NO: 1738, SEQ ID NO:
1891, SEQ ID NO: 1660, SEQ ID NO: 1793, SEQ ID NO: 1832, SEQ ID NO: 1841, SEQ
ID NO: 1860, SEQ ID NO: 1486, SEQ ID NO: 1465, SEQ ID NO: 1539, SEQ ID NO:
1693, SEQ ID NO: 1629, SEQ ID NO: 1540, SEQ ID NO: 1791, SEQ ID NO: 1525, SEQ
ID NO: 1558, SEQ ID NO: 1655, SEQ ID NO: 1517, SEQ ID NO: 875, SEQ ID NO: 676, SEQ ID NO: 801, SEQ ID NO: 860, SEQ ID NO: 747, SEQ ID NO: 529, SEQ ID NO:
387, SEQ ID NO: 391, SEQ ID NO: 515, SEQ ID NO: 625, SEQ ID NO: 568, SEQ ID
NO: 454, SEQ ID NO: 800, SEQ ID NO: 499, SEQ ID NO: 779, SEQ ID NO: 648, SEQ
ID NO: 643, SEQ ID NO: 537, SEQ ID NO: 511, SEQ ID NO: 616, SEQ ID NO: 829, SEQ ID NO: 546, SEQ ID NO: 780, SEQ ID NO: 553, SEQ ID NO: 549, SEQ ID NO:
410, SEQ ID NO: 608, SEQ ID NO: 513, SEQ ID NO: 656, SEQ ID NO: 845, SEQ ID
NO: 563, SEQ ID NO: 570, SEQ ID NO: 805, SEQ ID NO: 851, SEQ ID NO: 423, SEQ
ID NO: 810, SEQ ID NO: 604, SEQ ID NO: 636, SEQ ID NO: 757, SEQ ID NO: 412, SEQ ID NO: 816, SEQ ID NO: 771, SEQ ID NO: 418, SEQ ID NO: 662, SEQ ID NO:
512, SEQ ID NO: 679, SEQ ID NO: 605, SEQ ID NO: 421, SEQ ID NO: 552, SEQ ID

NO: 576, SEQ ID NO: 571, SEQ ID NO: 725, SEQ ID NO: 565, SEQ ID NO: 717, SEQ
ID NO: 536, SEQ ID NO: 647, SEQ ID NO: 501, SEQ ID NO: 838, SEQ ID NO: 428, SEQ ID NO: 494, SEQ ID NO: 479, SEQ ID NO: 711, SEQ ID NO: 722, SEQ ID NO:
645, SEQ ID NO: 670, SEQ ID NO: 746, SEQ ID NO: 493, SEQ ID NO: 540, SEQ ID
NO: 612, SEQ ID NO: 629, SEQ ID NO: 484, SEQ ID NO: 485, SEQ ID NO: 486, SEQ
ID NO: 433, SEQ ID NO: 385, and SEQ ID NO: 409.
74. The purified polypeptide of claim 73, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least one membrane spanning region selected from the group consisting of SEQ ID NO: 1511, SEQ ID NO: 1561, SEQ ID NO: 1563, SEQ ID NO: 1681, SEQ ID
NO: 1711, SEQ ID NO: 1731, SEQ ID NO: 1743, SEQ ID NO: 1747, SEQ ID NO: 1758, SEQ ID NO: 1893, SEQ ID NO: 1895, SEQ ID NO: 875, SEQ ID NO: 676, SEQ ID NO:
801, SEQ ID NO: 860, SEQ ID NO: 747, SEQ ID NO: 529, SEQ ID NO: 387, SEQ ID
NO: 391, SEQ ID NO: 515, SEQ ID NO: 625, SEQ ID NO: 568, SEQ ID NO: 454, SEQ
ID NO: 800, SEQ ID NO: 499, SEQ ID NO: 779, and SEQ ID NO: 385.
75. The purified polypeptide of claim 73, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least two membrane spanning regions selected from the group consisting of SEQ ID NO: 1573, SEQ ID NO: 1705, SEQ ID NO: 1707, SEQ ID NO: 1723, SEQ ID
NO: 1726,SEQ ID NO: 1760, SEQ ID NO: 1764, SEQ ID NO: 1798, SEQ ID NO: 1803, SEQ ID NO: 1807, SEQ ID NO: 1889, SEQ ID NO: 1892, SEQ ID NO: 1460, SEQ ID
NO: 1477, SEQ ID NO: 1499, SEQ ID NO: 1514, SEQ ID NO: 1641, SEQ ID NO: 648, SEQ ID NO: 643, SEQ ID NO: 537, SEQ ID NO: 511, SEQ ID NO: 616, SEQ ID NO:
829, SEQ ID NO: 546, SEQ ID NO: 780, SEQ ID NO: 553, SEQ ID NO: 549, SEQ ID
NO: 410, SEQ ID NO: 608, SEQ ID NO: 513, SEQ ID NO: 656, SEQ ID NO: 845, SEQ
ID NO: 563, SEQ ID NO: 570, SEQ ID NO: 805, and SEQ ID NO: 851.
76. The purified polypeptide of claim 73, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least three membrane spanning regions selected from the group consisting of SEQ ID NO: 1534, SEQ ID NO: 1564, SEQ ID NO: 1673, SEQ ID NO: 1746, SEQ ID
NO:1794, SEQ ID NO: 1843, SEQ ID NO: 1894, SEQ ID NO: 423, SEQ ID NO: 810, SEQ ID NO: 604, SEQ ID NO: 636,SEQ ID NO: 757, SEQ ID NO: 412, and SEQ ID NO:
816.
77. The purified polypeptide of claim 73, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least four membrane spanning regions selected from the group consisting of SEQ ID NO: 1536, SEQ ID NO: 1544, SEQ ID NO: 1568, SEQ ID NO: 1572, SEQ ID
NO: 1582, SEQ ID NO: 1738, SEQ ID NO: 1891, SEQ ID NO: 1660, SEQ ID NO: 771, SEQ ID NO: 418, SEQ ID NO: 662, SEQ ID NO: 512, SEQ ID NO: 679, SEQ ID NO:
605, SEQ ID NO: 421, SEQ ID NO: 552, SEQ ID NO: 576, and SEQ ID NO: 571.
78. The purified polypeptide of claim 73, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least five membrane spanning regions selected from the group consisting of SEQ ID NO: 1793, SEQ ID NO: 1832, SEQ ID NO: 1841, SEQ ID NO: 1860, SEQ ID
NO: 1486, SEQ ID NO: 725, SEQ ID NO: 565, SEQ ID NO: 717, SEQ ID NO: 536, SEQ
ID NO: 647, SEQ ID NO: 409.
79. The purified polypeptide of claim 73, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least six membrane spanning regions selected from the group consisting of SEQ ID NO: 1465, SEQ ID NO: 1539, SEQ ID NO: 1693, SEQ ID NO: 1629, SEQ ID
NO: 501, SEQ ID NO: 838, SEQ ID NO: 428, SEQ ID NO: 494, SEQ ID NO: 479, SEQ
ID NO: 711, and SEQ ID NO: 722.
80. The purified polypeptide of claim 73, wherein said H. pylori surface or membrane polypeptide or a fragment thereof is an H. pylori polypeptide or a fragment thereof having at least seven membrane spanning regions selected from the group consisting of SEQ ID NO: 1540, SEQ ID NO: 1791, SEQ ID NO: 1525, SEQ ID NO: 1558, SEQ ID NO: 1655, SEQ ID NO: 1517, SEQ ID NO: 645, SEQ ID NO: 670, SEQ ID NO:
746, SEQ ID NO: 493, SEQ ID NO: 540, SEQ ID NO: 612, SEQ ID NO: 629, SEQ ID
NO: 484, SEQ ID NO: 485, SEQ ID NO: 486, and SEQ ID NO: 433.
81. A vaccine composition for prevention or treatment of an H. pylori infection comprising an effective amount of an H. pylori polypeptide of claim 56.
82. A vaccine composition of claim 81, further comprising a pharmaceutically acceptable carrier.
83. A vaccine composition of claim 82, wherein the pharmaceutically acceptable carrier is an adjuvant.
84. A method of treating a subject for H. pylori infection comprising administering to a subject a vaccine composition of claim 81, such that treatment of H.
pylori infection occurs.
85. A method of claim 84, wherein the treatment is a prophylactic treatment.
86. A method of claim 84, wherein the treatment is a therapeutic treatment.
87. A vaccine composition for prevention or treatment of an H. pylori infection comprising an effective amount of an H. pylori polypeptide of claim 61.
88. A vaccine composition of claim 87, further comprising a pharmaceutically acceptable carrier.
89. A vaccine composition of claim 88, wherein the pharmaceutically acceptable carrier is an adjuvant.
90. A method of treating a subject for H. pylori infection comprising administering to a subject a vaccine composition of claim 87, such that treatment of H.
pylori infection occurs.
91. A method of claim 90, wherein the treatment is a prophylactic treatment.
92. A method of claim 90, wherein the treatment is a therapeutic treatment.
93. A vaccine composition for prevention or treatment of an H. pylori infection comprising an effective amount of an H. pylori polypeptide of claim 72.
94. A vaccine composition of claim 93, further comprising a pharmaceutically acceptable carrier.
95. A vaccine composition of claim 94, wherein the pharmaceutically acceptable carrier is an adjuvant.
96. A method of treating a subject for H. pylori infection comprising administering to a subject a vaccine composition of claim 93, such that treatment of H.
pylori infection occurs.
97. A method of claim 96, wherein the treatment is a prophylactic treatment.
98. A method of claim 96, wherein the treatment is a therapeutic treatment.
99. A vaccine composition for prevention or treatment of an H. pylori infection comprising an effective amount of an H. pylori polypeptide of claim 73.
100. A vaccine composition of claim 99, further comprising a pharmaceutically acceptable carrier.
101. A vaccine composition of claim 100, wherein the pharmaceutically acceptable carrier is an adjuvant.
102. A method of treating a subject for H. pylori infection comprising administering to a subject a vaccine composition of claim 99, such that of H.
pylori infection occurs.
103. A method of claim 102, wherein the treatment is a prophylactic treatment.
104. A method of claim 102, wherein the treatment is a therapeutic treatment.
105. A method for detecting the presence of a Helicobacter nucleic acid in a sample comprising:
(a) contacting a sample with a nucleic acid of claim 1 under conditions in which a hybrid can form between the probe and a Helicobacter nucleic acid in the sample; and (b) detecting the hybrid formed in step (a), wherein detection of a hybrid indicates the presence of a Helicobacter nucleic acid in the sample.
106. A method for detecting the presence of a Helicobacter nucleic acid in a sample comprising:
(a) contacting a sample with a nucleic acid of claim 9 under conditions in which a hybrid can form between the probe and a Helicobacter nucleic acid in the sample; and (b) detecting the hybrid formed in step (a), wherein detection of a hybrid indicates the presence of a Helicobacter nucleic acid in the sample.
107. A method for detecting the presence of a Helicobacter nucleic acid in a sample comprising:

(a) contacting a sample with a nucleic acid of claim 23 under conditions in which a hybrid can form between the probe and a Helicobacter nucleic acid in the sample; and (b) detecting the hybrid formed in step (a), wherein detection of a hybrid indicates the presence of a Helicobacter nucleic acid in the sample.
108. A method for detecting the presence of a Helicobacter nucleic acid in a sample comprising:
(a) contacting a sample with a nucleic acid of claim 27 under conditions in which a hybrid can form between the probe and a Helicobacter nucleic acid in the sample; and (b) detecting the hybrid formed in step (a), wherein detection of a hybrid indicates the presence of a Helicobacter nucleic acid in the sample.
CA002223395A 1995-06-07 1996-06-06 Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics Abandoned CA2223395A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48703295A 1995-06-07 1995-06-07
US08/487,032 1995-06-07
US63040596A 1996-04-01 1996-04-01
US08/630,405 1996-04-01

Publications (1)

Publication Number Publication Date
CA2223395A1 true CA2223395A1 (en) 1996-12-19

Family

ID=27048874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002223395A Abandoned CA2223395A1 (en) 1995-06-07 1996-06-06 Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics

Country Status (14)

Country Link
EP (1) EP0842270A4 (en)
JP (1) JPH11504220A (en)
KR (1) KR19990022600A (en)
CN (1) CN1186516A (en)
BR (1) BR9609430A (en)
CA (1) CA2223395A1 (en)
CZ (1) CZ388697A3 (en)
EE (1) EE9700373A (en)
HU (1) HUP9900766A3 (en)
IS (1) IS4630A (en)
NZ (1) NZ311874A (en)
PL (1) PL324826A1 (en)
RU (1) RU98100081A (en)
TR (1) TR199701538T1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10828358B2 (en) * 2015-12-14 2020-11-10 Technische Universität München Helicobacter pylori vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2098733A1 (en) * 1990-12-21 1992-06-22 Howard C. Krivan Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof
FR2682122B1 (en) * 1991-10-03 1995-06-09 Pasteur Institut NEW GENES OF HELICOBACTER PYLORI. THEIR USE FOR THE PREPARATION OF RECOMBINANT STRAINS OF H. PYLORI.
AR003125A1 (en) * 1995-06-01 1998-07-08 Astra Ab BACTERIAL ANTIGENS FOR THE DIAGNOSIS OF INFECTIONS WITH HELICOBACTER PYLORI, A DNA MOLECLE THAT CODES IT, A VECTOR, A HOST CELL, A PROCEDURE FOR PRODUCING THE POLIPEPTIDE, USE OF ELEPIPETICO, AND PROAPILY USE

Also Published As

Publication number Publication date
EE9700373A (en) 1998-06-15
BR9609430A (en) 1999-08-24
CZ388697A3 (en) 1998-08-12
HUP9900766A2 (en) 1999-06-28
RU98100081A (en) 2005-11-27
AU710880B2 (en) 1999-09-30
PL324826A1 (en) 1998-06-22
KR19990022600A (en) 1999-03-25
AU6327896A (en) 1996-12-30
EP0842270A1 (en) 1998-05-20
JPH11504220A (en) 1999-04-20
EP0842270A4 (en) 1999-02-24
TR199701538T1 (en) 1998-03-21
NZ311874A (en) 1999-11-29
IS4630A (en) 1997-12-05
CN1186516A (en) 1998-07-01
HUP9900766A3 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
AU745787B2 (en) Enterococcus faecalis polynucleotides and polypeptides
KR100760221B1 (en) Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
AU6909098A (en) Streptococcus pneumoniae polynucleotides and sequences
JPH09322781A (en) Staphylococcus aureus polynucleotide and sequence
EP1012157A1 (en) $i(BORRELIA BURGDORFERI) POLYNUCLEOTIDES AND SEQUENCES
AU734052B2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
AU739641B2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
CA2248985A1 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
WO1997019098A9 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
CA2223395A1 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
AU777190B2 (en) Streptococcus pneumoniae polynucleotides and sequences
AU2021240230B2 (en) Vaccines and vaccine components for inhibition of microbial cells
AU5266298A (en) Helicobacter polypeptides and corresponding polynucleotide molecules
AU713692B2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for therapeutics
AU3796099A (en) Assays using nucleic acid and amino acid sequences relating to helicobacter pylori
AU1546202A (en) Enterococcus faecalis polynucleotides and polypeptides
CZ198899A3 (en) Sequence of nucleic acids and amino acids connected with Helicobacter pylori and vaccine compositions prepared therefrom
MXPA99004890A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori
CZ148399A3 (en) Sequence of nucleic acids and amino acids connected with Helicobacter pylori and vaccine preparations

Legal Events

Date Code Title Description
FZDE Discontinued